Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1,4-alpha-glucan branching enzyme deficiency
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Abortion, Spontaneous
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Abortion, Spontaneous
The Slavic NBN Founder Mutation: A Role for Reproductive Fitness?
Acquired Immunodeficiency Syndrome
A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
Acquired Immunodeficiency Syndrome
A brief history of TRIM5alpha.
Acquired Immunodeficiency Syndrome
A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
Acquired Immunodeficiency Syndrome
Context dependent splicing functions of Bud31/Ycr063w define its role in budding and cell cycle progression.
Acquired Immunodeficiency Syndrome
Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
Acquired Immunodeficiency Syndrome
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Acquired Immunodeficiency Syndrome
eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Acquired Immunodeficiency Syndrome
Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G.
Acquired Immunodeficiency Syndrome
Restriction of the felid lentiviruses by a synthetic feline TRIM5-CypA fusion.
Acquired Immunodeficiency Syndrome
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Acquired Immunodeficiency Syndrome
TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.
Acquired Immunodeficiency Syndrome
TRIM5? and Species Tropism of HIV/SIV.
Acquired Immunodeficiency Syndrome
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys.
Acute Kidney Injury
WWP2 ameliorates acute kidney injury by mediating p53 ubiquitylation and degradation.
Acute Lung Injury
Parkin regulates lipopolysaccharide-induced proinflammatory responses in acute lung injury.
Adenocarcinoma
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
Adenocarcinoma
A novel BRCA1 mutation in a Spanish patient with ovarian cancer.
Adenocarcinoma
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
Adenocarcinoma
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Adenocarcinoma
AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway.
Adenocarcinoma
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
Adenocarcinoma
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Adenocarcinoma
Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.
Adenocarcinoma
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
Adenocarcinoma
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Adenocarcinoma
BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary.
Adenocarcinoma
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
Adenocarcinoma
Breast cancer in males, case presentation and literature review
Adenocarcinoma
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
Adenocarcinoma
Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
Adenocarcinoma
Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
Adenocarcinoma
Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review.
Adenocarcinoma
Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas.
Adenocarcinoma
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Adenocarcinoma
Dimeric switch of Hakai-truncated monomers during substrate recognition: insights from solution studies and NMR structure.
Adenocarcinoma
Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis.
Adenocarcinoma
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Adenocarcinoma
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Adenocarcinoma
Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Adenocarcinoma
Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review.
Adenocarcinoma
Expression of IAP family proteins in colon cancers from patients with different age groups.
Adenocarcinoma
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation.
Adenocarcinoma
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Adenocarcinoma
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.
Adenocarcinoma
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Adenocarcinoma
Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib.
Adenocarcinoma
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
Adenocarcinoma
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Adenocarcinoma
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
Adenocarcinoma
Hereditary forms of ovarian cancer.
Adenocarcinoma
High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.
Adenocarcinoma
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Adenocarcinoma
Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis.
Adenocarcinoma
In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin.
Adenocarcinoma
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
Adenocarcinoma
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
Adenocarcinoma
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Adenocarcinoma
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Adenocarcinoma
Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.
Adenocarcinoma
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
Adenocarcinoma
Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Adenocarcinoma
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer.
Adenocarcinoma
Pancreatic adenocarcinoma: epidemiology and genetics.
Adenocarcinoma
Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Adenocarcinoma
Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.
Adenocarcinoma
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Adenocarcinoma
Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma.
Adenocarcinoma
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Adenocarcinoma
Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15/107 group of miRNAs.
Adenocarcinoma
Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Adenocarcinoma
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
Adenocarcinoma
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
Adenocarcinoma
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
Adenocarcinoma
Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells.
Adenocarcinoma
RNF43 is frequently mutated in colorectal and endometrial cancers.
Adenocarcinoma
Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells.
Adenocarcinoma
SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Adenocarcinoma
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Adenocarcinoma
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Adenocarcinoma
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
Adenocarcinoma
The Role of E3 Ubiquitin Ligase Cbl Proteins in ?-Elemene Reversing Multi-Drug Resistance of Human Gastric Adenocarcinoma Cells.
Adenocarcinoma
The ubiquitin ligase RNF43 downregulation increases membrane expression of frizzled receptor in pancreatic ductal adenocarcinoma.
Adenocarcinoma
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
Adenocarcinoma
TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-? signaling.
Adenocarcinoma
Urological cancer related to familial syndromes.
Adenocarcinoma
[Analysis of K-ras, BRCA1/2, CHEK2 mutations and microsatellite markers (loss of heterozygosity at 9p, 17p and 18q) in sporadic pancreas adenocarcinomas]
Adenocarcinoma of Lung
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Adenocarcinoma of Lung
ALCAP2 inhibits lung adenocarcinoma cell proliferation, migration and invasion via the ubiquitination of ?-catenin by upregulating the E3 ligase NEDD4L.
Adenocarcinoma of Lung
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Adenocarcinoma of Lung
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
Adenocarcinoma of Lung
ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient derived xenografts.
Adenocarcinoma of Lung
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Adenocarcinoma of Lung
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Adenocarcinoma of Lung
DNA damage response signaling in lung adenocarcinoma A549 cells following gamma and carbon beam irradiation.
Adenocarcinoma of Lung
E3 ubiquitin ligase PJA1 regulates lung adenocarcinoma apoptosis and invasion through promoting FOXR2 degradation.
Adenocarcinoma of Lung
Effect of etoposide-induced alteration of the Mdm2-Rb signaling pathway on cellular senescence in A549 lung adenocarcinoma cells.
Adenocarcinoma of Lung
Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
Adenocarcinoma of Lung
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Adenocarcinoma of Lung
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Adenocarcinoma of Lung
Expression pattern of parkin isoforms in lung adenocarcinomas.
Adenocarcinoma of Lung
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Adenocarcinoma of Lung
Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.
Adenocarcinoma of Lung
Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma.
Adenocarcinoma of Lung
Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549.
Adenocarcinoma of Lung
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Adenocarcinoma of Lung
Loss of the tumour-suppressor genes CHK2 and BRCA1 results in chromosomal instability.
Adenocarcinoma of Lung
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.
Adenocarcinoma of Lung
Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells.
Adenocarcinoma of Lung
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Adenocarcinoma of Lung
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.
Adenocarcinoma of Lung
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
Adenocarcinoma of Lung
RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
Adenocarcinoma of Lung
Stratifin inhibits SCFFBW7 formation and blocks ubiquitination of oncoproteins during the course of lung adenocarcinogenesis.
Adenocarcinoma of Lung
The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts.
Adenocarcinoma of Lung
Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma.
Adenocarcinoma of Lung
Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.
Adenocarcinoma of Lung
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Adenocarcinoma, Mucinous
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Adenocarcinoma, Mucinous
Origins and molecular pathology of ovarian cancer.
Adenocarcinoma, Mucinous
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Adenocarcinoma, Papillary
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
Adenoma
Correlation of molecular and morphological features of appendiceal epithelial neoplasms.
Adenoma
Dysregulated Wnt?signalling and recurrent mutations?of?the tumour suppressor?RNF43?in early?gastric carcinogenesis.
Adenoma
Evaluation of the Expression of the Inhibitor of Apoptosis Protein Family and Human Telomerase Reverse Transcriptase in Patients With Advanced Colorectal Adenoma.
Adenoma
Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma.
Adenoma
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Adenoma
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
Adenoma
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Adenoma
Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis.
Adenoma
Mutated Rnf43 Aggravates Helicobacter Pylori-Induced Gastric Pathology.
Adenoma
RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
Adenoma
RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy.
Adenoma
RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps.
Adenoma
Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis.
Adenoma
[Changes in gene expression during the proliferative processes of parathyroid gland]
Adenomatous Polyposis Coli
BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes.
Adenomatous Polyposis Coli
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Adenomatous Polyposis Coli
Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast.
Adenomatous Polyposis Coli
Development of a universal gap repair vector for yeast-based screening of knockout rodents.
Adenomatous Polyposis Coli
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Adenomatous Polyposis Coli
Expression of Parkin, APC, APE1, and Bcl-xL in Colorectal Polyps.
Adenomatous Polyposis Coli
Familial pancreatic carcinoma in Jews.
Adenomatous Polyposis Coli
FIP200 inhibits ?-catenin-mediated transcription by promoting APC-independent ?-catenin ubiquitination.
Adenomatous Polyposis Coli
Genetic testing by cancer site: stomach.
Adenomatous Polyposis Coli
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
Adenomatous Polyposis Coli
HectD1 E3 ligase modifies adenomatous polyposis coli (APC) with polyubiquitin to promote the APC-axin interaction.
Adenomatous Polyposis Coli
Hereditary cancer syndromes.
Adenomatous Polyposis Coli
Hereditary common cancers: molecular and clinical genetics.
Adenomatous Polyposis Coli
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Adenomatous Polyposis Coli
Identification and management of inherited cancer susceptibility.
Adenomatous Polyposis Coli
Inheritance of cancer.
Adenomatous Polyposis Coli
Inherited predisposition to cancer: a historical overview.
Adenomatous Polyposis Coli
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Adenomatous Polyposis Coli
Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer.
Adenomatous Polyposis Coli
Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population.
Adenomatous Polyposis Coli
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Adenomatous Polyposis Coli
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Adenoviridae Infections
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Adenovirus Infections, Human
Human Adenovirus Infection Causes Cellular E3 Ubiquitin Ligase MKRN1 Degradation Involving the Viral Core Protein pVII.
Albinism
Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer.
Albinism, Oculocutaneous
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Alopecia
Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.
Alzheimer Disease
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Alzheimer Disease
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
Alzheimer Disease
Alzheimer disease: BRCA1 involved in AD-related cognitive deficits.
Alzheimer Disease
BRCA1 and p53 Tumor Suppressor Molecules in Alzheimer's Disease.
Alzheimer Disease
BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease.
Alzheimer Disease
Colocalization of BRCA1 with Tau Aggregates in Human Tauopathies.
Alzheimer Disease
Deficiency of TRIM32 Impairs Motor Function and Purkinje Cells in Mid-Aged Mice.
Alzheimer Disease
Diminished Parkin Solubility and Co-Localization with Intraneuronal Amyloid-? are Associated with Autophagic Defects in Alzheimer's Disease.
Alzheimer Disease
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Alzheimer Disease
E3 Ligase STUB1/CHIP Regulates NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Accumulation in Aged Brain, a Process Impaired in Certain Alzheimer Disease Patients.
Alzheimer Disease
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Alzheimer Disease
Isolated RING2 domain of parkin is sufficient for E2-dependent E3 ligase activity.
Alzheimer Disease
Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines.
Alzheimer Disease
Mitophagy in degenerative joint diseases.
Alzheimer Disease
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Alzheimer Disease
Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimer's disease.
Alzheimer Disease
NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease.
Alzheimer Disease
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Alzheimer Disease
Overactive BRCA1 Affects Presenilin 1 in Induced Pluripotent Stem Cell-Derived Neurons in Alzheimer's Disease.
Alzheimer Disease
Parkin and synphilin-1 isoform expression changes in Lewy body diseases.
Alzheimer Disease
Parkin overexpression ameliorates hippocampal long-term potentiation and ss-amyloid load in an Alzheimer's disease mouse model.
Alzheimer Disease
Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.
Alzheimer Disease
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
Alzheimer Disease
Parkin Regulation and Neurodegenerative Disorders.
Alzheimer Disease
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Alzheimer Disease
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.
Alzheimer Disease
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
Alzheimer Disease
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Alzheimer Disease
Quantitative interaction proteomics of neurodegenerative disease proteins.
Alzheimer Disease
Role of BRCA1 in Neuronal Death in Alzheimer's Disease.
Ameloblastoma
Expression profile of polycomb group proteins in odontogenic keratocyst and ameloblastoma.
Amnesia
Performance on tests sensitive to frontal lobe lesions by patients with organic amnesia: Leng & Parkin revisited.
Amyloidosis
Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice.
Amyloidosis
The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and A? amyloidosis.
Amyotrophic Lateral Sclerosis
Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy.
Amyotrophic Lateral Sclerosis
Genetic activation of parkin rescues TAF15-induced neurotoxicity in a Drosophila model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Mice lacking the PSD-95-interacting E3 ligase, Dorfin/Rnf19a, display reduced adult neurogenesis, enhanced long-term potentiation, and impaired contextual fear conditioning.
Amyotrophic Lateral Sclerosis
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Amyotrophic Lateral Sclerosis
Parkin expression reverses mitochondrial dysfunction in fused in sarcoma-induced amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Parkin Regulation and Neurodegenerative Disorders.
Anemia
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Anemia
BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.
Anemia
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Anemia
Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses.
Anemia
Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response.
Anemia
Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.
Anemia
Erratum: BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: A case report.
Anemia
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Anemia
Leukemic survival factor SALL4 contributes to defective DNA damage repair.
Anemia
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Anemia
RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Anemia
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1? Interaction.
Anemia, Refractory
A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Anemia, Sickle Cell
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Anemia, Sickle Cell
Metaplastic breast carcinoma: pathology and clinical outcome.
Aneurysm
Salvia miltiorrhiza-Derived Sal-miR-58 Induces Autophagy and Attenuates Inflammation in Vascular Smooth Muscle Cells.
Aneurysm, Dissecting
Disturbed P53-MDM2 feedback loop contributes to thoracic aortic dissection formation and may be a result of TRIM-25 overexpression.
Angelman Syndrome
A bipartite boundary element restricts UBE3A imprinting to mature neurons.
Angelman Syndrome
Adult Ube3a Gene Reinstatement Restores the Electrophysiological Deficits of Prefrontal Cortex Layer 5 Neurons in a Mouse Model of Angelman Syndrome.
Angelman Syndrome
An Angelman syndrome substitution in the HECT E3 ubiquitin ligase C-terminal Lobe of E6AP affects protein stability and activity.
Angelman Syndrome
Angelman Syndrome Protein Ube3a Regulates Synaptic Growth and Endocytosis by Inhibiting BMP Signaling in Drosophila.
Angelman Syndrome
Catalytically Important Residues of E6AP Ubiquitin Ligase Identified Using Acid-Cleavable Photo-Cross-Linkers.
Angelman Syndrome
Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination.
Angelman Syndrome
E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.
Angelman Syndrome
E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers.
Angelman Syndrome
Establishment of human induced pluripotent stem cell line from a patient with Angelman syndrome carrying the deletion of maternal chromosome 15q11.2-q13.
Angelman Syndrome
HAP1 is an in vivo UBE3A target that augments autophagy in a mouse model of Angelman syndrome.
Angelman Syndrome
Identification of Small-Molecule Activators of the Ubiquitin Ligase E6AP/UBE3A and Angelman Syndrome-Derived E6AP/UBE3A Variants.
Angelman Syndrome
Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity.
Angelman Syndrome
Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function.
Angelman Syndrome
Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways.
Angelman Syndrome
JNK signaling activation in the Ube3a maternal deficient mouse model: Its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
Angelman Syndrome
Modulation of hippocampal synapse maturation by activity-regulated E3 ligase via non-canonical pathway.
Angelman Syndrome
Proteomic profiling in Drosophila reveals potential Dube3a regulation of the actin cytoskeleton and neuronal homeostasis.
Angelman Syndrome
Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome.
Angelman Syndrome
The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
Angelman Syndrome
The Angelman Syndrome Protein Ube3a/E6AP Is Required for Golgi Acidification and Surface Protein Sialylation.
Angelman Syndrome
The Autism and Angelman Syndrome Protein Ube3A/E6AP: The Gene, E3 Ligase Ubiquitination Targets and Neurobiological Functions.
Angelman Syndrome
The Drosophila homologue of the Angelman syndrome ubiquitin ligase regulates the formation of terminal dendritic branches.
Angelman Syndrome
The E3 ligase ube3a is required for learning in Drosophila melanogaster.
Angelman Syndrome
Ube3a is required for experience-dependent maturation of the neocortex.
Angelman Syndrome
UBE3A regulates MC1R expression: a link to hypopigmentation in Angelman syndrome.
Angelman Syndrome
UBE3A Regulates Synaptic Plasticity and Learning and Memory by Controlling SK2 Channel Endocytosis.
Angelman Syndrome
Ube3a, the E3 ubiquitin ligase causing Angelman syndrome and linked to autism, regulates protein homeostasis through the proteasomal shuttle Rpn10.
Angelman Syndrome
UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology.
Angina Pectoris
Natural compound methyl protodioscin protects rat brain from ischemia/reperfusion injury through regulation of Mul1/SOD2 pathway.
Angiomyolipoma
Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors.
Anosmia
Nonmotor symptoms in Parkin gene-related parkinsonism.
Anosmia
Parkin is the most common causative gene in a cohort of mainland Chinese patients with sporadic early-onset Parkinson's disease.
Aortic Aneurysm
Ari-1 Regulates Myonuclear Organization Together with Parkin and Is Associated with Aortic Aneurysms.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arteritis
Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.
Arthritis
Critical roles of the E3 ubiquitin ligase FBW7 in B-cell response and the pathogenesis of experimental autoimmune arthritis.
Arthritis
Gene expression analysis approach to establish possible links between Parkinson's disease, cancer and cardiovascular diseases.
Arthritis
Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation.
Arthritis
Paraneoplastic fasciitis and polyarthritis syndrome as a manifestation of breast cancer recurrence in a BRCA1 gene-positive patient.
Arthritis
Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression.
Arthritis, Experimental
Forkhead box o3a suppresses lipopolysaccharide-stimulated proliferation and inflammation in fibroblast-like synoviocytes through regulating tripartite motif-containing protein 3.
Arthritis, Rheumatoid
Activation of synoviolin promoter in rheumatoid synovial cells by a novel transcription complex of interleukin enhancer binding factor 3 and GA binding protein alpha.
Arthritis, Rheumatoid
CUL1, a component of E3 ubiquitin ligase, alters lymphocyte signal transduction with possible effect on rheumatoid arthritis.
Arthritis, Rheumatoid
Identification of the inhibitory activity of walnut extract on the E3 ligase Syvn1.
Arthritis, Rheumatoid
Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation.
Arthritis, Rheumatoid
MicroRNA-17 Suppresses TNF-? Signaling by Interfering with TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts.
Arthritis, Rheumatoid
Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.
Arthritis, Rheumatoid
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
Arthritis, Rheumatoid
RING-finger type E3 ubiquitin ligase inhibitors as novel candidates for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression.
Arthritis, Rheumatoid
Synoviolin promotes IRE1 ubiquitination and degradation in synovial fibroblasts from mice with collagen-induced arthritis.
Arthritis, Rheumatoid
Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity.
Arthritis, Rheumatoid
The NRF2?PGC?1? pathway activates kynurenine aminotransferase 4 via attenuation of an E3 ubiquitin ligase, synoviolin, in a cecal ligation/perforation?induced septic mouse model.
Arthritis, Rheumatoid
The triptolide-induced apoptosis of osteoclast precursor by degradation of cIAP2 and treatment of rheumatoid arthritis of TNF-transgenic mice.
Arthritis, Rheumatoid
TRIM32 promotes inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Ubiquitin ligase substrate identification through quantitative proteomics at both the protein and peptide levels.
Arthritis, Rheumatoid
Upregulation of HRD1 promotes cell migration and invasion in colon cancer.
Arthritis, Rheumatoid
ZNRF3 Regulates Collagen-Induced Arthritis Through NF-kB and Wnt Pathways.
Asthma
A network approach predicts NFKBIA and BIRC3 as pathogenic genes in childhood asthma.
Asthma
A protein interaction network associated with asthma.
Asthma
BIRC3 single nucleotide polymorphism associate with asthma susceptibility and the abundance of eosinophils and neutrophils.
Asthma
E3 ubiquitin ligase Cbl-b suppresses human ORMDL3 expression through STAT6 mediation.
Asthma
March1 E3 Ubiquitin Ligase Modulates Features of Allergic Asthma in an Ovalbumin-Induced Mouse Model of Lung Inflammation.
Asthma
Parkin, an E3 ubiquitin ligase, enhances airway mitochondrial DNA release and inflammation.
Asthma
The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.
Astrocytoma
Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules.
Astrocytoma
E3 ubiquitin ligase siah?1 nuclear accumulation is critical for homocysteine?induced impairment of C6 astroglioma cells.
Astrocytoma
Expression profile of parkin isoforms in human gliomas.
Astrocytoma
Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
Astrocytoma
Mislocalization of the E3 ligase, beta-transducin repeat containing protein 1 ({beta}-TrCP1) in glioblastoma uncouples negative feedback between the PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) and Akt.
Astrocytoma
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Asymptomatic Infections
The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase.
Ataxia
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
Ataxia
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Ataxia
Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint.
Ataxia
Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.
Ataxia
Phosphorylation of the BRCA1 C terminus (BRCT) repeat inhibitor of hTERT (BRIT1) protein coordinates TopBP1 protein recruitment and amplifies ataxia telangiectasia-mutated and Rad3-related (ATR) Signaling.
Ataxia
Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha.
Ataxia
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Ataxia
RNF216 Regulates the Migration of Immortalized GnRH Neurons by Suppressing Beclin1-Mediated Autophagy.
Ataxia
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Ataxia
Ubiquitin Ligase RNF138 Promotes Episodic Ataxia Type 2-Associated Aberrant Degradation of Human Cav2.1 (P/Q-Type) Calcium Channels.
Ataxia Telangiectasia
A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
Ataxia Telangiectasia
Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies.
Ataxia Telangiectasia
Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining.
Ataxia Telangiectasia
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Ataxia Telangiectasia
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
Ataxia Telangiectasia
BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
Ataxia Telangiectasia
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
Ataxia Telangiectasia
BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis.
Ataxia Telangiectasia
CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110).
Ataxia Telangiectasia
CtIP protein dimerization is critical for its recruitment to chromosomal DNA double-stranded breaks.
Ataxia Telangiectasia
Current perspectives on radiation-induced breast cancer.
Ataxia Telangiectasia
DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.
Ataxia Telangiectasia
DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells.
Ataxia Telangiectasia
Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response.
Ataxia Telangiectasia
Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
Ataxia Telangiectasia
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Ataxia Telangiectasia
Familial pancreatic carcinoma in Jews.
Ataxia Telangiectasia
Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response.
Ataxia Telangiectasia
Gallic acid induces DNA damage and inhibits DNA repair-associated protein expression in human oral cancer SCC-4 cells.
Ataxia Telangiectasia
Gamma-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1.
Ataxia Telangiectasia
Germline genetic variants in men with prostate cancer and one or more additional cancers.
Ataxia Telangiectasia
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
Ataxia Telangiectasia
Inherited susceptibility to breast cancer.
Ataxia Telangiectasia
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Ataxia Telangiectasia
Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.
Ataxia Telangiectasia
Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner.
Ataxia Telangiectasia
Management of women with a family history of breast cancer.
Ataxia Telangiectasia
Melanoma cells express elevated levels of phosphorylated histone H2AX foci.
Ataxia Telangiectasia
Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation in comparison to ataxia telangiectasia heterozygote cells.
Ataxia Telangiectasia
Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.
Ataxia Telangiectasia
Phosphorylation of SMURF2 by ATM exerts a negative feedback control of DNA damage response.
Ataxia Telangiectasia
Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase.
Ataxia Telangiectasia
PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry.
Ataxia Telangiectasia
Recent advances in breast cancer biology.
Ataxia Telangiectasia
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Ataxia Telangiectasia
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
Ataxia Telangiectasia
Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex.
Ataxia Telangiectasia
Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage.
Atherosclerosis
Age-Associated Mitochondrial Dysfunction Accelerates Atherogenesis.
Atherosclerosis
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
Atherosclerosis
E3 Ligase FBXW2 Is a New Therapeutic Target in Obesity and Atherosclerosis.
Atherosclerosis
HRD1 prevents atherosclerosis-mediated endothelial cell apoptosis by promoting LOX-1 degradation.
Atherosclerosis
Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease.
Atherosclerosis
ITCH modulates SIRT6 and SREBP2 to influence lipid metabolism and atherosclerosis in ApoE null mice.
Atherosclerosis
Loss of Cellular Inhibitor of Apoptosis Protein 2 Reduces Atherosclerosis in Atherogenic apoE-/- C57BL/6 Mice on High-Fat Diet.
Atherosclerosis
Nedd4 Deficiency in Vascular Smooth Muscle Promotes Vascular Calcification by Stabilizing pSmad1.
Atherosclerosis
Polymicrobial Oral Infection with Four Periodontal Bacteria Orchestrates a Distinct Inflammatory Response and Atherosclerosis in ApoE null Mice.
Athetosis
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
Athetosis
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
Autoimmune Diseases
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
Autoimmune Diseases
CUL1, a component of E3 ubiquitin ligase, alters lymphocyte signal transduction with possible effect on rheumatoid arthritis.
Autoimmune Diseases
Decreased expression of TRIM21 indicates unfavorable outcome and promotes cell growth in breast cancer.
Autoimmune Diseases
E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
Autoimmune Diseases
Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease.
Autoimmune Diseases
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Autoimmune Diseases
Regulation of autoimmune disease by the E3 ubiquitin ligase Itch.
Autoimmune Diseases
SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production.
Autoimmune Diseases
The E3 ubiquitin ligase Itch deficiency promotes antigen-driven B-cell responses in mice.
Autoimmune Diseases
The E3 ubiquitin ligase Itch restricts antigen-driven B cell responses.
Autoimmune Diseases
The ROQUIN family of proteins localizes to stress granules via the ROQ domain and binds target mRNAs.
Autoimmune Diseases
TRIM21 Is Targeted for Chaperone-Mediated Autophagy during Salmonella Typhimurium Infection.
Autoimmune Diseases
TRIM22: A Diverse and Dynamic Antiviral Protein.
Avian Leukosis
Avian leukosis virus subgroup J and reticuloendotheliosis virus coinfection induced TRIM62 regulation of the actin cytoskeleton.
Avian Leukosis
Regulatory effects of chicken TRIM25 on the replication of ALV-A and the MDA5-mediated type I interferon response.
Bacterial Infections
A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response.
Bacterial Infections
A zebrafish (Danio rerio) bloodthirsty member 20 with E3 ubiquitin ligase activity involved in immune response against bacterial infection.
Bacterial Infections
AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections.
Bacterial Infections
Blocking of Birc3/TLR4/Myd88 signaling protects carbapenem-resistant klebsiella pneumoniae in a mouse model of infection.
Bacterial Infections
M1-linked ubiquitination by LUBEL is required for inflammatory responses to oral infection in Drosophila.
Bacterial Infections
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
Bacterial Infections
The ubiquitin ligase parkin mediates resistance to intracellular pathogens.
Bardet-Biedl Syndrome
Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11).
Basal Cell Nevus Syndrome
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Basal Ganglia Diseases
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism.
Bell Palsy
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations.
beta-Thalassemia
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Biliary Tract Neoplasms
Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Blast Crisis
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
Blast Crisis
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Blast Crisis
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Blast Crisis
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Blister
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Blister
c-Cbl-mediated selective virus-receptor translocations into lipid rafts regulate productive Kaposi's sarcoma-associated herpesvirus infection in endothelial cells.
Blister
Correction: Interaction of c-Cbl with Myosin IIA Regulates Bleb Associated Macropinocytosis of Kaposi's Sarcoma-Associated Herpesvirus.
Blister
ESCRT-I Protein Tsg101 Plays a Role in the Post-macropinocytic Trafficking and Infection of Endothelial Cells by Kaposi's Sarcoma-Associated Herpesvirus.
Blister
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Bloom Syndrome
Association of BLM and BRCA1 during Telomere Maintenance in ALT Cells.
Bloom Syndrome
Bloom syndrome cells undergo p53-dependent apoptosis and delayed assembly of BRCA1 and NBS1 repair complexes at stalled replication forks.
Bloom Syndrome
Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Bloom Syndrome
Coregulation of FANCA and BRCA1 in human cells.
Bloom Syndrome
Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
Bloom Syndrome
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
Bloom Syndrome
System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel SUMO target proteins and acceptor lysines relevant for genome stability.
Bone Diseases
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Bone Marrow Failure Disorders
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Bone Marrow Failure Disorders
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Bone Marrow Failure Disorders
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
Bone Marrow Failure Disorders
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
Bone Marrow Failure Disorders
Fanconi Anemia Complementation Group FANCD2 Protein Serine 331 Phosphorylation Is Important for Fanconi Anemia Pathway Function and BRCA2 Interaction.
Bone Marrow Failure Disorders
PALB2 (partner and localizer of BRCA2).
Bone Neoplasms
[Implication of the ubiquitin ligase c-Cbl in bone formation and tumorigenesis].
Bone Resorption
BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Bone Resorption
c-Cbl and Cbl-b Act redundantly to protect osteoclasts from apoptosis and to displace HDAC6 from {beta}-tubulin, stabilizing microtubules and podosomes.
Bone Resorption
c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption.
Bone Resorption
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.
Bone Resorption
[Biology of osteoclasts; their role in bone metastases]
Bone Resorption
[Cell biology of osteoclasts and molecular mechanisms of bone resorption]
Brain Diseases
Abnormal regulation of TSG101 in mice with spongiform neurodegeneration.
Brain Diseases
Dysfunction of mitochondrial respiratory chain complex I in neurological disorders: genetics and pathogenetic mechanisms.
Brain Diseases
Levels of the Mahogunin Ring Finger 1 E3 ubiquitin ligase do not influence prion disease.
Brain Diseases
LRSAM1 E3 ubiquitin ligase: molecular neurobiological perspectives linked with brain diseases.
Brain Diseases
Oligodendroglial deletion of ESCRT-I component TSG101 causes spongiform encephalopathy.
Brain Diseases
Prion topology and toxicity.
Brain Diseases
TDP-43 upregulation mediated by the NLRP3 inflammasome induces cognitive impairment in 2 2',4,4'-tetrabromodiphenyl ether (BDE-47)-treated mice.
Brain Diseases
TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability.
Brain Injuries
Mitochondrial E3 ubiquitin ligase 1 promotes brain injury by disturbing mitochondrial dynamics in a rat model of ischemic stroke.
Brain Injuries
Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke.
Brain Injuries
RNF34 overexpression exacerbates neurological deficits and brain injury in a mouse model of intracerebral hemorrhage by potentiating mitochondrial dysfunction-mediated oxidative stress.
Brain Injuries
SCY1-like 1 binding protein 1 (SCYL1-bp1) interacts with p53-induced RING H2 protein (Pirh2) after traumatic brain injury in rats.
Brain Injuries
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Brain Injuries, Traumatic
Changes in Pirh2 and p27(kip1) Expression Following Traumatic Brain Injury in Adult Rats.
Brain Injuries, Traumatic
SCY1-like 1 binding protein 1 (SCYL1-bp1) interacts with p53-induced RING H2 protein (Pirh2) after traumatic brain injury in rats.
Brain Ischemia
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Brain Ischemia
PINK1 overexpression protects against cerebral ischemia through Parkin regulation.
Brain Ischemia
Rehmapicroside ameliorates cerebral ischemia-reperfusion injury via attenuating peroxynitrite-mediated mitophagy activation.
Brain Ischemia
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Brain Ischemia
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
Brain Neoplasms
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Brain Neoplasms
BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
Brain Neoplasms
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Brain Neoplasms
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Brain Neoplasms
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Brain Neoplasms
High Expression of Pirh2 is Associated with Poor Prognosis in Glioma.
Brain Neoplasms
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Brain Neoplasms
Increased incidence of brain metastases in BRCA1-related ovarian cancers.
Brain Neoplasms
Loss of heterozygosity of TRIM3 in malignant gliomas.
Brain Neoplasms
Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin.
Brain Neoplasms
Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults.
Brain Neoplasms
No evidence for germline PTEN mutations in families with breast and brain tumours.
Brain Neoplasms
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Brain Neoplasms
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Brain Neoplasms
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
Brain Neoplasms
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
Brain Neoplasms
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.
Breast Carcinoma In Situ
Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
Breast Carcinoma In Situ
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Breast Carcinoma In Situ
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Breast Carcinoma In Situ
Screening and follow-up of the patient at high risk for breast cancer.
Breast Carcinoma In Situ
The role of MRI in breast cancer screening.
Breast Carcinoma In Situ
Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
Breast Diseases
BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China.
Breast Diseases
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer.
Breast Diseases
Current methods to prevent the development of breast cancer.
Breast Diseases
Folate and breast cancer: what about high-risk women?
Breast Diseases
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
Breast Diseases
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]
Breast Neoplasms
"An addendum to breast cancer": the triple negative experience.
Breast Neoplasms
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Breast Neoplasms
"Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
Breast Neoplasms
"Guys Don't Have Breasts": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer.
Breast Neoplasms
"Other" breast cancer susceptibility genes: searching for more holy grail.
Breast Neoplasms
"Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation.
Breast Neoplasms
"The race" to clone BRCA1.
Breast Neoplasms
17 beta Hydroxysteroid dehydrogenase 1 "pseudogene" is differentially transcribed: still a candidate for the breast-ovarian cancer susceptibility gene (BRCA1).
Breast Neoplasms
18. Genetics of breast cancer.
Breast Neoplasms
19p13.1 is a triple negative-specific breast cancer susceptibility locus.
Breast Neoplasms
1H, 13C and 15N backbone resonance assignment of BRCA1 fragment 219-504.
Breast Neoplasms
3,3'-Diindolymethane ameliorates adriamycin-induced cardiac fibrosis via activation of a BRCA1-dependent anti-oxidant pathway.
Breast Neoplasms
53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks.
Breast Neoplasms
655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.
Breast Neoplasms
?-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
Breast Neoplasms
?Np63? induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
Breast Neoplasms
A 12-year experience at a tertiary hospital on patients with multiple primary malignant neoplasms.
Breast Neoplasms
A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
Breast Neoplasms
A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
Breast Neoplasms
A 45-year follow-up of kindred 107 and the search for BRCA2.
Breast Neoplasms
A biochemical analysis demonstrates that the BRCA1 intronic variant IVS10-2A--> C is a mutation.
Breast Neoplasms
A BRCA1 deficient, NF?B driven immune signal predicts good outcome in triple negative breast cancer.
Breast Neoplasms
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Breast Neoplasms
A BRCA1 promoter variant (rs11655505) and breast cancer risk.
Breast Neoplasms
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.
Breast Neoplasms
A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes.
Breast Neoplasms
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes.
Breast Neoplasms
A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2.
Breast Neoplasms
A breast cancer prediction model incorporating familial and personal risk factors.
Breast Neoplasms
A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
Breast Neoplasms
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient.
Breast Neoplasms
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
Breast Neoplasms
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
Breast Neoplasms
A chromatin-based signalling mechanism directs the switch from mutagenic to error-free repair of DNA double strand breaks.
Breast Neoplasms
A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1.
Breast Neoplasms
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
Breast Neoplasms
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations.
Breast Neoplasms
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Breast Neoplasms
A common Greenlandic Inuit BRCA1 RING domain founder mutation.
Breast Neoplasms
A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer.
Breast Neoplasms
A comparison of bilateral breast cancers in BRCA carriers.
Breast Neoplasms
A comparison of breast, testicular and prostate cancer in mass print media (1996-2001).
Breast Neoplasms
A comparison of male attendees and nonattendees at a familial cancer clinic.
Breast Neoplasms
A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.
Breast Neoplasms
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
Breast Neoplasms
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
Breast Neoplasms
A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel.
Breast Neoplasms
A computational approach to the study of interactions between proteins and miR10-b, miR-335, and miR-21 involved in breast cancer.
Breast Neoplasms
A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element.
Breast Neoplasms
A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.
Breast Neoplasms
A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma.
Breast Neoplasms
A deletion map of chromosome 17q in sporadic human mammary carcinomas.
Breast Neoplasms
A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
Breast Neoplasms
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
Breast Neoplasms
A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2.
Breast Neoplasms
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient.
Breast Neoplasms
A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer.
Breast Neoplasms
A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Breast Neoplasms
A Frailty-Model-Based Approach to Estimating the Age-Dependent Penetrance Function of Candidate Genes Using Population-Based Case-Control Study Designs: An Application to Data on the BRCA1 Gene.
Breast Neoplasms
A Frailty-Model-Based Method for Estimating Age-Dependent Penetrance from Family Data.
Breast Neoplasms
A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dIg-A.
Breast Neoplasms
A genome wide linkage search for breast cancer susceptibility genes.
Breast Neoplasms
A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer.
Breast Neoplasms
A Genomewide Screen for Suppressors of Alu-Mediated Rearrangements Reveals a Role for PIF1.
Breast Neoplasms
A germline mosaic BRCA1 exon deletion in a woman with bilateral basal-like breast cancer.
Breast Neoplasms
A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.
Breast Neoplasms
A Germline Mutation in the BRCA1 3UTR Variant Predicts Susceptibility to Breast Cancer in a Saudi Arabian Population
Breast Neoplasms
A guide for functional analysis of BRCA1 variants of uncertain significance.
Breast Neoplasms
A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
Breast Neoplasms
A high frequency of BRCA mutations in young black women with breast cancer residing in Florida.
Breast Neoplasms
A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
Breast Neoplasms
A high frequent BRCA1 founder mutation identified in the Greenlandic population.
Breast Neoplasms
A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Breast Neoplasms
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
Breast Neoplasms
A high proportion of founder BRCA1 mutations in Polish breast cancer families.
Breast Neoplasms
A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene.
Breast Neoplasms
A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants.
Breast Neoplasms
A high-throughput mutation detection method based on heteroduplex analysis using graft copolymer matrixes: application to Brca1 and Brca2 analysis.
Breast Neoplasms
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
Breast Neoplasms
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
Breast Neoplasms
A High-Throughput Screening Strategy for Development of RNF8-Ubc13 Protein-Protein Interaction Inhibitors.
Breast Neoplasms
A label-free genosensor for BRCA1 related sequence based on impedance spectroscopy.
Breast Neoplasms
A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family.
Breast Neoplasms
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.
Breast Neoplasms
A low fouling electrochemical biosensor based on the zwitterionic polypeptide doped conducting polymer PEDOT for breast cancer marker BRCA1 detection.
Breast Neoplasms
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
Breast Neoplasms
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Breast Neoplasms
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
Breast Neoplasms
A microchip platform for structural oncology applications.
Breast Neoplasms
A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
Breast Neoplasms
A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1.
Breast Neoplasms
A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
Breast Neoplasms
A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
Breast Neoplasms
A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population.
Breast Neoplasms
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Breast Neoplasms
A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients.
Breast Neoplasms
A multigene test for the risk of sporadic breast carcinoma.
Breast Neoplasms
A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
Breast Neoplasms
A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.
Breast Neoplasms
A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency.
Breast Neoplasms
A Nano-Biosensor for the Detection of 185delAG Mutation in BRCA1 Gene, Leading to Breast Cancer.
Breast Neoplasms
A network-based approach to identify disease-associated gene modules through integrating DNA methylation and gene expression.
Breast Neoplasms
A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity.
Breast Neoplasms
A new bioinformatics tool to help assess the significance of BRCA1 variants.
Breast Neoplasms
A new BRCA1 germline mutation (E879X) in a Malaysian breast cancer patient of Chinese descent.
Breast Neoplasms
A new BRCA1 mutation in a Filipino woman with a family history of breast and ovarian cancer.
Breast Neoplasms
A new case of "de novo" BRCA1 mutation in a patient with early-onset breast cancer.
Breast Neoplasms
A new class of coumate benzimidazole hybrids as BRCA-1 mimetics through unconventional binding mode; Synthesis and preliminary cytotoxicity screening.
Breast Neoplasms
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.
Breast Neoplasms
A new look at molecular biology of breast cancer.
Breast Neoplasms
A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
Breast Neoplasms
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers.
Breast Neoplasms
A novel BRCA1 gene deletion detection in human breast carcinoma MCF-7 cells through FRET between quantum dots and silver nanoclusters.
Breast Neoplasms
A Novel BRCA1 Gene Mutation Detected With Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A Case Report.
Breast Neoplasms
A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
Breast Neoplasms
A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.
Breast Neoplasms
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer.
Breast Neoplasms
A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing.
Breast Neoplasms
A novel BRCA2 splice variant identified in a young woman.
Breast Neoplasms
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
Breast Neoplasms
A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
Breast Neoplasms
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.
Breast Neoplasms
A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.
Breast Neoplasms
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
Breast Neoplasms
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region.
Breast Neoplasms
A novel domain of BRCA1 interacts with p53 in breast cancer cells.
Breast Neoplasms
A novel frequent BRCA1 allele in Chinese patients with breast cancer.
Breast Neoplasms
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.
Breast Neoplasms
A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells.
Breast Neoplasms
A novel method to detect the Mexican founder mutation BRCA1 ex9?12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.
Breast Neoplasms
A Novel Model to Characterize Structure and Function of BRCA1.
Breast Neoplasms
A novel mutation in the BRCA1 gene in a German early-onset breast cancer family.
Breast Neoplasms
A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer
Breast Neoplasms
A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.
Breast Neoplasms
A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer.
Breast Neoplasms
A novel role for BRCA1 in regulating breast cancer cell spreading and motility.
Breast Neoplasms
A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis.
Breast Neoplasms
A Novel Splice Site Mutation in the Noncoding Region of BRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics.
Breast Neoplasms
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
Breast Neoplasms
A novel ubiquitin ligase is deficient in Fanconi anemia.
Breast Neoplasms
A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1.
Breast Neoplasms
A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype.
Breast Neoplasms
A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors.
Breast Neoplasms
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Breast Neoplasms
A Phylogenetic Approach to Analyze the Conservativeness of BRCA1 and BRCA2 Mutations.
Breast Neoplasms
A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21.
Breast Neoplasms
A Physical Mechanism and Global Quantification of Breast Cancer.
Breast Neoplasms
A pilot genome-wide association study of early-onset breast cancer.
Breast Neoplasms
A Pilot Study on Screening of BRCA1 Mutations (185delAG, 1294del40) in Nepalese Breast Cancer Patients.
Breast Neoplasms
A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro.
Breast Neoplasms
A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.
Breast Neoplasms
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
Breast Neoplasms
A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study.
Breast Neoplasms
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Breast Neoplasms
A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations.
Breast Neoplasms
A Population-Based Study of Genes Previously Implicated in Breast Cancer.
Breast Neoplasms
A porcine model system of BRCA1 driven breast cancer.
Breast Neoplasms
A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.
Breast Neoplasms
A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer.
Breast Neoplasms
A pre-emptive strike against breast cancer. Jessica Queller describes how she faced the BRCA1 gene.
Breast Neoplasms
A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
Breast Neoplasms
A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.
Breast Neoplasms
A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers.
Breast Neoplasms
A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer.
Breast Neoplasms
A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients.
Breast Neoplasms
A protective role for BRCA2 at stalled replication forks.
Breast Neoplasms
A protein truncating BRCA1 allele with a low penetrance of breast cancer.
Breast Neoplasms
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
Breast Neoplasms
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Breast Neoplasms
A radiation hybrid map of the BRCA1 region.
Breast Neoplasms
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Breast Neoplasms
A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.
Breast Neoplasms
A recurrent mutation in PALB2 in Finnish cancer families.
Breast Neoplasms
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
Breast Neoplasms
A region close to Tp53 shows LOH in familial breast cancer.
Breast Neoplasms
A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing.
Breast Neoplasms
A review of hereditary breast cancer: from screening to risk factor modification.
Breast Neoplasms
A role for BRCA1 in sporadic breast cancer.
Breast Neoplasms
A role for paralog-specific sumoylation in histone deacetylase 1 stability.
Breast Neoplasms
A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.
Breast Neoplasms
A Role of CREB in BRCA1 Constitutive Promoter Activity and Aromatase Basal Expression.
Breast Neoplasms
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation.
Breast Neoplasms
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
Breast Neoplasms
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.
Breast Neoplasms
A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens.
Breast Neoplasms
A simple tool for identifying unaffected women at a moderately increased or potentially high risk of breast cancer based on their family history.
Breast Neoplasms
A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining.
Breast Neoplasms
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
Breast Neoplasms
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
Breast Neoplasms
A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain.
Breast Neoplasms
A somatic mutation in the 5'UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency.
Breast Neoplasms
A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
Breast Neoplasms
A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1.
Breast Neoplasms
A strategy to apply quantitative epistasis analysis on developmental traits.
Breast Neoplasms
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Breast Neoplasms
A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer.
Breast Neoplasms
A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins.
Breast Neoplasms
A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
Breast Neoplasms
A survey of preventive measures among BRCA1 mutation carriers from Poland.
Breast Neoplasms
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Breast Neoplasms
A TGF?-miR-182-BRCA1 axis controls the mammary differentiation hierarchy.
Breast Neoplasms
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
Breast Neoplasms
A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
Breast Neoplasms
A young woman with bilateral breast cancer: identifying a genetic cause and implications for management.
Breast Neoplasms
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.
Breast Neoplasms
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
Breast Neoplasms
Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
Breast Neoplasms
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Breast Neoplasms
Aberrant promoter methylation of cancer-related genes in human breast cancer.
Breast Neoplasms
Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.
Breast Neoplasms
Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
Breast Neoplasms
Aberrant subcellular localization of BRCA1 in breast cancer.
Breast Neoplasms
Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization.
Breast Neoplasms
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Breast Neoplasms
Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
Breast Neoplasms
Abnormal Mammary Adipose Tissue Environment of Brca1 Mutant Mice Show a Persistent Deposition of Highly Vascularized Multilocular Adipocytes.
Breast Neoplasms
Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.
Breast Neoplasms
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
Breast Neoplasms
Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer.
Breast Neoplasms
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Breast Neoplasms
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification.
Breast Neoplasms
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.
Breast Neoplasms
Absence of commonly recurring BRCA1 mutations in black South African women with breast cancer.
Breast Neoplasms
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22.
Breast Neoplasms
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
Breast Neoplasms
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Breast Neoplasms
Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families.
Breast Neoplasms
Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
Breast Neoplasms
Accuracy of the BRCAPRO model among women with bilateral breast cancer.
Breast Neoplasms
Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage.
Breast Neoplasms
Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.
Breast Neoplasms
Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase.
Breast Neoplasms
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
Breast Neoplasms
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Breast Neoplasms
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Breast Neoplasms
Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study.
Breast Neoplasms
Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.
Breast Neoplasms
Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1.
Breast Neoplasms
Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications.
Breast Neoplasms
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Breast Neoplasms
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Breast Neoplasms
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Breast Neoplasms
Advances in breast cancer: pathways to personalized medicine.
Breast Neoplasms
Advocate's Viewpoint on Hereditary Breast/Ovarian Cancer.
Breast Neoplasms
AeQTL: eQTL analysis using region-based aggregation of rare genomic variants.
Breast Neoplasms
After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.
Breast Neoplasms
Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer.
Breast Neoplasms
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.
Breast Neoplasms
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
Breast Neoplasms
Age-dependent penetrance of different germline mutations in the BRCA1 gene.
Breast Neoplasms
Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway.
Breast Neoplasms
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
Breast Neoplasms
AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.
Breast Neoplasms
AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.
Breast Neoplasms
Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
Breast Neoplasms
Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium.
Breast Neoplasms
Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines.
Breast Neoplasms
All Paths Lead to TRIM25.
Breast Neoplasms
Allele age and a test for selection on rare alleles.
Breast Neoplasms
Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues.
Breast Neoplasms
Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
Breast Neoplasms
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.
Breast Neoplasms
Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer.
Breast Neoplasms
Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Breast Neoplasms
Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma.
Breast Neoplasms
Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset).
Breast Neoplasms
Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
Breast Neoplasms
Allelic variants of breast cancer susceptibility genes PALB2 and RECQL in the Latvian population.
Breast Neoplasms
Alteration of BRCA1 expression affects alcohol-induced transcription of RNA Pol III-dependent genes.
Breast Neoplasms
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Breast Neoplasms
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Breast Neoplasms
Alterations in replication timing of cancer-related genes in malignant human breast cancer cells.
Breast Neoplasms
Altered DNA Binding and Amplification of Human Breast Cancer Suppressor Gene BRCA1 Induced by a Novel Antitumor Compound, [Ru(η6-p-phenylethacrynate)Cl2(pta)].
Breast Neoplasms
Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.
Breast Neoplasms
Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts.
Breast Neoplasms
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Breast Neoplasms
Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Breast Neoplasms
Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.
Breast Neoplasms
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.
Breast Neoplasms
Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants.
Breast Neoplasms
Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a case study.
Breast Neoplasms
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
Breast Neoplasms
Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer.
Breast Neoplasms
AMIGOS: a method for the inspection of genomic organisation or structure and its application to characterise conserved gene arrangements.
Breast Neoplasms
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
Breast Neoplasms
Amplified label-free electrical detection of DNA hybridization.
Breast Neoplasms
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Breast Neoplasms
An analysis of age and family history on outcome after breast-conservation treatment: the University of Pennsylvania experience.
Breast Neoplasms
An efficient DNA-fueled molecular machine for the discrimination of single-base changes.
Breast Neoplasms
An epidemiology and molecular genetic study on breast cancer susceptibility.
Breast Neoplasms
An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women.
Breast Neoplasms
An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
Breast Neoplasms
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
Breast Neoplasms
An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification.
Breast Neoplasms
An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers.
Breast Neoplasms
An in vivo study of Cdh1/APC in breast cancer formation.
Breast Neoplasms
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.
Breast Neoplasms
An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).
Breast Neoplasms
An investigation into 53BP1 complex formation.
Breast Neoplasms
An open letter to my daughter.
Breast Neoplasms
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.
Breast Neoplasms
An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Breast Neoplasms
An overview of triple negative breast cancer for surgical oncologists.
Breast Neoplasms
An ultrasensitive electrochemical impedance sensor for a special BRCA1 breast cancer gene sequence based on lambda exonuclease assisted target recycling amplification.
Breast Neoplasms
An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Breast Neoplasms
An updated review of epidemiology, risk factors, and management of male breast cancer.
Breast Neoplasms
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Breast Neoplasms
Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer.
Breast Neoplasms
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Breast Neoplasms
Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula.
Breast Neoplasms
Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history.
Breast Neoplasms
Analysis of BRCA1 and BRCA2 mutations in southern Iranian Breast cancer patients.
Breast Neoplasms
Analysis of BRCA1 and mtDNA haplotypes and mtDNA polymorphism in familial breast cancer.
Breast Neoplasms
Analysis of BRCA1 Gene Rearrangements in Breast Carcinomas by RT-PCR and ER, PR, HER2NEU Status by IHC and HPE Correlation.
Breast Neoplasms
Analysis of BRCA1 involvement in breast cancer in Indian women.
Breast Neoplasms
Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.
Breast Neoplasms
Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.
Breast Neoplasms
Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit.
Breast Neoplasms
Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Breast Neoplasms
Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
Breast Neoplasms
Analysis of BRCA1and BRCA2 large genomic rearrangements in Sri Lankan familial breast cancer patients and at risk individuals.
Breast Neoplasms
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Breast Neoplasms
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
Breast Neoplasms
Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
Breast Neoplasms
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Breast Neoplasms
Analysis of DNA Repair-Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response.
Breast Neoplasms
Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.
Breast Neoplasms
Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique.
Breast Neoplasms
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy.
Breast Neoplasms
Analysis of KLLN as a high-penetrance breast cancer predisposition gene.
Breast Neoplasms
Analysis of loss of heterozygosity and immunohistochemistry in BRCA1 gene in sporadic breast cancers.
Breast Neoplasms
Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer.
Breast Neoplasms
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Breast Neoplasms
Analysis of novel mutations in BRCA1 in Iranian families with breast cancer.
Breast Neoplasms
Analysis of PALB2/FANCN-associated breast cancer families.
Breast Neoplasms
Analysis of PTEN in two BRCA1 and BRCA2 wild-type familial breast cancer patients.
Breast Neoplasms
Analysis of RAD51 polymorphism and BRCA1 mutations in Polish women with breast cancer.
Breast Neoplasms
Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases.
Breast Neoplasms
Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.
Breast Neoplasms
Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas.
Breast Neoplasms
Analysis of the DNA binding activity of BRCA1 and its modulation by the tumour suppressor p53.
Breast Neoplasms
Analysis of the G/C polymorphism in the 5'-untranslated region of the RAD51 gene in breast cancer.
Breast Neoplasms
Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Breast Neoplasms
Androgen pathway dysregulation in BRCA1-mutated breast tumors.
Breast Neoplasms
Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
Breast Neoplasms
Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
Breast Neoplasms
Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines.
Breast Neoplasms
Androgens and estrogens in the etiology and prevention of breast cancer.
Breast Neoplasms
ANKLE1 N6 -Methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability.
Breast Neoplasms
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Breast Neoplasms
Antibody-drug conjugates in triple negative breast cancer.
Breast Neoplasms
Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib.
Breast Neoplasms
Anticipation in hereditary breast cancer.
Breast Neoplasms
Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
Breast Neoplasms
Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.
Breast Neoplasms
APOE and Alzheimer disease: a major gene with semi-dominant inheritance.
Breast Neoplasms
Application of a miniature biochip using the molecular beacon probe in breast cancer gene BRCA1 detection.
Breast Neoplasms
Application of breast cancer risk prediction models in clinical practice.
Breast Neoplasms
Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histologic specimens.
Breast Neoplasms
Applications for breast magnetic resonance imaging.
Breast Neoplasms
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Breast Neoplasms
Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?
Breast Neoplasms
Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer.
Breast Neoplasms
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Breast Neoplasms
Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
Breast Neoplasms
Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer.
Breast Neoplasms
Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
Breast Neoplasms
Are VNTRs co-localizing with breast cancer-associated SNPs?
Breast Neoplasms
Aromatase, CYP1B1 and Fatty Acid Synthase Expression in Breast Tumors of BRCA1 Mutation Carriers.
Breast Neoplasms
Array-based mutation detection of BRCA1 using direct probe/target hybridization.
Breast Neoplasms
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Breast Neoplasms
Arsenic?induced BRCA1 CpG promoter methylation is associated with the downregulation of ER? and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
Breast Neoplasms
Artificial neural network-based exploration of gene-nutrient interactions in folate and xenobiotic metabolic pathways that modulate susceptibility to breast cancer.
Breast Neoplasms
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Breast Neoplasms
Assays for Hypermethylation of the BRCA1 Gene Promoter in Tumor Cells to Predict Sensitivity to PARP-Inhibitor Therapy.
Breast Neoplasms
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.
Breast Neoplasms
Assessing breast cancer risk and BRCA1/2 carrier probability.
Breast Neoplasms
Assessing Risk of Breast Cancer: A Review of Risk Prediction Models.
Breast Neoplasms
Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
Breast Neoplasms
Assessing the Knowledge and Attitudes Regarding Genetic Testing for Breast Cancer Risk in our Region of Southeastern Georgia.
Breast Neoplasms
Assessing the link between BACH1 and BRCA1 in the FA pathway.
Breast Neoplasms
Assessing the link between BACH1/FANCJ and MLH1 in DNA crosslink repair.
Breast Neoplasms
Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.
Breast Neoplasms
Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models.
Breast Neoplasms
Assessment and counseling for women with a family history of breast cancer. A guide for clinicians.
Breast Neoplasms
Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
Breast Neoplasms
Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.
Breast Neoplasms
Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer.
Breast Neoplasms
Association analysis identifies 65 new breast cancer risk loci.
Breast Neoplasms
Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk.
Breast Neoplasms
Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.
Breast Neoplasms
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis.
Breast Neoplasms
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Breast Neoplasms
Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
Breast Neoplasms
Association between BRCA1 polymorphisms rs799917 and rs1799966 and breast cancer risk: a meta-analysis.
Breast Neoplasms
Association between BRCA1 rs799917 polymorphism and breast cancer risk: A meta-analysis of 19,878 subjects.
Breast Neoplasms
Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis.
Breast Neoplasms
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Breast Neoplasms
Association between early-onset breast and laryngeal cancers.
Breast Neoplasms
Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Breast Neoplasms
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Breast Neoplasms
Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects.
Breast Neoplasms
Association between RAD51 polymorphism and breast cancer susceptibility: a meta analysis.
Breast Neoplasms
Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
Breast Neoplasms
Association between the c.*229C>T polymorphism of the topoisomerase II? binding protein 1 (TopBP1) gene and breast cancer.
Breast Neoplasms
Association of 8q24 rs13281615A > G polymorphism with breast cancer risk: evidence from 40,762 cases and 50,380 controls.
Breast Neoplasms
Association of a LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 35,671 controls.
Breast Neoplasms
Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Breast Neoplasms
Association of BRCA1 185 del AG with early age onset of breast cancer patients in selected cohort from Pakistani population.
Breast Neoplasms
Association of BRCA1 K1183R polymorphism with survival in BRCA1/2-negative chinese familial breast cancer.
Breast Neoplasms
Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis
Breast Neoplasms
Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer.
Breast Neoplasms
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Breast Neoplasms
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.
Breast Neoplasms
Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population.
Breast Neoplasms
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Breast Neoplasms
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Breast Neoplasms
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Breast Neoplasms
Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.
Breast Neoplasms
Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Breast Neoplasms
Association of DEAR1 Tagging Single Nucleotide Polymorphisms With Breast Cancer in a Sample of Colombian Population: A Case Control Study.
Breast Neoplasms
Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers.
Breast Neoplasms
Association of E-selectin S128R Polymorphism with Hereditary Breast Carcinoma Susceptibility in Turkish Patients Without BRCA1/2 Germline Mutations.
Breast Neoplasms
Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.
Breast Neoplasms
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.
Breast Neoplasms
Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer.
Breast Neoplasms
Association of loss of BRCA1 expression with centrosome aberration in human breast cancer.
Breast Neoplasms
Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk.
Breast Neoplasms
Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.
Breast Neoplasms
Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Breast Neoplasms
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Breast Neoplasms
Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast.
Breast Neoplasms
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer.
Breast Neoplasms
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Breast Neoplasms
Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort.
Breast Neoplasms
Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.
Breast Neoplasms
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Breast Neoplasms
Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer.
Breast Neoplasms
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors.
Breast Neoplasms
ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences?
Breast Neoplasms
ATM and genome maintenance: defining its role in breast cancer susceptibility.
Breast Neoplasms
ATM controls proper mitotic spindle structure.
Breast Neoplasms
Attitudes about genetic testing and genetic testing intentions in African American women at increased risk for hereditary breast cancer.
Breast Neoplasms
Attitudes and psychological impact of genetic testing, genetic counseling, and breast cancer risk assessment among women at increased risk.
Breast Neoplasms
Attitudes of obstetrician-gynecologists toward DNA testing for a genetic susceptibility to breast cancer.
Breast Neoplasms
Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Breast Neoplasms
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
Breast Neoplasms
Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation.
Breast Neoplasms
Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Breast Neoplasms
Autoantibodies to tumor-associated antigens in breast carcinoma.
Breast Neoplasms
Automated detection of prevalent mutations in BRCA1 and BRCA2 genes, using a fluorogenic PCR allelic discrimination assay.
Breast Neoplasms
Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration.
Breast Neoplasms
Autoubiquitination of feline E3 ubiquitin ligase BCA2.
Breast Neoplasms
Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.
Breast Neoplasms
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Breast Neoplasms
Awareness and attitudes concerning BRCA gene testing.
Breast Neoplasms
BACH1 is a DNA repair protein supporting BRCA1 damage response.
Breast Neoplasms
BACH1 Ser919Pro variant and breast cancer risk.
Breast Neoplasms
BAP1 and breast cancer risk.
Breast Neoplasms
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Breast Neoplasms
Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families.
Breast Neoplasms
BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
Breast Neoplasms
BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export.
Breast Neoplasms
BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
Breast Neoplasms
BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.
Breast Neoplasms
BARD1, a possible biomarker for breast and ovarian cancer.
Breast Neoplasms
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Breast Neoplasms
Basal Phenotype in Breast Carcinoma Occurring in Women Aged 35 or Younger.
Breast Neoplasms
Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer.
Breast Neoplasms
Basal-like breast cancer and the BRCA1 phenotype.
Breast Neoplasms
Basal-like breast cancer: a critical review.
Breast Neoplasms
Base pair mismatch recognition using plasmon resonant particle labels.
Breast Neoplasms
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Breast Neoplasms
Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.
Breast Neoplasms
BCoR-L1 variation and breast cancer.
Breast Neoplasms
Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.
Breast Neoplasms
Beneficial Molecular Adaptations In BRCA-Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study.
Breast Neoplasms
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Breast Neoplasms
Beyond BRCA1 and BRCA2.
Breast Neoplasms
Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.
Breast Neoplasms
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Breast Neoplasms
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype.
Breast Neoplasms
Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Breast Neoplasms
Bilateral breast cancers.
Breast Neoplasms
Bilateral breast reconstruction and the role of prophylactic mastectomy.
Breast Neoplasms
Bilateral Breast Reconstruction and the Role of Prophylactic Mastectomy.
Breast Neoplasms
Bilateral nipple-sparing mastectomy and breast reconstruction in BRCA1 mutation-positive simultaneous bilateral breast cancer: A case study.
Breast Neoplasms
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Breast Neoplasms
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Breast Neoplasms
Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
Breast Neoplasms
Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
Breast Neoplasms
Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence.
Breast Neoplasms
Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply.
Breast Neoplasms
Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed.
Breast Neoplasms
Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells.
Breast Neoplasms
Biobibliometrics (UGDH-TP53-BRCA1) Genes Connections in the Possible Relationship Between Breast Cancer and EEG.
Breast Neoplasms
Biochemical markers in breast cancer: which ones are clinically useful?
Breast Neoplasms
Bioinformatics Approaches to Explore the Phylogeny and Role of BRCA1 in Breast Cancer.
Breast Neoplasms
Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.
Breast Neoplasms
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Breast Neoplasms
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Breast Neoplasms
Bispecific Estrogen Receptor ? Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening.
Breast Neoplasms
Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation.
Breast Neoplasms
Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers.
Breast Neoplasms
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
Breast Neoplasms
BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer.
Breast Neoplasms
BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth.
Breast Neoplasms
BRCA 1 & 2 mutations in Sudanese secondary school girls with known breast cancer in their families.
Breast Neoplasms
BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer.
Breast Neoplasms
BRCA and Breast Cancer-Related High-Penetrance Genes.
Breast Neoplasms
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Breast Neoplasms
BRCA genes: lessons learned from experimental and clinical cancer.
Breast Neoplasms
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Breast Neoplasms
BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
Breast Neoplasms
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Breast Neoplasms
BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history.
Breast Neoplasms
BRCA mutation screening and patterns among high-risk Lebanese subjects.
Breast Neoplasms
BRCA mutation testing in determining breast cancer therapy.
Breast Neoplasms
BRCA Mutations and Breast Cancer Prevention.
Breast Neoplasms
BRCA mutations: is everything said?
Breast Neoplasms
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Breast Neoplasms
BRCA proteins and DNA damage checkpoints.
Breast Neoplasms
BRCA sequencing and large rearrangement testing in young Black women with breast cancer.
Breast Neoplasms
BRCA Testing by Single-Molecule Molecular Inversion Probes.
Breast Neoplasms
BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Breast Neoplasms
BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
Breast Neoplasms
BRCA1 - Conductor of the Breast Stem Cell Orchestra: The Role of BRCA1 in Mammary Gland Development and Identification of Cell of Origin of BRCA1 Mutant Breast Cancer.
Breast Neoplasms
BRCA1 2080insA mutation in familial breast cancer.
Breast Neoplasms
BRCA1 4153delA founder mutation in Russian ovarian cancer patients.
Breast Neoplasms
BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo.
Breast Neoplasms
BRCA1 accumulates in the nucleus in response to hypoxia and TRAIL and enhances TRAIL-induced apoptosis in breast cancer cells.
Breast Neoplasms
BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
Breast Neoplasms
BRCA1 activation of the GADD45 promoter.
Breast Neoplasms
BRCA1 affects global DNA methylation through regulation of DNMT1.
Breast Neoplasms
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Breast Neoplasms
BRCA1 Alternative splicing landscape in breast tissue samples.
Breast Neoplasms
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Breast Neoplasms
BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
Breast Neoplasms
BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing.
Breast Neoplasms
BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
Breast Neoplasms
BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding.
Breast Neoplasms
BRCA1 and BRCA2 and breast cancer incidence: a review.
Breast Neoplasms
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells.
Breast Neoplasms
BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
Breast Neoplasms
BRCA1 and BRCA2 bind Stat5a and suppress its transcriptional activity.
Breast Neoplasms
BRCA1 and BRCA2 Common Mutations in Iranian Breast Cancer Patients: a Meta Analysis.
Breast Neoplasms
Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice.
Breast Neoplasms
BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work
Breast Neoplasms
BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
Breast Neoplasms
BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives.
Breast Neoplasms
BRCA1 and BRCA2 Gene Mutations Screening In Sporadic Breast Cancer Patients In Kazakhstan.
Breast Neoplasms
BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan.
Breast Neoplasms
BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
Breast Neoplasms
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Breast Neoplasms
BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
Breast Neoplasms
BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
Breast Neoplasms
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population.
Breast Neoplasms
BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM).
Breast Neoplasms
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
Breast Neoplasms
BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients.
Breast Neoplasms
BRCA1 and BRCA2 Germline Mutations in Japanese with Hereditary Breast Cancer Families.
Breast Neoplasms
BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
Breast Neoplasms
BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 germline mutations in lymphoma patients.
Breast Neoplasms
BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.
Breast Neoplasms
BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling.
Breast Neoplasms
BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
Breast Neoplasms
BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
Breast Neoplasms
BRCA1 and BRCA2 have a limited role in familial prostate cancer.
Breast Neoplasms
BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage.
Breast Neoplasms
BRCA1 and BRCA2 heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity.
Breast Neoplasms
BRCA1 and BRCA2 in 2005.
Breast Neoplasms
BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
Breast Neoplasms
BRCA1 and BRCA2 in breast cancer predisposition and recombination control.
Breast Neoplasms
BRCA1 and BRCA2 in breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 in hereditary breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 in Indian breast cancer patients.
Breast Neoplasms
BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
Breast Neoplasms
BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen.
Breast Neoplasms
BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients.
Breast Neoplasms
BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.
Breast Neoplasms
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.
Breast Neoplasms
BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
Breast Neoplasms
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
Breast Neoplasms
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Breast Neoplasms
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
Breast Neoplasms
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Breast Neoplasms
BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines.
Breast Neoplasms
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
Breast Neoplasms
BRCA1 and BRCA2 mutations and breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Breast Neoplasms
BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.
Breast Neoplasms
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
Breast Neoplasms
BRCA1 and BRCA2 mutations in a study of African American breast cancer patients.
Breast Neoplasms
BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Syndrome: Reflection on the Creighton University Historical Series of High Risk Families.
Breast Neoplasms
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
Breast Neoplasms
BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia.
Breast Neoplasms
BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela.
Breast Neoplasms
BRCA1 and BRCA2 mutations in central and southern Italian patients.
Breast Neoplasms
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review.
Breast Neoplasms
BRCA1 and BRCA2 mutations in Russian familial breast cancer.
Breast Neoplasms
BRCA1 and BRCA2 mutations in Scotland and Northern Ireland.
Breast Neoplasms
BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
Breast Neoplasms
BRCA1 and BRCA2 mutations in women from Shanghai China.
Breast Neoplasms
BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite.
Breast Neoplasms
BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.
Breast Neoplasms
BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors.
Breast Neoplasms
BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.
Breast Neoplasms
BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients.
Breast Neoplasms
BRCA1 and BRCA2--breast cancer susceptibility genes.
Breast Neoplasms
BRCA1 and BRCA2: 1994 and beyond.
Breast Neoplasms
BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.
Breast Neoplasms
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double strand break repair.
Breast Neoplasms
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.
Breast Neoplasms
BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Breast Neoplasms
BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
Breast Neoplasms
BRCA1 and cell signaling.
Breast Neoplasms
Brca1 and differentiation.
Breast Neoplasms
BRCA1 and estrogen signaling in breast cancer.
Breast Neoplasms
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
Breast Neoplasms
BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1).
Breast Neoplasms
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
Breast Neoplasms
BRCA1 and Its Network of Interacting Partners.
Breast Neoplasms
BRCA1 and medullary breast cancer.
Breast Neoplasms
BRCA1 and p53: compensatory roles in DNA repair.
Breast Neoplasms
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships.
Breast Neoplasms
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Breast Neoplasms
BRCA1 and prostate cancer.
Breast Neoplasms
BRCA1 and TP53 Gene-Mutations: Family Predisposition and Radioecological Risk of Developing Breast Cancer.
Breast Neoplasms
BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Breast Neoplasms
BRCA1 and VDR gene polymorphisms are associated with prostate cancer risk in Mexican men.
Breast Neoplasms
BRCA1 as target for breast cancer prevention and therapy.
Breast Neoplasms
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.
Breast Neoplasms
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
Breast Neoplasms
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
Breast Neoplasms
BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews.
Breast Neoplasms
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Breast Neoplasms
BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
Breast Neoplasms
BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), c.798_799delTT and 943ins10 (exon11) mutations in Burkina Faso.
Breast Neoplasms
BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters.
Breast Neoplasms
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
Breast Neoplasms
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
Breast Neoplasms
BRCA1 degradation in response to mitochondrial damage in breast cancer cells.
Breast Neoplasms
BRCA1 down-regulates cellular levels of reactive oxygen species.
Breast Neoplasms
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
Breast Neoplasms
BRCA1 dysfunction in sporadic basal-like breast cancer.
Breast Neoplasms
BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer.
Breast Neoplasms
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
Breast Neoplasms
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Breast Neoplasms
BRCA1 establishes DNA damage signaling and pericentric heterochromatin of the X chromosome in male meiosis.
Breast Neoplasms
BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.
Breast Neoplasms
BRCA1 expression and molecular alterations in familial breast cancer.
Breast Neoplasms
BRCA1 expression during prenatal development of the human mammary gland.
Breast Neoplasms
BRCA1 expression in benign and malignant breast lesions.
Breast Neoplasms
BRCA1 expression in invasive breast carcinomas and clinicopathological correlations.
Breast Neoplasms
BRCA1 expression is not directly responsive to estrogen.
Breast Neoplasms
Brca1 expression is regulated by a bidirectional promoter that is shared by the Nbr1 gene in mouse.
Breast Neoplasms
BRCA1 expression levels predict distant metastasis of sporadic breast cancers.
Breast Neoplasms
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
Breast Neoplasms
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
Breast Neoplasms
BRCA1 founder mutations compared to ovarian cancer in Belarus.
Breast Neoplasms
BRCA1 functions as a breast stem cell regulator.
Breast Neoplasms
BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China.
Breast Neoplasms
BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters.
Breast Neoplasms
BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry.
Breast Neoplasms
BRCA1 gene in breast cancer.
Breast Neoplasms
BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients.
Breast Neoplasms
BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
Breast Neoplasms
BRCA1 Gene Mutations and Influence of Chemotherapy on Autophagy and Apoptotic Mechanisms in Egyptian Breast Cancer Patients.
Breast Neoplasms
BRCA1 Gene Mutations in Breast Cancer Patients from Kerman Province, Iran.
Breast Neoplasms
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
Breast Neoplasms
BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Breast Neoplasms
BRCA1 gene sequence variation in centenarians.
Breast Neoplasms
BRCA1 gene testing for breast and ovarian cancer in one family.
Breast Neoplasms
BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review.
Breast Neoplasms
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.
Breast Neoplasms
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients.
Breast Neoplasms
BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer.
Breast Neoplasms
BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer.
Breast Neoplasms
BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.
Breast Neoplasms
BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer.
Breast Neoplasms
BRCA1 germline mutations in Cypriot breast cancer patients from 26 families with family history.
Breast Neoplasms
BRCA1 germline mutations in Indian familial breast cancer.
Breast Neoplasms
BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination.
Breast Neoplasms
BRCA1 haploinsufficiency: consequences for breast cancer.
Breast Neoplasms
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
Breast Neoplasms
BRCA1 in cancer, cell cycle and genomic stability.
Breast Neoplasms
BRCA1 in clinical breast cancer.
Breast Neoplasms
BRCA1 in hormonal carcinogenesis: basic and clinical research.
Breast Neoplasms
BRCA1 in hormone-responsive cancers.
Breast Neoplasms
Brca1 in immunoglobulin gene conversion and somatic hypermutation.
Breast Neoplasms
BRCA1 in non-inherited breast carcinomas (Review).
Breast Neoplasms
BRCA1 in special populations.
Breast Neoplasms
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.
Breast Neoplasms
BRCA1 induces major energetic metabolism reprogramming in breast cancer cells.
Breast Neoplasms
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
Breast Neoplasms
BRCA1 inhibition of telomerase activity in cultured cells.
Breast Neoplasms
BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1.
Breast Neoplasms
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer.
Breast Neoplasms
BRCA1 interaction of centrosomal protein Nlp is required for successful mitotic progression.
Breast Neoplasms
BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
Breast Neoplasms
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
Breast Neoplasms
BRCA1 interacts with Smad3 and regulates Smad3-mediated TGF-beta signaling during oxidative stress responses.
Breast Neoplasms
BRCA1 is a cell cycle-regulated nuclear phosphoprotein.
Breast Neoplasms
BRCA1 is a negative modulator of the PRC2 complex.
Breast Neoplasms
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.
Breast Neoplasms
BRCA1 is differentially expressed in human tumor cells.
Breast Neoplasms
Brca1 is required for embryonic development of the mouse cerebral cortex to normal size by preventing apoptosis of early neural progenitors.
Breast Neoplasms
BRCA1 IVS16+6T-->C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site.
Breast Neoplasms
BRCA1 knock-down causes telomere dysfunction in mammary epithelial cells.
Breast Neoplasms
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
Breast Neoplasms
BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis.
Breast Neoplasms
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
Breast Neoplasms
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
Breast Neoplasms
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Breast Neoplasms
BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
Breast Neoplasms
BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells.
Breast Neoplasms
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Breast Neoplasms
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
Breast Neoplasms
BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.
Breast Neoplasms
BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
Breast Neoplasms
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Breast Neoplasms
BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
Breast Neoplasms
BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival.
Breast Neoplasms
BRCA1 mutation influences progesterone response in human benign mammary organoids.
Breast Neoplasms
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
Breast Neoplasms
BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far.
Breast Neoplasms
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
Breast Neoplasms
BRCA1 mutation update and analysis.
Breast Neoplasms
BRCA1 mutation, leptin and estrogen levels in breast cancer patients.
Breast Neoplasms
BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.
Breast Neoplasms
BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer.
Breast Neoplasms
BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer.
Breast Neoplasms
BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.
Breast Neoplasms
BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
Breast Neoplasms
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
Breast Neoplasms
BRCA1 mutations found in archived early onset breast tumours.
Breast Neoplasms
BRCA1 mutations in a population-based sample of young women with breast cancer.
Breast Neoplasms
BRCA1 mutations in a population-based study of breast cancer in Stockholm County.
Breast Neoplasms
BRCA1 mutations in a selected series of breast/ovarian cancer patients.
Breast Neoplasms
BRCA1 mutations in African Americans.
Breast Neoplasms
BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.
Breast Neoplasms
BRCA1 mutations in familial ovarian cancer.
Breast Neoplasms
BRCA1 mutations in patients with familial risk of breast cancer.
Breast Neoplasms
BRCA1 mutations in primary breast and ovarian carcinomas.
Breast Neoplasms
BRCA1 mutations in southern England.
Breast Neoplasms
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
Breast Neoplasms
BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
Breast Neoplasms
BRCA1 mutations in young women with breast cancer.
Breast Neoplasms
BRCA1 negatively regulates formation of autophagic vacuoles in MCF-7 breast cancer cells.
Breast Neoplasms
BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site.
Breast Neoplasms
BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells.
Breast Neoplasms
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
Breast Neoplasms
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.
Breast Neoplasms
BRCA1 pathway function in basal-like breast cancer cells.
Breast Neoplasms
BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.
Breast Neoplasms
BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis.
Breast Neoplasms
BRCA1 phosphorylation: biological consequences.
Breast Neoplasms
BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression.
Breast Neoplasms
BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan.
Breast Neoplasms
BRCA1 polymorphism in breast cancer patients from Argentina.
Breast Neoplasms
BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.
Breast Neoplasms
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
Breast Neoplasms
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.
Breast Neoplasms
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
Breast Neoplasms
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
Breast Neoplasms
BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population.
Breast Neoplasms
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Breast Neoplasms
BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia
Breast Neoplasms
BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
Breast Neoplasms
BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
Breast Neoplasms
BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Breast Neoplasms
BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer.
Breast Neoplasms
BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation.
Breast Neoplasms
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.
Breast Neoplasms
BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls.
Breast Neoplasms
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
Breast Neoplasms
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
Breast Neoplasms
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
Breast Neoplasms
BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Breast Neoplasms
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer.
Breast Neoplasms
BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.
Breast Neoplasms
BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
Breast Neoplasms
BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
Breast Neoplasms
BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.
Breast Neoplasms
BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
Breast Neoplasms
BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
Breast Neoplasms
BRCA1 Protein Expression Level and CD44(+)Phenotype in Breast Cancer Patients.
Breast Neoplasms
BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A.
Breast Neoplasms
BRCA1 protein level is not affected by peptide growth factors in MCF10A cell line.
Breast Neoplasms
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
Breast Neoplasms
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
Breast Neoplasms
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
Breast Neoplasms
BRCA1 Recruitment to Transcriptional Pause Sites Is Required for R-Loop-Driven DNA Damage Repair.
Breast Neoplasms
BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.
Breast Neoplasms
BRCA1 regulates gene expression for orderly mitotic progression.
Breast Neoplasms
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
Breast Neoplasms
BRCA1 regulates p53-dependent gene expression.
Breast Neoplasms
BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner.
Breast Neoplasms
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
Breast Neoplasms
BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.
Breast Neoplasms
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
Breast Neoplasms
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Breast Neoplasms
BRCA1 represses amphiregulin gene expression.
Breast Neoplasms
BRCA1 requirement for the fidelity of plasmid DNA double-strand break repair in cultured breast epithelial cells.
Breast Neoplasms
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Breast Neoplasms
BRCA1 role in the mitigation of radiotoxicity and chromosomal instability through repair of clustered DNA lesions.
Breast Neoplasms
BRCA1 screening in a woman with breast cancer: a patient's perspective with commentary.
Breast Neoplasms
BRCA1 screening in patients with a family history of breast or ovarian cancer.
Breast Neoplasms
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
Breast Neoplasms
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.
Breast Neoplasms
BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator.
Breast Neoplasms
BRCA1 status in Pakistani breast cancer patients with moderate family history.
Breast Neoplasms
BRCA1 suppresses osteopontin-mediated breast cancer.
Breast Neoplasms
BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.
Breast Neoplasms
BRCA1 susceptibility markers and postmenopausal breast cancer: the Iowa Women's Health Study.
Breast Neoplasms
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
Breast Neoplasms
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Breast Neoplasms
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
Breast Neoplasms
BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.
Breast Neoplasms
BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1).
Breast Neoplasms
BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.
Breast Neoplasms
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
Breast Neoplasms
BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.
Breast Neoplasms
BRCA1, a potential predictive biomarker in the treatment of breast cancer.
Breast Neoplasms
BRCA1, BRCA2 and breast cancer: a concise clinical review.
Breast Neoplasms
BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
Breast Neoplasms
BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.
Breast Neoplasms
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Breast Neoplasms
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
Breast Neoplasms
BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.
Breast Neoplasms
BRCA1, BRCA2, BRCA3 ... a myriad of breast cancer genes.
Breast Neoplasms
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Breast Neoplasms
BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study.
Breast Neoplasms
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
Breast Neoplasms
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?
Breast Neoplasms
BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms.
Breast Neoplasms
BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance.
Breast Neoplasms
BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
Breast Neoplasms
BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells.
Breast Neoplasms
BRCA1-BARD1 regulates axon regeneration in concert with the Gq?-DAG signaling network.
Breast Neoplasms
BRCA1-BRCT Mutations Alter the Subcellular Localization of BRCA1 In Vitro.
Breast Neoplasms
BRCA1-dependent and independent functions of BARD1.
Breast Neoplasms
BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.
Breast Neoplasms
BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations.
Breast Neoplasms
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
Breast Neoplasms
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Breast Neoplasms
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Breast Neoplasms
BRCA1-mediated inflammation and growth activated & inhibited transition mechanisms between no-tumor hepatitis/cirrhotic tissues and HCC.
Breast Neoplasms
BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.
Breast Neoplasms
BRCA1-mediated repression of select X chromosome genes.
Breast Neoplasms
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
Breast Neoplasms
BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
Breast Neoplasms
BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
Breast Neoplasms
BRCA1-No Matter How You Splice It.
Breast Neoplasms
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
Breast Neoplasms
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.
Breast Neoplasms
BRCA1-related gene signature in breast cancer: the role of ER status and molecular type.
Breast Neoplasms
BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
Breast Neoplasms
BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies.
Breast Neoplasms
BRCA1/2 mutation analysis in male breast cancer families from North West England.
Breast Neoplasms
BRCA1/2 Mutations and Triple Negative Breast Cancers.
Breast Neoplasms
BRCA1/2 predictive testing and gender: uptake, motivation and psychological characteristics.
Breast Neoplasms
BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer.
Breast Neoplasms
BRCA1/BARD1 E3 ubiquitin ligase can modify histones H2A and H2B in the nucleosome particle.
Breast Neoplasms
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
Breast Neoplasms
BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity.
Breast Neoplasms
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Breast Neoplasms
BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
Breast Neoplasms
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
Breast Neoplasms
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Breast Neoplasms
BRCA1/BRCA2 Mutations Shaped by Ancient Consanguinity Practice in Southern Mediterranean Populations
Breast Neoplasms
BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
Breast Neoplasms
BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Breast Neoplasms
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Breast Neoplasms
BRCA1: lessons learned from the breast cancer gene.
Breast Neoplasms
BRCA1: linking HOX to breast cancer suppression.
Breast Neoplasms
BRCA1: more than a hereditary breast cancer gene?
Breast Neoplasms
BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers.
Breast Neoplasms
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.
Breast Neoplasms
BRCA2 germline mutations in Japanese breast cancer families.
Breast Neoplasms
BRCA2 germline mutations in Swedish breast cancer families.
Breast Neoplasms
BRCA2 hypomorphic missense variants confer moderate risks of breast cancer.
Breast Neoplasms
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
Breast Neoplasms
BRCA2 mutations and triple-negative breast cancer.
Breast Neoplasms
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
Breast Neoplasms
BRCA2 T2722R is a deleterious allele that causes exon skipping.
Breast Neoplasms
BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.
Breast Neoplasms
BRCA2: a genetic risk factor for breast cancer.
Breast Neoplasms
Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF).
Breast Neoplasms
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Breast Neoplasms
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Breast Neoplasms
BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation.
Breast Neoplasms
BRCT domain interactions in the heterodimeric DNA repair protein XRCC1-DNA ligase III.
Breast Neoplasms
Breast and ovarian cancer genetics and prevention.
Breast Neoplasms
Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Breast Neoplasms
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Breast Neoplasms
Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women.
Breast Neoplasms
Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.
Breast Neoplasms
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Breast Neoplasms
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
Breast Neoplasms
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Breast Neoplasms
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Breast Neoplasms
Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.
Breast Neoplasms
Breast cancer 2004: Progress and promise on the clinical front.
Breast Neoplasms
Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
Breast Neoplasms
Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
Breast Neoplasms
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Breast cancer and BRCA1 mutations.
Breast Neoplasms
Breast cancer and family history: levels of lipid-associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors.
Breast Neoplasms
Breast cancer and genetic instability: the molecules behind the scenes.
Breast Neoplasms
Breast cancer and genetics.
Breast Neoplasms
Breast cancer and ovarian cancer genetics: an update.
Breast Neoplasms
Breast cancer and pregnancy.
Breast Neoplasms
Breast cancer associated pathogenic variants among women 61?years and older with triple negative breast cancer.
Breast Neoplasms
Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Breast Neoplasms
Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review.
Breast Neoplasms
Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
Breast Neoplasms
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Breast cancer epidemiology, prevention, and early detection.
Breast Neoplasms
Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair--perhaps through transcription.
Breast Neoplasms
Breast cancer genes: beyond BRCA1 and BRCA2.
Breast Neoplasms
Breast cancer genes: therapeutic strategies.
Breast Neoplasms
Breast cancer genetics in African Americans.
Breast Neoplasms
Breast cancer genetics: family history, heterogeneity, molecular genetic diagnosis, and genetic counselling.
Breast Neoplasms
Breast cancer in a patient with Birt-Hogg-Dubé syndrome (BHDS) with dramatic response to neoadjuvant chemotherapy.
Breast Neoplasms
Breast cancer in a patient with Kindlers syndrome.
Breast Neoplasms
Breast cancer in adolescents and young women.
Breast Neoplasms
Breast cancer in BRCA mutation carriers: medical treatment.
Breast Neoplasms
Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum.
Breast Neoplasms
Breast cancer in males, case presentation and literature review
Breast Neoplasms
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Breast Neoplasms
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
Breast Neoplasms
Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?
Breast Neoplasms
Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.
Breast Neoplasms
Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
Breast Neoplasms
Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
Breast Neoplasms
Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21.
Breast Neoplasms
Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors.
Breast Neoplasms
Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex.
Breast Neoplasms
Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program.
Breast Neoplasms
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Breast Neoplasms
Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.
Breast Neoplasms
Breast cancer predisposing alleles in Poland.
Breast Neoplasms
Breast cancer predisposition syndromes.
Breast Neoplasms
Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?
Breast Neoplasms
Breast cancer prevention in women with a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Breast Neoplasms
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Breast Neoplasms
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
Breast Neoplasms
Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.
Breast Neoplasms
Breast cancer risk and the BRCA1 interacting protein CTIP.
Breast Neoplasms
Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
Breast Neoplasms
Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2.
Breast Neoplasms
Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis of affected relatives.
Breast Neoplasms
Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations.
Breast Neoplasms
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Breast Neoplasms
Breast cancer risk associated with BRCA1/2 variants in the Pakistani population.
Breast Neoplasms
Breast cancer risk associated with CHEK2 mutations.
Breast Neoplasms
Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.
Breast Neoplasms
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
Breast Neoplasms
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Breast Neoplasms
Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.
Breast Neoplasms
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.
Breast Neoplasms
Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies.
Breast Neoplasms
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
Breast Neoplasms
Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history.
Breast Neoplasms
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
Breast Neoplasms
Breast cancer risk in BRCA1 mutation carriers: insight from mouse models.
Breast Neoplasms
Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations.
Breast Neoplasms
Breast Cancer Risk in Relation to Alcohol Consumption and BRCA Gene Mutations - A Case-Only Study of Gene-Environment Interaction.
Breast Neoplasms
Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.
Breast Neoplasms
Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland.
Breast Neoplasms
Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
Breast Neoplasms
Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
Breast Neoplasms
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.
Breast Neoplasms
Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.
Breast Neoplasms
Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology.
Breast Neoplasms
Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Breast Neoplasms
Breast cancer risk-assessment models.
Breast Neoplasms
Breast cancer risks and risk prediction models.
Breast Neoplasms
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Breast Neoplasms
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Breast Neoplasms
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
Breast Neoplasms
Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.
Breast Neoplasms
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Breast Neoplasms
Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations.
Breast Neoplasms
Breast cancer survival in BRCA1 carriers.
Breast Neoplasms
Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Breast Neoplasms
Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor.
Breast Neoplasms
Breast cancer susceptibility genes.
Breast Neoplasms
Breast cancer susceptibility genes. BRCA1 and BRCA2.
Breast Neoplasms
Breast cancer susceptibility protein 1 (BRCA1) rescues neurons from cerebral ischemia/reperfusion injury through NRF2-mediated antioxidant pathway.
Breast Neoplasms
Breast cancer susceptibility testing: past, present and future.
Breast Neoplasms
Breast cancer susceptibility variants alter risk in familial ovarian cancer.
Breast Neoplasms
Breast cancer susceptibility variants alter risks in familial disease.
Breast Neoplasms
Breast cancer susceptibility-A new look at an old model.
Breast Neoplasms
Breast cancer susceptibility: current knowledge and implications for genetic counselling.
Breast Neoplasms
Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
Breast Neoplasms
Breast cancer treatment in mutation carriers: surgical treatment.
Breast Neoplasms
Breast cancer-associated abraxas mutation disrupts nuclear localization and DNA damage response functions.
Breast Neoplasms
Breast cancer.
Breast Neoplasms
Breast cancer: genetic predisposition and exposure to radiation.
Breast Neoplasms
Breast cancer: major risk factors and recent developments in treatment.
Breast Neoplasms
Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate.
Breast Neoplasms
Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation.
Breast Neoplasms
Breast carcinoma in carriers of BRCA1 or BRCA2 mutations: implications of proposed distinct histologic phenotypes.
Breast Neoplasms
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.
Breast Neoplasms
Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
Breast Neoplasms
Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer.
Breast Neoplasms
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Breast Neoplasms
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Breast Neoplasms
Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Breast Neoplasms
Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.
Breast Neoplasms
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Breast Neoplasms
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells.
Breast Neoplasms
Breast-Specific Molecular Clocks Comprised of ELF5 Expression and Promoter Methylation Identify Individuals Susceptible to Cancer Initiation.
Breast Neoplasms
Breastfeeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors.
Breast Neoplasms
BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.
Breast Neoplasms
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Breast Neoplasms
BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer.
Breast Neoplasms
Building capacity for human genetics and genomics research in Trinidad and Tobago.
Breast Neoplasms
C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
Breast Neoplasms
c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.
Breast Neoplasms
c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Breast Neoplasms
c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells.
Breast Neoplasms
C-terminus of Hsc70-interacting protein regulates profilin1 and breast cancer cell migration.
Breast Neoplasms
CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Breast Neoplasms
Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype.
Breast Neoplasms
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Breast Neoplasms
CAG repeat size in Huntingtin alleles is associated with cancer prognosis.
Breast Neoplasms
Can genetic testing guide treatment in breast cancer?
Breast Neoplasms
Can Soy Phytoestrogens Decrease DNA Methylation in BRCA1 and BRCA2 Oncosuppressor Genes in Breast Cancer?
Breast Neoplasms
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Breast Neoplasms
Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
Breast Neoplasms
Cancer genetics in primary care.
Breast Neoplasms
Cancer genetics in the new era of molecular biology.
Breast Neoplasms
Cancer in Jews: introduction and overview.
Breast Neoplasms
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Breast Neoplasms
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.
Breast Neoplasms
Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Breast Neoplasms
Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
Breast Neoplasms
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals.
Breast Neoplasms
Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
Breast Neoplasms
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation.
Breast Neoplasms
Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Breast Neoplasms
Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status.
Breast Neoplasms
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.
Breast Neoplasms
Cancer stem cell heterogeneity in hereditary breast cancer.
Breast Neoplasms
Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours.
Breast Neoplasms
Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Breast Neoplasms
Candidate tumor suppressor LUCA-15/RBM5/H37 modulates expression of apoptosis and cell cycle genes.
Breast Neoplasms
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.
Breast Neoplasms
Cantharidin Induces DNA Damage and Inhibits DNA Repair-associated Protein Expressions in TSGH8301 Human Bladder Cancer Cell.
Breast Neoplasms
Carbon-nanotube-modified electrodes for amplified enzyme-based electrical detection of DNA hybridization.
Breast Neoplasms
Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis.
Breast Neoplasms
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
Breast Neoplasms
CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Breast Neoplasms
Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis.
Breast Neoplasms
Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.
Breast Neoplasms
Caucasian family with two independent mutations: 2594delC in BRCA1 and 5392delAG in BRCA2 gene.
Breast Neoplasms
Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells.
Breast Neoplasms
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Breast Neoplasms
cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors.
Breast Neoplasms
CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Breast Neoplasms
CDDO-Imidazolide Induces DNA Damage, G2/M Arrest and Apoptosis in BRCA1-Mutated Breast Cancer Cells.
Breast Neoplasms
Celebrity Health Announcements and Online Health Information Seeking: An Analysis of Angelina Jolie's Preventative Health Decision.
Breast Neoplasms
Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization.
Breast Neoplasms
Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.
Breast Neoplasms
Cell density is a critical determinant of aromatase expression in adipose stromal cells.
Breast Neoplasms
Cell fate takes a slug in BRCA1-associated breast cancer.
Breast Neoplasms
Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligo-ubiquitin for ubiquitylation.
Breast Neoplasms
Centriole separation in DNA damage-induced centrosome amplification.
Breast Neoplasms
CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
Breast Neoplasms
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q.
Breast Neoplasms
Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
Breast Neoplasms
Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.
Breast Neoplasms
Changes in BRCA2 expression during progression of the cell cycle.
Breast Neoplasms
Changes in classification of genetic variants in BRCA1 and BRCA2.
Breast Neoplasms
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
Breast Neoplasms
Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
Breast Neoplasms
Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Breast Neoplasms
Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.
Breast Neoplasms
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
Breast Neoplasms
Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
Breast Neoplasms
Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
Breast Neoplasms
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Breast Neoplasms
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Breast Neoplasms
Characteristics relating to ovarian cancer risk: implications for prevention and detection.
Breast Neoplasms
Characterization of 10 new polymorphic dinucleotide repeats and generation of a high-density microsatellite-based physical map of the BRCA1 region of chromosome 17q21.
Breast Neoplasms
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Breast Neoplasms
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Breast Neoplasms
Characterization of a negative transcriptional element in the BRCA1 promoter.
Breast Neoplasms
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Breast Neoplasms
Characterization of a novel germline BRCA1 splice variant, c.5332+4delA.
Breast Neoplasms
Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer.
Breast Neoplasms
Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain.
Breast Neoplasms
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.
Breast Neoplasms
Characterization of BRCA1 and BRCA2 genetic variants in a cohort of Bahraini breast cancer patients using next-generation sequencing.
Breast Neoplasms
Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Breast Neoplasms
Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study.
Breast Neoplasms
Characterization of Brca1 deficient mice.
Breast Neoplasms
Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome: A ROLE FOR THE NUCLEAR EXPORT SIGNAL, CRM1, AND AURORA A KINASE.
Breast Neoplasms
Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia.
Breast Neoplasms
Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Breast Neoplasms
Characterization of COBRA1 in human breast cancer cell lines using a new polyclonal antibody against COBRA1.
Breast Neoplasms
Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Breast Neoplasms
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Breast Neoplasms
Characterization of the BRCA1-like immunoreactivity of human seminal plasma.
Breast Neoplasms
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Breast Neoplasms
Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
Breast Neoplasms
Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.
Breast Neoplasms
CHEK2 1100delC and male breast cancer in the Netherlands.
Breast Neoplasms
CHEK2 1100delC is not a risk factor for male breast cancer population.
Breast Neoplasms
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
Breast Neoplasms
CHEK2 contribution to hereditary breast cancer in non-BRCA families.
Breast Neoplasms
CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda
Breast Neoplasms
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Breast Neoplasms
Chemoprevention for high-risk women: tamoxifen and beyond.
Breast Neoplasms
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
Breast Neoplasms
Chemoprevention of breast cancer.
Breast Neoplasms
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation.
Breast Neoplasms
Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer Clinic.
Breast Neoplasms
Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair.
Breast Neoplasms
Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1.
Breast Neoplasms
Chromogenic and fluorescent in situ hybridization in breast cancer.
Breast Neoplasms
Chromosomal aberrations involving telomeres in BRCA1 deficient human and mouse cell lines.
Breast Neoplasms
Chromosomal breakage syndromes and the BRCA1 genome surveillance complex.
Breast Neoplasms
Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay.
Breast Neoplasms
Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Chromosomal mutagen sensitivity associated with mutations in BRCA genes.
Breast Neoplasms
Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.
Breast Neoplasms
Chromosome 17q linkage studies of 18 Utah breast cancer kindreds.
Breast Neoplasms
Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer.
Breast Neoplasms
Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Breast Neoplasms
Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence.
Breast Neoplasms
CIP2A is associated with human breast cancer aggressivity.
Breast Neoplasms
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
Breast Neoplasms
Circulatory miRNA-155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development.
Breast Neoplasms
CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the Breast Cancer Family Registry.
Breast Neoplasms
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
Breast Neoplasms
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Breast Neoplasms
Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.
Breast Neoplasms
Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Breast Neoplasms
Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Breast Neoplasms
Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation.
Breast Neoplasms
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Breast Neoplasms
Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.
Breast Neoplasms
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
Breast Neoplasms
Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
Breast Neoplasms
Clinical and research issues in breast cancer genetics.
Breast Neoplasms
Clinical application of breast cancer risk assessment models.
Breast Neoplasms
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Breast Neoplasms
Clinical Characteristics in Patients with Triple Negative Breast Cancer.
Breast Neoplasms
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Breast Neoplasms
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.
Breast Neoplasms
Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.
Breast Neoplasms
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Breast Neoplasms
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.
Breast Neoplasms
Clinical follow up of mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes.
Breast Neoplasms
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Breast Neoplasms
Clinical implications for BRCA gene mutation in breast cancer.
Breast Neoplasms
Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
Breast Neoplasms
Clinical implications of germline mutations in breast cancer genes: RECQL.
Breast Neoplasms
Clinical implications of low-penetrance breast cancer susceptibility alleles.
Breast Neoplasms
Clinical implications of the breast cancer susceptibility genes BRCA1 and BRCA2.
Breast Neoplasms
Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice.
Breast Neoplasms
Clinical management of BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Clinical management of BRCA1- and BRCA2-associated breast cancer.
Breast Neoplasms
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.
Breast Neoplasms
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Breast Neoplasms
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Breast Neoplasms
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Breast Neoplasms
Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer.
Breast Neoplasms
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Breast Neoplasms
Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
Breast Neoplasms
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Breast Neoplasms
Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer.
Breast Neoplasms
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
Breast Neoplasms
Clinically relevant biology of hereditary breast cancer.
Breast Neoplasms
Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes Among Korean Breast Cancer Patients.
Breast Neoplasms
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.
Breast Neoplasms
Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
Breast Neoplasms
Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Breast Neoplasms
Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
Breast Neoplasms
Clinicopathological features and prognostic factors of young breast cancers in Eastern Guangdong of China.
Breast Neoplasms
Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
Breast Neoplasms
Clinicopathological Features of Hereditary Breast Cancer.
Breast Neoplasms
Clinicopathological Significance of BRCA1 Promoter Hypermethylation in Thai Breast Cancer Patients.
Breast Neoplasms
Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Breast Neoplasms
Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
Breast Neoplasms
Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis.
Breast Neoplasms
Cloning and functional identification of two novel BRCA1 splicing variants.
Breast Neoplasms
Cloning, genetic mapping and expression studies of the rat Brca1 gene.
Breast Neoplasms
Clues to the function of the tumour susceptibility gene BRCA2.
Breast Neoplasms
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer.
Breast Neoplasms
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Breast Neoplasms
Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers.
Breast Neoplasms
Co-occurrence of germline BRCA1 and CDH1 pathogenic variants.
Breast Neoplasms
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
Breast Neoplasms
Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.
Breast Neoplasms
Coffee and caffeine intake and breast cancer risk: An updated dose-response meta-analysis of 37 published studies.
Breast Neoplasms
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer.
Breast Neoplasms
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Breast Neoplasms
Collaboration of Brca1 and Chk2 in tumorigenesis.
Breast Neoplasms
Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan.
Breast Neoplasms
Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes.
Breast Neoplasms
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
Breast Neoplasms
College Women's Responses to a Celebrity Health Disclosure.
Breast Neoplasms
Colorectal cancer in hereditary breast cancer kindreds.
Breast Neoplasms
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Breast Neoplasms
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
Breast Neoplasms
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.
Breast Neoplasms
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population.
Breast Neoplasms
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Breast Neoplasms
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Breast Neoplasms
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Breast Neoplasms
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Breast Neoplasms
Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.
Breast Neoplasms
Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Breast Neoplasms
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
Breast Neoplasms
Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.
Breast Neoplasms
Common nonsense mutations in RAD52.
Breast Neoplasms
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families.
Breast Neoplasms
Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
Breast Neoplasms
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
Breast Neoplasms
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
Breast Neoplasms
Communicating genetic risk: pros, cons, and counsel.
Breast Neoplasms
Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Breast Neoplasms
Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants.
Breast Neoplasms
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Breast Neoplasms
Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
Breast Neoplasms
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Breast Neoplasms
Comparative pathology of mammary gland cancers in domestic and wild animals.
Breast Neoplasms
Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
Breast Neoplasms
Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Breast Neoplasms
Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations.
Breast Neoplasms
Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
Breast Neoplasms
Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.
Breast Neoplasms
Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols.
Breast Neoplasms
Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.
Breast Neoplasms
Comparisons of gene coexpression network modules in breast cancer and ovarian cancer.
Breast Neoplasms
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Breast Neoplasms
Competing risks analysis of correlated failure time data.
Breast Neoplasms
Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients.
Breast Neoplasms
Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer.
Breast Neoplasms
Complete mutation screening and haplotype characterization of the BRCA1 gene in 61 familial breast cancer patients from Norway.
Breast Neoplasms
Complex Characterization of Germline Large Genomic Rearrangements of the BRCA1 and BRCA2 Genes in High-Risk Breast Cancer Patients-Novel Variants from a Large National Center.
Breast Neoplasms
Compliance With Tamoxifen in Women With Breast Cancer and a BRCA1 or BRCA2 Mutation.
Breast Neoplasms
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Breast Neoplasms
Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Breast Neoplasms
Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil.
Breast Neoplasms
Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
Breast Neoplasms
Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
Breast Neoplasms
Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Breast Neoplasms
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Breast Neoplasms
Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
Breast Neoplasms
Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation.
Breast Neoplasms
Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants.
Breast Neoplasms
Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Breast Neoplasms
Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.
Breast Neoplasms
Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
Breast Neoplasms
Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.
Breast Neoplasms
Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Breast Neoplasms
Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
Breast Neoplasms
Concerted action of two avirulent spore effectors activates Reaction to Puccinia graminis 1 (Rpg1)-mediated cereal stem rust resistance.
Breast Neoplasms
Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells.
Breast Neoplasms
Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.
Breast Neoplasms
Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
Breast Neoplasms
Conditions for single-strand conformation polymorphism (SSCP) analysis of BRCA1 gene using an automated electrophoresis unit.
Breast Neoplasms
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.
Breast Neoplasms
Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families.
Breast Neoplasms
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Breast Neoplasms
Consanguinity Protecting Effect Against Breast Cancer among Tunisian Women: Analysis of BRCA1 Haplotypes.
Breast Neoplasms
Conservative management of breast cancer in BRCA1/2 mutation carriers.
Breast Neoplasms
Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA.
Breast Neoplasms
Considerations in genetic counseling for inherited breast cancer predisposition.
Breast Neoplasms
Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results.
Breast Neoplasms
CONSTITUTIONAL METHYLATION OF THE BRCA1 PROMOTER IS SPECIFICALLY ASSOCIATED WITH BRCA1 MUTATION-ASSOCIATED PATHOLOGY IN EARLY-ONSET BREAST CANCER.
Breast Neoplasms
Constitutional Mosaic Epimutations - a hidden cause of cancer?
Breast Neoplasms
Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer.
Breast Neoplasms
Constitutive expression of ?-H2AX has prognostic relevance in triple negative breast cancer.
Breast Neoplasms
Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Breast Neoplasms
Consumption of reused vegetable oil intensifies BRCA1 mutations.
Breast Neoplasms
Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
Breast Neoplasms
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report.
Breast Neoplasms
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Breast Neoplasms
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.
Breast Neoplasms
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
Breast Neoplasms
Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
Breast Neoplasms
Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients.
Breast Neoplasms
Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Breast Neoplasms
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Breast Neoplasms
Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Breast Neoplasms
Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer.
Breast Neoplasms
Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco.
Breast Neoplasms
Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus.
Breast Neoplasms
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.
Breast Neoplasms
Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
Breast Neoplasms
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.
Breast Neoplasms
Contribution of BRCA1 germline mutation in patients with sporadic breast cancer.
Breast Neoplasms
Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
Breast Neoplasms
Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
Breast Neoplasms
Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer.
Breast Neoplasms
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.
Breast Neoplasms
Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
Breast Neoplasms
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Breast Neoplasms
Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database.
Breast Neoplasms
Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues.
Breast Neoplasms
Controversial BRCA1 allelotypes in commonly used breast cancer cell lines.
Breast Neoplasms
Cooperation Between BRCA1 and p53 in Repair of Cyclobutane Pyrimidine Dimers.
Breast Neoplasms
Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells.
Breast Neoplasms
Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.
Breast Neoplasms
COP1 and GSK3? Cooperate to Promote c-Jun Degradation and Inhibit Breast Cancer Cell Tumorigenesis.
Breast Neoplasms
Correcting errors in the BRCA1 warning system.
Breast Neoplasms
Correction to: Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.
Breast Neoplasms
Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
Breast Neoplasms
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Correction: Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Breast Neoplasms
Correction: regulation of p53 level by UBE4B in breast cancer.
Breast Neoplasms
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Breast Neoplasms
Correlation between Candidate Single Nucleotide Variants and Several Clinicopathological Risk Factors Related to Breast Cancer in Jordanian Women: A Genotype-Phenotype Study.
Breast Neoplasms
Correlation between morphology, immunohistochemistry and molecular pathology in hereditary and sporadic breast cancer cases.
Breast Neoplasms
Correspondence re: A. Rothfuss et al., Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res., 60: 390-394, 2000.
Breast Neoplasms
Corrigendum to "PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice" [Bioelectrochemistry 2021 (140) 107832].
Breast Neoplasms
Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations.
Breast Neoplasms
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Breast Neoplasms
Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Breast Neoplasms
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Breast Neoplasms
Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Breast Neoplasms
Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
Breast Neoplasms
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
Breast Neoplasms
CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Breast Neoplasms
CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.
Breast Neoplasms
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
Breast Neoplasms
CRISPR-Cas9/long-read sequencing approach to identify cryptic mutations in BRCA1 and other tumour suppressor genes.
Breast Neoplasms
CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
Breast Neoplasms
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Breast Neoplasms
Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
Breast Neoplasms
Cross-talk between non-genomic and genomic signalling pathways - Distinct effect profiles of environmental estrogens.
Breast Neoplasms
Crystal structure of the BARD1 BRCT domains.
Breast Neoplasms
CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response.
Breast Neoplasms
Curcumin induces re?expression of BRCA1 and suppression of ? synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Breast Neoplasms
Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms.
Breast Neoplasms
Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
Breast Neoplasms
Current methods to prevent the development of breast cancer.
Breast Neoplasms
Current perspectives on BRCA1- and BRCA2-associated breast cancers.
Breast Neoplasms
Current perspectives on radiation-induced breast cancer.
Breast Neoplasms
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Breast Neoplasms
Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
Breast Neoplasms
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Breast Neoplasms
Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Breast Neoplasms
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Breast Neoplasms
Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines.
Breast Neoplasms
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Breast Neoplasms
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Breast Neoplasms
Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.
Breast Neoplasms
Data mining of micrornas in breast carcinogenesis which may be a potential target for cancer prevention.
Breast Neoplasms
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing.
Breast Neoplasms
DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
Breast Neoplasms
DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.
Breast Neoplasms
De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation.
Breast Neoplasms
De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.
Breast Neoplasms
Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer.
Breast Neoplasms
DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-?-Driven Epithelial-Mesenchymal Transition.
Breast Neoplasms
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Breast Neoplasms
DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity.
Breast Neoplasms
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Breast Neoplasms
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Breast Neoplasms
Decision-making about genetic testing among women at familial risk for breast cancer.
Breast Neoplasms
Decisions and outcomes of genetic testing for inherited breast cancer risk.
Breast Neoplasms
Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer.
Breast Neoplasms
Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.
Breast Neoplasms
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Breast Neoplasms
Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
Breast Neoplasms
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Breast Neoplasms
Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex.
Breast Neoplasms
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Breast Neoplasms
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition.
Breast Neoplasms
Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer.
Breast Neoplasms
Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.
Breast Neoplasms
Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Breast Neoplasms
Democratising access to genetic services.
Breast Neoplasms
Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells.
Breast Neoplasms
Depletion of eIF2.GTP.Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.
Breast Neoplasms
Deregulation of cofactor of BRCA1 expression in breast cancer cells.
Breast Neoplasms
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Breast Neoplasms
Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS).
Breast Neoplasms
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Breast Neoplasms
Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors.
Breast Neoplasms
Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth.
Breast Neoplasms
Designed hybridization properties of DNA-gold nanoparticle conjugates for the ultraselective detection of a single-base mutation in the breast cancer gene BRCA1.
Breast Neoplasms
Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours.
Breast Neoplasms
Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2.
Breast Neoplasms
Detection of a novel Alu-mediated BRCA1 exon 13 duplication in Chinese breast cancer patients and implications for genetic testing.
Breast Neoplasms
Detection of a novel mutation in exon 20 of the BRCA1 gene.
Breast Neoplasms
Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method.
Breast Neoplasms
Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure.
Breast Neoplasms
Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives.
Breast Neoplasms
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Breast Neoplasms
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization.
Breast Neoplasms
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2.
Breast Neoplasms
Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast.
Breast Neoplasms
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing.
Breast Neoplasms
Detection of large deletion in human BRCA1 gene in human breast carcinoma MCF-7 cells by using DNA-Silver Nanoclusters.
Breast Neoplasms
Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
Breast Neoplasms
Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Breast Neoplasms
Detection of New Point Mutations of BRCA1 and BRCA2 in Breast Cancer Patients.
Breast Neoplasms
Detection of novel germline mutations for breast cancer in non-BRCA1/2 families.
Breast Neoplasms
Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.
Breast Neoplasms
Determinants of preferences for genetic counselling in Jewish women.
Breast Neoplasms
Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Breast Neoplasms
Developing functional assays for BRCA1 unclassified variants.
Breast Neoplasms
Developing strategies for intervention and prevention in hereditary breast cancer.
Breast Neoplasms
Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA.
Breast Neoplasms
Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.
Breast Neoplasms
Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study.
Breast Neoplasms
Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.
Breast Neoplasms
Development of a universal gap repair vector for yeast-based screening of knockout rodents.
Breast Neoplasms
Development of an Interactive Decision Aid for Female BRCA1/BRCA2 Carriers.
Breast Neoplasms
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
Breast Neoplasms
Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
Breast Neoplasms
Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues.
Breast Neoplasms
Developmental studies of Brca1 and Brca2 knock-out mice.
Breast Neoplasms
Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation.
Breast Neoplasms
DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families.
Breast Neoplasms
Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations.
Breast Neoplasms
Diagnostic algorithm for identification of individuals with hereditary predisposition to breast cancer.
Breast Neoplasms
Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature.
Breast Neoplasms
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Diagnostic Chest X-Rays and Breast Cancer Risk before Age 50 Years for BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Diagnostic yield of a custom-designed multi-gene cancer panel in Irish patients with breast cancer.
Breast Neoplasms
Diet quality and BRCA-associated breast cancer risk.
Breast Neoplasms
Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians.
Breast Neoplasms
Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review.
Breast Neoplasms
Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
Breast Neoplasms
Differences in cysteine peptidases-like activity in sera of patients with breast cancer.
Breast Neoplasms
Differences in DNA methylation by extent of breast cancer family history in unaffected women.
Breast Neoplasms
Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
Breast Neoplasms
Differences of Variable Number Tandem Repeats in XRCC5 Promoter Are Associated with Increased or Decreased Risk of Breast Cancer in BRCA Gene Mutation Carriers.
Breast Neoplasms
Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Breast Neoplasms
Different cell cycle kinetic effects of N1,N11-diethylnorspermine-induced polyamine depletion in four human breast cancer cell lines.
Breast Neoplasms
Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
Breast Neoplasms
Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors.
Breast Neoplasms
Differential Chemotherapeutic Sensitivity for Breast Tumors With "BRCAness": A Review.
Breast Neoplasms
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.
Breast Neoplasms
Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
Breast Neoplasms
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines.
Breast Neoplasms
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.
Breast Neoplasms
Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Breast Neoplasms
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Breast Neoplasms
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Breast Neoplasms
Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
Breast Neoplasms
Differentially expressed genes and key molecules of BRCA1/2-mutant breast cancer: evidence from bioinformatics analyses.
Breast Neoplasms
Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.
Breast Neoplasms
Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
Breast Neoplasms
Direct and nondestructive verification of PNA immobilization using click chemistry.
Breast Neoplasms
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Breast Neoplasms
Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Breast Neoplasms
Direct visualization of the highly polymorphic RNU2 locus in proximity to the BRCA1 gene.
Breast Neoplasms
Direct-To-Consumer Genetic Testing: Is the Public Ready for Simple, At-Home DNA Tests to Detect Disease Risk?
Breast Neoplasms
Disclosure Pattern and Follow-Up After the Molecular Diagnosis of BRCA/CHEK2 Mutations.
Breast Neoplasms
Discordant pattern of BRCA1 gene epimutation in blood between mothers and daughters.
Breast Neoplasms
Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer.
Breast Neoplasms
Discovering moderate-risk breast cancer susceptibility genes.
Breast Neoplasms
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Breast Neoplasms
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
Breast Neoplasms
Discovery of the Anti-Tumor Mechanism of Calycosin Against Colorectal Cancer by Using System Pharmacology Approach.
Breast Neoplasms
Discussion: CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
Breast Neoplasms
Disease family history and modification of breast cancer risk in common BRCA2 variants.
Breast Neoplasms
Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.
Breast Neoplasms
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.
Breast Neoplasms
Dissecting systems-wide data using mixture models: application to identify affected cellular processes.
Breast Neoplasms
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Breast Neoplasms
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Breast Neoplasms
Distinct Ring1b complexes defined by DEAD-box helicases and EMT transcription factors synergistically enhance E-cadherin silencing in breast cancer.
Breast Neoplasms
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Breast Neoplasms
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
Breast Neoplasms
Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.
Breast Neoplasms
Distribution of family history of a disease as a function of mode of inheritance, genetic relative hazard, allele frequency and disease status of the proband, with application to female breast cancer.
Breast Neoplasms
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Breast Neoplasms
Diversifying selection of the tumor-growth promoter angiogenin in primate evolution.
Breast Neoplasms
DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter.
Breast Neoplasms
DNA damage induces p53-dependent BRCA1 nuclear export.
Breast Neoplasms
DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition.
Breast Neoplasms
DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells.
Breast Neoplasms
DNA double strand break repair and its association with inherited predispositions to breast cancer.
Breast Neoplasms
DNA double strand break repair in mammalian cells.
Breast Neoplasms
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
DNA hypermethylation in breast cancer and its association with clinicopathological features.
Breast Neoplasms
DNA ligase IV binds to XRCC4 via a motif located between rather than within its BRCT domains.
Breast Neoplasms
DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.
Breast Neoplasms
DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.
Breast Neoplasms
DNA methylation array analysis identifies breast cancer associated - RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
Breast Neoplasms
DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.
Breast Neoplasms
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
Breast Neoplasms
DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.
Breast Neoplasms
DNA methylation variations in familial female and male breast cancer.
Breast Neoplasms
DNA Polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
Breast Neoplasms
DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers.
Breast Neoplasms
DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.
Breast Neoplasms
DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
Breast Neoplasms
Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Breast Neoplasms
Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
Breast Neoplasms
Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer?
Breast Neoplasms
Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
Breast Neoplasms
Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
Breast Neoplasms
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.
Breast Neoplasms
Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.
Breast Neoplasms
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
Breast Neoplasms
Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Breast Neoplasms
Double heterozygosity in the BRCA1 and BRCA2 genes in Italian family.
Breast Neoplasms
Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Breast Neoplasms
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
Breast Neoplasms
Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair.
Breast Neoplasms
Double mutation of APC and BRCA1 in an Italian family.
Breast Neoplasms
Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
Breast Neoplasms
Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase.
Breast Neoplasms
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.
Breast Neoplasms
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Breast Neoplasms
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Breast Neoplasms
Down-regulation of tripartite-motif containing 22 expression in breast cancer is associated with a lack of p53-mediated induction.
Breast Neoplasms
Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.
Breast Neoplasms
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
Breast Neoplasms
Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1?, autophagy and ketone body production.
Breast Neoplasms
Drug Targeting of Genomic Instability in Multiple Myeloma.
Breast Neoplasms
DSS1 is required for the stability of BRCA2.
Breast Neoplasms
Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy.
Breast Neoplasms
Ductal carcinoma in situ in BRCA mutation carriers.
Breast Neoplasms
Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk.
Breast Neoplasms
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.
Breast Neoplasms
E3 ligase activity and suppression of breast cancer.
Breast Neoplasms
E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
Breast Neoplasms
E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation.
Breast Neoplasms
Early Onset Breast Cancer in a Registry-based Sample of African-American Women: BRCA Mutation Prevalence, and Other Personal and System-level Clinical Characteristics.
Breast Neoplasms
Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Breast Neoplasms
Early radiation exposures and BRCA1-associated breast cancer in young women from Poland.
Breast Neoplasms
Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.
Breast Neoplasms
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Breast Neoplasms
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
Breast Neoplasms
EDD inhibits ATM-mediated phosphorylation of P53.
Breast Neoplasms
Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan.
Breast Neoplasms
Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.
Breast Neoplasms
Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells.
Breast Neoplasms
Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice.
Breast Neoplasms
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Breast Neoplasms
Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Breast Neoplasms
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Breast Neoplasms
Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts.
Breast Neoplasms
Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Breast Neoplasms
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
Breast Neoplasms
Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial.
Breast Neoplasms
Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2.
Breast Neoplasms
Effect of omega-6 polyunsaturated fatty acid (linoleic acid) on BRCA1 gene expression in MCF-7 cell line.
Breast Neoplasms
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
Breast Neoplasms
Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Breast Neoplasms
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes.
Breast Neoplasms
Effect of variation in miRNA-binding site (rs8176318) of the BRCA1 gene in breast cancer patients
Breast Neoplasms
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
Breast Neoplasms
Effects of 3300 del A-1061 Ter BRCA1 frameshift mutation and calcium propionate on oxidative stress and breast carcinogenesis.
Breast Neoplasms
Effects of aluminium chloride and aluminium chlorohydrate on DNA repair in MCF10A immortalised non-transformed human breast epithelial cells.
Breast Neoplasms
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
Breast Neoplasms
Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Breast Neoplasms
Effects of individualized breast cancer risk counseling: a randomized trial.
Breast Neoplasms
Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
Breast Neoplasms
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Breast Neoplasms
Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines.
Breast Neoplasms
Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
Breast Neoplasms
Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
Breast Neoplasms
Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Breast Neoplasms
EGFR expression predicts BRCA1 status in patients with breast cancer.
Breast Neoplasms
EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.
Breast Neoplasms
Egr-1 regulates the transcription of the BRCA1 gene by etoposide.
Breast Neoplasms
Electrochemical detection of a breast cancer susceptible gene using cDNA immobilized chitosan-co-polyaniline electrode.
Breast Neoplasms
Electrochemical DNA Sensor for Sensitive BRCA1 Detection Based on DNA Tetrahedral-Structured Probe and Poly-Adenine Mediated Gold Nanoparticles.
Breast Neoplasms
Electrochemical genosensors for biomedical applications based on gold nanoparticles.
Breast Neoplasms
Electrophoresis of BRCA1 oncosuppressor.
Breast Neoplasms
Electroretinographic changes in eyes of patients with BRCA1 gene mutation.
Breast Neoplasms
Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.
Breast Neoplasms
Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.
Breast Neoplasms
Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.
Breast Neoplasms
Elevated radiation-induced ?H2AX foci in G2 phase heterozygous BRCA2 fibroblasts.
Breast Neoplasms
Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
Breast Neoplasms
Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines.
Breast Neoplasms
Elucidation of the transmission of a novel mutation in BRCA1 (1125delCT) in a family with multiple cases of breast cancer.
Breast Neoplasms
Emerging roles of BRCA1 in transcriptional regulation and DNA repair.
Breast Neoplasms
Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Breast Neoplasms
Endocrine metabolic disorders in patients with breast cancer, carriers of BRCA1 gene mutations.
Breast Neoplasms
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Breast Neoplasms
Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells.
Breast Neoplasms
Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Breast Neoplasms
Enhanced charge transfer by gold nanoparticle at DNA modified electrode and its application to label-free DNA detection.
Breast Neoplasms
Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.
Breast Neoplasms
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
Breast Neoplasms
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models.
Breast Neoplasms
Enhancing radiosensitivity: targeting the DNA repair pathways.
Breast Neoplasms
ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Breast Neoplasms
Entertainment-education in a media-saturated environment: examining the impact of single and multiple exposures to breast cancer storylines on two popular medical dramas.
Breast Neoplasms
Enzyme-catalyzed signal amplification for electrochemical DNA detection with a PNA-modified electrode.
Breast Neoplasms
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.
Breast Neoplasms
Epidemiology and prevention of breast cancer.
Breast Neoplasms
Epidemiology of breast cancer among BRCA mutation carriers: an overview.
Breast Neoplasms
Epidemiology of Breast Cancer in Women.
Breast Neoplasms
Epidemiology of pancreatic cancer: an overview.
Breast Neoplasms
Epidemiology of susceptibility to breast cancer.
Breast Neoplasms
Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
Breast Neoplasms
Epidemiology, prevention, and early detection of breast cancer.
Breast Neoplasms
Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor.
Breast Neoplasms
Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Breast Neoplasms
Epigenetic changes in BRCA1-mutated familial breast cancer.
Breast Neoplasms
Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours.
Breast Neoplasms
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Breast Neoplasms
Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes.
Breast Neoplasms
Epigenetic markers of early tumor development.
Breast Neoplasms
Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines.
Breast Neoplasms
Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Breast Neoplasms
Epigenetic repression of phosphatidylethanolamine, N-methyltransferase (PEMT) in BRCA1-mutated breast cancer.
Breast Neoplasms
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Breast Neoplasms
Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population.
Breast Neoplasms
Epithelial ovarian cancer.
Breast Neoplasms
Epstein Barr virus: a prime candidate of breast cancer aetiology in Sudanese patients.
Breast Neoplasms
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.
Breast Neoplasms
Erratum to "Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study" by Lieske H Schrijver et al.
Breast Neoplasms
Erratum to: Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.
Breast Neoplasms
Erratum to: recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
Breast Neoplasms
Erratum to: Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review.
Breast Neoplasms
Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line.
Breast Neoplasms
Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers.
Breast Neoplasms
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.
Breast Neoplasms
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.
Breast Neoplasms
Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.
Breast Neoplasms
Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1.
Breast Neoplasms
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Breast Neoplasms
Estrogen induces dynamic ER? and RING1B recruitment to control gene and enhancer activities in luminal breast cancer.
Breast Neoplasms
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-Dependent Manner.
Breast Neoplasms
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Breast Neoplasms
Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.
Breast Neoplasms
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Breast Neoplasms
Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Breast Neoplasms
Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.
Breast Neoplasms
Estrogen receptor-?, RBCK1, and protein kinase C ? 1 cooperate to regulate estrogen receptor-? gene expression.
Breast Neoplasms
Estrogens, BRCA1, and breast cancer.
Breast Neoplasms
Ethnic differences in cancer incidence: a marker for inherited susceptibility?
Breast Neoplasms
Ethnic differences in cancer risk resulting from genetic variation.
Breast Neoplasms
Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.
Breast Neoplasms
Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter.
Breast Neoplasms
Evaluating breast cancer risk: available models to assess individual breast cancer risk and probability to be a BRCA mutation carrier.
Breast Neoplasms
Evaluating cancer epidemiologic risk factors using multiple primary malignancies.
Breast Neoplasms
Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians.
Breast Neoplasms
Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
Breast Neoplasms
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Breast Neoplasms
Evaluation and treatment of BRCA-positive patients.
Breast Neoplasms
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).
Breast Neoplasms
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
Breast Neoplasms
Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Breast Neoplasms
Evaluation of BRCA1 Large Genomic Rearrangements in Group of Egyptian Female Breast Cancer Patients Using MLPA.
Breast Neoplasms
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Breast Neoplasms
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Breast Neoplasms
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Breast Neoplasms
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.
Breast Neoplasms
Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer.
Breast Neoplasms
Evaluation of genotype data in clinical risk assessment: methods and application to BRCA1, BRCA2, and N-acetyl transferase-2 genotypes in breast cancer.
Breast Neoplasms
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Breast Neoplasms
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium.
Breast Neoplasms
Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases.
Breast Neoplasms
Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
Breast Neoplasms
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.
Breast Neoplasms
Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer.
Breast Neoplasms
Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Breast Neoplasms
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
Breast Neoplasms
Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Breast Neoplasms
Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
Breast Neoplasms
Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.
Breast Neoplasms
Evidence for a transcriptional activation function of BRCA1 C-terminal region.
Breast Neoplasms
Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.
Breast Neoplasms
Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal.
Breast Neoplasms
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
Breast Neoplasms
Evidence for involvement of BRCA1 in sporadic breast carcinomas.
Breast Neoplasms
Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.
Breast Neoplasms
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.
Breast Neoplasms
Evolutionary pathways in BRCA1-associated breast tumors.
Breast Neoplasms
Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions.
Breast Neoplasms
Examining Women's Health: 1996-1997.
Breast Neoplasms
Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
Breast Neoplasms
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Breast Neoplasms
Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Breast Neoplasms
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.
Breast Neoplasms
Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
Breast Neoplasms
Experiences and decisions that motivate women at increased risk of breast cancer to participate in an experimental screening program.
Breast Neoplasms
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
Breast Neoplasms
Exploring the role of BRCA1, BRCA2 and RAD51 as biomarkers for breast cancer.
Breast Neoplasms
Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer.
Breast Neoplasms
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Breast Neoplasms
Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
Breast Neoplasms
Expression of Autophagy and Mitophagy Markers in Breast Cancer Tissues.
Breast Neoplasms
Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status.
Breast Neoplasms
Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
Breast Neoplasms
Expression of BRCA1 and BRCA2 in normal and neoplastic cells.
Breast Neoplasms
Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Breast Neoplasms
Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.
Breast Neoplasms
Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice.
Breast Neoplasms
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Breast Neoplasms
Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Breast Neoplasms
Expression of BRCA1, NBR1 and NBR2 genes in human breast cancer cells.
Breast Neoplasms
Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
Breast Neoplasms
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
Breast Neoplasms
Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Breast Neoplasms
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
Breast Neoplasms
Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Breast Neoplasms
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
Breast Neoplasms
Expression of HER2 and BRCA1 Correlates with Prognosis in Patients with Breast Cancer After Radiotherapy: A Case-Control Study.
Breast Neoplasms
Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
Breast Neoplasms
Expression of human BRCA1?17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response.
Breast Neoplasms
Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells.
Breast Neoplasms
Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.
Breast Neoplasms
Expression of PCNA-binding domain of CtIP, a motif required for CtIP localization at DNA replication foci, causes DNA damage and activation of DNA damage checkpoint.
Breast Neoplasms
Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer.
Breast Neoplasms
Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.
Breast Neoplasms
Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Breast Neoplasms
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.
Breast Neoplasms
Expression of the three components of linear ubiquitin assembly complex in breast cancer.
Breast Neoplasms
Expression patterns of the BRCA1 splicing variants in canine normal tissues and mammary gland tumors.
Breast Neoplasms
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Breast Neoplasms
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
Breast Neoplasms
External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years.
Breast Neoplasms
Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus.
Breast Neoplasms
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
Breast Neoplasms
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Breast Neoplasms
FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.
Breast Neoplasms
Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage.
Breast Neoplasms
Factors increasing local recurrence in breast-conserving surgery.
Breast Neoplasms
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Breast Neoplasms
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk.
Breast Neoplasms
Familial breast cancer in Costa Rica: an initial approach.
Breast Neoplasms
Familial breast cancer in southern Taiwan.
Breast Neoplasms
Familial breast cancer risk assessment.
Breast Neoplasms
Familial breast cancer, underlying genes, and clinical implications: a review.
Breast Neoplasms
Familial breast cancer.
Breast Neoplasms
Familial breast cancer. Approaching the isolation of a susceptibility gene.
Breast Neoplasms
Familial breast cancer. BRCA1 down, BRCA2 to go.
Breast Neoplasms
Familial breast cancer: an investigation into the outcome of treatment for early stage disease.
Breast Neoplasms
Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
Breast Neoplasms
Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Breast Neoplasms
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients.
Breast Neoplasms
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Breast Neoplasms
Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
Breast Neoplasms
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Breast Neoplasms
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.
Breast Neoplasms
Familial non-BRCA1/BRCA2-associated breast cancer.
Breast Neoplasms
Familial relative risks for breast cancer by pathological subtype: a population-based cohort study.
Breast Neoplasms
Familial risk and genetic susceptibility for breast cancer.
Breast Neoplasms
Familial risk, abortion and their interactive effect on the risk of breast cancer--a combined analysis of six case-control studies.
Breast Neoplasms
Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.
Breast Neoplasms
Familial sarcoma: challenging pedigrees.
Breast Neoplasms
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Breast Neoplasms
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Breast Neoplasms
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Breast Neoplasms
Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry.
Breast Neoplasms
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
Breast Neoplasms
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Breast Neoplasms
Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Breast Neoplasms
Family specific genetic predisposition to breast cancer: results from Tunisian whole exome sequenced breast cancer cases.
Breast Neoplasms
FANCD2 associated with sporadic breast cancer risk.
Breast Neoplasms
FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein.
Breast Neoplasms
FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress.
Breast Neoplasms
FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination.
Breast Neoplasms
Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells.
Breast Neoplasms
Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets.
Breast Neoplasms
Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
Breast Neoplasms
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
Breast Neoplasms
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.
Breast Neoplasms
Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.
Breast Neoplasms
Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer.
Breast Neoplasms
Filamin A inhibits tumor progression through regulating BRCA1 expression in human breast cancer.
Breast Neoplasms
Fine needle aspiration cytology of a myxoid adrenocortical adenoma. A case report.
Breast Neoplasms
First case of invasive breast cancer following prophylactic bilateral skin sparing mastectomy in a BRCA1 mutation carrier.
Breast Neoplasms
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
Breast Neoplasms
First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
Breast Neoplasms
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Breast Neoplasms
FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.
Breast Neoplasms
Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Breast Neoplasms
Folate and breast cancer: what about high-risk women?
Breast Neoplasms
Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.
Breast Neoplasms
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Breast Neoplasms
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Breast Neoplasms
Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
Breast Neoplasms
Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore.
Breast Neoplasms
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Breast Neoplasms
Founder mutations of BRCA1 and BRCA2 in North American families of Polish origin that are affected with breast cancer.
Breast Neoplasms
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Breast Neoplasms
Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing.
Breast Neoplasms
Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors.
Breast Neoplasms
FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
Breast Neoplasms
FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
Breast Neoplasms
FOXP3 Regulates Sensitivity of Cancer Cells to Irradiation by Transcriptional Repression of BRCA1.
Breast Neoplasms
Frailty Models for Familial Risk with Application to Breast Cancer.
Breast Neoplasms
Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.
Breast Neoplasms
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Breast Neoplasms
Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.
Breast Neoplasms
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Breast Neoplasms
Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing.
Breast Neoplasms
Frequency of BRCA1 mutation 5382insC in German breast cancer patients.
Breast Neoplasms
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
Breast Neoplasms
Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
Breast Neoplasms
Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
Breast Neoplasms
Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area.
Breast Neoplasms
Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Breast Neoplasms
Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Breast Neoplasms
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Breast Neoplasms
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Breast Neoplasms
Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer.
Breast Neoplasms
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.
Breast Neoplasms
Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Breast Neoplasms
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.
Breast Neoplasms
Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance.
Breast Neoplasms
Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset.
Breast Neoplasms
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Breast Neoplasms
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Breast Neoplasms
Fresh and ozonized black carbon promoted DNA damage and repair responses in A549 cells.
Breast Neoplasms
From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair.
Breast Neoplasms
From the small screen to breast cancer screening: examining the effects of a television storyline on awareness of genetic risk factors.
Breast Neoplasms
Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity.
Breast Neoplasms
Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families.
Breast Neoplasms
Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Breast Neoplasms
Functional characterization of BRCA1 gene variants by mini-gene splicing assay.
Breast Neoplasms
Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Breast Neoplasms
Functional domains of the BRCA1 and BRCA2 proteins.
Breast Neoplasms
Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
Breast Neoplasms
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
Breast Neoplasms
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Breast Neoplasms
Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer.
Breast Neoplasms
Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer.
Breast Neoplasms
Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif.
Breast Neoplasms
Functional investigation of the BRCA1 Val1714Gly and Asp1733Gly variants by computational tools and yeast transcription activation assay.
Breast Neoplasms
Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response.
Breast Neoplasms
Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: Potential breast cancer risk alleles and their distribution across human populations.
Breast Neoplasms
Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women.
Breast Neoplasms
Functional profiling of nucleotide Excision repair in breast cancer.
Breast Neoplasms
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Breast Neoplasms
Functions of the BRCA1 and BRCA2 genes.
Breast Neoplasms
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter.
Breast Neoplasms
Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence.
Breast Neoplasms
Gallic acid induces DNA damage and inhibits DNA repair-associated protein expression in human oral cancer SCC-4 cells.
Breast Neoplasms
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Breast Neoplasms
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Breast Neoplasms
Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer.
Breast Neoplasms
Gene expression in inherited breast cancer.
Breast Neoplasms
Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report.
Breast Neoplasms
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.
Breast Neoplasms
Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay.
Breast Neoplasms
Gene knockout experiments to quantify a G2/M genetic network simulation for mammary cancer susceptibility.
Breast Neoplasms
Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Gene panel testing for hereditary breast cancer.
Breast Neoplasms
Gene selection: a Bayesian variable selection approach.
Breast Neoplasms
Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.
Breast Neoplasms
Gene x Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study.
Breast Neoplasms
Gene-based association analysis of survival traits via functional regression-based mixed effect cox models for related samples.
Breast Neoplasms
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients.
Breast Neoplasms
Gene-environment interactions in breast cancer.
Breast Neoplasms
Gene-expression profiles in hereditary breast cancer.
Breast Neoplasms
Gene-gene interactions in breast cancer susceptibility.
Breast Neoplasms
Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.
Breast Neoplasms
Generation and analysis of Brca1 conditional knockout mice.
Breast Neoplasms
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Breast Neoplasms
Genes implicated in hereditary breast cancer syndromes.
Breast Neoplasms
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.
Breast Neoplasms
GENESIS: a French national resource to study the missing heritability of breast cancer.
Breast Neoplasms
Genetic alterations in breast cancer.
Breast Neoplasms
Genetic analyses of male breast cancer in Israel.
Breast Neoplasms
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Breast Neoplasms
Genetic analysis of BRCA1 function in a defined tumor cell line.
Breast Neoplasms
Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.
Breast Neoplasms
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
Breast Neoplasms
Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1.
Breast Neoplasms
Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
Breast Neoplasms
Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
Breast Neoplasms
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
Breast Neoplasms
Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Breast Neoplasms
Genetic anticipation is associated with telomere shortening in hereditary breast cancer.
Breast Neoplasms
Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations.
Breast Neoplasms
Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.
Breast Neoplasms
Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study.
Breast Neoplasms
Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today?
Breast Neoplasms
Genetic developments in breast cancer.
Breast Neoplasms
Genetic epidemiology of early onset breast cancer.
Breast Neoplasms
Genetic epidemiology of female breast cancer.
Breast Neoplasms
Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases.
Breast Neoplasms
Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in chinese women.
Breast Neoplasms
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Breast Neoplasms
Genetic heterogeneity in breast cancer susceptibility.
Breast Neoplasms
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
Breast Neoplasms
Genetic instability in the RAD51 and BRCA1 regions in breast cancer.
Breast Neoplasms
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.
Breast Neoplasms
Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.
Breast Neoplasms
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Breast Neoplasms
Genetic Landscape of Male Breast Cancer.
Breast Neoplasms
Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA.
Breast Neoplasms
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Genetic polymorphims of estrogen receptor alpha -397 PvuII (T>C) and -351 XbaI (A>G) in a portuguese population: prevalence and relation with breast cancer susceptibility.
Breast Neoplasms
Genetic polymorphisms and protein expression of P53 and BRCA1 in preneoplastic and neoplastic rat mammary glands.
Breast Neoplasms
Genetic polymorphisms and susceptibility to cancer development.
Breast Neoplasms
Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population.
Breast Neoplasms
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
Breast Neoplasms
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.
Breast Neoplasms
Genetic predisposition syndromes and their management.
Breast Neoplasms
Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Breast Neoplasms
Genetic predisposition to breast cancer: past, present, and future.
Breast Neoplasms
Genetic predisposition to male breast cancer in Poland.
Breast Neoplasms
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Breast Neoplasms
Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Breast Neoplasms
Genetic risk of breast cancer.
Breast Neoplasms
Genetic risk transmission in a family affected by familial breast cancer.
Breast Neoplasms
Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer.
Breast Neoplasms
Genetic steps of mammalian homologous repair with distinct mutagenic consequences.
Breast Neoplasms
Genetic suppression reveals DNA repair-independent antagonism between BRCA1 and COBRA1 in mammary gland development.
Breast Neoplasms
Genetic susceptibility for breast cancer--risk assessment and counseling.
Breast Neoplasms
Genetic susceptibility for breast cancer: how many more genes to be found?
Breast Neoplasms
Genetic susceptibility for breast cancer: testing and primary prevention options.
Breast Neoplasms
Genetic susceptibility testing for breast and ovarian cancer: a progress report.
Breast Neoplasms
Genetic susceptibility to breast and ovarian cancer.
Breast Neoplasms
Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions.
Breast Neoplasms
Genetic susceptibility to breast cancer.
Breast Neoplasms
Genetic Susceptibility to Triple-Negative Breast Cancer.
Breast Neoplasms
Genetic testing and interpretive complexity: a BRCA1 gene mutation example.
Breast Neoplasms
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Breast Neoplasms
Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group.
Breast Neoplasms
Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines.
Breast Neoplasms
Genetic testing for breast cancer risk, from BRCA1/2 to a seven gene panel: an ethical analysis.
Breast Neoplasms
Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
Breast Neoplasms
Genetic testing for susceptibility to breast cancer: findings from women's focus groups.
Breast Neoplasms
Genetic testing in a cohort of young patients with HER2-amplified breast cancer.
Breast Neoplasms
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Breast Neoplasms
Genetic testing in women with breast cancer: implications for treatment.
Breast Neoplasms
Genetic testing in young women with breast cancer: results from a Web-based survey.
Breast Neoplasms
Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.
Breast Neoplasms
Genetic Variants Associated with Clinicopathological Profiles in Sporadic Breast Cancer in Sri Lankan Women.
Breast Neoplasms
Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.
Breast Neoplasms
Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers.
Breast Neoplasms
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
Breast Neoplasms
Genetic variation of the brca1 and brca2 genes in macedonian patients.
Breast Neoplasms
Genetic Variations, Exposure to Persistent Organic Pollutants and Breast Cancer Risk: A Greenlandic Case-Control Study.
Breast Neoplasms
Genetically engineered ER? positive breast cancer mouse models.
Breast Neoplasms
Genetics and the young woman with breast cancer.
Breast Neoplasms
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
Breast Neoplasms
Genetics of breast and ovarian cancer.
Breast Neoplasms
Genetics of breast cancer.
Breast Neoplasms
Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe.
Breast Neoplasms
Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target.
Breast Neoplasms
Genistein Prevents BRCA1 CpG Methylation and Proliferation in Human Breast Cancer Cells with Activated Aromatic Hydrocarbon Receptor.
Breast Neoplasms
Genome instability in blood cells of a BRCA1+ breast cancer family.
Breast Neoplasms
Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation.
Breast Neoplasms
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
Breast Neoplasms
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
Breast Neoplasms
Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.
Breast Neoplasms
Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
Breast Neoplasms
Genome-wide linkage scan for breast cancer susceptibility loci in Swedish hereditary non-BRCA1/2 families: suggestive linkage to 10q23.32-q25.3.
Breast Neoplasms
Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-22 as a putative breast cancer susceptibility locus.
Breast Neoplasms
Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci.
Breast Neoplasms
Genome-wide scanning for linkage in Finnish breast cancer families.
Breast Neoplasms
Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
Breast Neoplasms
Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies.
Breast Neoplasms
Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.
Breast Neoplasms
Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.
Breast Neoplasms
Genomic analysis of the 8p11-12 amplicon in familial breast cancer.
Breast Neoplasms
Genomic approaches to identifying breast cancer susceptibility factors.
Breast Neoplasms
Genomic Biomarkers for Breast Cancer Risk.
Breast Neoplasms
Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma.
Breast Neoplasms
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Breast Neoplasms
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Breast Neoplasms
Genomic rearrangement screening of the BRCA1 from seventy Iranian high-risk breast cancer families.
Breast Neoplasms
Genomic rearrangements in BRCA1 and BRCA2: A literature review.
Breast Neoplasms
Genomic rearrangements of the BRCA1 gene in Chilean breast cancer families: an MLPA analysis.
Breast Neoplasms
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Breast Neoplasms
Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.
Breast Neoplasms
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
Breast Neoplasms
Genomics and pharmacogenomics of breast cancer: current knowledge and trends.
Breast Neoplasms
Genotype in BRCA-associated breast cancers.
Breast Neoplasms
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
Breast Neoplasms
Genotype/Phenotype correlations in patients with hereditary breast cancer.
Breast Neoplasms
Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer.
Breast Neoplasms
Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
Breast Neoplasms
Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Breast Neoplasms
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Breast Neoplasms
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.
Breast Neoplasms
Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations.
Breast Neoplasms
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Breast Neoplasms
German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
Breast Neoplasms
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Breast Neoplasms
Germline BRCA1 185delAG mutations in Jewish women with breast cancer.
Breast Neoplasms
Germline BRCA1 alterations in a population-based series of ovarian cancer cases.
Breast Neoplasms
Germline BRCA1 and BRCA2 testing for breast cancer survivors.
Breast Neoplasms
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
Breast Neoplasms
Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Breast Neoplasms
Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India.
Breast Neoplasms
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
Breast Neoplasms
Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer.
Breast Neoplasms
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Breast Neoplasms
Germline BRCA1 mutations in Iranian women with breast cancer.
Breast Neoplasms
Germline BRCA1 mutations increase prostate cancer risk.
Breast Neoplasms
Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination.
Breast Neoplasms
Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Breast Neoplasms
Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours.
Breast Neoplasms
Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Breast Neoplasms
Germline E-cadherin mutations in familial lobular breast cancer.
Breast Neoplasms
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
Breast Neoplasms
Germline Genetic Testing: What the Breast Surgeon Needs to Know.
Breast Neoplasms
Germline large genomic alterations on 7q in patients with multiple primary cancers.
Breast Neoplasms
Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Breast Neoplasms
Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Breast Neoplasms
Germline mutation of BRCA1 in Japanese breast cancer families.
Breast Neoplasms
Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer.
Breast Neoplasms
Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland.
Breast Neoplasms
Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population.
Breast Neoplasms
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Breast Neoplasms
Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
Breast Neoplasms
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Breast Neoplasms
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.
Breast Neoplasms
Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.
Breast Neoplasms
Germline mutations in RAD51C in Jewish high cancer risk families.
Breast Neoplasms
Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.
Breast Neoplasms
Germline mutations in the PTEN gene in Israeli patients with Bannayan-Riley-Ruvalcaba syndrome and women with familial breast cancer.
Breast Neoplasms
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Breast Neoplasms
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Breast Neoplasms
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.
Breast Neoplasms
Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Breast Neoplasms
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
Breast Neoplasms
Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Breast Neoplasms
Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
Breast Neoplasms
Germline RAP80 mutations and susceptibility to breast cancer.
Breast Neoplasms
Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability.
Breast Neoplasms
Germline RECQL mutations in high risk Chinese breast cancer patients.
Breast Neoplasms
Germline TP53 mutational spectrum in French Canadians with breast cancer.
Breast Neoplasms
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Breast Neoplasms
Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer.
Breast Neoplasms
Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico.
Breast Neoplasms
Giant Intrathoracic Meningocele and Breast Cancer in a Neurofibromatosis Type I Patient.
Breast Neoplasms
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Breast Neoplasms
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.
Breast Neoplasms
Glucose Concentration in Cell Culture Medium Influences the BRCA1-Mediated Regulation of the Lipogenic Action of IGF-I in Breast Cancer Cells.
Breast Neoplasms
Gold nanoparticle-based label-free detection of BRCA1 mutations utilizing DNA ligation on DNA microarray.
Breast Neoplasms
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Breast Neoplasms
Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity.
Breast Neoplasms
Growth retardation and tumour inhibition by BRCA1.
Breast Neoplasms
GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability.
Breast Neoplasms
GWAS identifies a common breast cancer risk allele among BRCA1 carriers.
Breast Neoplasms
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Breast Neoplasms
Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Breast Neoplasms
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Breast Neoplasms
H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.
Breast Neoplasms
Haplo-insufficiency of BRCA1 in sporadic breast cancer.
Breast Neoplasms
Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes.
Breast Neoplasms
Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence.
Breast Neoplasms
Haplotype Analysis of BRCA1 Gene D17S855 and D17S1322 Markers in Iranian Familial Breast Cancer Patients.
Breast Neoplasms
Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer.
Breast Neoplasms
Haplotype analysis of common variants in the BRCA1 gene and risk of sporadic breast cancer.
Breast Neoplasms
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.
Breast Neoplasms
Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
Breast Neoplasms
Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.
Breast Neoplasms
Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
Breast Neoplasms
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
Breast Neoplasms
Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
Breast Neoplasms
HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
Breast Neoplasms
HER2-positive breast cancer in a germline BRCA1 gene large deletion carrier.
Breast Neoplasms
HERC2 interacts with Claspin and regulates DNA origin firing and replication fork progression.
Breast Neoplasms
HERC2 is an E3 ligase that targets BRCA1 for degradation.
Breast Neoplasms
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Breast Neoplasms
Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.
Breast Neoplasms
Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
Breast Neoplasms
Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
Breast Neoplasms
Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Breast Neoplasms
Hereditary breast cancer and family cancer syndromes.
Breast Neoplasms
Hereditary breast cancer and handling of patients at risk.
Breast Neoplasms
Hereditary breast cancer and linkage analysis to BRCA1.
Breast Neoplasms
Hereditary breast cancer considering Cowden syndrome: a case study.
Breast Neoplasms
Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population.
Breast Neoplasms
Hereditary breast cancer.
Breast Neoplasms
Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
Breast Neoplasms
Hereditary breast cancer: a brief overview.
Breast Neoplasms
Hereditary breast cancer: clinical, pathological and molecular characteristics.
Breast Neoplasms
Hereditary breast cancer: from molecular pathology to tailored therapies.
Breast Neoplasms
Hereditary breast cancer: high risk genes, genetic testing and clinical implications.
Breast Neoplasms
Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Breast Neoplasms
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Breast Neoplasms
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage.
Breast Neoplasms
Hereditary breast cancer: the era of new susceptibility genes.
Breast Neoplasms
Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
Breast Neoplasms
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Breast Neoplasms
Hereditary breast-ovarian cancer: clinical findings and medical management.
Breast Neoplasms
Hereditary cancer: family history, diagnosis, molecular genetics, ecogenetics, and management strategies.
Breast Neoplasms
Hereditary ovarian cancer: molecular genetics and clinical implications.
Breast Neoplasms
Hereditary predisposition to breast cancer.
Breast Neoplasms
Hereditary predisposition to cancers of the digestive tract, breast, gynecological and gonadal: Focus on the Peutz-Jeghers.
Breast Neoplasms
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Breast Neoplasms
Hereditary risk of breast cancer: not only BRCA.
Breast Neoplasms
Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Breast Neoplasms
Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells.
Breast Neoplasms
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Breast Neoplasms
Heterochromatin instability in cancer: From the Barr body to satellites and the nuclear periphery.
Breast Neoplasms
Heterochromatin-Encoded Satellite RNAs Induce Breast Cancer.
Breast Neoplasms
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
Breast Neoplasms
Heterogenous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs.
Breast Neoplasms
Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
Breast Neoplasms
Heterozygote BRCA1 status and skewed chromosome X inactivation.
Breast Neoplasms
High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
Breast Neoplasms
High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.
Breast Neoplasms
High efficiency of BRCA1 knockout using rAAV-mediated gene targeting: developing a pig model for breast cancer.
Breast Neoplasms
High Expression of Stem Cell Marker ALDH1 is Associated with Reduced BRCA1 in Invasive Breast Carcinomas.
Breast Neoplasms
High expression of the breast cancer susceptibility gene BRCA1 in long-lived termite kings.
Breast Neoplasms
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
Breast Neoplasms
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Breast Neoplasms
High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas.
Breast Neoplasms
High frequency of BRCA1 5382insC mutation in Russian breast cancer patients.
Breast Neoplasms
High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer.
Breast Neoplasms
High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.
Breast Neoplasms
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
Breast Neoplasms
High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Breast Neoplasms
High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
Breast Neoplasms
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.
Breast Neoplasms
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
Breast Neoplasms
High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer.
Breast Neoplasms
High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
Breast Neoplasms
High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Breast Neoplasms
High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.
Breast Neoplasms
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Breast Neoplasms
High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.
Breast Neoplasms
High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
Breast Neoplasms
High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.
Breast Neoplasms
High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy.
Breast Neoplasms
High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
Breast Neoplasms
High-resolution oligonucleotide array-CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1.
Breast Neoplasms
High-throughput mutation detection method to scan BRCA1 and BRCA2 based on heteroduplex analysis by capillary array electrophoresis.
Breast Neoplasms
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Breast Neoplasms
Highlight: BRCA1 and BRCA2 proteins in breast cancer.
Breast Neoplasms
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Breast Neoplasms
Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer.
Breast Neoplasms
Histopathological criteria and selection algorithms for BRCA1 genetic testing.
Breast Neoplasms
Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
Breast Neoplasms
Histopathological features of breast cancer in carriers of ATM gene variants.
Breast Neoplasms
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
Breast Neoplasms
Histopathology of BRCA1- and BRCA2-associated breast cancer.
Breast Neoplasms
HMGA1 protein expression in familial breast carcinoma patients.
Breast Neoplasms
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
Breast Neoplasms
Homocysteine aggravates DNA damage by impairing the FA/Brca1 Pathway in NE4C murine neural stem cells.
Breast Neoplasms
Homologous recombinational repair of DNA ensures mammalian chromosome stability.
Breast Neoplasms
Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.
Breast Neoplasms
Hormonal and Surgical Treatment in Trans-Women with BRCA1 Mutations: A Controversial Topic.
Breast Neoplasms
Hormonal prevention of hereditary breast cancer.
Breast Neoplasms
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Breast Neoplasms
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Breast Neoplasms
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Breast Neoplasms
Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Breast Neoplasms
Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
Breast Neoplasms
Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects.
Breast Neoplasms
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Breast Neoplasms
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Breast Neoplasms
Hormone-dependent regulation of BRCA1 in human breast cancer cells.
Breast Neoplasms
How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens.
Breast Neoplasms
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
Breast Neoplasms
How do women at increased, but unexplained, familial risk of breast cancer perceive and manage their risk? A qualitative interview study.
Breast Neoplasms
How latent viruses cause breast cancer: An explanation based on the microcompetition model.
Breast Neoplasms
How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
Breast Neoplasms
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.
Breast Neoplasms
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Breast Neoplasms
Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors.
Breast Neoplasms
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.
Breast Neoplasms
Human FBXL8 Is a Novel E3 Ligase Which Promotes BRCA Metastasis by Stimulating Pro-Tumorigenic Cytokines and Inhibiting Tumor Suppressors.
Breast Neoplasms
Human gene patents: the possible impacts on genetic services healthcare.
Breast Neoplasms
Human immunodeficiency virus type 1 Vpr induces G2 checkpoint activation by interacting with the splicing factor SAP145.
Breast Neoplasms
Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.
Breast Neoplasms
Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins.
Breast Neoplasms
Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments.
Breast Neoplasms
Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex.
Breast Neoplasms
Human, canine and murine BRCA1 genes: sequence comparison among species.
Breast Neoplasms
HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.
Breast Neoplasms
Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer.
Breast Neoplasms
Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.
Breast Neoplasms
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Breast Neoplasms
Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
Breast Neoplasms
Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
Breast Neoplasms
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Breast Neoplasms
ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.
Breast Neoplasms
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Breast Neoplasms
Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families.
Breast Neoplasms
Identification and frequency of the rs12516 and rs8176318 BRCA1 gene polymorphisms among different populations.
Breast Neoplasms
Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1.
Breast Neoplasms
Identification and in silico analysis of functional SNPs of the BRCA1 gene.
Breast Neoplasms
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.
Breast Neoplasms
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Breast Neoplasms
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family.
Breast Neoplasms
Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
Breast Neoplasms
Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions.
Breast Neoplasms
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Breast Neoplasms
Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer.
Breast Neoplasms
Identification of a founder BRCA1 mutation in the Moroccan population.
Breast Neoplasms
Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
Breast Neoplasms
Identification of a Novel BRCA2 and CHEK2 A-C-G-C Haplotype in Turkish Patients Affected with Breast Cancer.
Breast Neoplasms
Identification of a novel breast cancer-causing mutation in the BRCA1 gene by targeted next generation sequencing: A case report.
Breast Neoplasms
Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
Breast Neoplasms
Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells.
Breast Neoplasms
Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients.
Breast Neoplasms
Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene.
Breast Neoplasms
Identification of a possible somatic BRCA1 mutation affecting translation efficiency in an early-onset sporadic breast cancer patient.
Breast Neoplasms
Identification of a recurrent BRCA1 exon 21-22 genomic rearrangement in Malay breast cancer patients.
Breast Neoplasms
Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Breast Neoplasms
Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBP? expression and contributes to transformation of breast tumor cells.
Breast Neoplasms
Identification of an apoptotic cleavage product of BARD1 as an autoantigen: a potential factor in the antitumoral response mediated by apoptotic bodies.
Breast Neoplasms
Identification of BAF57 mutations in human breast cancer cell lines.
Breast Neoplasms
Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC.
Breast Neoplasms
Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer.
Breast Neoplasms
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Breast Neoplasms
Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
Breast Neoplasms
Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis.
Breast Neoplasms
Identification of BRCA1/2 p.Ser1613Gly, p.Pro871Leu, p.Lys1183Arg, p.Glu1038Gly, p.Ser1140Gly, p.Ala2466Val, p.His2440Arg variants in women under 45 years old with breast nodules suspected of having breast cancer in Burkina Faso.
Breast Neoplasms
Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology.
Breast Neoplasms
Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation.
Breast Neoplasms
Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.
Breast Neoplasms
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Breast Neoplasms
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Breast Neoplasms
Identification of differentially expressed genes associated with colorectal cancer liver metastasis.
Breast Neoplasms
Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
Breast Neoplasms
Identification of Domains of BRCA1 Critical for the Ubiquitin-Dependent Inhibition of Centrosome Function.
Breast Neoplasms
Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.
Breast Neoplasms
Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.
Breast Neoplasms
Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17.
Breast Neoplasms
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.
Breast Neoplasms
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
Breast Neoplasms
Identification of genes induced by BRCA1 in breast cancer cells.
Breast Neoplasms
Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing.
Breast Neoplasms
Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Breast Neoplasms
Identification of Germline BRCA1 Mutations among Breast Cancer Families in Northeastern Iran.
Breast Neoplasms
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Breast Neoplasms
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
Breast Neoplasms
Identification of Mutation in Exon11 of BRCA1 Gene in Bangladeshi Patients with Breast Cancer.
Breast Neoplasms
Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues.
Breast Neoplasms
Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.
Breast Neoplasms
Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis.
Breast Neoplasms
Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients.
Breast Neoplasms
Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
Breast Neoplasms
Identification of novel intronic BRCA1 variants of uncertain significance in a Thai hereditary breast cancer family.
Breast Neoplasms
Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer.
Breast Neoplasms
Identification of potential binding sites for the FHA domain of human Chk2 by in vitro binding studies.
Breast Neoplasms
Identification of proteins that interact with BRCA1 by Far-Western library screening.
Breast Neoplasms
Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.
Breast Neoplasms
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Breast Neoplasms
Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage.
Breast Neoplasms
Identification of the BRCA1 breast cancer gene and its clinical implications.
Breast Neoplasms
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Breast Neoplasms
Identification of the first case of germline duplication of BRCA1 exon 13 in an Italian family.
Breast Neoplasms
Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
Breast Neoplasms
Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene.
Breast Neoplasms
Identification of Variants (rs11571707, rs144848, and rs11571769) in the BRCA2 Gene Associated with Hereditary Breast Cancer in Indigenous Populations of the Brazilian Amazon.
Breast Neoplasms
Identification of women with an increased risk of developing radiation-induced breast cancer.
Breast Neoplasms
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
Breast Neoplasms
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Breast Neoplasms
Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer.
Breast Neoplasms
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Breast Neoplasms
IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer.
Breast Neoplasms
IL-1? induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells.
Breast Neoplasms
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family.
Breast Neoplasms
Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast.
Breast Neoplasms
Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Breast Neoplasms
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Breast Neoplasms
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Breast Neoplasms
Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Breast Neoplasms
Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
Breast Neoplasms
Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
Breast Neoplasms
Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
Breast Neoplasms
Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer.
Breast Neoplasms
Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition.
Breast Neoplasms
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Breast Neoplasms
Impact of cancer predisposition and radiosensitivity on the population risk of radiation-induced cancers.
Breast Neoplasms
Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Breast Neoplasms
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
Breast Neoplasms
Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
Breast Neoplasms
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Breast Neoplasms
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Breast Neoplasms
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Breast Neoplasms
Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
Breast Neoplasms
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
Breast Neoplasms
Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Breast Neoplasms
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
Breast Neoplasms
Implication of BRCA1 gene in breast cancer.
Breast Neoplasms
Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study.
Breast Neoplasms
Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
Breast Neoplasms
In brief: BRCA1 and BRCA2.
Breast Neoplasms
In search of breast cancer culprits: suspecting the suspected and the unsuspected.
Breast Neoplasms
In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy.
Breast Neoplasms
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Breast Neoplasms
In Their Own Words: A Qualitative Study of Kenyan Breast Cancer Survivors' Knowledge, Experiences, and Attitudes Regarding Breast Cancer Genetics.
Breast Neoplasms
In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma.
Breast Neoplasms
In vitro diagnosis of DNA methylation biomarkers with digital PCR in breast tumors.
Breast Neoplasms
In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.
Breast Neoplasms
In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells.
Breast Neoplasms
In-situ breast cancer and BRCA1.
Breast Neoplasms
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Breast Neoplasms
Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer.
Breast Neoplasms
Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.
Breast Neoplasms
Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration.
Breast Neoplasms
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Breast Neoplasms
Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Breast Neoplasms
Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.
Breast Neoplasms
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Breast Neoplasms
Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.
Breast Neoplasms
Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay.
Breast Neoplasms
Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
Breast Neoplasms
Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.
Breast Neoplasms
Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history.
Breast Neoplasms
Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing.
Breast Neoplasms
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
Breast Neoplasms
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
Breast Neoplasms
Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study.
Breast Neoplasms
Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Breast Neoplasms
Increasing incidence of breast cancer in family with BRCA1 mutation.
Breast Neoplasms
Independent origin of 185delAG BRCA1 mutation in an Indian family.
Breast Neoplasms
Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies.
Breast Neoplasms
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Breast Neoplasms
Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet.
Breast Neoplasms
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Breast Neoplasms
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Breast Neoplasms
Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and nonmalignant MCF-10A cells.
Breast Neoplasms
Induction of apoptosis by the tumor suppressor protein BRCA1.
Breast Neoplasms
Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.
Breast Neoplasms
Induction of hemeoxygenase-1 expression after inhibition of hemeoxygenase activity promotes inflammation and worsens ischemic brain damage in mice.
Breast Neoplasms
Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage.
Breast Neoplasms
Induction of the long noncoding RNA NBR2 from the bidirectional BRCA1 promoter under hypoxic conditions.
Breast Neoplasms
Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
Breast Neoplasms
Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Breast Neoplasms
Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
Breast Neoplasms
Informed consent and BRCA1 mutation detection in archived breast tumor specimens.
Breast Neoplasms
Inheritance of cancer.
Breast Neoplasms
Inherited BRCA2 mutation associated with high grade breast cancer.
Breast Neoplasms
Inherited breast and ovarian cancer.
Breast Neoplasms
Inherited Breast Cancer in Nigerian Women.
Breast Neoplasms
Inherited breast cancer.
Breast Neoplasms
Inherited genetic susceptibility to breast cancer.
Breast Neoplasms
Inherited mutations in breast cancer genes-risk and response.
Breast Neoplasms
Inherited predisposition to breast cancer among African American women.
Breast Neoplasms
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study.
Breast Neoplasms
Inherited susceptibility to breast cancer.
Breast Neoplasms
Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells.
Breast Neoplasms
Inhibition of BACH1 (FANCJ) helicase by backbone discontinuity is overcome by increased motor ATPase or length of loading strand.
Breast Neoplasms
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
Breast Neoplasms
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Breast Neoplasms
Inhibition of E2-induced expression of BRCA1 by persistent organochlorines.
Breast Neoplasms
Inhibition of Karyopherin-?2 Augments Radiation-Induced Cell Death by Perturbing BRCA1-Mediated DNA Repair.
Breast Neoplasms
Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells.
Breast Neoplasms
Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
Breast Neoplasms
Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer.
Breast Neoplasms
INPP4B and RAD50 have an interactive effect on survival after breast cancer.
Breast Neoplasms
Insights into the Molecular Basis of Human Hereditary Breast Cancer from Studies of the BRCA1 BRCT Domain.
Breast Neoplasms
Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.
Breast Neoplasms
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Breast Neoplasms
Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.
Breast Neoplasms
Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.
Breast Neoplasms
Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.
Breast Neoplasms
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Breast Neoplasms
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NF?B pathway.
Breast Neoplasms
Integrative Bioinformatics and Functional Analyses of GEO, ENCODE, and TCGA Reveal FADD as a Direct Target of the Tumor Suppressor BRCA1.
Breast Neoplasms
Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional-structural assessments via protein informatics.
Breast Neoplasms
Integrative tumor board: a case report and discussion from Dana-Farber Cancer Institute.
Breast Neoplasms
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
Breast Neoplasms
Intensive radiologic surveillance: a focus on the psychological issues.
Breast Neoplasms
Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers.
Breast Neoplasms
Interaction between BRCA1 and human papilloma virus E7: an ontology study.
Breast Neoplasms
Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2.
Breast Neoplasms
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.
Breast Neoplasms
Interaction fallacy.
Breast Neoplasms
Interaction of p14(ARF) with Brca1 in cancer cell lines and primary breast cancer.
Breast Neoplasms
Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway.
Breast Neoplasms
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
Breast Neoplasms
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Breast Neoplasms
Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs).
Breast Neoplasms
Interest in BRCA1/2 testing in a primary care population.
Breast Neoplasms
Interferon-? signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer.
Breast Neoplasms
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation.
Breast Neoplasms
International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis.
Breast Neoplasms
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
Breast Neoplasms
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
Breast Neoplasms
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Breast Neoplasms
Investigating of variations in BRCA1 gene in Iranian families with breast cancer.
Breast Neoplasms
Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
Breast Neoplasms
Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey.
Breast Neoplasms
Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
Breast Neoplasms
Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers.
Breast Neoplasms
Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene.
Breast Neoplasms
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
Breast Neoplasms
Is BRCA1 associated with familial breast cancer in India?
Breast Neoplasms
Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?
Breast Neoplasms
Is early onset breast cancer with no family history a good criterion for testing BRCA1 and BRCA2 genes? A small population-based study.
Breast Neoplasms
Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK.
Breast Neoplasms
Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
Breast Neoplasms
Is there more to BARD1 than BRCA1?
Breast Neoplasms
Isolation of a diverged homeobox gene, MOX1, from the BRCA1 region on 17q21 by solution hybrid capture.
Breast Neoplasms
Isolation of a functional copy of the human BRCA1 gene by transformation-associated recombination in yeast.
Breast Neoplasms
Isolation, purification and quantification of BRCA1 protein from tumour cells by affinity perfusion chromatography.
Breast Neoplasms
Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
Breast Neoplasms
Japanese Late-Onset Breast Cancer Families: Their Clincopathological Characteristics and Absence of BRCA1 and BRCA2 Germline Mutations.
Breast Neoplasms
Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population.
Breast Neoplasms
Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells.
Breast Neoplasms
KIAA0101 Interacts with BRCA1 and Regulates Centrosome Number.
Breast Neoplasms
Kin-cohort designs for gene characterization.
Breast Neoplasms
Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.
Breast Neoplasms
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Breast Neoplasms
Knowledge Level and Educational Needs of Turkish Oncology Nurses Regarding the Genetics of Hereditary Breast and Ovarian Cancer.
Breast Neoplasms
Knowledge of Breast Cancer Genetics Among Breast Cancer Patients and First-Degree Relatives of Affected Individuals.
Breast Neoplasms
Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial.
Breast Neoplasms
KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients.
Breast Neoplasms
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
Breast Neoplasms
Laboratory determination of hereditary susceptibility to breast and ovarian cancer.
Breast Neoplasms
Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer.
Breast Neoplasms
Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area.
Breast Neoplasms
Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer.
Breast Neoplasms
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.
Breast Neoplasms
Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy.
Breast Neoplasms
Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families.
Breast Neoplasms
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.
Breast Neoplasms
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
Breast Neoplasms
Large genomic rearrangement of BRCA1 and BRCA2 genes in familial breast cancer patients in Korea.
Breast Neoplasms
Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features.
Breast Neoplasms
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Breast Neoplasms
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Breast Neoplasms
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Breast Neoplasms
Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Breast Neoplasms
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
Breast Neoplasms
Lessons learned from BRCA1 and BRCA2.
Breast Neoplasms
Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study.
Breast Neoplasms
Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion.
Breast Neoplasms
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Breast Neoplasms
Ligand binding prediction for BRCA1, a key molecule in the pathogenesis of breast cancer.
Breast Neoplasms
Liganded ER? Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation.
Breast Neoplasms
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Breast Neoplasms
Limited relevance of the CHEK2 gene in hereditary breast cancer.
Breast Neoplasms
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.
Breast Neoplasms
LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy.
Breast Neoplasms
Linc01638 promotes tumorigenesis in HER2+ breast cancer.
Breast Neoplasms
Linkage analysis of BRCA1 in Japanese breast cancer families.
Breast Neoplasms
Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer.
Breast Neoplasms
Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations.
Breast Neoplasms
Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
Breast Neoplasms
Living with the BRCA genetic mutation: An uncertain conclusion to an unending process.
Breast Neoplasms
LncRNA AY343892 inhibits breast cancer development by positively regulating BRCA1-mediated transcription of PTEN.
Breast Neoplasms
LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p.
Breast Neoplasms
Lobular breast cancer: incidence and genetic and non-genetic risk factors.
Breast Neoplasms
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Breast Neoplasms
Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM.
Breast Neoplasms
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
Breast Neoplasms
Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25.
Breast Neoplasms
Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.
Breast Neoplasms
Localization of BRCA1 protein in human breast cancer cells.
Breast Neoplasms
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.
Breast Neoplasms
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Breast Neoplasms
Localization of the human homolog of the yeast cell division control 27 gene (CDC27) proximal to ITGB3 on human chromosome 17q21.3.
Breast Neoplasms
Long-Range PCR and Next-Generation Sequencing of BRCA1 and BRCA2 in Breast Cancer.
Breast Neoplasms
Long-Term Follow-Up of a Female Patient Treated with Olaparib-Hope for a Long Life without Relapse?
Breast Neoplasms
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.
Breast Neoplasms
Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.
Breast Neoplasms
Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
Breast Neoplasms
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Breast Neoplasms
Longitudinal Changes in Patient Distress following Interactive Decision Aid Use among BRCA1/2 Carriers: A Randomized Trial.
Breast Neoplasms
Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Breast Neoplasms
Loss of BRCA1 expression in sporadic male breast carcinoma.
Breast Neoplasms
Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.
Breast Neoplasms
Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
Breast Neoplasms
Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
Breast Neoplasms
Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers.
Breast Neoplasms
Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
Breast Neoplasms
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Breast Neoplasms
Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
Breast Neoplasms
Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer.
Breast Neoplasms
Loss of heterozygosity at BRCA1, TP53, nm-23 and other loci on chromosome 17q in human breast carcinoma.
Breast Neoplasms
Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
Breast Neoplasms
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Breast Neoplasms
Loss of heterozygosity in familial breast carcinomas.
Breast Neoplasms
Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.
Breast Neoplasms
Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.
Breast Neoplasms
Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
Breast Neoplasms
Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer.
Breast Neoplasms
Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
Breast Neoplasms
Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Breast Neoplasms
Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.
Breast Neoplasms
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Breast Neoplasms
Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype.
Breast Neoplasms
Loss of nuclear BRCA1 localization in breast carcinoma is age dependent.
Breast Neoplasms
Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-?-mediated MDSC infiltration.
Breast Neoplasms
Loss of SIRT4 promotes the self-renewal of Breast Cancer Stem Cells.
Breast Neoplasms
Loss of the BRCA1-Interacting Helicase BRIP1 Results in Abnormal Mammary Acinar Morphogenesis.
Breast Neoplasms
Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.
Breast Neoplasms
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Breast Neoplasms
Low expression of bcl-2 in Brca1-associated breast cancers.
Breast Neoplasms
Low fouling label-free DNA sensor based on polyethylene glycols decorated with gold nanoparticles for the detection of breast cancer biomarkers.
Breast Neoplasms
Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer.
Breast Neoplasms
Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.
Breast Neoplasms
Low frequency of microsatellite instability in BRCA1 mutated breast tumours.
Breast Neoplasms
Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.
Breast Neoplasms
Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Breast Neoplasms
Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
Breast Neoplasms
Low penetrance genes associated with increased risk for breast cancer.
Breast Neoplasms
Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population.
Breast Neoplasms
Low prevalence of BRCA1 exon rearrangements in familial and young sporadic breast cancer patients.
Breast Neoplasms
Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history.
Breast Neoplasms
Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Breast Neoplasms
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Breast Neoplasms
Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
Breast Neoplasms
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Breast Neoplasms
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Breast Neoplasms
LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition.
Breast Neoplasms
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.
Breast Neoplasms
Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine.
Breast Neoplasms
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Breast Neoplasms
Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency.
Breast Neoplasms
Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre.
Breast Neoplasms
Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective.
Breast Neoplasms
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
Breast Neoplasms
MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer.
Breast Neoplasms
MALDI-TOF based mutation detection using tagged in vitro synthesized peptides.
Breast Neoplasms
Male breast cancer--an andrological disease: risk factors and diagnosis.
Breast Neoplasms
Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV.
Breast Neoplasms
Mammalian protein homologous to VAT-1 of Torpedo californica: isolation from Ehrlich ascites tumor cells, biochemical characterization, and organization of its gene.
Breast Neoplasms
Mammary gland development, reproductive history, and breast cancer risk.
Breast Neoplasms
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
Breast Neoplasms
Mammary tumor formation in p53- and BRCA1-deficient mice.
Breast Neoplasms
Mammary tumor induction and premature ovarian failure in ApcMin mice are not enhanced by Brca2 deficiency.
Breast Neoplasms
Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.
Breast Neoplasms
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Breast Neoplasms
Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.
Breast Neoplasms
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.
Breast Neoplasms
Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study.
Breast Neoplasms
Mammography of breast carcinoma in women who have mutations of the breast cancer gene BRCA1: initial experience.
Breast Neoplasms
Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Breast Neoplasms
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Breast Neoplasms
Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.
Breast Neoplasms
Management of early-onset breast cancer and BRCA1 or BRCA2 status.
Breast Neoplasms
Management of women with a family history of breast cancer.
Breast Neoplasms
Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer.
Breast Neoplasms
Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
Breast Neoplasms
Management updates for women with a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Manumycin polyketides act as molecular glues between UBR7 and P53.
Breast Neoplasms
Mapping and conformational characterization of the DNA-binding region of the breast cancer susceptibility protein BRCA1.
Breast Neoplasms
Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes.
Breast Neoplasms
Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations.
Breast Neoplasms
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.
Breast Neoplasms
MCPIP1 Selectively Destabilizes Transcripts Associated with an Antiapoptotic Gene Expression Program in Breast Cancer Cells That Can Elicit Complete Tumor Regression.
Breast Neoplasms
MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination.
Breast Neoplasms
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Breast Neoplasms
Mechanisms of the Synergistic Interaction between the Bisphosphonate Zoledronic Acid and the Chemotherapy Agent Paclitaxel in Breast Cancer Cells in vitro.
Breast Neoplasms
Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer.
Breast Neoplasms
Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry.
Breast Neoplasms
Medical students' attitudes toward genetic testing of minors.
Breast Neoplasms
Medullary carcinoma of breast with a novel germline mutation 1123t >g in exon 11 of brca1.
Breast Neoplasms
Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing.
Breast Neoplasms
MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks.
Breast Neoplasms
MERIT40 facilitates BRCA1 localization and DNA damage repair.
Breast Neoplasms
Meta-analysis of BRCA1 and BRCA2 penetrance.
Breast Neoplasms
Meta-Analysis of BRCA1 Polymorphisms and Breast Cancer Susceptibility.
Breast Neoplasms
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Breast Neoplasms
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Breast Neoplasms
Metachronous Contralateral Male Breast Cancer: Case Report and Literature Review.
Breast Neoplasms
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Breast Neoplasms
Metastatic Triple-negative Breast Cancer.
Breast Neoplasms
Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Breast Neoplasms
Methionine-Dependence Phenotype in the de novo Pathway in BRCA1 and BRCA2 Mutation Carriers with and without Breast Cancer.
Breast Neoplasms
Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
Breast Neoplasms
Methylated genes in breast cancer: Associations with clinical and histopathological features in a familial breast cancer cohort.
Breast Neoplasms
Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Breast Neoplasms
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.
Breast Neoplasms
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Breast Neoplasms
Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters.
Breast Neoplasms
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Breast Neoplasms
Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
Breast Neoplasms
Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events.
Breast Neoplasms
Methylation of the BRCA1 gene in sporadic breast cancer.
Breast Neoplasms
Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
Breast Neoplasms
Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.
Breast Neoplasms
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Breast Neoplasms
Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function.
Breast Neoplasms
Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer
Breast Neoplasms
Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.
Breast Neoplasms
Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes.
Breast Neoplasms
Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women.
Breast Neoplasms
Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation.
Breast Neoplasms
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
Breast Neoplasms
Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol.
Breast Neoplasms
Microarray-based detection of Korean-specific BRCA1 mutations.
Breast Neoplasms
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Breast Neoplasms
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
Breast Neoplasms
MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Breast Neoplasms
MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.
Breast Neoplasms
MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development.
Breast Neoplasms
MicroRNA signatures in hereditary breast cancer.
Breast Neoplasms
MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.
Breast Neoplasms
MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
Breast Neoplasms
Microsatellite instability of D17S513 on chromosome 17 is associated with progression of breast cancer.
Breast Neoplasms
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.
Breast Neoplasms
Minor role of BRCA2 mutation (Exon2 and Exon11) in patients with early-onset breast cancer amongst Iranian Azeri-Turkish women.
Breast Neoplasms
miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
Breast Neoplasms
miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro.
Breast Neoplasms
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
Breast Neoplasms
MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.
Breast Neoplasms
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
Breast Neoplasms
miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
Breast Neoplasms
miR-4513 promotes breast cancer progression through targeting TRIM3.
Breast Neoplasms
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Breast Neoplasms
miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors.
Breast Neoplasms
miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Breast Neoplasms
MiRNAs prognostic for basal and BRCA1 breast cancer.
Breast Neoplasms
Misbehaviour of XIST RNA in Breast Cancer Cells.
Breast Neoplasms
Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry.
Breast Neoplasms
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Breast Neoplasms
Missense mutations in the transactivation region of the BRCA1 gene in breast cancer.
Breast Neoplasms
Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Breast Neoplasms
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Breast Neoplasms
Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier.
Breast Neoplasms
MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
Breast Neoplasms
MMTV-trBrca1 mice display strain-dependent abnormalities in vaginal development.
Breast Neoplasms
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
Breast Neoplasms
Modeling familial clustered breast cancer using published data.
Breast Neoplasms
Modeling the study of DNA damage responses in mice.
Breast Neoplasms
Models of genetic susceptibility to breast cancer.
Breast Neoplasms
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
Breast Neoplasms
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
Breast Neoplasms
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
Breast Neoplasms
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.
Breast Neoplasms
Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers.
Breast Neoplasms
Modulating Effect of Hypnea musciformis (Red Seaweed) on Lipid Peroxidation, Antioxidants and Biotransforming Enzymes in 7,12-Dimethylbenz (a) Anthracene Induced Mammary Carcinogenesis in Experimental Animals.
Breast Neoplasms
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Breast Neoplasms
Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment.
Breast Neoplasms
Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin.
Breast Neoplasms
Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
Breast Neoplasms
Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress.
Breast Neoplasms
Molecular analysis of PALB2-associated breast cancers.
Breast Neoplasms
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Breast Neoplasms
Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing.
Breast Neoplasms
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families.
Breast Neoplasms
Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families.
Breast Neoplasms
Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia.
Breast Neoplasms
Molecular and in silico analysis of BRCA1 and BRCA2 variants.
Breast Neoplasms
Molecular and pathological characterization of inherited breast cancer.
Breast Neoplasms
Molecular aspects of breast cancer resistance to drugs (Review).
Breast Neoplasms
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Breast Neoplasms
Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2.
Breast Neoplasms
Molecular biology of breast cancer.
Breast Neoplasms
Molecular characteristics of breast cancer according to clinicopathological factors.
Breast Neoplasms
Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
Breast Neoplasms
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Breast Neoplasms
Molecular characterization of breast cancer in young Brazilian women.
Breast Neoplasms
Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan.
Breast Neoplasms
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
Breast Neoplasms
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Breast Neoplasms
Molecular cloning and characterization of a human homologue of TBPIP, a BRCA1 locus-related gene.
Breast Neoplasms
Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.
Breast Neoplasms
Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
Breast Neoplasms
Molecular dissection of a cosmid from a gene-rich region in 17q21 and characterization of a candidate gene for alpha-N-acetylglucosaminidase with two cDNA isoforms.
Breast Neoplasms
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
Breast Neoplasms
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Breast Neoplasms
Molecular genetics of breast cancer progression.
Breast Neoplasms
Molecular genetics of breast cancer.
Breast Neoplasms
Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer.
Breast Neoplasms
Molecular insights into the association of obesity with breast cancer risk: relevance to xenobiotic metabolism and CpG island methylation of tumor suppressor genes.
Breast Neoplasms
Molecular morphological approach to the pathological study of development and advancement of human breast cancer.
Breast Neoplasms
Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.
Breast Neoplasms
Molecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast Carcinogenesis.
Breast Neoplasms
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
Breast Neoplasms
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
Breast Neoplasms
Molecular structure of BRCA1-estrogen receptor alpha-estrogen complex: relevance to breast cancer?
Breast Neoplasms
Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer.
Breast Neoplasms
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Breast Neoplasms
More breast cancer genes?
Breast Neoplasms
More Modifiers Move on DNA Damage.
Breast Neoplasms
Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Breast Neoplasms
Morphological predictors of BRCA1 germline mutations in young women with breast cancer.
Breast Neoplasms
Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Breast Neoplasms
Motivations and concerns of women considering genetic testing for breast cancer: a comparison between affected and at-risk probands.
Breast Neoplasms
Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.
Breast Neoplasms
Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma.
Breast Neoplasms
Mouse models for breast cancer susceptibility.
Breast Neoplasms
Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis.
Breast Neoplasms
Mouse models of BRCA1 and their application to breast cancer research.
Breast Neoplasms
Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
Breast Neoplasms
MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
Breast Neoplasms
MRI and breast cancer: role in detection, diagnosis, and staging.
Breast Neoplasms
MRI in the early detection of breast cancer in women with high genetic risk.
Breast Neoplasms
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Breast Neoplasms
MRN Complex and Cancer Risk: Old Bottles, New Wine.
Breast Neoplasms
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Breast Neoplasms
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model.
Breast Neoplasms
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Breast Neoplasms
Multicolor FISH mapping with Alu-PCR-amplified YAC clone DNA determines the order of markers in the BRCA1 region on chromosome 17q12-q21.
Breast Neoplasms
Multifocal Breast Cancer in Young Women with Prolonged Contact between Their Breasts and Their Cellular Phones.
Breast Neoplasms
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
Breast Neoplasms
Multigene panel testing results in patients with multiple breast cancer primaries.
Breast Neoplasms
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer.
Breast Neoplasms
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Breast Neoplasms
Multiple fibroadenomas harbouring carcinoma in situ in a woman with a family history of breast/ovarian cancer.
Breast Neoplasms
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Breast Neoplasms
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Breast Neoplasms
Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.
Breast Neoplasms
Multiple Susceptibility Loci for Radiation-Induced Mammary Tumorigenesis in F2[Dahl S x R]-Intercross Rats.
Breast Neoplasms
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Breast Neoplasms
Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers.
Breast Neoplasms
Multiplex single-nucleotide primer extension analysis to simultaneously detect eleven BRCA1 mutations in breast cancer families.
Breast Neoplasms
Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families.
Breast Neoplasms
Multiplying functions for BRCA1 and BRCA2?. Meeting report, The Breakthrough Breast Cancer Second International Workshop on the function of BRCA1 and BRCA2, Cambridge, UK, 9-10 September 1999.
Breast Neoplasms
Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
Breast Neoplasms
Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Breast Neoplasms
Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy.
Breast Neoplasms
Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
Breast Neoplasms
Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Breast Neoplasms
Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families.
Breast Neoplasms
Mutation analysis of BRCA1 gene in African-American patients with breast cancer.
Breast Neoplasms
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Breast Neoplasms
Mutation analysis of BRCA1/2 mutations with special reference to polymorphic SNPs in Indian breast cancer patients.
Breast Neoplasms
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Breast Neoplasms
Mutation analysis of PALB2 gene in French breast cancer families.
Breast Neoplasms
Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.
Breast Neoplasms
Mutation analysis of the ATR gene in breast and ovarian cancer families.
Breast Neoplasms
Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families.
Breast Neoplasms
Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.
Breast Neoplasms
Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients.
Breast Neoplasms
Mutation analysis of the breast cancer gene BRCA1 among breast cancer Jordanian females.
Breast Neoplasms
Mutation analysis of the CHK2 gene in families with hereditary breast cancer.
Breast Neoplasms
Mutation analysis of the SHFM1 gene in breast/ovarian cancer families.
Breast Neoplasms
Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
Breast Neoplasms
Mutation and association analysis of GEN1 in breast cancer susceptibility.
Breast Neoplasms
Mutation detection in the breast cancer gene BRCA1 using the protein truncation test.
Breast Neoplasms
Mutation in Exon2 of BRCA1 Gene in Adult Bengali Bangladeshi Female Patients with Breast Cancer: An Experience from Two Tertiary-Care Hospitals.
Breast Neoplasms
Mutation of the PTCH1 gene predicts recurrence of breast cancer.
Breast Neoplasms
Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population.
Breast Neoplasms
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Breast Neoplasms
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Breast Neoplasms
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry.
Breast Neoplasms
Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population.
Breast Neoplasms
Mutation screening of the BRCA1 gene in Slovak patients.
Breast Neoplasms
Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations.
Breast Neoplasms
Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families.
Breast Neoplasms
Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Breast Neoplasms
Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2.
Breast Neoplasms
Mutational analysis of BARD1 in familial breast cancer patients in Japan.
Breast Neoplasms
Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.
Breast Neoplasms
Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer.
Breast Neoplasms
Mutational analysis of BRCA1 and BRCA2 genes in women with familial breast cancer from different regions of Colombia.
Breast Neoplasms
Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.
Breast Neoplasms
Mutational analysis of BRCA1/2 gene and pathologic characteristics from Kazakh population with sporadic breast cancer in northwestern China.
Breast Neoplasms
Mutational analysis of BRCA2 in Spanish breast cancer patients from Castilla-Leon: identification of four novel truncating mutations.
Breast Neoplasms
Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
Breast Neoplasms
Mutational analysis of telomere genes in BRCA1/2-negative breast cancer families with very short telomeres.
Breast Neoplasms
Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Breast Neoplasms
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Breast Neoplasms
Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers.
Breast Neoplasms
Mutational screening of breast cancer susceptibility gene 1 from early onset, bi-lateral, and familial breast cancer patients in Taiwan.
Breast Neoplasms
Mutational Screening of the BRCA1 Gene in Sporadic Breast Cancer in Kazakhstan Population.
Breast Neoplasms
Mutations analysis of BRCA1 gene in patients with breast cancer in South Khorasan province, East Iran.
Breast Neoplasms
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families.
Breast Neoplasms
Mutations and polymorphic BRCA variants transmission in breast cancer familial members.
Breast Neoplasms
Mutations at BRCA1: the medullary breast carcinoma revisited.
Breast Neoplasms
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
Breast Neoplasms
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Breast Neoplasms
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Breast Neoplasms
Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
Breast Neoplasms
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer.
Breast Neoplasms
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Breast Neoplasms
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Breast Neoplasms
Mutations of the BRCA1 gene in human cancer.
Breast Neoplasms
Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Breast Neoplasms
Mutator pathways unleashed by epigenetic silencing in human cancer.
Breast Neoplasms
MYB oncogene amplification in hereditary BRCA1 breast cancer.
Breast Neoplasms
MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
Breast Neoplasms
MYC and Breast Cancer.
Breast Neoplasms
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Breast Neoplasms
Myricetin Apoptotic Effects on T47D Breast Cancer Cells is a P53-Independent Approach.
Breast Neoplasms
Myricetin Exerts its Apoptotic Effects on MCF-7 Breast Cancer Cells through Evoking the BRCA1-GADD45 Pathway.
Breast Neoplasms
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Breast Neoplasms
Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.
Breast Neoplasms
Nano-LC based proteomic approach identifies that E6AP interacts with ENO1 and targets it for degradation in breast cancer cells.
Breast Neoplasms
Nanostructured SERS-electrochemical biosensors for testing of anticancer drug interactions with DNA.
Breast Neoplasms
Natural selection and mammalian BRCA1 sequences: elucidating functionally important sites relevant to breast cancer susceptibility in humans.
Breast Neoplasms
Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis.
Breast Neoplasms
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
Breast Neoplasms
Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Breast Neoplasms
Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
Breast Neoplasms
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.
Breast Neoplasms
Negotiating jurisdictional boundaries in response to new genetic possibilities in breast cancer care: The creation of an 'oncogenetic taskscape'.
Breast Neoplasms
Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Breast Neoplasms
Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons.
Breast Neoplasms
Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors.
Breast Neoplasms
Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database.
Breast Neoplasms
New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein.
Breast Neoplasms
New complexities for BRCA1 and BRCA2.
Breast Neoplasms
New concepts on BARD1: Regulator of BRCA pathways and beyond.
Breast Neoplasms
New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Breast Neoplasms
New insights into breast cancer genetics and impact on patient management.
Breast Neoplasms
New insights into the performance of multigene panel testing: Two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer.
Breast Neoplasms
New insights into the prevention and treatment of familial breast cancer.
Breast Neoplasms
New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines.
Breast Neoplasms
New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients.
Breast Neoplasms
New variants in the BRCA1 gene in Buryat Mongol breast cancer patients: Report from two families.
Breast Neoplasms
Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer.
Breast Neoplasms
Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Breast Neoplasms
Next-Generation Sequencing Identifies BRCA1 and/or BRCA2 Mutations in Women at High Hereditary Risk for Breast Cancer with Shorter Telomere Length.
Breast Neoplasms
Next-generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects.
Breast Neoplasms
NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
Breast Neoplasms
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin.
Breast Neoplasms
Nine novel conserved motifs in BRCA1 identified by the chicken orthologue.
Breast Neoplasms
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
Breast Neoplasms
Nitric Oxide: Genomic Instability And Synthetic Lethality.
Breast Neoplasms
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
Breast Neoplasms
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
Breast Neoplasms
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Breast Neoplasms
No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls.
Breast Neoplasms
No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.
Breast Neoplasms
No evidence for germline PTEN mutations in families with breast and brain tumours.
Breast Neoplasms
No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families.
Breast Neoplasms
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
Breast Neoplasms
No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
Breast Neoplasms
No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years.
Breast Neoplasms
No MSH6 germline mutations in breast cancer families with colorectal and/or endometrial cancer.
Breast Neoplasms
Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons.
Breast Neoplasms
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Breast Neoplasms
Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition.
Breast Neoplasms
Non-founder BRCA1 mutations in Russian breast cancer patients.
Breast Neoplasms
Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
Breast Neoplasms
Noncoding RNA Ginir functions as an oncogene by associating with centrosomal proteins.
Breast Neoplasms
Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
Breast Neoplasms
Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients.
Breast Neoplasms
Normal breast: myths, realities, and prospects.
Breast Neoplasms
Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.
Breast Neoplasms
Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients.
Breast Neoplasms
Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer.
Breast Neoplasms
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Breast Neoplasms
Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland.
Breast Neoplasms
Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
Breast Neoplasms
Novel BRCA2 pathogenic genotype and breast cancer phenotype discordance in monozygotic triplets.
Breast Neoplasms
Novel BRCA2 pathogenic variant c.5219 T > G; p.(Leu1740Ter) in a consanguineous Senegalese family with hereditary breast cancer.
Breast Neoplasms
Novel consensus DNA-binding sequence for BRCA1 protein complexes.
Breast Neoplasms
Novel deletion at codon 1254 of the BRCA1 gene in an Italian breast cancer kindred.
Breast Neoplasms
Novel Genetic Markers for Early Detection of Elevated Breast Cancer Risk in Women.
Breast Neoplasms
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Breast Neoplasms
Novel germline BRCA1 mutation (155del4) in an African American with early-onset breast cancer.
Breast Neoplasms
Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years.
Breast Neoplasms
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Breast Neoplasms
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Breast Neoplasms
Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients.
Breast Neoplasms
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.
Breast Neoplasms
Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population.
Breast Neoplasms
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.
Breast Neoplasms
Novel mutations in the RING-finger domain of BRCA1 gene in clinically diagnosed breast cancer patients.
Breast Neoplasms
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Breast Neoplasms
Novel RING E3 ubiquitin ligases in breast cancer.
Breast Neoplasms
Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.
Breast Neoplasms
Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals.
Breast Neoplasms
Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations.
Breast Neoplasms
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Breast Neoplasms
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Breast Neoplasms
Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
Breast Neoplasms
NPR3 protects cardiomyocytes from apoptosis through inhibition of cytosolic BRCA1 and TNF-?.
Breast Neoplasms
Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: \newline A retrospective study.
Breast Neoplasms
Nrf2 is associated with the regulation of basal transcription activity of the BRCA1 gene.
Breast Neoplasms
Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Breast Neoplasms
Nuclear export of BRCA1 occurs during early S phase and is calcium-dependent.
Breast Neoplasms
Nuclear location and cell cycle regulation of the BRCA2 protein.
Breast Neoplasms
Nucleolar localization of BRCA1 protein in human breast cancer.
Breast Neoplasms
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Breast Neoplasms
Numerous high-risk epithelial lesions in familial breast cancer.
Breast Neoplasms
Obesity alters the ovarian DNA damage response and apoptotic proteins.
Breast Neoplasms
Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Breast Neoplasms
Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Breast Neoplasms
Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells.
Breast Neoplasms
Olaparib for the treatment of breast cancer.
Breast Neoplasms
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
Breast Neoplasms
Old and new concepts in histopathological characterization of familial breast cancer.
Breast Neoplasms
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Breast Neoplasms
On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations.
Breast Neoplasms
On the use of familial aggregation in population-based case probands for calculating penetrance.
Breast Neoplasms
Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor.
Breast Neoplasms
Oncogenic pathways in hereditary and sporadic breast cancer.
Breast Neoplasms
One step direct detection of recurrent mutations in the breast cancer susceptibility gene, BRCA1.
Breast Neoplasms
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Oophorectomy benefits in breast cancer patients with BRCA1 mutation.
Breast Neoplasms
Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations.
Breast Neoplasms
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Breast Neoplasms
Opposing roles for mammary epithelial-specific PPAR? signaling and activation during breast tumour progression.
Breast Neoplasms
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.
Breast Neoplasms
Optimization of Porous Silicon Conditions for DNA-based Biosensing via Reflectometric Interference Spectroscopy.
Breast Neoplasms
Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Breast Neoplasms
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study.
Breast Neoplasms
Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
Breast Neoplasms
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
Breast Neoplasms
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
Breast Neoplasms
Oral contraceptives and risk of familial breast cancer.
Breast Neoplasms
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Breast Neoplasms
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Breast Neoplasms
Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase.
Breast Neoplasms
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.
Breast Neoplasms
Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis.
Breast Neoplasms
Out-RANKing BRCA1 in Mutation Carriers.
Breast Neoplasms
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Breast Neoplasms
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
Breast Neoplasms
Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Breast Neoplasms
Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
Breast Neoplasms
Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.
Breast Neoplasms
Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
Breast Neoplasms
Ovarian Cancer Gene Therapy with BRCA1-An Overview.
Breast Neoplasms
Ovarian cancer molecular pathology.
Breast Neoplasms
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Breast Neoplasms
Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.
Breast Neoplasms
Ovarian Pathology in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations, Emphasizing the Differential Diagnosis of Occult Primary and Metastatic Carcinoma.
Breast Neoplasms
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Breast Neoplasms
Ovary removal is linked to lower breast cancer mortality in BRCA1 carriers.
Breast Neoplasms
Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer.
Breast Neoplasms
Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles.
Breast Neoplasms
Overexpression of BRCA1 in Neural Stem Cells Enhances Cell Survival and Functional Recovery after Transplantation into Experimental Ischemic Stroke.
Breast Neoplasms
Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.
Breast Neoplasms
Oxidative stress induced carbonylation in human plasma.
Breast Neoplasms
P-Cadherin is Co-Expressed with Cd44 and Cd49f and Mediates Stem Cell Properties in Basal-Like Breast Cancer.
Breast Neoplasms
p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
Breast Neoplasms
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Breast Neoplasms
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
Breast Neoplasms
p53, BRCA1 and breast Cancer chemoresistance.
Breast Neoplasms
p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage.
Breast Neoplasms
p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Breast Neoplasms
Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
Breast Neoplasms
PALB2 and breast cancer: ready for clinical translation!
Breast Neoplasms
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Breast Neoplasms
PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function.
Breast Neoplasms
PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
Breast Neoplasms
PALB2/FANCN: recombining cancer and Fanconi anemia.
Breast Neoplasms
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Breast Neoplasms
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Breast Neoplasms
Paraneoplastic fasciitis and polyarthritis syndrome as a manifestation of breast cancer recurrence in a BRCA1 gene-positive patient.
Breast Neoplasms
Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Breast Neoplasms
Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
Breast Neoplasms
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Breast Neoplasms
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Breast Neoplasms
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Breast Neoplasms
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Breast Neoplasms
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Breast Neoplasms
PARP inhibitor development for systemic cancer targeting.
Breast Neoplasms
PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
Breast Neoplasms
PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
Breast Neoplasms
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Breast Neoplasms
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
Breast Neoplasms
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
Breast Neoplasms
PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
Breast Neoplasms
PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.
Breast Neoplasms
Partnering in Oncogenetic Research - The INHERIT BRCAs Experience: Opportunities and Challenges.
Breast Neoplasms
Pathobiologic characteristics of hereditary breast cancer.
Breast Neoplasms
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Breast Neoplasms
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
Breast Neoplasms
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Breast Neoplasms
Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.
Breast Neoplasms
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.
Breast Neoplasms
Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene.
Breast Neoplasms
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.
Breast Neoplasms
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.
Breast Neoplasms
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Breast Neoplasms
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Breast Neoplasms
Pathology of hereditary breast cancer.
Breast Neoplasms
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
Breast Neoplasms
Patients with pathogenic variants for breast cancer other than BRCA1 and BRCA2: qualitative interviews about health care experiences.
Breast Neoplasms
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives.
Breast Neoplasms
Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: A Study of 500 Patients.
Breast Neoplasms
Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer.
Breast Neoplasms
Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer.
Breast Neoplasms
Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
Breast Neoplasms
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Breast Neoplasms
Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
Breast Neoplasms
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Breast Neoplasms
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.
Breast Neoplasms
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Breast Neoplasms
Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.
Breast Neoplasms
Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Breast Neoplasms
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Breast Neoplasms
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Breast Neoplasms
Peroxisome proliferator-activated receptor gamma and BRCA1.
Breast Neoplasms
Personalized prevention in high risk individuals: Managing hormones and beyond.
Breast Neoplasms
Perspectives in the clinical management of BRCA mutations carriers.
Breast Neoplasms
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
Breast Neoplasms
PFKP is transcriptionally repressed by BRCA1/ZBRK1 and predicts prognosis in breast cancer.
Breast Neoplasms
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.
Breast Neoplasms
Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Breast Neoplasms
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.
Breast Neoplasms
Phenotypic analysis of familial breast cancer: Comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Breast Neoplasms
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Breast Neoplasms
PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis.
Breast Neoplasms
Phosphatidylinositol 3-kinase/Akt signaling enhances nuclear localization and transcriptional activity of BRCA1.
Breast Neoplasms
Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
Breast Neoplasms
PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome.
Breast Neoplasms
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
Breast Neoplasms
Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment.
Breast Neoplasms
Pitaya Extracts Induce Growth Inhibition and Proapoptotic Effects on Human Cell Lines of Breast Cancer via Downregulation of Estrogen Receptor Gene Expression.
Breast Neoplasms
PKC? Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Breast Neoplasms
Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence.
Breast Neoplasms
Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study.
Breast Neoplasms
Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Plasmonics nanoprobes: detection of single-nucleotide polymorphisms in the breast cancer BRCA1 gene.
Breast Neoplasms
Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer.
Breast Neoplasms
PLGA-PEG nano-delivery system for epigenetic therapy.
Breast Neoplasms
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Breast Neoplasms
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
Breast Neoplasms
PML protein expression in hereditary and sporadic breast cancer.
Breast Neoplasms
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Breast Neoplasms
Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms.
Breast Neoplasms
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
Breast Neoplasms
Polymer microfluidic chips with integrated waveguides for reading microarrays.
Breast Neoplasms
Polymorphic Repeat Length in the AIB1 Gene and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Meta-Analysis of Observational Studies.
Breast Neoplasms
Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.
Breast Neoplasms
Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.
Breast Neoplasms
Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk.
Breast Neoplasms
Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists.
Breast Neoplasms
Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
Breast Neoplasms
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Population and breast cancer patients' analysis reveals the diversity of genomic variation of the BRCA genes in the Mexican population.
Breast Neoplasms
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Breast Neoplasms
Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
Breast Neoplasms
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Breast Neoplasms
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Breast Neoplasms
Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.
Breast Neoplasms
Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers.
Breast Neoplasms
Population-based study of risk of breast cancer in carriers of BRCA2 mutation.
Breast Neoplasms
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Breast Neoplasms
Population-Calibrated Gene Characterization: Estimating Age at Onset Distributions Associated With Cancer Genes.
Breast Neoplasms
Positional analyses of BRCA1-dependent expression in Saccharomyces cerevisiae.
Breast Neoplasms
Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.
Breast Neoplasms
Positive regulation of the BRCA1 promoter.
Breast Neoplasms
Positive selection in the evolution of cancer.
Breast Neoplasms
Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.
Breast Neoplasms
Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Breast Neoplasms
Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
Breast Neoplasms
Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.
Breast Neoplasms
PP2C? inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
Breast Neoplasms
Practical consensus recommendation on when to do BRCA testing.
Breast Neoplasms
Practical implementation of frailty models in Mendelian risk prediction.
Breast Neoplasms
Preclinical mouse models for BRCA1-associated breast cancer.
Breast Neoplasms
Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
Breast Neoplasms
Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers.
Breast Neoplasms
Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Breast Neoplasms
Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
Breast Neoplasms
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Breast Neoplasms
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Breast Neoplasms
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.
Breast Neoplasms
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
Breast Neoplasms
Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
Breast Neoplasms
Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Breast Neoplasms
Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
Breast Neoplasms
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Breast Neoplasms
Predictors of mammographic density among women with a strong family history of breast cancer.
Breast Neoplasms
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Breast Neoplasms
Predictors of survival for breast cancer patients with a BRCA1 mutation.
Breast Neoplasms
Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
Breast Neoplasms
Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
Breast Neoplasms
Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
Breast Neoplasms
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers.
Breast Neoplasms
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
Breast Neoplasms
Pregnancy and breast cancer risk in women with BRCA1 or BRCA2 mutations.
Breast Neoplasms
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.
Breast Neoplasms
Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers.
Breast Neoplasms
Pregnancy-associated breast cancer.
Breast Neoplasms
Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth.
Breast Neoplasms
Preimplantation genetic diagnosis for inherited breast cancer: first clinical application and live birth in Spain.
Breast Neoplasms
Preliminary results of targeted sequencing of BRCA1 and BRCA2 in a cohort of breast cancer families: New insight into pathogenic variants in patients and at?risk relatives.
Breast Neoplasms
Premature menopause in patients with BRCA1 gene mutation.
Breast Neoplasms
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers.
Breast Neoplasms
Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.
Breast Neoplasms
Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis.
Breast Neoplasms
Prepubertal octylphenol exposure up-regulate BRCA1 expression, down-regulate ERalpha expression and reduce rat mammary tumorigenesis.
Breast Neoplasms
Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland.
Breast Neoplasms
Preserving the Self: The Process of Decision Making About Hereditary Breast Cancer and Ovarian Cancer Risk Reduction.
Breast Neoplasms
Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
Breast Neoplasms
Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon.
Breast Neoplasms
Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Breast Neoplasms
Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Breast Neoplasms
Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients.
Breast Neoplasms
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
Breast Neoplasms
Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.
Breast Neoplasms
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
Breast Neoplasms
Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.
Breast Neoplasms
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Breast Neoplasms
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Breast Neoplasms
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years.
Breast Neoplasms
Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.
Breast Neoplasms
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Breast Neoplasms
Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.
Breast Neoplasms
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Breast Neoplasms
Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing.
Breast Neoplasms
Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Breast Neoplasms
Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Breast Neoplasms
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
Breast Neoplasms
Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China.
Breast Neoplasms
Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients.
Breast Neoplasms
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Breast Neoplasms
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases.
Breast Neoplasms
Prevalence of BRCA1/2 germline mutations in 21?401 families with breast and ovarian cancer.
Breast Neoplasms
Prevalence of BRCA1/2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer.
Breast Neoplasms
Prevalence of BRCA1/BRCA2 pathogenic variation in Chinese Han population.
Breast Neoplasms
Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing.
Breast Neoplasms
Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.
Breast Neoplasms
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Breast Neoplasms
Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer.
Breast Neoplasms
Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.
Breast Neoplasms
Prevalence of germline variants in inflammatory breast cancer.
Breast Neoplasms
Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon.
Breast Neoplasms
Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer.
Breast Neoplasms
Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Breast Neoplasms
Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls.
Breast Neoplasms
Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry.
Breast Neoplasms
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.
Breast Neoplasms
Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group.
Breast Neoplasms
Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients.
Breast Neoplasms
Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland.
Breast Neoplasms
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Breast Neoplasms
Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country.
Breast Neoplasms
Prevalence of the most frequent BRCA1 mutations in Polish population.
Breast Neoplasms
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Breast Neoplasms
Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.
Breast Neoplasms
Preventing BRCA1/ ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.
Breast Neoplasms
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Breast Neoplasms
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Breast Neoplasms
Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
Breast Neoplasms
Prevention of breast cancer.
Breast Neoplasms
Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene.
Breast Neoplasms
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment.
Breast Neoplasms
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
Breast Neoplasms
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
Breast Neoplasms
Prioritizing candidate genetic modifiers of BRCA1 and BRCA2 using a combinatorial analysis of global expression and polymorphism association studies of breast cancer.
Breast Neoplasms
Prioritizing disease biomarkers using functional module based network analysis: A multilayer consensus driven scheme.
Breast Neoplasms
PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiation.
Breast Neoplasms
Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.
Breast Neoplasms
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Breast Neoplasms
Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer.
Breast Neoplasms
Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer.
Breast Neoplasms
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Breast Neoplasms
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Breast Neoplasms
Progestin and breast cancer. The missing pieces of a puzzle.
Breast Neoplasms
Prognosis of BRCA1 hereditary breast cancer.
Breast Neoplasms
Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Breast Neoplasms
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
Breast Neoplasms
Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Breast Neoplasms
Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients.
Breast Neoplasms
Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients.
Breast Neoplasms
Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
Breast Neoplasms
Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
Breast Neoplasms
Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas.
Breast Neoplasms
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas.
Breast Neoplasms
Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Breast Neoplasms
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.
Breast Neoplasms
Progress toward isolation of a breast cancer susceptibility gene, BRCA1.
Breast Neoplasms
Prolactin and androgen R1881 induce pro-survival carboxypeptidase-D and EDD E3 ligase in triple-negative and HER2+ breast cancer.
Breast Neoplasms
Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.
Breast Neoplasms
Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk.
Breast Neoplasms
Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines.
Breast Neoplasms
Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signalling, anti-apoptotic protein expression, and drug resistance in breast cancer cells.
Breast Neoplasms
Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Breast Neoplasms
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Breast Neoplasms
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Breast Neoplasms
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Breast Neoplasms
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Breast Neoplasms
Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk.
Breast Neoplasms
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Breast Neoplasms
Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Breast Neoplasms
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Breast Neoplasms
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Breast Neoplasms
Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer.
Breast Neoplasms
Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
Breast Neoplasms
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Breast Neoplasms
Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
Breast Neoplasms
Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer
Breast Neoplasms
Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Breast Neoplasms
Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients.
Breast Neoplasms
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
Breast Neoplasms
Prophylactic bilateral mastectomy: patterns of practice.
Breast Neoplasms
Prophylactic mastectomy and genetic testing: an update.
Breast Neoplasms
Prophylactic mastectomy and inherited predisposition to breast carcinoma.
Breast Neoplasms
Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Breast Neoplasms
Prophylactic mastectomy: indications, options, and reconstructive alternatives.
Breast Neoplasms
Prophylactic mastectomy: why and when?
Breast Neoplasms
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Breast Neoplasms
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
Breast Neoplasms
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Breast Neoplasms
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
Breast Neoplasms
Proposed roadmap to stepwise integration of genetics in family medicine and clinical research.
Breast Neoplasms
Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
Breast Neoplasms
Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women.
Breast Neoplasms
Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging.
Breast Neoplasms
Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Breast Neoplasms
Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'.
Breast Neoplasms
Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol.
Breast Neoplasms
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Breast Neoplasms
Prostate screening uptake in Australian BRCA1 and BRCA2 carriers.
Breast Neoplasms
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Breast Neoplasms
Protective effect of cigarette smoking on breast cancer risk in women with BRCA1 or BRCA2 mutations???
Breast Neoplasms
Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Breast Neoplasms
Protein stability versus function: effects of destabilizing missense mutations on BRCA1 DNA repair activity.
Breast Neoplasms
Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer.
Breast Neoplasms
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Breast Neoplasms
Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.
Breast Neoplasms
Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development.
Breast Neoplasms
Proteomic Analysis of Medicinal Plant Calotropis Gigantea by insilico Peptide Mass Fingerprinting.
Breast Neoplasms
Proteomic Profiling of ?-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Breast Neoplasms
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with diagnostic and prognostic value in human breast cancer.
Breast Neoplasms
Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
Breast Neoplasms
PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1.
Breast Neoplasms
PS2 expression in BRCA1-associated breast cancers.
Breast Neoplasms
Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study.
Breast Neoplasms
Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer.
Breast Neoplasms
Psychological issues in genetic testing for breast cancer.
Breast Neoplasms
Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes.
Breast Neoplasms
Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy.
Breast Neoplasms
Psychosocial impact of BRCA testing in young Black breast cancer survivors.
Breast Neoplasms
Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families.
Breast Neoplasms
Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Breast Neoplasms
Psychotherapy with a woman at high risk for developing breast cancer.
Breast Neoplasms
PTEN breast cancer susceptibility: a matter of dose.
Breast Neoplasms
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Breast Neoplasms
Purification and characterisation of a soluble N-terminal fragment of the breast cancer susceptibility protein BRCA1.
Breast Neoplasms
Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
Breast Neoplasms
Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient.
Breast Neoplasms
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.
Breast Neoplasms
Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene.
Breast Neoplasms
Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics.
Breast Neoplasms
Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Breast Neoplasms
Quantitative imaging of single mRNA splice variants in living cells.
Breast Neoplasms
Racial differences in genetic factors associated with breast cancer.
Breast Neoplasms
Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women.
Breast Neoplasms
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
Breast Neoplasms
RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies.
Breast Neoplasms
RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population.
Breast Neoplasms
RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.
Breast Neoplasms
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
Breast Neoplasms
RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families.
Breast Neoplasms
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Breast Neoplasms
RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2?deficient human acute myeloid leukemia.
Breast Neoplasms
Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.
Breast Neoplasms
RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Breast Neoplasms
Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition?
Breast Neoplasms
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.
Breast Neoplasms
Radiosensitivity of lymphoblastoid cell lines with a heterozygous BRCA1 mutation is not detected by the comet assay and pulsed field gel electrophoresis.
Breast Neoplasms
Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
Breast Neoplasms
Radiotherapy in the treatment of hereditary breast cancer.
Breast Neoplasms
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Breast Neoplasms
RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
Breast Neoplasms
RANKL/RANK control Brca1 mutation-driven mammary tumors.
Breast Neoplasms
RANKL/RANK: from bone loss to the prevention of breast cancer.
Breast Neoplasms
RAP80 responds to DNA damage induced by both ionizing radiation and UV irradiation and is phosphorylated at Ser 205.
Breast Neoplasms
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Breast Neoplasms
Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2.
Breast Neoplasms
Rapid and deep-scale ubiquitylation profiling for biology and translational research.
Breast Neoplasms
Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study.
Breast Neoplasms
Rapid mutation detection in complex genes by heteroduplex analysis with capillary array electrophoresis.
Breast Neoplasms
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
Breast Neoplasms
Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer.
Breast Neoplasms
Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network.
Breast Neoplasms
Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.
Breast Neoplasms
RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.
Breast Neoplasms
RASSF1A polymorphism in familial breast cancer.
Breast Neoplasms
Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
Breast Neoplasms
RBCK1 drives breast cancer cell proliferation by promoting transcription of estrogen receptor alpha and cyclin B1.
Breast Neoplasms
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
Breast Neoplasms
RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Re: Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Breast Neoplasms
Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
Breast Neoplasms
Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Breast Neoplasms
Re: Increased Cancer Risks for Relatives of Very Early-Onset Breast Cancer Cases With and Without BRCA1 and BRCA2 Mutations.
Breast Neoplasms
Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.
Breast Neoplasms
Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines.
Breast Neoplasms
Reappearance from Obscurity: Mammalian Rad52 in Homologous Recombination.
Breast Neoplasms
Recent advances in breast cancer biology.
Breast Neoplasms
Recent advances in molecular genetics of breast cancer.
Breast Neoplasms
Recent advances in understanding of genetic susceptibility to breast cancer.
Breast Neoplasms
Recent developments in critical genes in the molecular biology of breast cancer.
Breast Neoplasms
Recent patents on genes and gene sequences useful for developing breast cancer detection systems.
Breast Neoplasms
Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort.
Breast Neoplasms
Recognition and management of hereditary breast cancer syndromes.
Breast Neoplasms
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Breast Neoplasms
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Breast Neoplasms
Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk.
Breast Neoplasms
Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach.
Breast Neoplasms
Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates.
Breast Neoplasms
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry.
Breast Neoplasms
Recurrent BRCA1 and BRCA2 Mutations in Mexican Women with Breast Cancer.
Breast Neoplasms
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Breast Neoplasms
Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer.
Breast Neoplasms
Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family.
Breast Neoplasms
Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
Breast Neoplasms
Recurrent mutations of BRCA1 and BRCA2 in Poland: an update.
Breast Neoplasms
Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells.
Breast Neoplasms
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia.
Breast Neoplasms
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.
Breast Neoplasms
Reduced ligation during DNA base excision repair supported by BRCA2 mutant cells.
Breast Neoplasms
Reducing the risk of breast cancer with tamoxifen in women at increased risk.
Breast Neoplasms
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Breast Neoplasms
Reevaluation of RINT1 as a breast cancer predisposition gene.
Breast Neoplasms
Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
Breast Neoplasms
Referral and experience with genetic testing among women with early onset breast cancer.
Breast Neoplasms
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Breast Neoplasms
Refining clinical practice: transforming science research into the art of medicine.
Breast Neoplasms
Refining the role of BRCA1 in combating oxidative stress.
Breast Neoplasms
Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells.
Breast Neoplasms
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
Breast Neoplasms
Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.
Breast Neoplasms
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Breast Neoplasms
Regulation of BRCA1 expression and its relationship to sporadic breast cancer.
Breast Neoplasms
Regulation of BRCA1 expression by the Rb-E2F pathway.
Breast Neoplasms
Regulation of BRCA1 messenger RNA stability in human epithelial cell lines and during cell cycle progression.
Breast Neoplasms
Regulation of BRCA1 transcription by specific single-stranded DNA binding factors.
Breast Neoplasms
Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells.
Breast Neoplasms
Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.
Breast Neoplasms
Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer.
Breast Neoplasms
Regulation of p53 level by UBE4B in breast cancer.
Breast Neoplasms
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Breast Neoplasms
Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1.
Breast Neoplasms
Regulatory aspects of genetic research with residual human tissue: Effective and efficient data coding.
Breast Neoplasms
Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation.
Breast Neoplasms
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
Breast Neoplasms
Relationship between three novel SNPs of BRCA1 and canine mammary tumors.
Breast Neoplasms
Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence.
Breast Neoplasms
Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells.
Breast Neoplasms
Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Breast Neoplasms
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Breast Neoplasms
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study.
Breast Neoplasms
Repetitive demand for radical cancer risk reduction surgery in a young BRCA1 mutation carrier with strong family history of BRCA linked malignancies.
Breast Neoplasms
Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Breast Neoplasms
Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families.
Breast Neoplasms
Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1.
Breast Neoplasms
Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies.
Breast Neoplasms
Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study.
Breast Neoplasms
Reproductive factors in hereditary breast cancer.
Breast Neoplasms
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Breast Neoplasms
Requirement of heterogeneous nuclear ribonucleoprotein C for BRCA gene expression and homologous recombination.
Breast Neoplasms
Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy.
Breast Neoplasms
Response to "Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force".
Breast Neoplasms
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.
Breast Neoplasms
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Breast Neoplasms
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Breast Neoplasms
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.
Breast Neoplasms
Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
Breast Neoplasms
Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGE) in the analysis of BRCA1 exon 11 mutations in a high-risk breast cancer cohort.
Breast Neoplasms
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
Breast Neoplasms
Resveratrol Ameliorates Cardiac Hypertrophy by Down-regulation of miR-155 Through Activation of Breast Cancer Type 1 Susceptibility Protein.
Breast Neoplasms
Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines.
Breast Neoplasms
Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines.
Breast Neoplasms
Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity.
Breast Neoplasms
Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.
Breast Neoplasms
Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Breast Neoplasms
RING finger nuclear factor RNF168 is important for defects in homologous recombination caused by loss of the breast cancer susceptibility factor BRCA1.
Breast Neoplasms
RING finger protein 31 promotes p53 degradation in breast cancer cells.
Breast Neoplasms
Risk assessment for hereditary breast cancer: BRCA1 and BRCA2.
Breast Neoplasms
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Breast Neoplasms
Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Breast Neoplasms
Risk factors and risk reduction of breast and ovarian cancer.
Breast Neoplasms
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Breast Neoplasms
Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Breast Neoplasms
Risk factors for ovarian cancer and early-onset breast cancer in Mongolia.
Breast Neoplasms
Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
Breast Neoplasms
Risk models for familial ovarian and breast cancer.
Breast Neoplasms
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Breast Neoplasms
Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer.
Breast Neoplasms
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Breast Neoplasms
Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland).
Breast Neoplasms
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Breast Neoplasms
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.
Breast Neoplasms
Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
Breast Neoplasms
Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer.
Breast Neoplasms
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Breast Neoplasms
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.
Breast Neoplasms
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
Breast Neoplasms
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Breast Neoplasms
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Breast Neoplasms
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study.
Breast Neoplasms
Risk prediction models for familial breast cancer.
Breast Neoplasms
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
Breast Neoplasms
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Breast Neoplasms
Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Breast Neoplasms
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Breast Neoplasms
Risk-reducing mastectomy.
Breast Neoplasms
Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
Breast Neoplasms
Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Breast Neoplasms
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
Breast Neoplasms
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
Breast Neoplasms
Risks and Function of Breast Cancer Susceptibility Alleles.
Breast Neoplasms
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Breast Neoplasms
RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Breast Neoplasms
RNA structure analysis assisted by capillary electrophoresis.
Breast Neoplasms
RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21(Waf1/Cip1) for Ubiquitin-Mediated Degradation.
Breast Neoplasms
RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.
Breast Neoplasms
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.
Breast Neoplasms
RNF20 Is Critical for Snail-Mediated E-Cadherin Repression in Human Breast Cancer.
Breast Neoplasms
RNF4-dependent hybrid SUMO-ubiquitin chains are signals for RAP80 and thereby mediate the recruitment of BRCA1 to sites of DNA damage.
Breast Neoplasms
RNF8 Promotes Epithelial-Mesenchymal Transition in Lung Cancer Cells via Stabilization of Slug.
Breast Neoplasms
RNF8-dependent histone ubiquitination during DNA damage response and spermatogenesis.
Breast Neoplasms
Role for ATM in DNA damage-induced phosphorylation of BRCA1.
Breast Neoplasms
Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1.
Breast Neoplasms
Role of BRCA1 in Neuronal Death in Alzheimer's Disease.
Breast Neoplasms
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Breast Neoplasms
Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia.
Breast Neoplasms
Role of Breast Surgery in BRCA Mutation Carriers.
Breast Neoplasms
Role of calcium sensing receptor (CaSR) in tumorigenesis.
Breast Neoplasms
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.
Breast Neoplasms
Role of IFI16 in DNA damage and checkpoint.
Breast Neoplasms
Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study.
Breast Neoplasms
Role of steroid hormones and growth factors in breast cancer.
Breast Neoplasms
Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation.
Breast Neoplasms
Roscovitine and Trichostatin A promote DNA damage repair during porcine oocyte maturation.
Breast Neoplasms
rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility.
Breast Neoplasms
Rtt107/Esc4 binds silent chromatin and DNA repair proteins using different BRCT motifs.
Breast Neoplasms
S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Breast Neoplasms
Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?
Breast Neoplasms
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.
Breast Neoplasms
Scanning for clues to better use selective estrogen receptor modulators.
Breast Neoplasms
SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer.
Breast Neoplasms
Score tests for familial correlation in genotyped-proband designs.
Breast Neoplasms
Screening and clinical implications for BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Screening and follow-up of the patient at high risk for breast cancer.
Breast Neoplasms
Screening behaviors among African American women at high risk for breast cancer: do beliefs about god matter?
Breast Neoplasms
Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer.
Breast Neoplasms
Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.
Breast Neoplasms
Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.
Breast Neoplasms
Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective.
Breast Neoplasms
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Breast Neoplasms
Screening for BRCA1 large genomic rearrangements in female Egyptian hereditary breast cancer patients.
Breast Neoplasms
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Breast Neoplasms
Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.
Breast Neoplasms
Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage.
Breast Neoplasms
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Breast Neoplasms
Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Breast Neoplasms
Screening for Del 185 AG and 4627C>A BRCA1 Mutations in Breast Cancer Patients from Lahore, Pakistan.
Breast Neoplasms
Screening for genetic risk of breast cancer.
Breast Neoplasms
Screening for genomic rearrangements at BRCA1 locus in Iranian women with breast cancer using multiplex ligation-dependent probe amplification.
Breast Neoplasms
Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions.
Breast Neoplasms
Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil.
Breast Neoplasms
Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.
Breast Neoplasms
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Breast Neoplasms
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
Breast Neoplasms
Screening of 185DelAG, 1014DelGT and 3889DelAG BRCA1 mutations in breast cancer patients from North-East India.
Breast Neoplasms
Screening of BRCA1 variants c.190T>C, 1307delT, g.5331G>A and c.2612C>T in breast cancer patients from North India.
Breast Neoplasms
Screening of exon 11 of BRCA1 gene using the high resolution melting approach for diagnosis in Moroccan breast cancer patients.
Breast Neoplasms
Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
Breast Neoplasms
Screening of women at high risk for breast cancer.
Breast Neoplasms
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Breast Neoplasms
Screening, diagnosis and genetic study of breast cancer patients in Pakistan.
Breast Neoplasms
Search for large genomic alterations of the BRCA1 gene in a Finnish population.
Breast Neoplasms
Searching for genetic determinants of human aging and longevity: opportunities and challenges.
Breast Neoplasms
Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population.
Breast Neoplasms
Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
Breast Neoplasms
Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature.
Breast Neoplasms
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Breast Neoplasms
Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.
Breast Neoplasms
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Breast Neoplasms
Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
Breast Neoplasms
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
Breast Neoplasms
Selective immobilization of DNA and antibody probes on electrode arrays: simultaneous electrochemical detection of DNA and protein on a single platform.
Breast Neoplasms
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Breast Neoplasms
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Breast Neoplasms
Selective nanopore sequencing of human BRCA1 by Cas9-assisted targeting of chromosome segments (CATCH).
Breast Neoplasms
Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Breast Neoplasms
Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage.
Breast Neoplasms
Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers.
Breast Neoplasms
Selenomethionine protects hematopoietic stem/progenitor cells against cobalt nanoparticles by stimulating antioxidant actions and DNA repair functions.
Breast Neoplasms
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
Breast Neoplasms
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Breast Neoplasms
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers.
Breast Neoplasms
Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review.
Breast Neoplasms
Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer.
Breast Neoplasms
Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
Breast Neoplasms
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Breast Neoplasms
Should the use of contralateral prophylactic mastectomy be increasing as it is?
Breast Neoplasms
Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Breast Neoplasms
Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Breast Neoplasms
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Breast Neoplasms
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Breast Neoplasms
Significant contribution of germline BRCA2 rearrangements in male breast cancer families.
Breast Neoplasms
Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.
Breast Neoplasms
Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
Breast Neoplasms
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976-1999.
Breast Neoplasms
Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
Breast Neoplasms
Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.
Breast Neoplasms
Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers.
Breast Neoplasms
Single-nucleotide polymorphism genotyping by nanoparticle-enhanced surface plasmon resonance imaging measurements of surface ligation reactions.
Breast Neoplasms
Single-port versus conventional multiport access prophylactic laparoscopic bilateral salpingo-oophorectomy in high-risk patients for ovarian cancer: a comparison of surgical outcomes.
Breast Neoplasms
Single-strand conformation polymorphism analysis by capillary and microchip electrophoresis: a fast, simple method for detection of common mutations in BRCA1 and BRCA2.
Breast Neoplasms
SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
Breast Neoplasms
Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Breast Neoplasms
Skp2 is a promising therapeutic target in breast cancer.
Breast Neoplasms
Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness.
Breast Neoplasms
Small GTPase Rho regulates R-cadherin through Dia1/profilin-1.
Breast Neoplasms
Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis.
Breast Neoplasms
Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.
Breast Neoplasms
Smoking and the risk of breast cancer among carriers of BRCA mutations.
Breast Neoplasms
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.
Breast Neoplasms
Smurf2 E3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a CNKSR2 dependent manner.
Breast Neoplasms
SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation.
Breast Neoplasms
SNP-SNP interactions in breast cancer susceptibility.
Breast Neoplasms
SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER?-positive breast cancer through regulation of BRCA1.
Breast Neoplasms
Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions.
Breast Neoplasms
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Breast Neoplasms
Sociocultural predictors of breast cancer risk perceptions in African American breast cancer survivors.
Breast Neoplasms
Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
Breast Neoplasms
Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma.
Breast Neoplasms
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus.
Breast Neoplasms
Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer.
Breast Neoplasms
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Breast Neoplasms
Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer.
Breast Neoplasms
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Breast Neoplasms
Some public health issues in the current state of genetic testing for breast cancer in Australia.
Breast Neoplasms
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.
Breast Neoplasms
Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines.
Breast Neoplasms
Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus.
Breast Neoplasms
Specific BRCA1 gene variations amongst young Moroccan breast cancer patients.
Breast Neoplasms
Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
Breast Neoplasms
Specific H-Ras minisatellite alleles in breast cancer susceptibility.
Breast Neoplasms
Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer: the importance of whole-gene sequencing.
Breast Neoplasms
Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
Breast Neoplasms
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening.
Breast Neoplasms
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
Breast Neoplasms
Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.
Breast Neoplasms
Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families.
Breast Neoplasms
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Breast Neoplasms
Spiritual faith and genetic testing decisions among high-risk breast cancer probands.
Breast Neoplasms
Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary.
Breast Neoplasms
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Breast Neoplasms
Sporadic and Hereditary Breast Cancer Genetics.
Breast Neoplasms
Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2.
Breast Neoplasms
Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Breast Neoplasms
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Breast Neoplasms
Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
Breast Neoplasms
Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue.
Breast Neoplasms
Standardization of the methylation?specific PCR method for analyzing BRCA1 and ER methylation.
Breast Neoplasms
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2013.
Breast Neoplasms
Staurosporine-sensitive protein phosphorylation is required for postreplication DNA repair in human cells.
Breast Neoplasms
Stem cell therapy for hereditary breast cancer.
Breast Neoplasms
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Breast Neoplasms
Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
Breast Neoplasms
Strong feature sets from small samples.
Breast Neoplasms
Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online.
Breast Neoplasms
Structural analysis of BRCA1 reveals modification hotspot.
Breast Neoplasms
Structural basis for regulation of human acetyl-CoA carboxylase.
Breast Neoplasms
Structure meets function--centrosomes, genome maintenance and the DNA damage response.
Breast Neoplasms
Structure of an XRCC1 BRCT domain: a new protein-protein interaction module.
Breast Neoplasms
Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
Breast Neoplasms
Studies on the methylation status of CpG sequences located in promoters of selected tumour suppressor genes in breast cancer cells.
Breast Neoplasms
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study.
Breast Neoplasms
Study of BRCA1 gene in hereditary breast and ovarian cancer.
Breast Neoplasms
Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
Breast Neoplasms
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Breast Neoplasms
Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1.
Breast Neoplasms
Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene.
Breast Neoplasms
Subcellular localization of the BRCA1 gene product in mitotic cells.
Breast Neoplasms
Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors.
Breast Neoplasms
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
Breast Neoplasms
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
Breast Neoplasms
Subtypes of familial breast tumours revealed by expression and copy number profiling.
Breast Neoplasms
SUMO E3 ligase CBX4 regulates hTERT-mediated transcription of CDH1 and promotes breast cancer cell migration and invasion.
Breast Neoplasms
SUMOylation proteins in breast cancer.
Breast Neoplasms
Suppression and recovery of BRCA1-mediated transcription by HP1? via modulation of promoter occupancy.
Breast Neoplasms
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Breast Neoplasms
Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes.
Breast Neoplasms
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Breast Neoplasms
Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q.
Breast Neoplasms
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.
Breast Neoplasms
Surface plasmon resonance biosensor for label-free and highly sensitive detection of point mutation using polymerization extension reaction.
Breast Neoplasms
Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations.
Breast Neoplasms
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Breast Neoplasms
Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit.
Breast Neoplasms
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Survival and tumor characteristics of German hereditary breast cancer patients.
Breast Neoplasms
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
Breast Neoplasms
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Breast Neoplasms
Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group.
Breast Neoplasms
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Breast Neoplasms
Survival in Norwegian BRCA1 mutation carriers with breast cancer.
Breast Neoplasms
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.
Breast Neoplasms
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Breast Neoplasms
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland.
Breast Neoplasms
Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Breast Neoplasms
Survival of patients with breast cancer and BRCA1 mutations.
Breast Neoplasms
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Breast Neoplasms
SYK expression level distinguishes control from BRCA1-mutated lymphocytes.
Breast Neoplasms
Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer.
Breast Neoplasms
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Breast Neoplasms
Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
Breast Neoplasms
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.
Breast Neoplasms
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Breast Neoplasms
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Breast Neoplasms
Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer.
Breast Neoplasms
Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.
Breast Neoplasms
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Breast Neoplasms
Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.
Breast Neoplasms
Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
Breast Neoplasms
Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
Breast Neoplasms
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update.
Breast Neoplasms
Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
Breast Neoplasms
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Breast Neoplasms
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Breast Neoplasms
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
Breast Neoplasms
Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Breast Neoplasms
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Breast Neoplasms
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Breast Neoplasms
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.
Breast Neoplasms
Targeted Next-generation Sequencing for Reliable Detection of Genetic Status in Breast Cancer.
Breast Neoplasms
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
Breast Neoplasms
Targeted sequencing of crucial cancer causing genes of breast cancer in Saudi patients.
Breast Neoplasms
Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk.
Breast Neoplasms
Targeted Vaccination against Human ?-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
Breast Neoplasms
Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.
Breast Neoplasms
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-ribose) polymerase inhibition.
Breast Neoplasms
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
Breast Neoplasms
Targeting DNA damage and repair by curcumin.
Breast Neoplasms
Targeting DNA repair in breast cancer: A clinical and translational update.
Breast Neoplasms
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
Breast Neoplasms
Targeting of DNA Damage Signaling Pathway Induced Senescence and Reduced Migration of Cancer cells.
Breast Neoplasms
Targeting the Akt/mTOR pathway in Brca1-deficient cancers.
Breast Neoplasms
Targeting the BRCA1/2 tumor suppressors.
Breast Neoplasms
Targeting the epigenetics of the DNA damage response in breast cancer.
Breast Neoplasms
Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass.
Breast Neoplasms
Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent.
Breast Neoplasms
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Breast Neoplasms
TAT-ODD-p53 enhances the radiosensitivity of hypoxic breast cancer cells by inhibiting Parkin-mediated mitophagy.
Breast Neoplasms
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
Breast Neoplasms
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
Breast Neoplasms
Teaching efficacy of a medical education module on genetic testing for cancer.
Breast Neoplasms
Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Breast Neoplasms
Ten genes for inherited breast cancer.
Breast Neoplasms
Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer.
Breast Neoplasms
Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2-Reply.
Breast Neoplasms
Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2.
Breast Neoplasms
Testing for BRCA1 in hereditary breast cancer.
Breast Neoplasms
Testing for BRCA1 mutations: a cost-effectiveness analysis.
Breast Neoplasms
Testing for hereditary breast and ovarian cancer in the southeastern United States.
Breast Neoplasms
Testing for inherited susceptibility to breast cancer: a survey of informed consent forms for BRCA1 and BRCA2 mutation testing.
Breast Neoplasms
Testing for the breast cancer predisposition gene, BRCA1.
Breast Neoplasms
TGF? induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
Breast Neoplasms
TGFBR1 Signaling and Breast Cancer.
Breast Neoplasms
Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
Breast Neoplasms
The 12 base pair duplication/insertion alteration could be a regulatory mutation.
Breast Neoplasms
The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.
Breast Neoplasms
The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors.
Breast Neoplasms
The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.
Breast Neoplasms
The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives.
Breast Neoplasms
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The androgen receptor CAG repeat: a modifier of carcinogenesis?
Breast Neoplasms
The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.
Breast Neoplasms
The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Breast Neoplasms
The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells.
Breast Neoplasms
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Breast Neoplasms
The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.
Breast Neoplasms
The ATM gene and breast cancer: is it really a risk factor?
Breast Neoplasms
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor ? and modulates estrogen-stimulated breast cancer cell proliferation.
Breast Neoplasms
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Breast Neoplasms
The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population.
Breast Neoplasms
The basal phenotype of BRCA1-related breast cancer: past, present and future.
Breast Neoplasms
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Breast Neoplasms
The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
Breast Neoplasms
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
Breast Neoplasms
The BRCA1 and BRCA2 breast cancer genes.
Breast Neoplasms
The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients.
Breast Neoplasms
The Brca1 and Brca2 proteins and tumor pathogenesis.
Breast Neoplasms
The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations.
Breast Neoplasms
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
Breast Neoplasms
The BRCA1 E3 Ubiquitin Ligase Controls Centrosome Dynamics.
Breast Neoplasms
The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms.
Breast Neoplasms
The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci.
Breast Neoplasms
The BRCA1 Variant p.Ser36Tyr Abrogates BRCA1 Protein Function and Potentially Confers a Moderate Risk of Breast Cancer.
Breast Neoplasms
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
Breast Neoplasms
The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centrosomes.
Breast Neoplasms
The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Breast Neoplasms
The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation.
Breast Neoplasms
The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
Breast Neoplasms
The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.
Breast Neoplasms
The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
Breast Neoplasms
The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
Breast Neoplasms
The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model.
Breast Neoplasms
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
Breast Neoplasms
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Breast Neoplasms
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
Breast Neoplasms
The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Breast Neoplasms
The breast surgeon's role in BRCA1 and BRCA2 testing.
Breast Neoplasms
The cancer genetics and pathology of male breast cancer.
Breast Neoplasms
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
Breast Neoplasms
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Breast Neoplasms
The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.
Breast Neoplasms
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Breast Neoplasms
The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling.
Breast Neoplasms
The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
Breast Neoplasms
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Breast Neoplasms
The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.
Breast Neoplasms
The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis.
Breast Neoplasms
The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
Breast Neoplasms
The complex genetic landscape of familial breast cancer.
Breast Neoplasms
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.
Breast Neoplasms
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.
Breast Neoplasms
The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Breast Neoplasms
The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Breast Neoplasms
The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.
Breast Neoplasms
The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.
Breast Neoplasms
The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
Breast Neoplasms
The correlations between BRCA1 defect and environmental factors in the risk of breast cancer.
Breast Neoplasms
The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49.
Breast Neoplasms
The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
Breast Neoplasms
The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.
Breast Neoplasms
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Breast Neoplasms
The DNA double-strand break response pathway: becoming more BRCAish than ever.
Breast Neoplasms
The DNA resection protein CtIP promotes mammary tumorigenesis.
Breast Neoplasms
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
Breast Neoplasms
The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
Breast Neoplasms
The E3 ubiquitin ligase Cbl-b inhibits tumor growth in multidrug-resistant gastric and breast cancer cells.
Breast Neoplasms
The E3 Ubiquitin Ligase Cbl-b Predicts Favorable Prognosis in Breast Cancer.
Breast Neoplasms
The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients.
Breast Neoplasms
The effect of oral 3,3'-diindolylmethane supplementation on the 2:16?-OHE ratio in BRCA1 mutation carriers.
Breast Neoplasms
The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.
Breast Neoplasms
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
Breast Neoplasms
The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
Breast Neoplasms
The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression.
Breast Neoplasms
The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
Breast Neoplasms
The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Breast Neoplasms
The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
Breast Neoplasms
The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2.
Breast Neoplasms
The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
Breast Neoplasms
The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes.
Breast Neoplasms
The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.
Breast Neoplasms
The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells.
Breast Neoplasms
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
Breast Neoplasms
The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets.
Breast Neoplasms
The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.
Breast Neoplasms
The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
Breast Neoplasms
The first case report of a large deletion of the BRCA1 gene in Croatia: A case report.
Breast Neoplasms
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Breast Neoplasms
The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
Breast Neoplasms
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Breast Neoplasms
The frequency and outcome of breast cancer risk-reducing surgery in finnish BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine.
Breast Neoplasms
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Breast Neoplasms
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
Breast Neoplasms
The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.
Breast Neoplasms
The future of breast cancer systemic therapy: the next 10 years.
Breast Neoplasms
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.
Breast Neoplasms
The genetic basis of breast cancer and its clinical implications.
Breast Neoplasms
The genetic components of susceptibility to breast cancer in the rat.
Breast Neoplasms
The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium.
Breast Neoplasms
The genetics of breast and ovarian cancer.
Breast Neoplasms
The genetics of breast cancer susceptibility.
Breast Neoplasms
The genetics of breast cancer: risk factors for disease.
Breast Neoplasms
THe genetics of familial breast cancer.
Breast Neoplasms
The genetics of inherited breast cancer.
Breast Neoplasms
The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
Breast Neoplasms
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
Breast Neoplasms
The HLA class III subregion is responsible for an increased breast cancer risk.
Breast Neoplasms
The impact of a prevention effort on the community.
Breast Neoplasms
The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
Breast Neoplasms
The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
Breast Neoplasms
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.
Breast Neoplasms
The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
Breast Neoplasms
The importance of BRCA1 and BRCA2 genes mutations in breast cancer development.
Breast Neoplasms
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Breast Neoplasms
The influence of familial and hereditary factors on the prognosis of breast cancer.
Breast Neoplasms
The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations.
Breast Neoplasms
The influence of psychological distress on use of genetic testing for cancer risk.
Breast Neoplasms
The influence of reproductive factors on breast cancer risk in women with pathogenic mutations.
Breast Neoplasms
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors.
Breast Neoplasms
The Interaction of CtIP and Nbs1 Connects CDK and ATM to Regulate HR-Mediated Double-Strand Break Repair.
Breast Neoplasms
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
Breast Neoplasms
The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia.
Breast Neoplasms
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
Breast Neoplasms
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Breast Neoplasms
The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.
Breast Neoplasms
The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
Breast Neoplasms
The mammary gland carcinogens: the role of metal compounds and organic solvents.
Breast Neoplasms
The management of familial breast cancer.
Breast Neoplasms
The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance.
Breast Neoplasms
The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
Breast Neoplasms
The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.
Breast Neoplasms
The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer.
Breast Neoplasms
The molecular genetics of breast cancer and targeted therapy.
Breast Neoplasms
The molecular pathology of hereditary breast cancer.
Breast Neoplasms
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
Breast Neoplasms
The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females.
Breast Neoplasms
The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.
Breast Neoplasms
The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor.
Breast Neoplasms
The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.
Breast Neoplasms
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities.
Breast Neoplasms
The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.
Breast Neoplasms
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Breast Neoplasms
The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Breast Neoplasms
The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology.
Breast Neoplasms
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
Breast Neoplasms
The pathology of familial breast cancer: How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology?
Breast Neoplasms
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Breast Neoplasms
The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era: historical perspectives.
Breast Neoplasms
The pathology of hereditary breast cancer.
Breast Neoplasms
The pathology of inherited breast cancer.
Breast Neoplasms
The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness.
Breast Neoplasms
The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk.
Breast Neoplasms
The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells.
Breast Neoplasms
The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan.
Breast Neoplasms
The potential for aromatase inhibition in breast cancer prevention.
Breast Neoplasms
The PPAR? agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
Breast Neoplasms
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Breast Neoplasms
The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Breast Neoplasms
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
Breast Neoplasms
The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
Breast Neoplasms
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
Breast Neoplasms
The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer.
Breast Neoplasms
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
Breast Neoplasms
The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.
Breast Neoplasms
The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.
Breast Neoplasms
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.
Breast Neoplasms
The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
Breast Neoplasms
The prevention of hereditary breast cancer.
Breast Neoplasms
The problems with risk selection; scientific and psychosocial aspects.
Breast Neoplasms
The prodigious network of chromosome 17 miRNAs regulating cancer genes that influence the hallmarks of cancer.
Breast Neoplasms
The progestin ORG2058 but not retinoic acid stimulates BRCA1 mRNA expression in MCF-7 human breast cancer cells.
Breast Neoplasms
The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators.
Breast Neoplasms
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
Breast Neoplasms
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer.
Breast Neoplasms
The pros and cons of genetic testing for breast and ovarian cancer risk.
Breast Neoplasms
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript.
Breast Neoplasms
The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Breast Neoplasms
The RAD52-S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Breast Neoplasms
The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil.
Breast Neoplasms
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
Breast Neoplasms
The Retinoblastoma Gene Undergoes Rearrangements in BRCA1-Deficient Basal-like Breast Cancer.
Breast Neoplasms
The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
Breast Neoplasms
The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase.
Breast Neoplasms
The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
Breast Neoplasms
The risk of breast cancer in women with a BRCA1 mutation from north america and poland.
Breast Neoplasms
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Breast Neoplasms
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Breast Neoplasms
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Breast Neoplasms
The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.
Breast Neoplasms
The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.
Breast Neoplasms
The role of BRCA status on prognosis in patients with triple-negative breast cancer.
Breast Neoplasms
The role of BRCA1 and BRCA2 in prostate cancer.
Breast Neoplasms
The role of BRCA1 gene mutations and apoptosis phenomenon in sporadic breast cancer.
Breast Neoplasms
The role of BRCA1 in DNA double-strand repair: past and present.
Breast Neoplasms
The role of BRCA1 in non-homologous end-joining.
Breast Neoplasms
The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence.
Breast Neoplasms
The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression.
Breast Neoplasms
The Role of Genetic Testing in Patients With Breast Cancer: A Review.
Breast Neoplasms
The role of magnetic resonance imaging in screening women at high risk of breast cancer.
Breast Neoplasms
The role of pathologists in recognition of morphologic and biologic features of genetically mutated breast cancer.
Breast Neoplasms
The role of Rak in the regulation of stability and function of BRCA1.
Breast Neoplasms
The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
Breast Neoplasms
The Spectrum of BRCA1 and BRCA2 mutations in Breast Cancer Patients in the Bahamas.
Breast Neoplasms
The spectrum of mutations predisposing to familial breast cancer in Poland.
Breast Neoplasms
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.
Breast Neoplasms
The tumor suppressor BRCA1-BARD1 complex localizes to the synaptonemal complex and regulates recombination under meiotic dysfunction in Caenorhabditis elegans.
Breast Neoplasms
The unliganded glucocorticoid receptor positively regulates the tumour suppressor gene BRCA1 through GABP beta.
Breast Neoplasms
The UPS: a promising target for breast cancer treatment.
Breast Neoplasms
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
Breast Neoplasms
The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study.
Breast Neoplasms
The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay.
Breast Neoplasms
The validation of a simulation model incorporating radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk.
Breast Neoplasms
The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
Breast Neoplasms
The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women.
Breast Neoplasms
The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
Breast Neoplasms
Therapeutic Approaches for Women Predisposed to Breast Cancer.
Breast Neoplasms
Therapeutic exploitation of tumor cell defects in homologous recombination.
Breast Neoplasms
Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
Breast Neoplasms
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
Breast Neoplasms
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
Breast Neoplasms
Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
Breast Neoplasms
Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.
Breast Neoplasms
Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Breast Neoplasms
Time to reconsider subcutaneous mastectomy for breast-cancer prevention?
Breast Neoplasms
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Breast Neoplasms
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
Breast Neoplasms
Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
Breast Neoplasms
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
Breast Neoplasms
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Breast Neoplasms
Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Breast Neoplasms
Towards a dietary prevention of hereditary breast cancer.
Breast Neoplasms
Towards classification of BRCA1 missense variants using a biophysical approach.
Breast Neoplasms
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
Breast Neoplasms
TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.
Breast Neoplasms
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Breast Neoplasms
TP53 mutations in familial breast cancer: functional aspects.
Breast Neoplasms
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Breast Neoplasms
Transactivation of repair genes by BRCA1.
Breast Neoplasms
Transcript identification in the BRCA1 candidate region.
Breast Neoplasms
Transcriptional autoregulation by BRCA1.
Breast Neoplasms
Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.
Breast Neoplasms
Transcriptional Pathways Altered in Response to Vibration in a Model of Hand-Arm Vibration Syndrome.
Breast Neoplasms
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
Breast Neoplasms
Transcriptional regulation of BRCA1 expression by a metabolic switch.
Breast Neoplasms
Transcriptional regulation of the base excision repair pathway by BRCA1.
Breast Neoplasms
Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter.
Breast Neoplasms
Transcriptome mining of non-BRCA1/A2 and BRCA1/A2 familial breast cancer.
Breast Neoplasms
Treatment of hereditary breast cancer.
Breast Neoplasms
Treatment-focused DNA testing for newly diagnosed breast cancer patients: some implications for clinical practice.
Breast Neoplasms
Tree-based analysis of microarray data for classifying breast cancer.
Breast Neoplasms
Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status.
Breast Neoplasms
Trends in diagnosis and control of bovine mastitis: a review.
Breast Neoplasms
TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L.
Breast Neoplasms
TRIM25: A central factor in breast cancer.
Breast Neoplasms
TRIM27 Functions as a Novel Oncogene in Non-Triple-Negative Breast Cancer by Blocking Cellular Senescence through p21 Ubiquitination.
Breast Neoplasms
TRIM3 inhibits P53 signaling in breast cancer cells.
Breast Neoplasms
TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10.
Breast Neoplasms
Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.
Breast Neoplasms
Triple Negative Breast Cancer in BRCA1 Mutation Carriers With a Complete Radiologic Response to Neoadjuvant Paclitaxel: A Case Report.
Breast Neoplasms
Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
Breast Neoplasms
Triple negative breast cancers: clinical and prognostic implications.
Breast Neoplasms
Triple negative tumours: a critical review.
Breast Neoplasms
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Breast Neoplasms
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Breast Neoplasms
Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia.
Breast Neoplasms
Triple-negative breast cancer in African-American women: disparities versus biology.
Breast Neoplasms
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Breast Neoplasms
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Breast Neoplasms
Triple-Negative Breast Cancer: Clinical and Histological Correlations.
Breast Neoplasms
Triple-negative breast cancer: epidemiological considerations and recommendations.
Breast Neoplasms
TrkC-Targeted Kinase Inhibitors And PROTACs.
Breast Neoplasms
Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
Breast Neoplasms
Tumor classification using phylogenetic methods on expression data.
Breast Neoplasms
Tumor markers in breast cancer--evaluation of their clinical usefulness.
Breast Neoplasms
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Breast Neoplasms
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Breast Neoplasms
Tumor suppressor genes and breast cancer.
Breast Neoplasms
Tumor suppressor loss in pituitary tumors.
Breast Neoplasms
Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.
Breast Neoplasms
Tumoral Expression of BRCA1, Estrogen Receptor Alpha and ID4 Protein in Patients with Sporadic Breast Cancer.
Breast Neoplasms
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Breast Neoplasms
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Breast Neoplasms
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
Breast Neoplasms
Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
Breast Neoplasms
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden.
Breast Neoplasms
TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.
Breast Neoplasms
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Breast Neoplasms
Two approaches to mutation detection based on functional data.
Breast Neoplasms
Two contiguously located germline BRCA1 mutations in a Spanish early-onset breast cancer family.
Breast Neoplasms
Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
Breast Neoplasms
Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
Breast Neoplasms
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction.
Breast Neoplasms
Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
Breast Neoplasms
Two truncating variants in FANCC and breast cancer risk.
Breast Neoplasms
Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.
Breast Neoplasms
Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells.
Breast Neoplasms
Ubiquitination of NF-?B p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.
Breast Neoplasms
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.
Breast Neoplasms
ULK2 is essential for degradation of ubiquitinated protein aggregates and homeostasis in skeletal muscle.
Breast Neoplasms
Ultraselective electrochemiluminescence biosensor based on locked nucleic acid modified toehold-mediated strand displacement reaction and junction-probe.
Breast Neoplasms
Ultrasonographic characteristics and BI-RADS-US classification of BRCA1 mutation-associated breast cancer in Guangxi, China.
Breast Neoplasms
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
Breast Neoplasms
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
Breast Neoplasms
Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
Breast Neoplasms
Understanding BRCA Mutation Carriers' Preferences for Communication of Genetic Modifiers of Breast Cancer Risk.
Breast Neoplasms
Understanding missense mutations in the BRCA1 gene: an evolutionary approach.
Breast Neoplasms
Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.
Breast Neoplasms
Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
Breast Neoplasms
Update on breast cancer susceptibility genes.
Breast Neoplasms
Update on genetic predisposition to breast cancer.
Breast Neoplasms
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Breast Neoplasms
Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study.
Breast Neoplasms
Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women.
Breast Neoplasms
Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
Breast Neoplasms
Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Breast Neoplasms
Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
Breast Neoplasms
Use of Gene Expression Profiles of Peripheral Blood Lymphocytes to Distinguish BRCA1 Mutation Carriers in High Risk Breast Cancer Families.
Breast Neoplasms
Usefulness of breast MRI in a patient with genetic risk.
Breast Neoplasms
Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Breast Neoplasms
Using MLPA for large genomic rearrangements detection in breast cancer predisposition genes.
Breast Neoplasms
Using whole-genome sequencing data to derive the homologous recombination deficiency scores.
Breast Neoplasms
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
Breast Neoplasms
Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Breast Neoplasms
Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States.
Breast Neoplasms
Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.
Breast Neoplasms
Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation.
Breast Neoplasms
Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry.
Breast Neoplasms
Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.
Breast Neoplasms
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).
Breast Neoplasms
Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands.
Breast Neoplasms
Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer.
Breast Neoplasms
Variation in the RAD51 gene and familial breast cancer.
Breast Neoplasms
Variation of breast cancer risk among BRCA1/2 carriers.
Breast Neoplasms
Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients.
Breast Neoplasms
VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells.
Breast Neoplasms
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Breast Neoplasms
Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor ? are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
Breast Neoplasms
Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
Breast Neoplasms
What?s Happening to Your DNA Data?: Genetic Testing Services Abound, but Consumers Opting to Use Them Should Be Aware of the Pitfalls.
Breast Neoplasms
When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
Breast Neoplasms
Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.
Breast Neoplasms
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.
Breast Neoplasms
Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study.
Breast Neoplasms
Widespread bimodal intrachromosomal genomic instability in sporadic breast cancers associated with 13q allelic imbalance.
Breast Neoplasms
Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin.
Breast Neoplasms
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.
Breast Neoplasms
WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.
Breast Neoplasms
Withaferin a induces proteasome-dependent degradation of breast cancer susceptibility gene 1 and heat shock factor 1 proteins in breast cancer cells.
Breast Neoplasms
Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange.
Breast Neoplasms
WITHDRAWN: BRCA1 protein expression and TOP2A gene aberration and protein expression in four molecular subtypes of breast cancer.
Breast Neoplasms
Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Breast Neoplasms
Women with hereditary breast cancer predispositions should avoid using their smartphones, tablets, and laptops at night.
Breast Neoplasms
Women's Decision Making about Risk-Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic Review.
Breast Neoplasms
Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
Breast Neoplasms
Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory.
Breast Neoplasms
WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
Breast Neoplasms
WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells.
Breast Neoplasms
X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors.
Breast Neoplasms
X-chromosome inactivation: X marks the spot for BRCA1.
Breast Neoplasms
X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression.
Breast Neoplasms
X-rays increase breast cancer risk in women with gene mutation.
Breast Neoplasms
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Breast Neoplasms
YC-1 inhibits proliferation of breast cancer cells by downregulating EZH2 expression via activation of c-Cbl and ERK.
Breast Neoplasms
Yeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction.
Breast Neoplasms
Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation.
Breast Neoplasms
Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
Breast Neoplasms
ZNF365 promotes stalled replication forks recovery to maintain genome stability.
Breast Neoplasms
Zwitterionic peptide anchored to conducting polymer PEDOT for the development of antifouling and ultrasensitive electrochemical DNA sensor.
Breast Neoplasms
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
Breast Neoplasms
[5589del8: the recurrent mutation of BRCA1 gene in Chinese breast cancer patients]
Breast Neoplasms
[Advance in researches on BRCA1.]
Breast Neoplasms
[An immunohistochemical study of aromatase, estrogen 4-hydroxylase and fatty acid synthetase in breast cancer tissues from BRCA1 mutation carriers]
Breast Neoplasms
[An integrated early detection concept in women with a genetic predisposition for breast cancer]
Breast Neoplasms
[Analysis of BRCA1 gene mutations in patients with early-onset breast cancer and their affected relatives in Guangdong province]
Breast Neoplasms
[Analysis of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.]
Breast Neoplasms
[Analysis of loss of heterozygosity and microsatellite instability RAD52, RAD54 and RAD54B gene and BRCA1 gene mutation in breast cancer]
Breast Neoplasms
[Analysis of mutation sites of BRCA1 gene in Chinese patients with breast cancer]
Breast Neoplasms
[Analysis of mutations in genes BRCA1 and BRCA2 among patients with breast and ovarian cancer in northern Portugal and Galicia]
Breast Neoplasms
[Analysis of mutations in the BRCA1 gene in patients with cancer of the breast and/or the ovary in Portugal]
Breast Neoplasms
[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations]
Breast Neoplasms
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]
Breast Neoplasms
[Analysis of the mutations of BRCA1 in 9 familiar breast cancer patients]
Breast Neoplasms
[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?]
Breast Neoplasms
[Attitudes towards screening and prevention of breast and ovarian cancers with hereditary predisposition. Survey by female gynecologists in the north of France]
Breast Neoplasms
[BRCA mutations: from Angelina Jolie to specific therapies].
Breast Neoplasms
[BRCA1 1100delAT is a recurrent mutation in Chinese women with familial breast cancer]
Breast Neoplasms
[BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China]
Breast Neoplasms
[BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer]
Breast Neoplasms
[BRCA1 and BRCA2 mutations in families studied in the Program of Genetic Counselling in Cancer of the Valencian Community (Spain).]
Breast Neoplasms
[BRCA1 and BRCA2 mutations in patients with familial breast cancer]
Breast Neoplasms
[BRCA1 and BRCA2: mutations and other genetic changes--practical relevance]
Breast Neoplasms
[BRCA1 and Estrogen Receptor ? Expression Regulation in Breast Cancer Cells].
Breast Neoplasms
[BRCA1 gene mutations in early-onset breast cancer]
Breast Neoplasms
[BRCA1 germ line mutations in Chinese early-onset breast cancer patients.]
Breast Neoplasms
[BRCA1 inhibits progesterone-induced proliferation and migration of breast cancer cells].
Breast Neoplasms
[BRCA1 protein expression in sporadic breast and its clinical significance]
Breast Neoplasms
[BRCA1 regulates progesterone receptors A and B protein expressions in breast cancer cells in vitro]
Breast Neoplasms
[BRCA1 selectively regulates the expression of progesterone receptor A in sporadic invasive ductal breast carcinoma]
Breast Neoplasms
[BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases]
Breast Neoplasms
[Breast cancer after preventive subcutaneous mastectomy]
Breast Neoplasms
[Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]
Breast Neoplasms
[Breast cancer in BRCA1/2 mutation carriers].
Breast Neoplasms
[Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age].
Breast Neoplasms
[Breast cancer screening different from that used for the general population: who is concerned and with which approach?]
Breast Neoplasms
[Breast cancer susceptibility gene BRCA1 of hereditary breast cancer/ ovarian cancer syndrome]
Breast Neoplasms
[Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
Breast Neoplasms
[Characterization of the BRCA1 gene and its significance in hereditary breast cancer]
Breast Neoplasms
[CHEK2 and breast cancer risk]
Breast Neoplasms
[CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
Breast Neoplasms
[Choices for women at risk of hereditary breast cancer].
Breast Neoplasms
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]
Breast Neoplasms
[Clinical value of gene diagnosis in breast cancer]
Breast Neoplasms
[Cloning of BRCA1 cDNA and detection of BRCA1 mRNA expression in breast cancer cells]
Breast Neoplasms
[Comparative study on functional characters of MCF7 and HCC1937 cell lines in response to DNA damage].
Breast Neoplasms
[Correlation anslysis of sporadic breast cancer and BRCA1 gene plymorphisms in the Han Nationality and the Mongol Nationality of Inner Mongolia Region].
Breast Neoplasms
[Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer]
Breast Neoplasms
[Cytogenetic abnormalities, genetic alterations, and applications for genetic diagnosis in breast cancer]
Breast Neoplasms
[Detection of 5382insC mutation in human BRCA1 gene using fluorescent labeled oligonucleotides]
Breast Neoplasms
[Detection of a BRCA1 c.2013_2014ins GT variant an ethnic Han Chinese pedigree affected with breast cancer].
Breast Neoplasms
[Determination of a BRCA1 gene mutation in a family with hereditary breast cancer]
Breast Neoplasms
[Diagnostic molecular biology in breast cancer]
Breast Neoplasms
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
Breast Neoplasms
[Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1]
Breast Neoplasms
[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
Breast Neoplasms
[Estimation of individual breast cancer risk: relevance and limits of risk estimation models]
Breast Neoplasms
[Ethnic aspects of hereditary breast cancer in the region of Siberia].
Breast Neoplasms
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy]
Breast Neoplasms
[Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen]
Breast Neoplasms
[Expression of BRCA1 and WWOX and their clinicopathologic implication in breast carcinomas occurring in young women].
Breast Neoplasms
[Expression of E3 ligase HERC4 in breast cancer and its clinical implications].
Breast Neoplasms
[Familial breast cancer]
Breast Neoplasms
[Familial cancer and oncogenic factors]
Breast Neoplasms
[Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer]
Breast Neoplasms
[From gene to disease; from BRCA1 or BRCA2 to breast cancer]
Breast Neoplasms
[From gene to disease; from BRCA1 OR BRCA2 to breast cancer]
Breast Neoplasms
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Breast Neoplasms
[Function of BRCA1 and BRCA2 genes associated with hereditary predisposition to breast cancer]
Breast Neoplasms
[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer.]
Breast Neoplasms
[Genetic alterations and DNA-based diagnosis in breast cancer]
Breast Neoplasms
[Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
Breast Neoplasms
[Genetic predisposition to cancer: familial forms of medullary thyroid cancer and breast cancer]
Breast Neoplasms
[Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]
Breast Neoplasms
[Genetic test and prophylactic treatment in breast cancer families]
Breast Neoplasms
[Genetics and cancer: application to the breast]
Breast Neoplasms
[Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
Breast Neoplasms
[Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method]
Breast Neoplasms
[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people]
Breast Neoplasms
[Hereditary breast and ovarian cancer].
Breast Neoplasms
[Hereditary breast cancer in Norway]
Breast Neoplasms
[Hereditary breast cancers]
Breast Neoplasms
[Hereditary breast cancer]
Breast Neoplasms
[Hereditary breast carcinomas pathologist's perspective].
Breast Neoplasms
[Hereditary ovarian cancer. The role of BRCA1 gene dysfunction in response to chemotherapy].
Breast Neoplasms
[Hereditary predispositions to gynaecological cancers]
Breast Neoplasms
[Human genes patents: yes or no? Reflections on the ruling of the Supreme Court of the United States].
Breast Neoplasms
[Impact of recent oncogenetic progress on the management of high risk breast cancer patients: the example of BRCA1 and BRCA2 genes]
Breast Neoplasms
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]
Breast Neoplasms
[Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?]
Breast Neoplasms
[Inhibition of cellular proliferation by knockdown of MARCH6 gene expression in breast cancer cells].
Breast Neoplasms
[Initial Dutch results with a presymptomatic DNA tests in familial breast/ovarian carcinoma. Rotterdamse Werkgroep voor Erfelijke Tumoren]
Breast Neoplasms
[Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients]
Breast Neoplasms
[Is hereditary predisposition to breast cancer linked to BRCA1 a disease of response to genotoxic lesions?]
Breast Neoplasms
[Loss of heterozygosity and microsatellite instability in the region including BRCA1 of breast cancer in Chinese]
Breast Neoplasms
[Medical management of women with inherited predisposition to breast cancer: indications and procedures for mammographic screening]
Breast Neoplasms
[Molecular alterations in breast cancer: clinical implications and new analytical tools]
Breast Neoplasms
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]
Breast Neoplasms
[Molecular Diagnosis and Treatment of HBOC Syndrome].
Breast Neoplasms
[Molecular genetics and clinics of hereditary breast cancer]
Breast Neoplasms
[Molecular genetics of hereditary breast carcinoma]
Breast Neoplasms
[Molecular study of the BRCA1 and BRCA2 genes in 153 breast cancer families from Castilla and León (Spain): new nine unclassified variants identified]
Breast Neoplasms
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
Breast Neoplasms
[Mutation BRCA1 gene in 186 breast cancer patients]
Breast Neoplasms
[Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance]
Breast Neoplasms
[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai]
Breast Neoplasms
[Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women]
Breast Neoplasms
[Mutations in the BRCA1 gene (185delAG and 5382insC) are not present in any of the 30 breast cancer patients analyzed from eastern Colombia]
Breast Neoplasms
[Mutations in the BRCA1 gene in young Spanish women with breast cancer]
Breast Neoplasms
[Novel BRCA1 gene mutations in breast cancer patients from St. Petersburg]
Breast Neoplasms
[Opposition to Myriad Genetics patents and their total or partial revocation in Europe: early conclusions]
Breast Neoplasms
[Pathogenesis of Fanconi anemia: FA-BRCA network -- review]
Breast Neoplasms
[Penetrance of BRCA1 gene mutation and DNA mitochondrial in Tunisian breast cancer occurrence]
Breast Neoplasms
[Perception accuracy of BRCA1/2 mutation predisposition in breast cancer women and associated factors].
Breast Neoplasms
[Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer]
Breast Neoplasms
[Pregnancy and risk of early breast cancer in patients sith BRCA1 and BRCA2 mutations]
Breast Neoplasms
[Prevalence of mutations BRCA1 5382insC, and CHEK2 1100delC in the population of Siberian region].
Breast Neoplasms
[Prevalence of the 185Ag deletion of the BRCA1 gene in Chilean women with breast neoplasm]
Breast Neoplasms
[Prevalence of widespread BRCA1 gene mutations in patients with familial breast cancer from St. Petersburg]
Breast Neoplasms
[Preventive surgical prcedures for inherited risk of breast cancer]
Breast Neoplasms
[Primary ovarian malignant mixed mesodermal tumor (MMMT) as a second primary tumor in a patient with invasive breast carcinoma--case report].
Breast Neoplasms
[Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].
Breast Neoplasms
[Relationship between mutation of BRCA1 and susceptibility to early onset of breast cancer]
Breast Neoplasms
[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
Breast Neoplasms
[Report of the National Oncology Research and Developement Consortium, 2003]
Breast Neoplasms
[Report on the first year of the activity of the National Oncological RD Consortium]
Breast Neoplasms
[Roles of Aurora-A in tumorigenesis and prognosis of breast cancer.]
Breast Neoplasms
[Search for frequently encountered mutations in genes predisposing to breast cancer]
Breast Neoplasms
[Sequence analysis of BRCA1 gene in young breast cancer patients and/or positive family history]
Breast Neoplasms
[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: A review].
Breast Neoplasms
[Significance and expressions of BRCA1 and BRCA2 protein in sporadic breast cancer].
Breast Neoplasms
[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers]
Breast Neoplasms
[Surgical prevention of breast carcinoma in patients with hereditary risk].
Breast Neoplasms
[Surgical procedure in primary and metastatic breast carcinoma]
Breast Neoplasms
[Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer]
Breast Neoplasms
[The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Breast Neoplasms
[The human genome--chromosome 17]
Breast Neoplasms
[The importance of genetic factors for development of breast cancer]
Breast Neoplasms
[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]
Breast Neoplasms
[The risk-reducing mastectomy: unnecessary hysteria or life-saving prophylaxis?].
Breast Neoplasms
[The role of BRCA1 and BRCA2 genes in hereditary breast cancer]
Breast Neoplasms
[Triple Negative Breast Cancer].
Breast Neoplasms
[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
Breast Neoplasms
[What attitude to women at high risk of breast cancer?]
Breast Neoplasms
[What do we know about ATM protein expression in breast tissue?]
Breast Neoplasms, Male
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
Breast Neoplasms, Male
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
Breast Neoplasms, Male
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
Breast Neoplasms, Male
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
Breast Neoplasms, Male
BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Breast Neoplasms, Male
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
Breast Neoplasms, Male
BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review.
Breast Neoplasms, Male
BRCA1/2 mutation analysis in male breast cancer families from North West England.
Breast Neoplasms, Male
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms, Male
CHEK2 1100delC and male breast cancer in the Netherlands.
Breast Neoplasms, Male
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
Breast Neoplasms, Male
Colorado family physicians' knowledge of hereditary breast cancer and related practice.
Breast Neoplasms, Male
Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy.
Breast Neoplasms, Male
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Breast Neoplasms, Male
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Breast Neoplasms, Male
Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.
Breast Neoplasms, Male
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.
Breast Neoplasms, Male
Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Breast Neoplasms, Male
Genetic predisposition to male breast cancer in Poland.
Breast Neoplasms, Male
Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A?>?G founder variant could be associated with higher male breast cancer risk.
Breast Neoplasms, Male
Genomic Large Rearrangement Screening of BRCA1 and BRCA2 Genes in High-Risk Turkish Breast/Ovarian Cancer Patients by Using Multiplex Ligation-Dependent Probe Amplification Assay.
Breast Neoplasms, Male
Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Breast Neoplasms, Male
Hereditary predisposition to breast cancer.
Breast Neoplasms, Male
High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history.
Breast Neoplasms, Male
Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Breast Neoplasms, Male
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Breast Neoplasms, Male
Inherited breast and ovarian cancer.
Breast Neoplasms, Male
Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
Breast Neoplasms, Male
Large genomic BRCA2 rearrangements and male breast cancer.
Breast Neoplasms, Male
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
Breast Neoplasms, Male
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Breast Neoplasms, Male
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.
Breast Neoplasms, Male
Loss of BRCA1 expression in sporadic male breast carcinoma.
Breast Neoplasms, Male
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Breast Neoplasms, Male
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
Breast Neoplasms, Male
MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
Breast Neoplasms, Male
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
Breast Neoplasms, Male
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Breast Neoplasms, Male
Molecular and pathological characterization of inherited breast cancer.
Breast Neoplasms, Male
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Breast Neoplasms, Male
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
Breast Neoplasms, Male
Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
Breast Neoplasms, Male
Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer.
Breast Neoplasms, Male
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
Breast Neoplasms, Male
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Breast Neoplasms, Male
Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer.
Breast Neoplasms, Male
Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Breast Neoplasms, Male
Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
Breast Neoplasms, Male
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Breast Neoplasms, Male
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Breast Neoplasms, Male
Significant contribution of germline BRCA2 rearrangements in male breast cancer families.
Breast Neoplasms, Male
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976-1999.
Breast Neoplasms, Male
The cancer genetics and pathology of male breast cancer.
Brucellosis
Brucella infection inhibits macrophages apoptosis via Nedd4-dependent degradation of calpain2.
Bulbo-Spinal Atrophy, X-Linked
CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins.
Burkitt Lymphoma
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Canavan Disease
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Canavan Disease
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
Canavan Disease
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Carcinogenesis
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
Carcinogenesis
?-transducin repeat-containing E3 ubiquitin protein ligase inhibits migration, invasion and proliferation of glioma cells.
Carcinogenesis
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.
Carcinogenesis
A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest.
Carcinogenesis
A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis.
Carcinogenesis
A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1? activation, tumorigenesis and metastasis.
Carcinogenesis
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
Carcinogenesis
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
Carcinogenesis
A novel oncoprotein Pirh2: rising from the shadow of MDM2.
Carcinogenesis
A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer.
Carcinogenesis
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
Carcinogenesis
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
Carcinogenesis
A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
Carcinogenesis
A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer.
Carcinogenesis
A role for Brca1 in chromosome end maintenance.
Carcinogenesis
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation.
Carcinogenesis
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.
Carcinogenesis
A TGF?-miR-182-BRCA1 axis controls the mammary differentiation hierarchy.
Carcinogenesis
Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation.
Carcinogenesis
Abnormal Mammary Adipose Tissue Environment of Brca1 Mutant Mice Show a Persistent Deposition of Highly Vascularized Multilocular Adipocytes.
Carcinogenesis
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.
Carcinogenesis
Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
Carcinogenesis
Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach.
Carcinogenesis
Absence of mature microRNAs inactivates the response of gene expression to carcinogenesis induced by N-ethyl-N-nitrosourea in mouse liver.
Carcinogenesis
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Carcinogenesis
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members.
Carcinogenesis
Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF.
Carcinogenesis
Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: Implications for alcohol-related carcinogenesis.
Carcinogenesis
Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis.
Carcinogenesis
Activated Wnt/?-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer.
Carcinogenesis
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Carcinogenesis
Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
Carcinogenesis
Allelic loss and microsatellite instability in prostate cancers in Japan.
Carcinogenesis
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Carcinogenesis
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Carcinogenesis
Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN).
Carcinogenesis
Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.
Carcinogenesis
Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Carcinogenesis
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
Carcinogenesis
Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit.
Carcinogenesis
Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.
Carcinogenesis
Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Carcinogenesis
Aromatase expression is increased in BRCA1 mutation carriers.
Carcinogenesis
Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands.
Carcinogenesis
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Carcinogenesis
Association between prognostic survival of human colorectal carcinoma and ZNRF3 expression.
Carcinogenesis
Association between single-nucleotide polymorphisms in miRNA and breast cancer risk: an updated review.
Carcinogenesis
ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency.
Carcinogenesis
ATR/ATM-Mediated Phosphorylation of BRCA1 T1394 Promotes Homologous Recombinational Repair and G2-M Checkpoint Maintenance.
Carcinogenesis
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
Carcinogenesis
BCoR-L1 variation and breast cancer.
Carcinogenesis
Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease.
Carcinogenesis
beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor.
Carcinogenesis
Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells.
Carcinogenesis
Blood Cell DNA Methylation of Aging-Related Ubiquitination Gene DZIP3 Can Predict the Onset of Early Stage Colorectal Cancer.
Carcinogenesis
BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer.
Carcinogenesis
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Carcinogenesis
BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells.
Carcinogenesis
BRCA1 Alternative splicing landscape in breast tissue samples.
Carcinogenesis
BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
Carcinogenesis
Brca1 and differentiation.
Carcinogenesis
BRCA1 and estrogen signaling in breast cancer.
Carcinogenesis
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
Carcinogenesis
BRCA1 and homologous recombination: implications from mouse embryonic development.
Carcinogenesis
BRCA1 and Oxidative Stress.
Carcinogenesis
BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Carcinogenesis
BRCA1 and p53: compensatory roles in DNA repair.
Carcinogenesis
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
Carcinogenesis
BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells.
Carcinogenesis
BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Carcinogenesis
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
Carcinogenesis
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Carcinogenesis
BRCA1 gene in breast cancer.
Carcinogenesis
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
Carcinogenesis
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
Carcinogenesis
BRCA1 in cancer, cell cycle and genomic stability.
Carcinogenesis
BRCA1 in hormonal carcinogenesis: basic and clinical research.
Carcinogenesis
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
Carcinogenesis
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.
Carcinogenesis
BRCA1 involvement in toxicological responses and human cancer etiology.
Carcinogenesis
BRCA1 is associated with the centrosome during mitosis.
Carcinogenesis
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
Carcinogenesis
BRCA1 methylation: a significant role in tumour development?
Carcinogenesis
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
Carcinogenesis
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
Carcinogenesis
BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells.
Carcinogenesis
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
Carcinogenesis
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
Carcinogenesis
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
Carcinogenesis
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
Carcinogenesis
BRCA1 regulates human mammary stem/progenitor cell fate.
Carcinogenesis
BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
Carcinogenesis
BRCA1 regulates transforming growth factor-? (TGF-?1) signaling through Gadd45a by enhancing the protein stability of Smad4.
Carcinogenesis
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Carcinogenesis
BRCA1 requirement for the fidelity of plasmid DNA double-strand break repair in cultured breast epithelial cells.
Carcinogenesis
BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities.
Carcinogenesis
BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Carcinogenesis
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
Carcinogenesis
BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
Carcinogenesis
BRCA1-associated tumorigenesis: what have we learned from knockout mice?
Carcinogenesis
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
Carcinogenesis
BRCA1-mediated ubiquitylation.
Carcinogenesis
BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
Carcinogenesis
BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo.
Carcinogenesis
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Carcinogenesis
BRCA1: a movement toward cancer prevention.
Carcinogenesis
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.
Carcinogenesis
Breast Cancer Predisposition Genes and Synthetic Lethality.
Carcinogenesis
Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.
Carcinogenesis
c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination.
Carcinogenesis
C-Cbl protein in human cancer tissues is frequently tyrosine phosphorylated in a tumor-specific manner.
Carcinogenesis
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.
Carcinogenesis
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Carcinogenesis
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
Carcinogenesis
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Carcinogenesis
CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion.
Carcinogenesis
Cbx4 governs HIF-1? to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.
Carcinogenesis
Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner.
Carcinogenesis
Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.
Carcinogenesis
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
Carcinogenesis
Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Carcinogenesis
Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain.
Carcinogenesis
Characterization of FANCL variants observed in patient cancer cells.
Carcinogenesis
Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer.
Carcinogenesis
Chemopreventive efficacy of stampidine in a murine breast cancer model.
Carcinogenesis
Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay.
Carcinogenesis
cIAP2 Is an Independent Signaling and Survival Factor during Mammary Lactational Involution and Tumorigenesis.
Carcinogenesis
Classification of IVS1-10T-->C as a polymorphism of BRCA1.
Carcinogenesis
Collaboration of Brca1 and Chk2 in tumorigenesis.
Carcinogenesis
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.
Carcinogenesis
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
Carcinogenesis
Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Carcinogenesis
Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis?
Carcinogenesis
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.
Carcinogenesis
Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes.
Carcinogenesis
Context Matters: RNF168 Connects with PALB2 to Rewire Homologous Recombination in BRCA1 Haploinsufficiency.
Carcinogenesis
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice.
Carcinogenesis
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Carcinogenesis
CPNE1 silencing inhibits the proliferation, invasion and migration of human osteosarcoma cells.
Carcinogenesis
CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing.
Carcinogenesis
CUL4B promotes proliferation and inhibits apoptosis of human osteosarcoma cells.
Carcinogenesis
Cullin 3 and Its Role in Tumorigenesis.
Carcinogenesis
Cullin 4-DCAF Proteins in Tumorigenesis.
Carcinogenesis
Cullin-RING ligases in regulation of autophagy.
Carcinogenesis
Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.
Carcinogenesis
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Carcinogenesis
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Carcinogenesis
Decreased CUL4B expression inhibits malignant proliferation of glioma in vitro and in vivo.
Carcinogenesis
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Carcinogenesis
Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells.
Carcinogenesis
Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Carcinogenesis
Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Carcinogenesis
Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
Carcinogenesis
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines.
Carcinogenesis
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.
Carcinogenesis
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Carcinogenesis
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Carcinogenesis
DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter.
Carcinogenesis
DNA double-strand breaks: signaling, repair and the cancer connection.
Carcinogenesis
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
Carcinogenesis
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Carcinogenesis
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
Carcinogenesis
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Carcinogenesis
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Carcinogenesis
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Carcinogenesis
Downregulation of decidual SKP2 is associated with human recurrent miscarriage.
Carcinogenesis
Drosophila Brat and human ortholog TRIM3 maintain stem cell equilibrium and suppress brain tumorigenesis by attenuating Notch nuclear transport.
Carcinogenesis
Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer.
Carcinogenesis
Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis.
Carcinogenesis
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
Carcinogenesis
E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation.
Carcinogenesis
E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.
Carcinogenesis
E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
Carcinogenesis
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.
Carcinogenesis
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.
Carcinogenesis
Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Carcinogenesis
Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae.
Carcinogenesis
Effects of 3300 del A-1061 Ter BRCA1 frameshift mutation and calcium propionate on oxidative stress and breast carcinogenesis.
Carcinogenesis
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
Carcinogenesis
Elevated expression of WWP2 in human lung adenocarcinoma and its effect on migration and invasion.
Carcinogenesis
Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.
Carcinogenesis
Emerging roles of F-box proteins in cancer drug resistance.
Carcinogenesis
Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis.
Carcinogenesis
Endothelial reprograming stimulated by oncostatin M promotes inflammation and tumorigenesis in VHL-deficient kidney tissue.
Carcinogenesis
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Carcinogenesis
Epigenetic markers of early tumor development.
Carcinogenesis
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Carcinogenesis
Epstein Barr virus: a prime candidate of breast cancer aetiology in Sudanese patients.
Carcinogenesis
Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
Carcinogenesis
Erbin is a novel substrate of the Sag-?TrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis.
Carcinogenesis
Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma.
Carcinogenesis
ETS2 and Twist1 promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2.
Carcinogenesis
Eukaryotic translation elongation factor 1 delta inhibits the ubiquitin ligase activity of SIAH-1.
Carcinogenesis
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Carcinogenesis
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.
Carcinogenesis
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Carcinogenesis
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Carcinogenesis
Expression and purification of human WWP2 HECT domain in Escherichia coli.
Carcinogenesis
Expression of BRCA1 and BRCA2 in normal and neoplastic cells.
Carcinogenesis
Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Carcinogenesis
Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.
Carcinogenesis
Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma.
Carcinogenesis
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
Carcinogenesis
Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer.
Carcinogenesis
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
Carcinogenesis
EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development.
Carcinogenesis
FBXO31 Suppresses Gastric Cancer EMT by Targeting Snail1 for Proteasomal Degradation.
Carcinogenesis
Four and a half LIM domains 2 contributes to the development of human tongue squamous cell carcinoma.
Carcinogenesis
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Carcinogenesis
Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.
Carcinogenesis
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50?years.
Carcinogenesis
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Carcinogenesis
Functional analysis of Cullin 3 E3 ligases in tumorigenesis.
Carcinogenesis
Functional Analysis of Familial Asp67Glu and Thr1051Ser BRCA1 Mutations in Breast/Ovarian Carcinogenesis.
Carcinogenesis
Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Carcinogenesis
Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.
Carcinogenesis
Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer.
Carcinogenesis
G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
Carcinogenesis
Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence.
Carcinogenesis
Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.
Carcinogenesis
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Carcinogenesis
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Carcinogenesis
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.
Carcinogenesis
Gene expression profiling of taxol-resistant nasopharyngeal carcinoma cells with siRNA-mediated FOLR1 downregulation.
Carcinogenesis
Generation and analysis of Brca1 conditional knockout mice.
Carcinogenesis
Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.
Carcinogenesis
Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.
Carcinogenesis
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Carcinogenesis
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.
Carcinogenesis
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Carcinogenesis
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Carcinogenesis
Genetic predisposition and chromosome instability in neuroblastoma.
Carcinogenesis
Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis.
Carcinogenesis
Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.
Carcinogenesis
Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.
Carcinogenesis
Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: Evidence for metformin-based "starvation" strategies in BRCA1 carriers.
Carcinogenesis
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
Carcinogenesis
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Carcinogenesis
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Carcinogenesis
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Carcinogenesis
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
Carcinogenesis
Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis.
Carcinogenesis
Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-?B signaling pathway in liver cancer.
Carcinogenesis
Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
Carcinogenesis
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
Carcinogenesis
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer.
Carcinogenesis
High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.
Carcinogenesis
HMGA2 and high-grade serous ovarian carcinoma.
Carcinogenesis
Homologous repair of DNA damage and tumorigenesis: the BRCA connection.
Carcinogenesis
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
Carcinogenesis
HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response.
Carcinogenesis
Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells.
Carcinogenesis
HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.
Carcinogenesis
Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.
Carcinogenesis
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
Carcinogenesis
Identification of a gamma-tubulin-binding domain in BRCA1.
Carcinogenesis
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Carcinogenesis
Identification of DBC1 as a transcriptional repressor for BRCA1.
Carcinogenesis
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Carcinogenesis
Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1.
Carcinogenesis
Implication of BRCA1 gene in breast cancer.
Carcinogenesis
In vitro analysis of genomic instability triggered by BRCA1 missense mutations.
Carcinogenesis
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Carcinogenesis
Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.
Carcinogenesis
Inactivation of sag/rbx2/roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
Carcinogenesis
Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Carcinogenesis
Inactivation of the polycomb group protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion and cooperation with tumorigenesis associated with Ink4a deletion.
Carcinogenesis
Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer.
Carcinogenesis
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
Carcinogenesis
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
Carcinogenesis
Infantile Epithelioid Sarcoma with Genomic Segmental Amplification of BIRC3/YAP1 as Double Minutes Plus Trisomy 2: A Case Report.
Carcinogenesis
Inflammation and DNA Methylation-Dependent Down-Regulation of miR-34b-5p Mediates c-MYC Expression and CRL4DCAF4 E3 Ligase Activity in Colitis-Associated Cancer.
Carcinogenesis
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Carcinogenesis
Inherited breast cancer: an emerging picture.
Carcinogenesis
Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue.
Carcinogenesis
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NF?B pathway.
Carcinogenesis
Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Carcinogenesis
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Carcinogenesis
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
Carcinogenesis
Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations.
Carcinogenesis
Introduction: BRCA1 and BRCA2 in mammary gland development and tumorigenesis.
Carcinogenesis
Is there a link between ovarian cancer and tooth agenesis?
Carcinogenesis
Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling.
Carcinogenesis
Knockout mouse models and mammary tumorigenesis.
Carcinogenesis
Lack of Correlation between Aberrant p16, RAR-?2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation.
Carcinogenesis
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
Carcinogenesis
Linc01638 promotes tumorigenesis in HER2+ breast cancer.
Carcinogenesis
Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
Carcinogenesis
Loss of 53BP1 is a gain for BRCA1 mutant cells.
Carcinogenesis
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Carcinogenesis
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Carcinogenesis
Loss of COP1 expression determines poor prognosisin patients with gastric cancer.
Carcinogenesis
Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
Carcinogenesis
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Carcinogenesis
Loss of heterozygosity at BRCA1, TP53, nm-23 and other loci on chromosome 17q in human breast carcinoma.
Carcinogenesis
Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
Carcinogenesis
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.
Carcinogenesis
Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.
Carcinogenesis
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Carcinogenesis
Low expression of bcl-2 in Brca1-associated breast cancers.
Carcinogenesis
Mammalian Rad51 protein: a RecA homologue with pleiotropic functions.
Carcinogenesis
Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.
Carcinogenesis
MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2.
Carcinogenesis
MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
Carcinogenesis
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Carcinogenesis
Mechanisms of alcohol-associated cancers: introduction and summary of the symposium.
Carcinogenesis
Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity.
Carcinogenesis
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Carcinogenesis
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.
Carcinogenesis
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.
Carcinogenesis
Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.
Carcinogenesis
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Carcinogenesis
MEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathway.
Carcinogenesis
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Carcinogenesis
Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Carcinogenesis
Mitotic accumulation of dimethylated lysine 79 of histone h3 is important for maintaining genome integrity during mitosis in human cells.
Carcinogenesis
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.
Carcinogenesis
Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis.
Carcinogenesis
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Carcinogenesis
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Carcinogenesis
Molecular Role of RNF43 in Canonical and Noncanonical Wnt Signaling.
Carcinogenesis
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.
Carcinogenesis
Mouse models of BRCA1 and their application to breast cancer research.
Carcinogenesis
MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
Carcinogenesis
Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation.
Carcinogenesis
Multi-step process of human breast carcinogenesis: a role for BRCA1, BECN1, CCND1, PTEN and UVRAG.
Carcinogenesis
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Carcinogenesis
Multiplex ddPCR assay for screening copy number variations in BRCA1 gene.
Carcinogenesis
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Carcinogenesis
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Carcinogenesis
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation.
Carcinogenesis
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
Carcinogenesis
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Carcinogenesis
Mutational analysis of BARD1 in familial breast cancer patients in Japan.
Carcinogenesis
Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan.
Carcinogenesis
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Carcinogenesis
Mutations of the BRCA1 gene in human cancer.
Carcinogenesis
Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Carcinogenesis
Negative Regulation of AKT Activation by BRCA1.
Carcinogenesis
New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.
Carcinogenesis
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Carcinogenesis
Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice.
Carcinogenesis
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Carcinogenesis
NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels.
Carcinogenesis
Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP.
Carcinogenesis
Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-?B-activating potential.
Carcinogenesis
Oncogenic Wnt/?-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research.
Carcinogenesis
Opposing roles for mammary epithelial-specific PPAR? signaling and activation during breast tumour progression.
Carcinogenesis
OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity.
Carcinogenesis
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Carcinogenesis
Ovarian cancer stroma: pathophysiology and the roles in cancer development.
Carcinogenesis
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Carcinogenesis
Ovarian surface epithelium: family history and early events in ovarian cancer.
Carcinogenesis
Overexpression of HACE1 in gastric cancer inhibits tumor aggressiveness by impeding cell proliferation and migration.
Carcinogenesis
Overexpression of Ran GTPase Components Regulating Nuclear Export, but not Mitotic Spindle Assembly, Marks Chromosome Instability and Poor Prognosis in Breast Cancer.
Carcinogenesis
p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
Carcinogenesis
PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Carcinogenesis
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Carcinogenesis
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Carcinogenesis
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Carcinogenesis
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Carcinogenesis
Parkin in cancer: Mitophagy-related/unrelated tasks.
Carcinogenesis
Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.
Carcinogenesis
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Carcinogenesis
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect.
Carcinogenesis
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
Carcinogenesis
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
Carcinogenesis
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.
Carcinogenesis
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.
Carcinogenesis
Phytoestrogens regulate the expression of genes involved in different biological processes in BRCA2 knocked down MCF-7, MDA-MB-231 and MCF-10a cell lines.
Carcinogenesis
PINK1/Parkin Influences Cell Cycle by Sequestering TBK1 at Damaged Mitochondria, Inhibiting Mitosis.
Carcinogenesis
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
Carcinogenesis
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Carcinogenesis
Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis.
Carcinogenesis
Post-translational modification of Parkin and its research progress in cancer.
Carcinogenesis
Predicting high risk disease using serum and DNA biomarkers.
Carcinogenesis
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers.
Carcinogenesis
Premature menopause in patients with BRCA1 gene mutation.
Carcinogenesis
Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis.
Carcinogenesis
Prepubertal octylphenol exposure up-regulate BRCA1 expression, down-regulate ERalpha expression and reduce rat mammary tumorigenesis.
Carcinogenesis
Primary Squamous Cell Carcinoma of the Endometrium Unrelated to Human Papilloma Virus: A Molecular Study.
Carcinogenesis
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
Carcinogenesis
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Carcinogenesis
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Carcinogenesis
Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
Carcinogenesis
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
Carcinogenesis
Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.
Carcinogenesis
PTEN breast cancer susceptibility: a matter of dose.
Carcinogenesis
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
Carcinogenesis
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
Carcinogenesis
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Carcinogenesis
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Carcinogenesis
Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
Carcinogenesis
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.
Carcinogenesis
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Carcinogenesis
Regulation of BRCA1 expression and its relationship to sporadic breast cancer.
Carcinogenesis
Regulation of p53 level by UBE4B in breast cancer.
Carcinogenesis
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Carcinogenesis
Retroviral transduction of splice variant Brca1-Delta11 or mutant Brca1-W1777Stop causes mouse epithelial mammary atypical duct hyperplasia.
Carcinogenesis
Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma.
Carcinogenesis
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
Carcinogenesis
Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.
Carcinogenesis
RN181 suppressed tumor growth of hepatocellular carcinoma by inhibition of the ERK/MAPK pathway.
Carcinogenesis
RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma.
Carcinogenesis
RNF13: a novel RING-type ubiquitin ligase over-expressed in pancreatic cancer.
Carcinogenesis
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
Carcinogenesis
RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Carcinogenesis
RNF20 Suppresses Tumorigenesis by Inhibiting SREBP1c-PTTG1 Axis in Kidney Cancer.
Carcinogenesis
RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
Carcinogenesis
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
Carcinogenesis
RNF43 interacts with NEDL1 and regulates p53-mediated transcription.
Carcinogenesis
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Carcinogenesis
RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.
Carcinogenesis
Role of E3 ubiquitin ligases in lung cancer.
Carcinogenesis
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
Carcinogenesis
Role of RNF20 in cancer development and progression - a comprehensive review.
Carcinogenesis
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.
Carcinogenesis
Roles of BRCA1 in DNA damage repair: a link between development and cancer.
Carcinogenesis
Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
Carcinogenesis
SAG expression associates with COPB2-related signaling and a poorer prognosis in breast cancer.
Carcinogenesis
SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions.
Carcinogenesis
SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB.
Carcinogenesis
Screening and verification of proteins that interact with HSPC238.
Carcinogenesis
SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.
Carcinogenesis
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Carcinogenesis
Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.
Carcinogenesis
Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis.
Carcinogenesis
Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.
Carcinogenesis
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.
Carcinogenesis
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Carcinogenesis
Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets.
Carcinogenesis
SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis.
Carcinogenesis
Smurf2 regulates the senescence response and suppresses tumorigenesis in mice.
Carcinogenesis
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Carcinogenesis
Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
Carcinogenesis
Spinophilin loss contributes to tumorigenesis in vivo.
Carcinogenesis
SPOP inhibits mice pancreatic stellate cell activation by promoting FADD degradation in cerulein-induced chronic pancreatitis.
Carcinogenesis
SPOP promotes tumor progression via activation of ?-catenin/TCF4 complex in clear cell renal cell carcinoma.
Carcinogenesis
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Carcinogenesis
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Carcinogenesis
Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Carcinogenesis
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Carcinogenesis
Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors.
Carcinogenesis
Stromal adipocyte PPAR? protects against breast tumorigenesis.
Carcinogenesis
Structural Basis for the BRCA1 BRCT Interaction with the Proteins ATRIP and BAAT1.
Carcinogenesis
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Carcinogenesis
Structure and function of the papillomavirus E6 protein and its interacting proteins.
Carcinogenesis
Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex.
Carcinogenesis
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Carcinogenesis
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.
Carcinogenesis
Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition.
Carcinogenesis
Synthetic lethality: the road to novel therapies for breast cancer.
Carcinogenesis
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.
Carcinogenesis
Targeting Hedgehog Signalling through the Ubiquitylation Process: The Multiple Roles of the HECT-E3 Ligase Itch.
Carcinogenesis
Targeting the Akt/mTOR pathway in Brca1-deficient cancers.
Carcinogenesis
TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb.
Carcinogenesis
The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21.
Carcinogenesis
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
Carcinogenesis
The basal phenotype of BRCA1-related breast cancer: past, present and future.
Carcinogenesis
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Carcinogenesis
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
Carcinogenesis
The characteristics and roles of ?-TrCP1/2 in carcinogenesis.
Carcinogenesis
The correlations between BRCA1 defect and environmental factors in the risk of breast cancer.
Carcinogenesis
The E3 ubiquitin ligase CHIP/miR-92b/PTEN regulatory network contributes to tumorigenesis of glioblastoma.
Carcinogenesis
The E3 ubiquitin ligase RNF135 regulates the tumorigenesis activity of tongue cancer SCC25 cells.
Carcinogenesis
The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.
Carcinogenesis
The emerging role of SPOP protein in tumorigenesis and cancer therapy.
Carcinogenesis
The Environmental Sensor AHR Protects from Inflammatory Damage by Maintaining Intestinal Stem Cell Homeostasis and Barrier Integrity.
Carcinogenesis
The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2.
Carcinogenesis
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
Carcinogenesis
The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population.
Carcinogenesis
The future of breast cancer systemic therapy: the next 10 years.
Carcinogenesis
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
Carcinogenesis
The important molecular markers on chromosome 17 and their clinical impact in breast cancer.
Carcinogenesis
The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
Carcinogenesis
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
Carcinogenesis
The Isolated C-Terminal Domain of Ring1B Is a Dimer Made of Stable, Well-Structured Monomers.
Carcinogenesis
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
Carcinogenesis
The mammary gland carcinogens: the role of metal compounds and organic solvents.
Carcinogenesis
The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis.
Carcinogenesis
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.
Carcinogenesis
The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-?B.
Carcinogenesis
The role of BRCA1 and BRCA2 in prostate cancer.
Carcinogenesis
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Carcinogenesis
The role of cullin4B in human cancers.
Carcinogenesis
The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies.
Carcinogenesis
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
Carcinogenesis
The Role of Tripartite Motif Family Proteins in TGF-? Signaling Pathway and Cancer.
Carcinogenesis
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.
Carcinogenesis
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis.
Carcinogenesis
The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression.
Carcinogenesis
The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.
Carcinogenesis
The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7-mediated deubiquitination of ?-catenin.
Carcinogenesis
The unliganded glucocorticoid receptor positively regulates the tumour suppressor gene BRCA1 through GABP beta.
Carcinogenesis
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Carcinogenesis
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Carcinogenesis
Tracking evolution of BRCA1-associated breast cancer.
Carcinogenesis
TRAIP promotes malignant behaviors and correlates with poor prognosis in liver cancer.
Carcinogenesis
Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.
Carcinogenesis
Transcriptional autoregulation by BRCA1.
Carcinogenesis
Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
Carcinogenesis
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
Carcinogenesis
TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis.
Carcinogenesis
TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein.
Carcinogenesis
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
Carcinogenesis
TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF{alpha})-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP).
Carcinogenesis
TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC.
Carcinogenesis
TRIM65 in White Matter Lesions, Innate Immunity and Tumor.
Carcinogenesis
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Carcinogenesis
Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.
Carcinogenesis
Tripartite motif-containing protein 37 is overexpressed in human glioma and its downregulation inhibits human glioma cell growth in vitro.
Carcinogenesis
Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues.
Carcinogenesis
Tumor suppressor genes and breast cancer.
Carcinogenesis
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Carcinogenesis
Tumorigenesis in mice carrying a truncating Brca1 mutation.
Carcinogenesis
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Carcinogenesis
Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.
Carcinogenesis
Ubiquitination of NF-?B p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.
Carcinogenesis
Unique BIR domain sets determine inhibitor of apoptosis protein-driven cell death and NOD2 complex signal specificity.
Carcinogenesis
Using mouse models to investigate the biological and physiological consequences of defects in the Fanconi anaemia/breast cancer DNA repair signalling pathway.
Carcinogenesis
Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.
Carcinogenesis
Whence High-Grade Serous Ovarian Cancer.
Carcinogenesis
Widespread bimodal intrachromosomal genomic instability in sporadic breast cancers associated with 13q allelic imbalance.
Carcinogenesis
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Carcinogenesis
[A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers]
Carcinogenesis
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
Carcinogenesis
[CRL4B complex promotes the development of pancreatic cancer by inhibiting secreted frizzled related protein 1].
Carcinogenesis
[Effect of STIL on the Gene Expression Profile of Gastric Cancer Cells].
Carcinogenesis
[Implication of the ubiquitin ligase c-Cbl in bone formation and tumorigenesis].
Carcinogenesis
[Roles of Aurora-A in tumorigenesis and prognosis of breast cancer.]
Carcinogenesis
[The function of Aurora A and its role in the development of liver cancer].
Carcinogenesis
[Ubiquitination-mediated degradation of epidermal growth factor receptor]
Carcinoma
53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
Carcinoma
A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.
Carcinoma
A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Carcinoma
A descriptive study of BRCA1 testing and reactions to disclosure of test results.
Carcinoma
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
Carcinoma
A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma.
Carcinoma
A genetic epidemiological study of carcinoma of the fallopian tube.
Carcinoma
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
Carcinoma
A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
Carcinoma
A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.
Carcinoma
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1.
Carcinoma
A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
Carcinoma
A population-based analysis of germline BAP1 mutations in melanoma.
Carcinoma
A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
Carcinoma
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
Carcinoma
A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Carcinoma
Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer.
Carcinoma
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
Carcinoma
Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
Carcinoma
Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
Carcinoma
Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G?>?A (p.Asp1778Asn) variant.
Carcinoma
AGO Austria recommendations for genetic testing of patients with ovarian cancer.
Carcinoma
Allelic deletion on chromosome 17p13.3 in early ovarian cancer.
Carcinoma
Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
Carcinoma
Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.
Carcinoma
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Carcinoma
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Carcinoma
Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Carcinoma
Alternatives to risk-reducing surgery for ovarian cancer.
Carcinoma
An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
Carcinoma
An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer.
Carcinoma
Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer.
Carcinoma
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Carcinoma
Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.
Carcinoma
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
Carcinoma
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Carcinoma
Association between clinical pathology and multiple genes mRNA expression in Chinese patients with NSCLC.
Carcinoma
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Carcinoma
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA.
Carcinoma
Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.
Carcinoma
Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Carcinoma
Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Carcinoma
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Carcinoma
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Carcinoma
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Carcinoma
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Carcinoma
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Carcinoma
BRCA germline mutations in women with uterine serous carcinoma--still a debate.
Carcinoma
BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
Carcinoma
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.
Carcinoma
BRCA1 and ?H2AX as independent prognostic markers in oral squamous cell carcinoma.
Carcinoma
BRCA1 and BRCA2 families and the risk of skin cancer.
Carcinoma
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Carcinoma
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
Carcinoma
BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
Carcinoma
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
Carcinoma
BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features.
Carcinoma
BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.
Carcinoma
BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Carcinoma
BRCA1 Associated Protein Increases Invasiveness of Esophageal Squamous-Cell Carcinoma.
Carcinoma
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
Carcinoma
BRCA1 expression in benign and malignant breast lesions.
Carcinoma
BRCA1 expression in leukoplakia and carcinoma of the tongue.
Carcinoma
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
Carcinoma
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
Carcinoma
BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum.
Carcinoma
BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary.
Carcinoma
BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.
Carcinoma
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Carcinoma
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
Carcinoma
BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines.
Carcinoma
BRCA1 Loss Induces GADD153-Mediated Doxorubicin Resistance in Prostate Cancer.
Carcinoma
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Carcinoma
BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas.
Carcinoma
BRCA1 mutations in familial ovarian cancer.
Carcinoma
BRCA1 mutations in primary breast and ovarian carcinomas.
Carcinoma
BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
Carcinoma
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.
Carcinoma
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
Carcinoma
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
Carcinoma
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Carcinoma
BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
Carcinoma
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Carcinoma
BRCA1 supports XIST RNA concentration on the inactive X chromosome.
Carcinoma
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
Carcinoma
BRCA1, Ki67, and ?-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Carcinoma
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
Carcinoma
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
Carcinoma
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
Carcinoma
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease.
Carcinoma
BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma.
Carcinoma
BRCA1: the enigma of tissue-specific tumor development.
Carcinoma
BRCA2 mutations in primary breast and ovarian cancers.
Carcinoma
BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
Carcinoma
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Carcinoma
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.
Carcinoma
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Carcinoma
Can personality traits affect the quality of life of women with the BRCA1/BRCA2 mutations before and after prophylactic adnexectomy?
Carcinoma
Cancer in Jews: introduction and overview.
Carcinoma
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
Carcinoma
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Carcinoma
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Carcinoma
Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
Carcinoma
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
Carcinoma
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
Carcinoma
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Carcinoma
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Carcinoma
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Carcinoma
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Carcinoma
CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
Carcinoma
Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery.
Carcinoma
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Carcinoma
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
Carcinoma
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Carcinoma
Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Carcinoma
Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
Carcinoma
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Carcinoma
Cloning, genetic mapping and expression studies of the rat Brca1 gene.
Carcinoma
Coexistence of the BRCA1 and KRAS mutations in a patient with salivary gland carcinoma arising in mediastinal mature teratoma.
Carcinoma
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Carcinoma
Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
Carcinoma
Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
Carcinoma
Correction to: Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Carcinoma
Corrigendum: The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
Carcinoma
CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Carcinoma
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Carcinoma
Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma.
Carcinoma
Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Carcinoma
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Carcinoma
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Carcinoma
Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Carcinoma
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
Carcinoma
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
Carcinoma
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
Carcinoma
Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Carcinoma
Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
Carcinoma
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.
Carcinoma
Dysregulated Wnt?signalling and recurrent mutations?of?the tumour suppressor?RNF43?in early?gastric carcinogenesis.
Carcinoma
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
Carcinoma
E3 ligase STUB1 attenuates stemness and tumorigenicity of oral carcinoma cells via transglutaminase 2 regulation.
Carcinoma
E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.
Carcinoma
Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis.
Carcinoma
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Carcinoma
Electrophoresis of BRCA1 oncosuppressor.
Carcinoma
Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Carcinoma
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Carcinoma
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Carcinoma
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Carcinoma
Establishment and characterization of human ovarian carcinoma cell lines.
Carcinoma
Establishment of primary mixed cell cultures from spontaneous canine mammary tumors: Characterization of classic and new cancer-associated molecules.
Carcinoma
Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Carcinoma
Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions.
Carcinoma
Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
Carcinoma
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
Carcinoma
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Carcinoma
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Carcinoma
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Carcinoma
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Carcinoma
Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
Carcinoma
Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations.
Carcinoma
Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death.
Carcinoma
Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Carcinoma
Expression of inhibitors of apoptosis proteins in salivary gland adenoid cystic carcinoma: XIAP is an independent marker of impaired cause-specific survival.
Carcinoma
Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.
Carcinoma
Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
Carcinoma
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Carcinoma
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Carcinoma
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
Carcinoma
Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus.
Carcinoma
Frequent RNF43 mutation contributes to moderate activation of Wnt signaling in colorectal signet-ring cell carcinoma.
Carcinoma
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Carcinoma
Functional single-nucleotide polymorphisms in the BRCA1 gene and risk of salivary gland carcinoma.
Carcinoma
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Carcinoma
Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32.
Carcinoma
Genetic characterization of early onset ovarian carcinoma.
Carcinoma
Genetic factors in ovarian carcinoma.
Carcinoma
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Carcinoma
Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma.
Carcinoma
Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas.
Carcinoma
Genomic characterization of malignant progression in neoplastic pancreatic cysts.
Carcinoma
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Carcinoma
Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.
Carcinoma
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.
Carcinoma
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy.
Carcinoma
Germline BRCA1 mutated esophageal squamous cell carcinoma.
Carcinoma
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Carcinoma
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Carcinoma
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Carcinoma
Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Carcinoma
Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.
Carcinoma
Hereditary ovarian cancer: beyond the usual suspects.
Carcinoma
Heterozygote BRCA1 status and skewed chromosome X inactivation.
Carcinoma
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
Carcinoma
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Carcinoma
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
Carcinoma
High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Carcinoma
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Carcinoma
Histopathologic features of genetically determined ovarian cancer.
Carcinoma
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Carcinoma
HMGA1 protein expression in familial breast carcinoma patients.
Carcinoma
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
Carcinoma
Human Homolog of Drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies.
Carcinoma
HUWE1 ubiquitylates and degrades the RAC activator TIAM1 promoting cell-cell adhesion disassembly, migration, and invasion.
Carcinoma
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Carcinoma
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.
Carcinoma
Hysterectomy at the time of risk-reducing surgery in BRCA carriers.
Carcinoma
Identification of a BRCA1-associated kinase with potential biological relevance.
Carcinoma
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Carcinoma
Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.
Carcinoma
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Carcinoma
Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
Carcinoma
Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.
Carcinoma
Identification of Pirh2E and Pirh2F, two additional novel isoforms of Pirh2 ubiquitin ligase from human hepatocellular liver carcinoma cell line.
Carcinoma
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Carcinoma
Identification of TRIM25 as a Negative Regulator of Caspase-2 Expression Reveals a Novel Target for Sensitizing Colon Carcinoma Cells to Intrinsic Apoptosis.
Carcinoma
Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
Carcinoma
Immunohistochemical analysis of BRCA1 and acetyl-histone H3 in squamous cell carcinoma of the mobile tongue.
Carcinoma
Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Carcinoma
Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Carcinoma
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Carcinoma
Improved survival in women with BRCA-associated ovarian carcinoma.
Carcinoma
Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Carcinoma
Inactivation of SAG or ROC1 E3 Ligase Inhibits Growth and Survival of Renal Cell Carcinoma Cells: Effect of BIM.
Carcinoma
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
Carcinoma
Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Carcinoma
Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
Carcinoma
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Carcinoma
Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Carcinoma
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
Carcinoma
Inherited Mutations in Women With Ovarian Carcinoma.
Carcinoma
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Carcinoma
Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.
Carcinoma
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Carcinoma
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Carcinoma
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Carcinoma
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Carcinoma
Inverse correlation between Naa10p and Pirh2 expression and the combined prognostic value in oral squamous cell carcinoma patients.
Carcinoma
Involvement of general control nonderepressible kinase 2 in cancer cell apoptosis by posttranslational mechanisms.
Carcinoma
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Carcinoma
Knockdown of COUP-TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells.
Carcinoma
Lack of Correlation between Aberrant p16, RAR-?2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation.
Carcinoma
Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
Carcinoma
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
Carcinoma
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Carcinoma
Laparoscopic surgery for isolated inguinal node relapse of high grade serous ovarian cancer using a bipolar combination instrument.
Carcinoma
LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
Carcinoma
Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.
Carcinoma
Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
Carcinoma
Loss of BRCA1 expression in sporadic male breast carcinoma.
Carcinoma
Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma.
Carcinoma
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Carcinoma
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Carcinoma
Loss of heterozygosity of nucleotide excision repair factors in sporadic oral squamous cell carcinoma using microdissected tissue.
Carcinoma
Loss of heterozygosity of the PTH/PTHrP type 1 receptor in oral squamous cell carcinoma.
Carcinoma
Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner.
Carcinoma
Low expression of bcl-2 in Brca1-associated breast cancers.
Carcinoma
Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery.
Carcinoma
Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.
Carcinoma
Low-grade adenosquamous carcinoma of the breast-A case report with a BRCA1 germline mutation.
Carcinoma
Maternal BCAS2 protects genomic integrity in mouse early embryonic development.
Carcinoma
Measles virus: evidence for association with lung cancer.
Carcinoma
Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
Carcinoma
Mechanisms of BRCA1 Tumor Suppression.
Carcinoma
Metaplastic breast carcinoma: pathology and clinical outcome.
Carcinoma
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Carcinoma
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Carcinoma
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Carcinoma
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Carcinoma
Methylation of the HACE1 Gene is Frequently Detected in Hepatocellular Carcinoma.
Carcinoma
Microenvironmental Regulation of BRCA1 Gene Expression by c-Jun and Fra2 in Premalignant Human Ovarian Surface Epithelial Cells.
Carcinoma
Mitophagy in Carcinogenesis and Tumor progression- A New paradigm with Emerging Importance.
Carcinoma
Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier.
Carcinoma
Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis.
Carcinoma
Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.
Carcinoma
Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations.
Carcinoma
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Carcinoma
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Carcinoma
Molecular pathology of epithelial ovarian cancer.
Carcinoma
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
Carcinoma
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
Carcinoma
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Carcinoma
Mutated Rnf43 Aggravates Helicobacter Pylori-Induced Gastric Pathology.
Carcinoma
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Carcinoma
Mutation analysis of the BRCA1 gene in ovarian cancers.
Carcinoma
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.
Carcinoma
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Carcinoma
MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
Carcinoma
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.
Carcinoma
No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report.
Carcinoma
Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
Carcinoma
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Carcinoma
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Carcinoma
Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years.
Carcinoma
Nucleolar localization of BRCA1 protein in human breast cancer.
Carcinoma
Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.
Carcinoma
Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrier.
Carcinoma
Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas.
Carcinoma
One Case of a BRCA1 Germ Line Mutation Ovarian Carcinoma Patient Based on Abnormal Immunohistochemistry Finding.
Carcinoma
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
Carcinoma
Origins and molecular pathology of ovarian cancer.
Carcinoma
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Carcinoma
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Carcinoma
Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up.
Carcinoma
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Carcinoma
Ovarian surface epithelium: family history and early events in ovarian cancer.
Carcinoma
Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma.
Carcinoma
Pancancer survival analysis of cancer hallmark genes.
Carcinoma
Papers to appear in forthcoming issues
Carcinoma
Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population.
Carcinoma
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Carcinoma
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Carcinoma
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Carcinoma
Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.
Carcinoma
Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
Carcinoma
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Carcinoma
Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
Carcinoma
Phosphatase and tensin homolog regulates stability and activity of EphB1 receptor.
Carcinoma
Poly r(C) Binding Protein 1 Regulates Posttranscriptional Expression of the Ubiquitin Ligase TRIM56 in Ovarian Cancer.
Carcinoma
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Carcinoma
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Carcinoma
Precursors to pelvic serous carcinoma and their clinical implications.
Carcinoma
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Carcinoma
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Carcinoma
Prevalence of the BRCA1 founder mutation c.5266dup in Brazilian individuals at-risk for the Hereditary Breast and Ovarian Cancer Syndrome.
Carcinoma
Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Carcinoma
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.
Carcinoma
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas.
Carcinoma
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
Carcinoma
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Carcinoma
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Carcinoma
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Carcinoma
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
Carcinoma
PTEN and NEDD4 in Human Breast Carcinoma.
Carcinoma
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
Carcinoma
Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer.
Carcinoma
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Carcinoma
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Carcinoma
Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.
Carcinoma
Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Carcinoma
Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Carcinoma
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
Carcinoma
Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas.
Carcinoma
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Carcinoma
Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.
Carcinoma
Regulation of the BRCA1 promoter in ovarian surface epithelial cells and ovarian carcinoma cells.
Carcinoma
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Carcinoma
Retrospective study of a 16?year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
Carcinoma
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Carcinoma
RN181 regulates the biological behaviors of oral squamous cell carcinoma cells via mediating ERK/MAPK signaling pathway.
Carcinoma
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
Carcinoma
RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma.
Carcinoma
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
Carcinoma
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Carcinoma
Role of RNF20 in cancer development and progression - a comprehensive review.
Carcinoma
Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience.
Carcinoma
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Carcinoma
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Carcinoma
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Carcinoma
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.
Carcinoma
Selective toxicity of rose bengal to ovarian cancer cells in vitro.
Carcinoma
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Carcinoma
Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.
Carcinoma
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
Carcinoma
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
Carcinoma
SMURF1, a promoter of tumor cell progression?
Carcinoma
SNU cell lines and their application for cancer research.
Carcinoma
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Carcinoma
Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Carcinoma
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer.
Carcinoma
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Carcinoma
Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Carcinoma
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Carcinoma
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Carcinoma
Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Carcinoma
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
Carcinoma
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
Carcinoma
Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.
Carcinoma
Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.
Carcinoma
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Carcinoma
Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma.
Carcinoma
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Carcinoma
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Carcinoma
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
Carcinoma
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Carcinoma
The E3 ligase HECTD3 promotes esophageal squamous cell carcinoma (ESCC) growth and cell survival through targeting and inhibiting caspase-9 activation.
Carcinoma
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
Carcinoma
The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints.
Carcinoma
The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions.
Carcinoma
The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
Carcinoma
The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.
Carcinoma
The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Carcinoma
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
Carcinoma
The GADD45, ZBRK1 and BRCA1 pathway: quantitative analysis of mRNA expression in colon carcinomas.
Carcinoma
The genesis and evolution of high-grade serous ovarian cancer.
Carcinoma
The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls.
Carcinoma
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
Carcinoma
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.
Carcinoma
The molecular pathology of hereditary breast cancer.
Carcinoma
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
Carcinoma
The pathology of hereditary breast cancer.
Carcinoma
The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
Carcinoma
The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Carcinoma
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Carcinoma
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
Carcinoma
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
Carcinoma
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.
Carcinoma
The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.
Carcinoma
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
Carcinoma
Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier.
Carcinoma
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Carcinoma
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
Carcinoma
Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Carcinoma
Transitional cell ovarian carcinoma in a BRCA1 mutation carrier.
Carcinoma
TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3?.
Carcinoma
Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
Carcinoma
Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes.
Carcinoma
Use of adenoviral E1A protein to analyze K18 promoter deregulation in colon carcinoma cells discloses a role for CtBP1 and BRCA1.
Carcinoma
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Carcinoma
Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
Carcinoma
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
Carcinoma
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]
Carcinoma
[BRCA1 and BRCA2 - pathologists starting kit].
Carcinoma
[Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis]
Carcinoma
[Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
Carcinoma
[Expression and clinical significance of BRCA1 in human esophageal squamous cell carcinoma].
Carcinoma
[Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance]
Carcinoma
[Genetic diagnosis and therapy of hereditary breast carcinoma]
Carcinoma
[Hereditary breast and ovarian cancer].
Carcinoma
[Hereditary breast cancers]
Carcinoma
[Hereditary breast carcinomas pathologist's perspective].
Carcinoma
[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]
Carcinoma
[Molecular-genetic disruption in area near the BRCA1 gene, associated with ovarian carcinoma]
Carcinoma
[Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments]
Carcinoma
[Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer]
Carcinoma
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Carcinoma in Situ
A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Carcinoma in Situ
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Carcinoma in Situ
Evaluation of the Expression of the Inhibitor of Apoptosis Protein Family and Human Telomerase Reverse Transcriptase in Patients With Advanced Colorectal Adenoma.
Carcinoma in Situ
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Carcinoma in Situ
Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Carcinoma in Situ
Ovarian cancer.
Carcinoma in Situ
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Carcinoma in Situ
Precursors to pelvic serous carcinoma and their clinical implications.
Carcinoma in Situ
Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation.
Carcinoma in Situ
Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician.
Carcinoma in Situ
Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.
Carcinoma in Situ
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
Carcinoma in Situ
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Carcinoma, Acinar Cell
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Carcinoma, Adenoid Cystic
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Carcinoma, Adenoid Cystic
Expression of inhibitors of apoptosis proteins in salivary gland adenoid cystic carcinoma: XIAP is an independent marker of impaired cause-specific survival.
Carcinoma, Adenoid Cystic
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Carcinoma, Adenosquamous
Low-grade adenosquamous carcinoma of the breast-A case report with a BRCA1 germline mutation.
Carcinoma, Basal Cell
A population-based analysis of germline BAP1 mutations in melanoma.
Carcinoma, Basal Cell
BRCA1 and BRCA2 families and the risk of skin cancer.
Carcinoma, Basal Cell
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Carcinoma, Basal Cell
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Carcinoma, Ductal
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Carcinoma, Ductal
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
Carcinoma, Ductal
Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast.
Carcinoma, Ductal
Analysis of BRCA1 Gene Rearrangements in Breast Carcinomas by RT-PCR and ER, PR, HER2NEU Status by IHC and HPE Correlation.
Carcinoma, Ductal
Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Carcinoma, Ductal
Basal phenotype breast cancer: implications for treatment and prognosis.
Carcinoma, Ductal
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
Carcinoma, Ductal
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Carcinoma, Ductal
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
Carcinoma, Ductal
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Carcinoma, Ductal
Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Carcinoma, Ductal
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Carcinoma, Ductal
Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
Carcinoma, Ductal
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Carcinoma, Ductal
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Carcinoma, Ductal
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
Carcinoma, Ductal
DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas.
Carcinoma, Ductal
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Carcinoma, Ductal
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-Dependent Manner.
Carcinoma, Ductal
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Carcinoma, Ductal
Familial breast cancer in southern Taiwan.
Carcinoma, Ductal
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Carcinoma, Ductal
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50?years.
Carcinoma, Ductal
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Carcinoma, Ductal
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
Carcinoma, Ductal
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
Carcinoma, Ductal
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Carcinoma, Ductal
Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast.
Carcinoma, Ductal
Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Carcinoma, Ductal
Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
Carcinoma, Ductal
Lobular breast cancer: incidence and genetic and non-genetic risk factors.
Carcinoma, Ductal
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Carcinoma, Ductal
Loss of heterozygosity at BRCA1, TP53, nm-23 and other loci on chromosome 17q in human breast carcinoma.
Carcinoma, Ductal
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
Carcinoma, Ductal
p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Carcinoma, Ductal
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Carcinoma, Ductal
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Carcinoma, Ductal
Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Carcinoma, Ductal
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Carcinoma, Ductal
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Carcinoma, Ductal
Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women.
Carcinoma, Ductal
Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Carcinoma, Ductal
Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Carcinoma, Ductal
The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling.
Carcinoma, Ductal
The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
Carcinoma, Ductal
The pathology of hereditary breast cancer.
Carcinoma, Ductal
The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers.
Carcinoma, Ductal
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]
Carcinoma, Embryonal
Abnormal level of CUL4B-mediated histone H2A ubiquitination causes disruptive HOX gene expression.
Carcinoma, Embryonal
TRIM32 promotes retinoic acid receptor ?-mediated differentiation in human promyelogenous leukemic cell line HL60.
Carcinoma, Endometrioid
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
Carcinoma, Endometrioid
Origins and molecular pathology of ovarian cancer.
Carcinoma, Endometrioid
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Carcinoma, Endometrioid
Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Carcinoma, Endometrioid
Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma.
Carcinoma, Hepatocellular
A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating ?-TrCP E3 Ubiquitin Ligase.
Carcinoma, Hepatocellular
A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity.
Carcinoma, Hepatocellular
A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Activating transcription factor 6 limits intracellular accumulation of mutant ?(1)-antitrypsin Z and mitochondrial damage in hepatoma cells.
Carcinoma, Hepatocellular
Ajuba inhibits hepatocellular carcinoma cell growth via targeting of ?-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation.
Carcinoma, Hepatocellular
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
Carcinoma, Hepatocellular
BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
BRCA1-mediated inflammation and growth activated & inhibited transition mechanisms between no-tumor hepatitis/cirrhotic tissues and HCC.
Carcinoma, Hepatocellular
Cbx4 governs HIF-1? to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.
Carcinoma, Hepatocellular
Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks.
Carcinoma, Hepatocellular
cIAP2 via NF-?B signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cullin3-TNFAIP1 E3 Ligase Controls Inflammatory Response in Hepatocellular Carcinoma Cells via Ubiquitination of RhoB.
Carcinoma, Hepatocellular
Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma.
Carcinoma, Hepatocellular
Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
DNA damage induces down-regulation of Prp19 via impairing Prp19 stability in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.
Carcinoma, Hepatocellular
E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Carcinoma, Hepatocellular
E3 Ubiquitin Ligase Siah-1 is Down-regulated and Fails to Target Natural HBx Truncates for Degradation in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation.
Carcinoma, Hepatocellular
HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Heat shock protein gp96 decreases p53 stability by regulating Mdm2 E3 ligase activity in liver cancer.
Carcinoma, Hepatocellular
Hepatitis C Virus Non-Structural Protein 5A (NS5A) Disrupts Mitochondrial Dynamics and Induces Mitophagy.
Carcinoma, Hepatocellular
High expression of Parkin predicts easier recurrence of patients with adjuvant transarterial chemoembolization.
Carcinoma, Hepatocellular
Hint1 Up-Regulates I?B? by Targeting the ?-TrCP Subunit of SCF E3 Ligase in Human Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Identification of microRNA-124 in regulation of Hepatocellular carcinoma through BIRC3 and the NF-?B pathway.
Carcinoma, Hepatocellular
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Carcinoma, Hepatocellular
Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.
Carcinoma, Hepatocellular
LncRNA XIST upregulates TRIM25 via negatively regulating miR-192 in hepatitis B virus-related hepatocellular carcinoma.
Carcinoma, Hepatocellular
MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2.
Carcinoma, Hepatocellular
MiR-486-5p Suppresses Proliferation and Migration of Hepatocellular Carcinoma Cells through Downregulation of the E3 Ubiquitin Ligase CBL.
Carcinoma, Hepatocellular
Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.
Carcinoma, Hepatocellular
Nuclear expression of the ubiquitin ligase seven in absentia homologue (SIAH)-1 induces proliferation and migration of liver cancer cells.
Carcinoma, Hepatocellular
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Parkin gene alterations in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway.
Carcinoma, Hepatocellular
RLIM suppresses hepatocellular carcinogenesis by up-regulating p15 and p21.
Carcinoma, Hepatocellular
RN181 suppressed tumor growth of hepatocellular carcinoma by inhibition of the ERK/MAPK pathway.
Carcinoma, Hepatocellular
Role of fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance.
Carcinoma, Hepatocellular
Role of the E3 Ubiquitin Ligase TRIM4 in Predicting the Prognosis of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Screening and verification of proteins that interact with HSPC238.
Carcinoma, Hepatocellular
SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Structure of the FP domain of Fbxo7 reveals a novel mode of protein-protein interaction.
Carcinoma, Hepatocellular
The E3 ligase for metastasis associated 1 protein, TRIM25, is targeted by microRNA-873 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein.
Carcinoma, Hepatocellular
The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
Carcinoma, Hepatocellular
TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L.
Carcinoma, Hepatocellular
TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.
Carcinoma, Hepatocellular
TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination.
Carcinoma, Hepatocellular
TRIM65 triggers ?-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.
Carcinoma, Hepatocellular
Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway.
Carcinoma, Hepatocellular
Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain.
Carcinoma, Hepatocellular
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Carcinoma, Hepatocellular
Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19.
Carcinoma, Intraductal, Noninfiltrating
Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast.
Carcinoma, Intraductal, Noninfiltrating
Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Carcinoma, Intraductal, Noninfiltrating
Basal phenotype breast cancer: implications for treatment and prognosis.
Carcinoma, Intraductal, Noninfiltrating
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Carcinoma, Intraductal, Noninfiltrating
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
Carcinoma, Intraductal, Noninfiltrating
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
Carcinoma, Intraductal, Noninfiltrating
Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
Carcinoma, Intraductal, Noninfiltrating
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
Carcinoma, Intraductal, Noninfiltrating
Ductal carcinoma in situ in BRCA mutation carriers.
Carcinoma, Intraductal, Noninfiltrating
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-Dependent Manner.
Carcinoma, Intraductal, Noninfiltrating
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50?years.
Carcinoma, Intraductal, Noninfiltrating
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Carcinoma, Intraductal, Noninfiltrating
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
Carcinoma, Intraductal, Noninfiltrating
Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
Carcinoma, Intraductal, Noninfiltrating
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.
Carcinoma, Intraductal, Noninfiltrating
Molecular characterization of intraductal breast carcinomas.
Carcinoma, Intraductal, Noninfiltrating
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
Carcinoma, Intraductal, Noninfiltrating
Numerous high-risk epithelial lesions in familial breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Carcinoma, Intraductal, Noninfiltrating
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Screening and follow-up of the patient at high risk for breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
Carcinoma, Intraductal, Noninfiltrating
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
Carcinoma, Intraductal, Noninfiltrating
The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers.
Carcinoma, Intraductal, Noninfiltrating
Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
Carcinoma, Intraductal, Noninfiltrating
[Analyses of LOH and expression in healthy gland, DCIS and invasive breast cancer gland]
Carcinoma, Lobular
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Carcinoma, Lobular
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Carcinoma, Lobular
Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
Carcinoma, Lobular
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Carcinoma, Lobular
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Carcinoma, Lobular
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Carcinoma, Lobular
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Carcinoma, Lobular
Screening and follow-up of the patient at high risk for breast cancer.
Carcinoma, Lobular
The role of MRI in breast cancer screening.
Carcinoma, Lobular
Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
Carcinoma, Medullary
Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation.
Carcinoma, Medullary
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Carcinoma, Medullary
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
Carcinoma, Medullary
Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
Carcinoma, Medullary
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Carcinoma, Medullary
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Carcinoma, Medullary
Medullary carcinoma of breast with a novel germline mutation 1123t >g in exon 11 of brca1.
Carcinoma, Medullary
Medullary carcinoma of the breast and BRCA1 mutation.
Carcinoma, Medullary
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Carcinoma, Medullary
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
Carcinoma, Medullary
The pathology of familial breast cancer: Morphological aspects.
Carcinoma, Medullary
[Basal-like carcinoma of the breast--the actual review and clinico-pathological corelations]
Carcinoma, Neuroendocrine
Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.
Carcinoma, Non-Small-Cell Lung
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Carcinoma, Non-Small-Cell Lung
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Carcinoma, Non-Small-Cell Lung
Association between clinical pathology and multiple genes mRNA expression in Chinese patients with NSCLC.
Carcinoma, Non-Small-Cell Lung
Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Carcinoma, Non-Small-Cell Lung
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
Carcinoma, Non-Small-Cell Lung
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Carcinoma, Non-Small-Cell Lung
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Carcinoma, Non-Small-Cell Lung
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
Carcinoma, Non-Small-Cell Lung
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.
Carcinoma, Non-Small-Cell Lung
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4.
Carcinoma, Non-Small-Cell Lung
E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.
Carcinoma, Non-Small-Cell Lung
E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-?/nuclear factor kappaB pathway.
Carcinoma, Non-Small-Cell Lung
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Carcinoma, Non-Small-Cell Lung
FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
Carcinoma, Non-Small-Cell Lung
Genetic variants of BIRC3 and NRG1 in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival.
Carcinoma, Non-Small-Cell Lung
High expression of lncRNA MEG3 participates in non-small cell lung cancer by regulating microRNA-7-5p.
Carcinoma, Non-Small-Cell Lung
High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Carcinoma, Non-Small-Cell Lung
Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.
Carcinoma, Non-Small-Cell Lung
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
Carcinoma, Non-Small-Cell Lung
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Carcinoma, Non-Small-Cell Lung
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Carcinoma, Non-Small-Cell Lung
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Carcinoma, Non-Small-Cell Lung
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Carcinoma, Non-Small-Cell Lung
Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas.
Carcinoma, Non-Small-Cell Lung
Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Carcinoma, Non-Small-Cell Lung
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Carcinoma, Non-Small-Cell Lung
Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Regulation of autophagy flux by E3 ubiquitin ligase Pirh2 in lung cancer.
Carcinoma, Non-Small-Cell Lung
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
Carcinoma, Non-Small-Cell Lung
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Carcinoma, Non-Small-Cell Lung
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Carcinoma, Non-Small-Cell Lung
Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Carcinoma, Non-Small-Cell Lung
The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Carcinoma, Non-Small-Cell Lung
The role of BRCA1 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3?.
Carcinoma, Non-Small-Cell Lung
TRIM59 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Upregulating Cell Cycle Related Proteins.
Carcinoma, Non-Small-Cell Lung
Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Carcinoma, Non-Small-Cell Lung
[Detection of RRM1, ERCC1 and BRCA1 gene expression in non-small cell lung cancer tissues and peripheral blood by SYBR real-time fluorescent quantitative PCR].
Carcinoma, Non-Small-Cell Lung
[Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC].
Carcinoma, Non-Small-Cell Lung
[Relationship between the protein expression of ERCC1, BRCA, ?-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Carcinoma, Ovarian Epithelial
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Carcinoma, Ovarian Epithelial
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Carcinoma, Ovarian Epithelial
A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
Carcinoma, Ovarian Epithelial
A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
AGO Austria recommendations for genetic testing of patients with ovarian cancer.
Carcinoma, Ovarian Epithelial
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Carcinoma, Ovarian Epithelial
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Carcinoma, Ovarian Epithelial
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
Carcinoma, Ovarian Epithelial
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Carcinoma, Ovarian Epithelial
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Carcinoma, Ovarian Epithelial
BRCA and Early Events in the Development of Serous Ovarian Cancer.
Carcinoma, Ovarian Epithelial
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients.
Carcinoma, Ovarian Epithelial
BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy.
Carcinoma, Ovarian Epithelial
BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.
Carcinoma, Ovarian Epithelial
BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
Carcinoma, Ovarian Epithelial
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
Carcinoma, Ovarian Epithelial
BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
Carcinoma, Ovarian Epithelial
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Carcinoma, Ovarian Epithelial
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.
Carcinoma, Ovarian Epithelial
BRCA1 Mutation Status and Follicular Fluid Exposure Alters NF?B Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
Carcinoma, Ovarian Epithelial
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
Carcinoma, Ovarian Epithelial
BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
Carcinoma, Ovarian Epithelial
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
Carcinoma, Ovarian Epithelial
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
Carcinoma, Ovarian Epithelial
BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases.
Carcinoma, Ovarian Epithelial
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Carcinoma, Ovarian Epithelial
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Carcinoma, Ovarian Epithelial
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Carcinoma, Ovarian Epithelial
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Carcinoma, Ovarian Epithelial
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Carcinoma, Ovarian Epithelial
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Carcinoma, Ovarian Epithelial
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Carcinoma, Ovarian Epithelial
Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Carcinoma, Ovarian Epithelial
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
Carcinoma, Ovarian Epithelial
Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in BRCA1 5' and 3' Exons.
Carcinoma, Ovarian Epithelial
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
Carcinoma, Ovarian Epithelial
Epidemiologic analysis of breast and gynecologic cancers.
Carcinoma, Ovarian Epithelial
Epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Epithelial ovarian cancer: prevention, diagnosis, and treatment.
Carcinoma, Ovarian Epithelial
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.
Carcinoma, Ovarian Epithelial
Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Carcinoma, Ovarian Epithelial
Expression analysis of the MCPH1/BRIT1 and BRCA1 tumor suppressor genes and telomerase splice variants in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
Carcinoma, Ovarian Epithelial
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Carcinoma, Ovarian Epithelial
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Carcinoma, Ovarian Epithelial
Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
Carcinoma, Ovarian Epithelial
Frequency of BRCA1 dysfunction in ovarian cancer.
Carcinoma, Ovarian Epithelial
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Carcinoma, Ovarian Epithelial
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Carcinoma, Ovarian Epithelial
Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Genetic predisposition in gynecologic cancers.
Carcinoma, Ovarian Epithelial
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Carcinoma, Ovarian Epithelial
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy.
Carcinoma, Ovarian Epithelial
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Carcinoma, Ovarian Epithelial
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Carcinoma, Ovarian Epithelial
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.
Carcinoma, Ovarian Epithelial
Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
Carcinoma, Ovarian Epithelial
Hereditary Ovarian Cancer and Risk Reduction.
Carcinoma, Ovarian Epithelial
High Expression of RING Finger Protein 126 Predicts Unfavorable Prognosis of Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Carcinoma, Ovarian Epithelial
Improved survival in BRCA2 carriers with ovarian cancer.
Carcinoma, Ovarian Epithelial
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Carcinoma, Ovarian Epithelial
Long-Term Follow-Up of a Female Patient Treated with Olaparib-Hope for a Long Life without Relapse?
Carcinoma, Ovarian Epithelial
Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Carcinoma, Ovarian Epithelial
Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
Carcinoma, Ovarian Epithelial
Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Carcinoma, Ovarian Epithelial
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
Carcinoma, Ovarian Epithelial
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Carcinoma, Ovarian Epithelial
Mutation analysis of the BRCA1 gene in ovarian cancers.
Carcinoma, Ovarian Epithelial
No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
Carcinoma, Ovarian Epithelial
Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Carcinoma, Ovarian Epithelial
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
Carcinoma, Ovarian Epithelial
Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Carcinoma, Ovarian Epithelial
Ovarian surface epithelium: family history and early events in ovarian cancer.
Carcinoma, Ovarian Epithelial
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Carcinoma, Ovarian Epithelial
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Carcinoma, Ovarian Epithelial
Prevalence of BRCA1 expression in epithelial ovarian cancer: immunohistochemical study.
Carcinoma, Ovarian Epithelial
Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Carcinoma, Ovarian Epithelial
Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides.
Carcinoma, Ovarian Epithelial
Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
Carcinoma, Ovarian Epithelial
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Carcinoma, Ovarian Epithelial
Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Carcinoma, Ovarian Epithelial
Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study.
Carcinoma, Ovarian Epithelial
Role of genetic polymorphisms and ovarian cancer susceptibility.
Carcinoma, Ovarian Epithelial
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Carcinoma, Ovarian Epithelial
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Carcinoma, Ovarian Epithelial
Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Carcinoma, Ovarian Epithelial
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
Carcinoma, Ovarian Epithelial
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Carcinoma, Ovarian Epithelial
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
Carcinoma, Ovarian Epithelial
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
Carcinoma, Ovarian Epithelial
The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience.
Carcinoma, Ovarian Epithelial
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
Carcinoma, Ovarian Epithelial
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study.
Carcinoma, Ovarian Epithelial
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Carcinoma, Ovarian Epithelial
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Carcinoma, Ovarian Epithelial
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases.
Carcinoma, Ovarian Epithelial
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
Carcinoma, Ovarian Epithelial
Transitional cell ovarian carcinoma in a BRCA1 mutation carrier.
Carcinoma, Ovarian Epithelial
When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
Carcinoma, Ovarian Epithelial
[Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
Carcinoma, Ovarian Epithelial
[Clinical Management of HBOC in Our Hospital].
Carcinoma, Ovarian Epithelial
[Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer]
Carcinoma, Ovarian Epithelial
[Preventive surgical prcedures for inherited risk of breast cancer]
Carcinoma, Ovarian Epithelial
[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Carcinoma, Papillary
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Carcinoma, Papillary
BRCA1 germline mutations in women with uterine serous papillary carcinoma.
Carcinoma, Papillary
BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Carcinoma, Papillary
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Carcinoma, Papillary
Pancancer survival analysis of cancer hallmark genes.
Carcinoma, Papillary
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
Carcinoma, Papillary
Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.
Carcinoma, Renal Cell
A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.
Carcinoma, Renal Cell
A population-based analysis of germline BAP1 mutations in melanoma.
Carcinoma, Renal Cell
Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
Carcinoma, Renal Cell
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA.
Carcinoma, Renal Cell
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Carcinoma, Renal Cell
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Carcinoma, Renal Cell
Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
Carcinoma, Renal Cell
Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.
Carcinoma, Renal Cell
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Carcinoma, Renal Cell
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.
Carcinoma, Renal Cell
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Carcinoma, Renal Cell
Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
Carcinoma, Renal Cell
Inactivation of SAG or ROC1 E3 Ligase Inhibits Growth and Survival of Renal Cell Carcinoma Cells: Effect of BIM.
Carcinoma, Renal Cell
Insulin-induced gene 1 (INSIG1) inhibits HIV-1 production by degrading Gag via activity of the ubiquitin ligase TRC8.
Carcinoma, Renal Cell
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Carcinoma, Renal Cell
Knockdown of COUP-TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells.
Carcinoma, Renal Cell
Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-kappaB Agonist Card9 by CK2.
Carcinoma, Renal Cell
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Carcinoma, Renal Cell
RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Role of RNF20 in cancer development and progression - a comprehensive review.
Carcinoma, Renal Cell
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
Carcinoma, Renal Cell
SMURF1, a promoter of tumor cell progression?
Carcinoma, Renal Cell
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer.
Carcinoma, Renal Cell
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Carcinoma, Renal Cell
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
Carcinoma, Renal Cell
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.
Carcinoma, Renal Cell
The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER.
Carcinoma, Renal Cell
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
Carcinoma, Squamous Cell
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
Carcinoma, Squamous Cell
BRCA1 expression in leukoplakia and carcinoma of the tongue.
Carcinoma, Squamous Cell
CircDOCK1 suppresses cell apoptosis via inhibition of miR?196a?5p by targeting BIRC3 in OSCC.
Carcinoma, Squamous Cell
Corrigendum: The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Carcinoma, Squamous Cell
Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis.
Carcinoma, Squamous Cell
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Carcinoma, Squamous Cell
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Carcinoma, Squamous Cell
Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus.
Carcinoma, Squamous Cell
Human Homolog of Drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies.
Carcinoma, Squamous Cell
Immunohistochemical analysis of BRCA1 and acetyl-histone H3 in squamous cell carcinoma of the mobile tongue.
Carcinoma, Squamous Cell
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Carcinoma, Squamous Cell
Lack of Correlation between Aberrant p16, RAR-?2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation.
Carcinoma, Squamous Cell
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Carcinoma, Squamous Cell
Papers to appear in forthcoming issues
Carcinoma, Squamous Cell
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
Carcinoma, Squamous Cell
Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.
Carcinoma, Squamous Cell
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
Carcinoma, Squamous Cell
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Carcinoma, Squamous Cell
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
Carcinoma, Squamous Cell
The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Carcinosarcoma
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Carcinosarcoma
High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Cardiomegaly
Endogenous muscle atrophy F-box is involved in the development of cardiac rupture after myocardial infarction.
Cardiomegaly
Into the heart: The emerging role of the ubiquitin-proteasome system.
Cardiomegaly
MuRF1 Negatively Regulates Pathological Cardiac Hypertrophy Through Downregulation of Calcineurin A.
Cardiomegaly
Parkin does not prevent accelerated cardiac aging in mitochondrial DNA mutator mice.
Cardiomegaly
RBCK1, a protein kinase CbetaI (PKCbetaI)-interacting protein, regulates PKCbeta-dependent function.
Cardiomegaly
Resveratrol Ameliorates Cardiac Hypertrophy by Down-regulation of miR-155 Through Activation of Breast Cancer Type 1 Susceptibility Protein.
Cardiomegaly
Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload.
Cardiomegaly
Stability of F-box protein atrogin-1 is regulated by p38 mitogen-activated protein kinase pathway in cardiac H9c2 cells.
Cardiomegaly
Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination.
Cardiomegaly
The E3 ubiquitin ligase HectD3 attenuates cardiac hypertrophy and inflammation in mice.
Cardiomegaly
Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress.
Cardiomyopathies
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Cardiomyopathies
BRCA1 Reflects Myocardial Adverse Remodeling in Idiopathic Dilated Cardiomyopathy.
Cardiomyopathies
Cullin-RING ligases in regulation of autophagy.
Cardiomyopathies
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Cardiomyopathies
Identification of critical regions and candidate genes for cardiovascular malformations and cardiomyopathy associated with deletions of chromosome 1p36.
Cardiomyopathies
Interdependence of Parkin-Mediated Mitophagy and Mitochondrial Fission in Adult Mouse Hearts.
Cardiomyopathies
Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.
Cardiomyopathies
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
Cardiomyopathies
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Cardiomyopathy, Alcoholic
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Cardiomyopathy, Dilated
BRCA1 Reflects Myocardial Adverse Remodeling in Idiopathic Dilated Cardiomyopathy.
Cardiomyopathy, Dilated
Parkin regulation of CHOP modulates susceptibility to cardiac endoplasmic reticulum stress.
Cardiomyopathy, Dilated
The E3 ubiquitin ligase c-Cbl mediates integrin ?1 ubiquitination during dilated cardiomyopathy.
Cardiomyopathy, Dilated
Ufm1-Specific Ligase Ufl1 Regulates Endoplasmic Reticulum Homeostasis and Protects Against Heart Failure.
Cardiomyopathy, Hypertrophic
The E3 ubiquitin ligase Asb2? is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.
Cardiotoxicity
Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
Cardiotoxicity
An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity.
Cardiotoxicity
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Cardiotoxicity
Enhanced mitophagy mediated by the YAP/Parkin pathway protects against DOX-induced cardiotoxicity.
Cardiotoxicity
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Cardiotoxicity
TRIM25 Rescues Against Doxorubicin-Induced Pyroptosis Through Promoting NLRP1 Ubiquitination.
Cardiovascular Diseases
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Cardiovascular Diseases
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Cardiovascular Diseases
Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease.
Cardiovascular Diseases
Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations.
Cataract
TRIM69 inhibits cataractogenesis by negatively regulating p53.
Central Nervous System Diseases
Cytokines, signaling and diseases - a pharmacologist's view.
Central Nervous System Diseases
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Central Nervous System Diseases
Transcriptome sequencing of neurologic diseases associated genes in HHV-6A infected human astrocyte.
Cerebellar Ataxia
Parkin mutations are frequent in patients with isolated early-onset parkinsonism.
Charcot-Marie-Tooth Disease
SIMPLE mutations in Charcot-Marie-Tooth disease and the potential role of its protein product in protein degradation.
Cholangiocarcinoma
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Cholangiocarcinoma
BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
E3 ubiquitin ligase FBW7? inhibits cholangiocarcinoma cell proliferation by downregulating c-Myc and cyclin E.
Cholangiocarcinoma
Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
Cholangiocarcinoma
Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
Cholestasis
Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis.
Chondroma
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient.
Chondrosarcoma
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient.
Chordoma
C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Choroidal Neovascularization
Role of c-Cbl Dependent Regulation of Phospholipase C gamma 1 Activation in Experimental Choroidal Neovascularization.
Classical Swine Fever
Porcine RING finger protein 114 inhibits classical swine fever virus replication via the K27-linked polyubiquitination of viral NS4B.
Classical Swine Fever
Viral strategies for triggering and manipulating mitophagy.
Cleft Palate
Alteration of DNA Damage Response Causes Cleft Palate.
Cleft Palate
Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.
Cockayne Syndrome
BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein.
Cockayne Syndrome
Damage-induced ubiquitylation of human RNA polymerase II by the ubiquitin ligase Nedd4, but not Cockayne syndrome proteins or BRCA1.
Cockayne Syndrome
Overexpression of parkin rescues the defective mitochondrial phenotype and the increased apoptosis of Cockayne Syndrome A cells.
Cockayne Syndrome
ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB.
Cockayne Syndrome
Structural basis of human transcription-DNA repair coupling.
Cockayne Syndrome
Valosin-containing Protein (VCP)/p97 Segregase Mediates Proteolytic Processing of Cockayne Syndrome Group B (CSB) in Damaged Chromatin.
Coinfection
Avian leukosis virus subgroup J and reticuloendotheliosis virus coinfection induced TRIM62 regulation of the actin cytoskeleton.
Coinfection
Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.
Coinfection
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Coinfection
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Coinfection
Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.
Colitis
3, 3'-Diindolylmethane decreases VCAM-1 expression and alleviates experimental colitis via BRCA1-dependent antioxidant pathway.
Colitis
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Colitis
Dietary flaxseed intake exacerbates acute colonic mucosal injury and inflammation induced by dextran sodium sulfate.
Colitis
E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-?B activation.
Colitis
Ginsenoside Rb1 alleviates colitis in mice via activation of endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 signaling pathway.
Colitis
Gut Microbiota Contributes to Spontaneous Colitis in E3 Ligase Itch-Deficient Mice.
Colitis
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis, Ulcerative
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Colitis, Ulcerative
A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.
Colitis, Ulcerative
Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis.
Colitis, Ulcerative
Emerging views of mitophagy in immunity and autoimmune diseases.
Colitis, Ulcerative
Erratum: A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.
Colitis, Ulcerative
Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis.
Colitis, Ulcerative
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis, Ulcerative
Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis.
Colitis-Associated Neoplasms
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Colitis-Associated Neoplasms
Inflammation and DNA Methylation-Dependent Down-Regulation of miR-34b-5p Mediates c-MYC Expression and CRL4DCAF4 E3 Ligase Activity in Colitis-Associated Cancer.
Colitis-Associated Neoplasms
Inflammation-dependent overexpression of c-Myc enhances CRL4DCAF4 E3 ligase activity and promotes ubiquitination of ST7 in colitis-associated cancer.
Colonic Neoplasms
A cancer-associated RING finger protein, RNF43, is a ubiquitin ligase that interacts with a nuclear protein, HAP95.
Colonic Neoplasms
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
Colonic Neoplasms
A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
Colonic Neoplasms
An apoptosis-independent role of SMAC in tumor suppression.
Colonic Neoplasms
Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
Colonic Neoplasms
Assessment of tumor suppressor promoter methylation in healthy individuals.
Colonic Neoplasms
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
Colonic Neoplasms
Berberine binds RXR? to suppress ?-catenin signaling in colon cancer cells.
Colonic Neoplasms
Bias in intervention studies that enroll patients from high-risk clinics.
Colonic Neoplasms
BRCA1 expression serves a role in vincristine resistance in colon cancer cells.
Colonic Neoplasms
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
Colonic Neoplasms
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Colonic Neoplasms
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
Colonic Neoplasms
CDX2 inducible microRNAs sustain colon cancer by targeting multiple DNA damage response pathway factors.
Colonic Neoplasms
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Colonic Neoplasms
DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation.
Colonic Neoplasms
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.
Colonic Neoplasms
Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up.
Colonic Neoplasms
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
Colonic Neoplasms
Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer.
Colonic Neoplasms
Inheritance of cancer.
Colonic Neoplasms
KDM5c Promotes Colon Cancer Cell Proliferation Through the FBXW7-c-Jun Regulatory Axis.
Colonic Neoplasms
Long Noncoding RNA LINC01207 Promotes Colon Cancer Cell Proliferation and Invasion by Regulating miR-3125/TRIM22 Axis.
Colonic Neoplasms
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Colonic Neoplasms
Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer.
Colonic Neoplasms
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Colonic Neoplasms
Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer.
Colonic Neoplasms
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
Colonic Neoplasms
Modeling the study of DNA damage responses in mice.
Colonic Neoplasms
Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Colonic Neoplasms
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
Colonic Neoplasms
MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation.
Colonic Neoplasms
Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer.
Colonic Neoplasms
Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development.
Colonic Neoplasms
Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression.
Colonic Neoplasms
Ring finger protein 43 as a new target for cancer immunotherapy.
Colonic Neoplasms
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
Colonic Neoplasms
SMURF1, a promoter of tumor cell progression?
Colonic Neoplasms
The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
Colonic Neoplasms
The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated ?-catenin by sequestering TCF4 to the nuclear membrane.
Colonic Neoplasms
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Colonic Neoplasms
The role of genetic testing for cancer susceptibility in gynecologic practice.
Colonic Neoplasms
The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7-mediated deubiquitination of ?-catenin.
Colonic Neoplasms
Ubiquitin Ligase, Fbw7, Targets CDX2 for Degradation via Two Phosphodegron Motifs in a GSK3beta-dependent Manner.
Colonic Neoplasms
Variable NF-?B pathway responses in colon cancer cells treated with chemotherapeutic drugs.
Colonic Neoplasms
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
Colonic Neoplasms
[Hereditary predispositions to gynaecological cancers]
Colorectal Neoplasms
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Colorectal Neoplasms
A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis.
Colorectal Neoplasms
A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells of breast cancer patients.
Colorectal Neoplasms
A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer.
Colorectal Neoplasms
A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
Colorectal Neoplasms
Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1.
Colorectal Neoplasms
An Integrative Omics Approach Reveals Involvement of BRCA1 in Hepatic Metastatic Progression of Colorectal Cancer.
Colorectal Neoplasms
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Colorectal Neoplasms
Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family.
Colorectal Neoplasms
Aneuploidy is associated with TP53 expression but not with BRCA1 or TERT expression in sporadic colorectal cancer.
Colorectal Neoplasms
Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line.
Colorectal Neoplasms
Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer.
Colorectal Neoplasms
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
Colorectal Neoplasms
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Colorectal Neoplasms
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
Colorectal Neoplasms
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
Colorectal Neoplasms
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
Colorectal Neoplasms
BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
Colorectal Neoplasms
BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer.
Colorectal Neoplasms
BRCA1 in special populations.
Colorectal Neoplasms
BRCA1 mutations and colorectal cancer in Poland.
Colorectal Neoplasms
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
Colorectal Neoplasms
c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/?-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation.
Colorectal Neoplasms
c-Cbl mediates the degradation of tumorigenic nuclear ?-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors.
Colorectal Neoplasms
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
Colorectal Neoplasms
Case Report: Coinheritance of Germline Mutations in APC and BRCA1 in Colorectal Cancer.
Colorectal Neoplasms
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Colorectal Neoplasms
cIAP2 as a therapeutic target in colorectal cancer and other malignancies.
Colorectal Neoplasms
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Colorectal Neoplasms
Colorectal cancer in hereditary breast cancer kindreds.
Colorectal Neoplasms
Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region.
Colorectal Neoplasms
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Colorectal Neoplasms
Commonly observed RNF43 mutations retain functionality in attenuating Wnt/?-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers.
Colorectal Neoplasms
Constitutional Mosaic Epimutations - a hidden cause of cancer?
Colorectal Neoplasms
Copy number variation of E3 ubiquitin ligase genes in peripheral blood leukocyte and colorectal cancer.
Colorectal Neoplasms
Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway.
Colorectal Neoplasms
Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties.
Colorectal Neoplasms
Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
Colorectal Neoplasms
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.
Colorectal Neoplasms
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Colorectal Neoplasms
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.
Colorectal Neoplasms
Downregulation of HERC5 E3 ligase attenuates the ubiquitination of CtBP1 to inhibit apoptosis in colorectal cancer cells.
Colorectal Neoplasms
Downregulation of ring-finger protein 43 in glioma associates with poor prognosis.
Colorectal Neoplasms
E3 ubiquitin ligase SMURF2 prevents colorectal cancer by reducing the stability of the YY1 protein and inhibiting the SENP1/c-myc axis.
Colorectal Neoplasms
E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer.
Colorectal Neoplasms
Effect of NS398 on metastasis-associated gene expression in a human colon cancer cell line.
Colorectal Neoplasms
Enhancement of TGF-? signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer.
Colorectal Neoplasms
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
Colorectal Neoplasms
Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
Colorectal Neoplasms
Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer.
Colorectal Neoplasms
Familial sarcoma: challenging pedigrees.
Colorectal Neoplasms
FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.
Colorectal Neoplasms
Frameshift mutations of ubiquitination-related genes HERC2, HERC3, TRIP12, UBE2Q1 and UBE4B in gastric and colorectal carcinomas with microsatellite instability.
Colorectal Neoplasms
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
Colorectal Neoplasms
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Colorectal Neoplasms
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Colorectal Neoplasms
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Colorectal Neoplasms
Genetic testing by cancer site: ovary.
Colorectal Neoplasms
Genetics and the management of women at high risk for breast cancer.
Colorectal Neoplasms
Genital Cancers in Women: Ovarian Cancer.
Colorectal Neoplasms
Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
Colorectal Neoplasms
Germline genetic variation, cancer outcome, and pharmacogenetics.
Colorectal Neoplasms
Hereditary cancer syndromes.
Colorectal Neoplasms
Hereditary common cancers: molecular and clinical genetics.
Colorectal Neoplasms
Hereditary Factors in Gynecologic Cancer.
Colorectal Neoplasms
Hereditary risk of women's cancers.
Colorectal Neoplasms
Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.
Colorectal Neoplasms
Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.
Colorectal Neoplasms
Identification of differentially expressed genes associated with colorectal cancer liver metastasis.
Colorectal Neoplasms
Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
Colorectal Neoplasms
Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression.
Colorectal Neoplasms
Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.
Colorectal Neoplasms
Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study.
Colorectal Neoplasms
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.
Colorectal Neoplasms
Inhibition of Karyopherin-?2 Augments Radiation-Induced Cell Death by Perturbing BRCA1-Mediated DNA Repair.
Colorectal Neoplasms
Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer.
Colorectal Neoplasms
Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer.
Colorectal Neoplasms
Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?
Colorectal Neoplasms
Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Colorectal Neoplasms
Localization of human BRCA1 and BRCA2 in non-inherited colorectal carcinomas and matched normal mucosas.
Colorectal Neoplasms
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Colorectal Neoplasms
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Colorectal Neoplasms
Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation.
Colorectal Neoplasms
MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation.
Colorectal Neoplasms
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Colorectal Neoplasms
No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
Colorectal Neoplasms
Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer.
Colorectal Neoplasms
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Colorectal Neoplasms
Ovarian cancer screening.
Colorectal Neoplasms
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.
Colorectal Neoplasms
Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.
Colorectal Neoplasms
Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.
Colorectal Neoplasms
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Colorectal Neoplasms
Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development.
Colorectal Neoplasms
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Colorectal Neoplasms
Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer.
Colorectal Neoplasms
Proteomic identification of a PSF/p54nrb heterodimer as RNF43 oncoprotein-interacting proteins.
Colorectal Neoplasms
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
Colorectal Neoplasms
RBBP6, a RING finger-domain E3 ubiquitin ligase, induces epithelial-mesenchymal transition and promotes metastasis of colorectal cancer.
Colorectal Neoplasms
RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC).
Colorectal Neoplasms
Re: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
Colorectal Neoplasms
RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
Colorectal Neoplasms
Reduced Frequency and Prognostic Significance of Ring Finger Protein 43 Nucleotide Polymorphisms in a Chinese Colorectal Cancer Cohort.
Colorectal Neoplasms
Ribosomal protein RPS15A augments proliferation of colorectal cancer RKO cells via regulation of BIRC3, p38 MAPK and Chk1.
Colorectal Neoplasms
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Colorectal Neoplasms
Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
Colorectal Neoplasms
RNF180 Inhibits Proliferation and Promotes Apoptosis of Colorectal Cancer Through Ubiquitination of WISP1.
Colorectal Neoplasms
RNF43 interacts with NEDL1 and regulates p53-mediated transcription.
Colorectal Neoplasms
RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy.
Colorectal Neoplasms
RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Colorectal Neoplasms
RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps.
Colorectal Neoplasms
RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
Colorectal Neoplasms
RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.
Colorectal Neoplasms
RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer.
Colorectal Neoplasms
Segregation analysis of epithelial ovarian cancer in Finland.
Colorectal Neoplasms
Study uncovers mutation involved in two cancers.
Colorectal Neoplasms
The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition.
Colorectal Neoplasms
The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.
Colorectal Neoplasms
The CARM1-p300-c-Myc-Max (CPCM) transcriptional complex regulates the expression of CUL4A/4B and affects the stability of CRL4 E3 ligases in colorectal cancer.
Colorectal Neoplasms
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Colorectal Neoplasms
The E3 Ubiquitin Ligase Asb2? in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer.
Colorectal Neoplasms
The E3 ubiquitin ligase RNF146 promotes colorectal cancer by activating the Wnt/?-catenin pathway via ubiquitination of Axin1.
Colorectal Neoplasms
The E3 ubiquitin ligase RNF40 suppresses apoptosis in colorectal cancer cells.
Colorectal Neoplasms
The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients.
Colorectal Neoplasms
The genetics of uterine leiomyomata: what clinicians need to know.
Colorectal Neoplasms
The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability.
Colorectal Neoplasms
The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-?B.
Colorectal Neoplasms
The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis.
Colorectal Neoplasms
Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis.
Colorectal Neoplasms
Transcriptome analysis of paired primary colorectal carcinoma and liver metastases reveals fusion transcripts and similar gene expression profiles in primary carcinoma and liver metastases.
Colorectal Neoplasms
Translating genomics in cancer care.
Colorectal Neoplasms
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
Colorectal Neoplasms
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
Colorectal Neoplasms
Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF-? signaling.
Colorectal Neoplasms
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors.
Colorectal Neoplasms
Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.
Colorectal Neoplasms
Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer.
Colorectal Neoplasms
[Predictive genetic testing for hereditary breast cancer and hereditary nonpolyposis colorectal cancer]
Colorectal Neoplasms
[Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
Colorectal Neoplasms
[Prophylactic surgery of mammary and ovarian carcinoma.]
Colorectal Neoplasms
[Treatment outcome of peptide vaccination for advanced colorectal cancer].
Colorectal Neoplasms, Hereditary Nonpolyposis
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
Colorectal Neoplasms, Hereditary Nonpolyposis
A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Colorectal Neoplasms, Hereditary Nonpolyposis
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Colorectal Neoplasms, Hereditary Nonpolyposis
Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family.
Colorectal Neoplasms, Hereditary Nonpolyposis
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
Colorectal Neoplasms, Hereditary Nonpolyposis
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Colorectal Neoplasms, Hereditary Nonpolyposis
Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic.
Colorectal Neoplasms, Hereditary Nonpolyposis
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Colorectal Neoplasms, Hereditary Nonpolyposis
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Colorectal Neoplasms, Hereditary Nonpolyposis
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.
Colorectal Neoplasms, Hereditary Nonpolyposis
Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework.
Colorectal Neoplasms, Hereditary Nonpolyposis
Genetic testing by cancer site: ovary.
Colorectal Neoplasms, Hereditary Nonpolyposis
Genetic testing by cancer site: stomach.
Colorectal Neoplasms, Hereditary Nonpolyposis
Genetics and the management of women at high risk for breast cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Genital Cancers in Women: Ovarian Cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Germline genetic variation, cancer outcome, and pharmacogenetics.
Colorectal Neoplasms, Hereditary Nonpolyposis
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.
Colorectal Neoplasms, Hereditary Nonpolyposis
Germline pathogenic variants identified in women with ovarian tumors.
Colorectal Neoplasms, Hereditary Nonpolyposis
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Colorectal Neoplasms, Hereditary Nonpolyposis
Hereditary Factors in Gynecologic Cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Hereditary forms of ovarian cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.
Colorectal Neoplasms, Hereditary Nonpolyposis
Hereditary ovarian carcinomas: clinico-biological features and treatment.
Colorectal Neoplasms, Hereditary Nonpolyposis
HPV nonrelated endocervical adenocarcinoma in hereditary cancer syndromes.
Colorectal Neoplasms, Hereditary Nonpolyposis
Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Colorectal Neoplasms, Hereditary Nonpolyposis
Identification of germline genetic mutations in patients with pancreatic cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype.
Colorectal Neoplasms, Hereditary Nonpolyposis
Improving attendance to genetic counselling services for gynaecological oncology patients.
Colorectal Neoplasms, Hereditary Nonpolyposis
Inherited predisposition to cancer: a historical overview.
Colorectal Neoplasms, Hereditary Nonpolyposis
Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
Colorectal Neoplasms, Hereditary Nonpolyposis
Lifestyle Risk Factors Among People Who Have Had Cancer Genetic Testing.
Colorectal Neoplasms, Hereditary Nonpolyposis
Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population.
Colorectal Neoplasms, Hereditary Nonpolyposis
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Colorectal Neoplasms, Hereditary Nonpolyposis
Ovarian cancer screening.
Colorectal Neoplasms, Hereditary Nonpolyposis
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Colorectal Neoplasms, Hereditary Nonpolyposis
Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Colorectal Neoplasms, Hereditary Nonpolyposis
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Colorectal Neoplasms, Hereditary Nonpolyposis
Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.
Colorectal Neoplasms, Hereditary Nonpolyposis
Recent progress in the diagnosis and treatment of ovarian cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Colorectal Neoplasms, Hereditary Nonpolyposis
RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps.
Colorectal Neoplasms, Hereditary Nonpolyposis
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
The genetics of uterine leiomyomata: what clinicians need to know.
Colorectal Neoplasms, Hereditary Nonpolyposis
The role of genetic testing for cancer susceptibility in gynecologic practice.
Colorectal Neoplasms, Hereditary Nonpolyposis
Two Cases of Carcinosarcomas of the Ovary Involved in Hereditary Cancer Syndromes.
Colorectal Neoplasms, Hereditary Nonpolyposis
Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative.
Colorectal Neoplasms, Hereditary Nonpolyposis
[Chemoprevention and prophylactic surgery in ovarian carcinoma]
Colorectal Neoplasms, Hereditary Nonpolyposis
[Genetic consultation: hereditary cancer risk?].
Colorectal Neoplasms, Hereditary Nonpolyposis
[Predictive genetic testing for hereditary breast cancer and hereditary nonpolyposis colorectal cancer]
Colorectal Neoplasms, Hereditary Nonpolyposis
[Prophylactic surgery of mammary and ovarian carcinoma.]
Communicable Diseases
Autophagy in infection.
Confusion
MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Arsenite Binds to the RING Finger Domain of FANCL E3 Ubiquitin Ligase and Inhibits DNA Interstrand Crosslink Repair.
Coronary Artery Disease
How to keep on going: Editorial comment on The long-term effects of a randomized trial comparing aerobic interval versus continuous training in coronary artery disease patients: one-year data from the SAINTEX-CAD study.
Coronary Artery Disease
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Coronavirus Infections
The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination.
Corticobasal Degeneration
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
COVID-19
Coronavirus 2019 Silver Linings.
COVID-19
Lung expression of genes putatively involved in SARS-CoV-2 infection is modulated in cis by germline variants.
COVID-19
Protease cleavage of RNF20 facilitates coronavirus replication via stabilization of SREBP1.
COVID-19
Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Craniofacial Abnormalities
The polycomb group protein ring1b/rnf2 is specifically required for craniofacial development.
Craniosynostoses
A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders.
Creutzfeldt-Jakob Syndrome
Absence of Association between Two HECTD2 Polymorphisms and Sporadic Creutzfeldt-Jakob Disease.
Crohn Disease
Emerging views of mitophagy in immunity and autoimmune diseases.
Crohn Disease
Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes.
Crohn Disease
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Crohn Disease
Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease.
Cystadenocarcinoma
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Cystadenocarcinoma, Mucinous
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
Cystadenocarcinoma, Serous
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]
Cystadenoma
Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
Cystadenoma
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Cystadenoma
Reduction of BRCA1 expression in sporadic ovarian cancer.
Cystadenoma
Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
Cystadenoma, Serous
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
Cystadenoma, Serous
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
Cystadenoma, Serous
Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics.
Cystic Fibrosis
Application of DNA Machineries for the Barcode Patterned Detection of Genes or Proteins.
Cystic Fibrosis
c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells.
Cystic Fibrosis
c-Cbl reduces stability of rescued ?F508-CFTR in human airway epithelial cells: Implications for cystic fibrosis treatment.
Cystic Fibrosis
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Cystic Fibrosis
Medical students' attitudes toward genetic testing of minors.
Cystic Fibrosis
RNF185 is a novel E3 ligase of Endoplasmic Reticulum Associated Degradation (ERAD) that targets Cystic Fibrosis Transmembrane conductance Regulator (CFTR).
Cystic Fibrosis
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Cysts
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Cysts
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Cysts
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.
Cysts
Loss of Drosophila E3 Ubiquitin Ligase Hyd Promotes Extra Mitosis in Germline Cysts and Massive Cell Death During Oogenesis.
Cysts
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
Cysts
The Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis.
Cysts
The potato cyst nematode effector RHA1B is a ubiquitin ligase and uses two distinct mechanisms to suppress plant immune signaling.
Cytochrome-c Oxidase Deficiency
Mitochondrial pathology in muscle of a patient with a novel parkin mutation.
Cytomegalovirus Infections
Degradation of SAMHD1 Restriction Factor Through Cullin-Ring E3 Ligase Complexes During Human Cytomegalovirus Infection.
Deafness
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Dehydration
Arabidopsis BRCA1 represses RRTF1-mediated ROS production and ROS-responsive gene expression under dehydration stress.
Dehydration
Functional roles of the pepper RING finger protein gene, CaRING1, in abscisic acid signaling and dehydration tolerance.
Dehydration
The Arabidopsis RING E3 ubiquitin ligase AtAIRP2 plays combinatory roles with AtAIRP1 in abscisic acid-mediated drought stress responses.
Dehydration
The E3 Ligase AtRDUF1 Positively Regulates Salt Stress Responses in Arabidopsis thaliana.
Dementia
Altered ?-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
Dementia
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Dementia
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.
Dementia
Morphological substrates of mental dysfunction in Lewy body disease: an update.
Dementia
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Dementia
Parkin and synphilin-1 isoform expression changes in Lewy body diseases.
Dementia
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.
Dementia
Parkin Null Cortical Neuronal/Glial Cultures are Resistant to Amyloid-?1-42 Toxicity: A Role for Autophagy?
Dementia
Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease.
Dementia
RNF216 Regulates the Migration of Immortalized GnRH Neurons by Suppressing Beclin1-Mediated Autophagy.
Dementia
Special bioactive compounds and functional foods may exhibit neuroprotective effects in patients with dementia (Review).
Dementia
TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies.
Dementia
[Revisit to Kii ALS--the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology]
Dengue
Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness.
Dengue
Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3.
Dengue
The C-terminal Tail of TRIM56 Dictates Antiviral Restriction of Influenza A and B Viruses by Impeding Viral RNA Synthesis.
Dengue
The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Virus Infection.
Dengue
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Dengue
Viral strategies for triggering and manipulating mitophagy.
Diabetes Mellitus
Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study.
Diabetes Mellitus
Gene expression analysis approach to establish possible links between Parkinson's disease, cancer and cardiovascular diseases.
Diabetes Mellitus
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
Diabetes Mellitus
Parkin Coordinates Platelet Stress Response in Diabetes Mellitus: A Big Role in a Small Cell.
Diabetes Mellitus
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Diabetes Mellitus, Type 1
Clarifying the function of genes at the chromosome 16p13 locus in type 1 diabetes: CLEC16A and DEXI.
Diabetes Mellitus, Type 1
Diabetes Susceptibility Genes Pdx1 and Clec16a Function in a Pathway Regulating Mitophagy in ?-Cells.
Diabetes Mellitus, Type 1
Proteomic characterization of pancreatic islet {beta}-cells stimulated with pancreatic carcinoma cell conditioned medium.
Diabetes Mellitus, Type 1
Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes.
Diabetes Mellitus, Type 2
Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin Resistance.
Diabetes Mellitus, Type 2
Casitas b-Lineage Lymphoma-Deficient Mice Are Protected Against High-Fat Diet-Induced Obesity and Insulin Resistance.
Diabetes Mellitus, Type 2
Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
Diabetes Mellitus, Type 2
MG53: Biological Function and Potential as a Therapeutic Target.
Diabetes Mellitus, Type 2
Post-translational modification of Parkin and its research progress in cancer.
Diabetes Mellitus, Type 2
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Diabetes Mellitus, Type 2
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
Diabetes Mellitus, Type 2
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Diabetic Cardiomyopathies
Diabetic Cardiomyopathy: Role of the E3 Ubiquitin Ligase.
Diabetic Cardiomyopathies
Hydrogen Sulfide Regulates Muscle RING Finger-1 Protein S-Sulfhydration at Cys44 to Prevent Cardiac Structural Damage in Diabetic Cardiomyopathy.
Diabetic Cardiomyopathies
Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition.
Diabetic Nephropathies
Bone morphogenetic protein (BMP) 7 expression is regulated by the E3 ligase UBE4A in diabetic nephropathy.
Diabetic Nephropathies
Parkin ubiquitinates GATA4 and attenuates the GATA4/GAS1 signaling and detrimental effects on diabetic nephropathy.
Diabetic Retinopathy
Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes.
Digestive System Neoplasms
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
Disorders of Excessive Somnolence
Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.
Disorders of Excessive Somnolence
Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease.
Disorders of Excessive Somnolence
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
DNA Repair-Deficiency Disorders
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
DNA Repair-Deficiency Disorders
BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
DNA Repair-Deficiency Disorders
BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
DNA Repair-Deficiency Disorders
Links between genome integrity and BRCA1 tumor suppression.
DNA Repair-Deficiency Disorders
Radiosensitivity of lymphoblastoid cell lines with a heterozygous BRCA1 mutation is not detected by the comet assay and pulsed field gel electrophoresis.
DNA Repair-Deficiency Disorders
Solving the RIDDLE of 53BP1 recruitment to sites of damage.
DNA Virus Infections
Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes.
Down Syndrome
Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing.
Down Syndrome
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.
Down Syndrome
Using a Historical Lens to Envision the Next Generation of Genomic Translation Research.
Dwarfism
SIZ1 controls cell growth and plant development in Arabidopsis through salicylic acid.
Dwarfism
The Ubiquitin Ligase TRAIP: Double-Edged Sword at the Replisome.
Dysgerminoma
Mixed ovarian germ cell tumor in a BRCA2 mutation carrier.
Dysgerminoma
Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation.
Dysgerminoma
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Dyskinesias
A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Dyskinesias
Early Dyskinesias in Parkinson's Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?
Dyskinesias
Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.
Dyskinesias
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
Dyskinesias
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Dyskinesias
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Dyskinesias
Parkin disease: a phenotypic study of a large case series.
Dyskinesias
Parkin mutation and deep brain stimulation outcome.
Dyskinesias
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Dysplastic Nevus Syndrome
Inherited predisposition to cancer: a historical overview.
Dystonia
A novel family with an unusual early-onset generalized dystonia.
Dystonia
Camptocormia, axial dystonia, and parkinsonism: phenotypic heterogeneity of a parkin mutation.
Dystonia
Clinical findings in a large family with a parkin ex3delta40 mutation.
Dystonia
Diagnostic considerations in juvenile parkinsonism.
Dystonia
Early Dyskinesias in Parkinson's Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?
Dystonia
Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family.
Dystonia
Foot Drop Dystonia Resulting from parkin (PARK2) Mutation.
Dystonia
How much phenotypic variation can be attributed to parkin genotype?
Dystonia
Isolated limb dystonia as presenting feature of Parkin disease.
Dystonia
Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?
Dystonia
Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families.
Dystonia
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa.
Dystonia
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Dystonia
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Dystonia
Parkin Disease: A Clinicopathologic Entity?
Dystonia
Parkin mutations in a patient with hemiparkinsonism-hemiatrophy: a clinical-genetic and PET study.
Dystonia
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Dystonia
Quantitative gait analysis in parkin disease: Possible role of dystonia.
Dystonia
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Dystonia
Significance of the parkin gene and protein in understanding Parkinson's disease.
Dystonic Disorders
Parkin disease: a phenotypic study of a large case series.
Ectodermal Dysplasia
Recognition of p63 by the E3 ligase ITCH: Effect of an ectodermal dysplasia mutant.
Ectromelia
The poxvirus p28 virulence factor is an E3 ubiquitin ligase.
Encephalitis
Characterization of simian immunodeficiency virus (SIV) that induces SIV encephalitis in rhesus macaques with high frequency: role of TRIM5 and major histocompatibility complex genotypes and early entry to the brain.
Encephalitis
GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinson's disease in transgenic Parkin Q311X(A) mice.
Encephalitis
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
Encephalitis
Peli1 signaling blockade attenuates congenital zika syndrome.
Encephalitis
The E3 Ubiquitin Ligase c-Cbl Inhibits Microglia-Mediated CNS Inflammation by Regulating PI3K/Akt/NF-?B Pathway.
Encephalitis
The role of microglia in viral encephalitis: a review.
Encephalitis, Japanese
E3 Ubiquitin Ligase Nedd4 Promotes Japanese Encephalitis Virus Replication by Suppressing Autophagy in Human Neuroblastoma Cells.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.
Encephalomyelitis
PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
Encephalomyelitis
Peli1 facilitates virus replication and promotes neuroinflammation during West Nile virus infection.
Encephalomyelitis, Autoimmune, Experimental
Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.
Encephalomyelitis, Autoimmune, Experimental
PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
Endometrial Neoplasms
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
Endometrial Neoplasms
Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Endometrial Neoplasms
Association of genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 with the risk of endometrial carcinoma and clinicopathological parameters among Chinese Han women.
Endometrial Neoplasms
BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
Endometrial Neoplasms
BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
Endometrial Neoplasms
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
Endometrial Neoplasms
Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancer.
Endometrial Neoplasms
CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-?B signaling.
Endometrial Neoplasms
Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.
Endometrial Neoplasms
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data.
Endometrial Neoplasms
Effect of Ursolic Acid on MAPK in Cyclin D1 Signaling and RING-Type E3 Ligase (SCF E3s) in Two Endometrial Cancer Cell Lines.
Endometrial Neoplasms
Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis.
Endometrial Neoplasms
Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Endometrial Neoplasms
Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort.
Endometrial Neoplasms
Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-? protein turnover.
Endometrial Neoplasms
Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects.
Endometrial Neoplasms
Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Endometrial Neoplasms
eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants.
Endometrial Neoplasms
Expression of DNA repair proteins in endometrial cancer predicts disease outcome.
Endometrial Neoplasms
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Endometrial Neoplasms
Genetics of endometrial cancer.
Endometrial Neoplasms
Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer.
Endometrial Neoplasms
Hereditary gynaecological malignancies: advances in screening and treatment.
Endometrial Neoplasms
Hereditary non-BRCA gynaecological tumors.
Endometrial Neoplasms
Identification of TRIM22 as a progesterone-responsive gene in Ishikawa endometrial cancer cells.
Endometrial Neoplasms
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Endometrial Neoplasms
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Endometrial Neoplasms
Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
Endometrial Neoplasms
miR-182-5p and miR-96-5p Target PIAS1 and Mediate the Negative Feedback Regulatory Loop between PIAS1 and STAT3 in Endometrial Cancer.
Endometrial Neoplasms
Molecular basis of gynecological cancer.
Endometrial Neoplasms
Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma.
Endometrial Neoplasms
PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Endometrial Neoplasms
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Endometrial Neoplasms
Progesterone Receptor-B Induction of BIRC3 Protects Endometrial Cancer Cells from AP1-59-Mediated Apoptosis.
Endometrial Neoplasms
Progestin and breast cancer. The missing pieces of a puzzle.
Endometrial Neoplasms
Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series.
Endometrial Neoplasms
RE: Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Endometrial Neoplasms
Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families.
Endometrial Neoplasms
Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
Endometrial Neoplasms
RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Endometrial Neoplasms
RNF43 is frequently mutated in colorectal and endometrial cancers.
Endometrial Neoplasms
SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-?B signaling pathway.
Endometrial Neoplasms
Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue.
Endometrial Neoplasms
TGF-? activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.
Endometrial Neoplasms
The emerging role of speckle-type POZ protein (SPOP) in cancer development.
Endometrial Neoplasms
The genetics of uterine leiomyomata: what clinicians need to know.
Endometrial Neoplasms
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Endometrial Neoplasms
The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.
Endometrial Neoplasms
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
Endometrial Neoplasms
TRIM22 inhibits endometrial cancer progression through the NOD2/NF??B signaling pathway and confers a favorable prognosis.
Endometrial Neoplasms
[Genetic consultation: hereditary cancer risk?].
Endometrial Neoplasms
[Hereditary predispositions to gynaecological cancers]
Endometrial Neoplasms
[Prophylactic surgery of mammary and ovarian carcinoma.]
Endometriosis
Association Between Impairment of DNA Double Strand Break Repair and Decreased Ovarian Reserve in Patients With Endometriosis.
Endometriosis
BRCA1 alterations are associated with endometriosis, but BRCA2 alterations show no detectable endometriosis risk: a study in Indian population.
Endometriosis
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
Endometriosis
E3 ubiquitin ligase TRIM24 deficiency promotes NLRP3/caspase-1/IL-1?-mediated pyroptosis in endometriosis.
Endometriosis
Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis.
Endometriosis
Origins and molecular pathology of ovarian cancer.
Endometriosis
Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review).
Endometriosis
Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations.
Endotoxemia
Effect of Deletion of cIAP2 on Intestinal Microcirculation in Mouse Endotoxemia and Poly-bacterial Sepsis.
Endotoxemia
Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.
Enterovirus Infections
Regulation of mitochondrial antiviral signaling (MAVS) expression and signaling by the mitochondria-associated endoplasmic reticulum membrane (MAM) protein Gp78.
Ephemeral Fever
RACK1 degrades MAVS to promote bovine ephemeral fever virus replication via upregulating E3 ubiquitin ligase STUB1.
Epilepsies, Myoclonic
Unstable TTTTA/TTTCA expansions in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3.
Epilepsies, Partial
A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders.
Epilepsy
De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis.
Epilepsy
Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies.
Epilepsy
Glial overexpression of Dube3a causes seizures and synaptic impairments in Drosophila concomitant with down regulation of the Na(+)/K(+) pump ATP?.
Epilepsy
Uncovering the Pharmacological Mechanism of Chaibei Zhixian Decoction on Epilepsy by Network Pharmacology Analysis.
Epstein-Barr Virus Infections
BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-? Responses.
Epstein-Barr Virus Infections
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
Epstein-Barr Virus Infections
[Hierarchical clustering analysis to detect associations between clinical and pathological features of gastric tumors and hypermethylation of suppressor genes.]
Equine Infectious Anemia
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Equine Infectious Anemia
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Esophageal Neoplasms
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Esophageal Neoplasms
Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.
Esophageal Neoplasms
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.
Esophageal Neoplasms
Ubiquitination of NOTCH2 by DTX3 suppresses the proliferation and migration of human esophageal carcinoma.
Esophageal Neoplasms
[High throughput-targeted sequencing panel for exploring radiosensitivity associated genes in esophageal squamous cell carcinoma].
Esophageal Squamous Cell Carcinoma
A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Esophageal Squamous Cell Carcinoma
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Germline BRCA1 mutated esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
The E3 ligase HECTD3 promotes esophageal squamous cell carcinoma (ESCC) growth and cell survival through targeting and inhibiting caspase-9 activation.
Esophageal Squamous Cell Carcinoma
[Expression and clinical significance of BRCA1 in human esophageal squamous cell carcinoma].
Essential Tremor
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations.
Essential Tremor
Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor.
Exanthema
DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus.
Fallopian Tube Neoplasms
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Fallopian Tube Neoplasms
Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
Fallopian Tube Neoplasms
Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening.
Fallopian Tube Neoplasms
Laparoscopic total fallopian tube removal at the time of bilateral salpingo-oophorectomy in BRCA2 positive women.
Fallopian Tube Neoplasms
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Fallopian Tube Neoplasms
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Fallopian Tube Neoplasms
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
Fallopian Tube Neoplasms
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Fallopian Tube Neoplasms
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
Fallopian Tube Neoplasms
Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Fallopian Tube Neoplasms
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Fallopian Tube Neoplasms
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
Fallopian Tube Neoplasms
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Fallopian Tube Neoplasms
Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.
Fallopian Tube Neoplasms
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Fallopian Tube Neoplasms
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Fallopian Tube Neoplasms
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Fallopian Tube Neoplasms
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
Familial Mediterranean Fever
Structural and functional insights into the B30.2/SPRY domain.
Familial Mediterranean Fever
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function.
Fanconi Anemia
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient.
Fanconi Anemia
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.
Fanconi Anemia
A founder variant in the South Asian population leads to a high prevalence of FANCL Fanconi anemia cases in India.
Fanconi Anemia
A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance.
Fanconi Anemia
A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M.
Fanconi Anemia
A novel ubiquitin ligase is deficient in Fanconi anemia.
Fanconi Anemia
A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage.
Fanconi Anemia
A tough row to hoe: when replication forks encounter DNA damage.
Fanconi Anemia
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Fanconi Anemia
Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
Fanconi Anemia
Accelerated Evolution in Distinctive Species Reveals Candidate Elements for Clinically Relevant Traits, Including Mutation and Cancer Resistance.
Fanconi Anemia
Arsenite Binds to the RING Finger Domain of FANCL E3 Ubiquitin Ligase and Inhibits DNA Interstrand Crosslink Repair.
Fanconi Anemia
ATR-ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway.
Fanconi Anemia
Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia.
Fanconi Anemia
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Fanconi Anemia
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Fanconi Anemia
Biallelic Germline Mutations in RFWD3 May Induce Fanconi Anemia.
Fanconi Anemia
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype.
Fanconi Anemia
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
Fanconi Anemia
Biomarkers and mechanisms of FANCD2 function.
Fanconi Anemia
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
Fanconi Anemia
BRCA1 interacts directly with the Fanconi anemia protein FANCA.
Fanconi Anemia
BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.
Fanconi Anemia
Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers.
Fanconi Anemia
Chromosome breakage syndromes and cancer.
Fanconi Anemia
Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Fanconi Anemia
Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Fanconi Anemia
Connecting Fanconi anemia to BRCA1.
Fanconi Anemia
Conserved overlapping gene arrangement, restricted expression, and biochemical activities of DNA polymerase ? (POLN).
Fanconi Anemia
Corrigendum to "The conserved Fanconi anemia nuclease Fan1 and the SUMO E3 ligase Pli1 act in two novel Pso2-independent pathways of DNA interstrand crosslink repair in yeast" [DNA Repair 12 (December (12)) (2013) 1011-1023].
Fanconi Anemia
CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI.
Fanconi Anemia
Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.
Fanconi Anemia
Dedicated to the core: Understanding the Fanconi anemia complex.
Fanconi Anemia
Deep learning enables the atomic structure determination of the Fanconi Anemia core complex from cryoEM.
Fanconi Anemia
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Fanconi Anemia
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Fanconi Anemia
DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
Fanconi Anemia
Evaluation of Fanconi anaemia genes FANCA, FANCC and FANCL in cervical cancer susceptibility.
Fanconi Anemia
Exome sequencing of oral leukoplakia and oral squamous cell carcinoma implicates DNA damage repair gene defects in malignant transformation.
Fanconi Anemia
Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
Fanconi Anemia
FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.
Fanconi Anemia
FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein.
Fanconi Anemia
FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination.
Fanconi Anemia
FANCL ubiquitinates ?-catenin and enhances its nuclear function.
Fanconi Anemia
Fanconi Anemia Complementation Group FANCD2 Protein Serine 331 Phosphorylation Is Important for Fanconi Anemia Pathway Function and BRCA2 Interaction.
Fanconi Anemia
Fanconi Anemia Proteins Function in Mitophagy and Immunity.
Fanconi Anemia
Genetic basis of Fanconi anemia.
Fanconi Anemia
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Fanconi Anemia
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Fanconi Anemia
Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization.
Fanconi Anemia
Hallmarks of 'BRCAness' in sporadic cancers.
Fanconi Anemia
Hereditary breast cancer: from molecular pathology to tailored therapies.
Fanconi Anemia
High expression of UBE2T predicts poor prognosis and survival in multiple myeloma.
Fanconi Anemia
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Fanconi Anemia
Homocysteine aggravates DNA damage by impairing the FA/Brca1 Pathway in NE4C murine neural stem cells.
Fanconi Anemia
HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
Fanconi Anemia
Human disorders of ubiquitination and proteasomal degradation.
Fanconi Anemia
Identification and characterization of mutations in FANCL gene: A second case of Fanconi anemia belonging to FA-L complementation group.
Fanconi Anemia
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
Fanconi Anemia
Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.
Fanconi Anemia
Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.
Fanconi Anemia
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Fanconi Anemia
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
Fanconi Anemia
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
Fanconi Anemia
Interstrand crosslink-induced radials form between non-homologous chromosomes, but are absent in sex chromosomes.
Fanconi Anemia
Isomerization of BRCA1-BARD1 promotes replication fork protection.
Fanconi Anemia
Loss of GGN Leads to Pre-Implantation Embryonic Lethality and Compromised Male Meiotic DNA Double Strand Break Repair in the Mouse.
Fanconi Anemia
Loss-of-function FANCL Mutations Associate with Severe Fanconi Anemia Overlapping the VACTERL Association.
Fanconi Anemia
Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
Fanconi Anemia
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
Fanconi Anemia
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
Fanconi Anemia
Methodology for the identification of small molecule inhibitors of the Fanconi Anaemia ubiquitin E3 ligase complex.
Fanconi Anemia
Modularized functions of the Fanconi anemia core complex.
Fanconi Anemia
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Fanconi Anemia
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Fanconi Anemia
Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
Fanconi Anemia
Natural human knockouts and Mendelian disorders: deep phenotyping in Italian isolates.
Fanconi Anemia
New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein.
Fanconi Anemia
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
Fanconi Anemia
Novel homozygous FANCL mutation and somatic heterozygous SETBP1 mutation in a Chinese girl with Fanconi Anemia.
Fanconi Anemia
PALB2 (partner and localizer of BRCA2).
Fanconi Anemia
PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Fanconi Anemia
Rad18 confers hematopoietic progenitor cell DNA damage tolerance independently of the Fanconi Anemia pathway in vivo.
Fanconi Anemia
Rad18 E3 ubiquitin ligase activity mediates fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 Inhibition.
Fanconi Anemia
Revisiting the morbid genome of Mendelian disorders.
Fanconi Anemia
RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA and RAD51 from DNA Damage Sites to Facilitate Homologous Recombination.
Fanconi Anemia
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.
Fanconi Anemia
Role of fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance.
Fanconi Anemia
S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51.
Fanconi Anemia
Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.
Fanconi Anemia
siRNA depletion of BRCA1, but not BRCA2, causes increased genome instability in Fanconi anemia cells.
Fanconi Anemia
Structural analysis of human FANCL, the E3 ligase in the fanconi anemia pathway.
Fanconi Anemia
Structure of the human FANCL RING-Ube2T complex reveals determinants of cognate E3-E2 selection.
Fanconi Anemia
The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.
Fanconi Anemia
The Carboxy Terminus of FANCE Recruits FANCD2 to the FA E3 Ligase Complex to Promote the Fanconi Anemia DNA Repair Pathway.
Fanconi Anemia
The conserved Fanconi anemia nuclease Fan1 and the SUMO E3 ligase Pli1 act in two novel Pso2-independent pathways of DNA interstrand crosslink repair in yeast.
Fanconi Anemia
The FA Core Complex Contains a Homo-dimeric Catalytic Module for the Symmetric Mono-ubiquitination of FANCI-FANCD2.
Fanconi Anemia
The Fanconi Anemia DNA Repair Pathway Is Regulated by an Interaction between Ubiquitin and the E2-like Fold Domain of FANCL.
Fanconi Anemia
The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target.
Fanconi Anemia
The PI3K/Akt1 pathway enhances steady-state levels of FANCL.
Fanconi Anemia
The Role of Replication-Associated Repair Factors on R-Loops.
Fanconi Anemia
The structure of the catalytic subunit FANCL of the Fanconi anemia core complex.
Fanconi Anemia
The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly.
Fanconi Anemia
Transcriptional Silencing of ALDH2 Confers a Dependency on Fanconi Anemia Proteins in Acute Myeloid Leukemia.
Fanconi Anemia
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation.
Fanconi Anemia
UBE2W interacts with FANCL and regulates the monoubiquitination of Fanconi anemia protein FANCD2.
Fanconi Anemia
WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
Fanconi Anemia
Zalypsis displays preclinical activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
Fanconi Anemia
[Functions of FANCL in primordial germ cell formation and Fanconi anemia]
Fasciitis
Paraneoplastic fasciitis and polyarthritis syndrome as a manifestation of breast cancer recurrence in a BRCA1 gene-positive patient.
Fatty Liver
DDB1 E3 ligase controls dietary fructose-induced ChREBP? stabilization and liver steatosis via CRY1.
Fatty Liver
Increase of E3 ubiquitin ligase NEDD4 expression leads to degradation of its target proteins PTEN/IGF1R during the formation of goose fatty liver.
Fatty Liver
Parkin deficiency prevents chronic ethanol-induced hepatic lipid accumulation through ?-catenin accumulation.
Fatty Liver
Sirtuin 7-dependent deacetylation of DDB1 regulates the expression of nuclear receptor TR4.
Fatty Liver
Smurf1 aggravates non-alcoholic fatty liver disease by stabilizing SREBP-1c in an E3 activity-independent manner.
Fatty Liver
The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.
Fatty Liver
Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases.
Febrile Neutropenia
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Fetal Diseases
Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.
Fibroadenoma
Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Fibrocystic Breast Disease
Microglandular adenosis of the breast in a BRCA1 mutation carrier: radiological features.
Fibrocystic Breast Disease
[BRCA1 selectively regulates the expression of progesterone receptor A in sporadic invasive ductal breast carcinoma]
Fibrosarcoma
The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.
Flavivirus Infections
The E3 ligase TRIM56 is a host restriction factor of Zika virus and depends on its RNA-binding activity but not miRNA regulation, for antiviral function.
Friedreich Ataxia
E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia.
Frontotemporal Dementia
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Frontotemporal Dementia
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Frontotemporal Lobar Degeneration
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.
Gallbladder Neoplasms
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
Gallbladder Neoplasms
Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation.
Ganglioglioma
Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma.
Gastritis
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Gastritis, Atrophic
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Gastroenteritis
Putative E3 ubiquitin ligase of human rotavirus inhibits NF-?B activation by using molecular mimicry to target ?-TrCP.
Gastroenteritis
Viral strategies for triggering and manipulating mitophagy.
Gastrointestinal Neoplasms
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Gastrointestinal Neoplasms
Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.
Gaucher Disease
Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.
Gaucher Disease
Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Gaucher Disease
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.
Gaucher Disease
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Gaucher Disease
Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.
Gaucher Disease
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Genetic Diseases, Inborn
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Genetic Diseases, Inborn
Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.
Genetic Diseases, Inborn
Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.
Genetic Diseases, Inborn
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Genetic Diseases, Inborn
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
Genetic Diseases, Inborn
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
Genetic Diseases, Inborn
FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein.
Genetic Diseases, Inborn
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
Genetic Diseases, Inborn
OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Genetic Diseases, Inborn
Ovarian cancer genome.
Genetic Diseases, Inborn
Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity.
Genital Diseases, Female
GWAS of five gynecologic diseases and cross-trait analysis in Japanese.
Giant Axonal Neuropathy
Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts.
Giant Axonal Neuropathy
Explaining intermediate filament accumulation in giant axonal neuropathy.
Giant Axonal Neuropathy
Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Glaucoma
Overexpression of Optic Atrophy Type 1 Protects Retinal Ganglion Cells and Upregulates Parkin Expression in Experimental Glaucoma.
Glaucoma
Overexpression of parkin protects retinal ganglion cells in experimental glaucoma.
Glioblastoma
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.
Glioblastoma
A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.
Glioblastoma
BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats.
Glioblastoma
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Glioblastoma
BRCA1 germline mutation and glioblastoma development: report of cases.
Glioblastoma
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.
Glioblastoma
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity.
Glioblastoma
c-Cbl regulates ?Pix-mediated cell migration and invasion.
Glioblastoma
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Glioblastoma
Cool-1 mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Glioblastoma
Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.
Glioblastoma
Dissociation of mitochondrial HK-II elicits mitophagy and confers cardioprotection against ischemia.
Glioblastoma
Drosophila Brat and human ortholog TRIM3 maintain stem cell equilibrium and suppress brain tumorigenesis by attenuating Notch nuclear transport.
Glioblastoma
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Glioblastoma
Histone H2AX sensitizes glioma cells to genotoxic stimuli by recruiting DNA double-strand break repair proteins.
Glioblastoma
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Glioblastoma
Identification of a cullin5-RING E3 ligase transcriptome signature in glioblastoma multiforme.
Glioblastoma
Identification of key genes in glioblastoma-associated stromal cells using bioinformatics analysis.
Glioblastoma
Integrating cullin2-RING E3 ligase as a potential biomarker for glioblastoma multiforme prognosis and radiosensitivity profiling.
Glioblastoma
Mislocalization of the E3 ligase, beta-transducin repeat containing protein 1 ({beta}-TrCP1) in glioblastoma uncouples negative feedback between the PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) and Akt.
Glioblastoma
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
Glioblastoma
Next generation sequencing of BRCA genes in glioblastoma multiform Egyptian patients: a pilot study.
Glioblastoma
Parkin Regulates the Activity of Pyruvate Kinase M2.
Glioblastoma
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin.
Glioblastoma
PRAJA is overexpressed in glioblastoma and contributes to neural precursor development.
Glioblastoma
Redox biology in normal cells and cancer: Restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment.
Glioblastoma
RNF135, RING finger protein, promotes the proliferation of human glioblastoma cells in vivo and in vitro via the ERK pathway.
Glioblastoma
SMURF1, a promoter of tumor cell progression?
Glioblastoma
The E3 ubiquitin ligase CHIP/miR-92b/PTEN regulatory network contributes to tumorigenesis of glioblastoma.
Glioblastoma
TRIM22 activates NF-?B signaling in glioblastoma by accelerating the degradation of I?B?.
Glioblastoma
TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1).
Glioblastoma
TRIM8-driven transcriptomic profile of neural stem cells identified glioma-related nodal genes and pathways.
Glioblastoma
Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.
Glioblastoma
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Glioma
An E3 Ubiquitin Ligase RNF139 Serves as a Tumor-Suppressor in Glioma.
Glioma
An NF-?B p65-cIAP2 link is necessary for mediating resistance to TNF-? induced cell death in gliomas.
Glioma
Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.
Glioma
Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells.
Glioma
BIRC3 and BIRC5: multi-faceted inhibitors in cancer.
Glioma
BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.
Glioma
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity.
Glioma
C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Glioma
c-Cbl regulates ?Pix-mediated cell migration and invasion.
Glioma
c-Cbl regulates glioma invasion through matrix metalloproteinase 2.
Glioma
CacyBP/SIP protein reduces p53 stability by enhancing Mdm2 activity in p53 mutant glioma cells.
Glioma
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Glioma
Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis.
Glioma
Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.
Glioma
Development of a prognostic model of glioma based on immune-related genes.
Glioma
Downregulation of RNF138 inhibits cellular proliferation, migration, invasion and EMT in glioma cells via suppression of the Erk signaling pathway.
Glioma
Expression profile of parkin isoforms in human gliomas.
Glioma
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
Glioma
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Glioma
Hemoglobins, Hemorphins, and 11p15.5 Chromosomal Region in Cancer Biology and ?mmunity with Special Emphasis for Brain Tumors.
Glioma
High c-Cbl expression in gliomas is associated with tumor progression and poor prognosis.
Glioma
High Expression of Pirh2 is Associated with Poor Prognosis in Glioma.
Glioma
hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1.
Glioma
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Glioma
Identification and validation of RNA-binding protein-related gene signature revealed potential associations with immunosuppression and drug sensitivity in glioma.
Glioma
Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells.
Glioma
Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.
Glioma
Loss of heterozygosity of TRIM3 in malignant gliomas.
Glioma
Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin.
Glioma
Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells.
Glioma
Pancancer survival analysis of cancer hallmark genes.
Glioma
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Glioma
Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells.
Glioma
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Glioma
The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells.
Glioma
The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity.
Glioma
TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer.
Glioma
TRIM22 activates NF-?B signaling in glioblastoma by accelerating the degradation of I?B?.
Glioma
TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1).
Glioma
Tripartite motif-containing protein 37 is overexpressed in human glioma and its downregulation inhibits human glioma cell growth in vitro.
Glioma
Ubiquitination of p21 by E3 Ligase TRIM21 Promotes the Proliferation of Human Neuroblastoma Cells.
Glioma
[Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
Glucose Intolerance
Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet.
Glycogen Storage Disease
Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.
Glycogen Storage Disease
Update on new muscle glycogenosis.
Glycogen Storage Disease
What have we learned about glycogenosis in recent years?
glycogenin glucosyltransferase deficiency
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Gynecomastia
An updated review of epidemiology, risk factors, and management of male breast cancer.
Gynecomastia
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.
Gynecomastia
High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history.
Hamartoma
Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.
Hamartoma Syndrome, Multiple
Breast cancer predisposition syndromes.
Hamartoma Syndrome, Multiple
Can genetic testing guide treatment in breast cancer?
Hamartoma Syndrome, Multiple
Genetics of breast cancer.
Hamartoma Syndrome, Multiple
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Hamartoma Syndrome, Multiple
Hereditary breast cancer.
Hamartoma Syndrome, Multiple
Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.
Hamartoma Syndrome, Multiple
Management of women with a family history of breast cancer.
Hamartoma Syndrome, Multiple
PTEN breast cancer susceptibility: a matter of dose.
Hamartoma Syndrome, Multiple
Recent advances in understanding of genetic susceptibility to breast cancer.
Hamartoma Syndrome, Multiple
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Head and Neck Neoplasms
BRCA1 and MDM2 as independent blood-based biomarkers of head and neck cancer.
Head and Neck Neoplasms
Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer.
Head and Neck Neoplasms
Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Head and Neck Neoplasms
Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy.
Head and Neck Neoplasms
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
Head and Neck Neoplasms
Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer.
Head and Neck Neoplasms
Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
Head and Neck Neoplasms
[Genetic predeterminations of head and neck cancer]
Head and Neck Neoplasms
[Report on the first year of the activity of the National Oncological RD Consortium]
Heart Defects, Congenital
Human melanocortin 1 receptor-mediated ubiquitination of nonvisual arrestins. Role of Mahogunin Ring Finger 1 E3 ligase.
Heart Defects, Congenital
Mahogunin Ring Finger 1 Is Required for Genomic Stability and Modulates the Malignant Phenotype of Melanoma Cells.
Heart Defects, Congenital
Mahogunin Ring Finger-1 (MGRN1), a Multifaceted Ubiquitin Ligase: Recent Unraveling of Neurobiological Mechanisms.
Heart Defects, Congenital
Mice with mutations in Mahogunin ring finger-1 (Mgrn1) exhibit abnormal patterning of the left-right axis.
Heart Defects, Congenital
The MGRN1 E3 ubiquitin-ligase inhibits signaling from melanocortin receptors by competition with Galphas.
Heart Defects, Congenital
Ubiquitin-mediated regulation of the E3 ligase GP78 by MGRN1 in trans affects mitochondrial homeostasis.
Heart Failure
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
Heart Failure
Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin.
Heart Failure
Overexpression of Nrdp1 in the heart exacerbates doxorubicin-induced cardiac dysfunction in mice.
Heart Failure
Xin Fu Kang oral liquid inhibits excessive myocardial mitophagy in a rat model of advanced heart failure.
hect-type e3 ubiquitin transferase deficiency
Smurf2 regulates the senescence response and suppresses tumorigenesis in mice.
Hemangioma
Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report.
Hemangiosarcoma
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Hemangiosarcoma
Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature.
Hematologic Neoplasms
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
Hematologic Neoplasms
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
Hematologic Neoplasms
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.
Hematologic Neoplasms
Cbl proteins in platelet activation.
Hematologic Neoplasms
Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma.
Hemochromatosis
Structure and phylogenetic analysis of an endogenous retrovirus inserted into the human growth factor gene pleiotrophin.
Hemoglobinopathies
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Hemophilia A
The sampling distribution of disease-associated alleles.
Hepatitis B
A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification.
Hepatitis B
E3 ubiquitin ligase Siah-1 facilitates poly-ubiquitylation and proteasomal degradation of the hepatitis B viral X protein.
Hepatitis B
E3 ubiquitin ligase TRIM21 restricts hepatitis B virus replication by targeting HBx for proteasomal degradation.
Hepatitis B
HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability and Function.
Hepatitis B
Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex.
Hepatitis B
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.
Hepatitis B
Hepatitis B virus X protein activates E3 ubiquitin ligase Siah-1 to control virus propagation via a negative feedback loop.
Hepatitis B
Hepatitis B Virus X Protein Sensitizes TRAIL-Induced Hepatocyte Apoptosis by Inhibiting the E3 Ubiquitin Ligase A20.
Hepatitis B
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Hepatitis B
Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase.
Hepatitis B
LncRNA XIST upregulates TRIM25 via negatively regulating miR-192 in hepatitis B virus-related hepatocellular carcinoma.
Hepatitis B
Notch Signaling and Liver Cancer.
Hepatitis B
Promoter occupancy of MLL1 histone methyltransferase seems to specify the proliferative and apoptotic functions of E2F1 in a tumour microenvironment.
Hepatitis B
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Hepatitis B
SNU cell lines and their application for cancer research.
Hepatitis B
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
Hepatitis B
TRIM22: A Diverse and Dynamic Antiviral Protein.
Hepatitis B
Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain.
Hepatitis C
ENCODE tiling array analysis identifies differentially expressed annotated and novel 5' capped RNAs in hepatitis C infected liver.
Hepatitis C
Hepatitis C virus core protein suppresses mitophagy by interacting with parkin in the context of mitochondrial depolarization.
Hepatitis C
Hepatitis C virus induces the mitochondrial translocation of Parkin and subsequent mitophagy.
Hepatitis C
HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response.
Hepatitis C
Inhibition of Hepatitis C Virus RNA Replication by ISG15 does not Require Its Conjugation to Protein Substrates by the HERC5 E3 Ligase.
Hepatitis C
Innate Immune Responses against Viral Infection and Its Suppression by Viral Proteins.
Hepatitis C
Interferon alpha (IFN?)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A.
Hepatitis C
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Hepatitis C
The mitochondrial targeting chaperone 14-3-3? regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity.
Hepatitis C, Chronic
Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFN?-2a and ribavirin in Iranian patients with chronic hepatitis C.
Hepatitis C, Chronic
Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection.
Hepatitis C, Chronic
Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.
Hepatitis, Alcoholic
Aberrant modulation of the BRCA1 and G1/S cell cycle pathways in alcoholic hepatitis patients with Mallory Denk Bodies revealed by RNA sequencing.
Hepatoblastoma
Cellular cIAP2 gene expression associated with anti-HBV activity of TNF-alpha in hepatoblastoma cells.
Hereditary Breast and Ovarian Cancer Syndrome
A case series of three Sri Lankan families with hereditary breast and ovarian cancer syndrome due to pathogenic germline mutations in the BRCA1 gene
Hereditary Breast and Ovarian Cancer Syndrome
A highly accurate, low cost test for BRCA1 mutations.
Hereditary Breast and Ovarian Cancer Syndrome
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
A Novel Splice Site Mutation in the Noncoding Region of BRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics.
Hereditary Breast and Ovarian Cancer Syndrome
A tandem duplication of BRCA1 exons 1-19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Analysis of BRCA1 and BRCA2 mutations in an Iranian family with hereditary breast and ovarian cancer syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Hereditary Breast and Ovarian Cancer Syndrome
BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Hereditary Breast and Ovarian Cancer Syndrome
BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
Hereditary Breast and Ovarian Cancer Syndrome
Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
Hereditary Breast and Ovarian Cancer Syndrome
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Hereditary Breast and Ovarian Cancer Syndrome
Current condition of genetic medicine for hereditary breast cancer.
Hereditary Breast and Ovarian Cancer Syndrome
Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
Hereditary Breast and Ovarian Cancer Syndrome
Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future.
Hereditary Breast and Ovarian Cancer Syndrome
Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
Hereditary Breast and Ovarian Cancer Syndrome
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
Hereditary Breast and Ovarian Cancer Syndrome
Functional and structural analysis of C-terminal BRCA1 missense variants.
Hereditary Breast and Ovarian Cancer Syndrome
Genetic testing by cancer site: ovary.
Hereditary Breast and Ovarian Cancer Syndrome
Genetic testing by cancer site: stomach.
Hereditary Breast and Ovarian Cancer Syndrome
Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Hereditary breast and ovarian cancer susceptibility genes (Review).
Hereditary Breast and Ovarian Cancer Syndrome
Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
Hereditary Breast and Ovarian Cancer Syndrome
Hereditary breast cancer and family cancer syndromes.
Hereditary Breast and Ovarian Cancer Syndrome
Hereditary Ovarian Cancer and Risk Reduction.
Hereditary Breast and Ovarian Cancer Syndrome
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
Hereditary Breast and Ovarian Cancer Syndrome
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Hereditary Breast and Ovarian Cancer Syndrome
Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes.
Hereditary Breast and Ovarian Cancer Syndrome
Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
Hereditary Breast and Ovarian Cancer Syndrome
Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
Hereditary Breast and Ovarian Cancer Syndrome
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Hereditary Breast and Ovarian Cancer Syndrome
Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
Hereditary Breast and Ovarian Cancer Syndrome
Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
Hereditary Breast and Ovarian Cancer Syndrome
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Hereditary Breast and Ovarian Cancer Syndrome
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Hereditary Breast and Ovarian Cancer Syndrome
Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.
Hereditary Breast and Ovarian Cancer Syndrome
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Hereditary Breast and Ovarian Cancer Syndrome
Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Hereditary Breast and Ovarian Cancer Syndrome
Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
Hereditary Breast and Ovarian Cancer Syndrome
Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
Hereditary Breast and Ovarian Cancer Syndrome
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Hereditary Breast and Ovarian Cancer Syndrome
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Hereditary Breast and Ovarian Cancer Syndrome
Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers.
Hereditary Breast and Ovarian Cancer Syndrome
Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Prevalence of the BRCA1 founder mutation c.5266dup in Brazilian individuals at-risk for the Hereditary Breast and Ovarian Cancer Syndrome.
Hereditary Breast and Ovarian Cancer Syndrome
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Hereditary Breast and Ovarian Cancer Syndrome
Recent advances in molecular genetics of breast cancer.
Hereditary Breast and Ovarian Cancer Syndrome
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Hereditary Breast and Ovarian Cancer Syndrome
Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation.
Hereditary Breast and Ovarian Cancer Syndrome
The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
Hereditary Breast and Ovarian Cancer Syndrome
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Hereditary Breast and Ovarian Cancer Syndrome
The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
Hereditary Breast and Ovarian Cancer Syndrome
Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Hereditary Breast and Ovarian Cancer Syndrome
Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
Hereditary Breast and Ovarian Cancer Syndrome
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden.
Hereditary Breast and Ovarian Cancer Syndrome
Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
Hereditary Breast and Ovarian Cancer Syndrome
[A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
Hereditary Breast and Ovarian Cancer Syndrome
[Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations].
Hereditary Breast and Ovarian Cancer Syndrome
[Prophylactic surgery of mammary and ovarian carcinoma.]
Hernias, Diaphragmatic, Congenital
Decreased pulmonary c-Cbl expression and tyrosine phosphorylation in the nitrofen-induced rat model of congenital diaphragmatic hernia.
Herpes Simplex
A flow cytometric assay for the study of E3 ubiquitin ligase activity.
Herpes Simplex
A quantitative assay to monitor HSV-1 ICP0 ubiquitin ligase activity in vitro.
Herpes Simplex
A Tale of Two PMLs: Elements Regulating a Differential Substrate Recognition by the ICP0 E3 Ubiquitin Ligase of Herpes Simplex Virus 1.
Herpes Simplex
A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses.
Herpes Simplex
Cbl E3 Ligase Mediates the Removal of Nectin-1 from the Surface of Herpes Simplex Virus 1-Infected Cells.
Herpes Simplex
Centromere architecture breakdown induced by the viral E3 ubiquitin ligase ICP0 protein of herpes simplex virus type 1.
Herpes Simplex
Centromeric protein CENP-B proteasomal degradation induced by the viral protein ICP0.
Herpes Simplex
Characterization of Elements Regulating the Nuclear-to-Cytoplasmic Translocation of ICP0 in Late Herpes Simplex Virus 1 Infection.
Herpes Simplex
Characterization of the novel E3 ubiquitin ligase encoded in exon 3 of herpes simplex virus-1-infected cell protein 0.
Herpes Simplex
Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription.
Herpes Simplex
Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins.
Herpes Simplex
Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.
Herpes Simplex
Effect of SUMO-SIM Interaction on the ICP0-Mediated Degradation of PML Isoform II and Its Associated Proteins in Herpes Simplex Virus 1 Infection.
Herpes Simplex
Functional characterization of residues required for the herpes simplex virus 1 E3 ubiquitin ligase ICP0 to interact with the cellular E2 ubiquitin-conjugating enzyme UBE2D1 (UbcH5a).
Herpes Simplex
Herpes Simplex Virus 1 E3 Ubiquitin Ligase ICP0 Protein Inhibits TNF-?-induced NF-?B Activation by Interacting with p65/RelA and p50/NF-?B1.
Herpes Simplex
Herpes simplex virus 1 ICP0 phosphorylation site mutants are attenuated for viral replication and impaired for explant-induced reactivation.
Herpes Simplex
Herpes simplex virus 1 mutant in which the ICP0 HUL-1 E3 ubiquitin ligase site is disrupted stabilizes cdc34 but degrades D-type cyclins and exhibits diminished neurotoxicity.
Herpes Simplex
Herpes simplex virus 1-infected cell protein 0 contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes.
Herpes Simplex
Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation.
Herpes Simplex
Herpes simplex virus tegument ICP0 is capsid associated, and its E3 ubiquitin ligase domain is important for incorporation into virions.
Herpes Simplex
Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.
Herpes Simplex
HSV-1 ICP0: An E3 Ubiquitin Ligase That Counteracts Host Intrinsic and Innate Immunity.
Herpes Simplex
ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency.
Herpes Simplex
ICP0 dismantles microtubule networks in herpes simplex virus-infected cells.
Herpes Simplex
Identification of a novel higher molecular weight isoform of USP7/HAUSP that interacts with the Herpes simplex virus type-1 immediate early protein ICP0.
Herpes Simplex
Interaction between the cellular E3 ubiquitin ligase SIAH-1 and the viral immediate-early protein ICP0 enables efficient replication of Herpes Simplex Virus type 2 in vivo.
Herpes Simplex
Interaction With 14-3-3 Correlates With Inactivation of the RIG-I Signalosome by Herpesvirus Ubiquitin Deconjugases.
Herpes Simplex
Relative Contributions of Herpes Simplex Virus 1 ICP0 and vhs to Loss of Cellular IFI16 Vary in Different Human Cell Types.
Herpes Simplex
Roles of TRIM32 in Corneal Epithelial Cells After Infection with Herpes Simplex Virus.
Herpes Simplex
Sequences related to SUMO interaction motifs in herpes simplex virus 1 protein ICP0 act cooperatively to stimulate virus infection.
Herpes Simplex
Simian TRIM5alpha proteins reduce replication of herpes simplex virus.
Herpes Simplex
Temporal Analysis of the Nuclear-to-cytoplasmic Translocation of a Herpes Simplex Virus 1 Protein by Immunofluorescent Confocal Microscopy.
Herpes Simplex
The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity.
Herpes Simplex
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Herpes Simplex
TRIM23 mediates virus-induced autophagy via activation of TBK1.
Herpes Simplex
TRIM30? Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING.
Herpes Simplex
Ubiquitin-specific protease 9X in host cells interacts with herpes simplex virus 1 ICP0.
Herpes Simplex
Viral E3 Ubiquitin Ligase-Mediated Degradation of a Cellular E3: Viral Mimicry of a Cellular Phosphorylation Mark Targets the RNF8 FHA Domain.
Herpes Simplex
Viral strategies for triggering and manipulating mitophagy.
Herpes Simplex
ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.
Herpes Zoster
The E3 Ubiquitin Ligase Mahogunin Ubiquitinates the Melanocortin 2 Receptor.
Herpesviridae Infections
A genome-wide screen of Epstein-Barr virus proteins that modulate host SUMOylation identifies a SUMO E3 ligase conserved in herpesviruses.
Hirschsprung Disease
Aberrant UBR4 expressions in Hirschsprung disease patients.
Histiocytic Sarcoma
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
histone acetyltransferase deficiency
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
HIV Infections
Association of TRIM22 with Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection.
HIV Infections
BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection.
HIV Infections
Evolution of TRIM5alpha B30.2 (SPRY) domain in New World primates.
HIV Infections
Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease.
HIV Infections
Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy.
HIV Infections
Interpreting missense mutations in Human TRIM5alpha by computational methods.
HIV Infections
The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.
Hodgkin Disease
Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
Hodgkin Disease
Breast cancer in adolescents and young women.
Hodgkin Disease
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Hodgkin Disease
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Huntington Disease
Behavioral science in translational research and cancer control.
Huntington Disease
Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis.
Huntington Disease
Deregulation of BRCA1 leads to impaired spatiotemporal dynamics of ?-H2AX and DNA damage responses in Huntington's disease.
Huntington Disease
Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Huntington Disease
Medical students' attitudes toward genetic testing of minors.
Huntington Disease
Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing.
Huntington Disease
Quantitative interaction proteomics of neurodegenerative disease proteins.
Hydrocephalus
Deletion of the Parkin co-regulated gene causes defects in ependymal ciliary motility and hydrocephalus in the quakingviable mutant mouse.
Hyperaldosteronism
CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy.
Hyperalgesia
MYCBP2 Is a Guanosine Exchange Factor for Ran Protein and Determines Its Localization in Neurons of Dorsal Root Ganglia.
Hyperalgesia
Spinal RNF20-mediated histone H2B monoubiquitylation regulates mGluR5 transcription for neuropathic allodynia.
Hypercholesterolemia
Genetic variation of RNF145 gene and blood lipid levels in Xinjiang population, China.
Hyperglycemia
Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis.
Hyperglycemia
Mex3c mutation reduces adiposity partially through increasing physical activity.
Hyperhomocysteinemia
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Hyperinsulinism
Perspective of future drugs targeting sterile 20/SPS1-related proline/alanine-rich kinase for blood pressure control.
Hyperinsulinism
Rnf20 deficiency in adipocyte impairs adipose tissue development and thermogenesis.
Hyperkalemia
Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation.
Hyperlipidemias
Age-Associated Mitochondrial Dysfunction Accelerates Atherogenesis.
Hyperlipidemias
Mex3c mutation reduces adiposity partially through increasing physical activity.
Hyperpigmentation
Human melanocortin 1 receptor-mediated ubiquitination of nonvisual arrestins. Role of Mahogunin Ring Finger 1 E3 ligase.
Hyperpigmentation
Mahogunin Ring Finger 1 Is Required for Genomic Stability and Modulates the Malignant Phenotype of Melanoma Cells.
Hyperprolactinemia
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Hyperprolactinemia
Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments.
Hypersensitivity
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
Hypersensitivity
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
Hypersensitivity
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.
Hypersensitivity
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Hypersensitivity
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Hypersensitivity
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype.
Hypersensitivity
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
Hypersensitivity
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
Hypersensitivity
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
Hypersensitivity
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Hypersensitivity
Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Hypersensitivity
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.
Hypersensitivity
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Hypersensitivity
Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Hypersensitivity
Drosophila homologs of FANCD2 and FANCL function in DNA repair.
Hypersensitivity
Dysregulation of p53 and Parkin Induce Mitochondrial Dysfunction and Leads to the Diabetic Neuropathic Pain.
Hypersensitivity
Epithelial cell transforming factor ECT2 is an important regulator of DNA double-strand break repair and genome stability.
Hypersensitivity
Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2.
Hypersensitivity
Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
Hypersensitivity
Gene-specific chromatin damage in human spermatozoa can be blocked by antioxidants that target mitochondria.
Hypersensitivity
Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.
Hypersensitivity
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
Hypersensitivity
Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations.
Hypersensitivity
Interaction between DNA Polymerase ? and BRCA1.
Hypersensitivity
Lessons learned from BRCA1 and BRCA2.
Hypersensitivity
Links between genome integrity and BRCA1 tumor suppression.
Hypersensitivity
Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation in comparison to ataxia telangiectasia heterozygote cells.
Hypersensitivity
Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
Hypersensitivity
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
Hypersensitivity
New roads to FA/BRCA pathway: H2AX.
Hypersensitivity
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
Hypersensitivity
Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.
Hypersensitivity
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Hypersensitivity
SDIR1 is a RING finger E3 ligase that positively regulates stress-responsive abscisic acid signaling in Arabidopsis.
Hypersensitivity
The Arabidopsis RING Finger E3 Ligase RHA2b Acts Additively with RHA2a in Regulating ABA Signaling and Drought Response.
Hypersensitivity
The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Hypersensitivity
The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1
Hypersensitivity
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Hypersensitivity
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Hypertension
Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation.
Hypertension
Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study.
Hypertension
Cullin-Ring ubiquitin ligases in kidney health and disease.
Hypertension
Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.
Hypertension
Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.
Hypertension
Perspective of future drugs targeting sterile 20/SPS1-related proline/alanine-rich kinase for blood pressure control.
Hypertension
Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report.
Hypertension
The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction.
Hypertension
The CUL3/KLHL3-WNK-SPAK/OSR1 pathway as a target for antihypertensive therapy.
Hyperthyroidism
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Hypoglycemia
Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report.
Hypogonadism
RNF216 Regulates the Migration of Immortalized GnRH Neurons by Suppressing Beclin1-Mediated Autophagy.
Hypokalemia
Deletion of renal Nedd4-2 abolishes the effect of high sodium intake (HS) on Kir4.1, ENaC, and NCC and causes hypokalemia during high HS.
Hypokinesia
parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress.
Hypokinesia
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
Hypokinesia
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
Hypoventilation
The E3 ubiquitin ligase TRIM11 mediates the degradation of congenital central hypoventilation syndrome-associated polyalanine-expanded PHOX2B.
Immune System Diseases
Itch: a HECT-type E3 ligase regulating immunity, skin and cancer.
Immune System Diseases
The E3 ligase Itch knock-out mice show hyper-proliferation and wound healing alteration.
Immune System Diseases
The E3 ubiquitin ligase Itch in T cell activation, differentiation, and tolerance.
Immune System Diseases
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Incontinentia Pigmenti
Human disorders of ubiquitination and proteasomal degradation.
Infarction, Middle Cerebral Artery
BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains.
Infections
A brief history of TRIM5alpha.
Infections
A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus.
Infections
A non-canonical role for the autophagy machinery in anti-retroviral signaling mediated by TRIM5?.
Infections
A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.
Infections
A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer.
Infections
A protein complex required for polar growth of rhizobial infection threads.
Infections
A quantitative assay to monitor HSV-1 ICP0 ubiquitin ligase activity in vitro.
Infections
A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons.
Infections
A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction.
Infections
A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.
Infections
A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort.
Infections
A ubiquitin ligase of symbiosis receptor kinase involved in nodule organogenesis.
Infections
A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses.
Infections
Accumulation of substrates of the anaphase-promoting complex (APC) during human cytomegalovirus infection is associated with the phosphorylation of Cdh1 and the dissociation and relocalization of APC subunits.
Infections
Activation of non-canonical NF-{kappa}B signaling by the oncoprotein TIO.
Infections
Active Depletion of Host Cell Inhibitor-of-Apoptosis Proteins Triggers Apoptosis upon Baculovirus DNA Replication.
Infections
Adaptive evolution of primate TRIM5alpha, a gene restricting HIV-1 infection.
Infections
AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections.
Infections
An active TRIM5 protein in rabbits indicates a common antiviral ancestor for mammalian TRIM5 proteins.
Infections
An E3 ubiquitin ligase TRIM9 is involved in WSSV infection via interaction with ?-TrCP.
Infections
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Infections
Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery.
Infections
Anaplasma phagocytophilum Up-regulates some Anti-apoptotic Genes in Neutrophils and Pro-inflammatory Genes in Mononuclear Cells of Sheep.
Infections
Anti-retroviral activity of TRIM5 alpha.
Infections
Antiretroviral potential of human tripartite motif-5 and related proteins.
Infections
Antiviral molecules correlate with vitamin D pathway genes and are associated with natural resistance to HIV-1 infection.
Infections
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
Infections
Association of TRIM22 with Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection.
Infections
Autophagy in infection.
Infections
BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection.
Infections
BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.
Infections
BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-? Responses.
Infections
Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS.
Infections
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
Infections
c-Cbl-mediated selective virus-receptor translocations into lipid rafts regulate productive Kaposi's sarcoma-associated herpesvirus infection in endothelial cells.
Infections
Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.
Infections
Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are increased after labour in foetal membranes and myometrium and are essential for TNF-?-induced expression of pro-labour mediators.
Infections
Centromere architecture breakdown induced by the viral E3 ubiquitin ligase ICP0 protein of herpes simplex virus type 1.
Infections
Characterisation and function of TRIM23 in grass carp (Ctenopharyngodon idella).
Infections
CIB1 synergizes with EphrinA2 to regulate Kaposi's sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells.
Infections
Classification of barley U-box E3 ligases and their expression patterns in response to drought and pathogen stresses.
Infections
Close Relationship between cIAP2 and Human ARDS Induced by Severe H7N9 Infection.
Infections
Comparative Proteomic Analysis of Wild Type and Mutant Lacking an SCF E3 Ligase F-Box Protein in Magnaporthe oryzae.
Infections
Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription.
Infections
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Infections
Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins.
Infections
Control of Viral Infectivity by Tripartite Motif Proteins.
Infections
Control of viral infectivity by tripartite motif proteins.
Infections
CSFV induced mitochondrial fission and mitophagy to inhibit apoptosis.
Infections
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells.
Infections
Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.
Infections
Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1.
Infections
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.
Infections
DEAR1, a transcriptional repressor of DREB protein that mediates plant defense and freezing stress responses in Arabidopsis.
Infections
Determinants for the rhesus monkey TRIM5alpha-mediated block of the late phase of HIV-1 replication.
Infections
Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles.
Infections
Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals.
Infections
Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.
Infections
Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues.
Infections
DNA Geminivirus Infection Induces an Imprinted E3 Ligase Gene to Epigenetically Activate Viral Gene Transcription.
Infections
E3 Ubiquitin Ligase RNF114 Inhibits Innate Immune Response to Red-Spotted Grouper Nervous Necrosis Virus Infection in Sea Perch by Targeting MAVS and TRAF3 to Mediate Their Degradation.
Infections
E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers.
Infections
Ectopic Expression of TRIM25 Restores RIG-I Expression and IFN Production Reduced by Multiple Enteroviruses 3Cpro.
Infections
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.
Infections
Ehrlichia chaffeensis TRP120 Moonlights as a HECT E3 Ligase Involved in Self- and Host Ubiquitination To Influence Protein Interactions and Stability for Intracellular Survival.
Infections
EphrinA2 regulates clathrin mediated KSHV endocytosis in fibroblast cells by coordinating integrin-associated signaling and c-Cbl directed polyubiquitination.
Infections
Evolution of the rodent Trim5 cluster is marked by divergent paralogous expansions and independent acquisitions of TrimCyp fusions.
Infections
Exploring the associations of host genes for viral infection revealed by genome-wide RNAi and virus-host protein interactions.
Infections
Expression profiles and interaction suggest TBK1 can be regulated by Nrdp1 in response to immune stimulation in large yellow croaker Larimichthys crocea.
Infections
Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection.
Infections
Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha.
Infections
Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains.
Infections
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Infections
Gain-of-sensitivity mutations in a Trim5-resistant primary isolate of pathogenic SIV identify two independent conserved determinants of Trim5? specificity.
Infections
GBP5 Is an Interferon-Induced Inhibitor of Respiratory Syncytial Virus.
Infections
Generation and characterization of a stable full-length ecotropic murine leukemia virus molecular clone that produces novel phenotypes to Fv1 restriction.
Infections
Generation of an HIV-1 resistant immune system with CD34+ HSCs transduced with a triple combination anti-HIV lentiviral vector.
Infections
Generation of human TRIM5alpha mutants with high HIV-1 restriction activity.
Infections
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.
Infections
Genotyping of TRIM5 locus in northern pig-tailed macaques (Macaca leonina), a primate species susceptible to Human Immunodeficiency Virus type 1 infection.
Infections
GhCyP3 improves the resistance of cotton to Verticillium dahliae by inhibiting the E3 ubiquitin ligase activity of GhPUB17.
Infections
H. pylori infection confers resistance to apoptosis via Brd4-dependent BIRC3 eRNA synthesis.
Infections
HACE1, an E3 ubiquitin-protein ligase, Mitigates Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Infection Induced Oxidative Stress by Promoting Nrf2 Activity.
Infections
Heat shock perturbs TRIM5alpha restriction of human immunodeficiency virus type 1.
Infections
HECTD3 mediates TRAF3 polyubiquitination and type I interferon induction during bacterial infection.
Infections
Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis.
Infections
Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-?B signaling pathway in liver cancer.
Infections
Hepatitis C virus core protein suppresses mitophagy by interacting with parkin in the context of mitochondrial depolarization.
Infections
Hepatitis C virus induces the mitochondrial translocation of Parkin and subsequent mitophagy.
Infections
Heroin use is associated with lower levels of restriction factors and type I interferon expression and facilitates HIV-1 replication.
Infections
Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.
Infections
High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans.
Infections
HIV-1 Nef promotes ubiquitination and proteasomal degradation of p53 tumor suppressor protein by using E6AP.
Infections
HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection.
Infections
Host Intrinsic and Innate Intracellular Immunity During Herpes Simplex Virus Type 1 (HSV-1) Infection.
Infections
Hsp70 interacts with the retroviral restriction factor TRIM5alpha and assists the folding of TRIM5alpha.
Infections
HSV-1 ICP0: An E3 Ubiquitin Ligase That Counteracts Host Intrinsic and Innate Immunity.
Infections
Human cytomegalovirus evades ZAP detection by suppressing CpG dinucleotides in the major immediate early 1 gene.
Infections
Human Immunodeficiency Virus Type 1 Restriction by Human-Rhesus Chimeric Tripartite Motif 5alpha (TRIM 5alpha) in CD34(+) Cell-Derived Macrophages In Vitro and in T Cells In Vivo in Severe Combined Immunodeficient (SCID-hu) Mice Transplanted with Human Fetal Tissue.
Infections
Human Pirh2 is a novel inhibitor of prototype foamy virus replication.
Infections
Human TRIM5alpha Expression Levels and Reduced Susceptibility to HIV-1 Infection.
Infections
Human TRIM5alpha mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants.
Infections
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.
Infections
Hypothesis: Is there a link between the immune response to Human Herpes Virus type 6? (HHV-6?) infection and the interaction network (interactome) of the genes encoding the CTSS, PTX3, CHI3L1, Mx1, CXCL16, BIRC3 and BST2 proteins?
Infections
ICP0 enables and monitors the function of D cyclins in herpes simplex virus 1 infected cells.
Infections
ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells.
Infections
Identification of postentry restrictions to Mason-Pfizer monkey virus infection in New World monkey cells.
Infections
Identification of residues within the L2 region of rhesus TRIM5alpha that are required for retroviral restriction and cytoplasmic body localization.
Infections
Identification of TRAF6 as a ubiquitin ligase engaged in the ubiquitination of SopB, a virulence effector protein secreted by Salmonella typhimurium.
Infections
Identification of TRIM27 as a novel degradation target of herpes simplex virus 1 ICP0.
Infections
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.
Infections
Immune-Related Gene Expression Patterns in GPV- or H9N2-Infected Goose Spleens.
Infections
Impact of a single amino acid in the variable region 2 of the Old World monkey TRIM5alpha SPRY (B30.2) domain on anti-human immunodeficiency virus type 2 activity.
Infections
Impact of novel TRIM5alpha variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection.
Infections
Impact of TRIM5? in vivo.
Infections
Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities.
Infections
Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.
Infections
Independent evolution of an antiviral TRIMCyp in rhesus macaques.
Infections
Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.
Infections
Induction of cyclophilin A by influenza A virus infection facilitates group A Streptococcus coinfection.
Infections
Induction of HOX Genes by Hepatitis C Virus Infection via Impairment of Histone H2A Monoubiquitination.
Infections
InFLUencing host survival: cIAP2 tips the scales.
Infections
Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy.
Infections
Inhibitory effect of human TRIM5alpha on HIV-1 production.
Infections
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Infections
Interactions of the antiviral factor IFI16 mediate immune signaling and herpes simplex virus-1 immunosuppression.
Infections
Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha.
Infections
Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II.
Infections
Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3.
Infections
Intrinsic immunity: a front-line defense against viral attack.
Infections
IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity.
Infections
ISGylation of Hepatitis C Virus NS5A Protein Promotes Viral RNA Replication via Recruitment of Cyclophilin A.
Infections
Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection.
Infections
KDM2B Overexpression Facilitates Lytic De Novo KSHV Infection by Inducing AP-1 Activity Through Interaction with the SCF E3 Ubiquitin Ligase Complex.
Infections
KSHV Entry and Trafficking in Target Cells-Hijacking of Cell Signal Pathways, Actin and Membrane Dynamics.
Infections
Latency-Associated Nuclear Antigen E3 Ubiquitin Ligase Activity Impacts Gammaherpesvirus-Driven Germinal Center B Cell Proliferation.
Infections
Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex.
Infections
Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection.
Infections
Life History of the Oldest Lentivirus: Characterization of ELVgv Integrations in the Dermopteran Genome.
Infections
Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.
Infections
Long-term balancing selection maintains trans-specific polymorphisms in the human TRIM5 gene.
Infections
Long-Term BRCA1 Down-Regulation by Small Hairpin RNAs Targeting the 3' Untranslated Region.
Infections
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.
Infections
Lotus japonicus E3 ligase SEVEN IN ABSENTIA4 destabilizes the symbiosis receptor-like kinase SYMRK and negatively regulates rhizobial infection.
Infections
Macrophage migration inhibitory factor enhances influenza-associated mortality in mice.
Infections
MicroRNA-325-3p Facilitates Immune Escape of Mycobacterium tuberculosis through Targeting LNX1 via NEK6 Accumulation to Promote Anti-Apoptotic STAT3 Signaling.
Infections
MiR-202-5p Inhibits RIG-I-Dependent Innate Immune Responses to RGNNV Infection by Targeting TRIM25 to Mediate RIG-I Ubiquitination.
Infections
miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-?B Signaling.
Infections
Mitochondria-Derived Vesicles Deliver Antimicrobial Reactive Oxygen Species to Control Phagosome-Localized Staphylococcus aureus.
Infections
Mitofusin 2-Deficiency Suppresses Mycobacterium tuberculosis Survival in Macrophages.
Infections
Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha.
Infections
Molecular characterization, tissue distribution and expression analysis of TRIM25 in Gallus gallus domesticus.
Infections
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Infections
Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5alpha.
Infections
Murine gammaherpesvirus 68 evades host cytokine production via replication transactivator-induced RelA degradation.
Infections
NEURL3 is an inducible antiviral effector to inhibit HCV assembly by targeting viral E1 glycoprotein.
Infections
Nonproteolytic K29-Linked Ubiquitination of the PB2 Replication Protein of Influenza A Viruses by Proviral Cullin 4-Based E3 Ligases.
Infections
Not so unique to Primates: The independent adaptive evolution of TRIM5 in Lagomorpha lineage.
Infections
Novel TRIM5 Isoforms Expressed by Macaca nemestrina.
Infections
NtRNF217, Encoding a Putative RBR E3 Ligase Protein of Nicotiana tabacum, Plays an Important Role in the Regulation of Resistance to Ralstonia solanacearum Infection.
Infections
Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.
Infections
Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Infections
Nuclear redistribution of BRCA1 during viral infection.
Infections
Overexpression of feline tripartite motif-containing 25 interferes with the late stage of feline leukemia virus replication.
Infections
p47 licenses activation of the immune deficiency pathway in the tick Ixodes scapularis.
Infections
p62/Sequestosome1 associates with and sustains the expression of the retroviral restriction factor TRIM5{alpha}
Infections
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Infections
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Infections
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
Infections
Pathogen-induced ubiquitin-editing enzyme A20 bifunctionally shuts off NF-?B and caspase-8-dependent apoptotic cell death.
Infections
Perception of the plant immune signal salicylic acid.
Infections
Phosphorylation drives an apoptotic protein to activate antiapoptotic genes: paradigm of influenza A matrix 1 protein function.
Infections
Phytophthora infestans effector AVR3a is essential for virulence and manipulates plant immunity by stabilizing host E3 ligase CMPG1.
Infections
Phytophthora sojae effector Avr1d functions as an E2 competitor and inhibits ubiquitination activity of GmPUB13 to facilitate infection.
Infections
Pioneer surgeon drove ultra clean technology.
Infections
Polymicrobial Oral Infection with Four Periodontal Bacteria Orchestrates a Distinct Inflammatory Response and Atherosclerosis in ApoE null Mice.
Infections
Porcine Circovirus 2 Induction of ROS Is Responsible for Mitophagy in PK-15 Cells via Activation of Drp1 Phosphorylation.
Infections
Porcine reproductive and respiratory syndrome virus triggers mitochondrial fission and mitophagy to attenuate apoptosis.
Infections
Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components.
Infections
Potent inhibition of simian immunodeficiency virus (SIV) replication by an SIV-based lentiviral vector expressing antisense Env.
Infections
Preparation and Application of a Monoclonal Antibody Against Chicken TRIM62.
Infections
Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids.
Infections
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Infections
Proteasomal degradation of TRIM5alpha during retrovirus restriction.
Infections
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Infections
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
Infections
Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase.
Infections
PUB1 interacts with the receptor kinase DMI2 and negatively regulates rhizobial and arbuscular mycorrhizal symbioses through its ubiquitination activity in Medicago truncatula.
Infections
Pulmonary Pseudomonas aeruginosa infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice.
Infections
Quantitative Proteomics Reveals a Novel Role of the E3 Ubiquitin-Protein Ligase FANCL in the Activation of the Innate Immune Response through Regulation of TBK1 Phosphorylation during Peste des Petits Ruminants Virus Infection.
Infections
Regulation of Anti-Apoptotic SOD2 and BIRC3 in Periodontal Cells and Tissues.
Infections
Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection.
Infections
Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein.
Infections
Restriction of the felid lentiviruses by a synthetic feline TRIM5-CypA fusion.
Infections
Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription.
Infections
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
Infections
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates.
Infections
Rickettsia rickettsii Infection Protects Human Microvascular Endothelial Cells against Staurosporine-Induced Apoptosis by a cIAP(2)-Independent Mechanism.
Infections
RING domain is essential for the antiviral activity of TRIM25 from orange spotted grouper.
Infections
RIPLET, and not TRIM25, is required for endogenous RIG-I-dependent antiviral responses.
Infections
RKP, a RING finger E3 ligase induced by BSCTV C4 protein, affects geminivirus infection by regulation of the plant cell cycle.
Infections
RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis.
Infections
RNF111-facilitated neddylation potentiates cGAS-mediated antiviral innate immune response.
Infections
RNF220 mediates K63-linked polyubiquitination of STAT1 and promotes host defense.
Infections
Role of a novel pathogen-induced pepper C3-H-C4 type RING-finger protein gene, CaRFPI, in disease susceptibility and osmotic stress tolerance.
Infections
Role of common human TRIM5alpha variants in HIV-1 disease progression.
Infections
Role of potential COVID-19 immune system associated genes and the potential pathways linkage with type-2 diabetes.
Infections
Roles of TRIM32 in Corneal Epithelial Cells After Infection with Herpes Simplex Virus.
Infections
ROQUIN signalling pathways in innate and adaptive immunity.
Infections
Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.
Infections
Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid.
Infections
Selective autophagy limits cauliflower mosaic virus infection by NBR1-mediated targeting of viral capsid protein and particles.
Infections
Sequences related to SUMO interaction motifs in herpes simplex virus 1 protein ICP0 act cooperatively to stimulate virus infection.
Infections
Simian TRIM5alpha proteins reduce replication of herpes simplex virus.
Infections
Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
Infections
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.
Infections
Stabilized Human TRIM5 Alpha Protects Human T cells from HIV-1 Infection.
Infections
Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine.
Infections
Structural insights for HIV-1 therapeutic strategies targeting Vif.
Infections
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases.
Infections
Susceptibility to Repeated, Low-Dose, Rectal SHIVSF162P3 Challenge Is Independent of TRIM5 Genotype in Rhesus Macaques.
Infections
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Infections
The Arabidopsis MIEL1 E3 ligase negatively regulates ABA signalling by promoting protein turnover of MYB96.
Infections
The Arabidopsis transcriptional repressor ERF9 participates in resistance against necrotrophic fungi.
Infections
The chicken adenovirus Gam1 protein, an inhibitor of the sumoylation pathway, partially complements ICP0 null mutant HSV-1.
Infections
The Chlamydia pneumoniae invasin protein Pmp21 recruits the EGF receptor for host cell entry.
Infections
The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha.
Infections
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.
Infections
The E3 ubiquitin ligase HectD3 attenuates cardiac hypertrophy and inflammation in mice.
Infections
The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.
Infections
The E3 Ubiquitin Ligase Siah-1 Suppresses Avian Reovirus Infection by Targeting p10 for Degradation.
Infections
The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Virus Infection.
Infections
The E3 Ubiquitin Ligase Mind Bomb 1 Controls Adenovirus Genome Release at the Nuclear Pore Complex.
Infections
The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection.
Infections
The EHEC type III effector NleL is an E3 ubiquitin ligase that modulates pedestal formation.
Infections
The Human Adenovirus Type 5 E4orf6/E1B55K E3 Ubiquitin Ligase Complex Can Mimic E1A Effects on E2F.
Infections
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.
Infections
The Human IL-22 Receptor Is Regulated through the Action of the Novel E3 Ligase Subunit FBXW12, Which Functions as an Epithelial Growth Suppressor.
Infections
The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.
Infections
The Medicago truncatula E3 Ubiquitin Ligase PUB1 Interacts with the LYK3 Symbiotic Receptor and Negatively Regulates Infection and Nodulation.
Infections
The Pathogenic Effects of Fusobacterium nucleatum on the Proliferation, Osteogenic Differentiation, and Transcriptome of Osteoblasts.
Infections
The Pepper E3 Ubiquitin Ligase RING1 Gene, CaRING1, Is Required for Cell Death and the Salicylic Acid-Dependent Defense Response.
Infections
The poxvirus p28 virulence factor is an E3 ubiquitin ligase.
Infections
The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase.
Infections
The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association.
Infections
The TRIM5{alpha} Genotype of Rhesus Macaques Affects Acquisition of Simian Immunodeficiency Virus SIVsmE660 Infection after Repeated Limiting-Dose Intrarectal Challenge.
Infections
The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence.
Infections
Transcriptome analysis of liver elucidates key immune-related pathways in Nile tilapia Oreochromis niloticus following infection with tilapia lake virus.
Infections
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
Infections
TRIM22 inhibits respiratory syncytial virus replication by targeting JAK-STAT1/2 signaling.
Infections
TRIM22 regulates macrophage autophagy and enhances Mycobacterium tuberculosis clearance by targeting the nuclear factor-multiplicity ?B/beclin 1 pathway.
Infections
TRIM25 and its emerging RNA-binding roles in antiviral defense.
Infections
TRIM25 upregulation by Mycobacterium tuberculosis infection promotes intracellular survival of M.tb in RAW264.7 cells.
Infections
TRIM30? Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING.
Infections
TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Influenza A Virus Infection.
Infections
TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Vesicular Stomatitis Virus Infection.
Infections
TRIM5 allelic polymorphism in macaque species/populations of different geographic origins: its impact on SIV vaccine studies.
Infections
TRIM5 gene polymorphisms in HIV-1-infected patients and healthy controls from Northeastern Brazil.
Infections
TRIM5 is an innate immune sensor for the retrovirus capsid lattice.
Infections
TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.
Infections
TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species.
Infections
TRIM5? and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment.
Infections
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.
Infections
TRIM5alpha and TRIMCyp form apparent hexamers and their multimeric state is not affected by exposure to restriction-sensitive viruses or by treatment with pharmacological inhibitors.
Infections
TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity.
Infections
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells.
Infections
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys.
Infections
TRIM5alpha-independent anti-human immunodeficiency virus type 1 activity mediated by cyclophilin A in Old World monkey cells.
Infections
TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages.
Infections
TRIM5{alpha} Disrupts the Structure of Assembled HIV-1 Capsid Complexes in vitro.
Infections
TRIM62 From Chicken as a Negative Regulator of Reticuloendotheliosis Virus Replication.
Infections
TRIM62-mediated restriction of avian leukosis virus subgroup J replication is dependent on the SPRY domain.
Infections
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Infections
Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes.
Infections
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Infections
Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication.
Infections
Ubiquitin E3 Ligase c-Cbl Is a Host Negative Regulator of Nef Protein of HIV-1.
Infections
Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity.
Infections
Unique features of TRIM5alpha among closely related human TRIM family members.
Infections
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.
Infections
Viral E3 Ubiquitin Ligase-Mediated Degradation of a Cellular E3: Viral Mimicry of a Cellular Phosphorylation Mark Targets the RNF8 FHA Domain.
Infections
Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells.
Infections
Virus-specific effects of TRIM5?(rh) RING domain functions on restriction of retroviruses.
Infections
Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha.
Infections
Zebrafish TRIM25 Promotes Innate Immune Response to RGNNV Infection by Targeting 2CARD and RD Regions of RIG-I for K63-Linked Ubiquitination.
Infections
ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.
Infections
[Identification of the TRIM5/TRIMCyp heterozygous genotype in Macaca assamensis].
Infertility
A RING-type E3 ligase controls anther dehiscence by activating the jasmonate biosynthetic pathway gene DEFECTIVE IN ANTHER DEHISCENCE1 in Arabidopsis.
Infertility
Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers.
Infertility
Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.
Infertility
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Infertility
BARD1 expression during spermatogenesis is associated with apoptosis and hormonally regulated.
Infertility
BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
Infertility
Chronology of meiosis & synaptonemal complex abnormalities in normal & abnormal spermatogenesis.
Infertility
Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
Infertility
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Infertility
Pregnancy after in vitro fertilization-intracytoplasmic sperm injection obtained with a modified natural cycle in a BRCA1 mutation carrier.
Infertility
Preimplantation genetic diagnosis for inherited breast cancer: first clinical application and live birth in Spain.
Infertility
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Infertility
Silencing of unsynapsed meiotic chromosomes in the mouse.
Infertility
The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review.
Infertility
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Infertility, Female
Diminution of eIF4E activity suppresses parkin mutant phenotypes.
Infertility, Female
[Functions of FANCL in primordial germ cell formation and Fanconi anemia]
Infertility, Male
A homozygous RNF220 mutation leads to male infertility with small-headed sperm.
Infertility, Male
Deletion of the Parkin coregulated gene causes male sterility in the quaking(viable) mouse mutant.
Infertility, Male
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function.
Infertility, Male
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.
Infertility, Male
H2B ubiquitination regulates meiotic recombination by promoting chromatin relaxation.
Infertility, Male
Investigating the relationship between BRCA1 and BRCA2 genes methylation profile and sperm DNA fragmentation in infertile men.
Infertility, Male
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants.
Infertility, Male
Molecular analysis of the PArkin co-regulated gene and association with male infertility.
Infertility, Male
Parkin blushed by PINK1.
Infertility, Male
Parkin is protective against proteotoxic stress in a transgenic zebrafish model.
Infertility, Male
Parkin mutant in the fly is largely rescued by metal-responsive transcription factor (MTF-1).
Infertility, Male
The Arabidopsis U-box/ARM repeat E3 ligase AtPUB4 influences growth and degeneration of tapetal cells, and its mutation leads to conditional male sterility.
Inflammatory Bowel Diseases
E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Emerging views of mitophagy in immunity and autoimmune diseases.
Inflammatory Bowel Diseases
Ginsenoside Rb1 alleviates colitis in mice via activation of endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 signaling pathway.
Inflammatory Bowel Diseases
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Inflammatory Bowel Diseases
RNF20 and RNF40 regulate vitamin D receptor-dependent signaling in inflammatory bowel disease.
Inflammatory Bowel Diseases
The E3 ubiquitin ligase RNF186 and RNF186 risk variants regulate innate receptor-induced outcomes.
Inflammatory Bowel Diseases
The E3 ubiquitin ligase UBR5 interacts with TTC7A and may be associated with very early onset inflammatory bowel disease.
Inflammatory Bowel Diseases
Unique BIR domain sets determine inhibitor of apoptosis protein-driven cell death and NOD2 complex signal specificity.
Inflammatory Bowel Diseases
Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
[Protein ubiquitination on the regulation of inflammatory bowel disease].
Influenza in Birds
Duck PIAS2 Promotes H5N1 Avian Influenza Virus Replication Through Its SUMO E3 Ligase Activity.
Influenza, Human
A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes.
Influenza, Human
Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival.
Influenza, Human
E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3.
Influenza, Human
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Influenza, Human
InFLUencing host survival: cIAP2 tips the scales.
Influenza, Human
Influenza A Virus Infection Induces Muscle Wasting via IL-6 Regulation of the E3 Ubiquitin Ligase Atrogin-1.
Influenza, Human
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I.
Influenza, Human
Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy.
Influenza, Human
Influenza A virus TRIMs the type I interferon response.
Influenza, Human
Interactome Analysis of the NS1 Protein Encoded by Influenza A H1N1 Virus Reveals a Positive Regulatory Role of Host Protein PRP19 in Viral Replication.
Influenza, Human
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Influenza, Human
Molecular mechanism of influenza A NS1-mediated TRIM25 recognition and inhibition.
Influenza, Human
Mutations Conferring Increased Sensitivity to Tripartite Motif 22 Restriction Accumulated Progressively in the Nucleoprotein of Seasonal Influenza A (H1N1) Viruses between 1918 and 2009.
Influenza, Human
Nuclear TRIM25 Specifically Targets Influenza Virus Ribonucleoproteins to Block the Onset of RNA Chain Elongation.
Influenza, Human
Phosphatidylinositol-3-kinase (PI3K) is activated by influenza virus vRNA via the pathogen pattern receptor Rig-I to promote efficient type I interferon production.
Influenza, Human
Phosphorylation drives an apoptotic protein to activate antiapoptotic genes: paradigm of influenza A matrix 1 protein function.
Influenza, Human
RIPLET, and not TRIM25, is required for endogenous RIG-I-dependent antiviral responses.
Influenza, Human
Robust Lys63-Linked Ubiquitination of RIG-I Promotes Cytokine Eruption in Early Influenza B Virus Infection.
Influenza, Human
Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein.
Influenza, Human
Subcellular Localizations of RIG-I, TRIM25, and MAVS Complexes.
Influenza, Human
The nucleoprotein of influenza A virus induces p53 signaling and apoptosis via attenuation of host ubiquitin ligase RNF43.
Influenza, Human
TRIM proteins: another class of viral victims.
Influenza, Human
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
Influenza, Human
TRIM22. A Multitasking Antiviral Factor.
Influenza, Human
TRIM23 mediates virus-induced autophagy via activation of TBK1.
Influenza, Human
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Influenza, Human
Viral strategies for triggering and manipulating mitophagy.
Insulin Resistance
beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1.
Insulin Resistance
Breast cancer 1 (BrCa1) may be behind decreased lipogenesis in adipose tissue from obese subjects.
Insulin Resistance
Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.
Insulin Resistance
Evaluation of common variants in MG53 and the risk of type 2 diabetes and insulin resistance in Han Chinese.
Insulin Resistance
Genetic ablation of the c-Cbl ubiquitin ligase domain results in increased energy expenditure and improved insulin action.
Insulin Resistance
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
Insulin Resistance
HSP72 is a Mitochondrial Stress Sensor Critical for Parkin Action, Oxidative Metabolism, and Insulin Sensitivity in Skeletal Muscle.
Insulin Resistance
Infusion of adipose?derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats.
Insulin Resistance
Lack of the E3 Ubiquitin Ligase March1 Affects CD8 T Cell Fate and Exacerbates Insulin Resistance in Obese Mice.
Insulin Resistance
Liver-specific Prkn knockout mice are more susceptible to diet-induced hepatic steatosis and insulin resistance.
Insulin Resistance
Methylglyoxal attenuates insulin signaling and downregulates the enzymes involved in cholesterol biosynthesis.
Insulin Resistance
Mex3c mutation reduces adiposity partially through increasing physical activity.
Insulin Resistance
MG53 is a double-edged sword for human diseases.
Insulin Resistance
MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) Interaction Disruptor Sensitizes Insulin Signaling in Skeletal Muscle.
Insulin Resistance
MG53: Biological Function and Potential as a Therapeutic Target.
Insulin Resistance
Myostatin Induces Insulin Resistance via Casitas B-Lineage Lymphoma b (Cblb)-mediated Degradation of Insulin Receptor Substrate 1 (IRS1) Protein in Response to High Calorie Diet Intake.
Insulin Resistance
Parkin deficiency accentuates chronic alcohol intake-induced tissue injury and autophagy defects in brain, liver and skeletal muscle.
Insulin Resistance
RNF186 impairs insulin sensitivity by inducing ER stress in mouse primary hepatocytes.
Insulin Resistance
Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40.
Insulin Resistance
Targeting Trim69 alleviates high fat diet (HFD)-induced hippocampal injury in mice by inhibiting apoptosis and inflammation through ASK1 inactivation.
Insulin Resistance
The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.
Insulin Resistance
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
Insulin Resistance
The E3 ubiquitin ligase Pellino3 protects against obesity-induced inflammation and insulin resistance.
Insulin Resistance
The Pivotal Role of Mitsugumin 53 in Cardiovascular Diseases.
Insulin Resistance
Ubiquitin ligase Cbl-b and obesity-induced insulin resistance [Review].
Insulin Resistance
Upregulation of MG53 Induces Diabetic Cardiomyopathy Through Transcriptional Activation of Peroxisome Proliferation-Activated Receptor ?.
Insulinoma
Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas.
Intellectual Disability
Biallelic UBE4A loss-of-function variants cause intellectual disability and global developmental delay.
Intellectual Disability
Cereblon in health and disease.
Intellectual Disability
Functional Diversification of SRSF Protein Kinase to Control Ubiquitin-Dependent Neurodevelopmental Signaling.
Intellectual Disability
Functional modulation of AMP-activated protein kinase by cereblon.
Intellectual Disability
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
Intellectual Disability
HERC1 Ubiquitin Ligase Is Required for Hippocampal Learning and Memory.
Intellectual Disability
Impaired oxidative stress response characterizes HUWE1-promoted X-linked intellectual disability.
Intellectual Disability
Pathogenic variants in E3 ubiquitin ligase RLIM/RNF12 lead to a syndromic X-linked intellectual disability and behavior disorder.
Intellectual Disability
RNF12 X-Linked Intellectual Disability Mutations Disrupt E3 Ligase Activity and Neural Differentiation.
Intellectual Disability
RNF220/ZC4H2-mediated monoubiquitination of Phox2 is required for noradrenergic neuron development.
Intellectual Disability
Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation.
Intellectual Disability
The RING Domain of RING Finger 12 Efficiently Builds Degradative Ubiquitin Chains.
Intellectual Disability
The X-linked intellectual disability gene product and E3 ubiquitin ligase KLHL15 degrades doublecortin proteins to constrain neuronal dendritogenesis.
Intellectual Disability
Truncation of the E3 ubiquitin ligase component FBXO31 causes non-syndromic autosomal recessive intellectual disability in a Pakistani family.
Intellectual Disability
Ubiquitin ligase HUWE1 regulates axon branching through the Wnt/?-catenin pathway in a Drosophila model for intellectual disability.
Intervertebral Disc Degeneration
CRISPR/dCas9-Mediated Parkin Inhibition Impairs Mitophagy and Aggravates Apoptosis of Rat Nucleus Pulposus Cells Under Oxidative Stress.
Intervertebral Disc Degeneration
Mitophagy in degenerative joint diseases.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Iron Deficiencies
Iron-binding E3 ligase mediates iron response in plants by targeting basic helix-loop-helix transcription factors.
Iron Deficiencies
The bHLH transcription factor POPEYE regulates response to iron deficiency in Arabidopsis roots.
Irritable Bowel Syndrome
Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis.
Ischemic Attack, Transient
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Ischemic Stroke
Danhong injection facilitates recovery of post-stroke motion deficit via Parkin-enhanced mitochondrial function.
Ischemic Stroke
Mitochondrial E3 ubiquitin ligase 1 promotes brain injury by disturbing mitochondrial dynamics in a rat model of ischemic stroke.
Ischemic Stroke
Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke.
Ischemic Stroke
NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival.
Ischemic Stroke
Overexpression of BRCA1 in Neural Stem Cells Enhances Cell Survival and Functional Recovery after Transplantation into Experimental Ischemic Stroke.
Ischemic Stroke
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Ischemic Stroke
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
Joint Diseases
Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.
Joint Diseases
[Signal transduction of inflammatory synoviocytes in rheumatoid arthritis]
Keloid
A Role for the E3 Ubiquitin Ligase NEDD4 in Keloid Pathogenesis.
Keloid
Inactivating the ubiquitin ligase Parkin suppresses cell proliferation and induces apoptosis in human keloids.
Keloid
The Ubiquitin Proteasome System and Skin Fibrosis.
Kidney Neoplasms
A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.
Kidney Neoplasms
Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Kidney Neoplasms
Frequent genomic rearrangements of BRCA1 associated protein-1 (BAP1) gene in Japanese malignant mesothelioma-characterization of deletions at exon level.
Kidney Neoplasms
Identification and management of inherited cancer susceptibility.
Kidney Neoplasms
Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.
Kidney Neoplasms
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.
Kidney Neoplasms
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Kidney Neoplasms
RNF20 Suppresses Tumorigenesis by Inhibiting SREBP1c-PTTG1 Axis in Kidney Cancer.
Kidney Neoplasms
Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
Kidney Neoplasms
The sterol-sensing endoplasmic reticulum (ER) membrane protein TRC8 hampers ER to Golgi transport of sterol regulatory element-binding protein-2 (SREBP-2)/SREBP cleavage-activated protein and reduces SREBP-2 cleavage.
Kidney Neoplasms
The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER.
Kidney Neoplasms
TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation.
Kidney Neoplasms
Ufmylation Is Activated in Renal Cancer and Is Not Associated with von Hippel-Lindau Mutation.
Klatskin Tumor
Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma.
Klinefelter Syndrome
An updated review of epidemiology, risk factors, and management of male breast cancer.
Klinefelter Syndrome
Lobular carcinoma of the breast in an 85-year-old man.
Klinefelter Syndrome
Male breast cancer.
Klinefelter Syndrome
Vitamin D receptor gene polymorphisms and male breast cancer risk in Turkish population.
Kyphosis
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Lafora Disease
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Lafora Disease
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Lafora Disease
Glycogen hyperphosphorylation underlies lafora body formation.
Lafora Disease
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Lafora Disease
Lafora disease E3 ubiquitin ligase malin is recruited to the processing bodies and regulates the microRNA-mediated gene silencing process via the decapping enzyme Dcp1a.
Lafora Disease
Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Lafora Disease
Laforin-Malin Complex Degrades Polyglucosan Bodies in Concert with Glycogen Debranching Enzyme and Brain Isoform Glycogen Phosphorylase.
Lafora Disease
Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
Lafora Disease
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Lafora Disease
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Laminopathies
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Laminopathies
Lamin A ?exon9 mutation leads to telomere and chromatin defects but not genomic instability.
Language Development Disorders
PIAS4 is associated with macro/microcephaly in the novel interstitial 19p13.3 microdeletion/microduplication syndrome.
Laryngeal Neoplasms
Association between early-onset breast and laryngeal cancers.
Laryngeal Neoplasms
Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.
Latent Infection
Latency-Associated Nuclear Antigen E3 Ubiquitin Ligase Activity Impacts Gammaherpesvirus-Driven Germinal Center B Cell Proliferation.
Leiomyosarcoma
A role for BRCA1 in uterine leiomyosarcoma.
Leiomyosarcoma
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.
Leiomyosarcoma
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
Lentivirus Infections
SAMHD1: a novel antiviral factor in intrinsic immunity.
Lentivirus Infections
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.
Leprosy
Genetics of host response in leprosy.
Leprosy
Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
Leprosy
Post-translational modification of Parkin and its research progress in cancer.
Leukemia
"Trim"ming PolyQ proteins with engineered PML.
Leukemia
6-Formylindolo(3,2-b)Carbazole (FICZ) Modulates the Signalsome Responsible for RA-Induced Differentiation of HL-60 Myeloblastic Leukemia Cells.
Leukemia
A flow cytometric assay for the study of E3 ubiquitin ligase activity.
Leukemia
A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus.
Leukemia
A label-free quantitative proteomic strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
Leukemia
A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease.
Leukemia
A Potent Postentry Restriction to Primate Lentiviruses in a Yinpterochiropteran Bat.
Leukemia
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.
Leukemia
Adenovirus E1B 55-Kilodalton Protein Is a p53-SUMO1 E3 Ligase That Represses p53 and Stimulates Its Nuclear Export through Interactions with Promyelocytic Leukemia Nuclear Bodies.
Leukemia
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.
Leukemia
An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in MLL1-rearranged acute myeloid leukemia in mice.
Leukemia
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Leukemia
Analysis of alternative lengthening of telomere markers in BRCA1 defective cells.
Leukemia
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Leukemia
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
Leukemia
c-Cbl interacts with CD38 and promotes retinoic acid-induced differentiation and G0 arrest of human myeloblastic leukemia cells.
Leukemia
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
Leukemia
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
Leukemia
c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-? type II receptor.
Leukemia
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Leukemia
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Leukemia
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Leukemia
Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia.
Leukemia
Colostrum of Healthy Mothers Contains Broad Spectrum of Secretory IgA Autoantibodies.
Leukemia
Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice.
Leukemia
Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice.
Leukemia
Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues.
Leukemia
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Leukemia
Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.
Leukemia
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.
Leukemia
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.
Leukemia
Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
Leukemia
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia.
Leukemia
Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines.
Leukemia
Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.
Leukemia
GNL3L stabilizes the TRF1 complex and promotes mitotic transition.
Leukemia
Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation.
Leukemia
Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.
Leukemia
Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Leukemia
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Leukemia
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.
Leukemia
Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid.
Leukemia
Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha.
Leukemia
Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-monoblastic leukemia cells.
Leukemia
Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals.
Leukemia
Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury.
Leukemia
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Leukemia
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Leukemia
Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
Leukemia
MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair.
Leukemia
Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5alpha.
Leukemia
Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
Leukemia
Mutations in TOPORS Cause Autosomal Dominant Retinitis Pigmentosa with Perivascular Retinal Pigment Epithelium Atrophy.
Leukemia
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Leukemia
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Leukemia
Nuclear-cytoplasmic shuttling of a RING-IBR protein RBCK1 and its functional interaction with nuclear body proteins.
Leukemia
PALB2 (partner and localizer of BRCA2).
Leukemia
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Leukemia
PHOSPHORYLATION-DEPENDENT INTERACTION OF SATB1 AND PIAS1 DIRECTS SUMO-REGULATED CASPASE CLEAVAGE OF SATB1.
Leukemia
PML requirement for interferon-induced global cellular SUMOylation.
Leukemia
Proteasomal degradation of TRIM5alpha during retrovirus restriction.
Leukemia
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Leukemia
Proteomic Analysis of Medicinal Plant Calotropis Gigantea by insilico Peptide Mass Fingerprinting.
Leukemia
Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
Leukemia
Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7.
Leukemia
Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Leukemia
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Leukemia
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
Leukemia
Retrovirus restriction by TRIM5 proteins requires recognition of only a small fraction of viral capsid subunits.
Leukemia
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates.
Leukemia
Role of RNF20 in cancer development and progression - a comprehensive review.
Leukemia
Role of SUMO in RNF4-mediated PML degradation: PML sumoylation and phospho-switch control of its SUMO binding domain dissected in living cells"
Leukemia
SLAP2 Adaptor Binding Disrupts c-CBL Autoinhibition to Activate Ubiquitin Ligase Function.
Leukemia
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function.
Leukemia
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
Leukemia
The double life of MULE in preeclamptic and IUGR placentae.
Leukemia
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.
Leukemia
The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid.
Leukemia
The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.
Leukemia
The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.
Leukemia
The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.
Leukemia
The spectrum of genetic defects in chronic lymphocytic leukemia.
Leukemia
TRF1 averts chromatin remodelling, recombination and replication dependent-break induced replication at mouse telomeres.
Leukemia
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis.
Leukemia
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells.
Leukemia
Trim5alpha protein restricts both HIV-1 and murine leukemia virus.
Leukemia
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1.
Leukemia
Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha.
Leukemia, Erythroblastic, Acute
alpha4 phosphoprotein interacts with EDD E3 ubiquitin ligase and poly(A)-binding protein.
Leukemia, Erythroblastic, Acute
Expression of c-cbl proto-oncogene is modulated during differentiation but not during induction of proliferation.
Leukemia, Feline
Overexpression of feline tripartite motif-containing 25 interferes with the late stage of feline leukemia virus replication.
Leukemia, Lymphocytic, Chronic, B-Cell
A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Leukemia, Lymphocytic, Chronic, B-Cell
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.
Leukemia, Lymphocytic, Chronic, B-Cell
BIRC3 and BIRC5: multi-faceted inhibitors in cancer.
Leukemia, Lymphocytic, Chronic, B-Cell
BIRC3 mutations in chronic lymphocytic leukemia - uncommon and unfavorable.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Leukemia, Lymphocytic, Chronic, B-Cell
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Leukemia, Lymphocytic, Chronic, B-Cell
IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.
Leukemia, Lymphocytic, Chronic, B-Cell
Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
Leukemia, Lymphocytic, Chronic, B-Cell
NOTCH1, SF3B1, BIRC3 AND TP53 mutations in chronic lymphocytic leukemia patients undergoing first-line treatment: correlation with biological parameters and response to treatment.
Leukemia, Lymphocytic, Chronic, B-Cell
Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3.
Leukemia, Lymphocytic, Chronic, B-Cell
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2013.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of Oncogenic Kinase Bcr-Abl Impairs Mitotic Checkpoint and Promotes Aberrant Divisions and Resistance to Microtubule-Targeting Agents.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway.
Leukemia, Myeloid
A common environmental carcinogen unduly affects carriers of cancer mutations: Carriers of genetic mutations in a specific protective response are more susceptible to an environmental carcinogen.
Leukemia, Myeloid
A label-free quantitative proteomic strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
Leukemia, Myeloid
Chronic Deletion and Acute Knockdown of Parkin have Differential Responses to Acetaminophen-Induced Mitophagy and Liver Injury in Mice.
Leukemia, Myeloid
DNA damage induces down-regulation of Prp19 via impairing Prp19 stability in hepatocellular carcinoma cells.
Leukemia, Myeloid
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and a myeloproliferative disease.
Leukemia, Myeloid
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Leukemia, Myeloid
Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.
Leukemia, Myeloid
Shuttling imbalance of MLF1 results in p53 instability and increases susceptibility to oncogenic transformation.
Leukemia, Myeloid
The Cbl protooncogene product: from an enigmatic oncogene to center stage of signal transduction.
Leukemia, Myeloid
Tumor necrosis factor?related apoptosis?inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first?line chemotherapy.
Leukemia, Myeloid, Acute
A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Leukemia, Myeloid, Acute
BRCA1, PARP1 and ?H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Leukemia, Myeloid, Acute
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
Leukemia, Myeloid, Acute
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
Leukemia, Myeloid, Acute
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Leukemia, Myeloid, Acute
CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
E3 ligase SCFSKP2 ubiquitinates and degrades tumor suppressor C/EBP? in acute myeloid leukemia.
Leukemia, Myeloid, Acute
E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.
Leukemia, Myeloid, Acute
Gene expression analysis approach to establish possible links between Parkinson's disease, cancer and cardiovascular diseases.
Leukemia, Myeloid, Acute
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBP? to prevent Trib1-driven acute myeloid leukemia.
Leukemia, Myeloid, Acute
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.
Leukemia, Myeloid, Acute
Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting.
Leukemia, Myeloid, Acute
Stabilization of fatty acid synthesis enzyme acetyl-CoA carboxylase 1 suppresses acute myeloid leukemia development.
Leukemia, Myeloid, Acute
The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.
Leukemia, Myeloid, Acute
TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137.
Leukemia, Myelomonocytic, Chronic
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Leukemia, Myelomonocytic, Chronic
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Chronic
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Leukemia, Myelomonocytic, Juvenile
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Leukemia, Neutrophilic, Chronic
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia.
Leukemia, Promyelocytic, Acute
A label-free quantitative proteomic strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
Leukemia, Promyelocytic, Acute
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Leukemia, Promyelocytic, Acute
Role of SUMO in RNF4-mediated PML degradation: PML sumoylation and phospho-switch control of its SUMO binding domain dissected in living cells"
Leukemia, T-Cell
Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia.
Leukemia, T-Cell
The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.
Leukemia-Lymphoma, Adult T-Cell
The E3/E4 ubiquitin conjugation factor UBE4B interacts with and ubiquitinates the HTLV-1 Tax oncoprotein to promote NF-?B activation.
Leukoplakia
BRCA1 expression in leukoplakia and carcinoma of the tongue.
Lewy Body Disease
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Lewy Body Disease
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.
Lewy Body Disease
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
Lewy Body Disease
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
Lewy Body Disease
{alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE.
Li-Fraumeni Syndrome
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Li-Fraumeni Syndrome
Breast cancer predisposition syndromes.
Li-Fraumeni Syndrome
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Li-Fraumeni Syndrome
Familial sarcoma: challenging pedigrees.
Li-Fraumeni Syndrome
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Li-Fraumeni Syndrome
Genetic testing by cancer site: stomach.
Li-Fraumeni Syndrome
Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
Li-Fraumeni Syndrome
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Li-Fraumeni Syndrome
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Li-Fraumeni Syndrome
Hereditary breast cancer: practical pursuit for clinical translation.
Li-Fraumeni Syndrome
Hereditary common cancers: molecular and clinical genetics.
Li-Fraumeni Syndrome
Identification and management of inherited cancer susceptibility.
Li-Fraumeni Syndrome
Inheritance of cancer.
Li-Fraumeni Syndrome
Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Li-Fraumeni Syndrome
Management of women with a family history of breast cancer.
Li-Fraumeni Syndrome
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Li-Fraumeni Syndrome
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Li-Fraumeni Syndrome
Tumor suppressor loss in pituitary tumors.
Liddle Syndrome
ENaC and its regulatory proteins as drug targets for blood pressure control.
Lipoma
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Liposarcoma
Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity.
Liver Cirrhosis
E3 ubiquitin ligase synoviolin is involved in liver fibrogenesis.
Liver Cirrhosis
Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis.
Liver Cirrhosis
Identification of the inhibitory activity of walnut extract on the E3 ligase Syvn1.
Liver Cirrhosis
Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.
Liver Cirrhosis
Overexpression of ring finger protein 20 inhibits the progression of liver fibrosis via mediation of histone H2B lysine 120 ubiquitination.
Liver Cirrhosis
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Liver Cirrhosis
Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition.
Liver Cirrhosis
The NRF2?PGC?1? pathway activates kynurenine aminotransferase 4 via attenuation of an E3 ubiquitin ligase, synoviolin, in a cecal ligation/perforation?induced septic mouse model.
Liver Cirrhosis
TIM-4 interference in Kupffer cells against CCL4-induced liver fibrosis by mediating Akt1/Mitophagy signalling pathway.
Liver Cirrhosis
TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination.
Liver Cirrhosis, Biliary
Emerging views of mitophagy in immunity and autoimmune diseases.
Liver Diseases
Overexpression of ring finger protein 20 inhibits the progression of liver fibrosis via mediation of histone H2B lysine 120 ubiquitination.
Liver Diseases
Parkin deficiency prevents chronic ethanol-induced hepatic lipid accumulation through ?-catenin accumulation.
Liver Diseases
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Liver Diseases
Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases.
Liver Diseases
Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models.
Liver Neoplasms
cIAP2 via NF-?B signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Liver Neoplasms
Dysregulated PJA1-TGF-? signaling in cancer stem cell-associated liver cancers.
Liver Neoplasms
Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer.
Liver Neoplasms
Heat shock protein gp96 decreases p53 stability by regulating Mdm2 E3 ligase activity in liver cancer.
Liver Neoplasms
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.
Liver Neoplasms
Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-?B signaling pathway in liver cancer.
Liver Neoplasms
Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells.
Liver Neoplasms
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Liver Neoplasms
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Liver Neoplasms
Proliferation defects and genome instability in cells lacking Cul4A.
Liver Neoplasms
RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis.
Liver Neoplasms
Silencing of WWP2 inhibits adhesion, invasion, and migration in liver cancer cells.
Liver Neoplasms
The Neddylation-Cullin 2-RBX1 E3 Ligase Axis Targets Tumor Suppressor RhoB for Degradation in Liver Cancer.
Liver Neoplasms
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Lung Diseases
MID1-PP2A complex functions as new insights in human lung adenocarcinoma.
Lung Diseases
Tumor necrosis factor-alpha-induced lung cell expression of antiapoptotic genes TRAF1 and cIAP2.
Lung Injury
E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury.
Lung Injury
Lipoxin A4 reduces hyperoxia-induced lung injury in neonatal rats through PINK1 signaling pathway.
Lung Injury
Polydatin mediates Parkin-dependent mitophagy and protects against mitochondria-dependent apoptosis in acute respiratory distress syndrome.
Lung Neoplasms
A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes.
Lung Neoplasms
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.
Lung Neoplasms
A new efficient method to detect genetic interactions for lung cancer GWAS.
Lung Neoplasms
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Lung Neoplasms
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.
Lung Neoplasms
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Lung Neoplasms
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Lung Neoplasms
Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells.
Lung Neoplasms
Altered expression of microRNA-365 is related to the occurrence and development of non-small-cell lung cancer by inhibiting TRIM25 expression.
Lung Neoplasms
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
Lung Neoplasms
An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing.
Lung Neoplasms
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Lung Neoplasms
Application of Multilayer Evidence for Annotation of C-Terminal BRCA2 Variants.
Lung Neoplasms
Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer.
Lung Neoplasms
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
Lung Neoplasms
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Lung Neoplasms
Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer.
Lung Neoplasms
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Lung Neoplasms
BRCA1 and BRCA2 Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.
Lung Neoplasms
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Lung Neoplasms
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
Lung Neoplasms
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Lung Neoplasms
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
Lung Neoplasms
BRCA1: a new genomic marker for non-small-cell lung cancer.
Lung Neoplasms
BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer.
Lung Neoplasms
BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.
Lung Neoplasms
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Lung Neoplasms
Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors.
Lung Neoplasms
cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer.
Lung Neoplasms
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Lung Neoplasms
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
Lung Neoplasms
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Lung Neoplasms
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Neoplasms
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Lung Neoplasms
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.
Lung Neoplasms
Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase activity and inhibits lung cancer cell growth in response to type I interferon.
Lung Neoplasms
Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).
Lung Neoplasms
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Lung Neoplasms
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Lung Neoplasms
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Lung Neoplasms
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Lung Neoplasms
DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
Lung Neoplasms
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.
Lung Neoplasms
Drug Targeting of Genomic Instability in Multiple Myeloma.
Lung Neoplasms
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
Lung Neoplasms
E3 ubiquitin ligase Hakai regulates cell growth and invasion, and increases the chemosensitivity to cisplatin in non?small?cell lung cancer cells.
Lung Neoplasms
E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4.
Lung Neoplasms
E3 ubiquitin ligase TRIM7 negatively regulates NF-kappa B signaling pathway by degrading p65 in lung cancer.
Lung Neoplasms
E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-?/nuclear factor kappaB pathway.
Lung Neoplasms
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Lung Neoplasms
Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Lung Neoplasms
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Lung Neoplasms
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Lung Neoplasms
ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.
Lung Neoplasms
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Neoplasms
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Lung Neoplasms
ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
Lung Neoplasms
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Lung Neoplasms
Exosomes Derived From Macrophages Enhance Aerobic Glycolysis and Chemoresistance in Lung Cancer by Stabilizing c-Myc via the Inhibition of NEDD4L.
Lung Neoplasms
Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Lung Neoplasms
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
Lung Neoplasms
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Lung Neoplasms
Expression pattern of parkin isoforms in lung adenocarcinomas.
Lung Neoplasms
FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
Lung Neoplasms
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Lung Neoplasms
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Lung Neoplasms
Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer.
Lung Neoplasms
Genetic polymorphisms and haplotypes of BRCA1 gene associated with quality of life and survival among patients with non-small-cell lung cancer.
Lung Neoplasms
Genetic variants of BIRC3 and NRG1 in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival.
Lung Neoplasms
Germline mutations in young non-smoking women with lung adenocarcinoma.
Lung Neoplasms
Growth retardation and tumour inhibition by BRCA1.
Lung Neoplasms
High expression of lncRNA MEG3 participates in non-small cell lung cancer by regulating microRNA-7-5p.
Lung Neoplasms
High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Lung Neoplasms
Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
Lung Neoplasms
HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.
Lung Neoplasms
Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549.
Lung Neoplasms
In Silico and In Vitro Analysis of lncRNA XIST Reveals a Panel of Possible Lung Cancer Regulators and a Five-Gene Diagnostic Signature.
Lung Neoplasms
Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.
Lung Neoplasms
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
Lung Neoplasms
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Lung Neoplasms
Lipid metabolic pathways as lung cancer therapeutic targets: a computational study.
Lung Neoplasms
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
Lung Neoplasms
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Lung Neoplasms
MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
Lung Neoplasms
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
Lung Neoplasms
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Lung Neoplasms
Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease.
Lung Neoplasms
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
Lung Neoplasms
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Lung Neoplasms
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Lung Neoplasms
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
Lung Neoplasms
Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression.
Lung Neoplasms
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Lung Neoplasms
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Lung Neoplasms
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.
Lung Neoplasms
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Lung Neoplasms
Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
Lung Neoplasms
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer.
Lung Neoplasms
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Lung Neoplasms
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Lung Neoplasms
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Lung Neoplasms
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Lung Neoplasms
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations.
Lung Neoplasms
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Lung Neoplasms
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Lung Neoplasms
Prognostic significance of ERCC1, RRM1, TOP1, TOP2A, TYMS, TUBB3, GSTP1 AND BRCA1 mRNA expressions in patients with non-small-cell lung cancer receiving a platinum-based chemotherapy.
Lung Neoplasms
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lung Neoplasms
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.
Lung Neoplasms
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Lung Neoplasms
Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.
Lung Neoplasms
Regulation of autophagy flux by E3 ubiquitin ligase Pirh2 in lung cancer.
Lung Neoplasms
RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Lung Neoplasms
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
Lung Neoplasms
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
Lung Neoplasms
Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Lung Neoplasms
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
Lung Neoplasms
Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.
Lung Neoplasms
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Lung Neoplasms
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Lung Neoplasms
Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKI?.
Lung Neoplasms
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Lung Neoplasms
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.
Lung Neoplasms
Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Lung Neoplasms
The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
Lung Neoplasms
The E3 Ligase CHIP Mediates p21 Degradation to Maintain Radioresistance.
Lung Neoplasms
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Lung Neoplasms
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
Lung Neoplasms
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Lung Neoplasms
The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Lung Neoplasms
The role of BRCA1 in non-small cell lung cancer.
Lung Neoplasms
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Lung Neoplasms
TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer.
Lung Neoplasms
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
Lung Neoplasms
TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer.
Lung Neoplasms
TRIM59 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Upregulating Cell Cycle Related Proteins.
Lung Neoplasms
Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Lung Neoplasms
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Lung Neoplasms
Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Lung Neoplasms
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Lung Neoplasms
Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma.
Lung Neoplasms
UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
Lung Neoplasms
Upregulation of Neural Precursor Cell Expressed Developmentally Downregulated 4-1 is Associated with Poor Prognosis and Chemoresistance in Lung Adenocarcinoma.
Lung Neoplasms
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Lung Neoplasms
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Lung Neoplasms
[Detection of RRM1, ERCC1 and BRCA1 gene expression in non-small cell lung cancer tissues and peripheral blood by SYBR real-time fluorescent quantitative PCR].
Lung Neoplasms
[EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer].
Lung Neoplasms
[Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC].
Lung Neoplasms
[Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments]
Lung Neoplasms
[Relationship between the protein expression of ERCC1, BRCA, ?-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Lupus Erythematosus, Systemic
Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus.
Lupus Erythematosus, Systemic
E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
Lupus Erythematosus, Systemic
Emerging views of mitophagy in immunity and autoimmune diseases.
Lupus Erythematosus, Systemic
Lys63-Polyubiquitination by the E3 Ligase Casitas B-Lineage Lymphoma-b (Cbl-b) Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production.
Lupus Erythematosus, Systemic
Transcription factor RFX1 is ubiquitinated by E3 ligase STUB1 in systemic lupus erythematosus.
Lymphadenopathy
MRI and breast cancer: role in detection, diagnosis, and staging.
Lymphatic Metastasis
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Lymphatic Metastasis
BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer.
Lymphatic Metastasis
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Lymphatic Metastasis
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Lymphatic Metastasis
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
Lymphatic Metastasis
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Lymphatic Metastasis
Clinical implications for BRCA gene mutation in breast cancer.
Lymphatic Metastasis
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Lymphatic Metastasis
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Lymphatic Metastasis
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Lymphatic Metastasis
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Lymphatic Metastasis
Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Lymphatic Metastasis
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Lymphatic Metastasis
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
Lymphatic Metastasis
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Lymphatic Metastasis
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Lymphatic Metastasis
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Lymphatic Metastasis
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Lymphatic Metastasis
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Lymphatic Metastasis
Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Lymphatic Metastasis
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Lymphatic Metastasis
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
Lymphatic Metastasis
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Lymphatic Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphatic Metastasis
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Lymphatic Metastasis
Recurring Amplification at 11q22.1-q22.2 Locus Plays an Important Role in Lymph Node Metastasis and Radioresistance in OSCC.
Lymphatic Metastasis
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Lymphatic Metastasis
Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma.
Lymphatic Metastasis
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Lymphatic Metastasis
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
Lymphatic Metastasis
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
Lymphatic Metastasis
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Lymphocytic Choriomeningitis
Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection.
Lymphocytosis
Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
Lymphoma
53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
Lymphoma
?-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer.
Lymphoma
A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis.
Lymphoma
A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines.
Lymphoma
Absence of Grail promotes CD8(+) T cell anti-tumour activity.
Lymphoma
Activation of atypical protein kinase Czeta toward TC10 is regulated by high-fat diet and aerobic exercise in skeletal muscle.
Lymphoma
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Lymphoma
Alteration of BIRC3 and multiple other NF-?B pathway genes in splenic marginal zone lymphoma.
Lymphoma
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
Lymphoma
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Lymphoma
BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.
Lymphoma
BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response.
Lymphoma
Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.
Lymphoma
BRCA1 and BRCA2 germline mutations in lymphoma patients.
Lymphoma
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
Lymphoma
c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.
Lymphoma
c-Cbl Inhibition Improves Cardiac function and Survival in Response to Myocardial Ischemia.
Lymphoma
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Lymphoma
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
Lymphoma
c-Cbl Ubiquitin Ligase Regulates Focal Adhesion Protein Turnover and Myofibril Degeneration Induced by Neutrophil Protease Cathepsin G.
Lymphoma
c-Cbl, a ubiquitin E3 ligase that targets active ?-catenin: a novel layer of Wnt signaling regulation.
Lymphoma
c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action.
Lymphoma
c-Cbl-mediated ubiquitination of IRF3 negatively regulates IFN-? production and cellular antiviral response.
Lymphoma
Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin Resistance.
Lymphoma
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Lymphoma
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells.
Lymphoma
Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms.
Lymphoma
CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.
Lymphoma
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.
Lymphoma
cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.
Lymphoma
Complex Effects of Putative DRP-1 Inhibitors on Stress Responses in Mouse Heart and Rat Cardiomyoblasts.
Lymphoma
Correction for Pedersen et al., Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.
Lymphoma
Decreased protein levels of the c-Cbl protooncogene in murine AIDS.
Lymphoma
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Lymphoma
DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus.
Lymphoma
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA.
Lymphoma
Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration.
Lymphoma
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
Lymphoma
E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity.
Lymphoma
E3 ubiquitin ligase Cbl-b suppresses human ORMDL3 expression through STAT6 mediation.
Lymphoma
Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Lymphoma
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma
Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells.
Lymphoma
Increased expression of the Cbl family of E3 ubiquitin ligases decreases Interleukin-2 production in a rat model of peripheral neuropathy.
Lymphoma
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Lymphoma
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Lymphoma
Multipoint methylation analysis indicates a distinctive epigenetic phenotype among testicular germ cell tumors and testicular malignant lymphomas.
Lymphoma
NADPH Oxidase 1 Activity and ROS Generation Are Regulated by Grb2/Cbl-Mediated Proteasomal Degradation of NoxO1 in Colon Cancer Cells.
Lymphoma
Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.
Lymphoma
Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.
Lymphoma
Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice.
Lymphoma
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Lymphoma
PKC-theta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation.
Lymphoma
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Lymphoma
Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
Lymphoma
Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b.
Lymphoma
Regulator of epidermal growth factor signaling: Sprouty.
Lymphoma
Rsf?1 regulates malignant melanoma cell viability and chemoresistance via NF??B/Bcl?2 signaling.
Lymphoma
Silencing Autocrine Death: A Ubiquitin Ligase that Blocks Activation-Induced Cell Death in Cutaneous T-Cell Lymphoma.
Lymphoma
Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.
Lymphoma
Sp-CBL inhibits white spot syndrome virus replication by enhancing apoptosis in mud crab (Scylla paramamosain).
Lymphoma
Suppressed Expression of Cbl-b by NF-?B Mediates Icotinib Resistance in EGFR-mutant Non-Small-Cell Lung Cancer.
Lymphoma
T cell activation threshold regulated by E3 ubiquitin ligase Cbl-b determines fate of inducible regulatory T cells.
Lymphoma
Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Lymphoma
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Lymphoma
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Lymphoma
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
Lymphoma
The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination.
Lymphoma
The Cbl protooncogene product: from an enigmatic oncogene to center stage of signal transduction.
Lymphoma
The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
Lymphoma
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
Lymphoma
The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1.
Lymphoma
The role of aberrant proteolysis in lymphomagenesis.
Lymphoma
TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.
Lymphoma
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis.
Lymphoma
Ubiquitin ligase Cbl-b and obesity-induced insulin resistance [Review].
Lymphoma
ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.
Lymphoma
[Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance]
Lymphoma, B-Cell
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Lymphoma, B-Cell
Decreased protein levels of the c-Cbl protooncogene in murine AIDS.
Lymphoma, B-Cell
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
Lymphoma, B-Cell
Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
Lymphoma, B-Cell
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma, B-Cell
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).
Lymphoma, B-Cell
KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.
Lymphoma, B-Cell
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Lymphoma, B-Cell
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Lymphoma, B-Cell
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Lymphoma, B-Cell
Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1.
Lymphoma, B-Cell, Marginal Zone
Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.
Lymphoma, B-Cell, Marginal Zone
CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.
Lymphoma, B-Cell, Marginal Zone
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.
Lymphoma, B-Cell, Marginal Zone
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma, Follicular
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma, Large B-Cell, Diffuse
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma, Large B-Cell, Diffuse
Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.
Lymphoma, Large B-Cell, Diffuse
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Lymphoma, Large-Cell, Anaplastic
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells.
Lymphoma, Large-Cell, Anaplastic
cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.
Lymphoma, Mantle-Cell
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Lymphoma, Mantle-Cell
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA.
Lymphoma, Mantle-Cell
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Lymphoma, Mantle-Cell
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
Lymphoma, Mantle-Cell
The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1.
Lymphoma, Non-Hodgkin
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Lymphoma, Non-Hodgkin
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma, Non-Hodgkin
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Lymphoma, Primary Effusion
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Lymphoma, T-Cell, Cutaneous
A rearrangement of the c-cbl proto-oncogene in HUT78 T-lymphoma cells results in a truncated protein.
Lymphoma, T-Cell, Cutaneous
c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.
Lymphoma, T-Cell, Cutaneous
c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.
Lymphoproliferative Disorders
Unique BIR domain sets determine inhibitor of apoptosis protein-driven cell death and NOD2 complex signal specificity.
Lynch Syndrome II
Hereditary Factors in Gynecologic Cancer.
Machado-Joseph Disease
Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme.
Machado-Joseph Disease
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Malaria
Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads.
Malaria
Overexpression of the HECT ubiquitin ligase PfUT prolongs the intraerythrocytic cycle and reduces invasion efficiency of Plasmodium falciparum.
Malocclusion
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part I: evaluation of stomatognathic system in youth BRCA1 gene mutation carriers]
Mastitis
BRCA1: a new candidate gene for bovine mastitis and its association analysis between single nucleotide polymorphisms and milk somatic cell score.
Mastitis
Identification of Gene Modules and Hub Genes Involved in Mastitis Development Using a Systems Biology Approach.
Mastitis
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
Mastitis
Polymorphism in DNA repair gene BRCA1 associated with clinical mastitis and production traits in indigenous dairy cattle.
Mastocytosis
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and a myeloproliferative disease.
Measles
Inhibition of ubiquitination and stabilization of human ubiquitin E3 ligase PIRH2 by measles virus phosphoprotein.
Measles
Measles virus: evidence for association with lung cancer.
Measles
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Measles
Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling.
Measles
Viral strategies for triggering and manipulating mitophagy.
Medulloblastoma
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.
Medulloblastoma
RNF220 is required for cerebellum development and regulates medulloblastoma progression through epigenetic modulation of Shh signaling.
Medulloblastoma
Silencing of E3 ubiquitin ligase RNF8 enhances ionizing radiation sensitivity of 5 medulloblastoma cells by promoting the deubiquitination of PCNA.
Medulloblastoma
Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer.
Melanoma
"I Am Uncertain About What My Uncertainty Even Is": Men's Uncertainty and Information Management of Their BRCA-Related Cancer Risks.
Melanoma
A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.
Melanoma
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
Melanoma
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
Melanoma
A population-based analysis of germline BAP1 mutations in melanoma.
Melanoma
Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin.
Melanoma
ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation.
Melanoma
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Melanoma
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Melanoma
Bovine Delta Papillomavirus E5 Oncoprotein Interacts With TRIM25 and Hampers Antiviral Innate Immune Response Mediated by RIG-I-Like Receptors.
Melanoma
BRCA1 gene mutation in thymic malignant melanoma.
Melanoma
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Melanoma
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Melanoma
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
Melanoma
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Melanoma
Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance.
Melanoma
Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.
Melanoma
CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9.
Melanoma
CtBP1 Is Expressed in Melanoma and Represses the Transcription of p16INK4a and Brca1.
Melanoma
Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells.
Melanoma
DEAF1 Is a Pellino1-interacting Protein Required for Interferon Production by Sendai Virus and Double-stranded RNA.
Melanoma
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Melanoma
Differential expression of lncRNAs and predicted target genes in normal mouse melanocytes and B16 cells.
Melanoma
Digital Image Analysis of BAP-1 Accurately Predicts Uveal Melanoma Metastasis.
Melanoma
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
Melanoma
E2F1-dependent oncogenic addiction of melanoma cells to MDM2.
Melanoma
E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion.
Melanoma
E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Melanoma
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Melanoma
Emerging views of mitophagy in immunity and autoimmune diseases.
Melanoma
Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders.
Melanoma
Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Melanoma
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Melanoma
Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their c-Myc and p53 substrates in patients with dysplastic nevi or melanoma.
Melanoma
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Melanoma
Frequent genomic rearrangements of BRCA1 associated protein-1 (BAP1) gene in Japanese malignant mesothelioma-characterization of deletions at exon level.
Melanoma
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Melanoma
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Melanoma
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Melanoma
Genome-wide screening identifies novel genes and biological processes implicated in cisplatin resistance.
Melanoma
Genomic characterisation of acral melanoma cell lines.
Melanoma
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Melanoma
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
Melanoma
Germline mutations predisposing to melanoma.
Melanoma
Hereditary common cancers: molecular and clinical genetics.
Melanoma
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Melanoma
Identification of a Novel BRCA1 Alteration in Recurrent Melanocytoma Resulting in Increased Proliferation.
Melanoma
Inherited predisposition to cancer: a historical overview.
Melanoma
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Melanoma
MAGE-D1 regulates expression of depression-like behavior through serotonin transporter ubiquitylation.
Melanoma
Mahogunin Ring Finger 1 Is Required for Genomic Stability and Modulates the Malignant Phenotype of Melanoma Cells.
Melanoma
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Melanoma
Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
Melanoma
Melanoma cells express elevated levels of phosphorylated histone H2AX foci.
Melanoma
Melanoma predisposition-A limited role for germline BRCA1 and BRCA2 variants.
Melanoma
NEDD4 Negatively Regulates GITR via Ubiquitination in Immune Microenvironment of Melanoma.
Melanoma
PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Melanoma
Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.
Melanoma
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Melanoma
Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma.
Melanoma
Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Melanoma
Regulation of BRCA1 by protein degradation.
Melanoma
Regulation of MDA5-MAVS Antiviral Signaling Axis by TRIM25 through TRAF6-mediated NF-?B Activation.
Melanoma
Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7? modulates melanoma cell migration.
Melanoma
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Melanoma
Riok3 inhibits the antiviral immune response by facilitating TRIM40-mediated RIG-I and MDA5 degradation.
Melanoma
Skin Cancer Risk in BRCA1/2 Mutation Carriers.
Melanoma
The association between Parkinson's disease and melanoma.
Melanoma
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth.
Melanoma
The FBXO4 tumor suppressor functions as a barrier to BrafV600E-dependent metastatic melanoma.
Melanoma
The MGRN1 E3 ubiquitin-ligase inhibits signaling from melanocortin receptors by competition with Galphas.
Melanoma
The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells.
Melanoma
The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer.
Melanoma
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.
Melanoma
The Zinc-finger AN1-type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Melanoma
TRIM25 in the Regulation of the Antiviral Innate Immunity.
Melanoma
Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation.
Memory Disorders
Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease.
Memory Disorders
DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice.
Meningioma
A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.
Meningioma
A population-based analysis of germline BAP1 mutations in melanoma.
Meningioma
Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas.
Meningioma
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Meningioma
Hypermethylation of BRCA1 Gene in Meningioma in Elderly Males.
Meningioma
Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
Meningioma
Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development.
Meningioma
No evidence for germline PTEN mutations in families with breast and brain tumours.
Meningomyelocele
The Impact of BRCA1 on Spina Bifida Meningomyelocele Lesions.
Menopause, Premature
Age of natural menopause onset in BRCA1/2 carriers - systematic review and meta-analysis.
Menopause, Premature
Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.
Menopause, Premature
Premature menopause in patients with BRCA1 gene mutation.
Mental Retardation, X-Linked
Rescue of the genetically engineered Cul4b mutant mouse as a potential model for human X-linked mental retardation.
Mental Retardation, X-Linked
Targeted deep resequencing identifies MID2 mutation for X-linked intellectual disability with varied disease severity in a large kindred from India.
MERRF Syndrome
Parkin-mediated mitophagy and autophagy flux disruption in cellular models of MERRF syndrome.
Mesothelioma
A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.
Mesothelioma
A population-based analysis of germline BAP1 mutations in melanoma.
Mesothelioma
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Mesothelioma
BRCA1 is an essential mediator of vinorelbine induced apoptosis in mesothelioma.
Mesothelioma
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Mesothelioma
Germline BAP1 mutations predispose to malignant mesothelioma.
Mesothelioma
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
Mesothelioma
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Mesothelioma
Malignant Mesothelioma: Time to Translate?
Mesothelioma
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Mesothelioma
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
Mesothelioma
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Mesothelioma, Malignant
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Mesothelioma, Malignant
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Mesothelioma, Malignant
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Mesothelioma, Malignant
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Mesothelioma, Malignant
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
Mesothelioma, Malignant
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
Mesothelioma, Malignant
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
Metabolic Diseases
MG53 is a double-edged sword for human diseases.
Metabolic Diseases
MG53: Biological Function and Potential as a Therapeutic Target.
Metabolic Diseases
RNF186 impairs insulin sensitivity by inducing ER stress in mouse primary hepatocytes.
Metabolic Diseases
The E3 ubiquitin ligase TRIM25 regulates adipocyte differentiation via proteasome-mediated degradation of PPAR?.
Metabolic Syndrome
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Metabolic Syndrome
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
Metabolic Syndrome
Loss of the E3 ubiquitin ligase MKRN1 represses diet-induced metabolic syndrome through AMPK activation.
Metabolic Syndrome
SCFJFK is functionally linked to obesity and metabolic syndrome.
Metrorrhagia
Creating highly dense and uniform protein and DNA microarrays through photolithography and plasma modification of glass substrates.
Microcephaly
Coregulation of FANCA and BRCA1 in human cells.
Microcephaly
Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.
Microcephaly
Identification of microcephalin, a protein implicated in determining the size of the human brain.
Microcephaly
Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair.
Microcephaly
Systematic detection of brain protein-coding genes under positive selection during primate evolution and their roles in cognition.
Mitochondrial Diseases
AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging.
Mitochondrial Diseases
Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells.
Mitochondrial Diseases
Peripheral neuropathy in Parkinson's disease.
Motor Neuron Disease
[Revisit to Kii ALS--the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology]
Mouth Neoplasms
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Mouth Neoplasms
E3 ubiquitin ligase, RNF139, inhibits the progression of tongue cancer.
Mouth Neoplasms
E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Mouth Neoplasms
Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway.
Mouth Neoplasms
The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
Movement Disorders
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease.
Movement Disorders
Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain.
Movement Disorders
Genetic Variations and Neuropathologic Features of Patients with PRKN Mutations.
Movement Disorders
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
Movement Disorders
Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease.
Movement Disorders
Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An (18)F-dopa PET progression study.
Movement Disorders
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
Movement Disorders
parkin mutation analysis in clinic patients with early-onset Parkinson's disease.
Movement Disorders
Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism.
Movement Disorders
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Movement Disorders
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Moyamoya Disease
Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism.
Moyamoya Disease
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
Mucocele
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Mucositis
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.
Mulibrey Nanism
TRIM37 defective in mulibrey nanism is a novel RING finger ubiquitin E3 ligase.
Mulibrey Nanism
TRIM37 prevents formation of centriolar protein assemblies by regulating Centrobin.
Multiple Endocrine Neoplasia
Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation.
Multiple Endocrine Neoplasia
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Multiple Endocrine Neoplasia Type 1
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Multiple Endocrine Neoplasia Type 2a
Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation.
Multiple Myeloma
1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
Multiple Myeloma
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Multiple Myeloma
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Multiple Myeloma
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Multiple Myeloma
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Multiple Myeloma
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Multiple Myeloma
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA.
Multiple Myeloma
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Multiple Myeloma
Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V.
Multiple Myeloma
Homo-PROTACs for the Chemical Knockdown of Cereblon.
Multiple Myeloma
IAP antagonists induce anti-tumor immunity in multiple myeloma.
Multiple Myeloma
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Multiple Myeloma
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Multiple Myeloma
IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.
Multiple Myeloma
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment.
Multiple Myeloma
Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
Multiple Myeloma
Novel immunomodulatory drugs and neo-substrates.
Multiple Myeloma
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Multiple Myeloma
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Multiple Myeloma
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Multiple Myeloma
Targeting oncoproteins with a positive selection assay for protein degraders.
Multiple Myeloma
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
Multiple Myeloma
The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.
Multiple Myeloma
The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1.
Multiple Myeloma
[Expression down-regulation of c-Cbl and Cbl-b genes in peripheral blood mononuclear cells from multiple myeloma patients].
Multiple Sclerosis
A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
Multiple Sclerosis
Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification of a single-nucleotide polymorphism that impacts TRIM22 function.
Multiple Sclerosis
Co-occurrence of multiple sclerosis and cancer in a BRCA1 positive family.
Multiple Sclerosis
Evaluation of the Diagnostic and Predictive Value of Serum Levels of ANT1, ATG5, and Parkin in Multiple Sclerosis.
Multiple Sclerosis
Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.
Multiple Sclerosis
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Multiple Sclerosis
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Multiple Sclerosis
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Multiple Sclerosis
Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study.
Multiple Sclerosis
The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1.
Multiple System Atrophy
Altered ?-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
Multiple System Atrophy
LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Multiple System Atrophy
Mutational analysis of parkin and PINK1 in multiple system atrophy.
Multiple System Atrophy
Pael-R is accumulated in Lewy bodies of Parkinson's disease.
Multiple System Atrophy
Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson's disease.
Murine Acquired Immunodeficiency Syndrome
Decreased protein levels of the c-Cbl protooncogene in murine AIDS.
Muscle Hypotonia
De novo variants in SIAH1, encoding an E3 ubiquitin ligase, are associated with developmental delay, hypotonia and dysmorphic features.
Muscle Rigidity
Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).
Muscle Spasticity
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Muscle Weakness
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Muscle Weakness
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
Muscular Atrophy
A Discovery of a Genetic Mutation Causing Reduction of Atrogin-1 Expression in Broiler Chicken Muscle.
Muscular Atrophy
A subset of microRNAs in the Dlk1-Dio3 cluster regulates age-associated muscle atrophy by targeting Atrogin-1.
Muscular Atrophy
Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression.
Muscular Atrophy
Aspirin alleviates denervation-induced muscle atrophy via regulating the Sirt1/PGC-1? axis and STAT3 signaling.
Muscular Atrophy
Characterisation and differential regulation of MAFbx/Atrogin-1 alpha and beta transcripts in skeletal muscle of Atlantic salmon (Salmo salar).
Muscular Atrophy
CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins.
Muscular Atrophy
Continuous administration of poloxamer 188 reduces overload-induced muscular atrophy in dysferlin-deficient SJL mice.
Muscular Atrophy
Dexamethasone exacerbates cisplatin-induced muscle atrophy.
Muscular Atrophy
Dkk3 dependent transcriptional regulation controls age related skeletal muscle atrophy.
Muscular Atrophy
Effect of dexamethasone on the expression of atrogin-1/MAFbx in chick skeletal muscle.
Muscular Atrophy
Effects of Insulin-Like Growth Factor-I on the Expression of Atrogin-1/MAFbx in Chick Myotube Cultures.
Muscular Atrophy
Endogenous muscle atrophy F-box is involved in the development of cardiac rupture after myocardial infarction.
Muscular Atrophy
Endogenous muscle atrophy F-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-kappaB.
Muscular Atrophy
Exercise training has beneficial anti-atrophy effects by inhibiting oxidative stress-induced MuRF1 upregulation in rats with diabetes.
Muscular Atrophy
FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.
Muscular Atrophy
HDAC4 Knockdown Alleviates Denervation-Induced Muscle Atrophy by Inhibiting Myogenin-Dependent Atrogene Activation.
Muscular Atrophy
Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice.
Muscular Atrophy
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice.
Muscular Atrophy
Inhibition of Atrogin-1/MAFbx Expression by Adenovirus-Delivered Small Hairpin RNAs Attenuates Muscle Atrophy in Fasting Mice.
Muscular Atrophy
Insulin and amino acid availability regulate atrogin-1 in avian QT6 cells.
Muscular Atrophy
Intermittent reloading attenuates muscle atrophy through modulating Akt/mTOR pathway.
Muscular Atrophy
Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway.
Muscular Atrophy
Leucine attenuates skeletal muscle wasting via inhibition of ubiquitin ligases.
Muscular Atrophy
Loss of Parkin Impairs Mitochondrial Function and Leads to Muscle Atrophy.
Muscular Atrophy
Maintenance of muscle mass and load-induced growth in Muscle RING Finger 1 null mice with age.
Muscular Atrophy
MFB-1, an F-box-type ubiquitin ligase, regulates TGF-beta signalling.
Muscular Atrophy
MicroRNA351 targeting TRAF6 alleviates dexamethasone-induced myotube atrophy.
Muscular Atrophy
Molecular characterization of atrogin-1/F-box protein-32 (FBXO32) and F-box protein-25 (FBXO25) in rainbow trout (Oncorhynchus mykiss): Expression across tissues in response to feed deprivation.
Muscular Atrophy
MURF contributes to skeletal muscle atrophy through suppressing autophagy.
Muscular Atrophy
MuRF1/TRIM63, Master Regulator of Muscle Mass.
Muscular Atrophy
Opposite roles of myocardin and atrogin-1 in L6 myoblast differentiation.
Muscular Atrophy
P38?-MAPK Signaling Inhibition Attenuates Soleus Atrophy during Early Stages of Muscle Unloading.
Muscular Atrophy
Parkin Overexpression Attenuates Sepsis-Induced Muscle Wasting.
Muscular Atrophy
Ret finger protein mediates Pax7-induced ubiquitination of MyoD in skeletal muscle atrophy.
Muscular Atrophy
Role of altered proteostasis network in chronic hypobaric hypoxia induced skeletal muscle atrophy.
Muscular Atrophy
Sirtuin 3 deficiency accelerates Angiotensin II-induced skeletal muscle atrophy.
Muscular Atrophy
Skeletal muscle in MuRF1 null mice is not spared in low-gravity conditions, indicating atrophy proceeds by unique mechanisms in space.
Muscular Atrophy
Targeting the Ubiquitin E3 Ligase MuRF1 to Inhibit Muscle Atrophy.
Muscular Atrophy
The E3 Ubiquitin Ligase TRAF6 Intercedes in Starvation-Induced Skeletal Muscle Atrophy through Multiple Mechanisms.
Muscular Atrophy
The E3 ubiquitin ligase TRIM62 and inflammation-induced skeletal muscle atrophy.
Muscular Atrophy
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Muscular Atrophy
The regulation of Akt and FoxO transcription factors during dehydration in the African clawed frog (Xenopus laevis).
Muscular Atrophy
UBR5 is a novel E3 ubiquitin ligase involved in skeletal muscle hypertrophy and recovery from atrophy.
Muscular Atrophy
Unexpected regulation pattern of the IKK?/NF-?B/MuRF1 pathway with remarkable muscle plasticity in the Daurian ground squirrel (Spermophilus dauricus).
Muscular Atrophy, Spinal
Genetic zebrafish models of neurodegenerative diseases.
Muscular Diseases
AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging.
Muscular Diseases
Deficiency of the E3 ubiquitin ligase TRIM32 in mice leads to a myopathy with a neurogenic component.
Muscular Diseases
Impaired muscle morphology in a Drosophila model of myosin storage myopathy was supressed by overexpression of an E3 ubiquitin ligase.
Muscular Diseases
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Muscular Diseases
Mitochondrial pathology in muscle of a patient with a novel parkin mutation.
Muscular Diseases
Mutations outside the N-terminal part of RBCK1 may cause polyglucosan body myopathy with immunological dysfunction: expanding the genotype-phenotype spectrum.
Muscular Diseases
Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis.
Muscular Diseases
Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.
Muscular Diseases
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
Muscular Diseases
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Muscular Diseases
Update Review about Metabolic Myopathies.
Muscular Dystrophies
Analysis of the Zn-Binding Domains of TRIM32, the E3 Ubiquitin Ligase Mutated in Limb Girdle Muscular Dystrophy 2H.
Muscular Dystrophies
Generation of the short TRIM32 isoform is regulated by Lys 247 acetylation and a PEST sequence.
Muscular Dystrophies
Interaction with the Bardet-Biedl Gene Product TRIM32/BBS11 Modifies the Half-life and Localization of Glis2/NPHP7.
Muscular Dystrophies
The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2.
Muscular Dystrophies
TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF{alpha})-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP).
Muscular Dystrophies, Limb-Girdle
Analysis of the Zn-Binding Domains of TRIM32, the E3 Ubiquitin Ligase Mutated in Limb Girdle Muscular Dystrophy 2H.
Muscular Dystrophies, Limb-Girdle
Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H.
Muscular Dystrophies, Limb-Girdle
The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2.
Muscular Dystrophy, Duchenne
Detection of exon skipping events in BRCA1 RNA using MLPA kit P002.
Mycoses
CERBERUS and NSP1 of Lotus japonicus are Common Symbiosis Genes that Modulate Arbuscular Mycorrhiza Development.
Mycoses
Classification of barley U-box E3 ligases and their expression patterns in response to drought and pathogen stresses.
Mycoses
The KEEP ON GOING protein of Arabidopsis regulates intracellular protein trafficking and is degraded during fungal infection.
Myelodysplastic Syndromes
A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Myelodysplastic Syndromes
Acquired uniparental disomy and c-CBL mutation in myelodysplastic syndromes.
Myelodysplastic Syndromes
Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?
Myelodysplastic Syndromes
DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome.
Myeloproliferative Disorders
Role of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression.
Myocardial Infarction
Apigenin attenuates myocardial infarction-induced cardiomyocyte injury by modulating Parkin-mediated mitochondrial autophagy.
Myocardial Infarction
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
Myocardial Infarction
Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction.
Myocardial Infarction
Parkin Regulates Mitochondrial Autophagy After Myocardial Infarction in Rats.
Myocardial Infarction
PINK1 Is Dispensable for Mitochondrial Recruitment of Parkin and Activation of Mitophagy in Cardiac Myocytes.
Myocardial Infarction
The role of Parkin protein in cardiac function and ventricular remodeling in myocardial infarction rats.
Myocardial Infarction
[Overexpression of PPENK reduces myocardial ischemia reperfusion injury by promoting mitophagy in rats].
Myocardial Ischemia
c-Cbl Inhibition Improves Cardiac function and Survival in Response to Myocardial Ischemia.
Myocardial Ischemia
c-Cbl inhibition: A novel therapeutic approach for attenuating myocardial ischemia and reperfusion injury.
Myocardial Ischemia
Natural compound methyl protodioscin protects rat brain from ischemia/reperfusion injury through regulation of Mul1/SOD2 pathway.
Myoclonic Epilepsies, Progressive
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Myoclonic Epilepsies, Progressive
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Myoclonic Epilepsies, Progressive
Genetics of the epilepsies.
Myoclonic Epilepsies, Progressive
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Myoclonus
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Myoma
[Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen]
Myositis
Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers.
Myositis
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
Myositis
The ER-Bound RING Finger Protein 5 (RNF5/RMA1) Causes Degenerative Myopathy in Transgenic Mice and Is Deregulated in Inclusion Body Myositis.
Myositis, Inclusion Body
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
Myxoma
The poxviral scrapin MV-LAP requires a myxoma viral infection context to efficiently downregulate MHC-I molecules.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Narcolepsy
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Nasal Polyps
Expression and distributional patterns of the inhibitor of apoptosis protein family and caspase 3 in nasal polyps.
Nasopharyngeal Carcinoma
EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1.
Nasopharyngeal Carcinoma
Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy.
Nasopharyngeal Carcinoma
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.
Nasopharyngeal Carcinoma
Silencing UBE4B induces nasopharyngeal carcinoma apoptosis through the activation of caspase3 and p53.
Nasopharyngeal Carcinoma
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.
Nasopharyngeal Neoplasms
Parkin enhances sensitivity of paclitaxel to NPC by arresting cell cycle.
Neoplasm Metastasis
A Germline Mutation in the BRCA1 3UTR Variant Predicts Susceptibility to Breast Cancer in a Saudi Arabian Population
Neoplasm Metastasis
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
Neoplasm Metastasis
A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis.
Neoplasm Metastasis
A Novel Signature of CCNF-Associated E3 Ligases Collaborate and Counter Each Other in Breast Cancer.
Neoplasm Metastasis
A novel Ubc9 -dependent pathway regulates SIRT1- ER-? Axis and BRCA1-associated TNBC lung metastasis.
Neoplasm Metastasis
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
Neoplasm Metastasis
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
Neoplasm Metastasis
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.
Neoplasm Metastasis
An Integrative Omics Approach Reveals Involvement of BRCA1 in Hepatic Metastatic Progression of Colorectal Cancer.
Neoplasm Metastasis
An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82.
Neoplasm Metastasis
Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion.
Neoplasm Metastasis
ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation.
Neoplasm Metastasis
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Neoplasm Metastasis
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Neoplasm Metastasis
Basal phenotype breast cancer: implications for treatment and prognosis.
Neoplasm Metastasis
BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer.
Neoplasm Metastasis
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships.
Neoplasm Metastasis
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
Neoplasm Metastasis
BRCA1 expression levels predict distant metastasis of sporadic breast cancers.
Neoplasm Metastasis
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
Neoplasm Metastasis
BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Neoplasm Metastasis
Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF).
Neoplasm Metastasis
Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex.
Neoplasm Metastasis
BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.
Neoplasm Metastasis
C-terminus of Hsc70-interacting protein regulates profilin1 and breast cancer cell migration.
Neoplasm Metastasis
Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma.
Neoplasm Metastasis
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Neoplasm Metastasis
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Neoplasm Metastasis
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Neoplasm Metastasis
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
Neoplasm Metastasis
CHIP regulates osteoclast formation through promoting TRAF6 protein degradation.
Neoplasm Metastasis
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
Neoplasm Metastasis
circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.
Neoplasm Metastasis
Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Neoplasm Metastasis
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Neoplasm Metastasis
Clinical implications for BRCA gene mutation in breast cancer.
Neoplasm Metastasis
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Neoplasm Metastasis
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.
Neoplasm Metastasis
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Neoplasm Metastasis
Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer.
Neoplasm Metastasis
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Neoplasm Metastasis
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Neoplasm Metastasis
Computational exploration of the activated pathways associated with DNA damage response in breast cancer.
Neoplasm Metastasis
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Neoplasm Metastasis
Corrigendum: E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Neoplasm Metastasis
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Neoplasm Metastasis
Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin ?1.
Neoplasm Metastasis
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Neoplasm Metastasis
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Neoplasm Metastasis
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Neoplasm Metastasis
Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Neoplasm Metastasis
Digital Image Analysis of BAP-1 Accurately Predicts Uveal Melanoma Metastasis.
Neoplasm Metastasis
Distinct Ring1b complexes defined by DEAD-box helicases and EMT transcription factors synergistically enhance E-cadherin silencing in breast cancer.
Neoplasm Metastasis
DNA damage response genes and the development of cancer metastasis.
Neoplasm Metastasis
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
Neoplasm Metastasis
E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Neoplasm Metastasis
E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
Neoplasm Metastasis
E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4.
Neoplasm Metastasis
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
Neoplasm Metastasis
E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Neoplasm Metastasis
ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
Neoplasm Metastasis
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Neoplasm Metastasis
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
Neoplasm Metastasis
Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis.
Neoplasm Metastasis
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
Neoplasm Metastasis
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Neoplasm Metastasis
Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
Neoplasm Metastasis
Exosomal TRIM3 is a novel marker and therapy target for gastric cancer.
Neoplasm Metastasis
Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Neoplasm Metastasis
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Neoplasm Metastasis
Extent of breast cancer type 1 promoter methylation correlates with clinicopathological features in breast cancers.
Neoplasm Metastasis
F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
Neoplasm Metastasis
FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.
Neoplasm Metastasis
Formal modeling and analysis of ER-? associated Biological Regulatory Network in breast cancer.
Neoplasm Metastasis
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Neoplasm Metastasis
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
Neoplasm Metastasis
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Neoplasm Metastasis
Human FBXL8 Is a Novel E3 Ligase Which Promotes BRCA Metastasis by Stimulating Pro-Tumorigenic Cytokines and Inhibiting Tumor Suppressors.
Neoplasm Metastasis
Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
Neoplasm Metastasis
Hypermethylation of SHISA3 Promotes Nasopharyngeal Carcinoma Metastasis by Reducing SGSM1 Stability.
Neoplasm Metastasis
Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Neoplasm Metastasis
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Neoplasm Metastasis
Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells.
Neoplasm Metastasis
Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma.
Neoplasm Metastasis
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Neoplasm Metastasis
Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
Neoplasm Metastasis
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Neoplasm Metastasis
Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.
Neoplasm Metastasis
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Neoplasm Metastasis
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Neoplasm Metastasis
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Neoplasm Metastasis
Increased incidence of brain metastases in BRCA1-related ovarian cancers.
Neoplasm Metastasis
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Neoplasm Metastasis
Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.
Neoplasm Metastasis
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Neoplasm Metastasis
Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey.
Neoplasm Metastasis
LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.
Neoplasm Metastasis
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Neoplasm Metastasis
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Neoplasm Metastasis
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Neoplasm Metastasis
Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior.
Neoplasm Metastasis
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Neoplasm Metastasis
Loss of ZBRK1 Contributes to the Increase of KAP1 and Promotes KAP1-Mediated Metastasis and Invasion in Cervical Cancer.
Neoplasm Metastasis
Mechanism of TRIM25 mediated ubiquitination of metastasis associated protein (MTA) 1 in normal liver cells.
Neoplasm Metastasis
Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine.
Neoplasm Metastasis
Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Neoplasm Metastasis
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Neoplasm Metastasis
MEX3C promotes osteosarcoma malignant progression through negatively regulating FGF14.
Neoplasm Metastasis
MicroRNA-324-5p suppresses the migration and invasion of MM cells by inhibiting the SCF?-TrCP E3 ligase.
Neoplasm Metastasis
Mind Bomb 1 Promotes Pancreatic Cancer Proliferation by Activating ?-Catenin Signaling.
Neoplasm Metastasis
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
Neoplasm Metastasis
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
Neoplasm Metastasis
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Neoplasm Metastasis
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Neoplasm Metastasis
New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.
Neoplasm Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Neoplasm Metastasis
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Neoplasm Metastasis
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Neoplasm Metastasis
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Neoplasm Metastasis
Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer.
Neoplasm Metastasis
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.
Neoplasm Metastasis
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
Neoplasm Metastasis
p27kip1 Expression in non-small cell lung cancer is not an independent prognostic factor.
Neoplasm Metastasis
Pancancer survival analysis of cancer hallmark genes.
Neoplasm Metastasis
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Neoplasm Metastasis
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
Neoplasm Metastasis
Pathology of Breast Cancer Metastasis and A View of Metastasis to The Brain.
Neoplasm Metastasis
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Neoplasm Metastasis
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Neoplasm Metastasis
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Neoplasm Metastasis
PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis.
Neoplasm Metastasis
Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
Neoplasm Metastasis
Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L.
Neoplasm Metastasis
Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms.
Neoplasm Metastasis
Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Neoplasm Metastasis
Prognostic values of F-box members in breast cancer: an online database analysis and literature review.
Neoplasm Metastasis
Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway.
Neoplasm Metastasis
Punicalagin suppresses osteosarcoma growth and metastasis by regulating NF-?B signaling.
Neoplasm Metastasis
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Neoplasm Metastasis
RBBP6, a RING finger-domain E3 ubiquitin ligase, induces epithelial-mesenchymal transition and promotes metastasis of colorectal cancer.
Neoplasm Metastasis
Recent advances in SCF ubiquitin ligase complex: Clinical implications.
Neoplasm Metastasis
Recurring Amplification at 11q22.1-q22.2 Locus Plays an Important Role in Lymph Node Metastasis and Radioresistance in OSCC.
Neoplasm Metastasis
Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer.
Neoplasm Metastasis
Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.
Neoplasm Metastasis
Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-?/catenin signaling pathway.
Neoplasm Metastasis
RING-finger protein 6 enhances c-Myc-mediated Warburg effect by promoting MAD1 degradation to facilitate pancreatic cancer metastasis.
Neoplasm Metastasis
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Neoplasm Metastasis
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
Neoplasm Metastasis
RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.
Neoplasm Metastasis
RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers.
Neoplasm Metastasis
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
Neoplasm Metastasis
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
Neoplasm Metastasis
RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
Neoplasm Metastasis
RNF8 Promotes Epithelial-Mesenchymal Transition in Lung Cancer Cells via Stabilization of Slug.
Neoplasm Metastasis
RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer.
Neoplasm Metastasis
SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer.
Neoplasm Metastasis
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Neoplasm Metastasis
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
Neoplasm Metastasis
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
Neoplasm Metastasis
Studies on selected molecular factors in endometrial cancers.
Neoplasm Metastasis
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Neoplasm Metastasis
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Neoplasm Metastasis
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Neoplasm Metastasis
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Neoplasm Metastasis
The basal phenotype of BRCA1-related breast cancer: past, present and future.
Neoplasm Metastasis
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Neoplasm Metastasis
The Drosophila F-box protein Slimb controls dSmurf protein turnover to regulate the Hippo pathway.
Neoplasm Metastasis
The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
Neoplasm Metastasis
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Neoplasm Metastasis
The E3 ligase for metastasis associated 1 protein, TRIM25, is targeted by microRNA-873 in hepatocellular carcinoma.
Neoplasm Metastasis
The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
Neoplasm Metastasis
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Neoplasm Metastasis
The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Neoplasm Metastasis
The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients.
Neoplasm Metastasis
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
Neoplasm Metastasis
The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.
Neoplasm Metastasis
The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
Neoplasm Metastasis
TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/?-catenin degradation and is targeted for GSK3B/GSK3?-mediated phosphorylation and degradation.
Neoplasm Metastasis
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
Neoplasm Metastasis
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
Neoplasm Metastasis
TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10.
Neoplasm Metastasis
Tripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signaling-mediated epithelial-mesenchymal transition in cervical cancer.
Neoplasm Metastasis
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Neoplasm Metastasis
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Neoplasm Metastasis
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
Neoplasm Metastasis
Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.
Neoplasm Metastasis
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.
Neoplasm Metastasis
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
Neoplasm Metastasis
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
Neoplasm Metastasis
[Nasosinusal adenocarcinoma: molecular and genetic analysis by MLPA]
Neoplasm Metastasis
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Neoplasm, Residual
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Neoplasm, Residual
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Neoplasm, Residual
High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
Neoplasm, Residual
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
Neoplasms
"I Am Uncertain About What My Uncertainty Even Is": Men's Uncertainty and Information Management of Their BRCA-Related Cancer Risks.
Neoplasms
"It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
Neoplasms
"Ring-fencing" BRCA1 tumor suppressor activity.
Neoplasms
"Smurf"-ing tumors on the chromatin through RNF20.
Neoplasms
14-3-3-protein regulates Nedd4-2 by modulating interactions between HECT and WW domains.
Neoplasms
17 beta Hydroxysteroid dehydrogenase 1 "pseudogene" is differentially transcribed: still a candidate for the breast-ovarian cancer susceptibility gene (BRCA1).
Neoplasms
19F NMR tagging and PRE-based conformational analysis of intrinsically disordered protein complexes.
Neoplasms
2-oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia-inducible factor-1alpha and inhibits angiogenesis.
Neoplasms
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.
Neoplasms
53BP1 ablation rescues genomic instability in mice expressing 'RING-less' BRCA1.
Neoplasms
53BP1 fosters fidelity of homology-directed DNA repair.
Neoplasms
53BP1 is a positive regulator of the BRCA1 promoter.
Neoplasms
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
Neoplasms
53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
Neoplasms
53BP1 promotes ATM activity through direct interactions with the MRN complex.
Neoplasms
53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks.
Neoplasms
655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.
Neoplasms
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.
Neoplasms
?-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
Neoplasms
?Np63? induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
Neoplasms
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17.
Neoplasms
A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating ?-TrCP E3 Ubiquitin Ligase.
Neoplasms
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
Neoplasms
A 45-year follow-up of kindred 107 and the search for BRCA2.
Neoplasms
A bicyclic monoterpene diol and UVB stimulate BRCA1 phosphorylation in human keratinocytes.
Neoplasms
A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Neoplasms
A BRCA1 deficient, NF?B driven immune signal predicts good outcome in triple negative breast cancer.
Neoplasms
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.
Neoplasms
A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing.
Neoplasms
A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2.
Neoplasms
A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression.
Neoplasms
A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
Neoplasms
A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature.
Neoplasms
A case of neurofibromatosis and breast cancer: loss of heterozygosity of NF1 in breast cancer.
Neoplasms
A CD146 FACS Protocol Enriches for Luminal Keratin 14/19 Double Positive Human Breast Progenitors.
Neoplasms
A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation.
Neoplasms
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.
Neoplasms
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Neoplasms
A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1.
Neoplasms
A common Greenlandic Inuit BRCA1 RING domain founder mutation.
Neoplasms
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.
Neoplasms
A common SNP in the uracil-DNA glycosylase gene UNG decreases ovarian cancer risk in BRCA2 mutation carriers.
Neoplasms
A comparison of 100 human genes using an alu element-based instability model.
Neoplasms
A comparison of bilateral breast cancers in BRCA carriers.
Neoplasms
A comparison of male attendees and nonattendees at a familial cancer clinic.
Neoplasms
A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing.
Neoplasms
A computer model to simulate family history of breast/ovarian cancer in BRCA1 mutation carriers.
Neoplasms
A conditional mouse model for measuring the frequency of homologous recombination events in vivo in the absence of essential genes.
Neoplasms
A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites.
Neoplasms
A critical re-appraisal of BRCA1 methylation studies in ovarian cancer.
Neoplasms
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.
Neoplasms
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Neoplasms
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.
Neoplasms
A critical role for noncoding 5S rRNA in regulating Mdmx stability.
Neoplasms
A death-associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and regulates the cellular levels of DAPK.
Neoplasms
A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred.
Neoplasms
A deletion map of chromosome 17q in sporadic human mammary carcinomas.
Neoplasms
A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
Neoplasms
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
Neoplasms
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
Neoplasms
A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services.
Neoplasms
A Drosophila Model of HPV E6-Induced Malignancy Reveals Essential Roles for Magi and the Insulin Receptor.
Neoplasms
A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.
Neoplasms
A family with three germline mutations in BRCA1 and BRCA2.
Neoplasms
A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance.
Neoplasms
A gene hypermethylation profile of human cancer.
Neoplasms
A genetic epidemiological study of carcinoma of the fallopian tube.
Neoplasms
A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer.
Neoplasms
A Genomewide Screen for Suppressors of Alu-Mediated Rearrangements Reveals a Role for PIF1.
Neoplasms
A guide for functional analysis of BRCA1 variants of uncertain significance.
Neoplasms
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.
Neoplasms
A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors.
Neoplasms
A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
Neoplasms
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
Neoplasms
A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Neoplasms
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
Neoplasms
A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
Neoplasms
A high proportion of founder BRCA1 mutations in Polish breast cancer families.
Neoplasms
A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene.
Neoplasms
A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis.
Neoplasms
A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.
Neoplasms
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Neoplasms
A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.
Neoplasms
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Neoplasms
A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
Neoplasms
A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance.
Neoplasms
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
Neoplasms
A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase.
Neoplasms
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Neoplasms
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
Neoplasms
A microchip platform for structural oncology applications.
Neoplasms
A MicroRNA/Ubiquitin Ligase Feedback Loop Regulates Slug-Mediated Invasion in Breast Cancer.
Neoplasms
A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1.
Neoplasms
A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
Neoplasms
A Molecular Toolkit to Visualize Native Protein Assemblies in the Context of Human Disease.
Neoplasms
A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
Neoplasms
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
Neoplasms
A mouse model of basal-like breast carcinoma with metaplastic elements.
Neoplasms
A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.
Neoplasms
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Neoplasms
A multi-lock inhibitory mechanism for fine-tuning enzyme activities of the HECT family E3 ligases.
Neoplasms
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604).
Neoplasms
A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.
Neoplasms
A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.
Neoplasms
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Neoplasms
A naturally occurring mutation in an ATP-binding domain of the recombination repair gene XRCC3 ablates its function without causing cancer susceptibility.
Neoplasms
A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Neoplasms
A new alternative splice variant of BRCA1 containing an additional in-frame exon.
Neoplasms
A new bioinformatics tool to help assess the significance of BRCA1 variants.
Neoplasms
A new class of coumate benzimidazole hybrids as BRCA-1 mimetics through unconventional binding mode; Synthesis and preliminary cytotoxicity screening.
Neoplasms
A new founder BRCA1 haplotype identified in the Puglia region is associated with a specific age-related cancer onset in three unrelated families.
Neoplasms
A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers.
Neoplasms
A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Neoplasms
A New Rapid Methodological Strategy to Assess BRCA Mutational Status.
Neoplasms
A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
Neoplasms
A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
Neoplasms
A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
Neoplasms
A novel BRCA1 gene deletion detection in human breast carcinoma MCF-7 cells through FRET between quantum dots and silver nanoclusters.
Neoplasms
A novel BRCA1 mutation in an identical twin pair with similar clinical histories.
Neoplasms
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer.
Neoplasms
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
Neoplasms
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.
Neoplasms
A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.
Neoplasms
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
Neoplasms
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region.
Neoplasms
A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20?years of BRCA1/2 research in the Baltic region: cohort study and literature review.
Neoplasms
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
Neoplasms
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.
Neoplasms
A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines.
Neoplasms
A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
Neoplasms
A Novel Mechanism to Induce BRCAness in Cancer Cells.
Neoplasms
A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells.
Neoplasms
A novel method to detect the Mexican founder mutation BRCA1 ex9?12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.
Neoplasms
A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer
Neoplasms
A novel oncoprotein Pirh2: rising from the shadow of MDM2.
Neoplasms
A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.
Neoplasms
A novel role for BRCA1 in regulating breast cancer cell spreading and motility.
Neoplasms
A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis.
Neoplasms
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
Neoplasms
A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein.
Neoplasms
A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
Neoplasms
A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
Neoplasms
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
Neoplasms
A nuclear function for the tumor suppressor BRCA1.
Neoplasms
A paradigm for class prediction using gene expression profiles.
Neoplasms
A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors.
Neoplasms
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
Neoplasms
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Neoplasms
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.
Neoplasms
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Neoplasms
A phenotypic mouse model of basaloid breast tumors.
Neoplasms
A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
Neoplasms
A Physical Mechanism and Global Quantification of Breast Cancer.
Neoplasms
A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study.
Neoplasms
A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease.
Neoplasms
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
Neoplasms
A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study.
Neoplasms
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Neoplasms
A porcine model system of BRCA1 driven breast cancer.
Neoplasms
A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function.
Neoplasms
A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Neoplasms
A PP1-binding motif present in BRCA1 plays a role in its DNA repair function.
Neoplasms
A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
Neoplasms
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
Neoplasms
A profile on the FoundationFocus CDxBRCA tests.
Neoplasms
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
Neoplasms
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Neoplasms
A radiation hybrid map of the BRCA1 region.
Neoplasms
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Neoplasms
A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes.
Neoplasms
A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Neoplasms
A Regulatory Axis of circ_0008193/miR-1180-3p/TRIM62 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Lung Adenocarcinoma Cells Under Hypoxia.
Neoplasms
A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing.
Neoplasms
A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Neoplasms
A Review of Cancer Genetics and Genomics Studies in Africa.
Neoplasms
A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.
Neoplasms
A role for Brca1 in chromosome end maintenance.
Neoplasms
A role for BRCA1 in sporadic breast cancer.
Neoplasms
A role for BRCA1 in uterine leiomyosarcoma.
Neoplasms
A role for KAI1 in promotion of cell proliferation and mammary gland hyperplasia by the gp78 ubiquitin ligase.
Neoplasms
A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining.
Neoplasms
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation.
Neoplasms
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
Neoplasms
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.
Neoplasms
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.
Neoplasms
A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens.
Neoplasms
A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Neoplasms
A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize.
Neoplasms
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
Neoplasms
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
Neoplasms
A small ubiquitin binding domain inhibits ubiquitin-dependent protein recruitment to DNA repair foci.
Neoplasms
A somatic BRCA1 mutation in an ovarian tumour.
Neoplasms
A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain.
Neoplasms
A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
Neoplasms
A splice variant of stress response gene ATF3 counteracts NF-kappaB-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivator.
Neoplasms
A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1.
Neoplasms
A survey of preventive measures among BRCA1 mutation carriers from Poland.
Neoplasms
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.
Neoplasms
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Neoplasms
A synthetic oxygen sensor for plants based on animal hypoxia signalling.
Neoplasms
A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing.
Neoplasms
A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.
Neoplasms
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Neoplasms
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.
Neoplasms
A transcription-based mechanism for oncogenic ?-catenin-induced lethality in BRCA1/2-deficient cells.
Neoplasms
A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats.
Neoplasms
A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20.
Neoplasms
A twist of cell fate.
Neoplasms
A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation.
Neoplasms
A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination.
Neoplasms
A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
Neoplasms
A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Neoplasms
A Variant Smurf2 Protects Mice Against Colitis-Associated Colon Cancer by Inducing Transforming Growth Factor ? Signaling.
Neoplasms
A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models.
Neoplasms
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
Neoplasms
A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
Neoplasms
A ZNRF3-dependent Wnt/?-catenin signaling gradient is required for adrenal homeostasis.
Neoplasms
A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma.
Neoplasms
A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.
Neoplasms
Aberrant DNA methylation as a cancer-inducing mechanism.
Neoplasms
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.
Neoplasms
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
Neoplasms
Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer.
Neoplasms
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Neoplasms
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
Neoplasms
Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential.
Neoplasms
Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.
Neoplasms
Aberrant subcellular localization of BRCA1 in breast cancer.
Neoplasms
Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization.
Neoplasms
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Neoplasms
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
Neoplasms
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
Neoplasms
Abrogation of FBW7?-dependent p53 degradation enhances p53's function as a tumor suppressor.
Neoplasms
Absence of 185delAG and 6174delT Mutations among Breast Cancer Patients of Eastern India.
Neoplasms
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.
Neoplasms
Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach.
Neoplasms
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Neoplasms
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
Neoplasms
Absence of Grail promotes CD8(+) T cell anti-tumour activity.
Neoplasms
Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
Neoplasms
Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics.
Neoplasms
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members.
Neoplasms
Abundance of BRCA1 transcripts in human cancer and lymphoblastoid cell lines carrying BRCA1 germ-line alterations.
Neoplasms
ACAA1 Is a Predictive Factor of Survival and Is Correlated With T Cell Infiltration in Non-Small Cell Lung Cancer.
Neoplasms
ACCA phosphopeptide recognition by the BRCT repeats of BRCA1.
Neoplasms
Accelerated regeneration of the skeletal muscle in RNF13-knockout mice is mediated by macrophage-secreted IL-4/IL-6.
Neoplasms
Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers.
Neoplasms
Acceleration of chromosomal instability of BRCA1-associated hereditary breast cancers by p53 abnormality.
Neoplasms
Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred.
Neoplasms
Accumulated promoter methylation as a potential biomarker for esophageal cancer.
Neoplasms
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Neoplasms
Accuracy of cancer family histories: comparison of two breast cancer syndromes.
Neoplasms
Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer.
Neoplasms
Accurate classification of BRCA1 variants with saturation genome editing.
Neoplasms
Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN.
Neoplasms
Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
Neoplasms
Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.
Neoplasms
Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Neoplasms
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Neoplasms
Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Neoplasms
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
Neoplasms
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Neoplasms
Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains.
Neoplasms
Activation of TNF-?/NF-?B axis enhances CRL4B
Neoplasms
Activation of transcription in vitro by the BRCA1 carboxyl-terminal domain.
Neoplasms
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Neoplasms
Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study.
Neoplasms
Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants.
Neoplasms
Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing.
Neoplasms
Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.
Neoplasms
Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.
Neoplasms
Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.
Neoplasms
Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications.
Neoplasms
Advances in the use of PARP inhibitor therapy for breast cancer.
Neoplasms
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers.
Neoplasms
Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer.
Neoplasms
Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.
Neoplasms
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
Neoplasms
Age of natural menopause onset in BRCA1/2 carriers - systematic review and meta-analysis.
Neoplasms
AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway.
Neoplasms
Aggressiveness of non-EMT breast cancer cells relies on FBXO11 activity.
Neoplasms
AGO Austria recommendations for genetic testing of patients with ovarian cancer.
Neoplasms
AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.
Neoplasms
AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.
Neoplasms
AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers.
Neoplasms
Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.
Neoplasms
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Neoplasms
Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours.
Neoplasms
Allele loss of tumour suppressor genes on chromosome 17 in human testicular germ cell tumours.
Neoplasms
Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
Neoplasms
Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer.
Neoplasms
Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Neoplasms
Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.
Neoplasms
Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset).
Neoplasms
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Neoplasms
Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
Neoplasms
Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation.
Neoplasms
Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Neoplasms
Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
Neoplasms
Alteration of BRCA1 expression affects alcohol-induced transcription of RNA Pol III-dependent genes.
Neoplasms
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Neoplasms
Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs.
Neoplasms
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Neoplasms
Alterations in replication timing of cancer-related genes in malignant human breast cancer cells.
Neoplasms
Alterations in the common fragile site gene Parkin in ovarian and other cancers.
Neoplasms
Alterations of pre-mRNA splicing in cancer.
Neoplasms
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.
Neoplasms
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Neoplasms
Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN).
Neoplasms
Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.
Neoplasms
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Neoplasms
Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia.
Neoplasms
Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Neoplasms
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Neoplasms
Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a case study.
Neoplasms
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
Neoplasms
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
Neoplasms
Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer.
Neoplasms
Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?
Neoplasms
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Neoplasms
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
Neoplasms
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Neoplasms
An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression.
Neoplasms
An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
Neoplasms
An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
Neoplasms
An amino-terminal motif functions as a second nuclear export sequence in BRCA1.
Neoplasms
An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue.
Neoplasms
An apoptosis-independent role of SMAC in tumor suppression.
Neoplasms
An E3 Ubiquitin Ligase RNF139 Serves as a Tumor-Suppressor in Glioma.
Neoplasms
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
Neoplasms
An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition.
Neoplasms
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
Neoplasms
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.
Neoplasms
An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
Neoplasms
An evolving role for DEPTOR in tumor development and progression.
Neoplasms
An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers.
Neoplasms
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
Neoplasms
An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
Neoplasms
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.
Neoplasms
An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
Neoplasms
An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).
Neoplasms
An RNF168 fragment defective for focal accumulation at DNA damage is proficient for inhibition of homologous recombination in BRCA1 deficient cells.
Neoplasms
An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2.
Neoplasms
An unorthodox partnership in DNA repair pathway choice.
Neoplasms
An unusual BRCA mutation distribution in a high risk cancer genetics clinic.
Neoplasms
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Neoplasms
An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer.
Neoplasms
An update on PARP inhibitors--moving to the adjuvant setting.
Neoplasms
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Neoplasms
Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
Neoplasms
Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.
Neoplasms
Analysis of alternative lengthening of telomere markers in BRCA1 defective cells.
Neoplasms
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Neoplasms
Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula.
Neoplasms
Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer.
Neoplasms
Analysis of BRCA1 and BRCA2 mutations in southern Iranian Breast cancer patients.
Neoplasms
Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer.
Neoplasms
Analysis of BRCA1 involvement in breast cancer in Indian women.
Neoplasms
Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit.
Neoplasms
Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Neoplasms
Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
Neoplasms
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Neoplasms
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
Neoplasms
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Neoplasms
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Neoplasms
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Neoplasms
Analysis of estrogen-responsive finger protein expression in benign and malignant human breast.
Neoplasms
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
Neoplasms
Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.
Neoplasms
Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family.
Neoplasms
Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example.
Neoplasms
Analysis of loss of heterozygosity and immunohistochemistry in BRCA1 gene in sporadic breast cancers.
Neoplasms
Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family.
Neoplasms
Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
Neoplasms
Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.
Neoplasms
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Neoplasms
Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases.
Neoplasms
Analysis of somatic microsatellite indels identifies driver events in human tumors.
Neoplasms
Analysis of the DNA binding activity of BRCA1 and its modulation by the tumour suppressor p53.
Neoplasms
Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.
Neoplasms
Ancestry dependent DNA methylation and influence of maternal nutrition.
Neoplasms
Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification of a single-nucleotide polymorphism that impacts TRIM22 function.
Neoplasms
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Neoplasms
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Neoplasms
Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion.
Neoplasms
Aneuploidy is associated with TP53 expression but not with BRCA1 or TERT expression in sporadic colorectal cancer.
Neoplasms
Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway.
Neoplasms
Annotation of Sequence Variants in Cancer Samples: Processes and Pitfalls for Routine Assays in the Clinical Laboratory.
Neoplasms
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
Neoplasms
Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells.
Neoplasms
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Neoplasms
Antibody-drug conjugates in triple negative breast cancer.
Neoplasms
Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
Neoplasms
Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs.
Neoplasms
Antimony exposure promotes bladder tumor cell growth by inhibiting PINK1-Parkin-mediated mitophagy.
Neoplasms
Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
Neoplasms
Antiproliferative effect of D-glucuronyl C5-epimerase in human breast cancer cells.
Neoplasms
Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Neoplasms
Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.
Neoplasms
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Neoplasms
Antitumor effects of recombinant human adenovirus-p53 against human cutaneous squamous cell carcinoma in mice.
Neoplasms
APC shuttling to the membrane, nucleus and beyond.
Neoplasms
Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.
Neoplasms
Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
Neoplasms
Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
Neoplasms
Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer.
Neoplasms
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Neoplasms
Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
Neoplasms
Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer.
Neoplasms
Are Parkinson disease patients protected from some but not all cancers?
Neoplasms
Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report.
Neoplasms
Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
Neoplasms
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Neoplasms
Aromatase expression is increased in BRCA1 mutation carriers.
Neoplasms
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Neoplasms
Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Neoplasms
Arsenic?induced BRCA1 CpG promoter methylation is associated with the downregulation of ER? and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
Neoplasms
Artemisitene suppresses tumorigenesis by inducing DNA damage through deregulating c-Myc-topoisomerase pathway.
Neoplasms
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Neoplasms
ASPM promotes homologous recombination-mediated DNA repair by safeguarding BRCA1 stability.
Neoplasms
Assays for Hypermethylation of the BRCA1 Gene Promoter in Tumor Cells to Predict Sensitivity to PARP-Inhibitor Therapy.
Neoplasms
Assembly of an Evolutionarily Conserved Alternative Proteasome Isoform in Human Cells.
Neoplasms
Assessing breast cancer risk and BRCA1/2 carrier probability.
Neoplasms
Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
Neoplasms
Assessment of DNA Repair Gene Expressions in Vitrified Mouse Preantral Follicles.
Neoplasms
Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.
Neoplasms
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Neoplasms
ASSESSMENT OF THE VALUE OF METHYLATION FEATURES IN DIFFERENT TISSUES FOR PREOPERATIVE IDENTIFICATION OF HIGH-RISK BREAST TUMORS.
Neoplasms
Assessment of tumor suppressor promoter methylation in healthy individuals.
Neoplasms
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Neoplasms
Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
Neoplasms
Association between BRCA1 P871L polymorphism and cancer risk: evidence from a meta-analysis.
Neoplasms
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Neoplasms
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Neoplasms
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
Neoplasms
Association between hereditary predisposition to common cancers and congenital multimalformations.
Neoplasms
Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Neoplasms
Association between Presenilin-1 and TRAF6 modulates regulated intramembrane proteolysis of the p75NTR neurotrophin receptor.
Neoplasms
Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study.
Neoplasms
Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers.
Neoplasms
Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Neoplasms
Association of BLM and BRCA1 during Telomere Maintenance in ALT Cells.
Neoplasms
Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
Neoplasms
Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Neoplasms
Association of BRCA1 185 del AG with early age onset of breast cancer patients in selected cohort from Pakistani population.
Neoplasms
Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.
Neoplasms
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Neoplasms
Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis
Neoplasms
Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer.
Neoplasms
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Neoplasms
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.
Neoplasms
Association of BRCA1 with the inactive X chromosome and XIST RNA.
Neoplasms
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Neoplasms
Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Neoplasms
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Neoplasms
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Neoplasms
Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Neoplasms
Association of DEAR1 Tagging Single Nucleotide Polymorphisms With Breast Cancer in a Sample of Colombian Population: A Case Control Study.
Neoplasms
Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.
Neoplasms
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Neoplasms
Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer.
Neoplasms
Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer.
Neoplasms
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
Neoplasms
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Neoplasms
Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.
Neoplasms
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Neoplasms
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer.
Neoplasms
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA.
Neoplasms
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Neoplasms
Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.
Neoplasms
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
Neoplasms
Asymmetric recruitment of cIAPs by TRAF2.
Neoplasms
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
Neoplasms
ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors.
Neoplasms
ATM and genome maintenance: defining its role in breast cancer susceptibility.
Neoplasms
ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage.
Neoplasms
Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.
Neoplasms
ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85? Deficient Cancer Cells and Influence Platinum Sensitivity.
Neoplasms
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Neoplasms
ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1.
Neoplasms
ATR/ATM-Mediated Phosphorylation of BRCA1 T1394 Promotes Homologous Recombinational Repair and G2-M Checkpoint Maintenance.
Neoplasms
ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance.
Neoplasms
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
Neoplasms
Attitudes about genetic testing for breast-ovarian cancer susceptibility.
Neoplasms
Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation.
Neoplasms
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
Neoplasms
Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Neoplasms
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
Neoplasms
Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1? in Prostate Cancer Cells.
Neoplasms
Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Neoplasms
Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer.
Neoplasms
Autophagic Degradation of NBR1 Restricts Metastatic Outgrowth during Mammary Tumor Progression.
Neoplasms
Autophagy defects and related genetic variations in renal cell carcinoma with eosinophilic cytoplasmic inclusions.
Neoplasms
Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.
Neoplasms
Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Neoplasms
Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase.
Neoplasms
Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.
Neoplasms
Axin determines cell fate by controlling the p53 activation threshold after DNA damage.
Neoplasms
Axl/Gas6/NF?B signalling in schwannoma pathological proliferation, adhesion and survival.
Neoplasms
BACH1 is a DNA repair protein supporting BRCA1 damage response.
Neoplasms
BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response.
Neoplasms
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Neoplasms
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Neoplasms
BAP1, a candidate tumor suppressor protein that interacts with BRCA1.
Neoplasms
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.
Neoplasms
BARD1 and breast cancer in Poland.
Neoplasms
BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
Neoplasms
BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility.
Neoplasms
BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
Neoplasms
BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export.
Neoplasms
BARD1 may be renamed ROW1 because it functions mainly as a REPRESSOR OF WUSCHEL1.
Neoplasms
BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks.
Neoplasms
BARD1 Pathogenic Variants are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort.
Neoplasms
BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
Neoplasms
BARD1 regulates BRCA1-mediated transactivation of the p21(WAF1/CIP1) and Gadd45 promoters.
Neoplasms
BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
Neoplasms
Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers.
Neoplasms
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Neoplasms
Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites.
Neoplasms
Basal-like breast cancer and the BRCA1 phenotype.
Neoplasms
Basal-like breast cancer displays distinct patterns of promoter methylation.
Neoplasms
Basal-like breast cancer: a critical review.
Neoplasms
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Neoplasms
Basal-like breast cancers: the phenotypic disparity between the cancer-initiating cells and tumor histology.
Neoplasms
Basal-like breast carcinoma: from expression profiling to routine practice.
Neoplasms
Basal-like subtype and BRCA1 dysfunction in breast cancers.
Neoplasms
Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance.
Neoplasms
BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms.
Neoplasms
Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.
Neoplasms
BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
Neoplasms
Behavioral science in translational research and cancer control.
Neoplasms
Being 'at-risk' for developing cancer: cognitive representations and psychological outcomes.
Neoplasms
Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers.
Neoplasms
Beyond triple-negative breast cancer: the need to define new subtypes.
Neoplasms
Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.
Neoplasms
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Neoplasms
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Neoplasms
Biallelic inactivation of BRCA2 in Fanconi anemia.
Neoplasms
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
Neoplasms
Bid Promotes K63-Linked Polyubiquitination of Tumor Necrosis Factor Receptor Associated Factor 6 (TRAF6) and Sensitizes to Mutant SOD1-Induced Proinflammatory Signaling in Microglia.
Neoplasms
Bilateral breast cancers.
Neoplasms
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Neoplasms
Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence.
Neoplasms
Bilateral Triple-Negative Invasive Breast Cancer with a BRCA2 Mutation, and Glioblastoma: A Case Report and Literature Review.
Neoplasms
Bile acids upregulate BRCA1 and downregulate estrogen receptor 1 gene expression in ovarian cancer cells.
Neoplasms
Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
Neoplasms
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage.
Neoplasms
Biobibliometrics (UGDH-TP53-BRCA1) Genes Connections in the Possible Relationship Between Breast Cancer and EEG.
Neoplasms
Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1).
Neoplasms
Bioinformatics Approaches to Explore the Phylogeny and Role of BRCA1 in Breast Cancer.
Neoplasms
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Neoplasms
Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes.
Neoplasms
Biomarker-Guided Development of DNA Repair Inhibitors.
Neoplasms
Biomarkers and mechanisms of FANCD2 function.
Neoplasms
Biomarkers in the ovary.
Neoplasms
Biomarkers in triple negative breast cancer: A review.
Neoplasms
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Neoplasms
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Neoplasms
BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.
Neoplasms
BIRC3 and BIRC5: multi-faceted inhibitors in cancer.
Neoplasms
BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats.
Neoplasms
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-?B Activation, and Is Active in Patient-Derived Xenograft Models.
Neoplasms
Bispecific Estrogen Receptor ? Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening.
Neoplasms
Bivalent smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
Neoplasms
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Neoplasms
Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers.
Neoplasms
Both sides of the same coin: Rac1 alternative splicing by EGF signaling.
Neoplasms
Box BRCA1 tumour inhibition.
Neoplasms
BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer.
Neoplasms
BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
Neoplasms
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis.
Neoplasms
BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer.
Neoplasms
BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes.
Neoplasms
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Neoplasms
BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
Neoplasms
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
Neoplasms
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Neoplasms
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Neoplasms
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients.
Neoplasms
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Neoplasms
BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
Neoplasms
BRCA Mutations in the Young, High-Risk Female Population: Genetic Testing, Management of Prophylactic Therapies, and Implications for Plastic Surgeons.
Neoplasms
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Neoplasms
BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
Neoplasms
BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Neoplasms
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.
Neoplasms
BRCA1 - Conductor of the Breast Stem Cell Orchestra: The Role of BRCA1 in Mammary Gland Development and Identification of Cell of Origin of BRCA1 Mutant Breast Cancer.
Neoplasms
BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications.
Neoplasms
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Neoplasms
BRCA1 4153delA founder mutation in Russian ovarian cancer patients.
Neoplasms
BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo.
Neoplasms
BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
Neoplasms
BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients.
Neoplasms
BRCA1 affects global DNA methylation through regulation of DNMT1.
Neoplasms
BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase.
Neoplasms
BRCA1 affects protein phosphatase 6 signalling through its interaction with ANKRD28.
Neoplasms
BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
Neoplasms
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Neoplasms
BRCA1 and ?H2AX as independent prognostic markers in oral squamous cell carcinoma.
Neoplasms
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Neoplasms
BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
Neoplasms
BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin.
Neoplasms
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.
Neoplasms
BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells.
Neoplasms
BRCA1 and BRCA2 as ovarian cancer susceptibility genes.
Neoplasms
BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
Neoplasms
BRCA1 and BRCA2 cancer risks.
Neoplasms
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
Neoplasms
BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
Neoplasms
BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives.
Neoplasms
BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Neoplasms
BRCA1 and BRCA2 genetic testing for ovarian cancer: is it all good news?
Neoplasms
BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
Neoplasms
BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
Neoplasms
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population.
Neoplasms
BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.
Neoplasms
BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries.
Neoplasms
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
Neoplasms
BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients.
Neoplasms
BRCA1 and BRCA2 Germline Mutations in Japanese with Hereditary Breast Cancer Families.
Neoplasms
BRCA1 and BRCA2 germline mutations in lymphoma patients.
Neoplasms
BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
Neoplasms
BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
Neoplasms
BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
Neoplasms
BRCA1 and BRCA2 heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity.
Neoplasms
BRCA1 and BRCA2 in 2005.
Neoplasms
BRCA1 and BRCA2 in breast cancer.
Neoplasms
BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients.
Neoplasms
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
Neoplasms
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Neoplasms
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Neoplasms
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
Neoplasms
BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Neoplasms
BRCA1 and BRCA2 mutation type associated with cancer risk.
Neoplasms
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Neoplasms
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
Neoplasms
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
Neoplasms
BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
Neoplasms
BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
Neoplasms
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
Neoplasms
BRCA1 and BRCA2 mutations in a South American population.
Neoplasms
BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Syndrome: Reflection on the Creighton University Historical Series of High Risk Families.
Neoplasms
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
Neoplasms
BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
Neoplasms
BRCA1 and BRCA2 mutations in central and southern Italian patients.
Neoplasms
BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
Neoplasms
BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
Neoplasms
BRCA1 and BRCA2 mutations in Russian familial breast cancer.
Neoplasms
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
Neoplasms
BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
Neoplasms
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry.
Neoplasms
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
Neoplasms
BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer.
Neoplasms
BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants.
Neoplasms
BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis.
Neoplasms
BRCA1 and BRCA2 tumor suppressors in neural crest cells are essential for craniofacial bone development.
Neoplasms
BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
Neoplasms
BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Neoplasms
BRCA1 and BRCA2 Variation in Taiwanese General Population and the Cancer Cohort.
Neoplasms
BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.
Neoplasms
BRCA1 and BRCA2--breast cancer susceptibility genes.
Neoplasms
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double strand break repair.
Neoplasms
BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
Neoplasms
BRCA1 and cell signaling.
Neoplasms
BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.
Neoplasms
Brca1 and differentiation.
Neoplasms
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
Neoplasms
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Neoplasms
BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1.
Neoplasms
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.
Neoplasms
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
Neoplasms
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
Neoplasms
BRCA1 and implications for response to chemotherapy in ovarian cancer.
Neoplasms
BRCA1 and Its Network of Interacting Partners.
Neoplasms
BRCA1 and its toolbox for the maintenance of genome integrity.
Neoplasms
BRCA1 and MDM2 as independent blood-based biomarkers of head and neck cancer.
Neoplasms
BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets.
Neoplasms
BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Neoplasms
BRCA1 and p53 regulate critical prostate cancer pathways.
Neoplasms
BRCA1 and p53 Tumor Suppressor Molecules in Alzheimer's Disease.
Neoplasms
BRCA1 and p53: compensatory roles in DNA repair.
Neoplasms
BRCA1 and PALB2 in a Messy Breakup.
Neoplasms
BRCA1 and prostate cancer.
Neoplasms
BRCA1 and RNAi factors promote repair mediated by small RNAs and PALB2-RAD52.
Neoplasms
BRCA1 and S phase DNA repair pathways restrict LINE-1 retrotransposition in human cells.
Neoplasms
BRCA1 and stem cells: tumour typecasting.
Neoplasms
BRCA1 and transcription.
Neoplasms
BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.
Neoplasms
BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.
Neoplasms
BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control.
Neoplasms
BRCA1 as target for breast cancer prevention and therapy.
Neoplasms
BRCA1 as tumor suppressor: lord without its RING?
Neoplasms
BRCA1 associates with human papillomavirus type 18 E2 and stimulates E2-dependent transcription.
Neoplasms
BRCA1 associates with processive RNA polymerase II.
Neoplasms
BRCA1 associates with the inactive X chromosome in late S-phase, coupled with transient H2AX phosphorylation.
Neoplasms
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.
Neoplasms
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
Neoplasms
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit.
Neoplasms
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
Neoplasms
BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells.
Neoplasms
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Neoplasms
BRCA1 c.2845insA is a founder mutation in Singaporean Malay women with early onset breast/ovarian cancer.
Neoplasms
BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer.
Neoplasms
BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Neoplasms
BRCA1 Circos: a visualisation resource for functional analysis of missense variants.
Neoplasms
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Neoplasms
BRCA1 control of steroid receptor ubiquitination.
Neoplasms
BRCA1 controls homologous recombination at Tus/Ter-stalled mammalian replication forks.
Neoplasms
Brca1 controls homology-directed DNA repair.
Neoplasms
BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells.
Neoplasms
BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II.
Neoplasms
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
Neoplasms
BRCA1 DEFICIENCY EXACERBATES ESTROGEN INDUCED DNA DAMAGE AND GENOMIC INSTABILITY.
Neoplasms
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
Neoplasms
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.
Neoplasms
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
Neoplasms
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Neoplasms
Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities.
Neoplasms
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
Neoplasms
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Neoplasms
BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.
Neoplasms
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
Neoplasms
BRCA1 degradation in response to mitochondrial damage in breast cancer cells.
Neoplasms
BRCA1 disease-associated haplotypes in Singapore Malay women with early-onset breast/ovarian cancer.
Neoplasms
BRCA1 DNA-binding activity is stimulated by BARD1.
Neoplasms
BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin.
Neoplasms
BRCA1 dysfunction in sporadic basal-like breast cancer.
Neoplasms
BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer.
Neoplasms
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
Neoplasms
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Neoplasms
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
Neoplasms
BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.
Neoplasms
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Neoplasms
BRCA1 expression and molecular alterations in familial breast cancer.
Neoplasms
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
Neoplasms
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
Neoplasms
BRCA1 expression in benign and malignant breast lesions.
Neoplasms
BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables.
Neoplasms
BRCA1 expression in leukoplakia and carcinoma of the tongue.
Neoplasms
BRCA1 expression in triple negative sporadic breast cancers.
Neoplasms
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
Neoplasms
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.
Neoplasms
Brca1 expression is regulated by a bidirectional promoter that is shared by the Nbr1 gene in mouse.
Neoplasms
BRCA1 expression levels predict distant metastasis of sporadic breast cancers.
Neoplasms
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
Neoplasms
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
Neoplasms
BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers.
Neoplasms
BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
Neoplasms
BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines.
Neoplasms
BRCA1 foci in normal S-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin.
Neoplasms
BRCA1 forks over new roles in DNA-damage response- before and beyond the breaks.
Neoplasms
BRCA1 Forms a Functional Complex with ?-H2AX as a Late Response to Genotoxic Stress.
Neoplasms
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
Neoplasms
BRCA1 function in T lymphocytes: a cellular specificity of a different kind.
Neoplasms
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Neoplasms
BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters.
Neoplasms
BRCA1 gene in breast cancer.
Neoplasms
BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.
Neoplasms
BRCA1 gene mutation in thymic malignant melanoma.
Neoplasms
BRCA1 Gene Mutations and Influence of Chemotherapy on Autophagy and Apoptotic Mechanisms in Egyptian Breast Cancer Patients.
Neoplasms
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
Neoplasms
BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum.
Neoplasms
BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Neoplasms
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Neoplasms
BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review.
Neoplasms
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.
Neoplasms
BRCA1 genetic testing in a Pakistani breast-ovarian cancer family with multiple consanguineous marriages.
Neoplasms
BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer.
Neoplasms
BRCA1 germline mutation and glioblastoma development: report of cases.
Neoplasms
BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer.
Neoplasms
BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.
Neoplasms
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Neoplasms
BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer.
Neoplasms
BRCA1 germline mutations in Cypriot breast cancer patients from 26 families with family history.
Neoplasms
BRCA1 germline mutations in women with uterine serous papillary carcinoma.
Neoplasms
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Neoplasms
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
Neoplasms
BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development.
Neoplasms
BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination.
Neoplasms
BRCA1 haploinsufficiency: consequences for breast cancer.
Neoplasms
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
Neoplasms
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Neoplasms
BRCA1 in breast and ovarian cancer predisposition.
Neoplasms
BRCA1 in cancer, cell cycle and genomic stability.
Neoplasms
BRCA1 in hormonal carcinogenesis: basic and clinical research.
Neoplasms
BRCA1 in hormone-responsive cancers.
Neoplasms
BRCA1 in non-inherited breast carcinomas (Review).
Neoplasms
BRCA1 in the DNA damage response and at telomeres.
Neoplasms
Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland.
Neoplasms
BRCA1 induces major energetic metabolism reprogramming in breast cancer cells.
Neoplasms
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
Neoplasms
BRCA1 inhibition of telomerase activity in cultured cells.
Neoplasms
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer.
Neoplasms
BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting homologous recombination or radiation-induced gene activation of p21 or Mdm2.
Neoplasms
BRCA1 interacts with FHL2 and enhances FHL2 transactivation function.
Neoplasms
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.
Neoplasms
BRCA1 interacts with poly(A)-binding protein: implication of BRCA1 in translation regulation.
Neoplasms
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
Neoplasms
BRCA1 involvement in toxicological responses and human cancer etiology.
Neoplasms
BRCA1 is a component of the RNA polymerase II holoenzyme.
Neoplasms
BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
Neoplasms
BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma.
Neoplasms
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
Neoplasms
BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells.
Neoplasms
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
Neoplasms
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.
Neoplasms
BRCA1 is differentially expressed in human tumor cells.
Neoplasms
Brca1 is expressed independently of hormonal stimulation in the mouse ovary.
Neoplasms
BRCA1 is regulated by Chk2 in response to spindle damage.
Neoplasms
BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function.
Neoplasms
BRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M Arrest during DNA Cross-Link Repair in DT40 Cells.
Neoplasms
BRCA1 is required for meiotic spindle assembly and spindle assembly checkpoint activation in mouse oocytes.
Neoplasms
BRCA1 is secreted and exhibits properties of a granin.
Neoplasms
BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage.
Neoplasms
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
Neoplasms
BRCA1 Loss Induces GADD153-Mediated Doxorubicin Resistance in Prostate Cancer.
Neoplasms
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.
Neoplasms
BRCA1 methylation: a significant role in tumour development?
Neoplasms
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
Neoplasms
BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
Neoplasms
BRCA1 modulates the expression of hnRNPA2B1 and KHSRP.
Neoplasms
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer.
Neoplasms
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Neoplasms
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.
Neoplasms
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
Neoplasms
BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families.
Neoplasms
BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
Neoplasms
BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
Neoplasms
BRCA1 mutation influences progesterone response in human benign mammary organoids.
Neoplasms
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
Neoplasms
BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas.
Neoplasms
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
Neoplasms
BRCA1 mutation- oncological treatment- reconstructive surgery of the breast- pregnancy: diagnostic and therapeutic procedures in a 28 year old patient diagnosed with a tumor in the left breast with a BRCA1 mutation.
Neoplasms
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Neoplasms
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Neoplasms
BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer.
Neoplasms
BRCA1 mutations and colorectal cancer in Poland.
Neoplasms
BRCA1 mutations and luminal-basal transformation.
Neoplasms
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
Neoplasms
BRCA1 mutations found in archived early onset breast tumours.
Neoplasms
BRCA1 mutations in a selected series of breast/ovarian cancer patients.
Neoplasms
BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.
Neoplasms
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
Neoplasms
BRCA1 mutations in familial ovarian cancer.
Neoplasms
BRCA1 mutations in German breast-cancer families.
Neoplasms
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
Neoplasms
BRCA1 mutations in primary breast and ovarian carcinomas.
Neoplasms
BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families.
Neoplasms
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
Neoplasms
BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
Neoplasms
BRCA1 negatively regulates formation of autophagic vacuoles in MCF-7 breast cancer cells.
Neoplasms
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
Neoplasms
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
Neoplasms
BRCA1 partially reverses the transforming activity of the ras oncogene.
Neoplasms
BRCA1 participates in DNA decatenation.
Neoplasms
BRCA1 pathway function in basal-like breast cancer cells.
Neoplasms
BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.
Neoplasms
BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis.
Neoplasms
BRCA1 phosphorylation: biological consequences.
Neoplasms
BRCA1 physically and functionally interacts with ATF1.
Neoplasms
BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Neoplasms
BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression.
Neoplasms
BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan.
Neoplasms
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
Neoplasms
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.
Neoplasms
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
Neoplasms
BRCA1 promoter hypermethylation in human placenta: A hidden link with ?-hCG expression.
Neoplasms
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
Neoplasms
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
Neoplasms
BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population.
Neoplasms
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Neoplasms
BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
Neoplasms
BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
Neoplasms
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.
Neoplasms
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
Neoplasms
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
Neoplasms
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
Neoplasms
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer.
Neoplasms
BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies.
Neoplasms
BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.
Neoplasms
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Neoplasms
BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
Neoplasms
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Neoplasms
BRCA1 promotes induction of ssDNA by ionizing radiation.
Neoplasms
BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork.
Neoplasms
BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.
Neoplasms
BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
Neoplasms
BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
Neoplasms
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.
Neoplasms
BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A.
Neoplasms
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
Neoplasms
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
Neoplasms
BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9.
Neoplasms
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
Neoplasms
BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels.
Neoplasms
BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.
Neoplasms
BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness.
Neoplasms
BRCA1 Regulates g-Tubulin Binding to Centrosomes.
Neoplasms
BRCA1 regulates gene expression for orderly mitotic progression.
Neoplasms
BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.
Neoplasms
Brca1 regulates in vitro differentiation of mammary epithelial cells.
Neoplasms
BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex.
Neoplasms
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
Neoplasms
BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
Neoplasms
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
Neoplasms
BRCA1 regulates the interferon gamma-mediated apoptotic response.
Neoplasms
BRCA1 regulates transforming growth factor-? (TGF-?1) signaling through Gadd45a by enhancing the protein stability of Smad4.
Neoplasms
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
Neoplasms
BRCA1 regulation of transcription.
Neoplasms
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Neoplasms
BRCA1 represses amphiregulin gene expression.
Neoplasms
BRCA1 requirement for the fidelity of plasmid DNA double-strand break repair in cultured breast epithelial cells.
Neoplasms
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Neoplasms
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
Neoplasms
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.
Neoplasms
BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest.
Neoplasms
BRCA1 signals ARF-dependent stabilization and coactivation of p53.
Neoplasms
BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator.
Neoplasms
BRCA1 supports XIST RNA concentration on the inactive X chromosome.
Neoplasms
BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Neoplasms
BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1.
Neoplasms
BRCA1 suppresses osteopontin-mediated breast cancer.
Neoplasms
BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation.
Neoplasms
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Neoplasms
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
Neoplasms
BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sample.
Neoplasms
BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.
Neoplasms
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation.
Neoplasms
BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.
Neoplasms
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
Neoplasms
BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.
Neoplasms
BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma.
Neoplasms
BRCA1 tumor suppressor network: focusing on its tail.
Neoplasms
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.
Neoplasms
BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.
Neoplasms
BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP.
Neoplasms
BRCA1 ubiquitinates RPB8 in response to DNA damage.
Neoplasms
BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg?
Neoplasms
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
Neoplasms
BRCA1, a 'complex' protein involved in the maintenance of genomic stability.
Neoplasms
BRCA1, BRCA2 and breast cancer: a concise clinical review.
Neoplasms
BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
Neoplasms
BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.
Neoplasms
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
Neoplasms
BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study.
Neoplasms
BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation.
Neoplasms
BRCA1, hormone, and tissue-specific tumor suppression.
Neoplasms
BRCA1, microRNAs and cancer predisposition: challenging the dogma.
Neoplasms
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
Neoplasms
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
Neoplasms
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?
Neoplasms
BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance.
Neoplasms
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
Neoplasms
BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
Neoplasms
BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
Neoplasms
BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining.
Neoplasms
BRCA1-associated tumorigenesis: what have we learned from knockout mice?
Neoplasms
BRCA1-BARD1 regulates axon regeneration in concert with the Gq?-DAG signaling network.
Neoplasms
BRCA1-BARD1 regulates transcription through BRD4 in Xenopus nucleoplasmic extract.
Neoplasms
BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.
Neoplasms
BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest.
Neoplasms
BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
Neoplasms
BRCA1-directed, enhanced and aberrant homologous recombination: Mechanism and potential treatment strategies.
Neoplasms
BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.
Neoplasms
BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number.
Neoplasms
BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Neoplasms
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.
Neoplasms
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
Neoplasms
BRCA1-Ku80 Protein Interaction Enhances End-joining Fidelity of Chromosomal Double-strand Breaks in the G1 Phase of the Cell Cycle.
Neoplasms
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Neoplasms
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Neoplasms
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Neoplasms
BRCA1-mediated chromatin silencing is limited to oocytes with a small number of asynapsed chromosomes.
Neoplasms
BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.
Neoplasms
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
Neoplasms
BRCA1-mediated ubiquitylation.
Neoplasms
BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
Neoplasms
BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
Neoplasms
BRCA1-No Matter How You Splice It.
Neoplasms
BRCA1-p53 relationship in hereditary breast cancer.
Neoplasms
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity.
Neoplasms
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
Neoplasms
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease.
Neoplasms
BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene.
Neoplasms
BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer : hope or reality?
Neoplasms
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
Neoplasms
BRCA1/2 Mutations and Triple Negative Breast Cancers.
Neoplasms
BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer.
Neoplasms
BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer.
Neoplasms
BRCA1/BARD1 complex interacts with steroidogenic factor 1--A potential mechanism for regulation of aromatase expression by BRCA1.
Neoplasms
BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II.
Neoplasms
BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans.
Neoplasms
BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II.
Neoplasms
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
Neoplasms
BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Neoplasms
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
Neoplasms
BRCA1/P53: Two strengths in cancer chemoprevention.
Neoplasms
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Neoplasms
BRCA1: a movement toward cancer prevention.
Neoplasms
BRCA1: Beyond double-strand break repair.
Neoplasms
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.
Neoplasms
BRCA1: exploring the links to transcription.
Neoplasms
BRCA1: linking HOX to breast cancer suppression.
Neoplasms
BRCA1: mechanisms of inactivation and implications for management of patients.
Neoplasms
BRCA1: the enigma of tissue-specific tumor development.
Neoplasms
BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers.
Neoplasms
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.
Neoplasms
BRCA2 and Other DDR Genes in Prostate Cancer.
Neoplasms
BRCA2 carriers with male breast cancer show elevated tumour methylation.
Neoplasms
BRCA2 founder mutation in Slovenian breast cancer families.
Neoplasms
BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Neoplasms
BRCA2 germline mutations in Japanese breast cancer families.
Neoplasms
BRCA2 germline mutations in male breast cancer cases and breast cancer families.
Neoplasms
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
Neoplasms
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
Neoplasms
BRCA2 mutation analysis of 87 Spanish breast/ovarian cancer families.
Neoplasms
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Neoplasms
BRCA2 mutations and triple-negative breast cancer.
Neoplasms
BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.
Neoplasms
BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells.
Neoplasms
BRCA2: a genetic risk factor for breast cancer.
Neoplasms
Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF).
Neoplasms
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Neoplasms
BRCAness revisited.
Neoplasms
BRCC36A is epistatic to BRCA1 in DNA crosslink repair and homologous recombination in Arabidopsis thaliana.
Neoplasms
BRCT domains: phosphopeptide binding and signaling modules.
Neoplasms
BRD7: a novel tumor suppressor gene in different cancers.
Neoplasms
Breast and Axillary Lymph Node Metastasis from Ovarian Cancer: A Case Report.
Neoplasms
Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Neoplasms
Breast and Ovarian Cancer Risk due to Prevalence of BRCA1 and BRCA2 Variants in Pakistani Population: A Pakistani Database Report.
Neoplasms
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Neoplasms
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Neoplasms
Breast and ovarian cancer: the forgotten paternal contribution.
Neoplasms
Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
Neoplasms
Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
Neoplasms
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Neoplasms
Breast cancer and genetic instability: the molecules behind the scenes.
Neoplasms
Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Neoplasms
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Neoplasms
Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair--perhaps through transcription.
Neoplasms
Breast cancer genes: therapeutic strategies.
Neoplasms
Breast cancer genetics and managed care. The Kaiser Permanente experience.
Neoplasms
Breast cancer genetics: family history, heterogeneity, molecular genetic diagnosis, and genetic counselling.
Neoplasms
Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice.
Neoplasms
Breast cancer in a patient with Birt-Hogg-Dubé syndrome (BHDS) with dramatic response to neoadjuvant chemotherapy.
Neoplasms
Breast cancer in BRCA mutation carriers: medical treatment.
Neoplasms
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Neoplasms
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
Neoplasms
Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors.
Neoplasms
Breast cancer markers.
Neoplasms
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Neoplasms
Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.
Neoplasms
Breast Cancer Predisposition Genes and Synthetic Lethality.
Neoplasms
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Neoplasms
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Neoplasms
Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
Neoplasms
Breast cancer risk associated with BRCA1/2 variants in the Pakistani population.
Neoplasms
Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.
Neoplasms
Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
Neoplasms
Breast cancer risks and risk prediction models.
Neoplasms
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Neoplasms
Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Neoplasms
Breast cancer stem cell markers - the rocky road to clinical applications.
Neoplasms
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Neoplasms
Breast cancer susceptibility genes. BRCA1 and BRCA2.
Neoplasms
Breast cancer susceptibility protein 1 (BRCA1) rescues neurons from cerebral ischemia/reperfusion injury through NRF2-mediated antioxidant pathway.
Neoplasms
Breast cancer susceptibility testing: past, present and future.
Neoplasms
Breast cancer-associated abraxas mutation disrupts nuclear localization and DNA damage response functions.
Neoplasms
Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy.
Neoplasms
Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
Neoplasms
Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
Neoplasms
Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer.
Neoplasms
Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.
Neoplasms
Breast MRI as a screening tool: the appropriate role.
Neoplasms
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Neoplasms
Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors.
Neoplasms
Bringing prostate cancer germline genetics into clinical practice.
Neoplasms
BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer.
Neoplasms
BRIT-1 expression and its relationship with PARP-1 and CAF-1/p60 in cutaneous melanoma.
Neoplasms
BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer.
Neoplasms
BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice.
Neoplasms
C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Neoplasms
c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/?-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation.
Neoplasms
c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLC?1.
Neoplasms
c-Cbl is a suppressor of the neu oncogene.
Neoplasms
c-Cbl mediates the degradation of tumorigenic nuclear ?-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors.
Neoplasms
C-Cbl protein in human cancer tissues is frequently tyrosine phosphorylated in a tumor-specific manner.
Neoplasms
c-Cbl regulates ?Pix-mediated cell migration and invasion.
Neoplasms
C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
Neoplasms
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
Neoplasms
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
Neoplasms
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.
Neoplasms
c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Neoplasms
c9t11-Conjugated linoleic acid-rich oil fails to attenuate wasting in colon-26 tumor-induced late-stage cancer cachexia in male CD2F1 mice.
Neoplasms
CA 125: fundamental and clinical aspects.
Neoplasms
Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype.
Neoplasms
Caenorhabditis elegans RBX1 is essential for meiosis, mitotic chromosomal condensation and segregation, and cytokinesis.
Neoplasms
CAF-like state in primary skin fibroblasts with constitutional BRCA1 epimutation sheds new light on tumor suppressor deficiency-related changes in healthy tissue.
Neoplasms
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Neoplasms
CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
Neoplasms
CAG repeat size in Huntingtin alleles is associated with cancer prognosis.
Neoplasms
Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?
Neoplasms
Can personality traits affect the quality of life of women with the BRCA1/BRCA2 mutations before and after prophylactic adnexectomy?
Neoplasms
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?
Neoplasms
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Neoplasms
Cancer and heterogeneity of obesity: a potential contribution of brown fat.
Neoplasms
Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.
Neoplasms
Cancer control in susceptible groups: opportunities and challenges.
Neoplasms
Cancer gene therapy and immunotherapy (review).
Neoplasms
Cancer genetics and reproduction.
Neoplasms
Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
Neoplasms
Cancer genetics in primary care.
Neoplasms
Cancer genetics in the new era of molecular biology.
Neoplasms
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Neoplasms
Cancer Incidence in BRCA1 mutation carriers.
Neoplasms
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.
Neoplasms
Cancer predisposing mutations in BRCT domains.
Neoplasms
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. II. A Mendelian single-locus model of cancer predisposition and radiosensitivity for predicting cancer risks in populations.
Neoplasms
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals.
Neoplasms
Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations.
Neoplasms
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Neoplasms
Cancer research. Transatlantic war over BRCA1 patent.
Neoplasms
Cancer risk assessment at the atomic level.
Neoplasms
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
Neoplasms
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation.
Neoplasms
Cancer Risk Management Decisions of Women with BRCA1 or BRCA2 Variants of Uncertain Significance.
Neoplasms
Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
Neoplasms
Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.
Neoplasms
Cancer risks among BRCA1 and BRCA2 mutation carriers.
Neoplasms
Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Neoplasms
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Neoplasms
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
Neoplasms
Cancer risks in BRCA1 carriers: time for the next generation of studies.
Neoplasms
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Neoplasms
Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status.
Neoplasms
Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.
Neoplasms
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
Neoplasms
Cancer Selective Target Degradation by Folate-Caged PROTACs.
Neoplasms
Cancer stem cell heterogeneity in hereditary breast cancer.
Neoplasms
Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer.
Neoplasms
Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.
Neoplasms
Cancer susceptibility and the functions of BRCA1 and BRCA2.
Neoplasms
Cancer treatment according to BRCA1 and BRCA2 mutations.
Neoplasms
Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor.
Neoplasms
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.
Neoplasms
Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study.
Neoplasms
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Neoplasms
Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Neoplasms
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Neoplasms
Candidate gene association studies: successes and failures.
Neoplasms
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Neoplasms
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.
Neoplasms
Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant.
Neoplasms
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
Neoplasms
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Neoplasms
Carcinoid tumor of lung and BRCA mutation: a case report.
Neoplasms
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
Neoplasms
CARP-1/CCAR1: a biphasic regulator of cancer cell growth and apoptosis.
Neoplasms
Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma.
Neoplasms
Caspase-1 and caspase-8 cleave and inactivate cellular parkin.
Neoplasms
Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis.
Neoplasms
Catalytically Important Residues of E6AP Ubiquitin Ligase Identified Using Acid-Cleavable Photo-Cross-Linkers.
Neoplasms
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Neoplasms
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Neoplasms
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Neoplasms
CBP/p300 interact with and function as transcriptional coactivators of BRCA1.
Neoplasms
Cbx2 stably associates with mitotic chromosomes via a PRC2- or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes.
Neoplasms
CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Neoplasms
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Neoplasms
Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy.
Neoplasms
CDDO-Imidazolide Induces DNA Damage, G2/M Arrest and Apoptosis in BRCA1-Mutated Breast Cancer Cells.
Neoplasms
CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.
Neoplasms
Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner.
Neoplasms
Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.
Neoplasms
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Neoplasms
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Neoplasms
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
Neoplasms
CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
Neoplasms
cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Neoplasms
cDNA sequence and chromosomal localization of mouse Dlgh3 gene adjacent to the BRCA1 tumor suppressor locus.
Neoplasms
Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy.
Neoplasms
Celebrity Health Announcements and Online Health Information Seeking: An Analysis of Angelina Jolie's Preventative Health Decision.
Neoplasms
Cell biology of cancer: BRCA1 and sister chromatid pairing reactions?
Neoplasms
Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization.
Neoplasms
Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells.
Neoplasms
Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.
Neoplasms
Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest.
Neoplasms
Cell cycle-dependent ubiquitylation and destruction of NDE1 by CDK5-FBW7 regulates ciliary length.
Neoplasms
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Neoplasms
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
Neoplasms
Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?
Neoplasms
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Neoplasms
Cellular inhibitors of apoptosis (cIAP) 1 and 2 are increased in placenta from obese pregnant women.
Neoplasms
Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Neoplasms
Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer.
Neoplasms
Centriole separation in DNA damage-induced centrosome amplification.
Neoplasms
Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination.
Neoplasms
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
Neoplasms
Centrosome amplification, chromosome instability and cancer development.
Neoplasms
Cereblon attenuates DNA damage-induced apoptosis by regulating the transcription-independent function of p53.
Neoplasms
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q.
Neoplasms
Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
Neoplasms
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
Neoplasms
Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
Neoplasms
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.
Neoplasms
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Neoplasms
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses.
Neoplasms
Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Neoplasms
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
Neoplasms
Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry.
Neoplasms
Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series.
Neoplasms
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Neoplasms
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Neoplasms
Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging.
Neoplasms
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Neoplasms
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Neoplasms
Characterization of a carboxy-terminal BRCA1 interacting protein.
Neoplasms
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Neoplasms
Characterization of a novel germline BRCA1 splice variant, c.5332+4delA.
Neoplasms
Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.
Neoplasms
Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study.
Neoplasms
Characterization of Brca1 deficient mice.
Neoplasms
Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia.
Neoplasms
Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Neoplasms
Characterization of COBRA1 in human breast cancer cell lines using a new polyclonal antibody against COBRA1.
Neoplasms
Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus.
Neoplasms
Characterization of FANCL variants observed in patient cancer cells.
Neoplasms
Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells.
Neoplasms
Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
Neoplasms
Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein-protein and protein-DNA interactions?
Neoplasms
Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks.
Neoplasms
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Neoplasms
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Neoplasms
Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer.
Neoplasms
Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family.
Neoplasms
Characterization of tumor-associated Chk2 mutations.
Neoplasms
Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.
Neoplasms
Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.
Neoplasms
Characterizing the novel protein p33MONOX.
Neoplasms
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Neoplasms
Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.
Neoplasms
CHEK2 1100delC is not a risk factor for male breast cancer population.
Neoplasms
Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.
Neoplasms
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Neoplasms
Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer.
Neoplasms
Chemopreventive efficacy of stampidine in a murine breast cancer model.
Neoplasms
Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
Neoplasms
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Neoplasms
Chicoric acid (CA) induces autophagy in gastric cancer through promoting endoplasmic reticulum (ER) stress regulated by AMPK.
Neoplasms
Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer Clinic.
Neoplasms
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
Neoplasms
CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin.
Neoplasms
CHIP involves in non-small cell lung cancer prognosis through VEGF pathway.
Neoplasms
CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR.
Neoplasms
CHIP regulates osteoclast formation through promoting TRAF6 protein degradation.
Neoplasms
CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
Neoplasms
Chk1 phosphorylated at serine(345) is a predictor of early local recurrence and radio-resistance in breast cancer.
Neoplasms
Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair.
Neoplasms
CHK2-BRCA1 tumor-suppressor axis restrains oncogenic Aurora-A kinase to ensure proper mitotic microtubule assembly.
Neoplasms
Chl1p, a DNA helicase-like protein in budding yeast, functions in sister-chromatid cohesion.
Neoplasms
Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells.
Neoplasms
Chromogenic and fluorescent in situ hybridization in breast cancer.
Neoplasms
Chromosomal breakage syndromes and the BRCA1 genome surveillance complex.
Neoplasms
Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers.
Neoplasms
Chromosome 17q linkage studies of 18 Utah breast cancer kindreds.
Neoplasms
Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer.
Neoplasms
Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Neoplasms
Chromosome breakage syndromes and cancer.
Neoplasms
Chromothripsis in human breast cancer.
Neoplasms
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination.
Neoplasms
cIAP2 as a therapeutic target in colorectal cancer and other malignancies.
Neoplasms
cIAP2 expression and clinical significance in pigmented villonodular synovitis.
Neoplasms
cIAP2 Is an Independent Signaling and Survival Factor during Mammary Lactational Involution and Tumorigenesis.
Neoplasms
cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.
Neoplasms
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
Neoplasms
cIAP2 represses IKK?/?-mediated activation of MDM2 to prevent p53 degradation.
Neoplasms
cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer.
Neoplasms
circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.
Neoplasms
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
Neoplasms
Circulating tumor cells and breast cancer-specific mutations in primary breast cancer.
Neoplasms
ciRs-6 upregulates March1 to suppress bladder cancer growth by sponging miR-653.
Neoplasms
Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability.
Neoplasms
Cisplatin-damaged BRCA1 exhibits altered thermostability and transcriptional transactivation.
Neoplasms
CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the Breast Cancer Family Registry.
Neoplasms
Classification of BRCA1 missense variants of unknown clinical significance.
Neoplasms
Classification of IVS1-10T-->C as a polymorphism of BRCA1.
Neoplasms
Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
Neoplasms
Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
Neoplasms
Classification of the spliceogenic BRCA1 c.4096+3A>G variant as likely benign based on cosegregation data and identification of a healthy homozygous carrier.
Neoplasms
Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort.
Neoplasms
Classification of VUS and unclassified variants in BRCA1 BRCT repeats by molecular dynamics simulation.
Neoplasms
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Neoplasms
Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Neoplasms
Clinical and ethical issues in the diagnosis of hereditary breast cancer (review).
Neoplasms
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Neoplasms
Clinical and genetic characterization of hereditary breast cancer in a Chinese population.
Neoplasms
Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Neoplasms
Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.
Neoplasms
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Neoplasms
Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
Neoplasms
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Neoplasms
Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.
Neoplasms
Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.
Neoplasms
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
Neoplasms
Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
Neoplasms
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Neoplasms
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Neoplasms
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.
Neoplasms
Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.
Neoplasms
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Neoplasms
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Neoplasms
Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2.
Neoplasms
Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
Neoplasms
Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.
Neoplasms
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Neoplasms
Clinical implications for BRCA gene mutation in breast cancer.
Neoplasms
Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
Neoplasms
Clinical management of BRCA1 and BRCA2 mutation carriers.
Neoplasms
Clinical management of BRCA1- and BRCA2-associated breast cancer.
Neoplasms
Clinical management of hereditary breast cancer syndromes.
Neoplasms
Clinical management of women with genomic BRCA1 and BRCA2 mutations.
Neoplasms
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.
Neoplasms
Clinical outcome of hereditary breast cancer in the lithuanian population.
Neoplasms
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Neoplasms
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Neoplasms
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Neoplasms
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Neoplasms
Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer.
Neoplasms
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Neoplasms
Clinical significance of large rearrangements in BRCA1 and BRCA2.
Neoplasms
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Neoplasms
Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
Neoplasms
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
Neoplasms
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.
Neoplasms
Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.
Neoplasms
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Neoplasms
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.
Neoplasms
Clinicopathologic Characteristics and Survival in BRCA1- and BRCA2-Related Adnexal Cancer: Are They Different?
Neoplasms
Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
Neoplasms
Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
Neoplasms
Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
Neoplasms
Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
Neoplasms
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer.
Neoplasms
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Neoplasms
Clinicopathological Significance of BRCA1 Promoter Hypermethylation in Thai Breast Cancer Patients.
Neoplasms
Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Neoplasms
Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas.
Neoplasms
Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
Neoplasms
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.
Neoplasms
Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis.
Neoplasms
Cloning and functional identification of two novel BRCA1 splicing variants.
Neoplasms
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Neoplasms
Co-occurrence of multiple sclerosis and cancer in a BRCA1 positive family.
Neoplasms
Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages.
Neoplasms
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Neoplasms
Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer.
Neoplasms
Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Neoplasms
Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes.
Neoplasms
Colorado family physicians' knowledge of hereditary breast cancer and related practice.
Neoplasms
Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.
Neoplasms
Combination of photoactive hypericin and Manumycin A exerts multiple anticancer effects on oxaliplatin-resistant colorectal cells.
Neoplasms
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Neoplasms
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Neoplasms
Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists.
Neoplasms
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
Neoplasms
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms.
Neoplasms
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.
Neoplasms
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
Neoplasms
Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
Neoplasms
Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study.
Neoplasms
Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk.
Neoplasms
Combining intracellular antibodies to restore function of mutated p53 in cancer.
Neoplasms
Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46.
Neoplasms
Commentary: The unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP beta.
Neoplasms
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Neoplasms
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Neoplasms
Common breast cancer risk variants in the post-COGS era: a comprehensive review.
Neoplasms
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Neoplasms
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant.
Neoplasms
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Neoplasms
Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Neoplasms
Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.
Neoplasms
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
Neoplasms
Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.
Neoplasms
Common, germline genetic variations in the novel tumor suppressor
Neoplasms
Commonly observed RNF43 mutations retain functionality in attenuating Wnt/?-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers.
Neoplasms
Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups.
Neoplasms
Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
Neoplasms
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Neoplasms
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Neoplasms
Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
Neoplasms
Comparative genomics and protein domain graph analyses link ubiquitination and RNA metabolism.
Neoplasms
Comparative inhibitory profile and distribution of bacterial PARPs, using Clostridioides difficile CD160 PARP as a model.
Neoplasms
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Neoplasms
Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Neoplasms
Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations.
Neoplasms
Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
Neoplasms
Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
Neoplasms
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations.
Neoplasms
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Neoplasms
Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Neoplasms
Comparisons of gene coexpression network modules in breast cancer and ovarian cancer.
Neoplasms
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Neoplasms
Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
Neoplasms
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.
Neoplasms
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Neoplasms
Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
Neoplasms
Complex Breakpoints and Template Switching Associated with Non-canonical Termination of Homologous Recombination in Mammalian Cells.
Neoplasms
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Neoplasms
Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Neoplasms
Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil.
Neoplasms
Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
Neoplasms
Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.
Neoplasms
Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
Neoplasms
Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.
Neoplasms
Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
Neoplasms
Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
Neoplasms
Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer.
Neoplasms
Comprehensive molecular biomarker identification in breast cancer brain metastases.
Neoplasms
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Neoplasms
Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.
Neoplasms
Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.
Neoplasms
Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Neoplasms
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Neoplasms
Computational and Experimental Characterization of NF023, A Candidate Anticancer Compound Inhibiting cIAP2/TRAF2 Assembly.
Neoplasms
Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?
Neoplasms
Conclusions and recommendations from the Helene Harris Memorial Trust Fourth Biennial International Forum on Ovarian Cancer 11-14 May 1993, Toronto, Canada.
Neoplasms
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Neoplasms
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.
Neoplasms
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.
Neoplasms
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.
Neoplasms
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.
Neoplasms
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Neoplasms
Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein.
Neoplasms
Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA.
Neoplasms
Considerations in genetic counseling for inherited breast cancer predisposition.
Neoplasms
Considering the Role of Murine Double Minute 2 in the Cardiovascular System?
Neoplasms
Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories.
Neoplasms
Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
Neoplasms
CONSTITUTIONAL METHYLATION OF THE BRCA1 PROMOTER IS SPECIFICALLY ASSOCIATED WITH BRCA1 MUTATION-ASSOCIATED PATHOLOGY IN EARLY-ONSET BREAST CANCER.
Neoplasms
Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer.
Neoplasms
Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes.
Neoplasms
Consulting prostate cancer cohort data uncovers transcriptional control: Regulation of the MARCH6 gene.
Neoplasms
Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
Neoplasms
Context Matters: RNF168 Connects with PALB2 to Rewire Homologous Recombination in BRCA1 Haploinsufficiency.
Neoplasms
Context-dependent AMPK activation distinctly regulates TAp73 stability and transcriptional activity.
Neoplasms
Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Neoplasms
Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer.
Neoplasms
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.
Neoplasms
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Neoplasms
Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Neoplasms
Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
Neoplasms
Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Neoplasms
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.
Neoplasms
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Neoplasms
Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database.
Neoplasms
Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization.
Neoplasms
Control of biochemical reactions through supramolecular RING domain self-assembly.
Neoplasms
Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
Neoplasms
Cool-1 mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Neoplasms
Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells.
Neoplasms
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice.
Neoplasms
COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer.
Neoplasms
Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies.
Neoplasms
Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation.
Neoplasms
Correcting errors in the BRCA1 warning system.
Neoplasms
Correction for Ho et al., Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability.
Neoplasms
Correction to: BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
Neoplasms
Correction: Møller, P.; et al. Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift. Cancers 2019, 11, 132.
Neoplasms
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Neoplasms
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Neoplasms
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Neoplasms
Correlation between morphology, immunohistochemistry and molecular pathology in hereditary and sporadic breast cancer cases.
Neoplasms
Correlation between MR imaging - prognosis factors and molecular classification of breast cancers.
Neoplasms
Correlation of molecular and morphological features of appendiceal epithelial neoplasms.
Neoplasms
Correspondence re: A. Rothfuss et al., Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res., 60: 390-394, 2000.
Neoplasms
Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
Neoplasms
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Neoplasms
Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Neoplasms
Counselling framework for moderate-penetrance cancer-susceptibility mutations.
Neoplasms
Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase activity and inhibits lung cancer cell growth in response to type I interferon.
Neoplasms
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
Neoplasms
CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Neoplasms
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
Neoplasms
CRISPR-Cas9/long-read sequencing approach to identify cryptic mutations in BRCA1 and other tumour suppressor genes.
Neoplasms
CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.
Neoplasms
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Neoplasms
Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.
Neoplasms
CRL4BRBBP7 targets HUWE1 for ubiquitination and proteasomal degradation.
Neoplasms
CRL4Cdt2: master coordinator of cell cycle progression and genome stability.
Neoplasms
Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.
Neoplasms
Crosstalk between ubiquitin and other post-translational modifications on chromatin during double-strand break repair.
Neoplasms
Crucial Role for Early Growth Response-1 in the Transcriptional Regulation of miR-20b in Breast Cancer.
Neoplasms
CRY2 and FBXL3 Cooperatively Degrade c-MYC.
Neoplasms
Crystal Structure and Interaction Studies of the Human FBxo3 ApaG Domain.
Neoplasms
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Neoplasms
Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences.
Neoplasms
Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1.
Neoplasms
CSE1L/CAS: its role in proliferation and apoptosis.
Neoplasms
CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR.
Neoplasms
CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis.
Neoplasms
CtIP, a candidate tumor susceptibility gene is a team player with luminaries.
Neoplasms
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Neoplasms
Cul4a as a New Interaction Protein of PARP1 Inhibits Oxidative Stress-Induced H9c2 Cell Apoptosis.
Neoplasms
CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation.
Neoplasms
Cullin 3 and Its Role in Tumorigenesis.
Neoplasms
Cullin-4A·DNA damage-binding protein 1 E3 ligase complex targets tumor suppressor RASSF1A for degradation during mitosis.
Neoplasms
Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells.
Neoplasms
Curcumin homing to the nucleolus: mechanism for initiation of an apoptotic program.
Neoplasms
Current and emerging breast cancer biomarkers.
Neoplasms
Current condition of genetic medicine for hereditary breast cancer.
Neoplasms
Current perspectives on BRCA1- and BRCA2-associated breast cancers.
Neoplasms
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Neoplasms
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Neoplasms
Current Treatment Options in Triple Negative Breast Cancer.
Neoplasms
Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Neoplasms
CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID.
Neoplasms
Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
Neoplasms
Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Neoplasms
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Neoplasms
Cyclin F: A component of an E3 ubiquitin ligase complex with roles in neurodegeneration and cancer.
Neoplasms
Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers.
Neoplasms
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Neoplasms
Cytokines, signaling and diseases - a pharmacologist's view.
Neoplasms
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Neoplasms
Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.
Neoplasms
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Neoplasms
Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.
Neoplasms
Damage-induced BRCA1 phosphorylation by Chk2 contributes to the timing of end resection.
Neoplasms
Daxx Represses Expression of a Subset of Antiapoptotic Genes Regulated by Nuclear Factor-{kappa}B.
Neoplasms
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Neoplasms
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Neoplasms
De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes.
Neoplasms
De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer.
Neoplasms
De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.
Neoplasms
DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-?-Driven Epithelial-Mesenchymal Transition.
Neoplasms
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Neoplasms
DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity.
Neoplasms
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Neoplasms
Deciphering the BRCA1 Tumor Suppressor Network.
Neoplasms
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Neoplasms
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Neoplasms
Decision-making about genetic testing among women at familial risk for breast cancer.
Neoplasms
Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer.
Neoplasms
Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.
Neoplasms
Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
Neoplasms
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Neoplasms
Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex.
Neoplasms
Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Neoplasms
Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma.
Neoplasms
Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer.
Neoplasms
Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma.
Neoplasms
Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.
Neoplasms
Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Neoplasms
Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers.
Neoplasms
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Neoplasms
Defective homologous recombination in human cancers.
Neoplasms
Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining.
Neoplasms
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Neoplasms
Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1.
Neoplasms
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex.
Neoplasms
Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.
Neoplasms
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Neoplasms
Deletion of Exons 1a-2 of BRCA1: A Rather Frequent Pathogenic Abnormality.
Neoplasms
Deletion of tumor suppressor genes in Chinese non-small cell lung cancer.
Neoplasms
Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Neoplasms
Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancers.
Neoplasms
Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
Neoplasms
Dependence of Human Colorectal Cells Lacking the FBW7 Tumor Suppressor on the Spindle Assembly Checkpoint.
Neoplasms
Depletion of NBR1 in urothelial carcinoma cells enhances rapamycin-induced apoptosis through impaired autophagy and mitochondrial dysfunction.
Neoplasms
Depletion of the 26S Proteasome Adaptor Ecm29 Increases Toll-Like Receptor 3 Signaling.
Neoplasms
Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Neoplasms
Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
Neoplasms
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Neoplasms
Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine.
Neoplasms
Design and Activity of Specific Hypoxia-Inducible Factor 2? (HIF-2?) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Neoplasms
Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
Neoplasms
Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
Neoplasms
Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
Neoplasms
Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks.
Neoplasms
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Neoplasms
Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing.
Neoplasms
Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
Neoplasms
Detection of clustered DNA lesions: Biological and clinical applications.
Neoplasms
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Neoplasms
Detection of exon skipping events in BRCA1 RNA using MLPA kit P002.
Neoplasms
Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.
Neoplasms
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization.
Neoplasms
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
Neoplasms
Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
Neoplasms
Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Neoplasms
Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21.
Neoplasms
Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
Neoplasms
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Neoplasms
Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Neoplasms
Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods.
Neoplasms
Detoxification: A Novel Function of BRCA1 in Tumor Suppression?
Neoplasms
Deubiquitination of Chfr, a checkpoint protein, by USP7/HAUSP regulates its stability and activity.
Neoplasms
Developing culturally sensitive cancer genetics communication aids for African Americans.
Neoplasms
Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Neoplasms
Development and pilot evaluation of novel genetic educational materials designed for an underserved patient population.
Neoplasms
Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Neoplasms
Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing.
Neoplasms
Development of a high risk pancreatic screening clinic using 3.0 T MRI.
Neoplasms
Development of a homogeneous AlphaLISA ubiquitination assay using ubiquitin binding matrices as universal components for the detection of ubiquitinated proteins.
Neoplasms
Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
Neoplasms
Development of PARP inhibitors in oncology.
Neoplasms
Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins.
Neoplasms
Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
Neoplasms
Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
Neoplasms
Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues.
Neoplasms
Developmental studies of Brca1 and Brca2 knock-out mice.
Neoplasms
Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic".
Neoplasms
Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast.
Neoplasms
DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families.
Neoplasms
Diagnostic criteria for testing for BRCA1 and BRCA2: the experience of the Department of Defense Familial Breast/Ovarian Cancer Research Project.
Neoplasms
Dideoxy fingerprinting assay for BRCA1 mutation analysis.
Neoplasms
Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Neoplasms
Differences in cysteine peptidases-like activity in sera of patients with breast cancer.
Neoplasms
Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined.
Neoplasms
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.
Neoplasms
Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
Neoplasms
Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Neoplasms
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
Neoplasms
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation.
Neoplasms
Differential Chemotherapeutic Sensitivity for Breast Tumors With "BRCAness": A Review.
Neoplasms
Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
Neoplasms
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.
Neoplasms
Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma: an immunohistochemical approach.
Neoplasms
Differential Display Analysis of 2,3,7,8-Tetrachlorodibenzo-p-dioxin Identified Induction of Ras-related Nuclear Protein Binding Protein2 (RanBP2) Gene.
Neoplasms
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data.
Neoplasms
Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.
Neoplasms
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines.
Neoplasms
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.
Neoplasms
Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Neoplasms
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Neoplasms
Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.
Neoplasms
Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase.
Neoplasms
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Neoplasms
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Neoplasms
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.
Neoplasms
Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
Neoplasms
Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
Neoplasms
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Neoplasms
Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Neoplasms
DiNeR: a Differential graphical model for analysis of co-regulation Network Rewiring.
Neoplasms
Diosgenin inhibits the expression of NEDD4 in prostate cancer cells.
Neoplasms
Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis.
Neoplasms
Direct DNA binding by Brca1.
Neoplasms
Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
Neoplasms
Direct genomic multiplex PCR for BRCA1 and application to mutation detection by single-strand conformation and heteroduplex analysis.
Neoplasms
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Neoplasms
Direct stimulation of transcription initiation by BRCA1 requires both its amino and carboxyl termini.
Neoplasms
Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer.
Neoplasms
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Neoplasms
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.
Neoplasms
Discovery of cell-permeable inhibitors that target the BRCT domain of BRCA1 protein by using a small-molecule microarray.
Neoplasms
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
Neoplasms
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.
Neoplasms
Discovery of small molecule WWP2 ubiquitin ligase inhibitors.
Neoplasms
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Neoplasms
Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers.
Neoplasms
Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases.
Neoplasms
Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines.
Neoplasms
Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.
Neoplasms
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.
Neoplasms
Dissecting PARP inhibitor resistance with functional genomics.
Neoplasms
Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function.
Neoplasms
Distinct claudin expression characterizes BRCA1-related breast cancer.
Neoplasms
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Neoplasms
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Neoplasms
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Neoplasms
Distinct Ring1b complexes defined by DEAD-box helicases and EMT transcription factors synergistically enhance E-cadherin silencing in breast cancer.
Neoplasms
Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Neoplasms
Distinct roles of TRAF6 and TAK1 in the regulation of adipocyte survival, thermogenesis program, and high-fat diet-induced obesity.
Neoplasms
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Neoplasms
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
Neoplasms
DLG1 is an anchor for the E3 ligase MARCH2 at sites of cell-cell contact.
Neoplasms
DNA array-based method for detection of large rearrangements in the BRCA1 gene.
Neoplasms
DNA damage induces p53-dependent BRCA1 nuclear export.
Neoplasms
DNA damage repair functions and targeted treatment in breast cancer.
Neoplasms
DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'.
Neoplasms
DNA damage response genes and the development of cancer metastasis.
Neoplasms
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Neoplasms
DNA damage-induced activation of CUL4B targets HUWE1 for proteasomal degradation.
Neoplasms
DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis.
Neoplasms
DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation.
Neoplasms
DNA double strand break repair and its association with inherited predispositions to breast cancer.
Neoplasms
DNA double-strand break repair pathway choice and cancer.
Neoplasms
DNA double-strand breaks: signaling, repair and the cancer connection.
Neoplasms
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.
Neoplasms
DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.
Neoplasms
DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.
Neoplasms
DNA methylome profiling identifies novel methylated genes in epithelial ovarian cancer patients with platinum resistance.
Neoplasms
DNA polymerase stalling, sister chromatid recombination and the BRCA genes.
Neoplasms
DNA Polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
Neoplasms
DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
Neoplasms
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
Neoplasms
DNA repair and synthetic lethality.
Neoplasms
DNA repair deficiency as a therapeutic target in cancer.
Neoplasms
DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.
Neoplasms
DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
Neoplasms
DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus.
Neoplasms
Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
Neoplasms
Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
Neoplasms
Does familial breast cancer and thymoma suggest a cancer syndrome? A family perspective.
Neoplasms
Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?
Neoplasms
Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility?
Neoplasms
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Neoplasms
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.
Neoplasms
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
Neoplasms
Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Neoplasms
Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
Neoplasms
Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing.
Neoplasms
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
Neoplasms
Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
Neoplasms
Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.
Neoplasms
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.
Neoplasms
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Neoplasms
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Neoplasms
Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2.
Neoplasms
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.
Neoplasms
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Neoplasms
Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.
Neoplasms
Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.
Neoplasms
Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy.
Neoplasms
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
Neoplasms
Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.
Neoplasms
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Neoplasms
Downregulation of ring-finger protein 43 in glioma associates with poor prognosis.
Neoplasms
Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1?, autophagy and ketone body production.
Neoplasms
Downregulation of TGF-?1 suppressed proliferation and increased chemosensitivity of ovarian cancer cells by promoting BRCA1/Smad3 signaling.
Neoplasms
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.
Neoplasms
Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.
Neoplasms
Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy.
Neoplasms
Drugging the Cancers Addicted to DNA Repair.
Neoplasms
Dual immunofluorescence labeling with cell-specific markers localizes BRCA1 in both basal and luminal epithelial cells in primary outgrowth from noncancerous mammary ductal and alveolar preparations.
Neoplasms
Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy.
Neoplasms
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.
Neoplasms
Dualistic Role of BARD1 in Cancer.
Neoplasms
Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.
Neoplasms
Dynamics in the p53-Mdm2 ubiquitination pathway.
Neoplasms
Dynamics of DNA repair suggested by the subcellular localization of Brca1 and Brca2 proteins.
Neoplasms
Dysfunction of the MDM2/p53 axis is linked to premature aging.
Neoplasms
Dysfunctional BRCA1 is only indirectly linked to multiple centrosomes.
Neoplasms
Dysregulated Wnt?signalling and recurrent mutations?of?the tumour suppressor?RNF43?in early?gastric carcinogenesis.
Neoplasms
Dysregulation of Parkin-mediated mitophagy in thyroid Hürthle cell tumors.
Neoplasms
Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis.
Neoplasms
Dysregulation of x chromosome inactivation in high grade ovarian serous adenocarcinoma.
Neoplasms
E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.
Neoplasms
E2F1 interactive with BRCA1 pathway induces HCC two different small molecule metabolism or cell cycle regulation via mitochondrion or CD4+T to cytosol.
Neoplasms
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
Neoplasms
E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9.
Neoplasms
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
Neoplasms
E3 ligase activity of XIAP RING domain is required for XIAP-mediated cancer cell migration, but not for its RhoGDI binding activity.
Neoplasms
E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60.
Neoplasms
E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
Neoplasms
E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc.
Neoplasms
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Neoplasms
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
Neoplasms
E3 ligase RCHY1 negatively regulates HDAC2.
Neoplasms
E3 ligase SCFSKP2 ubiquitinates and degrades tumor suppressor C/EBP? in acute myeloid leukemia.
Neoplasms
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
Neoplasms
E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
Neoplasms
E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.
Neoplasms
E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion.
Neoplasms
E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.
Neoplasms
E3 Ubiquitin Ligase RLIM Negatively Regulates c-Myc Transcriptional Activity and Restrains Cell Proliferation.
Neoplasms
E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
Neoplasms
E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation.
Neoplasms
E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
Neoplasms
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.
Neoplasms
E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Neoplasms
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.
Neoplasms
E6AP promotes prostate cancer by reducing p27 expression.
Neoplasms
Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines.
Neoplasms
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Neoplasms
Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Neoplasms
Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Neoplasms
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Neoplasms
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
Neoplasms
ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
Neoplasms
Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Neoplasms
Ectopic expression of RNF168 and 53BP1 increases mutagenic but not physiological non-homologous end joining.
Neoplasms
Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks.
Neoplasms
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Neoplasms
Editorial: Childhood Cancer in sub-Saharan Africa.
Neoplasms
Educational review: role of the surgeon in hereditary breast cancer.
Neoplasms
Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration.
Neoplasms
Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice.
Neoplasms
Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Neoplasms
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Neoplasms
Effect of omega-6 polyunsaturated fatty acid (linoleic acid) on BRCA1 gene expression in MCF-7 cell line.
Neoplasms
Effect of pentoxifylline on tumor suppressor and proto-oncogene apoptosis in sperm.
Neoplasms
Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
Effect of S-phase kinase-associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients.
Neoplasms
Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression.
Neoplasms
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Neoplasms
Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population.
Neoplasms
Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epithelial cells.
Neoplasms
Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia.
Neoplasms
Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Neoplasms
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Neoplasms
Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.
Neoplasms
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Neoplasms
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
Neoplasms
Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
Neoplasms
Egr-1 regulates the transcription of the BRCA1 gene by etoposide.
Neoplasms
Ehrlichia chaffeensis TRP120-mediated ubiquitination and proteasomal degradation of tumor suppressor FBW7 increases oncoprotein stability and promotes infection.
Neoplasms
eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Neoplasms
Electrophoresis of BRCA1 oncosuppressor.
Neoplasms
Elevated estrogen receptor-? in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction.
Neoplasms
Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
Neoplasms
Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.
Neoplasms
Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.
Neoplasms
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
Neoplasms
ELL targets c-Myc for proteasomal degradation and suppresses tumour growth.
Neoplasms
Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
Neoplasms
Emerging PARP inhibitors for treating breast cancer.
Neoplasms
Emerging roles of BRCA1 alternative splicing.
Neoplasms
Emerging roles of BRCA1 in transcriptional regulation and DNA repair.
Neoplasms
Emerging roles of F-box proteins in cancer drug resistance.
Neoplasms
Emerging views of mitophagy in immunity and autoimmune diseases.
Neoplasms
Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study.
Neoplasms
EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
Neoplasms
Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis.
Neoplasms
Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.
Neoplasms
Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects.
Neoplasms
Endorepellin remodels the endothelial transcriptome toward a pro-autophagic and pro-mitophagic gene signature.
Neoplasms
Endothelial deletion of Sag/Rbx2/Roc2 E3 ubiquitin ligase causes embryonic lethality and blocks tumor angiogenesis.
Neoplasms
Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Neoplasms
Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders.
Neoplasms
Enhanced charge transfer by gold nanoparticle at DNA modified electrode and its application to label-free DNA detection.
Neoplasms
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Neoplasms
Enhanced metastasis in RNF13 knockout mice is mediated by a reduction in GM-CSF levels.
Neoplasms
Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Neoplasms
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Neoplasms
Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.
Neoplasms
Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein.
Neoplasms
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
Neoplasms
Enhancement of TGF-? signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer.
Neoplasms
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
Neoplasms
Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.
Neoplasms
Epigenetic alterations in patients with type 2 diabetes mellitus.
Neoplasms
Epigenetic alterations of BRG1 leads to cancer development through its nuclear-cytoplasmic shuttling abnormalities.
Neoplasms
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Neoplasms
Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours.
Neoplasms
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Neoplasms
Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis.
Neoplasms
Epigenetic modification and cancer: mark or stamp?
Neoplasms
Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy.
Neoplasms
Epigenetic pathogenesis of human papillomavirus in upper aerodigestive tract cancers.
Neoplasms
Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Neoplasms
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Neoplasms
Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population.
Neoplasms
Epigenetic tumor suppression by BRCA1.
Neoplasms
Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review).
Neoplasms
Epistasis in genomic and survival data of cancer patients.
Neoplasms
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.
Neoplasms
Epstein Barr virus: a prime candidate of breast cancer aetiology in Sudanese patients.
Neoplasms
ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca(2+) signaling.
Neoplasms
ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1.
Neoplasms
Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
Neoplasms
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
Neoplasms
ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
Neoplasms
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Neoplasms
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Neoplasms
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Neoplasms
Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Neoplasms
Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
Neoplasms
Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
Neoplasms
Establishment and characterization of a breast cell strain containing a BRCA1 185delAG mutation.
Neoplasms
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.
Neoplasms
Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
Neoplasms
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.
Neoplasms
Estimating genetic influence on disease from population-based case-control data: application to cancers of the breast and ovary.
Neoplasms
Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1.
Neoplasms
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Neoplasms
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Neoplasms
Estrogen receptor ? is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Neoplasms
Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.
Neoplasms
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
Neoplasms
Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling.
Neoplasms
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Neoplasms
Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Neoplasms
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
Neoplasms
Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice.
Neoplasms
Estrogen upregulation of BRCA1 expression with no effect on localization.
Neoplasms
Estrogens, BRCA1, and breast cancer.
Neoplasms
Ethical issues in cancer genetics: I 1) whose information is it?
Neoplasms
Ethical issues related to BRCA gene testing in orthodox Jewish women.
Neoplasms
Ethics of predictive DNA-testing for hereditary breast and ovarian cancer.
Neoplasms
Ethnic differences in cancer incidence: a marker for inherited susceptibility?
Neoplasms
Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk.
Neoplasms
ETS2 and Twist1 promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2.
Neoplasms
Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric cancer.
Neoplasms
Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk.
Neoplasms
Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection.
Neoplasms
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.
Neoplasms
Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
Neoplasms
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Neoplasms
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Neoplasms
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.
Neoplasms
Evaluation of data quality at the Gambia national cancer registry.
Neoplasms
Evaluation of expression profiles of microRNAs and two target genes, FOXO3a and RUNX2, effectively supports diagnostics and therapy predictions in breast cancer.
Neoplasms
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Neoplasms
Evaluation of observed and the expected incidence of common cancers: An experience from Southwestern of Iran, 2010-2014.
Neoplasms
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.
Neoplasms
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Neoplasms
Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.
Neoplasms
Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats.
Neoplasms
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
Neoplasms
Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Neoplasms
Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.
Neoplasms
Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer.
Neoplasms
Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal.
Neoplasms
Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.
Neoplasms
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer.
Neoplasms
Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2.
Neoplasms
Evidence of independent origin of multiple tumors from patients with prostate cancer.
Neoplasms
Evironmental pollutant perfluorodecanoic acid upregulates cIAP2 to suppress gastric cell senescence.
Neoplasms
Evolution and cancer: a mathematical biology approach.
Neoplasms
Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
Neoplasms
Evolutionary analysis of DNA-protein-coding regions based on a genetic code cube metric.
Neoplasms
Evolutionary constraint helps unmask a splicing regulatory region in BRCA1 exon 11.
Neoplasms
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.
Neoplasms
Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions.
Neoplasms
Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model.
Neoplasms
Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review.
Neoplasms
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Neoplasms
Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
Neoplasms
Exome sequencing and characterization of 49,960 individuals in the UK Biobank.
Neoplasms
Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
Neoplasms
Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient.
Neoplasms
Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants.
Neoplasms
Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Neoplasms
Exosomal TRIM3 is a novel marker and therapy target for gastric cancer.
Neoplasms
Exosome-mediated Delivery of the Intrinsic C-terminus Domain of PTEN Protects It From Proteasomal Degradation and Ablates Tumorigenesis.
Neoplasms
Exosomes Secreted from Human Cancer Cell Lines Contain Inhibitors of Apoptosis (IAP).
Neoplasms
Expanding perspectives on the significance of mitophagy in cancer.
Neoplasms
Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.
Neoplasms
Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
Neoplasms
Exploiting DNA repair defects in colorectal cancer.
Neoplasms
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Neoplasms
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.
Neoplasms
Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients.
Neoplasms
Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan Low-Density Array (TLDA).
Neoplasms
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
Neoplasms
Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues.
Neoplasms
Expression analysis of the MCPH1/BRIT1 and BRCA1 tumor suppressor genes and telomerase splice variants in epithelial ovarian cancer.
Neoplasms
Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
Neoplasms
Expression and localization of inhibitor of apoptosis proteins in normal human tissues.
Neoplasms
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Neoplasms
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Neoplasms
Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
Neoplasms
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Neoplasms
Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their c-Myc and p53 substrates in patients with dysplastic nevi or melanoma.
Neoplasms
Expression microarray identifies the unliganded glucocorticoid receptor as a regulator of gene expression in mammary epithelial cells.
Neoplasms
Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice.
Neoplasms
Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells.
Neoplasms
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
Neoplasms
Expression of androgen receptor coregulators in prostate cancer.
Neoplasms
Expression of Autophagy and Mitophagy Markers in Breast Cancer Tissues.
Neoplasms
Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status.
Neoplasms
Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
Neoplasms
Expression of BRCA1 and BRCA2 in normal and neoplastic cells.
Neoplasms
Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Neoplasms
Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.
Neoplasms
Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice.
Neoplasms
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Neoplasms
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Neoplasms
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Neoplasms
Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Neoplasms
Expression of BRCA1, NBR1 and NBR2 genes in human breast cancer cells.
Neoplasms
Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
Neoplasms
Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Neoplasms
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
Neoplasms
Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations.
Neoplasms
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy.
Neoplasms
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
Neoplasms
Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma.
Neoplasms
Expression of IAP family proteins in esophageal cancer.
Neoplasms
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Neoplasms
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Neoplasms
Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.
Neoplasms
Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.
Neoplasms
Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.
Neoplasms
Expression of Parkin, APC, APE1, and Bcl-xL in Colorectal Polyps.
Neoplasms
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
Neoplasms
Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation.
Neoplasms
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Neoplasms
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Neoplasms
Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas.
Neoplasms
Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.
Neoplasms
Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Neoplasms
Expression of the three components of linear ubiquitin assembly complex in breast cancer.
Neoplasms
Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.
Neoplasms
Expression pattern of parkin isoforms in lung adenocarcinomas.
Neoplasms
Expression patterns of the BRCA1 splicing variants in canine normal tissues and mammary gland tumors.
Neoplasms
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Neoplasms
Expression profile of parkin isoforms in human gliomas.
Neoplasms
Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines.
Neoplasms
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
Neoplasms
Extensive post-translational modification of active and inactivated forms of endogenous p53.
Neoplasms
Extent of breast cancer type 1 promoter methylation correlates with clinicopathological features in breast cancers.
Neoplasms
Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus.
Neoplasms
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
Neoplasms
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Neoplasms
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
Neoplasms
F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase kinase 6 (MKK6).
Neoplasms
F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
Neoplasms
Factors associated with the mammalian RNA polymerase II holoenzyme.
Neoplasms
Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
Neoplasms
Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
Neoplasms
Factors Influencing Men's Interest in Gene Testing for Prostate Cancer Susceptibility.
Neoplasms
Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Neoplasms
Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway.
Neoplasms
Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening.
Neoplasms
Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
Neoplasms
Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study.
Neoplasms
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Neoplasms
Familial aggregation of breast/ovarian cancer: age of onset along subsequent generations in Brazil.
Neoplasms
Familial and Racial Determinants of Tumor Suppressor Genes Promoter Hypermethylation in Breast Tissues from Healthy Women.
Neoplasms
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk.
Neoplasms
Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function.
Neoplasms
Familial breast cancer. Approaching the isolation of a susceptibility gene.
Neoplasms
Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Neoplasms
Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.
Neoplasms
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients.
Neoplasms
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Neoplasms
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Neoplasms
Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
Neoplasms
Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing.
Neoplasms
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Neoplasms
Familial non-BRCA1/BRCA2-associated breast cancer.
Neoplasms
Familial pancreatic carcinoma in Jews.
Neoplasms
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Neoplasms
Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH.
Neoplasms
Family communication about positive BRCA1 and BRCA2 genetic test results.
Neoplasms
Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
Neoplasms
Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Neoplasms
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Neoplasms
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Neoplasms
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
Neoplasms
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Neoplasms
Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
Neoplasms
FANCJ compensates for RAP80 deficiency and suppresses genomic instability induced by interstrand cross-links.
Neoplasms
FANCJ helicase controls the balance between short- and long-tract gene conversions between sister chromatids.
Neoplasms
Fanconi Anemia Complementation Group FANCD2 Protein Serine 331 Phosphorylation Is Important for Fanconi Anemia Pathway Function and BRCA2 Interaction.
Neoplasms
Fanconi anemia genes are highly expressed in primitive CD34+ hematopoietic cells.
Neoplasms
Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets.
Neoplasms
Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
Neoplasms
FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
Neoplasms
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Neoplasms
Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.
Neoplasms
FBW7 suppresses cell proliferation and G2/M cell cycle transition via promoting ?-catenin K63-linked ubiquitylation.
Neoplasms
FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.
Neoplasms
FBW7-mediated ubiquitination and degradation of KLF5.
Neoplasms
FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.
Neoplasms
FBXO16-mediated hnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer.
Neoplasms
FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.
Neoplasms
FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
Neoplasms
FBXO25 Promotes Cutaneous Squamous Cell Carcinoma Growth and Metastasis through Cyclin D1.
Neoplasms
FBXO38 Drives PD-1 to Destruction.
Neoplasms
Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.
Neoplasms
Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival.
Neoplasms
FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
Neoplasms
Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Neoplasms
Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway.
Neoplasms
Fbxw7 regulates tumor apoptosis, growth arrest and the epithelial-to-mesenchymal transition in part through the RhoA signaling pathway in gastric cancer.
Neoplasms
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Neoplasms
FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
Neoplasms
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
Neoplasms
Feed-forward regulatory loop driven by IRF4 and NF-?B in adult T-cell leukemia/lymphoma.
Neoplasms
FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Neoplasms
Fertility preservation in BRCA mutation carriers.
Neoplasms
Fibrosis and hypoxia-inducible factor-1?-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors.
Neoplasms
Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations.
Neoplasms
Filamin A inhibits tumor progression through regulating BRCA1 expression in human breast cancer.
Neoplasms
Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
Neoplasms
Fine tuning chemotherapy to match BRCA1 status.
Neoplasms
First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene.
Neoplasms
First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
Neoplasms
First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
Neoplasms
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Neoplasms
FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.
Neoplasms
Fish TRIM8 exerts antiviral roles through regulation of the proinflammatory factors and interferon signaling.
Neoplasms
Five families living with hereditary breast and ovarian cancer risk.
Neoplasms
Five Italian Families with Two Mutations in BRCA Genes.
Neoplasms
Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Neoplasms
Fixed and modifiable risk factors for breast cancer.
Neoplasms
FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
Neoplasms
FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.
Neoplasms
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Neoplasms
Folic acid supplementation in vitro induces cell type-specific changes in BRCA1 and BRCA 2 mRNA expression, but does not alter DNA methylation of their promoters or DNA repair.
Neoplasms
Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells.
Neoplasms
Forkhead box o3a suppresses lipopolysaccharide-stimulated proliferation and inflammation in fibroblast-like synoviocytes through regulating tripartite motif-containing protein 3.
Neoplasms
Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL).
Neoplasms
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Neoplasms
Formal modeling and analysis of ER-? associated Biological Regulatory Network in breast cancer.
Neoplasms
Formation of the retinotectal projection requires Esrom, an ortholog of PAM (protein associated with Myc).
Neoplasms
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Neoplasms
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Neoplasms
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Neoplasms
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
Neoplasms
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
Neoplasms
Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore.
Neoplasms
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Neoplasms
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Neoplasms
Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families.
Neoplasms
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Neoplasms
Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors.
Neoplasms
FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
Neoplasms
FOXO3a-dependent Parkin regulates the development of gastric cancer by targeting ATP-binding cassette transporter E1.
Neoplasms
FOXP3 Regulates Sensitivity of Cancer Cells to Irradiation by Transcriptional Repression of BRCA1.
Neoplasms
Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability.
Neoplasms
Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women.
Neoplasms
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Neoplasms
Frequency of BRCA1 dysfunction in ovarian cancer.
Neoplasms
Frequency of BRCA1 mutation 5382insC in German breast cancer patients.
Neoplasms
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Neoplasms
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Neoplasms
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Neoplasms
Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Neoplasms
Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland.
Neoplasms
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.
Neoplasms
Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report).
Neoplasms
Frequent engagement of RelB activation is critical for cell survival in multiple myeloma.
Neoplasms
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Neoplasms
Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers.
Neoplasms
Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset.
Neoplasms
Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.
Neoplasms
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Neoplasms
Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer.
Neoplasms
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Neoplasms
Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Neoplasms
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Neoplasms
Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.
Neoplasms
Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.
Neoplasms
Fully integrated monolithic optoelectronic transducer for real-time protein and DNA detection: The NEMOSLAB approach.
Neoplasms
Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Neoplasms
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
Neoplasms
Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families.
Neoplasms
Functional analysis of BRCA1 RING domain variants: computationally derived structural data can improve upon experimental features for training predictive models.
Neoplasms
Functional analysis of CpG methylation in the BRCA1 promoter region.
Neoplasms
Functional Analysis of Familial Asp67Glu and Thr1051Ser BRCA1 Mutations in Breast/Ovarian Carcinogenesis.
Neoplasms
Functional analysis of the transcription repressor PLU-1/JARID1B.
Neoplasms
Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
Neoplasms
Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Neoplasms
Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Neoplasms
Functional assays for BRCA1 and BRCA2.
Neoplasms
Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making.
Neoplasms
Functional assessment of intrinsic disorder central domains of BRCA1.
Neoplasms
Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.
Neoplasms
Functional characterization of BRCA1 and BRCA2: clues from their interacting proteins.
Neoplasms
Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.
Neoplasms
Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.
Neoplasms
Functional classification of proteins and protein variants.
Neoplasms
Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
Neoplasms
Functional dissection of transcription factor ZBRK1 reveals zinc fingers with dual roles in DNA-binding and BRCA1-dependent transcriptional repression.
Neoplasms
Functional domains of the BRCA1 and BRCA2 proteins.
Neoplasms
Functional impact of missense variants in BRCA1 predicted by supervised learning.
Neoplasms
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Neoplasms
Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer.
Neoplasms
Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Neoplasms
Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development.
Neoplasms
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
Neoplasms
Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.
Neoplasms
Functional investigation of the BRCA1 Val1714Gly and Asp1733Gly variants by computational tools and yeast transcription activation assay.
Neoplasms
Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
Neoplasms
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Neoplasms
Functional Polymorphisms in BARD1 Association with Neuroblastoma in a regional Han Chinese Population.
Neoplasms
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.
Neoplasms
Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer.
Neoplasms
Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
Neoplasms
Functional single-nucleotide polymorphisms in the BRCA1 gene and risk of salivary gland carcinoma.
Neoplasms
Functional Variant Analyses (FVAs) Predict Pathogenicity in the BRCA1 DNA Double-Strand Break Repair Pathway.
Neoplasms
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Neoplasms
Functions and characteristics of PINK1 and Parkin in cancer.
Neoplasms
Functions of BRCA1 and BRCA2 in the biological response to DNA damage.
Neoplasms
Further evidence for the contribution of the BRCA1-interacting protein-terminal helicase 1 (BRIP1) gene in breast cancer susceptibility.
Neoplasms
Fusion kinases identified by genomic analyses of sporadic microsatellite instability-high colorectal cancers.
Neoplasms
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
Neoplasms
G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
Neoplasms
G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
Neoplasms
Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress.
Neoplasms
Gadd45a Interacts with Aurora-A and Inhibits Its Kinase Activity.
Neoplasms
Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence.
Neoplasms
Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Neoplasms
Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.
Neoplasms
Gain-of-function mutation of c-CBL tumor suppressor gene in myeloid neoplasms.
Neoplasms
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Neoplasms
Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues.
Neoplasms
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Neoplasms
Gene expression in inherited breast cancer.
Neoplasms
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Neoplasms
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status.
Neoplasms
Gene expression profiling in breast cancer research.
Neoplasms
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.
Neoplasms
Gene expression profiling predicts clinical outcome of breast cancer.
Neoplasms
Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo.
Neoplasms
Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Neoplasms
Gene Panel Testing in Hereditary Breast Cancer.
Neoplasms
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2.
Neoplasms
Gene promoter methylation is associated with increased mortality among women with breast cancer.
Neoplasms
Gene selection: a Bayesian variable selection approach.
Neoplasms
Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.
Neoplasms
Gene-expression profiles in hereditary breast cancer.
Neoplasms
Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.
Neoplasms
Generation and characterization of induced pluripotent stem cells from a family carrying the BRCA1 mutation c.3612delA.
Neoplasms
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Neoplasms
Generation of the short TRIM32 isoform is regulated by Lys 247 acetylation and a PEST sequence.
Neoplasms
Genes, chromatin, and breast cancer: an epigenetic tale.
Neoplasms
Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma.
Neoplasms
Genetic alterations in hereditary breast cancer.
Neoplasms
Genetic analyses of male breast cancer in Israel.
Neoplasms
Genetic analysis in the clinical management of biliary tract cancer.
Neoplasms
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Neoplasms
Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
Neoplasms
Genetic analysis of BRCA1 function in a defined tumor cell line.
Neoplasms
Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.
Neoplasms
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
Neoplasms
Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB.
Neoplasms
Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1.
Neoplasms
Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
Neoplasms
Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.
Neoplasms
Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
Neoplasms
Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors.
Neoplasms
Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Neoplasms
Genetic Counseling, Cancer Screening, Breast Cancer Characteristics, and General Health among a Diverse Population of BRCA Genetic Testers.
Neoplasms
Genetic determinants at the interface of cancer and neurodegenerative disease.
Neoplasms
Genetic diagnosis of familial breast cancer using clonal sequencing.
Neoplasms
Genetic epidemiology of BRCA1.
Neoplasms
Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in chinese women.
Neoplasms
Genetic evidence supporting the taxonomic separation of the Arabian and Northwest African subspecies of the desert hedgehog (Paraechinus aethiopicus).
Neoplasms
Genetic factors in ovarian carcinoma.
Neoplasms
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Neoplasms
Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers.
Neoplasms
Genetic heterogeneity in breast cancer susceptibility.
Neoplasms
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
Neoplasms
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.
Neoplasms
Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.
Neoplasms
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Neoplasms
Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma.
Neoplasms
Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA.
Neoplasms
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
Neoplasms
Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes.
Neoplasms
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Neoplasms
Genetic polymorphisms and protein expression of P53 and BRCA1 in preneoplastic and neoplastic rat mammary glands.
Neoplasms
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.
Neoplasms
Genetic predisposition to breast cancer: a surgical perspective.
Neoplasms
Genetic profiles distinguish different types of hereditary ovarian cancer.
Neoplasms
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Neoplasms
Genetic susceptibility to breast cancer.
Neoplasms
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Neoplasms
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Neoplasms
Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
Neoplasms
Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group.
Neoplasms
Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
Neoplasms
Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
Neoplasms
Genetic testing in women with breast cancer: implications for treatment.
Neoplasms
Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis.
Neoplasms
Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma.
Neoplasms
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
Neoplasms
Genetic variations of BRCA1 and BRCA2 genes in dogs with mammary tumours.
Neoplasms
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Neoplasms
Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
Neoplasms
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.
Neoplasms
Genetics and ovarian carcinoma.
Neoplasms
Genetics and the management of women at high risk for breast cancer.
Neoplasms
Genetics of breast and ovarian cancer.
Neoplasms
Genetics of breast cancer.
Neoplasms
Genetics of host response in leprosy.
Neoplasms
Genetics of triple-negative breast cancer: Implications for patient care.
Neoplasms
Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status.
Neoplasms
Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe.
Neoplasms
Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target.
Neoplasms
Genistein Prevents BRCA1 CpG Methylation and Proliferation in Human Breast Cancer Cells with Activated Aromatic Hydrocarbon Receptor.
Neoplasms
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Neoplasms
Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation.
Neoplasms
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
Neoplasms
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
Neoplasms
Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
Neoplasms
Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2.
Neoplasms
Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.
Neoplasms
Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
Neoplasms
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Neoplasms
Genome-wide screening identifies novel genes and biological processes implicated in cisplatin resistance.
Neoplasms
Genome-wide transcriptome profiling of homologous recombination DNA repair.
Neoplasms
Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology.
Neoplasms
Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
Neoplasms
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
Neoplasms
Genomic and non-genomic effects of glucocorticoids: implications for breast cancer.
Neoplasms
Genomic characterisation of acral melanoma cell lines.
Neoplasms
Genomic Characterization of de novo Metastatic Breast Cancer.
Neoplasms
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
Neoplasms
Genomic characterization reveals potential biomarkers in nasopharyngeal carcinoma patients with relapse.
Neoplasms
Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.
Neoplasms
Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
Neoplasms
Genomic instability and cancer: Networks involved in response to DNA damage.
Neoplasms
Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Neoplasms
Genomic instability in breast cancer: Pathogenesis and clinical implications.
Neoplasms
Genomic Large Rearrangement Screening of BRCA1 and BRCA2 Genes in High-Risk Turkish Breast/Ovarian Cancer Patients by Using Multiplex Ligation-Dependent Probe Amplification Assay.
Neoplasms
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Neoplasms
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Neoplasms
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Neoplasms
Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families.
Neoplasms
Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer.
Neoplasms
Genomic rearrangements in BRCA1 and BRCA2: A literature review.
Neoplasms
Genomic rearrangements of the BRCA1 gene in Chilean breast cancer families: an MLPA analysis.
Neoplasms
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Neoplasms
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Neoplasms
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.
Neoplasms
Genotype in BRCA-associated breast cancers.
Neoplasms
Genotype/Phenotype correlations in patients with hereditary breast cancer.
Neoplasms
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed.
Neoplasms
Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
Neoplasms
Germ line mutations associated with breast cancer susceptibility.
Neoplasms
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Neoplasms
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.
Neoplasms
Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations.
Neoplasms
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Neoplasms
Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
Neoplasms
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.
Neoplasms
German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
Neoplasms
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
Neoplasms
Germline alterations in the CLSPN gene in breast cancer families.
Neoplasms
Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Neoplasms
Germline and somatic mutation profile in Cancer patients revealed by a medium-sized pan-Cancer panel.
Neoplasms
Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Neoplasms
Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer.
Neoplasms
Germline BRCA mutation in male carriers-ripe for precision oncology?
Neoplasms
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Neoplasms
Germline BRCA1 185delAG mutations in Jewish women with breast cancer.
Neoplasms
Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India.
Neoplasms
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
Neoplasms
Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Neoplasms
Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India.
Neoplasms
Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation.
Neoplasms
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
Neoplasms
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Neoplasms
Germline BRCA1 mutations in Iranian women with breast cancer.
Neoplasms
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
Neoplasms
Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Neoplasms
Germline E-cadherin mutations in familial lobular breast cancer.
Neoplasms
Germline genetic variation, cancer outcome, and pharmacogenetics.
Neoplasms
Germline large genomic alterations on 7q in patients with multiple primary cancers.
Neoplasms
Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation.
Neoplasms
Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families.
Neoplasms
Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Neoplasms
Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors.
Neoplasms
Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.
Neoplasms
Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Neoplasms
Germline mutation of BRCA1 in Japanese breast cancer families.
Neoplasms
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Neoplasms
Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer.
Neoplasms
Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
Neoplasms
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Neoplasms
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Neoplasms
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Neoplasms
Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Neoplasms
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Neoplasms
Germline mutations in young non-smoking women with lung adenocarcinoma.
Neoplasms
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Neoplasms
Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families.
Neoplasms
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Neoplasms
Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Neoplasms
Germline mutations predisposing to melanoma.
Neoplasms
Germline PTEN mutations in Cowden syndrome-like families.
Neoplasms
Germline TP53 mutational spectrum in French Canadians with breast cancer.
Neoplasms
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Neoplasms
Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms.
Neoplasms
Germline Variation in Cancer-Susceptibility Genes in a Healthy, Ancestrally Diverse Cohort: Implications for Individual Genome Sequencing.
Neoplasms
GFP-centrin as a marker for centriole dynamics in the human breast cancer cell line MCF-7.
Neoplasms
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Neoplasms
Global Disparities in Breast Cancer Genetics Testing, Counselling and Management.
Neoplasms
Glucose Concentration in Cell Culture Medium Influences the BRCA1-Mediated Regulation of the Lipogenic Action of IGF-I in Breast Cancer Cells.
Neoplasms
Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Neoplasms
Good COP1 or bad COP1? In vivo veritas.
Neoplasms
Good timing in the cell cycle for precise DNA repair by BRCA1.
Neoplasms
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
Neoplasms
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
Neoplasms
Graphical methods for class prediction using dimension reduction techniques on DNA microarray data.
Neoplasms
Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.
Neoplasms
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Neoplasms
Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).
Neoplasms
Grouper TRIM13 exerts negative regulation of antiviral immune response against nodavirus.
Neoplasms
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.
Neoplasms
Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity.
Neoplasms
Growth retardation and tumour inhibition by BRCA1.
Neoplasms
Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Neoplasms
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Neoplasms
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes.
Neoplasms
HACE1 is a potential tumor suppressor in osteosarcoma.
Neoplasms
HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations.
Neoplasms
HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms.
Neoplasms
HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.
Neoplasms
HACE1-dependent protein degradation provides cardiac protection in response to haemodynamic stress.
Neoplasms
Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF.
Neoplasms
HAF : the new player in oxygen-independent HIF-1alpha degradation.
Neoplasms
Hallmarks of 'BRCAness' in sporadic cancers.
Neoplasms
Haplo-insufficiency of BRCA1 in sporadic breast cancer.
Neoplasms
Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes.
Neoplasms
Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence.
Neoplasms
Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins.
Neoplasms
Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion.
Neoplasms
Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer.
Neoplasms
Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation.
Neoplasms
Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families.
Neoplasms
Haplotype and linkage disequilibrium architecture for human cancer-associated genes.
Neoplasms
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
Neoplasms
Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin.
Neoplasms
Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.
Neoplasms
Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer.
Neoplasms
Harnessing DNA Double-Strand Break Repair for Cancer Treatment.
Neoplasms
HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.
Neoplasms
HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability and Function.
Neoplasms
Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
Neoplasms
Health professional and at-risk BRCA young adult perspectives about information needs: What does Gen Y need to know?
Neoplasms
Hemoglobins, Hemorphins, and 11p15.5 Chromosomal Region in Cancer Biology and ?mmunity with Special Emphasis for Brain Tumors.
Neoplasms
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.
Neoplasms
HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
Neoplasms
HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours.
Neoplasms
Hereditary and familial ovarian cancer in southern Ontario.
Neoplasms
Hereditary and sporadic ovarian cancer: genetic testing and clinical implications (review).
Neoplasms
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Neoplasms
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.
Neoplasms
Hereditary breast and ovarian cancer susceptibility genes (Review).
Neoplasms
Hereditary breast cancer.
Neoplasms
Hereditary breast cancer: a brief overview.
Neoplasms
Hereditary breast cancer: from molecular pathology to tailored therapies.
Neoplasms
Hereditary breast cancer: new genetic developments, new therapeutic avenues.
Neoplasms
Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Neoplasms
Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Neoplasms
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Neoplasms
Hereditary breast cancer: practical pursuit for clinical translation.
Neoplasms
Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
Neoplasms
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Neoplasms
Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
Neoplasms
Hereditary cancer syndromes.
Neoplasms
Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis.
Neoplasms
Hereditary cancers in obstetrics and gynecology.
Neoplasms
Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.
Neoplasms
Hereditary Factors in Gynecologic Cancer.
Neoplasms
Hereditary forms of ovarian cancer.
Neoplasms
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NF?B activation in the tumor stroma.
Neoplasms
Hereditary ovarian cancer.
Neoplasms
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.
Neoplasms
Hereditary ovarian carcinomas: clinico-biological features and treatment.
Neoplasms
Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Neoplasms
Hereditary premenopausal breast cancer.
Neoplasms
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Neoplasms
Hereditary risk of women's cancers.
Neoplasms
Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells.
Neoplasms
Heterochromatin instability in cancer: From the Barr body to satellites and the nuclear periphery.
Neoplasms
Heterochromatin-Encoded Satellite RNAs Induce Breast Cancer.
Neoplasms
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
Neoplasms
Heterogenous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs.
Neoplasms
Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
Neoplasms
Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.
Neoplasms
Hexabromocyclododecane-induced Genotoxicity in Cultured Human Breast Cells through DNA Damage.
Neoplasms
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.
Neoplasms
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
Neoplasms
HIF-1? promotes autophagic proteolysis of Dicer and enhances tumor metastasis.
Neoplasms
HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
Neoplasms
HIF2?-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.
Neoplasms
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
Neoplasms
High c-Cbl expression in gliomas is associated with tumor progression and poor prognosis.
Neoplasms
High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.
Neoplasms
High epithelial and stromal genetic instability of chromosome 17 in ulcerative colitis-associated carcinogenesis.
Neoplasms
High Expression of Pirh2 is Associated with Poor Prognosis in Glioma.
Neoplasms
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
Neoplasms
High Expression of Stem Cell Marker ALDH1 is Associated with Reduced BRCA1 in Invasive Breast Carcinomas.
Neoplasms
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
Neoplasms
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Neoplasms
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Neoplasms
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer.
Neoplasms
High frequency of BRCA1 5382insC mutation in Russian breast cancer patients.
Neoplasms
High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.
Neoplasms
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.
Neoplasms
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population.
Neoplasms
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
Neoplasms
High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families.
Neoplasms
High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Neoplasms
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Neoplasms
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
Neoplasms
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.
Neoplasms
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Neoplasms
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.
Neoplasms
High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability.
Neoplasms
High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
Neoplasms
High prevalence of cancer-associated TP53 variants in the gnomAD database: a word of caution concerning the use of variant filtering.
Neoplasms
High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients.
Neoplasms
High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Neoplasms
High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain).
Neoplasms
High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
Neoplasms
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Neoplasms
High SINE RNA Expression Correlates with Post-Transcriptional Downregulation of BRCA1.
Neoplasms
High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells.
Neoplasms
High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.
Neoplasms
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
Neoplasms
High-density genetic map of the BRCA1 region of chromosome 17q12-q21.
Neoplasms
High-dose folic acid supplementation alters the human sperm methylome and is influenced by the MTHFR C677T polymorphism.
Neoplasms
High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Neoplasms
High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Neoplasms
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Neoplasms
High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq.
Neoplasms
High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions.
Neoplasms
Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes.
Neoplasms
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Neoplasms
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Neoplasms
Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
Neoplasms
Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer.
Neoplasms
Histopathologic features of genetically determined ovarian cancer.
Neoplasms
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Neoplasms
Histopathological criteria and selection algorithms for BRCA1 genetic testing.
Neoplasms
Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
Neoplasms
Histopathological features of breast cancer in carriers of ATM gene variants.
Neoplasms
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
Neoplasms
Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.
Neoplasms
Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Neoplasms
HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy.
Neoplasms
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
Neoplasms
HMGA2 is regulated by LIN28 and BRCA1 in human placental cells.
Neoplasms
Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20.
Neoplasms
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer.
Neoplasms
Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance.
Neoplasms
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Neoplasms
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
Neoplasms
Homologous recombination in cancer development, treatment and development of drug resistance.
Neoplasms
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
Neoplasms
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
Neoplasms
Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway.
Neoplasms
Homozygous deficiency of ubiquitin-ligase ring-finger protein RNF168 mimics the radiosensitivity syndrome of ataxia-telangiectasia.
Neoplasms
Homozygous deletion of p16(INK4a) and tobacco carcinogen exposure in nonsmall cell lung cancer.
Neoplasms
Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.
Neoplasms
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Neoplasms
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Neoplasms
Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
Neoplasms
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
Neoplasms
How do real tumors become resistant to cisplatin?
Neoplasms
How does a hydrocarbon staple affect peptide hydrophobicity?
Neoplasms
How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression.
Neoplasms
How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.
Neoplasms
How latent viruses cause breast cancer: An explanation based on the microcompetition model.
Neoplasms
How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
Neoplasms
How to manage BRCA mutation carriers?
Neoplasms
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.
Neoplasms
HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response.
Neoplasms
HPV nonrelated endocervical adenocarcinoma in hereditary cancer syndromes.
Neoplasms
HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.
Neoplasms
HRD1 sensitizes breast cancer cells to Tamoxifen by promoting S100A8 degradation.
Neoplasms
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Neoplasms
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Neoplasms
HTLV-1 Tax oncoprotein inhibits the estrogen-induced-ER ?-Mediated BRCA1 expression by interaction with CBP/p300 cofactors.
Neoplasms
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Neoplasms
Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice.
Neoplasms
Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing.
Neoplasms
Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors.
Neoplasms
Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor.
Neoplasms
Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation.
Neoplasms
Human CtIP: A 'double agent' in DNA repair and tumorigenesis.
Neoplasms
Human FBXL8 Is a Novel E3 Ligase Which Promotes BRCA Metastasis by Stimulating Pro-Tumorigenic Cytokines and Inhibiting Tumor Suppressors.
Neoplasms
Human ovarian cancer of the surface epithelium.
Neoplasms
Human papillomavirus 16 E6 contributes HIF-1? induced Warburg effect by attenuating the VHL-HIF-1? interaction.
Neoplasms
Human papillomavirus E7 oncoprotein targets RNF168 to hijack the host DNA damage response.
Neoplasms
Human papillomavirus-16 (HPV-16) infection association with CIAP-2 expression in head and neck cancer.
Neoplasms
HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.
Neoplasms
HUWE1 ubiquitylates and degrades the RAC activator TIAM1 promoting cell-cell adhesion disassembly, migration, and invasion.
Neoplasms
Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
Neoplasms
Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.
Neoplasms
Hydrogen alleviated organ injury and dysfunction in sepsis: The role of cross-talk between autophagy and endoplasmic reticulum stress: Experimental research.
Neoplasms
Hypermethylation in histologically distinct classes of breast cancer.
Neoplasms
Hypermethylation of BRCA1 Gene in Meningioma in Elderly Males.
Neoplasms
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Neoplasms
Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
Neoplasms
Hyperphosphorylation of the BARD1 tumor suppressor in mitotic cells.
Neoplasms
Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform.
Neoplasms
Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.
Neoplasms
Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Neoplasms
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.
Neoplasms
Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter.
Neoplasms
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Neoplasms
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Neoplasms
Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells.
Neoplasms
ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.
Neoplasms
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Neoplasms
Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells.
Neoplasms
Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.
Neoplasms
Identification and frequency of the rs12516 and rs8176318 BRCA1 gene polymorphisms among different populations.
Neoplasms
Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1.
Neoplasms
Identification and functional characterization of a PP1-binding site in BRCA1.
Neoplasms
Identification and management of inherited cancer susceptibility.
Neoplasms
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Neoplasms
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family.
Neoplasms
Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families.
Neoplasms
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Neoplasms
Identification of a functional nuclear export sequence in BRCA1.
Neoplasms
Identification of a large rearrangement of the BRCA1 gene using colour bar code on combed DNA in an American breast/ovarian cancer family previously studied by direct sequencing.
Neoplasms
Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma.
Neoplasms
Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
Neoplasms
Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer.
Neoplasms
Identification of a Novel BRCA2 and CHEK2 A-C-G-C Haplotype in Turkish Patients Affected with Breast Cancer.
Neoplasms
Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
Neoplasms
Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer.
Neoplasms
Identification of a potential tumor suppressor gene, UBL3, in non-small cell lung cancer.
Neoplasms
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Neoplasms
Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Neoplasms
Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.
Neoplasms
Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer.
Neoplasms
Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.
Neoplasms
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Neoplasms
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
Neoplasms
Identification of BAF57 mutations in human breast cancer cell lines.
Neoplasms
Identification of BARD1 splice-isoforms involved in human trophoblast invasion.
Neoplasms
Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer.
Neoplasms
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Neoplasms
Identification of BRCA1 germline mutation, 797delAA, in a Japanese breast-ovarian cancer patient.
Neoplasms
Identification of BRCA1-deficient ovarian cancers.
Neoplasms
Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.
Neoplasms
Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis.
Neoplasms
Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach.
Neoplasms
Identification of cancer-associated missense mutations in hace1 that impair cell growth control and Rac1 ubiquitylation.
Neoplasms
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Neoplasms
Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.
Neoplasms
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Neoplasms
Identification of differentially expressed genes associated with colorectal cancer liver metastasis.
Neoplasms
Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
Neoplasms
Identification of DNA Repair Pathways that Affect the Survival of Ovarian Cancer Cells Treated with a PARP Inhibitor in a Novel Drug Combination.
Neoplasms
Identification of Domains of BRCA1 Critical for the Ubiquitin-Dependent Inhibition of Centrosome Function.
Neoplasms
Identification of FDA-approved Drugs that Computationally Bind to MDM2.
Neoplasms
Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.
Neoplasms
Identification of genes induced by BRCA1 in breast cancer cells.
Neoplasms
Identification of Germline BRCA1 Mutations among Breast Cancer Families in Northeastern Iran.
Neoplasms
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.
Neoplasms
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.
Neoplasms
Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Neoplasms
Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer.
Neoplasms
Identification of Multiple Proteins Coupling Transcriptional Gene Silencing to Genome Stability in Arabidopsis thaliana.
Neoplasms
Identification of Mutation in Exon11 of BRCA1 Gene in Bangladeshi Patients with Breast Cancer.
Neoplasms
Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer.
Neoplasms
Identification of nuclear export signal in KLLN suggests potential role in proteasomal degradation in cancer cells.
Neoplasms
Identification of Patients at High Risk of Psychological Distress after BRCA1 Genetic Testing.
Neoplasms
Identification of peptidomimetic telomere dysfunction inhibitor (TELODIN) through telomere dysfunction-induced foci (TIF) assay.
Neoplasms
Identification of Pirh2D, an Additional Novel Isoform of Pirh2 Ubiquitin Ligase.
Neoplasms
Identification of Pirh2E and Pirh2F, two additional novel isoforms of Pirh2 ubiquitin ligase from human hepatocellular liver carcinoma cell line.
Neoplasms
Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients.
Neoplasms
Identification of prognostic genes in uveal melanoma microenvironment.
Neoplasms
Identification of proteins that interact with BRCA1 by Far-Western library screening.
Neoplasms
Identification of putative phenotype-modifying genetic factors associated with phenotypic diversity in Brooke-Spiegler syndrome.
Neoplasms
Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.
Neoplasms
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Neoplasms
Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
Neoplasms
Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage.
Neoplasms
Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families.
Neoplasms
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Neoplasms
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Neoplasms
Identification of the first case of germline duplication of BRCA1 exon 13 in an Italian family.
Neoplasms
Identification of the tumor metastasis suppressor Nm23-H1/Nm23-R1 as a constituent of the centrosome.
Neoplasms
Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted.
Neoplasms
Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
Neoplasms
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Neoplasms
Identifying and managing hereditary risk of breast and ovarian cancer.
Neoplasms
Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
Neoplasms
Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Neoplasms
Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
Neoplasms
IGF-1 and BRCA1 signalling pathways in familial cancer.
Neoplasms
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.
Neoplasms
Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
Neoplasms
Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Neoplasms
Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel.
Neoplasms
Immunohistochemical analysis of BRCA1 expression in normal human buccal cells.
Neoplasms
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family.
Neoplasms
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Neoplasms
Immunohistochemical expression of BRCA1 and lethal prostate cancer.
Neoplasms
Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Neoplasms
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
Neoplasms
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Neoplasms
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Neoplasms
Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Neoplasms
Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
Neoplasms
Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
Neoplasms
Immunoprofile from tissue microarrays to stratify familial breast cancer patients.
Neoplasms
Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Neoplasms
Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition.
Neoplasms
Impact of BRCA1 testing on women with cancer: a pilot study.
Neoplasms
Impact of cancer predisposition and radiosensitivity on the population risk of radiation-induced cancers.
Neoplasms
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
Neoplasms
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Neoplasms
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Neoplasms
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Neoplasms
Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression.
Neoplasms
Impact of mitochondrial transcription factor A expression on the outcomes of ovarian, endometrial and cervical cancers.
Neoplasms
Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.
Neoplasms
Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage.
Neoplasms
Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549.
Neoplasms
Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach.
Neoplasms
Impaired DNA damage response - An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.
Neoplasms
Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1.
Neoplasms
Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.
Neoplasms
Implication of BRCA1 gene in breast cancer.
Neoplasms
Implications of a novel cryptic splice site in the BRCA1 gene.
Neoplasms
Implications of the age range in a population-based BRCA1 testing program with eligibility based on family history of breast and ovarian cancer.
Neoplasms
Importance of DNA damage checkpoints in the pathogenesis of human cancers.
Neoplasms
Importin-? and CRM1 control a RANBP2 spatiotemporal switch essential for mitotic kinetochore function.
Neoplasms
Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
Neoplasms
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
Neoplasms
Improving attendance to genetic counselling services for gynaecological oncology patients.
Neoplasms
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.
Neoplasms
In brief: BRCA1 and BRCA2.
Neoplasms
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Neoplasms
In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.
Neoplasms
In vitro analysis of genomic instability triggered by BRCA1 missense mutations.
Neoplasms
In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.
Neoplasms
In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.
Neoplasms
In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells.
Neoplasms
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Neoplasms
Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Neoplasms
Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency.
Neoplasms
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Neoplasms
Inactivation of sag/rbx2/roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
Neoplasms
Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Neoplasms
Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
Neoplasms
Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development.
Neoplasms
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Neoplasms
Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Neoplasms
Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer.
Neoplasms
Inbred Strain Characteristics Impact the NKT Cell Repertoire.
Neoplasms
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Neoplasms
Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Neoplasms
Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
Neoplasms
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.
Neoplasms
Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration.
Neoplasms
Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations.
Neoplasms
Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
Neoplasms
Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.
Neoplasms
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Neoplasms
Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report.
Neoplasms
Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer.
Neoplasms
Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction.
Neoplasms
Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Neoplasms
Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
Neoplasms
Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.
Neoplasms
Increased BRCA1 protein in mammary tumours of rats fed marine omega-3 fatty acids.
Neoplasms
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Neoplasms
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
Neoplasms
Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
Neoplasms
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Neoplasms
Increased expression of MARCH8, an E3 ubiquitin ligase, is associated with growth of esophageal tumor.
Neoplasms
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.
Neoplasms
Increased gene expression variability in BRCA1-associated and basal-like breast tumours.
Neoplasms
Increased heterogeneity of chromosome 17 aneuploidy in endometriosis.
Neoplasms
Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Neoplasms
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
Neoplasms
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
Neoplasms
Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation.
Neoplasms
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Neoplasms
Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Neoplasms
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.
Neoplasms
Independent origin of 185delAG BRCA1 mutation in an Indian family.
Neoplasms
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.
Neoplasms
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Neoplasms
Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells.
Neoplasms
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Neoplasms
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Neoplasms
Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells.
Neoplasms
Inducing Synthetic Lethality using PARP Inhibitors.
Neoplasms
Induction of apoptosis by the tumor suppressor protein BRCA1.
Neoplasms
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
Neoplasms
Induction of the long noncoding RNA NBR2 from the bidirectional BRCA1 promoter under hypoxic conditions.
Neoplasms
Induction of the von Hippel-Lindau tumor suppressor gene by late hypoxia limits HIF-1 expression.
Neoplasms
Infantile Epithelioid Sarcoma with Genomic Segmental Amplification of BIRC3/YAP1 as Double Minutes Plus Trisomy 2: A Case Report.
Neoplasms
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Neoplasms
Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Neoplasms
Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.
Neoplasms
Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Neoplasms
Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
Neoplasms
Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Neoplasms
Influence of tumour suppressor gene (TP53, BRCA1 and BRCA2) polymorphisms on polycystic ovary syndrome in South Indian women.
Neoplasms
Information Needs of Mothers Regarding Communicating BRCA1/2 Cancer Genetic Test Results to Their Children.
Neoplasms
Informed consent for BRCA1 and BRCA2 testing.
Neoplasms
Ingenuity pathway analysis of human facet joint tissues: Insight into facet joint osteoarthritis.
Neoplasms
Inheritance of cancer.
Neoplasms
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.
Neoplasms
Inherited BRCA2 mutation associated with high grade breast cancer.
Neoplasms
Inherited breast and ovarian cancer.
Neoplasms
Inherited breast cancer: an emerging picture.
Neoplasms
Inherited genetic susceptibility to breast cancer.
Neoplasms
Inherited Mutations in Women With Ovarian Carcinoma.
Neoplasms
Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk.
Neoplasms
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study.
Neoplasms
Inherited predisposition to cancer: a historical overview.
Neoplasms
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Neoplasms
Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis.
Neoplasms
Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors.
Neoplasms
Inhibition of apoptosis via CHIP-mediated proteasomal degradation of TAp73?.
Neoplasms
Inhibition of Atrogin-1/MAFbx Expression by Adenovirus-Delivered Small Hairpin RNAs Attenuates Muscle Atrophy in Fasting Mice.
Neoplasms
Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Neoplasms
Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide.
Neoplasms
Inhibition of E2-induced expression of BRCA1 by persistent organochlorines.
Neoplasms
Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation.
Neoplasms
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Neoplasms
Inhibition of IAP's and activation of p53 leads to caspase-dependent apoptosis in gastric cancer cells treated with Scutellarein.
Neoplasms
Inhibition of ITCH Suppresses Proliferation and Induces Apoptosis of Lung Cancer Cells.
Neoplasms
Inhibition of p53 degradation by Mdm2 acetylation.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Neoplasms
Inhibition of RIF1 by SCAI Allows BRCA1-Mediated Repair.
Neoplasms
Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib.
Neoplasms
Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation.
Neoplasms
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Neoplasms
Insights into BRCA Cancer Predisposition from Integrated Germline and Somatic Analyses in 7632 Cancers.
Neoplasms
Insights into Cullin-RING E3 Ubiquitin Ligase Recruitment: Structure of the VHL-EloBC-Cul2 Complex.
Neoplasms
Insights into the functions of BRCA1 and BRCA2.
Neoplasms
Insights into the Molecular Basis of Human Hereditary Breast Cancer from Studies of the BRCA1 BRCT Domain.
Neoplasms
Insights into the targeted elimination of BRCA1-defective cancer stem cells.
Neoplasms
Insufficient evidence of endocervical origin in germline BRCA1 and MSH2-associated tumors.
Neoplasms
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Neoplasms
Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.
Neoplasms
Insurance adjudication favoring prophylactic surgery in hereditary breast-ovarian cancer syndrome.
Neoplasms
INT6/EIF3E interacts with ATM and is required for proper execution of the DNA damage response in human cells.
Neoplasms
Integrated genomic analyses of ovarian carcinoma.
Neoplasms
Integrated genomic characterization of adrenocortical carcinoma.
Neoplasms
Integrating PARP inhibitors into the management of breast cancer: where are we?
Neoplasms
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NF?B pathway.
Neoplasms
Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Neoplasms
Integrative Bioinformatics and Functional Analyses of GEO, ENCODE, and TCGA Reveal FADD as a Direct Target of the Tumor Suppressor BRCA1.
Neoplasms
Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional-structural assessments via protein informatics.
Neoplasms
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Neoplasms
Integrative mining of traditional Chinese medicine literature and MEDLINE for functional gene networks.
Neoplasms
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
Neoplasms
Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers.
Neoplasms
Interaction between BRCA1 and human papilloma virus E7: an ontology study.
Neoplasms
Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.
Neoplasms
Interaction of p14(ARF) with Brca1 in cancer cell lines and primary breast cancer.
Neoplasms
Interactions between BRCT repeats and phosphoproteins: tangled up in two.
Neoplasms
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Neoplasms
Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.
Neoplasms
Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines.
Neoplasms
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Neoplasms
Interlaboratory diagnostic validation of conformation-sensitive capillary electrophoresis for mutation scanning.
Neoplasms
Interleukin-1 and TRAF6-dependent activation of TAK1 in the absence of TAB2 and TAB3.
Neoplasms
International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Neoplasms
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Neoplasms
Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis.
Neoplasms
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
Neoplasms
Interplay between Fanconi anemia and homologous recombination pathways in genome integrity.
Neoplasms
Interplay between Parkin and p53 Governs a Physiological Homeostasis That Is Disrupted in Parkinson's Disease and Cerebral Cancer.
Neoplasms
Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined.
Neoplasms
Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.
Neoplasms
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Neoplasms
Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition?
Neoplasms
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Neoplasms
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Neoplasms
Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
Neoplasms
Intrinsic ubiquitin E3 ligase activity of histone acetyltransferase Hbo1 for estrogen receptor ?.
Neoplasms
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
Neoplasms
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Neoplasms
Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.
Neoplasms
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Neoplasms
Inverse correlation between Naa10p and Pirh2 expression and the combined prognostic value in oral squamous cell carcinoma patients.
Neoplasms
Investigating of variations in BRCA1 gene in Iranian families with breast cancer.
Neoplasms
Investigation of the Involvement of Parkin in Parkinson's Disease and Cancer by Monitoring the Changes in SH-SY5Y Cells at the Nuclear Proteome Level.
Neoplasms
Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene.
Neoplasms
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Neoplasms
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
Neoplasms
iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression.
Neoplasms
Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?
Neoplasms
Is hereditary site-specific ovarian cancer a distinct genetic condition?
Neoplasms
Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
Neoplasms
Is p53 intronic variant G13964C associated with predisposition to cancer?
Neoplasms
Is PARKIN parkinsonism a cancer predisposition syndrome?
Neoplasms
Is there a specific magnetic resonance phenotype characteristic of hereditary breast cancer?
Neoplasms
Is there more to BARD1 than BRCA1?
Neoplasms
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Neoplasms
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Neoplasms
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Neoplasms
Isoform-specific SCF(Fbw7) ubiquitination mediates differential regulation of PGC-1?.
Neoplasms
Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.
Neoplasms
Isolation, purification and quantification of BRCA1 protein from tumour cells by affinity perfusion chromatography.
Neoplasms
Issues in the genetic assessment of predispositions for familial breast and ovarian cancer.
Neoplasms
Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
Neoplasms
Itch E3 ubiquitin ligase regulates large tumor suppressor 1 tumor-suppressor stability.
Neoplasms
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
Neoplasms
Japanese Late-Onset Breast Cancer Families: Their Clincopathological Characteristics and Absence of BRCA1 and BRCA2 Germline Mutations.
Neoplasms
Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
Neoplasms
JP3, an antiangiogenic peptide, inhibits growth and metastasis of gastric cancer through TRIM25/SP1/MMP2 axis.
Neoplasms
JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction.
Neoplasms
Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 4 Targets MDM2 to Deregulate the p53 Tumor Suppressor Pathway.
Neoplasms
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Neoplasms
Klotho gene polymorphisms are associated with healthy aging and longevity: Evidence from a meta-analysis.
Neoplasms
Knockdown of COUP-TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells.
Neoplasms
Knockdown of endogenous RNF4 exacerbates ischaemia-induced cardiomyocyte apoptosis in mice.
Neoplasms
Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
Neoplasms
Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells.
Neoplasms
Knockout mouse models and mammary tumorigenesis.
Neoplasms
Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African-American kindred with a BRCA1 mutation.
Neoplasms
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.
Neoplasms
Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Neoplasms
KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
Neoplasms
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
Neoplasms
Laboratory determination of hereditary susceptibility to breast and ovarian cancer.
Neoplasms
Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer.
Neoplasms
Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families.
Neoplasms
Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
Neoplasms
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.
Neoplasms
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
Neoplasms
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Neoplasms
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Neoplasms
Laparoscopic total fallopian tube removal at the time of bilateral salpingo-oophorectomy in BRCA2 positive women.
Neoplasms
Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Neoplasms
Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families.
Neoplasms
Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.
Neoplasms
Large chromosomal deletions and impaired homologous recombination repairing in HEK293T cells exposed to polychlorinated biphenyl 153.
Neoplasms
Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing.
Neoplasms
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Neoplasms
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Neoplasms
Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.
Neoplasms
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Neoplasms
Learning about a twist in the road: perspectives of at-risk relatives learning of potential for cancer.
Neoplasms
Learning Healthcare System for the Prescription of Genetic Testing in the Gynecological Cancer Risk.
Neoplasms
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
Neoplasms
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.
Neoplasms
Lessons learned from BRCA1 and BRCA2.
Neoplasms
Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
Neoplasms
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Neoplasms
Lifestyle behaviors in women with a BRCA1 or BRCA2 genetic mutation: an exploratory study guided by concepts derived from the Health Belief Model.
Neoplasms
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.
Neoplasms
Linear ubiquitination signals in adaptive immune responses.
Neoplasms
Linkage analysis of 26 Canadian breast and breast-ovarian cancer families.
Neoplasms
Linkage to markers for the chromosome region 17q12-q21 in 13 Dutch breast cancer kindreds.
Neoplasms
Linking distant relatives with BRCA gene mutations: potential for cost savings.
Neoplasms
Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment.
Neoplasms
Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
Neoplasms
Links between genome integrity and BRCA1 tumor suppression.
Neoplasms
Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B.
Neoplasms
Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
Neoplasms
Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia.
Neoplasms
Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.
Neoplasms
lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter.
Neoplasms
LncRNA NBR2 inhibits epithelial-mesenchymal transition by regulating Notch1 signaling in osteosarcoma cells.
Neoplasms
LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling.
Neoplasms
LncRNA NBR2 inhibits tumorigenesis by regulating autophagy in hepatocellular carcinoma.
Neoplasms
Lobular breast cancer: incidence and genetic and non-genetic risk factors.
Neoplasms
Lobular carcinoma of the breast in an 85-year-old man.
Neoplasms
Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM.
Neoplasms
Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25.
Neoplasms
Localization of BRCA1 and a splice variant identifies the nuclear localization signal.
Neoplasms
Localization of BRCA1 gene expression in adult cynomolgus monkey tissues.
Neoplasms
Localization of human BRCA1 and BRCA2 in non-inherited colorectal carcinomas and matched normal mucosas.
Neoplasms
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Neoplasms
Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer.
Neoplasms
Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.
Neoplasms
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Neoplasms
LOH of chromosome 6q compared with LOH of 17q and 18q in ovarian cancers: relationship to p53 expression and clinicopathological findings.
Neoplasms
Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs.
Neoplasms
Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell renal cell carcinoma progression.
Neoplasms
Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
Neoplasms
Long-Term BRCA1 Down-Regulation by Small Hairpin RNAs Targeting the 3' Untranslated Region.
Neoplasms
Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
Neoplasms
Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma.
Neoplasms
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Neoplasms
Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability.
Neoplasms
Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Neoplasms
Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.
Neoplasms
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Neoplasms
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor-inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Neoplasms
Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions.
Neoplasms
Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Neoplasms
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Neoplasms
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Neoplasms
Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint.
Neoplasms
Loss of cIAP1 in Endothelial Cells Limits Metastatic Extravasation through Tumor-Derived Lymphotoxin Alpha.
Neoplasms
Loss of COP1 expression determines poor prognosisin patients with gastric cancer.
Neoplasms
Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Neoplasms
Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Neoplasms
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Neoplasms
Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
Neoplasms
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Neoplasms
Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors.
Neoplasms
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Neoplasms
Loss of heterozygosity at 9p and 17q in human laryngeal tumors.
Neoplasms
Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer.
Neoplasms
Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.
Neoplasms
Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
Neoplasms
Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Neoplasms
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Neoplasms
Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.
Neoplasms
Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior.
Neoplasms
Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
Neoplasms
Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
Neoplasms
Loss of heterozygosity of nucleotide excision repair factors in sporadic oral squamous cell carcinoma using microdissected tissue.
Neoplasms
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
Neoplasms
Loss of heterozygosity of the PTH/PTHrP type 1 receptor in oral squamous cell carcinoma.
Neoplasms
Loss of heterozygosity of TRIM3 in malignant gliomas.
Neoplasms
Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.
Neoplasms
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Neoplasms
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
Neoplasms
Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer.
Neoplasms
Loss of MIEF1/MiD51 confers susceptibility to BAX-mediated cell death and PINK1-PRKN-dependent mitophagy.
Neoplasms
Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype.
Neoplasms
Loss of nuclear BRCA1 localization in breast carcinoma is age dependent.
Neoplasms
Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-?-mediated MDSC infiltration.
Neoplasms
Loss of parkin reduces lung tumor development by blocking p21 degradation.
Neoplasms
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.
Neoplasms
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.
Neoplasms
Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.
Neoplasms
Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.
Neoplasms
Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis.
Neoplasms
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Neoplasms
Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction.
Neoplasms
Loss of the tumour-suppressor genes CHK2 and BRCA1 results in chromosomal instability.
Neoplasms
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Neoplasms
Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression.
Neoplasms
Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner.
Neoplasms
Low expression of bcl-2 in Brca1-associated breast cancers.
Neoplasms
Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer.
Neoplasms
Low frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families.
Neoplasms
Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.
Neoplasms
Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer.
Neoplasms
Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Neoplasms
Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer.
Neoplasms
Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population.
Neoplasms
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Neoplasms
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Neoplasms
Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer.
Neoplasms
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Neoplasms
Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.
Neoplasms
Low-grade adenosquamous carcinoma of the breast-A case report with a BRCA1 germline mutation.
Neoplasms
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Neoplasms
Luring BRCA1 to the scene of the crime.
Neoplasms
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.
Neoplasms
Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine.
Neoplasms
Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours.
Neoplasms
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Neoplasms
Lymphocyte telomere length is longer in BRCA1 and BRCA2 mutation carriers but does not affect subsequent cancer risk.
Neoplasms
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Neoplasms
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
Neoplasms
Making the best of PARP inhibitors in ovarian cancer.
Neoplasms
Male breast cancer is not congruent with the female disease.
Neoplasms
Mammalian Rad51 protein: a RecA homologue with pleiotropic functions.
Neoplasms
Mammalian stanniocalcins and cancer.
Neoplasms
Mammary gland development, reproductive history, and breast cancer risk.
Neoplasms
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
Neoplasms
Mammary tumor formation in p53- and BRCA1-deficient mice.
Neoplasms
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Neoplasms
Mammographic, US, and MR imaging phenotypes of familial breast cancer.
Neoplasms
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Neoplasms
Management of gynecological tumors associated with BRCA1 and BRCA2 germline mutations. Case report and literature review.
Neoplasms
Management options in triple-negative breast cancer.
Neoplasms
Management updates for women with a BRCA1 or BRCA2 mutation.
Neoplasms
Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
Neoplasms
Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
Neoplasms
Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase.
Neoplasms
Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.
Neoplasms
Maternal Obesity Alters Placental Cell Cycle Regulators in the First Trimester of Human Pregnancy: New Insights for BRCA1.
Neoplasms
MCPIP1 Selectively Destabilizes Transcripts Associated with an Antiapoptotic Gene Expression Program in Breast Cancer Cells That Can Elicit Complete Tumor Regression.
Neoplasms
MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice.
Neoplasms
Mdm2 and tumorigenesis: evolving theories and unsolved mysteries.
Neoplasms
MDM2 binds and inhibits vitamin D receptor.
Neoplasms
MDM2 chaperones the p53 tumor suppressor.
Neoplasms
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation.
Neoplasms
MDM2 inhibition: an important step forward in cancer therapy.
Neoplasms
MDM2 inhibitor ameliorates cisplatin-induced nephropathy via NF?? signal inhibition.
Neoplasms
Mdm2 is a target and mediator of IRP2 in cell growth control.
Neoplasms
MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.
Neoplasms
MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.
Neoplasms
Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
Neoplasms
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Neoplasms
MDM2-C Functions as an E3 Ubiquitin Ligase.
Neoplasms
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity.
Neoplasms
MDM2-mediated ubiquitination of NUMB: Identification of a 2nd physiological substrate of MDM2 that employs a Dual-Site docking mechanism.
Neoplasms
MdmX inhibits ARF mediated Mdm2 sumoylation.
Neoplasms
Mechanism by which TRAF6 Participates in the Immune Regulation of Autoimmune Diseases and Cancer.
Neoplasms
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
Neoplasms
Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
Neoplasms
Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564.
Neoplasms
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
Neoplasms
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Neoplasms
Mechanisms of alcohol-associated cancers: introduction and summary of the symposium.
Neoplasms
Mechanisms of BRCA1 Tumor Suppression.
Neoplasms
Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation.
Neoplasms
Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy.
Neoplasms
Mechanisms of PARP inhibitor resistance in ovarian cancer.
Neoplasms
Mechanisms of PARP inhibitor sensitivity and resistance.
Neoplasms
Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
Neoplasms
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Neoplasms
Mechanisms promoting escape from mitotic stress-induced tumor cell death.
Neoplasms
Mechanistic phenotypes: an aggregative phenotyping strategy to identify disease mechanisms using GWAS data.
Neoplasms
Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter.
Neoplasms
Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control.
Neoplasms
Medullary carcinoma of breast with a novel germline mutation 1123t >g in exon 11 of brca1.
Neoplasms
Meiotic Double-Strand Break Processing and Crossover Patterning Are Regulated in a Sex-Specific Manner by BRCA1-BARD1 in Caenorhabditiselegans.
Neoplasms
MEKK3 and TAK1 synergize to activate IKK complex in Helicobacter pylori infection.
Neoplasms
Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1).
Neoplasms
Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275.
Neoplasms
Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis.
Neoplasms
Meta-analysis of BRCA1 and BRCA2 penetrance.
Neoplasms
Meta-Analysis of BRCA1 Polymorphisms and Breast Cancer Susceptibility.
Neoplasms
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Neoplasms
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Neoplasms
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Neoplasms
Metastatic Triple-negative Breast Cancer.
Neoplasms
Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Neoplasms
Metformin Pharmacogenomics: A genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.
Neoplasms
Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
Neoplasms
Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy.
Neoplasms
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Neoplasms
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Neoplasms
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Neoplasms
Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
Neoplasms
Methylation of the BRCA1 gene in sporadic breast cancer.
Neoplasms
Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
Neoplasms
Methylation of the HACE1 Gene is Frequently Detected in Hepatocellular Carcinoma.
Neoplasms
Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function.
Neoplasms
Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
Neoplasms
Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer
Neoplasms
Methylation profiles of hereditary and sporadic ovarian cancer.
Neoplasms
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
Neoplasms
Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.
Neoplasms
Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes.
Neoplasms
Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women.
Neoplasms
Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation.
Neoplasms
MEX3C promotes osteosarcoma malignant progression through negatively regulating FGF14.
Neoplasms
MEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathway.
Neoplasms
MGRN1-dependent pigment-type switching requires its ubiquitination activity but not its interaction with TSG101 or NEDD4.
Neoplasms
MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation.
Neoplasms
Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis.
Neoplasms
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Neoplasms
Microenvironmental Regulation of BRCA1 Gene Expression by c-Jun and Fra2 in Premalignant Human Ovarian Surface Epithelial Cells.
Neoplasms
MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development.
Neoplasms
MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.
Neoplasms
MicroRNA-206 is differentially expressed in Brca1-deficient mice and regulates epithelial and stromal cell compartments of the mouse mammary gland.
Neoplasms
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.
Neoplasms
MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
Neoplasms
MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability.
Neoplasms
Microsatellite instability of D17S513 on chromosome 17 is associated with progression of breast cancer.
Neoplasms
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.
Neoplasms
Mind Bomb 1 Promotes Pancreatic Cancer Proliferation by Activating ?-Catenin Signaling.
Neoplasms
miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
Neoplasms
MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3.
Neoplasms
miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.
Neoplasms
miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade.
Neoplasms
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
Neoplasms
miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
Neoplasms
miR-454-3p promotes proliferation and induces apoptosis in human cervical cancer cells by targeting TRIM3.
Neoplasms
miR-7-5p overexpression suppresses cell proliferation and promotes apoptosis through inhibiting the ability of DNA damage repair of PARP-1 and BRCA1 in TK6 cells exposed to hydroquinone.
Neoplasms
MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.
Neoplasms
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Neoplasms
Mislocalization of the E3 ligase, beta-transducin repeat containing protein 1 ({beta}-TrCP1) in glioblastoma uncouples negative feedback between the PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) and Akt.
Neoplasms
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Neoplasms
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Neoplasms
Missense mutations in disease genes: a Bayesian approach to evaluate causality.
Neoplasms
Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Neoplasms
Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
Neoplasms
Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Neoplasms
Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics.
Neoplasms
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.
Neoplasms
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Neoplasms
Mitophagy contributes to alpha-tocopheryl succinate toxicity in GSNOR-deficient hepatocellular carcinoma.
Neoplasms
Mitophagy in Carcinogenesis and Tumor progression- A New paradigm with Emerging Importance.
Neoplasms
Mitophagy in degenerative joint diseases.
Neoplasms
Mitotic accumulation of dimethylated lysine 79 of histone h3 is important for maintaining genome integrity during mitosis in human cells.
Neoplasms
Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier.
Neoplasms
MLN4924 and 2DG combined treatment enhances the efficiency of radiotherapy in breast cancer cells.
Neoplasms
MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
Neoplasms
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.
Neoplasms
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
Neoplasms
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Neoplasms
Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing.
Neoplasms
Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
Neoplasms
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
Neoplasms
Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.
Neoplasms
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
Neoplasms
Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
Neoplasms
Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Neoplasms
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
Neoplasms
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Neoplasms
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Neoplasms
Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment.
Neoplasms
Modulation of multidrug resistance in cancer cells by the E3 ubiquitin ligase seven-in-absentia homologue 1.
Neoplasms
Molecular Analysis of an Intestinal Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) Reveals MLH1 Methylation-driven Microsatellite Instability and a Monoclonal Origin: Diagnostic and Clinical Implications.
Neoplasms
Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
Neoplasms
Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress.
Neoplasms
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Neoplasms
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families.
Neoplasms
Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families.
Neoplasms
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
Neoplasms
Molecular analysis-based treatment strategies for non-small cell lung cancer.
Neoplasms
Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia.
Neoplasms
Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin.
Neoplasms
Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Neoplasms
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.
Neoplasms
Molecular and pathological characterization of inherited breast cancer.
Neoplasms
Molecular aspects of breast and ovarian cancer.
Neoplasms
Molecular aspects of breast cancer resistance to drugs (Review).
Neoplasms
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Neoplasms
Molecular Basis for Impaired DNA Damage Response Function Associated with the RAP80 ?E81 Defect.
Neoplasms
Molecular basis of gynecological cancer.
Neoplasms
Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Neoplasms
Molecular biology and genetics of breast cancer development: a clinical perspective.
Neoplasms
Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2.
Neoplasms
Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
Neoplasms
Molecular biosensing system based on intrinsically disordered proteins.
Neoplasms
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women.
Neoplasms
Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
Neoplasms
Molecular characterization of breast cancer in young Brazilian women.
Neoplasms
Molecular characterization of late stomal recurrence following total laryngectomy.
Neoplasms
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
Neoplasms
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Neoplasms
Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Neoplasms
Molecular determinants of PAM2 recognition by the MLLE domain of poly(A)-binding protein.
Neoplasms
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Neoplasms
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
Neoplasms
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Neoplasms
Molecular functions of BRCA1 in the DNA damage response.
Neoplasms
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Neoplasms
Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Neoplasms
Molecular genetics of breast cancer progression.
Neoplasms
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Neoplasms
Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.
Neoplasms
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Neoplasms
Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.
Neoplasms
Molecular patterns of nuclear and mitochondrial microsatellite alterations in breast tumors.
Neoplasms
Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRER) and Beyond.
Neoplasms
Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.
Neoplasms
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
Neoplasms
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
Neoplasms
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
Neoplasms
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
Neoplasms
Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.
Neoplasms
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Neoplasms
Molecular Profiling of Triple Negative Breast Cancer.
Neoplasms
Molecular Role of RNF43 in Canonical and Noncanonical Wnt Signaling.
Neoplasms
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Neoplasms
Molecular testing in breast cancer.
Neoplasms
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Neoplasms
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Neoplasms
Monitoring regulation of DNA repair activities of cultured cells in-gel using the comet assay.
Neoplasms
Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer.
Neoplasms
More about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
Neoplasms
More breast cancer genes?
Neoplasms
More Modifiers Move on DNA Damage.
Neoplasms
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
Neoplasms
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Neoplasms
Morphological predictors of BRCA1 germline mutations in young women with breast cancer.
Neoplasms
Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Neoplasms
Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Neoplasms
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Neoplasms
Mouse Double Minute 2 Homolog-Mediated Ubiquitination Facilitates Forkhead Box P3 Stability and Positively Modulates Human Regulatory T Cell Function.
Neoplasms
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.
Neoplasms
Mouse models of BRCA1 and their application to breast cancer research.
Neoplasms
Mouse models of human familial cancer syndromes.
Neoplasms
Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
Neoplasms
Moving towards population-based genetic risk prediction for ovarian cancer.
Neoplasms
MRN Complex and Cancer Risk: Old Bottles, New Wine.
Neoplasms
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
Neoplasms
MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
Neoplasms
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Neoplasms
MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.
Neoplasms
MUC1-C activates EZH2 expression and function in human cancer cells.
Neoplasms
MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.
Neoplasms
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
Neoplasms
MUC13 protects colorectal cancer cells from death by activating the NF-?B pathway and is a potential therapeutic target.
Neoplasms
Mul1 promotes autophagy flux to suppress the development of clear cell renal cell carcinomas.
Neoplasms
Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15.
Neoplasms
Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Neoplasms
Multi-step process of human breast carcinogenesis: a role for BRCA1, BECN1, CCND1, PTEN and UVRAG.
Neoplasms
Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment.
Neoplasms
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
Neoplasms
Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation.
Neoplasms
Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
Neoplasms
Multifunctional transcription factor TFII-I is an activator of BRCA1 function.
Neoplasms
Multigene assessment of genetic risk for women for two or more breast cancers.
Neoplasms
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
Neoplasms
Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.
Neoplasms
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Neoplasms
Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Neoplasms
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.
Neoplasms
Multigene panel testing results in patients with multiple breast cancer primaries.
Neoplasms
Multimodal approach to explore the pathogenicity of BARD1, ARG 658 CYS, and ILE 738 VAL mutants.
Neoplasms
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
Neoplasms
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Neoplasms
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Neoplasms
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Neoplasms
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Neoplasms
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
Neoplasms
Multiple intracerebral haemangioblastomas in identical twins with von Hippel-Lindau disease--a clinical and molecular study.
Neoplasms
Multiple primary cancers in BRCA 1/2 carriers - A review of literature and our observations.
Neoplasms
Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.
Neoplasms
Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer.
Neoplasms
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Neoplasms
Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers.
Neoplasms
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.
Neoplasms
Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay.
Neoplasms
Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.
Neoplasms
Multiplying functions for BRCA1 and BRCA2?. Meeting report, The Breakthrough Breast Cancer Second International Workshop on the function of BRCA1 and BRCA2, Cambridge, UK, 9-10 September 1999.
Neoplasms
Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells.
Neoplasms
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Neoplasms
Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
Neoplasms
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Neoplasms
Mutated Rnf43 Aggravates Helicobacter Pylori-Induced Gastric Pathology.
Neoplasms
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Neoplasms
Mutation analysis in the BRCA2 gene in primary breast cancers.
Neoplasms
Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
Neoplasms
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
Neoplasms
Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
Neoplasms
Mutation analysis of BRCA1 gene in African-American patients with breast cancer.
Neoplasms
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Neoplasms
Mutation analysis of PALB2 gene in French breast cancer families.
Neoplasms
Mutation analysis of the ATR gene in breast and ovarian cancer families.
Neoplasms
Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.
Neoplasms
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation.
Neoplasms
Mutation analysis of the BRCA1 gene in ovarian cancers.
Neoplasms
Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
Neoplasms
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
Neoplasms
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Neoplasms
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Neoplasms
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry.
Neoplasms
Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population.
Neoplasms
Mutation screening of the BRCA1 gene in Slovak patients.
Neoplasms
Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia.
Neoplasms
Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2.
Neoplasms
Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Neoplasms
Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan.
Neoplasms
Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma.
Neoplasms
Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Neoplasms
Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas.
Neoplasms
Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Neoplasms
Mutational analysis of UBR5 gene encoding an E3 ubiquitin ligase in common human cancers.
Neoplasms
Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers.
Neoplasms
Mutational processes molding the genomes of 21 breast cancers.
Neoplasms
Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Neoplasms
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families.
Neoplasms
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Neoplasms
Mutations in a gene encoding a midbody protein in binucleated Reed-Sternberg cells of Hodgkin lymphoma.
Neoplasms
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
Neoplasms
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
Neoplasms
Mutations in Drosophila myb lead to centrosome amplification and genomic instability.
Neoplasms
Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer.
Neoplasms
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.
Neoplasms
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Neoplasms
Mutations in the BRCA1 gene: implications of inter-population differences for predicting the risk of radiation-induced breast cancers.
Neoplasms
Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.
Neoplasms
Mutations in the RAD54 recombination gene in primary cancers.
Neoplasms
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer.
Neoplasms
Mutations of c-Cbl in myeloid malignancies.
Neoplasms
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Neoplasms
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Neoplasms
Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic.
Neoplasms
Mutations of the BRCA1 gene in human cancer.
Neoplasms
Mutator pathways unleashed by epigenetic silencing in human cancer.
Neoplasms
Mutual exclusivity analysis identifies oncogenic network modules.
Neoplasms
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
Neoplasms
MYB oncogene amplification in hereditary BRCA1 breast cancer.
Neoplasms
MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
Neoplasms
MYC and Breast Cancer.
Neoplasms
MYC is amplified in BRCA1-associated breast cancers.
Neoplasms
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Neoplasms
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells.
Neoplasms
Myoglobin induces mitochondrial fusion, thereby inhibiting breast cancer cell proliferation.
Neoplasms
Myriad Genetics Sues BRCA Diagnostic Rivals.
Neoplasms
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Neoplasms
N6-Isopentenyladenosine promoted HeLa cell apoptosis through inhibitions of AKT and transforming growth factor ?-activated kinase 1 activation.
Neoplasms
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
Neoplasms
Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples.
Neoplasms
NBR2: A former junk gene emerges as a key player in tumor suppression.
Neoplasms
NEDD4 E3 ligase: Functions and mechanism in human cancer.
Neoplasms
NEDD4 promotes cell growth and motility in hepatocellular carcinoma.
Neoplasms
NEDD4 triggers FOXA1 ubiquitination and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation.
Neoplasms
NEDD4: a promising target for cancer therapy.
Neoplasms
NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL.
Neoplasms
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
Neoplasms
Negative Regulation of AKT Activation by BRCA1.
Neoplasms
Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
Neoplasms
Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.
Neoplasms
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Neoplasms
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
Neoplasms
Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Neoplasms
Neoadjuvant treatments for triple-negative breast cancer (TNBC).
Neoplasms
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Neoplasms
Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth.
Neoplasms
New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
Neoplasms
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Neoplasms
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.
Neoplasms
New players in the BRCA1-mediated DNA damage responsive pathway.
Neoplasms
New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.
Neoplasms
New sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis in an elderly healthy female population in Croatia.
Neoplasms
Next generation sequencing of BRCA genes in glioblastoma multiform Egyptian patients: a pilot study.
Neoplasms
Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Neoplasms
Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer.
Neoplasms
Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Neoplasms
Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
Neoplasms
Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer.
Neoplasms
NF-?B functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
Neoplasms
NF-?B is a critical mediator of BRCA1-induced chemoresistance.
Neoplasms
NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway.
Neoplasms
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
Neoplasms
Night Shift Work, DNA Methylation and Telomere Length: An Investigation on Hospital Female Nurses.
Neoplasms
Niraparib Shrinks BRCA-Mutated Prostate Tumors.
Neoplasms
Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
Neoplasms
Nitroxoline induces cell apoptosis by inducing MDM2 degradation in small-cell lung cancer.
Neoplasms
No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
Neoplasms
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
Neoplasms
No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report.
Neoplasms
No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.
Neoplasms
No evidence for deletions of the NBS1 gene in lymphomas.
Neoplasms
No evidence for PALB2 methylation in high-grade serous ovarian cancer.
Neoplasms
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families.
Neoplasms
No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers.
Neoplasms
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-?B Signaling after Nuclear DNA Damage.
Neoplasms
Non-homologous end joining is more important than proton linear energy transfer in dictating cell death.
Neoplasms
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Neoplasms
Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
Neoplasms
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Neoplasms
Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
Neoplasms
Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity.
Neoplasms
Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients.
Neoplasms
Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania.
Neoplasms
Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
Neoplasms
Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients.
Neoplasms
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Neoplasms
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Neoplasms
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Neoplasms
Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
Neoplasms
Novel consensus DNA-binding sequence for BRCA1 protein complexes.
Neoplasms
Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
Neoplasms
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Neoplasms
Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
Neoplasms
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Neoplasms
Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Neoplasms
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
Neoplasms
Novel indications for BRCA1 screening using individual clinical and morphological features.
Neoplasms
Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
Neoplasms
Novel mechanism of platinum resistance: Rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ovarian cancer (OC) in BRCA1 germ-line mutation carriers.
Neoplasms
Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
Neoplasms
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.
Neoplasms
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Neoplasms
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Neoplasms
Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals.
Neoplasms
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Neoplasms
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Neoplasms
Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
Neoplasms
Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome.
Neoplasms
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Neoplasms
Npr2, yeast homolog of the human tumor suppressor NPRL2, is a target of Grr1 required for adaptation to growth on diverse nitrogen sources.
Neoplasms
NPR3 protects cardiomyocytes from apoptosis through inhibition of cytosolic BRCA1 and TNF-?.
Neoplasms
Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: \newline A retrospective study.
Neoplasms
Nuclear accumulation of seven in absentia homologue (SIAH)-2 supports motility and proliferation of liver cancer cells.
Neoplasms
Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Neoplasms
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
Neoplasms
Nuclear expression of the ubiquitin ligase seven in absentia homologue (SIAH)-1 induces proliferation and migration of liver cancer cells.
Neoplasms
Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.
Neoplasms
Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor.
Neoplasms
Nuclear location and cell cycle regulation of the BRCA2 protein.
Neoplasms
Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Neoplasms
Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2.
Neoplasms
Nucleation capacity and presence of centrioles define a distinct category of centrosome abnormalities that induces multipolar mitoses in cancer cells.
Neoplasms
Nucleolar localization of BRCA1 protein in human breast cancer.
Neoplasms
Nucleolar Stress Induces Ubiquitination-independent Proteasomal Degradation of PICT1 Protein.
Neoplasms
Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase.
Neoplasms
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Neoplasms
Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.
Neoplasms
Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells.
Neoplasms
Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line.
Neoplasms
O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.
Neoplasms
Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Neoplasms
Occult gynecologic malignancies in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Neoplasms
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
Neoplasms
Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Neoplasms
Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Neoplasms
Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast.
Neoplasms
Of mice and (wo)men: genotype-phenotype correlations in BRCA1.
Neoplasms
Oh what a tangled web it weaves: BRCA1 and DNA decatenation.
Neoplasms
Olaparib , PARP1 inhibitor in ovarian cancer.
Neoplasms
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Neoplasms
Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan.
Neoplasms
Olaparib effective in four advanced cancers.
Neoplasms
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
Olaparib for the treatment of breast cancer.
Neoplasms
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Neoplasms
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Neoplasms
Olaparib shows promise in multiple tumor types.
Neoplasms
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
Neoplasms
Old and new concepts in histopathological characterization of familial breast cancer.
Neoplasms
Oligodendroglial deletion of ESCRT-I component TSG101 causes spongiform encephalopathy.
Neoplasms
On the use of familial aggregation in population-based case probands for calculating penetrance.
Neoplasms
Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-?B-activating potential.
Neoplasms
Oncogenic BARD1 isoforms expressed in gynecological cancers.
Neoplasms
Oncogenic Wnt/?-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research.
Neoplasms
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
Neoplasms
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Neoplasms
Online tool to guide decisions for BRCA1/2 mutation carriers.
Neoplasms
Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Neoplasms
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Neoplasms
Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
Neoplasms
Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
Neoplasms
Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Neoplasms
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.
Neoplasms
Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.
Neoplasms
Organization and running of the first comprehensive hereditary cancer clinic in India.
Neoplasms
Origins and molecular pathology of ovarian cancer.
Neoplasms
Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer.
Neoplasms
OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity.
Neoplasms
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Neoplasms
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Neoplasms
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
Neoplasms
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Neoplasms
Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
Neoplasms
Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
Neoplasms
Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.
Neoplasms
Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Neoplasms
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Neoplasms
Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.
Neoplasms
Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Neoplasms
Ovarian cancer death reduction for women at high risk: workload implications for gynaecology services.
Neoplasms
Ovarian Cancer Gene Therapy with BRCA1-An Overview.
Neoplasms
Ovarian cancer molecular pathology.
Neoplasms
Ovarian cancer screening.
Neoplasms
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Neoplasms
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors.
Neoplasms
Ovarian cancer: epidemiology, biology, and prognostic factors.
Neoplasms
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Neoplasms
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Neoplasms
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Neoplasms
Ovarian surface epithelium: family history and early events in ovarian cancer.
Neoplasms
Ovarian tumors associated with multiple endocrine neoplasias and related syndromes (Carney complex, Peutz-Jeghers syndrome, von Hippel-Lindau disease, Cowden's disease).
Neoplasms
Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/?-catenin signaling.
Neoplasms
Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer.
Neoplasms
Over-representation of two specific haplotypes among chromosomes harbouring BRCA1 mutations.
Neoplasms
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
Neoplasms
Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells.
Neoplasms
Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and ?-Catenin Signaling.
Neoplasms
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer.
Neoplasms
Overexpression of HACE1 in gastric cancer inhibits tumor aggressiveness by impeding cell proliferation and migration.
Neoplasms
Overexpression of Raf-1 in basal-like carcinoma of the breast: correlation with clinicopathology and prognosis.
Neoplasms
Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation.
Neoplasms
Overexpression of RNF146 in non-small cell lung cancer enhances proliferation and invasion of tumors through the Wnt/?-catenin signaling pathway.
Neoplasms
Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression.
Neoplasms
Overview of history and progress in BRCA1 research: the first BRCA1 decade.
Neoplasms
Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson's Disease.
Neoplasms
Oxygen sensing: recent insights from idiopathic erythrocytosis.
Neoplasms
Oxygen sensors and angiogenesis.
Neoplasms
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
Neoplasms
p16 loss rescues functional decline of Brca1-deficient mammary stem cells.
Neoplasms
p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
Neoplasms
p27kip1 Expression in non-small cell lung cancer is not an independent prognostic factor.
Neoplasms
p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb.
Neoplasms
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Neoplasms
p53 mRNA controls p53 activity by managing Mdm2 functions.
Neoplasms
P53 mRNA controls p53 activity by managing Mdm2 functions.
Neoplasms
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
Neoplasms
p53 suppresses hyper-recombination by modulating BRCA1 function.
Neoplasms
p53 Ubiquitination: Mdm2 and beyond.
Neoplasms
p53, BRCA1 and breast Cancer chemoresistance.
Neoplasms
p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage.
Neoplasms
p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection.
Neoplasms
p97 Promotes a Conserved Mechanism of Helicase Unloading During DNA Crosslink Repair.
Neoplasms
PALB2 (partner and localizer of BRCA2).
Neoplasms
PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1.
Neoplasms
PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response.
Neoplasms
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Neoplasms
PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Neoplasms
Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
Neoplasms
PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma.
Neoplasms
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.
Neoplasms
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
Neoplasms
Pan-cancer Analysis of NEDD4L and Its Tumor Suppressor Effects in Clear Cell Renal Cell Carcinoma.
Neoplasms
Pancreatic adenocarcinoma: epidemiology and genetics.
Neoplasms
Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Neoplasms
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Neoplasms
PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Neoplasms
Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Neoplasms
Papers to appear in forthcoming issues
Neoplasms
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
Neoplasms
PARK2 orchestrates cyclins to avoid cancer.
Neoplasms
Parkin and mitophagy in cancer.
Neoplasms
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Neoplasms
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Neoplasms
Parkin enhances sensitivity of paclitaxel to NPC by arresting cell cycle.
Neoplasms
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Neoplasms
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Neoplasms
Parkin gene alterations in hepatocellular carcinoma.
Neoplasms
Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population.
Neoplasms
Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
Neoplasms
Parkin in cancer: Mitophagy-related/unrelated tasks.
Neoplasms
Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.
Neoplasms
Parkin induces apoptotic cell death in TNF-?-treated cervical cancer cells.
Neoplasms
Parkin induces G2/M cell cycle arrest in TNF-?-treated HeLa cells.
Neoplasms
Parkin Induces Upregulation of 40S Ribosomal Protein SA and Posttranslational Modification of Cytokeratins 8 and 18 in Human Cervical Cancer Cells.
Neoplasms
Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy.
Neoplasms
Parkin inhibits necroptosis to prevent cancer.
Neoplasms
Parkin Is Dispensable for Mitochondrial Function, but Its Ubiquitin Ligase Activity Is Critical for Macroautophagy and Neurotransmitters: Therapeutic Potential beyond Parkinson's Disease.
Neoplasms
Parkin modulates expression of HIF-1? and HIF-3? during hypoxia in gliobastoma-derived cell lines in vitro.
Neoplasms
Parkin negatively regulates the antiviral signaling pathway by targeting TRAF3 for degradation.
Neoplasms
Parkin New Cargos: a New ROS Independent Role for Parkin in Regulating Cell Division.
Neoplasms
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
Neoplasms
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Neoplasms
Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.
Neoplasms
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Neoplasms
Parkin Regulates the Activity of Pyruvate Kinase M2.
Neoplasms
Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.
Neoplasms
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Neoplasms
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Neoplasms
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.
Neoplasms
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect.
Neoplasms
Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma.
Neoplasms
Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells.
Neoplasms
Parkin: A targetable linchpin in human malignancies.
Neoplasms
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
Neoplasms
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Neoplasms
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Neoplasms
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Neoplasms
PARP inhibitor combination therapy.
Neoplasms
PARP inhibitor development for systemic cancer targeting.
Neoplasms
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Neoplasms
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Neoplasms
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
Neoplasms
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Neoplasms
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Neoplasms
PARP inhibitors in the management of breast cancer: current data and future prospects.
Neoplasms
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
Neoplasms
PARP inhibitors: an interesting pathway also for Non-Small Cell Lung Cancer?
Neoplasms
PARP inhibitors: Synthetic lethality in the clinic.
Neoplasms
PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
Neoplasms
PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
Neoplasms
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
Neoplasms
PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.
Neoplasms
PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.
Neoplasms
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Neoplasms
Patho-biological aspects of basal-like breast cancer.
Neoplasms
Pathobiologic characteristics of hereditary breast cancer.
Neoplasms
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.
Neoplasms
Pathogenic Germline Variants in 10,389 Adult Cancers.
Neoplasms
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Neoplasms
Pathogenicity Evaluation of BRCA1 and BRCA2 Unclassified Variants Identified in Portuguese Breast/Ovarian Cancer Families.
Neoplasms
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Neoplasms
Pathologic Features and Immunophenotype of Estrogen Receptor-positive Breast Cancers in BRCA1 Mutation Carriers.
Neoplasms
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Neoplasms
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Neoplasms
Pathological characteristics of BRCA-associated breast cancers in Hispanics.
Neoplasms
Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Neoplasms
Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.
Neoplasms
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.
Neoplasms
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.
Neoplasms
Pathology and heredity of breast cancer in younger women.
Neoplasms
Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Neoplasms
Pathology of Breast Cancer Metastasis and A View of Metastasis to The Brain.
Neoplasms
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Neoplasms
Pathology of Hereditary Breast and Ovarian Cancer.
Neoplasms
Pathology of hereditary breast cancer.
Neoplasms
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Neoplasms
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
Neoplasms
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Neoplasms
Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
Neoplasms
Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
Neoplasms
Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility.
Neoplasms
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives.
Neoplasms
Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer.
Neoplasms
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Neoplasms
PDGFR? is an essential therapeutic target for BRCA1-deficient mammary tumors.
Neoplasms
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Neoplasms
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Neoplasms
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Neoplasms
Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
Neoplasms
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Neoplasms
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Neoplasms
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
Neoplasms
Persistent double strand break accumulation does not precede cell death in an Olaparib-sensitive BRCA-deficient colorectal cancer cell model.
Neoplasms
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Neoplasms
Perspective on BRCA1.
Neoplasms
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma.
Neoplasms
Pharmacogenomics and gemcitabine.
Neoplasms
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Neoplasms
Pharmacoprevention for hereditary breast and ovarian cancer.
Neoplasms
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Neoplasms
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Neoplasms
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Neoplasms
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Neoplasms
Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Neoplasms
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.
Neoplasms
Phenotype-directed analysis of genotype in early-onset, familial breast cancers.
Neoplasms
Phenotype-genotype correlation in familial breast cancer.
Neoplasms
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Neoplasms
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Neoplasms
PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis.
Neoplasms
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Neoplasms
Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria.
Neoplasms
Phosphorylation of Pirh2 by Calmodulin-dependent kinase II impairs its ability to ubiquitinate p53.
Neoplasms
Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
Neoplasms
Phosphorylation of Rictor at Thr1135 impairs the Rictor/Cullin-1 complex to ubiquitinate SGK1.
Neoplasms
Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation.
Neoplasms
Phosphorylation of SMURF2 by ATM exerts a negative feedback control of DNA damage response.
Neoplasms
Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Neoplasms
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.
Neoplasms
Physical Activity and Breast Cancer: Focusing on High-Risk Subgroups and Putting Recommendations in Context.
Neoplasms
Physical mapping, cloning, and identification of genes within a 500-kb region containing BRCA1.
Neoplasms
Physicians' experiences with BRCA1/2 testing in community settings.
Neoplasms
Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats.
Neoplasms
PI 3 kinase related kinases-independent proteolysis of BRCA1 regulates Rad51 recruitment during genotoxic stress in human cells.
Neoplasms
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
Neoplasms
PIASx? ligase enhances SUMO1 modification of PTEN protein as a SUMO E3 ligase.
Neoplasms
PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome.
Neoplasms
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
Neoplasms
PINK1/Parkin Influences Cell Cycle by Sequestering TBK1 at Damaged Mitochondria, Inhibiting Mitosis.
Neoplasms
Pirh2 E3 Ubiquitin Ligase Monoubiquitinates DNA Polymerase eta to Suppress Translesion DNA Synthesis.
Neoplasms
Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation.
Neoplasms
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
Neoplasms
Pirh2, an E3 ligase, regulates the AIP4-p73 regulatory pathway by modulating AIP4 expression and ubiquitination.
Neoplasms
Pirh2: An E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation.
Neoplasms
PKCzetaII is a target for degradation through the tumour suppressor protein pVHL.
Neoplasms
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Neoplasms
PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53.
Neoplasms
Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence.
Neoplasms
Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study.
Neoplasms
Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients.
Neoplasms
Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.
Neoplasms
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Neoplasms
Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
Neoplasms
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
Neoplasms
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.
Neoplasms
Playing Tag with HIF: The VHL Story.
Neoplasms
Plk1 interacts with RNF2 and promotes its ubiquitin?dependent degradation.
Neoplasms
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
Neoplasms
Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Neoplasms
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Neoplasms
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Neoplasms
Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Neoplasms
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Neoplasms
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Neoplasms
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Neoplasms
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Neoplasms
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Neoplasms
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Neoplasms
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Neoplasms
Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms.
Neoplasms
Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells.
Neoplasms
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Neoplasms
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
Neoplasms
Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.
Neoplasms
Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression.
Neoplasms
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin.
Neoplasms
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Neoplasms
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Neoplasms
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Neoplasms
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
Neoplasms
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Neoplasms
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Neoplasms
Positive regulation of the BRCA1 promoter.
Neoplasms
Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.
Neoplasms
Possible Role of PHD Inhibitors as Hypoxia-Mimicking Agents in the Maintenance of Neural Stem Cells' Self-Renewal Properties.
Neoplasms
Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Neoplasms
Post translational modification of Parkin.
Neoplasms
Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.
Neoplasms
Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15/107 group of miRNAs.
Neoplasms
Post-translational modification of Parkin and its research progress in cancer.
Neoplasms
Post-translational modification profiling - A novel tool for mapping the protein modification landscape in cancer.
Neoplasms
Post-translational Wnt receptor regulation: Is the fog slowly clearing?: The molecular mechanism of RNF43/ZNRF3 ubiquitin ligases is not yet fully elucidated and still controversial.
Neoplasms
Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.
Neoplasms
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
Neoplasms
Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development.
Neoplasms
PPAR? is an E3 ligase that induces the degradation of NF?B/p65.
Neoplasms
Practical Cancer Genetics and Genomics in Women's Health.
Neoplasms
PRAJA is overexpressed in glioblastoma and contributes to neural precursor development.
Neoplasms
Pre-counseling education materials for BRCA testing: does tailoring make a difference?
Neoplasms
Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.
Neoplasms
Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
Neoplasms
Precursors to pelvic serous carcinoma and their clinical implications.
Neoplasms
Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
Neoplasms
Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers.
Neoplasms
Predicting Ovarian/Breast Cancer Pathogenic Risks of Human BRCA1 Gene Variants of Unknown Significance.
Neoplasms
Predicting the Disease Risk of Protein Mutation Sequences With Pre-training Model.
Neoplasms
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Neoplasms
Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
Neoplasms
Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
Neoplasms
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Neoplasms
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Neoplasms
Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.
Neoplasms
Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy.
Neoplasms
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
Neoplasms
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study.
Neoplasms
Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC).
Neoplasms
Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents.
Neoplasms
Predictive value of gene methylation for second recurrence following surgical treatment of first bladder recurrence of a primary upper-tract urothelial carcinoma.
Neoplasms
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Neoplasms
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
Neoplasms
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Neoplasms
Predisposing genes in breast and ovarian cancer: an overview.
Neoplasms
Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
Neoplasms
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers.
Neoplasms
Preferential binding of IFI16 protein to cruciform structure and superhelical DNA.
Neoplasms
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Neoplasms
Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth.
Neoplasms
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Neoplasms
Preliminary studies on DNA retardation by MutS applied to the detection of point mutations in clinical samples.
Neoplasms
Preparation and Application of a Monoclonal Antibody Against Chicken TRIM62.
Neoplasms
Preparing a re-sequencing DNA library of 2 cancer candidate genes using the ligation-by-amplification protocol by two PCR reactions.
Neoplasms
Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis.
Neoplasms
Prepubertal octylphenol exposure up-regulate BRCA1 expression, down-regulate ERalpha expression and reduce rat mammary tumorigenesis.
Neoplasms
Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland.
Neoplasms
Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
Neoplasms
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Neoplasms
Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.
Neoplasms
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.
Neoplasms
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Neoplasms
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Neoplasms
Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients.
Neoplasms
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
Neoplasms
Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification.
Neoplasms
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
Neoplasms
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Neoplasms
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Neoplasms
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
Neoplasms
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years.
Neoplasms
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.
Neoplasms
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Neoplasms
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Neoplasms
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.
Neoplasms
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
Neoplasms
Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.
Neoplasms
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Neoplasms
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Neoplasms
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.
Neoplasms
Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Neoplasms
Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.
Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.
Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.
Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.
Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Neoplasms
Prevalence of BRCA1 founder mutations in western Poland.
Neoplasms
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations.
Neoplasms
Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites.
Neoplasms
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Neoplasms
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases.
Neoplasms
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
Neoplasms
Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing.
Neoplasms
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Neoplasms
Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families.
Neoplasms
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Neoplasms
Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer.
Neoplasms
Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
Neoplasms
Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
Neoplasms
Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Neoplasms
Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer.
Neoplasms
Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country.
Neoplasms
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Neoplasms
Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.
Neoplasms
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
Neoplasms
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.
Neoplasms
Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Neoplasms
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Neoplasms
Preventing ovarian cancer through genetic testing: a population-based study.
Neoplasms
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Neoplasms
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Neoplasms
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Neoplasms
Prevention of breast cancer: focus on chemoprevention.
Neoplasms
Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Neoplasms
Primary cancer cell culture: mammary-optimized vs conditional reprogramming.
Neoplasms
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
Neoplasms
Primary immunodeficiency with chronic enteropathy and developmental delay in a boy arising from a novel homozygous RIPK1 variant.
Neoplasms
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
Neoplasms
Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation.
Neoplasms
Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.
Neoplasms
Primary transitional cell carcinoma of the fallopian tube.
Neoplasms
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
Neoplasms
Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Neoplasms
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Neoplasms
Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer.
Neoplasms
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Neoplasms
Progesterone Receptor A Stability Is Mediated by Glycogen Synthase Kinase-3? in the Brca1-deficient Mammary Gland.
Neoplasms
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Neoplasms
Progestin and breast cancer. The missing pieces of a puzzle.
Neoplasms
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
Neoplasms
Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Neoplasms
Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Neoplasms
Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.
Neoplasms
Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
Neoplasms
Prognostic role of HuR in hereditary breast cancer.
Neoplasms
Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas.
Neoplasms
Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
Neoplasms
Prognostic significance of BRCA1 expression in gastric cancer.
Neoplasms
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas.
Neoplasms
Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Neoplasms
Prognostic Significance of Fbw7 in Human Melanoma and Its Role in Cell Migration.
Neoplasms
Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma.
Neoplasms
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.
Neoplasms
Prognostic value of CtIP/RBBP8 expression in breast cancer.
Neoplasms
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Neoplasms
Prognostic Value of the Expression of DNA Repair-Related Biomarkers Mediated by Alcohol in Gastric Cancer Patients.
Neoplasms
Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
Neoplasms
Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.
Neoplasms
Progress toward isolation of a breast cancer susceptibility gene, BRCA1.
Neoplasms
Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.
Neoplasms
Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
Neoplasms
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Neoplasms
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
Neoplasms
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Neoplasms
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Neoplasms
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Neoplasms
Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
Neoplasms
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Neoplasms
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Neoplasms
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Neoplasms
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Neoplasms
Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
Neoplasms
Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer
Neoplasms
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Neoplasms
Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Neoplasms
Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients.
Neoplasms
Promoter mutation and reduced expression of BRCA1 in canine mammary tumors.
Neoplasms
Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
Neoplasms
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
Neoplasms
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
Neoplasms
Prophylactic mastectomy and inherited predisposition to breast carcinoma.
Neoplasms
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Neoplasms
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
Neoplasms
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Neoplasms
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Neoplasms
Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer.
Neoplasms
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
Neoplasms
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
Neoplasms
Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet.
Neoplasms
Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging.
Neoplasms
Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Neoplasms
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
Neoplasms
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Neoplasms
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Neoplasms
Protease associated domain of RNF43 is not necessary for the suppression of Wnt/?-catenin signaling in human cells.
Neoplasms
Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12.
Neoplasms
Proteasomal regulation of caspase-8 in cancer cell apoptosis.
Neoplasms
Proteasomal Regulation of the Hypoxic Response Modulates Aging in C. elegans.
Neoplasms
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Neoplasms
Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase.
Neoplasms
Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.
Neoplasms
Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.
Neoplasms
Protein kinase CK1delta phosphorylates key sites in the acidic domain of murine double-minute clone 2 protein (MDM2) that regulate p53 turnover.
Neoplasms
Protein partners of the BRCA1 tumor suppressor.
Neoplasms
Protein stability versus function: effects of destabilizing missense mutations on BRCA1 DNA repair activity.
Neoplasms
Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays.
Neoplasms
Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas.
Neoplasms
Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.
Neoplasms
Proteome-wide analysis reveals substrates of E3 ligase RNF146 targeted for degradation.
Neoplasms
Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.
Neoplasms
Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development.
Neoplasms
Proteomic characterization of pancreatic islet {beta}-cells stimulated with pancreatic carcinoma cell conditioned medium.
Neoplasms
Proteomic Profiling of ?-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Neoplasms
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with diagnostic and prognostic value in human breast cancer.
Neoplasms
Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
Neoplasms
Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
Neoplasms
Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells.
Neoplasms
Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway.
Neoplasms
Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway.
Neoplasms
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
Neoplasms
Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer.
Neoplasms
Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review.
Neoplasms
Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer.
Neoplasms
Psychological impact of genetic testing in women from high-risk breast cancer families.
Neoplasms
Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
Neoplasms
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
Neoplasms
Purification and characterisation of a soluble N-terminal fragment of the breast cancer susceptibility protein BRCA1.
Neoplasms
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-kappaB Agonist Card9 by CK2.
Neoplasms
pVHL Negatively Regulates Antiviral Signaling by Targeting MAVS for Proteasomal Degradation.
Neoplasms
pVHL promotes lysosomal degradation of YAP in lung adenocarcinoma.
Neoplasms
Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
Neoplasms
Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma.
Neoplasms
Pyrrolidine Dithiocarbamate Facilitates Arsenic Trioxide Against Pancreatic Cancer via Perturbing Ubiquitin-Proteasome Pathway.
Neoplasms
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.
Neoplasms
Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene.
Neoplasms
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Neoplasms
Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics.
Neoplasms
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
Neoplasms
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Neoplasms
Quantitative Lys-?-Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1.
Neoplasms
Quantitative proteomic identification of the BRCA1 ubiquitination substrates.
Neoplasms
Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.
Neoplasms
R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.
Neoplasms
Race and cancer genetics: lessons from BRCA1.
Neoplasms
RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells.
Neoplasms
Rad18 confers hematopoietic progenitor cell DNA damage tolerance independently of the Fanconi Anemia pathway in vivo.
Neoplasms
RAD18 contributes to the migration and invasion of human cervical cancer cells via the interleukin?1? pathway.
Neoplasms
Rad18 mediates specific mutational signatures and shapes the genomic landscape of carcinogen-induced tumors in vivo.
Neoplasms
Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population.
Neoplasms
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Neoplasms
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
Neoplasms
RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2?deficient human acute myeloid leukemia.
Neoplasms
Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.
Neoplasms
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Neoplasms
RANKL/RANK control Brca1 mutation-driven mammary tumors.
Neoplasms
RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage.
Neoplasms
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.
Neoplasms
Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments.
Neoplasms
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group.
Neoplasms
Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80.
Neoplasms
Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era.
Neoplasms
Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Neoplasms
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
Neoplasms
Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.
Neoplasms
RASSF6 tumor suppressor regulates apoptosis and cell cycle via MDM2 and p53.
Neoplasms
Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
Neoplasms
Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
Neoplasms
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Neoplasms
RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC).
Neoplasms
RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation.
Neoplasms
RBR E3 ubiquitin ligases in tumorigenesis.
Neoplasms
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
Neoplasms
RBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival.
Neoplasms
Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients.
Neoplasms
Re: Cancer risks in BRCA1 carriers: time for the next generation of studies.
Neoplasms
Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.
Neoplasms
Re: Increased Cancer Risks for Relatives of Very Early-Onset Breast Cancer Cases With and Without BRCA1 and BRCA2 Mutations.
Neoplasms
Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
Neoplasms
Re: probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Neoplasms
Reactivation of p53 by Inhibiting Mdm2 E3 Ligase: A Novel Antitumor Approach.
Neoplasms
Real-time detection of BRCA1 gene mutations using a monolithic silicon optocoupler array.
Neoplasms
Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines.
Neoplasms
Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families.
Neoplasms
Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.
Neoplasms
Recent advances in breast cancer biology.
Neoplasms
Recent advances in SCF ubiquitin ligase complex: Clinical implications.
Neoplasms
Recent developments in ovarian cancer genetics.
Neoplasms
Recessive oncogenes: current status.
Neoplasms
Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers.
Neoplasms
Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort.
Neoplasms
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network.
Neoplasms
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Neoplasms
Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.
Neoplasms
Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
Neoplasms
Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways.
Neoplasms
Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Neoplasms
Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
Neoplasms
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
Neoplasms
Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series.
Neoplasms
Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
Neoplasms
Redox biology in normal cells and cancer: Restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment.
Neoplasms
Redox regulation in cancer: a double-edged sword with therapeutic potential.
Neoplasms
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
Neoplasms
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia.
Neoplasms
Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas.
Neoplasms
Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
Neoplasms
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.
Neoplasms
Reduced PDZRN4 promotes breast cancer progression and predicts poor prognosis.
Neoplasms
Reduction of BRCA1 expression in sporadic ovarian cancer.
Neoplasms
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Neoplasms
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
Neoplasms
Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
Neoplasms
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Neoplasms
Refining the role of BRCA1 in combating oxidative stress.
Neoplasms
Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells.
Neoplasms
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Neoplasms
Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation.
Neoplasms
Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.
Neoplasms
Regulating the balance between necroptosis, apoptosis and inflammation by inhibitors of apoptosis proteins.
Neoplasms
Regulating the levels of key factors in cell cycle and DNA repair: new pathways revealed by lamins.
Neoplasms
Regulation of APC(Cdh1) E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7.
Neoplasms
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Neoplasms
Regulation of BRCA1 by protein degradation.
Neoplasms
Regulation of BRCA1 expression and its relationship to sporadic breast cancer.
Neoplasms
Regulation of BRCA1 expression by the Rb-E2F pathway.
Neoplasms
Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha.
Neoplasms
Regulation of BRCA1 transcription by specific single-stranded DNA binding factors.
Neoplasms
Regulation of cancer stem cells by RING finger ubiquitin ligases.
Neoplasms
Regulation of centrosomes by the BRCA1-dependent ubiquitin ligase.
Neoplasms
Regulation of DNA Damage Response by Estrogen Receptor ?-Mediated Inhibition of Breast Cancer Associated Gene 2.
Neoplasms
Regulation of glioma migration and invasion via modification of Rap2a activity by the ubiquitin ligase Nedd4-1.
Neoplasms
Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Neoplasms
Regulation of Krüppel-like factor 8 by the NEDD4 E3 ubiquitin ligase.
Neoplasms
Regulation of Oxidative Stress Contributes to BRCA1 Tumor Suppression.
Neoplasms
Regulation of p53 level by UBE4B in breast cancer.
Neoplasms
Regulation of Parkin expression as the key balance between neural survival and cancer cell death.
Neoplasms
Regulation of PCTAIRE1 protein stability by AKT1, LKB1 and BRCA1.
Neoplasms
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Neoplasms
Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7? modulates melanoma cell migration.
Neoplasms
Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1.
Neoplasms
Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer.
Neoplasms
Regulation of the p53 response and its relationship to cancer.
Neoplasms
Regulation of the p53 tumor suppressor pathway: the problems and promises of studying Mdm2's E3 ligase function.
Neoplasms
Regulation of tumor suppressors by nuclear-cytoplasmic shuttling.
Neoplasms
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Neoplasms
Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the P2rx3/P2rx7 axis in mouse hippocampal neuronal cells.
Neoplasms
Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8(+) T cells combined with a DC vaccine.
Neoplasms
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
Neoplasms
Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma.
Neoplasms
Relationship between three novel SNPs of BRCA1 and canine mammary tumors.
Neoplasms
Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence.
Neoplasms
Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Neoplasms
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Neoplasms
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.
Neoplasms
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study.
Neoplasms
Relevance of DNA methylation in the management of cancer.
Neoplasms
Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
Neoplasms
Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature.
Neoplasms
Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Neoplasms
Repair of chromosomal double-strand breaks by precise ligation in human cells.
Neoplasms
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Neoplasms
Repetitive demand for radical cancer risk reduction surgery in a young BRCA1 mutation carrier with strong family history of BRCA linked malignancies.
Neoplasms
Replicated chromatin curtails 53BP1 recruitment in BRCA1-proficient and BRCA1-deficient cells.
Neoplasms
Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Neoplasms
Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions.
Neoplasms
Repression of BRCA1 through a feedback loop involving p53.
Neoplasms
Repression of the putative tumor suppressor gene Bard1 or expression of Notch4(int-3) oncogene subvert the morphogenetic properties of mammary epithelial cells.
Neoplasms
Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.
Neoplasms
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Neoplasms
Requirement of heterogeneous nuclear ribonucleoprotein C for BRCA gene expression and homologous recombination.
Neoplasms
Residues 240-250 in the C-terminus of the Pirh2 protein complement the function of the RING domain in self-ubiquitination of the Pirh2 protein.
Neoplasms
Resources to increase genetics and genomics capacity of oncology nurses.
Neoplasms
Response and resistance to the endocrine prevention of breast cancer.
Neoplasms
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.
Neoplasms
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Neoplasms
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.
Neoplasms
RESPONSE: more about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
Neoplasms
Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.
Neoplasms
Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers.
Neoplasms
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Neoplasms
Restriction of Src activity by Cullin-5.
Neoplasms
Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines.
Neoplasms
Retention of African American women in cancer genetics research.
Neoplasms
Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.
Neoplasms
Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population.
Neoplasms
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Neoplasms
Return of Results from Genomic Sequencing: A Policy Discussion of Secondary Findings for Cancer Predisposition.
Neoplasms
Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma.
Neoplasms
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Neoplasms
Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.
Neoplasms
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Neoplasms
Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
Neoplasms
Revisiting the BRCA-pathway through the lens of replication gap suppression: "Gaps determine therapy response in BRCA mutant cancer".
Neoplasms
Rho guanosine nucleotide exchange factors are not such bad guys after all in cancer
Neoplasms
Ribosomal protein L6 (RPL6) is recruited to DNA damage sites in a poly(ADP-ribose) polymerase-dependent manner and regulates the DNA damage response.
Neoplasms
Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction.
Neoplasms
RING finger E(3) ubiquitin ligases: structure and drug discovery.
Neoplasms
Ring Finger Protein 11 acts on ligand-activated EGFR via the direct interaction with the UIM region of ANKRD13 protein family.
Neoplasms
Ring finger protein 43 as a new target for cancer immunotherapy.
Neoplasms
Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-?/catenin signaling pathway.
Neoplasms
Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
Neoplasms
RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer.
Neoplasms
RING-finger protein 5 promotes hepatocellular carcinoma progression and predicts poor prognosis.
Neoplasms
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoprotein.
Neoplasms
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
Neoplasms
Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis.
Neoplasms
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.
Neoplasms
Rise of TRIM8: A Molecule of Duality.
Neoplasms
Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
Neoplasms
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Neoplasms
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Neoplasms
Risk modifiers in carriers of BRCA1 mutations.
Neoplasms
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Neoplasms
Risk of breast and ovarian cancer in women with strong family histories.
Neoplasms
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
Neoplasms
Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
Neoplasms
Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland).
Neoplasms
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.
Neoplasms
Risk of endometrial carcinoma associated with BRCA mutation.
Neoplasms
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Neoplasms
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.
Neoplasms
Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
Neoplasms
Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.
Neoplasms
Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
Neoplasms
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Neoplasms
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Neoplasms
Risk-reducing mastectomy.
Neoplasms
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Neoplasms
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Neoplasms
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Neoplasms
Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.
Neoplasms
Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment and pathology report.
Neoplasms
Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Neoplasms
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry.
Neoplasms
Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
Neoplasms
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Neoplasms
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Neoplasms
RN181 regulates the biological behaviors of oral squamous cell carcinoma cells via mediating ERK/MAPK signaling pathway.
Neoplasms
RN181 suppressed tumor growth of hepatocellular carcinoma by inhibition of the ERK/MAPK pathway.
Neoplasms
RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing.
Neoplasms
RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Neoplasms
RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
Neoplasms
RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator.
Neoplasms
RNA-Primed Amplification for Noise-Suppressed Visualization of Single-Cell Splice Variants.
Neoplasms
RNF11 is a GGA protein cargo and acts as a molecular adaptor for GGA3 ubiquitination mediated by Itch.
Neoplasms
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
Neoplasms
RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
Neoplasms
RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.
Neoplasms
RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.
Neoplasms
RNF144A suppresses ovarian cancer stem cell properties and tumor progression through regulation of LIN28B degradation via the ubiquitin-proteasome pathway.
Neoplasms
RNF180 Inhibits Proliferation and Promotes Apoptosis of Colorectal Cancer Through Ubiquitination of WISP1.
Neoplasms
RNF180 mediates STAT3 activity by regulating the expression of RhoC via the proteasomal pathway in gastric cancer cells.
Neoplasms
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Neoplasms
RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development.
Neoplasms
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.
Neoplasms
RNF20 inhibits TFIIS-facilitated transcriptional elongation to suppress pro-oncogenic gene expression.
Neoplasms
RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer.
Neoplasms
RNF20 promotes the polyubiquitination and proteasome-dependent degradation of AP-2? protein.
Neoplasms
RNF20 Suppresses Tumorigenesis by Inhibiting SREBP1c-PTTG1 Axis in Kidney Cancer.
Neoplasms
RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response.
Neoplasms
RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers.
Neoplasms
RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer.
Neoplasms
RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
Neoplasms
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
Neoplasms
RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
Neoplasms
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
Neoplasms
RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma.
Neoplasms
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
Neoplasms
RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy.
Neoplasms
RNF43 is frequently mutated in colorectal and endometrial cancers.
Neoplasms
RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Neoplasms
RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
Neoplasms
RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
Neoplasms
RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor.
Neoplasms
RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.
Neoplasms
RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer.
Neoplasms
RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1.
Neoplasms
RNF8 E3 Ubiquitin Ligase Stimulates Ubc13 E2 Conjugating Activity that is Essential for DNA Double-Strand Break Signaling and BRCA1 Tumor Suppressor Recruitment.
Neoplasms
RNF8 promotes efficient DSB repair by inhibiting the pro-apoptotic activity of p53 through regulating the function of Tip60.
Neoplasms
RNF8 Promotes Epithelial-Mesenchymal Transition in Lung Cancer Cells via Stabilization of Slug.
Neoplasms
RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.
Neoplasms
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.
Neoplasms
ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence.
Neoplasms
Role for ATM in DNA damage-induced phosphorylation of BRCA1.
Neoplasms
Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability.
Neoplasms
Role of a BRCT domain in the interaction of DNA ligase III-alpha with the DNA repair protein XRCC1.
Neoplasms
Role of Apoptotic Regulators in Human Epithelial Ovarian Cancer.
Neoplasms
Role of BRCA gene dysfunction in breast and ovarian cancer predisposition.
Neoplasms
Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
Neoplasms
Role of BRCA1 in brain development.
Neoplasms
Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
Neoplasms
Role of BRCA1 in Neuronal Death in Alzheimer's Disease.
Neoplasms
Role of BRCA1 mutation screening in the management of familial ovarian cancer.
Neoplasms
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Neoplasms
Role of E3 ubiquitin ligases in lung cancer.
Neoplasms
Role of IFI16 in DNA damage and checkpoint.
Neoplasms
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
Neoplasms
Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha.
Neoplasms
Role of RNF20 in cancer development and progression - a comprehensive review.
Neoplasms
Role of steroid hormones and growth factors in breast cancer.
Neoplasms
Role of the GH-IGF1 system in progression of cancer.
Neoplasms
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.
Neoplasms
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
Neoplasms
Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses.
Neoplasms
Role of TRIM33 in Wnt signaling during mesendoderm differentiation.
Neoplasms
Role of tumor suppressor molecules in genomic perturbations and damaged DNA repair involved in the pathogenesis of cancer and neurodegeneration (Review).
Neoplasms
Role played by BRCA1 in regulating the cellular response to stress.
Neoplasms
Role played by BRCA1 in transcriptional regulation in response to therapy.
Neoplasms
Roles of BRCA1 and its interacting proteins.
Neoplasms
Roles of BRCA1 in DNA damage repair: a link between development and cancer.
Neoplasms
Roles of DNA mutation in the coding region and DNA methylation in the 5' flanking region of BRCA1 in canine mammary tumors.
Neoplasms
Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
Neoplasms
Rotating night work, lifestyle factors, obesity and promoter methylation in BRCA1 and BRCA2 genes among nurses and midwives.
Neoplasms
Routine use of gene panel testing in hereditary breast cancer should be performed with caution.
Neoplasms
RPL32 Promotes Lung Cancer Progression by Facilitating p53 Degradation.
Neoplasms
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.
Neoplasms
RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer.
Neoplasms
S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Neoplasms
SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27.
Neoplasms
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Neoplasms
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.
Neoplasms
SCF E3 Ubiquitin Ligases as Anticancer Targets.
Neoplasms
Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women.
Neoplasms
Screening and clinical implications for BRCA1 and BRCA2 mutation carriers.
Neoplasms
Screening and prevention of hereditary gynecologic cancers.
Neoplasms
Screening and verification of proteins that interact with HSPC238.
Neoplasms
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Neoplasms
Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Neoplasms
Screening for genetic risk of breast cancer.
Neoplasms
Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Neoplasms
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.
Neoplasms
Screening for microsatellite instability target genes in colorectal cancers.
Neoplasms
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Neoplasms
Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
Neoplasms
Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers.
Neoplasms
Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer.
Neoplasms
Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases.
Neoplasms
Screening of male breast cancer and of breast-ovarian cancer families for BRCA2 mutations using large bifluorescent amplicons.
Neoplasms
Screening of women at high risk for breast cancer.
Neoplasms
Screening strategies for ovarian cancer.
Neoplasms
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Neoplasms
scribble (scrib) knockdown induces tumorigenesis by modulating Drp1-Parkin mediated mitochondrial dynamics in the wing imaginal tissues of Drosophila.
Neoplasms
SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.
Neoplasms
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Neoplasms
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Neoplasms
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
Neoplasms
Secondary mutations of BRCA1/2 and drug resistance.
Neoplasms
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Neoplasms
Seeking Balance: Decision Support Needs of Women Without Cancer and a Deleterious BRCA1 or BRCA2 Mutation.
Neoplasms
Selected aspects of genetic counselling for BRCA1 mutation carriers.
Neoplasms
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Neoplasms
Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
Neoplasms
Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
Neoplasms
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.
Neoplasms
Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Neoplasms
Selective immobilization of DNA and antibody probes on electrode arrays: simultaneous electrochemical detection of DNA and protein on a single platform.
Neoplasms
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Neoplasms
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Neoplasms
Selective removal of the selenocysteine tRNA [Ser]Sec gene (Trsp) in mouse mammary epithelium.
Neoplasms
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Neoplasms
Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers.
Neoplasms
Sensitive and selective DNA probe based on "turn-on" photoluminescence of C-dots@RGO.
Neoplasms
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Neoplasms
Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing.
Neoplasms
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
Neoplasms
Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Neoplasms
Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.
Neoplasms
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Neoplasms
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Neoplasms
Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3.
Neoplasms
Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer.
Neoplasms
Sequence, chromosomal location and expression analysis of the murine homologue of human RAD51L2/RAD51C.
Neoplasms
Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest.
Neoplasms
Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics.
Neoplasms
Serum (circulating) tumor markers for breast cancer.
Neoplasms
Setting up a breast cancer family history clinic.
Neoplasms
Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report.
Neoplasms
Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
Neoplasms
Shaping the regulation of the p53 mRNA tumour suppressor: the co-evolution of genetic signatures.
Neoplasms
Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis.
Neoplasms
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Neoplasms
Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
Neoplasms
Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
Neoplasms
Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Neoplasms
Shuttling imbalance of MLF1 results in p53 instability and increases susceptibility to oncogenic transformation.
Neoplasms
Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2.
Neoplasms
Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer.
Neoplasms
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Neoplasms
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.
Neoplasms
Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells.
Neoplasms
Silencing of unsynapsed meiotic chromosomes in the mouse.
Neoplasms
Silencing RBBP6 (Retinoblastoma Binding Protein 6) sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death.
Neoplasms
Silencing UBE4B induces nasopharyngeal carcinoma apoptosis through the activation of caspase3 and p53.
Neoplasms
Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways.
Neoplasms
Silibinin-induced mitochondria fission leads to mitophagy, which attenuates silibinin-induced apoptosis in MCF-7 and MDA-MB-231 cells.
Neoplasms
Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Neoplasms
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Neoplasms
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
Neoplasms
Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1.
Neoplasms
Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers.
Neoplasms
Single-Cell Transcriptome Analysis Dissects the Replicating Process of Pancreatic Beta Cells in Partial Pancreatectomy Model.
Neoplasms
Single-molecule DNA visualization using AT-specific red and non-specific green DNA-binding fluorescent proteins.
Neoplasms
Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Neoplasms
SIRT6 Is a Target of Regulation by UBE3A That Contributes to Liver Tumorigenesis in an ANXA2-Dependent Manner.
Neoplasms
SIRTing through breast cancer is just a survivin' game.
Neoplasms
Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Neoplasms
Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells.
Neoplasms
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Neoplasms
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.
Neoplasms
Slug promotes p53 and p21 protein degradation by inducing Mdm2 expression in HCT116 colon cancer cells.
Neoplasms
Smac mimetics and TNFalpha: a dangerous liaison?
Neoplasms
Smad7 Binds Differently to Individual and Tandem WW3 and WW4 Domains of WWP2 Ubiquitin Ligase Isoforms.
Neoplasms
Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of Arf tumor suppressor-deficient mice.
Neoplasms
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Neoplasms
Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets.
Neoplasms
Small RNA sequencing reveals a comprehensive miRNA signature of BRCA1-associated high-grade serous ovarian cancer.
Neoplasms
Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells.
Neoplasms
Small-molecule SMAC mimetics as new cancer therapeutics.
Neoplasms
SMURF1 amplification promotes invasiveness in pancreatic cancer.
Neoplasms
SMURF1, a promoter of tumor cell progression?
Neoplasms
SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis.
Neoplasms
SMURF2-mediated ubiquitin signaling plays an essential role in the regulation of PARP1 PARylating activity, molecular interactions, and functions in mammalian cells.
Neoplasms
Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions.
Neoplasms
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Neoplasms
Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.
Neoplasms
Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.
Neoplasms
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
Neoplasms
Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.
Neoplasms
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Neoplasms
Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
Neoplasms
Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma.
Neoplasms
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Neoplasms
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.
Neoplasms
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus.
Neoplasms
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Neoplasms
Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Neoplasms
Somatic mutations in early onset luminal breast cancer.
Neoplasms
Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer.
Neoplasms
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Neoplasms
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Neoplasms
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
Neoplasms
Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.
Neoplasms
Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors.
Neoplasms
Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response.
Neoplasms
Sorting Nexin 5 Controls Head and Neck Squamous Cell Carcinoma Progression by Modulating FBW7.
Neoplasms
SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer.
Neoplasms
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.
Neoplasms
Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Neoplasms
Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.
Neoplasms
Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Neoplasms
Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Neoplasms
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.
Neoplasms
Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.
Neoplasms
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Neoplasms
Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes.
Neoplasms
Speed matters: How subtle changes in DNA end resection rate affect repair.
Neoplasms
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation.
Neoplasms
Spinophilin loss contributes to tumorigenesis in vivo.
Neoplasms
Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma.
Neoplasms
Spinophilin: a new tumor suppressor at 17q21.
Neoplasms
Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.
Neoplasms
Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer.
Neoplasms
Spliceogenic analysis of BRCA1 c.439T>C (rs794727800) variant by High Resolution Melting Analysis.
Neoplasms
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
Neoplasms
SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.
Neoplasms
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Neoplasms
SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Neoplasms
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Neoplasms
SPSB1 enhances ovarian cancer cell survival by destabilizing p21.
Neoplasms
Squamous differentiation in surgically resected malignant pleural mesothelioma with neoadjuvant chemotherapy.
Neoplasms
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.
Neoplasms
Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
Neoplasms
STAT3 and STAT5 Activation in Solid Cancers.
Neoplasms
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2014.
Neoplasms
State of the Art: Advances in Malignant Pleural Mesothelioma in 2017.
Neoplasms
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
Neoplasms
Stem cell therapy for hereditary breast cancer.
Neoplasms
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Neoplasms
Stimulation of lactate receptor (HCAR1) affects cellular DNA repair capacity.
Neoplasms
STRAD in Peutz-Jeghers syndrome and sporadic cancers.
Neoplasms
Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic reponse diagnostics.
Neoplasms
Strategies for ovarian cancer prevention.
Neoplasms
Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.
Neoplasms
Strong feature sets from small samples.
Neoplasms
Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online.
Neoplasms
Strong preference of BRCA1 protein to topologically constrained non-B DNA structures.
Neoplasms
Structural analysis of BRCA1 reveals modification hotspot.
Neoplasms
Structural and biochemical characterization of TRAF5 from Notothenia coriiceps and its implications in fish immune cell signaling.
Neoplasms
Structural Basis for Bivalent Smac-Mimetics Recognition in the IAP Protein Family.
Neoplasms
Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
Neoplasms
Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
Neoplasms
Structural Basis of BRCC36 Function in DNA Repair and Immune Regulation.
Neoplasms
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Neoplasms
Structural basis of homologous recombination.
Neoplasms
Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
Neoplasms
Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
Neoplasms
Structural Characterization of the Trimerization of TRAF6 Protein Through Molecular Dynamics Simulations.
Neoplasms
Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
Neoplasms
Structural determinants of BRCA1 translational regulation.
Neoplasms
Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.
Neoplasms
Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
Neoplasms
Structure activity relationship of plumbagin in BRCA1 related cancer cells.
Neoplasms
Structure and expression of variant BRCA2a lacking the transactivation domain.
Neoplasms
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases.
Neoplasms
Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
Neoplasms
Structure based virtual screening of natural products to disrupt the structural integrity of TRAF6 C-terminal domain homotrimer.
Neoplasms
Structure meets function--centrosomes, genome maintenance and the DNA damage response.
Neoplasms
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Neoplasms
Structure of a second BRCT domain identified in the nijmegen breakage syndrome protein Nbs1 and its function in an MDC1-dependent localization of Nbs1 to DNA damage sites.
Neoplasms
Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Neoplasms
Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
Neoplasms
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Neoplasms
Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
Neoplasms
Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Neoplasms
Structure-based design of covalent siah inhibitors.
Neoplasms
Structure-based functional analysis of BRCA1 RING domain variants: Concordance of computational mutagenesis, experimental assay, and clinical data.
Neoplasms
Structure-Function Of The Tumor Suppressor BRCA1.
Neoplasms
STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling.
Neoplasms
Studies of ATM Kinase Activity Using Engineered ATM Sensitive to ATP Analogues (ATM-AS).
Neoplasms
Studies on selected molecular factors in endometrial cancers.
Neoplasms
Study designs in genetic epidemiology.
Neoplasms
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Neoplasms
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Neoplasms
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Neoplasms
Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation.
Neoplasms
Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1.
Neoplasms
Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors.
Neoplasms
Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
Neoplasms
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
Neoplasms
Substrates of the BRCA1-Dependent Ubiquitin Ligase.
Neoplasms
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Neoplasms
Subtypes of familial breast tumours revealed by expression and copy number profiling.
Neoplasms
Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
Neoplasms
SUMO boosts the DNA damage response barrier against cancer.
Neoplasms
SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.
Neoplasms
SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy.
Neoplasms
SUMOylation proteins in breast cancer.
Neoplasms
Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia.
Neoplasms
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Neoplasms
Suppression of DNA Polymerase ? Activity Is Synthetically Lethal in BRCA1-Deficient Cells.
Neoplasms
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Neoplasms
Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q.
Neoplasms
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.
Neoplasms
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification.
Neoplasms
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
Neoplasms
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Neoplasms
Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit.
Neoplasms
Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
Neoplasms
Survey of differentially methylated promoters in prostate cancer cell lines.
Neoplasms
Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.
Neoplasms
Survival and tumor characteristics of German hereditary breast cancer patients.
Neoplasms
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
Neoplasms
Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group.
Neoplasms
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Neoplasms
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.
Neoplasms
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Neoplasms
Survival of BRCA1 negative ovarian cancer patients based on family history.
Neoplasms
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
Neoplasms
Switch of FANCL, a key FA-BRCA component, between tumor suppressor and promoter by alternative splicing.
Neoplasms
Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer.
Neoplasms
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Neoplasms
Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
Neoplasms
Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
Neoplasms
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.
Neoplasms
Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.
Neoplasms
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Neoplasms
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Neoplasms
Synthetic lethal targeting of DNA double strand break repair deficient cells by human apurinic/apyrimidinic endonuclease (APE1) inhibitors.
Neoplasms
Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition.
Neoplasms
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Neoplasms
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Neoplasms
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Neoplasms
Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-?
Neoplasms
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Neoplasms
Synthetic lethality: the road to novel therapies for breast cancer.
Neoplasms
Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage.
Neoplasms
Systemic treatment strategies for triple-negative breast cancer.
Neoplasms
Systemic VHL gene functions and the VHL disease.
Neoplasms
Systems consequences of amplicon formation in human breast cancer.
Neoplasms
SYT-SSX1 (Synovial Sarcoma Translocated) regulates PIASy to cause overexpression of NCOA3.
Neoplasms
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
Neoplasms
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Neoplasms
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Neoplasms
Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk.
Neoplasms
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Neoplasms
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.
Neoplasms
Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Neoplasms
Targeted degradation of proteins by small molecules: a novel tool for functional proteomics.
Neoplasms
Targeted disruption of Brca1 in restricted compartments of the mouse mammary epithelia.
Neoplasms
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.
Neoplasms
Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
Neoplasms
Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Neoplasms
Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk.
Neoplasms
Targeted therapy for cancer using PARP inhibitors.
Neoplasms
Targeted Vaccination against Human ?-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
Neoplasms
Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.
Neoplasms
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-ribose) polymerase inhibition.
Neoplasms
Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Neoplasms
Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
Neoplasms
Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy.
Neoplasms
Targeting DNA repair in breast cancer: A clinical and translational update.
Neoplasms
Targeting Hedgehog Signalling through the Ubiquitylation Process: The Multiple Roles of the HECT-E3 Ligase Itch.
Neoplasms
Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Neoplasms
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
Neoplasms
Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics.
Neoplasms
Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.
Neoplasms
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Neoplasms
Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
Neoplasms
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
Neoplasms
Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma.
Neoplasms
Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.
Neoplasms
Targeting the BRCA1/2 tumor suppressors.
Neoplasms
Targeting the DNA Damage Response in Cancer.
Neoplasms
Targeting the DNA damage response in oncology: past, present and future perspectives.
Neoplasms
Targeting the DNA Double Strand Breaks Repair for Cancer Therapy.
Neoplasms
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Neoplasms
Targeting the DNA repair defect of BRCA tumours.
Neoplasms
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Neoplasms
Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGF-? Signaling.
Neoplasms
Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Neoplasms
Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.
Neoplasms
Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
Neoplasms
Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Neoplasms
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
Neoplasms
Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent.
Neoplasms
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Neoplasms
Targeting the PIAS1 SUMO ligase pathway to control inflammation.
Neoplasms
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1? Interaction.
Neoplasms
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Neoplasms
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
Neoplasms
TCTP increases stability of hypoxia-inducible factor 1? by interaction with and degradation of the tumour suppressor VHL.
Neoplasms
Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease.
Neoplasms
Telephone Genetic Counseling for High-Risk Women Undergoing BRCA1 and BRCA2 Testing: Rationale and Development of a Randomized Controlled Trial.
Neoplasms
Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial.
Neoplasms
Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Neoplasms
Telomere length shows no association with BRCA1 and BRCA2 mutation status.
Neoplasms
Ten genes for inherited breast cancer.
Neoplasms
Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
Neoplasms
Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.
Neoplasms
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Neoplasms
TGF-? activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.
Neoplasms
TGF-? promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85?.
Neoplasms
TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb.
Neoplasms
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.
Neoplasms
The "portrait" of hereditary breast cancer.
Neoplasms
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.
Neoplasms
The 2014 society of surgical oncology susan g. Komen for the cure symposium: triple-negative breast cancer.
Neoplasms
The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.
Neoplasms
The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21.
Neoplasms
The ability of TRIM3 to induce growth arrest depends on RING-dependent E3 ligase activity.
Neoplasms
The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors.
Neoplasms
The Akt DUBbed InAktive.
Neoplasms
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
Neoplasms
The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2.
Neoplasms
The Angelina effect: immediate reach, grasp, and impact of going public.
Neoplasms
The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Neoplasms
The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells.
Neoplasms
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Neoplasms
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
Neoplasms
The association between BRCA1 gene polymorphism and cancer risk: a meta-analysis.
Neoplasms
The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
Neoplasms
The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.
Neoplasms
The association of a single-nucleotide variant in the microRNA-146a with advanced colorectal cancer prognosis.
Neoplasms
The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer.
Neoplasms
The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
Neoplasms
The basal phenotype of BRCA1-related breast cancer: past, present and future.
Neoplasms
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Neoplasms
The basis for somatic gene therapy of cancer.
Neoplasms
The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
Neoplasms
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Neoplasms
The biological effects and clinical implications of BRCA mutations: where do we go from here?
Neoplasms
The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination.
Neoplasms
The BRCA1 3'-UTR: 5711+421T/T_5711+1286T/T Genotype Is a Possible Breast and Ovarian Cancer Risk Factor.
Neoplasms
The Brca1 and Brca2 proteins and tumor pathogenesis.
Neoplasms
The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations.
Neoplasms
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
Neoplasms
The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.
Neoplasms
The BRCA1 E3 Ubiquitin Ligase Controls Centrosome Dynamics.
Neoplasms
The BRCA1 exon 13 duplication: clinical characteristics of 22 families in Northern Sweden.
Neoplasms
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Neoplasms
The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci.
Neoplasms
The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients.
Neoplasms
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Neoplasms
The BRCA1 Tumor Suppressor Binds to Inositol 1,4,5-Trisphosphate Receptors to Stimulate Apoptotic Calcium Release.
Neoplasms
The BRCA1-?11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Neoplasms
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
Neoplasms
The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centrosomes.
Neoplasms
The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Neoplasms
The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression.
Neoplasms
The BRCA1-RAP80 Complex Regulates DNA Repair Mechanism Utilization by Restricting End Resection.
Neoplasms
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
Neoplasms
The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin.
Neoplasms
The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.
Neoplasms
The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation.
Neoplasms
The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
Neoplasms
The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
Neoplasms
The BRCA2 is a histone acetyltransferase.
Neoplasms
The BRCA2 polymorphic stop codon: stuff or nonsense?
Neoplasms
The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection.
Neoplasms
The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature.
Neoplasms
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
Neoplasms
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Neoplasms
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
Neoplasms
The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Neoplasms
The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression.
Neoplasms
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
Neoplasms
The cancer genetics and pathology of male breast cancer.
Neoplasms
The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain.
Neoplasms
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Neoplasms
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.
Neoplasms
The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition.
Neoplasms
The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling.
Neoplasms
The cellular abundance of the essential transcription termination factor TTF-I regulates ribosome biogenesis and is determined by MDM2 ubiquitinylation.
Neoplasms
The central region of BRCA1 binds preferentially to supercoiled DNA.
Neoplasms
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.
Neoplasms
The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis.
Neoplasms
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Neoplasms
The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
Neoplasms
The clinical management of BRCA1 and BRCA2 mutation carriers.
Neoplasms
The Clinical Significance of Unknown Sequence Variants in BRCA Genes.
Neoplasms
The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Neoplasms
The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.
Neoplasms
The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer.
Neoplasms
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
Neoplasms
The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
Neoplasms
The complex genetic landscape of familial breast cancer.
Neoplasms
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.
Neoplasms
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.
Neoplasms
The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.
Neoplasms
The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.
Neoplasms
The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls.
Neoplasms
The CRL3BTBD9 E3 ubiquitin ligase complex targets TNFAIP1 for degradation to suppress cancer cell migration.
Neoplasms
The CRM1 nuclear export protein in normal development and disease.
Neoplasms
The CUL4B/AKT/?-Catenin Axis Restricts the Accumulation of Myeloid-Derived Suppressor Cells to Prohibit the Establishment of a Tumor-Permissive Microenvironment.
Neoplasms
The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations.
Neoplasms
The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.
Neoplasms
The deubiquitinase USP10 restores PTEN activity and inhibits non-small cell lung cancer cell proliferation.
Neoplasms
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.
Neoplasms
The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study.
Neoplasms
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Neoplasms
The DNA resection protein CtIP promotes mammary tumorigenesis.
Neoplasms
The double life of MULE in preeclamptic and IUGR placentae.
Neoplasms
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
Neoplasms
The Drosophila F-box protein Slimb controls dSmurf protein turnover to regulate the Hippo pathway.
Neoplasms
The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
Neoplasms
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Neoplasms
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers.
Neoplasms
The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion.
Neoplasms
The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells.
Neoplasms
The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival.
Neoplasms
The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated ?-catenin by sequestering TCF4 to the nuclear membrane.
Neoplasms
The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1.
Neoplasms
The E3 Ubiquitin Ligase ARIH1 Protects against Genotoxic Stress by Initiating a 4EHP-Mediated mRNA Translation Arrest.
Neoplasms
The E3 Ubiquitin Ligase Asb2? in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer.
Neoplasms
The E3 ubiquitin ligase Cbl-b inhibits tumor growth in multidrug-resistant gastric and breast cancer cells.
Neoplasms
The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
Neoplasms
The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner.
Neoplasms
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Neoplasms
The E3 ubiquitin ligase RNF146 promotes colorectal cancer by activating the Wnt/?-catenin pathway via ubiquitination of Axin1.
Neoplasms
The E3 Ubiquitin Ligase TRAF6 Intercedes in Starvation-Induced Skeletal Muscle Atrophy through Multiple Mechanisms.
Neoplasms
The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia.
Neoplasms
The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.
Neoplasms
The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel-Lindau tumor suppressor.
Neoplasms
The effect of disease-associated HRPT2 mutations on splicing.
Neoplasms
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Neoplasms
The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.
Neoplasms
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.
Neoplasms
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
Neoplasms
The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
Neoplasms
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
Neoplasms
The Eighth AACR American Cancer Society Award lecture on cancer epidemiology and prevention. Genetically tailored preventive strategies: an effective plan for the twenty-first century? American Association for Cancer Research.
Neoplasms
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Neoplasms
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
Neoplasms
The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment.
Neoplasms
The emerging role of SPOP protein in tumorigenesis and cancer therapy.
Neoplasms
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics.
Neoplasms
The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Neoplasms
The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.
Neoplasms
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
Neoplasms
The ERK signaling target RNF126 regulates anoikis resistance in cancer cells by changing the mitochondrial metabolic flux.
Neoplasms
The established and future biomarkers of malignant pleural mesothelioma.
Neoplasms
The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2.
Neoplasms
The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2.
Neoplasms
The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
Neoplasms
The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Neoplasms
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.
Neoplasms
The Expression of VHL (Von Hippel-Lindau) After Traumatic Spinal Cord Injury and Its Role in Neuronal Apoptosis.
Neoplasms
The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.
Neoplasms
The Fanconi Anemia Pathway in Cancer.
Neoplasms
The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target.
Neoplasms
The Fbw7/hCDC4 tumor suppressor targets pro-proliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs.
Neoplasms
The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation.
Neoplasms
The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
Neoplasms
The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways.
Neoplasms
The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
Neoplasms
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Neoplasms
The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
Neoplasms
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Neoplasms
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
Neoplasms
The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer.
Neoplasms
The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population.
Neoplasms
The Functional Hallmarks of Cancer Predisposition Genes.
Neoplasms
The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition.
Neoplasms
The functional role of RNF113A in cervical carcinogenesis.
Neoplasms
The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.
Neoplasms
The future of breast cancer systemic therapy: the next 10 years.
Neoplasms
The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
Neoplasms
The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21.
Neoplasms
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.
Neoplasms
The genetic basis of breast cancer and its clinical implications.
Neoplasms
The genetic components of susceptibility to breast cancer in the rat.
Neoplasms
The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium.
Neoplasms
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
Neoplasms
The genetics of breast cancer susceptibility.
Neoplasms
The genetics of breast cancer: risk factors for disease.
Neoplasms
THe genetics of familial breast cancer.
Neoplasms
The genetics of inherited breast cancer.
Neoplasms
The genetics of uterine leiomyomata: what clinicians need to know.
Neoplasms
The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review.
Neoplasms
The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders.
Neoplasms
The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8.
Neoplasms
The HIF pathway: implications for patterns of gene expression in cancer.
Neoplasms
The Hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFbeta-TrCP E3 ligase.
Neoplasms
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
Neoplasms
The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells.
Neoplasms
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
Neoplasms
The Histone Variant MacroH2A1 Is a BRCA1 Ubiquitin Ligase Substrate.
Neoplasms
The hormone-bound vitamin D receptor enhances the FBW7-dependent turnover of NF-?B subunits.
Neoplasms
The HRAS1 minisatellite locus and risk of ovarian cancer.
Neoplasms
The human insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer.
Neoplasms
The ICR639 CPG NGS validation series: A resource to assess analytical sensitivity of cancer predisposition gene testing.
Neoplasms
The ICR96 exon CNV validation series: a resource for orthogonal assessment of exon CNV calling in NGS data.
Neoplasms
The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription.
Neoplasms
The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches.
Neoplasms
The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
Neoplasms
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
Neoplasms
The important molecular markers on chromosome 17 and their clinical impact in breast cancer.
Neoplasms
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Neoplasms
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.
Neoplasms
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Neoplasms
The influence of psychological distress on use of genetic testing for cancer risk.
Neoplasms
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Neoplasms
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors.
Neoplasms
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Neoplasms
The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression.
Neoplasms
The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis.
Neoplasms
The interplay between BRCA1 and 53BP1 influences death, aging, senescence and cancer.
Neoplasms
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
Neoplasms
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Neoplasms
The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
Neoplasms
The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.
Neoplasms
The Links between Parkinson's Disease and Cancer.
Neoplasms
The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
Neoplasms
The management of familial breast cancer.
Neoplasms
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.
Neoplasms
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
Neoplasms
The molecular basis of cytotoxicity of ?-spinasterol from Ganoderma resinaceum: Induction of apoptosis and overexpression of p53 in breast and ovarian cancer cell lines.
Neoplasms
The molecular basis of ovarian cancer.
Neoplasms
The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer.
Neoplasms
The molecular genetics of breast cancer and targeted therapy.
Neoplasms
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
Neoplasms
The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Neoplasms
The MULE/HUWE1 E3 ubiquitin ligase is a tumor suppressor.
Neoplasms
The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair.
Neoplasms
The nanotube express: Delivering a stapled peptide to the cell surface.
Neoplasms
The Neddylation-Cullin 2-RBX1 E3 Ligase Axis Targets Tumor Suppressor RhoB for Degradation in Liver Cancer.
Neoplasms
The noncanonical NF-?B pathway.
Neoplasms
The nonreceptor tyrosine kinase c-Src attenuates SCF(?-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Neoplasms
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons.
Neoplasms
The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
Neoplasms
The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.
Neoplasms
The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.
Neoplasms
The oncogenic E3 ligase TRIP12 suppresses epithelial-mesenchymal transition (EMT) and mesenchymal traits through ZEB1/2.
Neoplasms
The Oncogenic Properties Of The Redox Inflammatory Protein Inducible Nitric Oxide Synthase In ER(-) Breast Cancer.
Neoplasms
The Oncormed approach to genetic testing.
Neoplasms
The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.
Neoplasms
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Neoplasms
The p53 response to DNA damage.
Neoplasms
The p53 target gene TRIM22 directly or indirectly interacts with the translation initiation factor eIF4E and inhibits the binding of eIF4E to eIF4G.
Neoplasms
The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development.
Neoplasms
The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
Neoplasms
The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology.
Neoplasms
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
Neoplasms
The pathology of familial breast cancer: How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology?
Neoplasms
The pathology of familial breast cancer: Immunohistochemistry and molecular analysis.
Neoplasms
The pathology of familial breast cancer: Morphological aspects.
Neoplasms
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Neoplasms
The pathology of hereditary breast cancer.
Neoplasms
The pathology of inherited breast cancer.
Neoplasms
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
Neoplasms
The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk.
Neoplasms
The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells.
Neoplasms
The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
Neoplasms
The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan.
Neoplasms
The potential for aromatase inhibition in breast cancer prevention.
Neoplasms
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.
Neoplasms
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma.
Neoplasms
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
Neoplasms
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.
Neoplasms
The potential role of ubiquitin c-terminal hydrolases in oncogenesis.
Neoplasms
The PPAR? agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
Neoplasms
The preclinical natural history of serous ovarian cancer: defining the target for early detection.
Neoplasms
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
Neoplasms
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
Neoplasms
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Neoplasms
The Prevalence of Founder Mutations Among Individuals from Families with Familial Pancreatic Cancer Syndrome.
Neoplasms
The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Neoplasms
The prevention of hereditary breast and ovarian cancer: a personal view.
Neoplasms
The prodigious network of chromosome 17 miRNAs regulating cancer genes that influence the hallmarks of cancer.
Neoplasms
The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators.
Neoplasms
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.
Neoplasms
The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
Neoplasms
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Neoplasms
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
Neoplasms
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer.
Neoplasms
The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Neoplasms
The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2.
Neoplasms
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
Neoplasms
The relationship between coping strategies and anxiety in women from families with familial breast-ovarian cancer in the absence of demonstrated mutations.
Neoplasms
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.
Neoplasms
The relationship of REL proto-oncogene to pathobiology and chemoresistance in follicular and transformed follicular lymphoma.
Neoplasms
The Retinoblastoma Gene Undergoes Rearrangements in BRCA1-Deficient Basal-like Breast Cancer.
Neoplasms
The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression.
Neoplasms
The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.
Neoplasms
The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
Neoplasms
The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs.
Neoplasms
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Neoplasms
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.
Neoplasms
The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-?B.
Neoplasms
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.
Neoplasms
The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.
Neoplasms
The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
Neoplasms
The role of BRCA1 and BRCA2 in prostate cancer.
Neoplasms
The role of BRCA1 gene mutations and apoptosis phenomenon in sporadic breast cancer.
Neoplasms
The role of BRCA1 in DNA damage response.
Neoplasms
The role of BRCA1 in DNA double-strand repair: past and present.
Neoplasms
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Neoplasms
The role of BRCA1 in non-small cell lung cancer.
Neoplasms
The role of BRCA1 in the cellular response to chemotherapy.
Neoplasms
The role of E3 ubiquitin ligase HECTD3 in cancer and beyond.
Neoplasms
The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies.
Neoplasms
The Role of Genetic Testing in Patients With Breast Cancer: A Review.
Neoplasms
The role of p53 mutation in BRCA1-associated ovarian cancer.
Neoplasms
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
Neoplasms
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
Neoplasms
The role of testing for BRCA1 and BRCA2 mutations in cancer prevention.
Neoplasms
The role of the BRCA1 tumor suppressor in DNA double-strand break repair.
Neoplasms
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
Neoplasms
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.
Neoplasms
The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer.
Neoplasms
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
Neoplasms
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.
Neoplasms
The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
Neoplasms
The search for BRCA1.
Neoplasms
The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.
Neoplasms
The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
Neoplasms
The spectrum of genetic defects in chronic lymphocytic leukemia.
Neoplasms
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Neoplasms
The stem cell E3-ligase Lin-41 promotes liver cancer progression through inhibition of microRNA-mediated gene silencing.
Neoplasms
The Stil protein regulates centrosome integrity and mitosis through suppression of Chfr.
Neoplasms
The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer.
Neoplasms
The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery.
Neoplasms
The TRAF-interacting protein (TRIP) is a regulator of keratinocyte proliferation.
Neoplasms
The tripartite motif-containing protein 3 on the proliferation and cytokine secretion of rheumatoid arthritis fibroblast-like synoviocytes.
Neoplasms
The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.
Neoplasms
The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.
Neoplasms
The tumor suppressor archipelago E3 ligase is required for spermatid differentiation in Drosophila testis.
Neoplasms
The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination.
Neoplasms
The tumor suppressor FBW7 and the vitamin D receptor are mutual cofactors in protein turnover and transcriptional regulation.
Neoplasms
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.
Neoplasms
The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate.
Neoplasms
The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation.
Neoplasms
The Tumour Suppressor TMEM127 Is a Nedd4-Family E3 Ligase Adaptor Required by Salmonella SteD to Ubiquitinate and Degrade MHC Class II Molecules.
Neoplasms
The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.
Neoplasms
The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain.
Neoplasms
The ubiquitin E3 ligase activity of BRCA1 and its biological functions.
Neoplasms
The ubiquitin ligase c-CBL is expressed in undifferentiated marmoset monkey pluripotent stem cells but is not a general stem cell marker.
Neoplasms
The ubiquitin ligase CHIP modulates cellular behaviors of gastric cancer cells by regulating TRAF2.
Neoplasms
The Ubiquitin Ligase COP1 Promotes Glioma Cell Proliferation by Preferentially Downregulating Tumor Suppressor p53.
Neoplasms
The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.
Neoplasms
The ubiquitin ligase RNF43 downregulation increases membrane expression of frizzled receptor in pancreatic ductal adenocarcinoma.
Neoplasms
The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
Neoplasms
The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
Neoplasms
The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response.
Neoplasms
The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation.
Neoplasms
The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function.
Neoplasms
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings.
Neoplasms
The unliganded glucocorticoid receptor positively regulates the tumour suppressor gene BRCA1 through GABP beta.
Neoplasms
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
Neoplasms
The validation of a simulation model incorporating radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk.
Neoplasms
The Vhl E3 ubiquitin ligase complex regulates melanisation via sima, cnc and the copper import protein Ctr1A.
Neoplasms
The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
Neoplasms
The VHL Tumor Suppressor: Master Regulator of HIF.
Neoplasms
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Neoplasms
The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11.
Neoplasms
The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Neoplasms
The Yin and Yang of YY1 in tumor growth and suppression.
Neoplasms
Therapeutic Approaches for Women Predisposed to Breast Cancer.
Neoplasms
Therapeutic exploitation of tumor cell defects in homologous recombination.
Neoplasms
Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages.
Neoplasms
Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
Neoplasms
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Neoplasms
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
Neoplasms
Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.
Neoplasms
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
Neoplasms
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases.
Neoplasms
Thermal and chemical denaturation of the BRCT functional module of human 53BP1.
Neoplasms
Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1.
Neoplasms
Thermal unfolding of human BRCA1 BRCT-domain variants.
Neoplasms
Three novel BRCA1 germline mutations (1104delAA, 1276delTT, 3747delGA) detected in breast/ovarian cancer families identified in the south of France.
Neoplasms
Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier.
Neoplasms
Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex.
Neoplasms
Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model.
Neoplasms
Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.
Neoplasms
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Neoplasms
Timing of dietary estrogenic exposures and breast cancer risk.
Neoplasms
Tissue-specific and age-dependent effects of global Mdm2 loss.
Neoplasms
Tissue-specific tumor suppression by BRCA1.
Neoplasms
TNF signaling, but not TWEAK triggered cellular Inhibitor of APoptosis protein 1 (cIAP1) degradation, requires cIAP1 RING dimerization and E2 binding.
Neoplasms
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
Neoplasms
Tobramycin suppresses HUWE1 degradation to control MCL-1 stability during tumour development.
Neoplasms
Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers.
Neoplasms
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Neoplasms
Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Neoplasms
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
Neoplasms
TOPORS Functions As A SUMO-1 E3 Ligase for Chromatin-Modifying Proteins.
Neoplasms
Toward Greater Precision in Cancer Radiotherapy.
Neoplasms
TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.
Neoplasms
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Neoplasms
TP53 mutations in familial breast cancer: functional aspects.
Neoplasms
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.
Neoplasms
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Neoplasms
Trabectedin is a promising antitumour agent for synovial sarcoma.
Neoplasms
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
Neoplasms
Tracking evolution of BRCA1-associated breast cancer.
Neoplasms
Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
Neoplasms
TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation.
Neoplasms
TRAF2 Is a Novel Ubiquitin E3 Ligase for the Na,K-ATPase ?-Subunit That Drives Alveolar Epithelial Dysfunction in Hypercapnia.
Neoplasms
TRAF3: a novel tumor suppressor gene in macrophages.
Neoplasms
TRAF6 inhibition rescues dexamethasone-induced muscle atrophy.
Neoplasms
TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains.
Neoplasms
TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host.
Neoplasms
TRAF6 suppresses the apoptosis of hemocytes by activating pellino in Crassostrea hongkongensis.
Neoplasms
TRAF6-mediated ubiquitination regulates nuclear translocation of NRIF, the p75 receptor interactor.
Neoplasms
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis.
Neoplasms
Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Neoplasms
Transactivation of repair genes by BRCA1.
Neoplasms
Transactivation of the estrogen receptor promoter by BRCA1.
Neoplasms
Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
Neoplasms
Transactivation-dependent and -independent regulation of p73 stability.
Neoplasms
Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.
Neoplasms
Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53.
Neoplasms
Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter.
Neoplasms
Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
Neoplasms
Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.
Neoplasms
Transcriptional Pathways Altered in Response to Vibration in a Model of Hand-Arm Vibration Syndrome.
Neoplasms
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
Neoplasms
Transcriptional regulation of BRCA1 expression by a metabolic switch.
Neoplasms
Transcriptional regulation of the base excision repair pathway by BRCA1.
Neoplasms
Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer.
Neoplasms
Transcriptional Silencing of ALDH2 Confers a Dependency on Fanconi Anemia Proteins in Acute Myeloid Leukemia.
Neoplasms
Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients.
Neoplasms
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.
Neoplasms
Transgenic mouse models of breast cancer.
Neoplasms
Translating genomics in cancer care.
Neoplasms
Translational advances regarding hereditary breast cancer syndromes.
Neoplasms
Translational research on hereditary colon, breast, and ovarian cancers.
Neoplasms
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
Neoplasms
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
Neoplasms
TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Neoplasms
TRIM13 inhibits cell migration and invasion in clear-cell renal cell carcinoma.
Neoplasms
TRIM22 can activate the noncanonical NF-?B pathway by affecting IKK?
Neoplasms
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
Neoplasms
TRIM22 inhibits endometrial cancer progression through the NOD2/NF??B signaling pathway and confers a favorable prognosis.
Neoplasms
TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein.
Neoplasms
TRIM22 inhibits the TRAF6-stimulated NF-?B pathway by targeting TAB2 for degradation.
Neoplasms
TRIM22: A Diverse and Dynamic Antiviral Protein.
Neoplasms
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
Neoplasms
TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer.
Neoplasms
TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-? signaling.
Neoplasms
TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137.
Neoplasms
TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Neoplasms
TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.
Neoplasms
TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination.
Neoplasms
TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1).
Neoplasms
TRIM32 promotes cell proliferation and invasion by activating ?-catenin signalling in gastric cancer.
Neoplasms
TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF{alpha})-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP).
Neoplasms
TRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination-dependent manner.
Neoplasms
TRIM37 prevents formation of centriolar protein assemblies by regulating Centrobin.
Neoplasms
TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination.
Neoplasms
TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination.
Neoplasms
TRIM58 Interacts with Pyruvate Kinase M2 to Inhibit Tumorigenicity in Human Osteosarcoma Cells.
Neoplasms
TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10.
Neoplasms
TRIM65 negatively regulates p53 through ubiquitination.
Neoplasms
TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability.
Neoplasms
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Neoplasms
Tripartite Motif Containing 11 Interacts with DUSP6 to Promote the Growth of Human Osteosarcoma Cells through Regulating ERK1/2 Pathway.
Neoplasms
Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF-? signaling.
Neoplasms
Tripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signaling-mediated epithelial-mesenchymal transition in cervical cancer.
Neoplasms
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Neoplasms
Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.
Neoplasms
Tripartite motif-containing protein 37 is overexpressed in human glioma and its downregulation inhibits human glioma cell growth in vitro.
Neoplasms
Triple negative breast cancers: clinical and prognostic implications.
Neoplasms
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Neoplasms
Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
Neoplasms
Triple negative tumours: a critical review.
Neoplasms
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Neoplasms
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Neoplasms
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Neoplasms
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Neoplasms
Triple-negative breast cancer: are we making headway at least?
Neoplasms
Triple-negative breast cancer: disease entity or title of convenience?
Neoplasms
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Neoplasms
Triple-negative breast cancer: epidemiological considerations and recommendations.
Neoplasms
Triple-negative breast cancer: epidemiology and management options.
Neoplasms
Triple-negative breast cancer: therapeutic options.
Neoplasms
Triple-Negative Breast Carcinoma.
Neoplasms
Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
Neoplasms
Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer.
Neoplasms
Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers.
Neoplasms
Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Neoplasms
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
Neoplasms
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Neoplasms
Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
Neoplasms
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
Neoplasms
Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.
Neoplasms
Tumor classification using phylogenetic methods on expression data.
Neoplasms
Tumor formation in Brca1 conditional mutant mice.
Neoplasms
Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues.
Neoplasms
Tumor markers for breast cancer.
Neoplasms
Tumor markers for breast cancer. Current utilities and future prospects.
Neoplasms
Tumor Metabolism: MAGE-A Proteins Help TRIM Turn Over AMPK.
Neoplasms
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Neoplasms
Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system.
Neoplasms
Tumor necrosis factor receptor-associated factor 6 (TRAF6) inhibition modulates bone loss and matrix metalloproteinase expression levels in collagen-induced rheumatoid arthritis rat.
Neoplasms
Tumor necrosis factor receptor-associated factor 6 contributes to malignant behavior of human cancers through promoting AKT ubiquitination and phosphorylation.
Neoplasms
Tumor necrosis factor receptor-associated factor 6 interaction with alpha-synuclein enhances cell death through the Nuclear Factor-kB pathway.
Neoplasms
Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.
Neoplasms
Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkappaB kinase complex in vascular smooth muscle cells.
Neoplasms
Tumor necrosis factor-alpha-induced lung cell expression of antiapoptotic genes TRAF1 and cIAP2.
Neoplasms
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
Neoplasms
Tumor suppressor activities of the fbw7 e3 ubiquitin ligase receptor.
Neoplasms
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.
Neoplasms
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Neoplasms
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.
Neoplasms
Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability.
Neoplasms
Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma.
Neoplasms
Tumor suppressor genes and breast cancer.
Neoplasms
Tumor suppressor genes and their alterations in breast cancer.
Neoplasms
Tumor suppressor lnc-CTSLP4 inhibits EMT and metastasis of gastric cancer by attenuating HNRNPAB-dependent Snail transcription.
Neoplasms
Tumor suppressor loss in pituitary tumors.
Neoplasms
Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.
Neoplasms
Tumor suppressor p53 is required to modulate BRCA1 expression.
Neoplasms
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Neoplasms
Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects.
Neoplasms
Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2Prame complex.
Neoplasms
Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.
Neoplasms
Tumor-protective and tumor-promoting actions of dietary whey proteins in an N-methyl-N-nitrosourea model of rat mammary carcinogenesis.
Neoplasms
Tumor-suppressing function of caspase-2 requires catalytic site C320 and site S139 in mice.
Neoplasms
Tumoral Expression of BRCA1, Estrogen Receptor Alpha and ID4 Protein in Patients with Sporadic Breast Cancer.
Neoplasms
Tumorigenesis and neurodegeneration: two sides of the same coin?
Neoplasms
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Neoplasms
Tumorigenesis in mice carrying a truncating Brca1 mutation.
Neoplasms
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Neoplasms
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Neoplasms
Tumour lineage shapes BRCA-mediated phenotypes.
Neoplasms
Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
Neoplasms
Tumour suppressor genes in chemotherapeutic drug response.
Neoplasms
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors.
Neoplasms
Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom.
Neoplasms
Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.
Neoplasms
TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.
Neoplasms
TWEAKing death.
Neoplasms
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Neoplasms
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Neoplasms
Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
Neoplasms
Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
Neoplasms
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Neoplasms
Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds.
Neoplasms
Two founder BRCA2 mutations predispose to breast cancer in young women.
Neoplasms
Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
Neoplasms
Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Neoplasms
Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
Neoplasms
Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.
Neoplasms
UbcH5A, a member of human E2 ubiquitin-conjugating enzymes, is closely related to SFT, a stimulator of iron transport, and is up-regulated in hereditary hemochromatosis.
Neoplasms
UBE3C promotes proliferation and inhibits apoptosis by activating the ?-catenin signaling via degradation of AXIN1 in gastric cancer.
Neoplasms
UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
Neoplasms
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.
Neoplasms
UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation.
Neoplasms
Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer.
Neoplasms
Ubiquitin Ligase Activities of WWP1 Germline Variants K740N and N745S.
Neoplasms
Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer.
Neoplasms
Ubiquitin ligase Fbw7 restricts the replication of hepatitis C virus by targeting NS5B for ubiquitination and degradation.
Neoplasms
Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation.
Neoplasms
Ubiquitin pathway and ovarian cancer.
Neoplasms
Ubiquitin pathway in VHL cancer syndrome.
Neoplasms
Ubiquitin Recognition of BAP1: Understanding its Enzymatic Function.
Neoplasms
Ubiquitin systems mark pathogen-containing vacuoles as targets for host defense by guanylate binding proteins.
Neoplasms
Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer.
Neoplasms
Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage.
Neoplasms
Ubiquitin-dependent and -independent functions of OTULIN in cell fate control and beyond.
Neoplasms
Ubiquitin-specific protease 7 regulates nucleotide excision repair through deubiquitinating XPC protein and preventing XPC protein from undergoing ultraviolet light-induced and VCP/p97 protein-regulated proteolysis.
Neoplasms
Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression.
Neoplasms
Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
Neoplasms
Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.
Neoplasms
Ubiquitination of NF-?B p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.
Neoplasms
Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity.
Neoplasms
Ubiquitylome profiling of Parkin-null brain reveals dysregulation of calcium homeostasis factors ATP1A2, Hippocalcin and GNA11, reflected by altered firing of noradrenergic neurons.
Neoplasms
UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
Neoplasms
UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4.
Neoplasms
UBTD1 is a mechano-regulator controlling cancer aggressiveness.
Neoplasms
Uncertainty in BRCA1 cancer susceptibility testing.
Neoplasms
Unclassified variants identified in BRCA1 exon 11: Consequences on splicing.
Neoplasms
Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.
Neoplasms
Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.
Neoplasms
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
Neoplasms
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
Neoplasms
Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
Neoplasms
Understanding and treating triple-negative breast cancer.
Neoplasms
Understanding germ-line mutations in BRCA1.
Neoplasms
Understanding the functions of BRCA1 in the DNA-damage response.
Neoplasms
Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Neoplasms
Unexpected Findings in a Child with Atypical Hemolytic Uremic Syndrome: An Example of How Genomics Is Changing the Clinical Diagnostic Paradigm.
Neoplasms
Unlocking the Mdm2-p53 loop: ubiquitin is the key.
Neoplasms
Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
Neoplasms
Unsolved mystery: the role of BRCA1 in DNA end-joining.
Neoplasms
Up-regulation of cullin7 promotes proliferation and migration of pulmonary artery smooth muscle cells in hypoxia-induced pulmonary hypertension.
Neoplasms
Update on PARP1 inhibitors in ovarian cancer.
Neoplasms
Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer.
Neoplasms
Upregulation of IL-6 in CUL4B-deficient myeloid-derived suppressive cells increases the aggressiveness of cancer cells.
Neoplasms
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Neoplasms
Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Neoplasms
Uptake of BRCA1 rearrangement panel testing: in individuals previously tested for BRCA1/2 mutations.
Neoplasms
Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
Neoplasms
Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network.
Neoplasms
Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent.
Neoplasms
Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
Neoplasms
Uptake of testing for germline BRCA mutations in patients with non-mucinous epithelial ovarian cancers in Western Australia: a comparison of different genetic counseling methods.
Neoplasms
Urological cancer related to familial syndromes.
Neoplasms
Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Neoplasms
Use of Gene Expression Profiles of Peripheral Blood Lymphocytes to Distinguish BRCA1 Mutation Carriers in High Risk Breast Cancer Families.
Neoplasms
Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation.
Neoplasms
Using BRCA1 to treat cancer.
Neoplasms
Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.
Neoplasms
Using core public health functions to promote BRCA best practices among health plans.
Neoplasms
Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Neoplasms
Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.
Neoplasms
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
Neoplasms
USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
Neoplasms
USP11: A key regulator of cIAP2 stability and sensitivity to SMAC mimetics.
Neoplasms
USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates.
Neoplasms
Usp28 counteracts Fbw7 in intestinal homeostasis and cancer.
Neoplasms
USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1.
Neoplasms
USP42 protects ZNRF3/RNF43 from R-spondin-dependent clearance and inhibits Wnt signalling.
Neoplasms
USP9X destabilizes pVHL and promotes cell proliferation.
Neoplasms
USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
Neoplasms
USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
Neoplasms
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Neoplasms
Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.
Neoplasms
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
Neoplasms
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The papanicolaou society of cytopathology guidelines for pancreatobiliary cytology.
Neoplasms
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines.
Neoplasms
Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation.
Neoplasms
UV-induced proteolysis of RNA polymerase II is mediated by VCP/p97 segregase and timely orchestration by Cockayne syndrome B protein.
Neoplasms
UVB-induced cell death signaling is associated with G1-S progression and transcription inhibition in primary human fibroblasts.
Neoplasms
Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry.
Neoplasms
Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target.
Neoplasms
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.
Neoplasms
Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
Neoplasms
Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.
Neoplasms
Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women.
Neoplasms
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Neoplasms
Variation in BRCA1 cancer risks by mutation position.
Neoplasms
Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation.
Neoplasms
Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer.
Neoplasms
VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells.
Neoplasms
VEGF, HIF-1? expression and MVD as an angiogenic network in familial breast cancer.
Neoplasms
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Neoplasms
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
Neoplasms
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
Neoplasms
Viperin interacts with the kinase IRAK1 and the E3 ubiquitin ligase TRAF6, coupling innate immune signaling to antiviral ribonucleotide synthesis.
Neoplasms
Viral ubiquitin ligase WSSV222 is required for efficient white spot syndrome virus (WSSV) replication in shrimp.
Neoplasms
Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor ? are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
Neoplasms
Voies de réparation de l'ADN et cancers bronchiques non à petites cellules : perspectives cliniques.
Neoplasms
Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function.
Neoplasms
von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination.
Neoplasms
Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.
Neoplasms
Western Analysis of Breast Cancer 1 Protein (BRCA1).
Neoplasms
What drives breast cancer heterogeneity: oncogenic events or cell of origin?
Neoplasms
What is triple-negative breast cancer?
Neoplasms
What makes tumors multidrug resistant?
Neoplasms
What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians.
Neoplasms
When the SWI/SNF complex remodels...the cell cycle.
Neoplasms
Which Holds the Key to BRCAness: Inability to Repair the Break, Protect the Fork, or Prevent the Gap?
Neoplasms
White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination.
Neoplasms
Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma.
Neoplasms
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.
Neoplasms
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.
Neoplasms
Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
Neoplasms
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
Neoplasms
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
Neoplasms
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Neoplasms
Widespread bimodal intrachromosomal genomic instability in sporadic breast cancers associated with 13q allelic imbalance.
Neoplasms
Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer.
Neoplasms
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.
Neoplasms
Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
Neoplasms
Wingless and Archipelago, a fly E3 ubiquitin ligase and a homolog of human tumor suppressor FBW7, show an antagonistic relationship in wing development.
Neoplasms
Wip1 and ATM in tumor evolution: role for BRCA1.
Neoplasms
With the ends in sight: images from the BRCA1 tumor suppressor.
Neoplasms
WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
Neoplasms
Wnt-induced proteolytic targeting.
Neoplasms
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Neoplasms
Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Neoplasms
Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
Neoplasms
WRN Loss Induces Switching of Telomerase-Independent Mechanisms of Telomere Elongation.
Neoplasms
WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
Neoplasms
WSB1 promotes tumor metastasis by inducing pVHL degradation.
Neoplasms
WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis.
Neoplasms
WWP1 Gain-of-Function Variants Inactivate PTEN to Raise Cancer Risk.
Neoplasms
WWP2 regulates proliferation of gastric cancer cells in a PTEN-dependent manner.
Neoplasms
X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors.
Neoplasms
X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis.
Neoplasms
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Neoplasms
Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
Neoplasms
XY chromosomal bivalent: nucleolar attraction.
Neoplasms
Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
Neoplasms
Yeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction.
Neoplasms
Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation.
Neoplasms
Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
Neoplasms
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
Neoplasms
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.
Neoplasms
ZNF313 is a novel cell cycle activator with an E3 ligase activity inhibiting cellular senescence by destabilizing p21(WAF1.).
Neoplasms
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer.
Neoplasms
ZNRF3 and RNF43 cooperate to safeguard metabolic liver zonation and hepatocyte proliferation.
Neoplasms
ZNRF3 Inhibits the Invasion and Tumorigenesis in Nasopharyngeal Carcinoma Cells by Inactivating the Wnt/?-Catenin Pathway.
Neoplasms
ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells.
Neoplasms
[A CASE REPORT OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A BREAST CANCER PATIENT].
Neoplasms
[A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers]
Neoplasms
[Advance in researches on BRCA1.]
Neoplasms
[Analyses of LOH and expression in healthy gland, DCIS and invasive breast cancer gland]
Neoplasms
[Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips]
Neoplasms
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
Neoplasms
[Analysis of mutations in the BRCA1 gene in patients with cancer of the breast and/or the ovary in Portugal]
Neoplasms
[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations]
Neoplasms
[Apropos of tests for predisposition for cancers of the breast and ovary related to the BRCA1 gene]
Neoplasms
[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?]
Neoplasms
[Assessment of applicability of archived cytological lung cancer specimens for molecular genetic analysis].
Neoplasms
[Attitudes towards screening and prevention of breast and ovarian cancers with hereditary predisposition. Survey by female gynecologists in the north of France]
Neoplasms
[Basal-like carcinoma of the breast--the actual review and clinico-pathological corelations]
Neoplasms
[BRCA1 (breast cancer type 1). Tumor suppressor gene]
Neoplasms
[BRCA1 and BRCA2 - pathologists starting kit].
Neoplasms
[BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer]
Neoplasms
[BRCA1 and BRCA2 mutations in families studied in the Program of Genetic Counselling in Cancer of the Valencian Community (Spain).]
Neoplasms
[BRCA1 and BRCA2 mutations in patients with familial breast cancer]
Neoplasms
[BRCA1 and BRCA2--breast cancer susceptibility genes]
Neoplasms
[BRCA1 and cancer: a new lead]
Neoplasms
[BRCA1 and Estrogen Receptor ? Expression Regulation in Breast Cancer Cells].
Neoplasms
[BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Neoplasms
[BRCA1 germ line mutations in Chinese early-onset breast cancer patients.]
Neoplasms
[BRCA1- and BRCA2- associated breast carcinomas.]
Neoplasms
[BRCA1: from the gene identification to the cancer risk estimation]
Neoplasms
[Breast cancer in BRCA1/2 mutation carriers].
Neoplasms
[Breast cancer susceptibility genes.]
Neoplasms
[Case of encapsulated solid papillary carcinoma with triple-negative and basal-like phenotype occurred in pregnant woman with review of the literature].
Neoplasms
[Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
Neoplasms
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Neoplasms
[Clinical aspects of familial ovarian cancer - current status and issues in Japan].
Neoplasms
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Neoplasms
[Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].
Neoplasms
[Determination of a BRCA1 gene mutation in a family with hereditary breast cancer]
Neoplasms
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
Neoplasms
[DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines]
Neoplasms
[Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1]
Neoplasms
[Epidemiology and diagnosis of breast cancer].
Neoplasms
[Epidemiology and genetics of cancers of the ovary]
Neoplasms
[Ethnic aspects of hereditary breast cancer in the region of Siberia].
Neoplasms
[Evaluation of cancer risk through genetic analysis?]
Neoplasms
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy]
Neoplasms
[Familial cancer and oncogenic factors]
Neoplasms
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Neoplasms
[Gadd45 mediated G2/M cell cycle arrest induced by BRCA1]
Neoplasms
[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer.]
Neoplasms
[Genes involved in breast cancers]
Neoplasms
[Genetic alterations and DNA-based diagnosis in breast cancer]
Neoplasms
[Genetic consultation: hereditary cancer risk?].
Neoplasms
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
Neoplasms
[Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
Neoplasms
[Genetic predisposition to breast cancer: a review in April 1998]
Neoplasms
[Genetical aspects of surgical treatment in patients with hereditary breast cancer].
Neoplasms
[Germ-line epimutations and human cancer]
Neoplasms
[Germ-line mutations of the BRCA1 gene in northeastern France]
Neoplasms
[Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers].
Neoplasms
[Haplotype of the BRCA2 6857delAA mutation in 4 families with breast/ovarian cancer]
Neoplasms
[Hemangiosarcoma after breast-conserving therapy of breast cancer: Report of four cases with molecular genetic diagnosis and literature review.]
Neoplasms
[Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
Neoplasms
[Hereditary breast and ovarian cancers].
Neoplasms
[Hereditary breast carcinomas pathologist's perspective].
Neoplasms
[Hereditary neoplastic diseases (genetic predisposition and cancer syndromes)]
Neoplasms
[Hereditary ovarian cancer]
Neoplasms
[Hereditary predisposition for the development of breast and ovarian carcinoma]
Neoplasms
[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]
Neoplasms
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]
Neoplasms
[In Process Citation].
Neoplasms
[Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
Neoplasms
[Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?]
Neoplasms
[Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.]
Neoplasms
[Is hereditary predisposition to breast cancer linked to BRCA1 a disease of response to genotoxic lesions?]
Neoplasms
[Isolation and characterization of a BRCA1-interacting protein]
Neoplasms
[Knock-down of Pre-mRNA Splicing Factor Prp19 Causes Chromosome Misalignment and Prometaphase Arrest].
Neoplasms
[Malignant phyllode tumor of the breast with features of intraductal carcinoma]
Neoplasms
[Management of families at high risk for hereditary breast-ovarian cancers: the endocrinologist's point of view]
Neoplasms
[Markers of effectiveness of preoperative taxane-based chemotherapy for locally advanced breast cancer].
Neoplasms
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]
Neoplasms
[Molecular basis of gynecological oncology--TopBP1 protein and its participation in the transcription process].
Neoplasms
[Molecular Diagnosis and Treatment of HBOC Syndrome].
Neoplasms
[Molecular study of the BRCA1 and BRCA2 genes in 153 breast cancer families from Castilla and León (Spain): new nine unclassified variants identified]
Neoplasms
[Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer].
Neoplasms
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
Neoplasms
[Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance]
Neoplasms
[Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women]
Neoplasms
[Mutations in the BRCA1 gene in young Spanish women with breast cancer]
Neoplasms
[Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Neoplasms
[Overexpression of CHIP in Chronic Myeloid Leukemia K562 Cells Induces Mitotic Abnormality.]
Neoplasms
[PALB2, a major susceptibility gene for breast cancer].
Neoplasms
[PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Neoplasms
[Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments]
Neoplasms
[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Neoplasms
[Possibilities of examination of familial breast cancers and ovarian cancers. Use of molecular-genetic analysis of the BRCA1 gene and the BRCA2 gene]
Neoplasms
[Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Neoplasms
[Progress in the effects of BRAP gene on cardiovascular diseases].
Neoplasms
[Prophylactic surgery of mammary and ovarian carcinoma.]
Neoplasms
[Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].
Neoplasms
[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
Neoplasms
[Retrospective NGS Study in High-risk Hereditary Cancer Patients at Masaryk Memorial Cancer Institute].
Neoplasms
[Review of risk factors for breast cancer--what's new?]
Neoplasms
[Risk assessment for familial occurrence of breast cancer]
Neoplasms
[Roles of BRCA1 and BRCA2 in DNA repair and tumor suppression]
Neoplasms
[Selection and quantitative detection of target genes in oral squamous cell carcinoma]
Neoplasms
[Sequence analysis of BRCA1 gene in young breast cancer patients and/or positive family history]
Neoplasms
[Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation?].
Neoplasms
[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: A review].
Neoplasms
[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers]
Neoplasms
[Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
Neoplasms
[The importance of genetic factors for development of breast cancer]
Neoplasms
[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]
Neoplasms
[The supply of breast/ovarian cancer genetic susceptibility tests in France]
Neoplasms
[Translational research and diagnostics for breast cancer].
Neoplasms
[Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
Neoplasms
[Tumor risk consultation for predisposed women from high risk cancer families]
Neoplasms, Germ Cell and Embryonal
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Neoplasms, Germ Cell and Embryonal
Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.
Neoplasms, Radiation-Induced
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals.
Neoplasms, Radiation-Induced
Impact of cancer predisposition and radiosensitivity on the population risk of radiation-induced cancers.
Neoplasms, Second Primary
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
Neoplasms, Second Primary
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Neoplasms, Second Primary
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Neoplasms, Second Primary
Identification of BRCA1 and BRCA2 carriers by allele-specific gene expression (AGE) analysis.
Neoplasms, Second Primary
Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Neoplasms, Second Primary
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.
Neoplasms, Second Primary
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Neoplasms, Second Primary
Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
Neoplasms, Second Primary
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Neoplasms, Second Primary
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Neoplasms, Second Primary
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
Neoplastic Cells, Circulating
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.
Neoplastic Cells, Circulating
Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Neoplastic Cells, Circulating
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Neoplastic Syndromes, Hereditary
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Neoplastic Syndromes, Hereditary
BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer : hope or reality?
Neoplastic Syndromes, Hereditary
Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
Neoplastic Syndromes, Hereditary
Development of a high risk pancreatic screening clinic using 3.0 T MRI.
Neoplastic Syndromes, Hereditary
Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Neoplastic Syndromes, Hereditary
Hereditary cancer syndromes.
Neoplastic Syndromes, Hereditary
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Neoplastic Syndromes, Hereditary
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Neoplastic Syndromes, Hereditary
Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer.
Neoplastic Syndromes, Hereditary
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Neoplastic Syndromes, Hereditary
Resources to increase genetics and genomics capacity of oncology nurses.
Neoplastic Syndromes, Hereditary
[Prophylactic surgery of mammary and ovarian carcinoma.]
Nervous System Diseases
A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders.
Nervous System Diseases
Deficiency of TRIM32 Impairs Motor Function and Purkinje Cells in Mid-Aged Mice.
Nervous System Diseases
Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination.
Nervous System Diseases
Explaining intermediate filament accumulation in giant axonal neuropathy.
Nervous System Diseases
Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Nervous System Diseases
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Nervous System Diseases
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Nervous System Diseases
Part I: parkin-associated proteins and Parkinson's disease.
Nervous System Diseases
Phosphorylation of CHIP at Ser20 by Cdk5 promotes tAIF-mediated neuronal death.
Nervous System Diseases
Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease.
Nervous System Diseases
RNF20 controls astrocytic differentiation through epigenetic regulation of STAT3 in the developing brain.
Nervous System Diseases
The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
Nervous System Diseases
The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders.
Neuralgia
Dysregulation of p53 and Parkin Induce Mitochondrial Dysfunction and Leads to the Diabetic Neuropathic Pain.
Neuralgia
Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain.
Neuralgia
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
Neuralgia
Increased expression of the Cbl family of E3 ubiquitin ligases decreases Interleukin-2 production in a rat model of peripheral neuropathy.
Neurilemmoma
Axl/Gas6/NF?B signalling in schwannoma pathological proliferation, adhesion and survival.
Neuroblastoma
Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells.
Neuroblastoma
Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
Neuroblastoma
Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria.
Neuroblastoma
DJ-1 is indispensable for the S-nitrosylation of Parkin, which maintains function of mitochondria.
Neuroblastoma
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Neuroblastoma
E3 Ubiquitin Ligase Nedd4 Promotes Japanese Encephalitis Virus Replication by Suppressing Autophagy in Human Neuroblastoma Cells.
Neuroblastoma
Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues.
Neuroblastoma
Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease.
Neuroblastoma
Gene expression profiles and protein-protein interaction networks in neuroblastoma with MEIS2 depletion.
Neuroblastoma
Induction of parkin expression in the presence of oxidative stress.
Neuroblastoma
K27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase.
Neuroblastoma
Lack of direct role of parkin in the steady-state level and aggregation of alpha-synuclein and the clearance of pre-formed aggregates.
Neuroblastoma
Linking a compound-heterozygous Parkin mutant (Q311R and A371T) to Parkinson's disease by using proteomic and molecular approaches.
Neuroblastoma
Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.
Neuroblastoma
N-myc regulates parkin expression.
Neuroblastoma
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Neuroblastoma
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Neuroblastoma
Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter.
Neuroblastoma
Parkin Interacts with Apoptosis-Inducing Factor and Interferes with Its Translocation to the Nucleus in Neuronal Cells.
Neuroblastoma
Parkin is metabolized by the ubiquitin/proteosome system.
Neuroblastoma
Parkin is not regulated by the unfolded protein response in human neuroblastoma cells.
Neuroblastoma
Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival.
Neuroblastoma
Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity.
Neuroblastoma
Parkin promotes intracellular Abeta1-42 clearance.
Neuroblastoma
Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways.
Neuroblastoma
Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.
Neuroblastoma
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair.
Neuroblastoma
Parkin Selectively Alters the Intrinsic Threshold for Mitochondrial Cytochrome C Release.
Neuroblastoma
Parkin suppresses the expression of monoamine oxidases.
Neuroblastoma
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation.
Neuroblastoma
Parkin-mediated Ubiquitination Regulates Phospholipase C-gamma1.
Neuroblastoma
Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway.
Neuroblastoma
Repeated exposure of cocaine alters mitochondrial dynamics in mouse neuroblastoma Neuro2a.
Neuroblastoma
Restriction of trophic factors and nutrients induces PARKIN expression.
Neuroblastoma
Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants.
Neuroblastoma
Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action.
Neuroblastoma
Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation.
Neuroblastoma
The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.
Neuroblastoma
The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.
Neuroblastoma
TRIM32 promotes retinoic acid receptor ?-mediated differentiation in human promyelogenous leukemic cell line HL60.
Neuroblastoma
UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
Neuroblastoma
UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation.
Neuroblastoma
Ubiquitination of IGF2BP3 by E3 ligase MKRN2 regulates the proliferation and migration of human neuroblastoma SHSY5Y cells.
Neuroblastoma
Ubiquitination of p21 by E3 Ligase TRIM21 Promotes the Proliferation of Human Neuroblastoma Cells.
Neurodegenerative Diseases
A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging?
Neurodegenerative Diseases
Altered Transcriptional Profile of Mitochondrial DNA-Encoded OXPHOS Subunits, Mitochondria Quality Control Genes, and Intracellular ATP Levels in Blood Samples of Patients with Parkinson's Disease.
Neurodegenerative Diseases
Ambra1: A Parkin-binding protein involved in mitophagy.
Neurodegenerative Diseases
Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme.
Neurodegenerative Diseases
Autoregulation of Parkin activity through its ubiquitin-like domain.
Neurodegenerative Diseases
Both thapsigargin- and tunicamycin-induced endoplasmic reticulum stress increases expression of Hrd1 in IRE1-dependent fashion.
Neurodegenerative Diseases
Brain banking for neurodegenerative diseases.
Neurodegenerative Diseases
Clinical and Genetic Characterization of Autosomal Recessive Spinocerebellar Ataxia Type 16 (SCAR16) in Taiwan.
Neurodegenerative Diseases
Comparative genomics and protein domain graph analyses link ubiquitination and RNA metabolism.
Neurodegenerative Diseases
Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Neurodegenerative Diseases
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Neurodegenerative Diseases
Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis.
Neurodegenerative Diseases
Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin.
Neurodegenerative Diseases
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse.
Neurodegenerative Diseases
Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases.
Neurodegenerative Diseases
Eukaryotic translation elongation factor 1 delta inhibits the ubiquitin ligase activity of SIAH-1.
Neurodegenerative Diseases
Expression in the mammalian retina of parkin and UCH-L1, two components of the ubiquitin-proteasome system.
Neurodegenerative Diseases
Folic Acid Supplementation Ameliorates Oxidative Stress, Metabolic Functions and Developmental Anomalies in a Novel Fly Model of Parkinson's Disease.
Neurodegenerative Diseases
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Neurodegenerative Diseases
Glutathione s-transferase omega 1 activity is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease.
Neurodegenerative Diseases
Haploinsufficiency of the TDP43 ubiquitin E3 ligase RNF220 leads to ALS-like motor neuron defects in the mouse.
Neurodegenerative Diseases
Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene.
Neurodegenerative Diseases
Impact of altered phosphorylation on loss of function of juvenile Parkinsonism-associated genetic variants of the E3 ligase parkin.
Neurodegenerative Diseases
Isolated RING2 domain of parkin is sufficient for E2-dependent E3 ligase activity.
Neurodegenerative Diseases
Loss of malin, but not laforin, results in compromised autophagic flux and proteasomal dysfunction in cells exposed to heat shock.
Neurodegenerative Diseases
Mechanisms of neuronal homeostasis: autophagy in the axon.
Neurodegenerative Diseases
Minocycline protects, rescues and prevents knockdown transgenic parkin Drosophila against paraquat/iron toxicity: Implications for autosomic recessive juvenile parkinsonism.
Neurodegenerative Diseases
Mitochondria-affecting small molecules ameliorate proteostasis defects associated with neurodegenerative diseases.
Neurodegenerative Diseases
Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging.
Neurodegenerative Diseases
Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin.
Neurodegenerative Diseases
Mitochondrial dysfunction precedes neurodegeneration in mahogunin (Mgrn1) mutant mice.
Neurodegenerative Diseases
Mitophagy in neurodegeneration and aging.
Neurodegenerative Diseases
Molecular insights into Parkinson's disease.
Neurodegenerative Diseases
Neurodegeneration in mnd2 mutant mice is not prevented by parkin transgene.
Neurodegenerative Diseases
Neurodegenerative disease: pink, parkin and the brain.
Neurodegenerative Diseases
Overexpression of parkin protects retinal ganglion cells in experimental glaucoma.
Neurodegenerative Diseases
p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria.
Neurodegenerative Diseases
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Neurodegenerative Diseases
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Neurodegenerative Diseases
Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
Neurodegenerative Diseases
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.
Neurodegenerative Diseases
Parkin mutant in the fly is largely rescued by metal-responsive transcription factor (MTF-1).
Neurodegenerative Diseases
Parkin promotes intracellular Abeta1-42 clearance.
Neurodegenerative Diseases
Parkin Regulation and Neurodegenerative Disorders.
Neurodegenerative Diseases
Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis.
Neurodegenerative Diseases
Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation: IMPLICATION OF DYSREGULATED MITOCHONDRIAL DYNAMICS IN PARKINSON DISEASE.
Neurodegenerative Diseases
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity.
Neurodegenerative Diseases
Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson's disease.
Neurodegenerative Diseases
Quantitative model of R-loop forming structures reveals a novel level of RNA-DNA interactome complexity.
Neurodegenerative Diseases
Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in microglia.
Neurodegenerative Diseases
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Neurodegenerative Diseases
Salubrinal, ER stress inhibitor, attenuates kainic acid-induced hippocampal cell death.
Neurodegenerative Diseases
Solution Structure of the Ubiquitin-associated (UBA) Domain of Human Autophagy Receptor NBR1 and its Interaction with Ubiquitin and Polyubiquitin.
Neurodegenerative Diseases
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Neurodegenerative Diseases
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Neurodegenerative Diseases
Structure of the human Parkin ligase domain in an autoinhibited state.
Neurodegenerative Diseases
Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.
Neurodegenerative Diseases
The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?
Neurodegenerative Diseases
The PINK1-Parkin axis: An Overview.
Neurodegenerative Diseases
The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.
Neurodegenerative Diseases
The role of synphilin-1 in the pathogenesis of Parkinson's disease.
Neurodegenerative Diseases
The role of ubiquitin-protein ligases in neurodegenerative disease.
Neurodegenerative Diseases
The synaptic function of parkin.
Neurodegenerative Diseases
The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons.
Neurodegenerative Diseases
UBE4B: A Promising Regulatory Molecule in Neuronal Death and Survival.
Neurodegenerative Diseases
Using proteomics to identify ubiquitin ligase-substrate pairs: how novel methods may unveil therapeutic targets for neurodegenerative diseases.
Neurodegenerative Diseases
[Regulation of the protein degradation pathway by the ubiquitin family: its implication in neurodegenerative diseases]
Neuroendocrine Tumors
Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.
Neurofibromatoses
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Neurofibromatoses
Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.
Neurofibromatoses
Giant Intrathoracic Meningocele and Breast Cancer in a Neurofibromatosis Type I Patient.
Neurofibromatoses
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Neurofibromatoses
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Neurofibromatosis 1
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Neurofibromatosis 1
Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.
Neurofibromatosis 2
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Neurofibromatosis 2
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Neurofibrosarcoma
Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.
Neurofibrosarcoma
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.
Neuroinflammatory Diseases
A systematic review of molecular approaches that link mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
Neuroinflammatory Diseases
Genetic Imaging of Neuroinflammation in Parkinson's Disease: Recent Advancements.
Neuroinflammatory Diseases
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Neuroinflammatory Diseases
Loss of Microglial Parkin Inhibits Necroptosis and Contributes to Neuroinflammation.
Neuroinflammatory Diseases
Neuroinflammation in Parkinson's Disease.
Neuroinflammatory Diseases
Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy.
Neuroinflammatory Diseases
PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
Neuroinflammatory Diseases
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Neuroinflammatory Diseases
Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study.
Neuroinflammatory Diseases
The E3 Ubiquitin Ligase c-Cbl Inhibits Microglia-Mediated CNS Inflammation by Regulating PI3K/Akt/NF-?B Pathway.
Neuroinflammatory Diseases
The E3 ubiquitin ligase HectD3 attenuates cardiac hypertrophy and inflammation in mice.
Neuroinflammatory Diseases
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
Neuroinflammatory Diseases
USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation.
Neutropenia
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Neutropenia
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Nevus
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Nevus
Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance.
Nevus
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Nevus, Pigmented
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Newcastle Disease
Molecular characterization, tissue distribution and expression analysis of TRIM25 in Gallus gallus domesticus.
Newcastle Disease
Newcastle Disease Virus V Protein Degrades Mitochondrial Antiviral Signaling Protein To Inhibit Host Type I Interferon Production via E3 Ubiquitin Ligase RNF5.
Newcastle Disease
Viral strategies for triggering and manipulating mitophagy.
Nijmegen Breakage Syndrome
Inactivation of the Nijmegen breakage syndrome gene leads to excess centrosome duplication via the ATR/BRCA1 pathway.
Nijmegen Breakage Syndrome
Interactions of the Nijmegen breakage syndrome protein with ATM and BRCA1.
Nijmegen Breakage Syndrome
Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding.
Nijmegen Breakage Syndrome
The forkhead-associated domain of NBS1 is essential for nuclear foci formation after irradiation but not essential for hRAD50[middle dot]hMRE11[middle dot]NBS1 complex DNA repair activity.
Nijmegen Breakage Syndrome
The Interaction of CtIP and Nbs1 Connects CDK and ATM to Regulate HR-Mediated Double-Strand Break Repair.
Non-alcoholic Fatty Liver Disease
Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.
Non-alcoholic Fatty Liver Disease
Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer.
Non-alcoholic Fatty Liver Disease
Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD.
Non-alcoholic Fatty Liver Disease
Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases.
non-specific serine/threonine protein kinase deficiency
Inhibition of LRRK2 restores parkin-mediated mitophagy and attenuates intervertebral disc degeneration.
Noonan Syndrome
Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.
Obesity
Alarming Burden of Triple-negative Breast Cancer in India.
Obesity
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Obesity
Breast cancer 1 (BrCa1) may be behind decreased lipogenesis in adipose tissue from obese subjects.
Obesity
Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin Resistance.
Obesity
Casitas b-Lineage Lymphoma-Deficient Mice Are Protected Against High-Fat Diet-Induced Obesity and Insulin Resistance.
Obesity
Decrease of Cardiac Parkin Protein in Obese Mice.
Obesity
E3 Ligase FBXW2 Is a New Therapeutic Target in Obesity and Atherosclerosis.
Obesity
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations.
Obesity
Enhanced susceptibility of ovaries from obese mice to 7,12-dimethylbenz[a]anthracene-induced DNA damage.
Obesity
Identification of the inhibitory activity of walnut extract on the E3 ligase Syvn1.
Obesity
Inactivation of the E3 Ubiquitin Ligase IDOL (Inducible Degrader of the Low-Density Lipoprotein Receptor) Attenuates Diet-Induced Obesity and Metabolic Dysfunction in Mice.
Obesity
ITCH deficiency protects from diet-induced obesity.
Obesity
Mex3c mutation reduces adiposity partially through increasing physical activity.
Obesity
Obesity alters phosphoramide mustard-induced ovarian DNA repair in mice.
Obesity
Obesity alters the ovarian DNA damage response and apoptotic proteins.
Obesity
Obesity alters the ovarian proteomic response to zearalenone exposure.
Obesity
Requirement of SRC-family tyrosine kinases in fat accumulation.
Obesity
Rotating night work, lifestyle factors, obesity and promoter methylation in BRCA1 and BRCA2 genes among nurses and midwives.
Obesity
SCFJFK is functionally linked to obesity and metabolic syndrome.
Obesity
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
Obesity
The mahoganoid mutation (Mgrn1md) improves insulin sensitivity in mice with mutations in the melanocortin signaling pathway independently of effects on adiposity.
Obesity
The NRF2?PGC?1? pathway activates kynurenine aminotransferase 4 via attenuation of an E3 ubiquitin ligase, synoviolin, in a cecal ligation/perforation?induced septic mouse model.
Obesity
Ubiquitin ligase Cbl-b and obesity-induced insulin resistance [Review].
Obesity
What model organisms and interactomics can reveal about the genetics of human obesity.
Obesity, Maternal
Cellular inhibitors of apoptosis (cIAP) 1 and 2 are increased in placenta from obese pregnant women.
Obesity, Maternal
Maternal Obesity Alters Placental Cell Cycle Regulators in the First Trimester of Human Pregnancy: New Insights for BRCA1.
Obesity, Morbid
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Ocular Motility Disorders
Eye movement disorders are different in Parkin-linked and idiopathic early-onset PD.
Odontogenic Cysts
Expression profile of polycomb group proteins in odontogenic keratocyst and ameloblastoma.
Olfaction Disorders
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study.
Olfaction Disorders
Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models.
Oligodendroglioma
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Oligodendroglioma
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Oligodendroglioma
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
Oligospermia
Investigating the relationship between BRCA1 and BRCA2 genes methylation profile and sperm DNA fragmentation in infertile men.
Optic Atrophy
Overexpression of Optic Atrophy Type 1 Protects Retinal Ganglion Cells and Upregulates Parkin Expression in Experimental Glaucoma.
Optic Atrophy, Autosomal Dominant
Curcumin prevents cisplatin-induced renal alterations in mitochondrial bioenergetics and dynamic.
Optic Atrophy, Autosomal Dominant
Mitochondrial Dynamics of Proximal Tubular Epithelial Cells in Nephropathic Cystinosis.
Optic Atrophy, Autosomal Dominant
Overexpression of Optic Atrophy Type 1 Protects Retinal Ganglion Cells and Upregulates Parkin Expression in Experimental Glaucoma.
Optic Atrophy, Autosomal Dominant
Selective packaging of mitochondrial proteins into extracellular vesicles prevents the release of mitochondrial DAMPs.
Oropharyngeal Neoplasms
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
Osteoarthritis
Mitophagy in degenerative joint diseases.
Osteoarthritis
The E3 ubiquitin ligase Itch limits the progression of post-traumatic osteoarthritis in mice by inhibiting macrophage polarization.
Osteoarthritis
Upregulation of Atrogin-1/FBXO32 is not necessary for cartilage destruction in mouse models of osteoarthritis.
Osteonecrosis
P53 and Parkin co-regulate mitophagy in bone marrow mesenchymal stem cells to promote the repair of early steroid-induced osteonecrosis of the femoral head.
Osteoporosis
Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid.
Osteoporosis
Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
Osteoporosis
Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
Osteosarcoma
Activation of TNF-?/NF-?B axis enhances CRL4B
Osteosarcoma
BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.
Osteosarcoma
Cooperation Between BRCA1 and p53 in Repair of Cyclobutane Pyrimidine Dimers.
Osteosarcoma
CRL4B(DCAF11) E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.
Osteosarcoma
Dissociation of mammalian Polycomb-group proteins, Ring1B and Rae28/Ph1, from the chromatin correlates with configuration changes of the chromatin in mitotic and meiotic prophase.
Osteosarcoma
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Osteosarcoma
Geranylgeranylacetone promotes human osteosarcoma cell apoptosis by inducing the degradation of PRMT1 through the E3 ubiquitin ligase CHIP.
Osteosarcoma
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
Osteosarcoma
LncRNA NBR2 inhibits epithelial-mesenchymal transition by regulating Notch1 signaling in osteosarcoma cells.
Osteosarcoma
MEX3C promotes osteosarcoma malignant progression through negatively regulating FGF14.
Osteosarcoma
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.
Osteosarcoma
Polycomb group molecule PHC3 regulates polycomb complex composition and prognosis of osteosarcoma.
Osteosarcoma
Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.
Osteosarcoma
Punicalagin suppresses osteosarcoma growth and metastasis by regulating NF-?B signaling.
Osteosarcoma
RLIM interacts with Smurf2 and promotes TGF-? induced U2OS cell migration.
Osteosarcoma
Rlim, an E3 ubiquitin ligase, influences the stability of Stathmin protein in human osteosarcoma cells.
Osteosarcoma
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
Osteosarcoma
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Osteosarcoma
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Osteosarcoma
The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase.
Osteosarcoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Osteosarcoma
The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice.
Osteosarcoma
YWHAZ Binds to TRIM21 but Is Not Involved in TRIM21-stimulated Osteosarcoma Cell Proliferation.
Osteosarcoma
[Implication of the ubiquitin ligase c-Cbl in bone formation and tumorigenesis].
Ovarian Cysts
Laparoscopic Salpingo-oophorectomy in Conscious Sedation.
Ovarian Neoplasms
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
"It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
Ovarian Neoplasms
"Other" breast cancer susceptibility genes: searching for more holy grail.
Ovarian Neoplasms
"Ring-fencing" BRCA1 tumor suppressor activity.
Ovarian Neoplasms
"Sequencing-grade" screening for BRCA1 variants by oligo-arrays.
Ovarian Neoplasms
19p13.1 is a triple negative-specific breast cancer susceptibility locus.
Ovarian Neoplasms
1H, 13C and 15N backbone resonance assignment of BRCA1 fragment 219-504.
Ovarian Neoplasms
22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors.
Ovarian Neoplasms
53BP1 ablation rescues genomic instability in mice expressing 'RING-less' BRCA1.
Ovarian Neoplasms
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Ovarian Neoplasms
53BP1 is a positive regulator of the BRCA1 promoter.
Ovarian Neoplasms
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
Ovarian Neoplasms
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17.
Ovarian Neoplasms
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
Ovarian Neoplasms
A 45-year follow-up of kindred 107 and the search for BRCA2.
Ovarian Neoplasms
A biochemical analysis demonstrates that the BRCA1 intronic variant IVS10-2A--> C is a mutation.
Ovarian Neoplasms
A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells.
Ovarian Neoplasms
A BRCA1 mutation in Native North American families.
Ovarian Neoplasms
A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing.
Ovarian Neoplasms
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient.
Ovarian Neoplasms
A case series of three Sri Lankan families with hereditary breast and ovarian cancer syndrome due to pathogenic germline mutations in the BRCA1 gene
Ovarian Neoplasms
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations.
Ovarian Neoplasms
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.
Ovarian Neoplasms
A common BRCA1 mutation in Norwegian breast and ovarian cancer families?
Ovarian Neoplasms
A common Greenlandic Inuit BRCA1 RING domain founder mutation.
Ovarian Neoplasms
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.
Ovarian Neoplasms
A common SNP in the uracil-DNA glycosylase gene UNG decreases ovarian cancer risk in BRCA2 mutation carriers.
Ovarian Neoplasms
A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer.
Ovarian Neoplasms
A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
Ovarian Neoplasms
A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.
Ovarian Neoplasms
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
Ovarian Neoplasms
A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays.
Ovarian Neoplasms
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Ovarian Neoplasms
A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants.
Ovarian Neoplasms
A critical re-appraisal of BRCA1 methylation studies in ovarian cancer.
Ovarian Neoplasms
A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.
Ovarian Neoplasms
A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2.
Ovarian Neoplasms
A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair.
Ovarian Neoplasms
A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Ovarian Neoplasms
A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.
Ovarian Neoplasms
A family with three germline mutations in BRCA1 and BRCA2.
Ovarian Neoplasms
A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene.
Ovarian Neoplasms
A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer.
Ovarian Neoplasms
A frameshift mutation in BRCA1 leads to hereditary breast and ovarian cancer in one part of a family and to familial pancreatic cancer in another.
Ovarian Neoplasms
A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair.
Ovarian Neoplasms
A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
Ovarian Neoplasms
A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dIg-A.
Ovarian Neoplasms
A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer.
Ovarian Neoplasms
A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.
Ovarian Neoplasms
A guide for functional analysis of BRCA1 variants of uncertain significance.
Ovarian Neoplasms
A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
Ovarian Neoplasms
A high frequent BRCA1 founder mutation identified in the Greenlandic population.
Ovarian Neoplasms
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
Ovarian Neoplasms
A high proportion of founder BRCA1 mutations in Polish breast cancer families.
Ovarian Neoplasms
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.
Ovarian Neoplasms
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Ovarian Neoplasms
A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants.
Ovarian Neoplasms
A highly accurate, low cost test for BRCA1 mutations.
Ovarian Neoplasms
A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers.
Ovarian Neoplasms
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
Ovarian Neoplasms
A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.
Ovarian Neoplasms
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Ovarian Neoplasms
A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet.
Ovarian Neoplasms
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Ovarian Neoplasms
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
Ovarian Neoplasms
A missense mutation in the BRCA2 gene in three siblings with ovarian cancer.
Ovarian Neoplasms
A model for estimating ovarian cancer risk: application for preventive oophorectomy.
Ovarian Neoplasms
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
Ovarian Neoplasms
A multi-exonic BRCA1 deletion identified in multiple families through single nucleotide polymorphism haplotype pair analysis and gene amplification with widely dispersed primer sets.
Ovarian Neoplasms
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Ovarian Neoplasms
A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
Ovarian Neoplasms
A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.
Ovarian Neoplasms
A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.
Ovarian Neoplasms
A Nano-Biosensor for the Detection of 185delAG Mutation in BRCA1 Gene, Leading to Breast Cancer.
Ovarian Neoplasms
A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein.
Ovarian Neoplasms
A new bioinformatics tool to help assess the significance of BRCA1 variants.
Ovarian Neoplasms
A new BRCA1 mutation in a Filipino woman with a family history of breast and ovarian cancer.
Ovarian Neoplasms
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.
Ovarian Neoplasms
A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Ovarian Neoplasms
A new pathogenic mutation of the BRCA1 gene in a patient with ovarian cancer: A case report.
Ovarian Neoplasms
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
Ovarian Neoplasms
A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap.
Ovarian Neoplasms
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers.
Ovarian Neoplasms
A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer.
Ovarian Neoplasms
A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.
Ovarian Neoplasms
A novel BRCA1 mutation in a Spanish patient with ovarian cancer.
Ovarian Neoplasms
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer.
Ovarian Neoplasms
A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer.
Ovarian Neoplasms
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
Ovarian Neoplasms
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region.
Ovarian Neoplasms
A novel domain of BRCA1 interacts with p53 in breast cancer cells.
Ovarian Neoplasms
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
Ovarian Neoplasms
A novel method to detect the Mexican founder mutation BRCA1 ex9?12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.
Ovarian Neoplasms
A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation.
Ovarian Neoplasms
A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer
Ovarian Neoplasms
A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.
Ovarian Neoplasms
A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
Ovarian Neoplasms
A Novel Splice Site Mutation in the Noncoding Region of BRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics.
Ovarian Neoplasms
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
Ovarian Neoplasms
A nuclear function for the tumor suppressor BRCA1.
Ovarian Neoplasms
A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis.
Ovarian Neoplasms
A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1.
Ovarian Neoplasms
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Ovarian Neoplasms
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
Ovarian Neoplasms
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Ovarian Neoplasms
A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21.
Ovarian Neoplasms
A physical map encompassing GP2B, EPB3, D17S183, D17S78, D17S1183, and D17S1184.
Ovarian Neoplasms
A Pilot Study on Screening of BRCA1 Mutations (185delAG, 1294del40) in Nepalese Breast Cancer Patients.
Ovarian Neoplasms
A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study.
Ovarian Neoplasms
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Ovarian Neoplasms
A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
Ovarian Neoplasms
A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.
Ovarian Neoplasms
A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center.
Ovarian Neoplasms
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
Ovarian Neoplasms
A profile on the FoundationFocus CDxBRCA tests.
Ovarian Neoplasms
A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers.
Ovarian Neoplasms
A protective role for BRCA2 at stalled replication forks.
Ovarian Neoplasms
A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Ovarian Neoplasms
A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.
Ovarian Neoplasms
A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
Ovarian Neoplasms
A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
Ovarian Neoplasms
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
Ovarian Neoplasms
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.
Ovarian Neoplasms
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
Ovarian Neoplasms
A somatic mutation in the 5'UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency.
Ovarian Neoplasms
A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
Ovarian Neoplasms
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Ovarian Neoplasms
A survey of preventive measures among BRCA1 mutation carriers from Poland.
Ovarian Neoplasms
A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing.
Ovarian Neoplasms
A tandem duplication of BRCA1 exons 1-19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome.
Ovarian Neoplasms
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Ovarian Neoplasms
A Turn-On Detection of DNA Sequences by Means of Fluorescence of DNA-Templated Silver Nanoclusters via Unique Interactions of a Hydrated Ionic Liquid.
Ovarian Neoplasms
A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination.
Ovarian Neoplasms
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
Ovarian Neoplasms
Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Ovarian Neoplasms
Aberrant subcellular localization of BRCA1 in breast cancer.
Ovarian Neoplasms
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Ovarian Neoplasms
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
Ovarian Neoplasms
Absence of 185delAG and 6174delT Mutations among Breast Cancer Patients of Eastern India.
Ovarian Neoplasms
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22.
Ovarian Neoplasms
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Ovarian Neoplasms
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
Ovarian Neoplasms
Acceptance of, inclination for, and barriers in genetic testing for gene mutations that increase the risk of breast and ovarian cancers among female residents of Warsaw.
Ovarian Neoplasms
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Ovarian Neoplasms
Accurate classification of BRCA1 variants with saturation genome editing.
Ovarian Neoplasms
Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
Ovarian Neoplasms
Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells.
Ovarian Neoplasms
Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival.
Ovarian Neoplasms
Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries.
Ovarian Neoplasms
Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.
Ovarian Neoplasms
Advances in breast cancer: pathways to personalized medicine.
Ovarian Neoplasms
Advances in the biology of gynecologic cancer.
Ovarian Neoplasms
Advances in the management of epithelial ovarian cancer.
Ovarian Neoplasms
Advances in the understanding of risk factors for ovarian cancer.
Ovarian Neoplasms
Advances in the use of PARP inhibitor therapy for breast cancer.
Ovarian Neoplasms
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
Ovarian Neoplasms
Advances in using PARP inhibitors to treat cancer.
Ovarian Neoplasms
Age and Geographical Distribution in Families with BRCA1/BRCA2 Mutations in the Slovak Republic.
Ovarian Neoplasms
Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer.
Ovarian Neoplasms
Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.
Ovarian Neoplasms
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
Ovarian Neoplasms
Age-dependent penetrance of different germline mutations in the BRCA1 gene.
Ovarian Neoplasms
Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway.
Ovarian Neoplasms
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
Ovarian Neoplasms
AKT regulates BRCA1 stability in response to hormone signaling.
Ovarian Neoplasms
ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
Ovarian Neoplasms
ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Ovarian Neoplasms
Allelic imbalance in BRCA1 and BRCA2 gene expression and familial ovarian cancer.
Ovarian Neoplasms
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Ovarian Neoplasms
Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
Ovarian Neoplasms
Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs.
Ovarian Neoplasms
Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers.
Ovarian Neoplasms
Alterations in the common fragile site gene Parkin in ovarian and other cancers.
Ovarian Neoplasms
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Ovarian Neoplasms
Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants.
Ovarian Neoplasms
Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a case study.
Ovarian Neoplasms
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
Ovarian Neoplasms
An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10.
Ovarian Neoplasms
An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue.
Ovarian Neoplasms
An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
Ovarian Neoplasms
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
Ovarian Neoplasms
An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
Ovarian Neoplasms
An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification.
Ovarian Neoplasms
An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews.
Ovarian Neoplasms
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Ovarian Neoplasms
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
Ovarian Neoplasms
An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2.
Ovarian Neoplasms
Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Ovarian Neoplasms
Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
Ovarian Neoplasms
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Ovarian Neoplasms
Analysis of BRCA1 and BRCA2 mutations in an Iranian family with hereditary breast and ovarian cancer syndrome.
Ovarian Neoplasms
Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer.
Ovarian Neoplasms
Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome.
Ovarian Neoplasms
Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.
Ovarian Neoplasms
Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
Ovarian Neoplasms
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Ovarian Neoplasms
Analysis of centrosome localization of BRCA1 and its activity in suppressing centrosomal aster formation.
Ovarian Neoplasms
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Ovarian Neoplasms
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
Ovarian Neoplasms
Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
Ovarian Neoplasms
Analysis of PALB2 in a cohort of Italian breast cancer patients: identification of a novel PALB2 truncating mutation.
Ovarian Neoplasms
Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas.
Ovarian Neoplasms
Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
Ovarian Neoplasms
Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
Ovarian Neoplasms
Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells.
Ovarian Neoplasms
Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.
Ovarian Neoplasms
Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Ovarian Neoplasms
Appraising iniparib, the PARP inhibitor that never was--what must we learn?
Ovarian Neoplasms
Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?
Ovarian Neoplasms
Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer.
Ovarian Neoplasms
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Ovarian Neoplasms
Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Ovarian Neoplasms
Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants.
Ovarian Neoplasms
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.
Ovarian Neoplasms
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Ovarian Neoplasms
Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.
Ovarian Neoplasms
Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.
Ovarian Neoplasms
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Ovarian Neoplasms
Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
Ovarian Neoplasms
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Ovarian Neoplasms
Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Ovarian Neoplasms
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Ovarian Neoplasms
Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
Ovarian Neoplasms
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.
Ovarian Neoplasms
Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers.
Ovarian Neoplasms
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Ovarian Neoplasms
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.
Ovarian Neoplasms
Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.
Ovarian Neoplasms
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Ovarian Neoplasms
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Ovarian Neoplasms
Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers.
Ovarian Neoplasms
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Ovarian Neoplasms
Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Ovarian Neoplasms
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Ovarian Neoplasms
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Ovarian Neoplasms
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer.
Ovarian Neoplasms
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Ovarian Neoplasms
Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer.
Ovarian Neoplasms
Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler.
Ovarian Neoplasms
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Ovarian Neoplasms
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Ovarian Neoplasms
Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland.
Ovarian Neoplasms
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
Ovarian Neoplasms
Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Ovarian Neoplasms
Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer.
Ovarian Neoplasms
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Ovarian Neoplasms
Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
Ovarian Neoplasms
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Ovarian Neoplasms
Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.
Ovarian Neoplasms
BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
Ovarian Neoplasms
Being Young, Female, and BRCA Positive.
Ovarian Neoplasms
Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection.
Ovarian Neoplasms
Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.
Ovarian Neoplasms
Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
Ovarian Neoplasms
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Ovarian Neoplasms
Bias in intervention studies that enroll patients from high-risk clinics.
Ovarian Neoplasms
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Ovarian Neoplasms
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Bile acids upregulate BRCA1 and downregulate estrogen receptor 1 gene expression in ovarian cancer cells.
Ovarian Neoplasms
Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
Ovarian Neoplasms
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Ovarian Neoplasms
Biomarkers in the ovary.
Ovarian Neoplasms
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
Ovarian Neoplasms
BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
Ovarian Neoplasms
BRC-1 acts in the inter-sister pathway of meiotic double-strand break repair.
Ovarian Neoplasms
BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer.
Ovarian Neoplasms
BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes.
Ovarian Neoplasms
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Ovarian Neoplasms
BRCA genes: BRCA 1 and BRCA 2.
Ovarian Neoplasms
BRCA genes: lessons learned from experimental and clinical cancer.
Ovarian Neoplasms
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Ovarian Neoplasms
BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African.
Ovarian Neoplasms
BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.
Ovarian Neoplasms
BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group.
Ovarian Neoplasms
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Ovarian Neoplasms
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees.
Ovarian Neoplasms
BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Ovarian Neoplasms
BRCA mutations and reproduction.
Ovarian Neoplasms
BRCA Share: A Collection of Clinical BRCA Gene Variants.
Ovarian Neoplasms
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Ovarian Neoplasms
BRCA-associated ovarian cancer: from molecular genetics to risk management.
Ovarian Neoplasms
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Ovarian Neoplasms
BRCA1 185delAG Mutation Enhances Interleukin-1? Expression in Ovarian Surface Epithelial Cells.
Ovarian Neoplasms
BRCA1 185delAG mutation in a non-Ashkenazi Jewish woman with early-onset breast and ovarian cancer.
Ovarian Neoplasms
BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells.
Ovarian Neoplasms
BRCA1 4153delA founder mutation in Russian ovarian cancer patients.
Ovarian Neoplasms
BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients.
Ovarian Neoplasms
BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase.
Ovarian Neoplasms
BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy.
Ovarian Neoplasms
BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing.
Ovarian Neoplasms
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells.
Ovarian Neoplasms
BRCA1 and BRCA2 as ovarian cancer susceptibility genes.
Ovarian Neoplasms
BRCA1 and BRCA2 families and the risk of skin cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 gene mutations in hereditary and sporadic ovarian cancer and the clinical implications.
Ovarian Neoplasms
BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Ovarian Neoplasms
BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
Ovarian Neoplasms
BRCA1 and BRCA2 genetic testing for ovarian cancer: is it all good news?
Ovarian Neoplasms
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Ovarian Neoplasms
BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
Ovarian Neoplasms
BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
Ovarian Neoplasms
BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.
Ovarian Neoplasms
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
Ovarian Neoplasms
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Ovarian Neoplasms
BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients.
Ovarian Neoplasms
BRCA1 and BRCA2 germline mutations in lymphoma patients.
Ovarian Neoplasms
BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Ovarian Neoplasms
BRCA1 and BRCA2 in breast cancer predisposition and recombination control.
Ovarian Neoplasms
BRCA1 and BRCA2 in breast cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 in hereditary breast cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 in Indian breast cancer patients.
Ovarian Neoplasms
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Ovarian Neoplasms
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
Ovarian Neoplasms
BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Ovarian Neoplasms
BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in a South American population.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Syndrome: Reflection on the Creighton University Historical Series of High Risk Families.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in Scotland and Northern Ireland.
Ovarian Neoplasms
BRCA1 and BRCA2 Mutations in the Ovarian Cancer Population across Race and Ethnicity: Special Reference to Asia.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in women from Shanghai China.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
Ovarian Neoplasms
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
Ovarian Neoplasms
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ovarian Neoplasms
BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
Ovarian Neoplasms
BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite.
Ovarian Neoplasms
BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.
Ovarian Neoplasms
BRCA1 and BRCA2 sequence variations detected with next-generation sequencing in patients with premature ovarian insufficiency.
Ovarian Neoplasms
BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Ovarian Neoplasms
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double strand break repair.
Ovarian Neoplasms
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.
Ovarian Neoplasms
BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
Ovarian Neoplasms
BRCA1 and cell signaling.
Ovarian Neoplasms
Brca1 and differentiation.
Ovarian Neoplasms
BRCA1 and estrogen signaling in breast cancer.
Ovarian Neoplasms
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.
Ovarian Neoplasms
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
Ovarian Neoplasms
BRCA1 and implications for response to chemotherapy in ovarian cancer.
Ovarian Neoplasms
BRCA1 and Its Network of Interacting Partners.
Ovarian Neoplasms
BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets.
Ovarian Neoplasms
BRCA1 and p53 regulate critical prostate cancer pathways.
Ovarian Neoplasms
BRCA1 and PALB2 in a Messy Breakup.
Ovarian Neoplasms
BRCA1 and prostate cancer.
Ovarian Neoplasms
BRCA1 and sex ratio.
Ovarian Neoplasms
BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
Ovarian Neoplasms
BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control.
Ovarian Neoplasms
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.
Ovarian Neoplasms
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
Ovarian Neoplasms
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit.
Ovarian Neoplasms
BRCA1 can modulate RNA polymerase II carboxy-terminal domain phosphorylation levels.
Ovarian Neoplasms
BRCA1 can stimulate gene transcription by a unique mechanism.
Ovarian Neoplasms
BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Ovarian Neoplasms
BRCA1 Circos: a visualisation resource for functional analysis of missense variants.
Ovarian Neoplasms
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Ovarian Neoplasms
BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein.
Ovarian Neoplasms
BRCA1 DEFICIENCY EXACERBATES ESTROGEN INDUCED DNA DAMAGE AND GENOMIC INSTABILITY.
Ovarian Neoplasms
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.
Ovarian Neoplasms
BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
Ovarian Neoplasms
Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities.
Ovarian Neoplasms
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
Ovarian Neoplasms
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Ovarian Neoplasms
BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.
Ovarian Neoplasms
BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin.
Ovarian Neoplasms
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
Ovarian Neoplasms
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
Ovarian Neoplasms
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
Ovarian Neoplasms
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Ovarian Neoplasms
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
Ovarian Neoplasms
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
Ovarian Neoplasms
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
Ovarian Neoplasms
BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.
Ovarian Neoplasms
BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines.
Ovarian Neoplasms
BRCA1 founder mutations compared to ovarian cancer in Belarus.
Ovarian Neoplasms
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
Ovarian Neoplasms
BRCA1 gene in breast cancer.
Ovarian Neoplasms
BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.
Ovarian Neoplasms
BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
Ovarian Neoplasms
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
Ovarian Neoplasms
BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum.
Ovarian Neoplasms
BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Ovarian Neoplasms
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ovarian Neoplasms
BRCA1 gene testing for breast and ovarian cancer in one family.
Ovarian Neoplasms
BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia.
Ovarian Neoplasms
BRCA1 gene: function and deficiency.
Ovarian Neoplasms
BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
Ovarian Neoplasms
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.
Ovarian Neoplasms
BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.
Ovarian Neoplasms
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Ovarian Neoplasms
BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer.
Ovarian Neoplasms
BRCA1 germline mutations in Indian familial breast cancer.
Ovarian Neoplasms
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
Ovarian Neoplasms
BRCA1 in breast and ovarian cancer predisposition.
Ovarian Neoplasms
BRCA1 in cancer, cell cycle and genomic stability.
Ovarian Neoplasms
BRCA1 in hormone-responsive cancers.
Ovarian Neoplasms
BRCA1 in special populations.
Ovarian Neoplasms
BRCA1 in the DNA damage response and at telomeres.
Ovarian Neoplasms
BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
Ovarian Neoplasms
BRCA1 interacts with components of the histone deacetylase complex.
Ovarian Neoplasms
BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting homologous recombination or radiation-induced gene activation of p21 or Mdm2.
Ovarian Neoplasms
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
Ovarian Neoplasms
BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells.
Ovarian Neoplasms
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
Ovarian Neoplasms
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.
Ovarian Neoplasms
BRCA1 is secreted and exhibits properties of a granin.
Ovarian Neoplasms
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
Ovarian Neoplasms
BRCA1 methylation and BRCA1 mutations in ovarian cancer.
Ovarian Neoplasms
BRCA1 methylation: a significant role in tumour development?
Ovarian Neoplasms
BRCA1 modulates ionizing radiation-induced nuclear focus formation by the replication protein A p34 subunit.
Ovarian Neoplasms
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer.
Ovarian Neoplasms
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.
Ovarian Neoplasms
BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
Ovarian Neoplasms
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Ovarian Neoplasms
BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival.
Ovarian Neoplasms
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
Ovarian Neoplasms
BRCA1 Mutation Status and Follicular Fluid Exposure Alters NF?B Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
Ovarian Neoplasms
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
Ovarian Neoplasms
BRCA1 mutations and survival in women with ovarian cancer.
Ovarian Neoplasms
BRCA1 mutations in a population-based sample of young women with breast cancer.
Ovarian Neoplasms
BRCA1 mutations in a population-based study of breast cancer in Stockholm County.
Ovarian Neoplasms
BRCA1 mutations in a selected series of breast/ovarian cancer patients.
Ovarian Neoplasms
BRCA1 mutations in familial ovarian cancer.
Ovarian Neoplasms
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
Ovarian Neoplasms
BRCA1 mutations in primary breast and ovarian carcinomas.
Ovarian Neoplasms
BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families.
Ovarian Neoplasms
BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
Ovarian Neoplasms
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
Ovarian Neoplasms
BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
Ovarian Neoplasms
BRCA1 mutations in women with ovarian cancer.
Ovarian Neoplasms
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.
Ovarian Neoplasms
BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
Ovarian Neoplasms
BRCA1 partially reverses the transforming activity of the ras oncogene.
Ovarian Neoplasms
BRCA1 physically and functionally interacts with ATF1.
Ovarian Neoplasms
BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Ovarian Neoplasms
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.
Ovarian Neoplasms
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
Ovarian Neoplasms
BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis.
Ovarian Neoplasms
BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
Ovarian Neoplasms
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Ovarian Neoplasms
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Ovarian Neoplasms
BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.
Ovarian Neoplasms
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
Ovarian Neoplasms
BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9.
Ovarian Neoplasms
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
Ovarian Neoplasms
BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels.
Ovarian Neoplasms
BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.
Ovarian Neoplasms
BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
Ovarian Neoplasms
BRCA1 Regulates g-Tubulin Binding to Centrosomes.
Ovarian Neoplasms
BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs.
Ovarian Neoplasms
BRCA1 regulates gene expression for orderly mitotic progression.
Ovarian Neoplasms
BRCA1 regulates HMGA2 levels in the Swan71 trophoblast cell line.
Ovarian Neoplasms
BRCA1 regulates human mammary stem/progenitor cell fate.
Ovarian Neoplasms
BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.
Ovarian Neoplasms
Brca1 regulates in vitro differentiation of mammary epithelial cells.
Ovarian Neoplasms
BRCA1 regulates insulin-like growth factor 1 receptor levels in ovarian cancer.
Ovarian Neoplasms
BRCA1 regulates p53-dependent gene expression.
Ovarian Neoplasms
BRCA1 regulation of transcription.
Ovarian Neoplasms
BRCA1 required for transcription-coupled repair of oxidative DNA damage.
Ovarian Neoplasms
BRCA1 screening in patients with a family history of breast or ovarian cancer.
Ovarian Neoplasms
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
Ovarian Neoplasms
BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1.
Ovarian Neoplasms
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
Ovarian Neoplasms
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
Ovarian Neoplasms
BRCA1 tumor suppressor network: focusing on its tail.
Ovarian Neoplasms
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.
Ovarian Neoplasms
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
Ovarian Neoplasms
BRCA1 variants in a family study of African-American and Latina women.
Ovarian Neoplasms
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
Ovarian Neoplasms
BRCA1 Zinc RING Finger Domain Disruption Alters Caspase Response in Ovarian Surface Epithelial Cells.
Ovarian Neoplasms
BRCA1, a 'complex' protein involved in the maintenance of genomic stability.
Ovarian Neoplasms
BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer.
Ovarian Neoplasms
BRCA1, BRCA2 and breast cancer: a concise clinical review.
Ovarian Neoplasms
BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
Ovarian Neoplasms
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
Ovarian Neoplasms
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
Ovarian Neoplasms
BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.
Ovarian Neoplasms
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Ovarian Neoplasms
BRCA1, hormone, and tissue-specific tumor suppression.
Ovarian Neoplasms
BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Ovarian Neoplasms
BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge.
Ovarian Neoplasms
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?
Ovarian Neoplasms
BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
Ovarian Neoplasms
BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms.
Ovarian Neoplasms
BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance.
Ovarian Neoplasms
BRCA1-associated growth arrest is RB-dependent.
Ovarian Neoplasms
BRCA1-BARD1 associate with the synaptonemal complex and pro-crossover factors and influence RAD-51 dynamics during Caenorhabditis elegans meiosis.
Ovarian Neoplasms
BRCA1-directed, enhanced and aberrant homologous recombination: Mechanism and potential treatment strategies.
Ovarian Neoplasms
BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.
Ovarian Neoplasms
BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.
Ovarian Neoplasms
BRCA1-IRIS Overexpression Promotes Cisplatin Resistance in Ovarian Cancer Cells.
Ovarian Neoplasms
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Ovarian Neoplasms
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
Ovarian Neoplasms
BRCA1-p53 relationship in hereditary breast cancer.
Ovarian Neoplasms
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
Ovarian Neoplasms
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.
Ovarian Neoplasms
BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Ovarian Neoplasms
BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer.
Ovarian Neoplasms
BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer.
Ovarian Neoplasms
BRCA1/2 testing: complex themes in result interpretation.
Ovarian Neoplasms
BRCA1/BARD1 complex interacts with steroidogenic factor 1--A potential mechanism for regulation of aromatase expression by BRCA1.
Ovarian Neoplasms
BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans.
Ovarian Neoplasms
BRCA1/BARD1 site-specific ubiquitylation of nucleosomal H2A is directed by BARD1.
Ovarian Neoplasms
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
Ovarian Neoplasms
BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
Ovarian Neoplasms
BRCA1: a locus-specific "liaison" in gene expression and genetic integrity.
Ovarian Neoplasms
BRCA1: a movement toward cancer prevention.
Ovarian Neoplasms
BRCA1: a review of structure and putative functions.
Ovarian Neoplasms
BRCA1: exploring the links to transcription.
Ovarian Neoplasms
BRCA1: genetic testing and hereditary breast and ovarian cancer.
Ovarian Neoplasms
BRCA1: mechanisms of inactivation and implications for management of patients.
Ovarian Neoplasms
BRCA1: the enigma of tissue-specific tumor development.
Ovarian Neoplasms
BRCA2 founder mutation in Slovenian breast cancer families.
Ovarian Neoplasms
BRCA2 gene mutations in Greek patients with familial breast cancer.
Ovarian Neoplasms
BRCA2 germline mutations in primary cancer of the fallopian tube.
Ovarian Neoplasms
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
Ovarian Neoplasms
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
Ovarian Neoplasms
BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
Ovarian Neoplasms
BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells.
Ovarian Neoplasms
BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
Ovarian Neoplasms
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Ovarian Neoplasms
BRCT repeats as phosphopeptide-binding modules involved in protein targeting.
Ovarian Neoplasms
Breast and ovarian cancer genetics and prevention.
Ovarian Neoplasms
Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Ovarian Neoplasms
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Ovarian Neoplasms
Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women.
Ovarian Neoplasms
Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Breast and Ovarian Cancer Risk due to Prevalence of BRCA1 and BRCA2 Variants in Pakistani Population: A Pakistani Database Report.
Ovarian Neoplasms
Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.
Ovarian Neoplasms
Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
Ovarian Neoplasms
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Ovarian Neoplasms
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Ovarian Neoplasms
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
Ovarian Neoplasms
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
Ovarian Neoplasms
Breast and ovarian cancer: the forgotten paternal contribution.
Ovarian Neoplasms
Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.
Ovarian Neoplasms
Breast cancer and ovarian cancer genetics: an update.
Ovarian Neoplasms
Breast cancer genes: therapeutic strategies.
Ovarian Neoplasms
Breast cancer genetics in African Americans.
Ovarian Neoplasms
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
Ovarian Neoplasms
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
Ovarian Neoplasms
Breast cancer mortality among Ashkenazi Jewish women in São Paulo and Porto Alegre, Brazil.
Ovarian Neoplasms
Breast Cancer Predisposition Genes and Synthetic Lethality.
Ovarian Neoplasms
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Ovarian Neoplasms
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Ovarian Neoplasms
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.
Ovarian Neoplasms
Breast cancer risks and risk prediction models.
Ovarian Neoplasms
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Breast cancer susceptibility variants alter risk in familial ovarian cancer.
Ovarian Neoplasms
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
Ovarian Neoplasms
CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Ovarian Neoplasms
CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
Ovarian Neoplasms
CAG repeat size in Huntingtin alleles is associated with cancer prognosis.
Ovarian Neoplasms
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
Ovarian Neoplasms
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?
Ovarian Neoplasms
Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Cancer genetics.
Ovarian Neoplasms
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Ovarian Neoplasms
Cancer Incidence in BRCA1 mutation carriers.
Ovarian Neoplasms
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer.
Ovarian Neoplasms
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
Ovarian Neoplasms
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation.
Ovarian Neoplasms
Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.
Ovarian Neoplasms
Cancer risks among BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Ovarian Neoplasms
Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status.
Ovarian Neoplasms
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.
Ovarian Neoplasms
Cancer treatment according to BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Ovarian Neoplasms
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
Ovarian Neoplasms
Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin.
Ovarian Neoplasms
Caretaker Brca1: keeping the genome in the straight and narrow.
Ovarian Neoplasms
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
Ovarian Neoplasms
CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Ovarian Neoplasms
Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis.
Ovarian Neoplasms
Catalysts towards cancer risk management action: A longitudinal study of reproductive-aged women with BRCA1/2 mutations.
Ovarian Neoplasms
Caucasian family with two independent mutations: 2594delC in BRCA1 and 5392delAG in BRCA2 gene.
Ovarian Neoplasms
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Ovarian Neoplasms
cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Ovarian Neoplasms
Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells.
Ovarian Neoplasms
Cell cycle regulation of the BRCA1/acetyl-CoA-carboxylase complex.
Ovarian Neoplasms
Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.
Ovarian Neoplasms
Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.
Ovarian Neoplasms
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
Ovarian Neoplasms
Cellular functions of the BRCA tumour-suppressor proteins.
Ovarian Neoplasms
Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer.
Ovarian Neoplasms
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
Ovarian Neoplasms
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q.
Ovarian Neoplasms
Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
Ovarian Neoplasms
Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants.
Ovarian Neoplasms
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
Ovarian Neoplasms
Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
Ovarian Neoplasms
Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
Ovarian Neoplasms
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.
Ovarian Neoplasms
Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.
Ovarian Neoplasms
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
Ovarian Neoplasms
Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
Ovarian Neoplasms
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Ovarian Neoplasms
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Ovarian Neoplasms
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
Ovarian Neoplasms
Characteristics relating to ovarian cancer risk: implications for prevention and detection.
Ovarian Neoplasms
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Ovarian Neoplasms
Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.
Ovarian Neoplasms
Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer.
Ovarian Neoplasms
Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain.
Ovarian Neoplasms
Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Ovarian Neoplasms
Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Ovarian Neoplasms
Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Ovarian Neoplasms
Characterization of Brca1 deficient mice.
Ovarian Neoplasms
Characterization of COBRA1 in human breast cancer cell lines using a new polyclonal antibody against COBRA1.
Ovarian Neoplasms
Characterization of common BRCA1 and BRCA2 variants.
Ovarian Neoplasms
Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells.
Ovarian Neoplasms
Characterization of LGALS3 (galectin-3) as a player in DNA damage response.
Ovarian Neoplasms
Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study.
Ovarian Neoplasms
Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.
Ovarian Neoplasms
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Ovarian Neoplasms
Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg).
Ovarian Neoplasms
Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
Ovarian Neoplasms
Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.
Ovarian Neoplasms
CHEK2 1100 delC mutation in Russian ovarian cancer patients.
Ovarian Neoplasms
Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer.
Ovarian Neoplasms
Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
Ovarian Neoplasms
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Ovarian Neoplasms
Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer Clinic.
Ovarian Neoplasms
Choice of Management of Southern Chinese BRCA Mutation Carriers.
Ovarian Neoplasms
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas.
Ovarian Neoplasms
Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
Ovarian Neoplasms
Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients.
Ovarian Neoplasms
Circ_0007841 accelerates ovarian cancer development through facilitating MEX3C expression by restraining miR-151-3p activity.
Ovarian Neoplasms
Classification of BRCA1 missense variants of unknown clinical significance.
Ovarian Neoplasms
Classification of IVS1-10T-->C as a polymorphism of BRCA1.
Ovarian Neoplasms
Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.
Ovarian Neoplasms
Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
Ovarian Neoplasms
Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery.
Ovarian Neoplasms
Clinical and genetic evaluation of thirty ovarian cancer families.
Ovarian Neoplasms
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Ovarian Neoplasms
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Ovarian Neoplasms
Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer.
Ovarian Neoplasms
Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.
Ovarian Neoplasms
Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2.
Ovarian Neoplasms
Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
Ovarian Neoplasms
Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
Ovarian Neoplasms
Clinical implications of using molecular diagnostics for ovarian cancers.
Ovarian Neoplasms
Clinical management of women with genomic BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
Ovarian Neoplasms
Clinical outcome of hereditary breast cancer in the lithuanian population.
Ovarian Neoplasms
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Ovarian Neoplasms
Clinical significance of large rearrangements in BRCA1 and BRCA2.
Ovarian Neoplasms
Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia.
Ovarian Neoplasms
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Ovarian Neoplasms
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
Ovarian Neoplasms
Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Ovarian Neoplasms
Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis.
Ovarian Neoplasms
Cloning and functional identification of two novel BRCA1 splicing variants.
Ovarian Neoplasms
Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers.
Ovarian Neoplasms
Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements.
Ovarian Neoplasms
Colorado family physicians' knowledge of hereditary breast cancer and related practice.
Ovarian Neoplasms
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Ovarian Neoplasms
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Ovarian Neoplasms
Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk.
Ovarian Neoplasms
Commentary regarding Schayek et al., entitled "The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil".
Ovarian Neoplasms
Comments on: Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
Ovarian Neoplasms
Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.
Ovarian Neoplasms
Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.
Ovarian Neoplasms
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population.
Ovarian Neoplasms
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Ovarian Neoplasms
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
Ovarian Neoplasms
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families.
Ovarian Neoplasms
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
Ovarian Neoplasms
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups.
Ovarian Neoplasms
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Ovarian Neoplasms
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Ovarian Neoplasms
Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.
Ovarian Neoplasms
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations.
Ovarian Neoplasms
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.
Ovarian Neoplasms
Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer.
Ovarian Neoplasms
Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Ovarian Neoplasms
Comparisons of gene coexpression network modules in breast cancer and ovarian cancer.
Ovarian Neoplasms
Competing risks analysis of correlated failure time data.
Ovarian Neoplasms
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Ovarian Neoplasms
Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
Ovarian Neoplasms
Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer.
Ovarian Neoplasms
Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer.
Ovarian Neoplasms
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Ovarian Neoplasms
Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Ovarian Neoplasms
Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
Ovarian Neoplasms
Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium.
Ovarian Neoplasms
Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.
Ovarian Neoplasms
Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Ovarian Neoplasms
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Ovarian Neoplasms
Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients.
Ovarian Neoplasms
Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
Ovarian Neoplasms
Conclusions and recommendations from the Helene Harris Memorial Trust Fourth Biennial International Forum on Ovarian Cancer 11-14 May 1993, Toronto, Canada.
Ovarian Neoplasms
Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Ovarian Neoplasms
Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis?
Ovarian Neoplasms
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.
Ovarian Neoplasms
Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein.
Ovarian Neoplasms
Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers.
Ovarian Neoplasms
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.
Ovarian Neoplasms
Constitutional Mosaic Epimutations - a hidden cause of cancer?
Ovarian Neoplasms
Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
Ovarian Neoplasms
Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Ovarian Neoplasms
Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
Ovarian Neoplasms
Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
Ovarian Neoplasms
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.
Ovarian Neoplasms
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
Ovarian Neoplasms
Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
Ovarian Neoplasms
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.
Ovarian Neoplasms
Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Ovarian Neoplasms
Contribution of BRCA1 mutations to ovarian cancer.
Ovarian Neoplasms
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Ovarian Neoplasms
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.
Ovarian Neoplasms
Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic.
Ovarian Neoplasms
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Ovarian Neoplasms
Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
Ovarian Neoplasms
Convenient, nonradioactive, heteroduplex-based methods for identifying recurrent mutations in the BRCA1 and BRCA2 genes.
Ovarian Neoplasms
Cooperation Between BRCA1 and p53 in Repair of Cyclobutane Pyrimidine Dimers.
Ovarian Neoplasms
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome.
Ovarian Neoplasms
Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation.
Ovarian Neoplasms
Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Ovarian Neoplasms
Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
Ovarian Neoplasms
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.
Ovarian Neoplasms
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Ovarian Neoplasms
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Ovarian Neoplasms
Cost Effectiveness Analysis of Genetic Testing for Breast and Ovarian Cancer Susceptibility Genes: BRCA1 and BRCA2.
Ovarian Neoplasms
Cost-Effectiveness Analysis of Testing for Brca1 and Brca2 Mutations In Women Diagnosed With Ovarian Cancer and Their Female First- And Second Degree Relatives Using A Discrete Event Simulation: A Uk Health Service Perspective.
Ovarian Neoplasms
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Ovarian Neoplasms
Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
Ovarian Neoplasms
Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.
Ovarian Neoplasms
Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
Ovarian Neoplasms
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Ovarian Neoplasms
Costs and benefits of diagnosing familial breast cancer.
Ovarian Neoplasms
Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?
Ovarian Neoplasms
Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Ovarian Neoplasms
Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.
Ovarian Neoplasms
Curcumin induces re?expression of BRCA1 and suppression of ? synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Ovarian Neoplasms
Current condition of genetic medicine for hereditary breast cancer.
Ovarian Neoplasms
Current practices on genetic testing in ovarian cancer.
Ovarian Neoplasms
Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
Ovarian Neoplasms
Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
Ovarian Neoplasms
Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Ovarian Neoplasms
Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines.
Ovarian Neoplasms
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Ovarian Neoplasms
Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.
Ovarian Neoplasms
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Ovarian Neoplasms
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Ovarian Neoplasms
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Ovarian Neoplasms
Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
Ovarian Neoplasms
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Ovarian Neoplasms
Deletion of Exons 1a-2 of BRCA1: A Rather Frequent Pathogenic Abnormality.
Ovarian Neoplasms
Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
Ovarian Neoplasms
Depletion of eIF2.GTP.Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.
Ovarian Neoplasms
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases.
Ovarian Neoplasms
Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine.
Ovarian Neoplasms
Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
Ovarian Neoplasms
Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours.
Ovarian Neoplasms
Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method.
Ovarian Neoplasms
Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing.
Ovarian Neoplasms
Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives.
Ovarian Neoplasms
Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.
Ovarian Neoplasms
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Ovarian Neoplasms
Detection of false positive mutations in BRCA gene by next generation sequencing.
Ovarian Neoplasms
Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.
Ovarian Neoplasms
Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel.
Ovarian Neoplasms
Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis.
Ovarian Neoplasms
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
Ovarian Neoplasms
Detection of the most frequent mutations in BRCA1 gene on polyacrylamide gels containing Spreadex Polymer NAB.
Ovarian Neoplasms
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Ovarian Neoplasms
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.
Ovarian Neoplasms
Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods.
Ovarian Neoplasms
Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.
Ovarian Neoplasms
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Ovarian Neoplasms
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
Ovarian Neoplasms
Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
Ovarian Neoplasms
Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
Ovarian Neoplasms
Developmental studies of Brca1 and Brca2 knock-out mice.
Ovarian Neoplasms
Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
Ovarian Neoplasms
Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations.
Ovarian Neoplasms
Diagnostic testing of genetic disorders: limiting the scope of patent claims through disclosure requirements.
Ovarian Neoplasms
Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Ovarian Neoplasms
Differences in BRCA counseling and testing practices based on ordering provider type.
Ovarian Neoplasms
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.
Ovarian Neoplasms
Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
Ovarian Neoplasms
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation.
Ovarian Neoplasms
Differential effects of HTLV-1 Tax oncoprotein on the different estrogen-induced-ER ?-mediated transcriptional activities.
Ovarian Neoplasms
Differential expression and subcellular localization of murine BRCA1 and BRCA1-delta 11 isoforms in murine and human cell lines.
Ovarian Neoplasms
Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
Ovarian Neoplasms
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
Ovarian Neoplasms
Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Ovarian Neoplasms
Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis.
Ovarian Neoplasms
Direct to confusion: lessons learned from marketing BRCA testing.
Ovarian Neoplasms
Dissecting PARP inhibitor resistance with functional genomics.
Ovarian Neoplasms
Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot.
Ovarian Neoplasms
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
Ovarian Neoplasms
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Ovarian Neoplasms
DNA array-based method for detection of large rearrangements in the BRCA1 gene.
Ovarian Neoplasms
DNA double strand break repair and its association with inherited predispositions to breast cancer.
Ovarian Neoplasms
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.
Ovarian Neoplasms
DNA polymerase stalling, sister chromatid recombination and the BRCA genes.
Ovarian Neoplasms
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
Ovarian Neoplasms
DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.
Ovarian Neoplasms
DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
Ovarian Neoplasms
Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
Ovarian Neoplasms
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
Ovarian Neoplasms
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
Ovarian Neoplasms
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
Ovarian Neoplasms
Double mutation of APC and BRCA1 in an Italian family.
Ovarian Neoplasms
Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.
Ovarian Neoplasms
Downregulation of the cancer susceptibility protein WRAP53? in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome.
Ovarian Neoplasms
Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data.
Ovarian Neoplasms
Drug therapy for hereditary cancers.
Ovarian Neoplasms
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.
Ovarian Neoplasms
Dysregulation of x chromosome inactivation in high grade ovarian serous adenocarcinoma.
Ovarian Neoplasms
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
Ovarian Neoplasms
Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Ovarian Neoplasms
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Ovarian Neoplasms
Effect of BRCA1 and XPG Mutations on Treatment Response to Trabectedin and Pegylated Liposomal Doxorubicin in Patients with Advanced Ovarian Cancer - Exploratory Analysis of the Phase 3 OVA-301 Study.
Ovarian Neoplasms
Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae.
Ovarian Neoplasms
Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.
Ovarian Neoplasms
Effect of misreported family history on Mendelian mutation prediction models.
Ovarian Neoplasms
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.
Ovarian Neoplasms
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
Ovarian Neoplasms
Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression.
Ovarian Neoplasms
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Ovarian Neoplasms
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Ovarian Neoplasms
Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population.
Ovarian Neoplasms
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
Ovarian Neoplasms
Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Ovarian Neoplasms
Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk.
Ovarian Neoplasms
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Ovarian Neoplasms
Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.
Ovarian Neoplasms
Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Ovarian Neoplasms
Egr-1 regulates the transcription of the BRCA1 gene by etoposide.
Ovarian Neoplasms
Electrophoresis of BRCA1 oncosuppressor.
Ovarian Neoplasms
Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls.
Ovarian Neoplasms
Emerging roles of BRCA1 alternative splicing.
Ovarian Neoplasms
Emerging roles of lamins and DNA damage repair mechanisms in ovarian cancer.
Ovarian Neoplasms
Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Ovarian Neoplasms
Enhanced high density oligonucleotide array-based sequence analysis using modified nucleoside triphosphates.
Ovarian Neoplasms
Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
Ovarian Neoplasms
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
Ovarian Neoplasms
Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
Ovarian Neoplasms
Epidemiology of breast cancer among BRCA mutation carriers: an overview.
Ovarian Neoplasms
Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.
Ovarian Neoplasms
Epidemiology, prevention, and early detection of breast cancer.
Ovarian Neoplasms
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Ovarian Neoplasms
Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
Ovarian Neoplasms
Epigenetic synthetic lethality approaches in cancer therapy.
Ovarian Neoplasms
Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy.
Ovarian Neoplasms
Epithelial ovarian cancer: prevention, diagnosis, and treatment.
Ovarian Neoplasms
Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography.
Ovarian Neoplasms
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.
Ovarian Neoplasms
Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 BRCA2 Icelandic founder mutation.
Ovarian Neoplasms
Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
Ovarian Neoplasms
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.
Ovarian Neoplasms
Estimating genetic influence on disease from population-based case-control data: application to cancers of the breast and ovary.
Ovarian Neoplasms
Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Ovarian Neoplasms
Estrogen upregulation of BRCA1 expression with no effect on localization.
Ovarian Neoplasms
Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents.
Ovarian Neoplasms
Ethical issues related to BRCA gene testing in orthodox Jewish women.
Ovarian Neoplasms
Ethnic differences in cancer risk resulting from genetic variation.
Ovarian Neoplasms
Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations.
Ovarian Neoplasms
Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.
Ovarian Neoplasms
Evaluating the genetic risk of breast cancer.
Ovarian Neoplasms
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Ovarian Neoplasms
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
Ovarian Neoplasms
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.
Ovarian Neoplasms
Evaluation and management of women with BRCA1/2 mutations.
Ovarian Neoplasms
Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations.
Ovarian Neoplasms
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
Ovarian Neoplasms
Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Ovarian Neoplasms
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Ovarian Neoplasms
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.
Ovarian Neoplasms
Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Ovarian Neoplasms
Evaluation of hereditary risk in a mammography population.
Ovarian Neoplasms
Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
Ovarian Neoplasms
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
Ovarian Neoplasms
Evaluation of Rare Variants in the New Fanconi Anemia Gene ERCC4 (FANCQ) as Familial Breast/Ovarian Cancer Susceptibility Alleles.
Ovarian Neoplasms
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Ovarian Neoplasms
Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families.
Ovarian Neoplasms
Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
Ovarian Neoplasms
Evidence for a transcriptional activation function of BRCA1 C-terminal region.
Ovarian Neoplasms
Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Ovarian Neoplasms
Evidence of a founder BRCA1 mutation in Scotland.
Ovarian Neoplasms
Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
Ovarian Neoplasms
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
Ovarian Neoplasms
Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families.
Ovarian Neoplasms
Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future.
Ovarian Neoplasms
Exploring and comparing adverse events between PARP inhibitors.
Ovarian Neoplasms
Exploring genetic counselors' perceptions of usefulness and intentions to use refined risk models in clinical care based on the Technology Acceptance Model (TAM).
Ovarian Neoplasms
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
Ovarian Neoplasms
Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
Ovarian Neoplasms
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Ovarian Neoplasms
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Ovarian Neoplasms
Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
Ovarian Neoplasms
Expression of EMSY gene in sporadic ovarian cancer.
Ovarian Neoplasms
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Ovarian Neoplasms
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Ovarian Neoplasms
Ex vivo retrieval and cryopreservation of oocytes from oophorectomized specimens for fertility preservation in a BRCA1 mutation carrier with ovarian cancer.
Ovarian Neoplasms
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Ovarian Neoplasms
Factors associated with decisions about clinical BRCA1/2 testing.
Ovarian Neoplasms
Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
Ovarian Neoplasms
Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Ovarian Neoplasms
Familial breast and ovarian cancers.
Ovarian Neoplasms
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Ovarian Neoplasms
Familial breast cancer. Approaching the isolation of a susceptibility gene.
Ovarian Neoplasms
Familial breast cancer. BRCA1 down, BRCA2 to go.
Ovarian Neoplasms
Familial Breast Cancer: Clinical Response to Induction Chemotherapy or Radiotherapy Related to BRCA1/2 Mutations Status.
Ovarian Neoplasms
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients.
Ovarian Neoplasms
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Ovarian Neoplasms
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Ovarian Neoplasms
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Ovarian Neoplasms
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.
Ovarian Neoplasms
Familial ovarian cancer.
Ovarian Neoplasms
Familial risk and genetic susceptibility for breast cancer.
Ovarian Neoplasms
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Ovarian Neoplasms
Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
Ovarian Neoplasms
Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Ovarian Neoplasms
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Ovarian Neoplasms
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Ovarian Neoplasms
FBXO16-mediated hnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer.
Ovarian Neoplasms
FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
Ovarian Neoplasms
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
Ovarian Neoplasms
Fertility preservation in BRCA-mutated women: when and how?
Ovarian Neoplasms
Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations.
Ovarian Neoplasms
Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
Ovarian Neoplasms
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
Ovarian Neoplasms
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
Ovarian Neoplasms
First recurrent large genomic rearrangement in the BRCA1 gene found in Poland.
Ovarian Neoplasms
FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.
Ovarian Neoplasms
Five families living with hereditary breast and ovarian cancer risk.
Ovarian Neoplasms
Five Italian Families with Two Mutations in BRCA Genes.
Ovarian Neoplasms
Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Ovarian Neoplasms
Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.
Ovarian Neoplasms
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Ovarian Neoplasms
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Ovarian Neoplasms
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Ovarian Neoplasms
Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
Ovarian Neoplasms
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
Ovarian Neoplasms
Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.
Ovarian Neoplasms
Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome.
Ovarian Neoplasms
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Ovarian Neoplasms
Founder mutations in BRCA1 and BRCA2 genes.
Ovarian Neoplasms
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Ovarian Neoplasms
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Ovarian Neoplasms
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Ovarian Neoplasms
Frequencies of single-nucleotide polymorphisms and mutations in the BRCA1 gene in patients with hereditary breast or ovarian cancer.
Ovarian Neoplasms
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Ovarian Neoplasms
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Ovarian Neoplasms
Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Ovarian Neoplasms
Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing.
Ovarian Neoplasms
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
Ovarian Neoplasms
Frequency of BRCA1 dysfunction in ovarian cancer.
Ovarian Neoplasms
Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
Ovarian Neoplasms
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Ovarian Neoplasms
Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.
Ovarian Neoplasms
Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Ovarian Neoplasms
Frequency of Rearrangements Versus Small Indels Mutations in BRCA1 and BRCA2 Genes in Turkish Patients with High Risk Breast and Ovarian Cancer.
Ovarian Neoplasms
Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Ovarian Neoplasms
Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls.
Ovarian Neoplasms
Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland.
Ovarian Neoplasms
Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report).
Ovarian Neoplasms
Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers.
Ovarian Neoplasms
Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia.
Ovarian Neoplasms
From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair.
Ovarian Neoplasms
Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.
Ovarian Neoplasms
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
Ovarian Neoplasms
Functional Analysis of Familial Asp67Glu and Thr1051Ser BRCA1 Mutations in Breast/Ovarian Carcinogenesis.
Ovarian Neoplasms
Functional and structural analysis of C-terminal BRCA1 missense variants.
Ovarian Neoplasms
Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Ovarian Neoplasms
Functional assessment of intrinsic disorder central domains of BRCA1.
Ovarian Neoplasms
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
Ovarian Neoplasms
Functional characterization of BRCA1 and BRCA2: clues from their interacting proteins.
Ovarian Neoplasms
Functional coding and non-coding variants in human BRCA1 gene and their use in genetic screening.
Ovarian Neoplasms
Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development.
Ovarian Neoplasms
Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
Ovarian Neoplasms
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Ovarian Neoplasms
Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer.
Ovarian Neoplasms
Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development.
Ovarian Neoplasms
Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
Ovarian Neoplasms
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Ovarian Neoplasms
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
Ovarian Neoplasms
Gene expression and prognostic significance in ovarian cancer.
Ovarian Neoplasms
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Ovarian Neoplasms
Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures.
Ovarian Neoplasms
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2.
Ovarian Neoplasms
Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.
Ovarian Neoplasms
Gene therapy for breast and ovarian cancer with BRCA1.
Ovarian Neoplasms
Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.
Ovarian Neoplasms
Generation and analysis of Brca1 conditional knockout mice.
Ovarian Neoplasms
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Ovarian Neoplasms
Genetic alterations in hereditary breast cancer.
Ovarian Neoplasms
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Ovarian Neoplasms
Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
Ovarian Neoplasms
Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic.
Ovarian Neoplasms
Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.
Ovarian Neoplasms
Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today?
Ovarian Neoplasms
Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
Ovarian Neoplasms
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
Ovarian Neoplasms
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Ovarian Neoplasms
Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women.
Ovarian Neoplasms
Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Ovarian Neoplasms
Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Ovarian Neoplasms
Genetic profiles distinguish different types of hereditary ovarian cancer.
Ovarian Neoplasms
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
Ovarian Neoplasms
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Ovarian Neoplasms
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Ovarian Neoplasms
Genetic susceptibility to breast cancer.
Ovarian Neoplasms
Genetic testing and familial implications in breast-ovarian cancer families.
Ovarian Neoplasms
Genetic testing and first presymptomatic diagnosis in Moroccan families at high risk for breast/ovarian cancer.
Ovarian Neoplasms
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Ovarian Neoplasms
Genetic testing by cancer site: ovary.
Ovarian Neoplasms
Genetic testing by cancer site: stomach.
Ovarian Neoplasms
Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
Ovarian Neoplasms
Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.
Ovarian Neoplasms
Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.
Ovarian Neoplasms
Genetic testing for breast cancer predisposition.
Ovarian Neoplasms
Genetic testing for RAD51C mutations: in the clinic and community.
Ovarian Neoplasms
Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
Ovarian Neoplasms
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Ovarian Neoplasms
Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
Ovarian Neoplasms
Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.
Ovarian Neoplasms
Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer.
Ovarian Neoplasms
Genetic Variants in the 3'UTR of BRCA1 and BRCA2 Genes and their Putative Effects on the microRNA Mechanism in Hereditary Breast and Ovarian Cancer.
Ovarian Neoplasms
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Genetic variation of the brca1 and brca2 genes in macedonian patients.
Ovarian Neoplasms
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Ovarian Neoplasms
Genetics and ovarian carcinoma.
Ovarian Neoplasms
Genetics and the management of women at high risk for breast cancer.
Ovarian Neoplasms
Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status.
Ovarian Neoplasms
Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation.
Ovarian Neoplasms
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
Ovarian Neoplasms
Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
Ovarian Neoplasms
Genome-wide methylation profiles in monozygotic twins with discordance for ovarian carcinoma.
Ovarian Neoplasms
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Ovarian Neoplasms
Genomic rearrangements in the BRCA1 and BRCA2 genes.
Ovarian Neoplasms
Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.
Ovarian Neoplasms
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
Ovarian Neoplasms
Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome.
Ovarian Neoplasms
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed.
Ovarian Neoplasms
Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
Ovarian Neoplasms
Germ line mutations associated with breast cancer susceptibility.
Ovarian Neoplasms
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Ovarian Neoplasms
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Ovarian Neoplasms
Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
Ovarian Neoplasms
German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
Ovarian Neoplasms
Germline BRCA1 alterations in a population-based series of ovarian cancer cases.
Ovarian Neoplasms
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy.
Ovarian Neoplasms
Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Ovarian Neoplasms
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Ovarian Neoplasms
Germline BRCA1 mutations in patients from 84 families with breast and/or ovarian cancers in northern France.
Ovarian Neoplasms
Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Ovarian Neoplasms
Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
Ovarian Neoplasms
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Ovarian Neoplasms
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Ovarian Neoplasms
Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
Ovarian Neoplasms
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Ovarian Neoplasms
Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population.
Ovarian Neoplasms
Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.
Ovarian Neoplasms
Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.
Ovarian Neoplasms
Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
Ovarian Neoplasms
Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations.
Ovarian Neoplasms
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Ovarian Neoplasms
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Ovarian Neoplasms
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Ovarian Neoplasms
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.
Ovarian Neoplasms
Germline pathogenic variants identified in women with ovarian tumors.
Ovarian Neoplasms
Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
Ovarian Neoplasms
Germline testing for homologous recombination repair genes-opportunities and challenges.
Ovarian Neoplasms
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Ovarian Neoplasms
Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
Ovarian Neoplasms
Ginkgo may prevent genetic-associated ovarian cancer risk: multiple biomarkers and anticancer pathways induced by ginkgolide B in BRCA1-mutant ovarian epithelial cells.
Ovarian Neoplasms
Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.
Ovarian Neoplasms
Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
Ovarian Neoplasms
Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Ovarian Neoplasms
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
Ovarian Neoplasms
Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
Ovarian Neoplasms
Growth retardation and tumour inhibition by BRCA1.
Ovarian Neoplasms
Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice.
Ovarian Neoplasms
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Ovarian Neoplasms
Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Ovarian Neoplasms
Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Ovarian Neoplasms
Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion.
Ovarian Neoplasms
Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer.
Ovarian Neoplasms
Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.
Ovarian Neoplasms
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
Ovarian Neoplasms
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.
Ovarian Neoplasms
Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
Ovarian Neoplasms
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Ovarian Neoplasms
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Ovarian Neoplasms
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Ovarian Neoplasms
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.
Ovarian Neoplasms
Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
Ovarian Neoplasms
Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Ovarian Neoplasms
Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
Ovarian Neoplasms
Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
Ovarian Neoplasms
Hereditary breast and ovarian cancer: new genes in confined pathways.
Ovarian Neoplasms
Hereditary breast cancer and handling of patients at risk.
Ovarian Neoplasms
Hereditary breast cancer: a review.
Ovarian Neoplasms
Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Ovarian Neoplasms
Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Ovarian Neoplasms
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Ovarian Neoplasms
Hereditary breast-ovarian cancer: clinical findings and medical management.
Ovarian Neoplasms
Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis.
Ovarian Neoplasms
Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.
Ovarian Neoplasms
Hereditary common cancers: molecular and clinical genetics.
Ovarian Neoplasms
Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.
Ovarian Neoplasms
Hereditary gynaecological malignancies: advances in screening and treatment.
Ovarian Neoplasms
Hereditary non-BRCA gynaecological tumors.
Ovarian Neoplasms
Hereditary Ovarian Cancer and Risk Reduction.
Ovarian Neoplasms
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NF?B activation in the tumor stroma.
Ovarian Neoplasms
Hereditary ovarian cancer in Ashkenazi Jews.
Ovarian Neoplasms
Hereditary ovarian cancer in Poland.
Ovarian Neoplasms
Hereditary ovarian cancer.
Ovarian Neoplasms
Hereditary ovarian cancer: molecular genetics and clinical implications.
Ovarian Neoplasms
Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
Ovarian Neoplasms
Hereditary ovarian carcinoma.
Ovarian Neoplasms
Hereditary predisposition to breast cancer.
Ovarian Neoplasms
Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Ovarian Neoplasms
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Ovarian Neoplasms
Hereditary risk of women's cancers.
Ovarian Neoplasms
Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Ovarian Neoplasms
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
Ovarian Neoplasms
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Ovarian Neoplasms
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Ovarian Neoplasms
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer.
Ovarian Neoplasms
High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history.
Ovarian Neoplasms
High frequency of BRCA1 and BRCA2 mutations in Ashkenazi Jewish ovarian cancer patients.
Ovarian Neoplasms
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.
Ovarian Neoplasms
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population.
Ovarian Neoplasms
High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
Ovarian Neoplasms
High grade serous ovarian carcinomas originate in the fallopian tube.
Ovarian Neoplasms
High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families.
Ovarian Neoplasms
High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer.
Ovarian Neoplasms
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
Ovarian Neoplasms
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.
Ovarian Neoplasms
High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing.
Ovarian Neoplasms
High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Ovarian Neoplasms
High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
Ovarian Neoplasms
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Ovarian Neoplasms
High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
Ovarian Neoplasms
High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Ovarian Neoplasms
Highlight: BRCA1 and BRCA2 proteins in breast cancer.
Ovarian Neoplasms
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Ovarian Neoplasms
Histopathology of BRCA1- and BRCA2-associated breast cancer.
Ovarian Neoplasms
Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Ovarian Neoplasms
HMGA2 and high-grade serous ovarian carcinoma.
Ovarian Neoplasms
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Ovarian Neoplasms
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
Ovarian Neoplasms
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Ovarian Neoplasms
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Ovarian Neoplasms
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Ovarian Neoplasms
How do real tumors become resistant to cisplatin?
Ovarian Neoplasms
How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.
Ovarian Neoplasms
HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
Ovarian Neoplasms
HTLV-1 Tax oncoprotein inhibits the estrogen-induced-ER ?-Mediated BRCA1 expression by interaction with CBP/p300 cofactors.
Ovarian Neoplasms
Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing.
Ovarian Neoplasms
Human disorders of ubiquitination and proteasomal degradation.
Ovarian Neoplasms
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.
Ovarian Neoplasms
Human ovarian cancer of the surface epithelium.
Ovarian Neoplasms
Human VAT-1: a calcium-regulated activation marker of human epithelial cells.
Ovarian Neoplasms
Human, canine and murine BRCA1 genes: sequence comparison among species.
Ovarian Neoplasms
Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
Ovarian Neoplasms
Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma.
Ovarian Neoplasms
Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
Ovarian Neoplasms
Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes.
Ovarian Neoplasms
Identification and management of inherited cancer susceptibility.
Ovarian Neoplasms
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.
Ovarian Neoplasms
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Ovarian Neoplasms
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family.
Ovarian Neoplasms
Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families.
Ovarian Neoplasms
Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability.
Ovarian Neoplasms
Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.
Ovarian Neoplasms
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
Ovarian Neoplasms
Identification of a functional nuclear export sequence in BRCA1.
Ovarian Neoplasms
Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
Ovarian Neoplasms
Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer.
Ovarian Neoplasms
Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls.
Ovarian Neoplasms
Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families.
Ovarian Neoplasms
Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Ovarian Neoplasms
Identification of a Splice Variant (c.5074+3A>C) of BRCA1 by RNA Sequencing and TOPO Cloning.
Ovarian Neoplasms
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Ovarian Neoplasms
Identification of BRCA1 and BRCA2 carriers by allele-specific gene expression (AGE) analysis.
Ovarian Neoplasms
Identification of BRCA1-deficient ovarian cancers.
Ovarian Neoplasms
Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology.
Ovarian Neoplasms
Identification of DBC1 as a transcriptional repressor for BRCA1.
Ovarian Neoplasms
Identification of DNA Repair Pathways that Affect the Survival of Ovarian Cancer Cells Treated with a PARP Inhibitor in a Novel Drug Combination.
Ovarian Neoplasms
Identification of Domains of BRCA1 Critical for the Ubiquitin-Dependent Inhibition of Centrosome Function.
Ovarian Neoplasms
Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.
Ovarian Neoplasms
Identification of filamin A as a BRCA1-interacting protein required for efficient DNA repair.
Ovarian Neoplasms
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
Ovarian Neoplasms
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Ovarian Neoplasms
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.
Ovarian Neoplasms
Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer.
Ovarian Neoplasms
Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues.
Ovarian Neoplasms
Identification of phosphorylation sites on the E3 ubiquitin ligase UBR5/EDD.
Ovarian Neoplasms
Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients.
Ovarian Neoplasms
Identification of residues required for the interaction of BARD1 with BRCA1.
Ovarian Neoplasms
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Ovarian Neoplasms
Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
Ovarian Neoplasms
Identifying and managing hereditary risk of breast and ovarian cancer.
Ovarian Neoplasms
Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Ovarian Neoplasms
Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
Ovarian Neoplasms
IGF-1 and BRCA1 signalling pathways in familial cancer.
Ovarian Neoplasms
Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
Ovarian Neoplasms
Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel.
Ovarian Neoplasms
Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families.
Ovarian Neoplasms
Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family.
Ovarian Neoplasms
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Ovarian Neoplasms
Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
Ovarian Neoplasms
Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
Ovarian Neoplasms
Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Ovarian Neoplasms
Impact of BRCA mutations on female fertility and offspring sex ratio.
Ovarian Neoplasms
Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Ovarian Neoplasms
Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage.
Ovarian Neoplasms
Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Ovarian Neoplasms
Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
Ovarian Neoplasms
Implication of BRCA1 gene in breast cancer.
Ovarian Neoplasms
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
Ovarian Neoplasms
Implications of the age range in a population-based BRCA1 testing program with eligibility based on family history of breast and ovarian cancer.
Ovarian Neoplasms
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Ovarian Neoplasms
Improved survival in BRCA2 carriers with ovarian cancer.
Ovarian Neoplasms
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
Ovarian Neoplasms
In search of the tumour-suppressor functions of BRCA1 and BRCA2.
Ovarian Neoplasms
In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
Ovarian Neoplasms
In-frame deletions of BRCA1 may define critical functional domains.
Ovarian Neoplasms
Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers.
Ovarian Neoplasms
Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Ovarian Neoplasms
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Ovarian Neoplasms
Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Ovarian Neoplasms
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.
Ovarian Neoplasms
Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
Ovarian Neoplasms
Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.
Ovarian Neoplasms
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Ovarian Neoplasms
Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Ovarian Neoplasms
Incorporating medical interventions into carrier probability estimation for genetic counseling.
Ovarian Neoplasms
Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Ovarian Neoplasms
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Increased incidence of brain metastases in BRCA1-related ovarian cancers.
Ovarian Neoplasms
Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers.
Ovarian Neoplasms
Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation.
Ovarian Neoplasms
Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study.
Ovarian Neoplasms
Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Ovarian Neoplasms
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Ovarian Neoplasms
Induction of apoptosis by the tumor suppressor protein BRCA1.
Ovarian Neoplasms
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
Ovarian Neoplasms
Inefficacité du dépistage des cancers tubo-ovariens dans les situations de risque héréditaire de cancer de l'ovaire ; l'expérience du Centre Oscar-Lambret.
Ovarian Neoplasms
Influence of estrogen and variations at the BRCA1 promoter region on transcription and translation.
Ovarian Neoplasms
Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Ovarian Neoplasms
Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
Ovarian Neoplasms
Informed consent documents for BRCA1 and BRCA2 screening: how large is the readability gap?
Ovarian Neoplasms
Inherited breast and ovarian cancer.
Ovarian Neoplasms
Inherited breast cancer.
Ovarian Neoplasms
Inherited genetic susceptibility to breast cancer.
Ovarian Neoplasms
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Ovarian Neoplasms
Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk.
Ovarian Neoplasms
Inherited predisposition to breast cancer among African American women.
Ovarian Neoplasms
Inherited susceptibility to breast and ovarian cancer.
Ovarian Neoplasms
Inherited susceptibility to breast cancer.
Ovarian Neoplasms
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Ovarian Neoplasms
Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells.
Ovarian Neoplasms
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ovarian Neoplasms
Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
Ovarian Neoplasms
Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa).
Ovarian Neoplasms
Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.
Ovarian Neoplasms
Integrated genomic analyses of ovarian carcinoma.
Ovarian Neoplasms
Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
Ovarian Neoplasms
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
Ovarian Neoplasms
Interaction of E3 Ubiquitin Ligase MARCH7 with Long Noncoding RNA MALAT1 and Autophagy-Related Protein ATG7 Promotes Autophagy and Invasion in Ovarian Cancer.
Ovarian Neoplasms
Interferon-? signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer.
Ovarian Neoplasms
International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition : Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer.
Ovarian Neoplasms
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Ovarian Neoplasms
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
Ovarian Neoplasms
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Ovarian Neoplasms
Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population.
Ovarian Neoplasms
Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
Ovarian Neoplasms
Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
Ovarian Neoplasms
Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore.
Ovarian Neoplasms
Is hereditary site-specific ovarian cancer a distinct genetic condition?
Ovarian Neoplasms
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Ovarian Neoplasms
Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?
Ovarian Neoplasms
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Ovarian Neoplasms
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Ovarian Neoplasms
Isolation and characterisation of the NBR2 gene which lies head to head with the human BRCA1 gene.
Ovarian Neoplasms
Isolation of tetranucleotide repeat polymorphisms flanking the BRCA1 gene.
Ovarian Neoplasms
Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse chromosome 11.
Ovarian Neoplasms
Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
Ovarian Neoplasms
It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.
Ovarian Neoplasms
Keeping it simple: genetics referrals for all invasive serous ovarian cancers.
Ovarian Neoplasms
Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
Ovarian Neoplasms
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Ovarian Neoplasms
Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
Ovarian Neoplasms
Laboratory determination of hereditary susceptibility to breast and ovarian cancer.
Ovarian Neoplasms
Laboratory Verification of a BRCA1 and BRCA2 Massively Parallel Sequencing Assay from Wet Bench to Bioinformatics for Germline DNA Analysis.
Ovarian Neoplasms
Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
Ovarian Neoplasms
Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si?SA?B1 in ovarian cancer.
Ovarian Neoplasms
Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies.
Ovarian Neoplasms
Laparoscopic Salpingo-oophorectomy in Conscious Sedation.
Ovarian Neoplasms
Laparoscopic total fallopian tube removal at the time of bilateral salpingo-oophorectomy in BRCA2 positive women.
Ovarian Neoplasms
Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Ovarian Neoplasms
Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.
Ovarian Neoplasms
Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families.
Ovarian Neoplasms
Large genomic deletions inactivate the BRCA2 gene in breast cancer families.
Ovarian Neoplasms
Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland.
Ovarian Neoplasms
Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features.
Ovarian Neoplasms
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Ovarian Neoplasms
Large Genomic Rearrangements of BRCA1 and BRCA2 among Patients Referred for Genetic Analysis in Galicia (NW Spain): Delimitation and Mechanism of Three Novel BRCA1 Rearrangements.
Ovarian Neoplasms
Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation.
Ovarian Neoplasms
Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Ovarian Neoplasms
Leveraging DNA repair deficiency in gynecologic oncology.
Ovarian Neoplasms
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.
Ovarian Neoplasms
Linkage analysis of 26 Canadian breast and breast-ovarian cancer families.
Ovarian Neoplasms
Linking genotoxicity and cytotoxicity with membrane fluidity: A comparative study in ovarian cancer cell lines following exposure to auranofin.
Ovarian Neoplasms
Linking up and interacting with BRCT domains.
Ovarian Neoplasms
Links between genome integrity and BRCA1 tumor suppression.
Ovarian Neoplasms
Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
Ovarian Neoplasms
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Ovarian Neoplasms
Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM.
Ovarian Neoplasms
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
Ovarian Neoplasms
Localization of BRCA1 and a splice variant identifies the nuclear localization signal.
Ovarian Neoplasms
Localization of BRCA1 gene expression in adult cynomolgus monkey tissues.
Ovarian Neoplasms
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Ovarian Neoplasms
Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.
Ovarian Neoplasms
Location of BRCA1 in human breast and ovarian cancer cells.
Ovarian Neoplasms
Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).
Ovarian Neoplasms
Long non-coding RNA GEHT1 promoted the proliferation of ovarian cancer cells via modulating the protein stability of HIF1?.
Ovarian Neoplasms
Long-Range PCR and Next-Generation Sequencing of BRCA1 and BRCA2 in Breast Cancer.
Ovarian Neoplasms
Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
Ovarian Neoplasms
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Ovarian Neoplasms
Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Ovarian Neoplasms
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Ovarian Neoplasms
Loss of BRCA1-A complex function in RAP80 null tumor cells.
Ovarian Neoplasms
Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells.
Ovarian Neoplasms
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Ovarian Neoplasms
Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer.
Ovarian Neoplasms
Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations.
Ovarian Neoplasms
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
Ovarian Neoplasms
Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.
Ovarian Neoplasms
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Ovarian Neoplasms
Low frequency of large genomic rearrangements of BRCA1 and BRCA2 in western Denmark.
Ovarian Neoplasms
Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer.
Ovarian Neoplasms
Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Ovarian Neoplasms
Low prevalence of BRCA1 exon rearrangements in familial and young sporadic breast cancer patients.
Ovarian Neoplasms
Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
Ovarian Neoplasms
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine.
Ovarian Neoplasms
Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective.
Ovarian Neoplasms
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Ovarian Neoplasms
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
Ovarian Neoplasms
Making the best of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ovarian Neoplasms
Mammalian stanniocalcins and cancer.
Ovarian Neoplasms
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Ovarian Neoplasms
Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.
Ovarian Neoplasms
Management Options After Prophylactic Surgeries in Women With BRCA Mutations: A Review.
Ovarian Neoplasms
Management updates for women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
Ovarian Neoplasms
Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase.
Ovarian Neoplasms
Massive Parallel Sequencing for Diagnostic Genetic Testing of BRCA Genes--a Single Center Experience.
Ovarian Neoplasms
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.
Ovarian Neoplasms
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
Ovarian Neoplasms
Mechanism of tandem duplication formation in BRCA1-mutant cells.
Ovarian Neoplasms
Medium-sized deletion in the BRCA1 gene: Limitations of Sanger sequencing and MLPA analyses.
Ovarian Neoplasms
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis.
Ovarian Neoplasms
Meta-analysis of BRCA1 and BRCA2 penetrance.
Ovarian Neoplasms
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Ovarian Neoplasms
Metformin inhibits the growth of ovarian cancer cells by promoting the Parkin-induced p53 ubiquitination.
Ovarian Neoplasms
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Ovarian Neoplasms
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Ovarian Neoplasms
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Ovarian Neoplasms
Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
Ovarian Neoplasms
Methylation profiles of hereditary and sporadic ovarian cancer.
Ovarian Neoplasms
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
Ovarian Neoplasms
Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks.
Ovarian Neoplasms
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
Ovarian Neoplasms
Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol.
Ovarian Neoplasms
Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
Ovarian Neoplasms
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
Ovarian Neoplasms
Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis.
Ovarian Neoplasms
Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks.
Ovarian Neoplasms
miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Ovarian Neoplasms
miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Ovarian Neoplasms
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Ovarian Neoplasms
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Ovarian Neoplasms
Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
Ovarian Neoplasms
Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Ovarian Neoplasms
Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
Ovarian Neoplasms
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Ovarian Neoplasms
Model of transcriptional regulation of the BRCA1-NBR2 bi-directional transcriptional unit.
Ovarian Neoplasms
Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
Ovarian Neoplasms
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
Ovarian Neoplasms
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Ovarian Neoplasms
Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Modifiers of risk of hereditary breast cancer.
Ovarian Neoplasms
Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers.
Ovarian Neoplasms
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Ovarian Neoplasms
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Ovarian Neoplasms
Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
Ovarian Neoplasms
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Ovarian Neoplasms
Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing.
Ovarian Neoplasms
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families.
Ovarian Neoplasms
Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families.
Ovarian Neoplasms
Molecular approaches to diagnosis and management of ovarian cancer.
Ovarian Neoplasms
Molecular aspects of breast cancer resistance to drugs (Review).
Ovarian Neoplasms
Molecular biology of breast cancer.
Ovarian Neoplasms
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Ovarian Neoplasms
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
Ovarian Neoplasms
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Ovarian Neoplasms
Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.
Ovarian Neoplasms
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Ovarian Neoplasms
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India.
Ovarian Neoplasms
Molecular genetics of hereditary ovarian cancer.
Ovarian Neoplasms
Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.
Ovarian Neoplasms
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Ovarian Neoplasms
Molecular modeling of the amino-terminal zinc ring domain of BRCA1.
Ovarian Neoplasms
Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or truncated Brca1 mutant.
Ovarian Neoplasms
Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.
Ovarian Neoplasms
Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?
Ovarian Neoplasms
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Ovarian Neoplasms
Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Ovarian Neoplasms
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Ovarian Neoplasms
Mouse Brca1: localization sequence analysis and identification of evolutionarily conserved domains.
Ovarian Neoplasms
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.
Ovarian Neoplasms
Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis.
Ovarian Neoplasms
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.
Ovarian Neoplasms
Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
Ovarian Neoplasms
Moving towards population-based genetic risk prediction for ovarian cancer.
Ovarian Neoplasms
MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks.
Ovarian Neoplasms
MRI in the early detection of breast cancer in women with high genetic risk.
Ovarian Neoplasms
MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
Ovarian Neoplasms
Much more than a gene: hereditary breast and ovarian cancer, reproductive choices and family life.
Ovarian Neoplasms
MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
Ovarian Neoplasms
Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Ovarian Neoplasms
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Ovarian Neoplasms
Multifunctional transcription factor TFII-I is an activator of BRCA1 function.
Ovarian Neoplasms
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Ovarian Neoplasms
Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO.
Ovarian Neoplasms
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Ovarian Neoplasms
Multiplex ddPCR assay for screening copy number variations in BRCA1 gene.
Ovarian Neoplasms
Murine Brca1: sequence and significance for human missense mutations.
Ovarian Neoplasms
Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families.
Ovarian Neoplasms
Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
Ovarian Neoplasms
Mutation analysis of BRCA1 gene in African-American patients with breast cancer.
Ovarian Neoplasms
Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada.
Ovarian Neoplasms
Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
Ovarian Neoplasms
Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
Ovarian Neoplasms
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation.
Ovarian Neoplasms
Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients.
Ovarian Neoplasms
Mutation analysis of the BRCA1 gene in ovarian cancers.
Ovarian Neoplasms
Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
Ovarian Neoplasms
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Ovarian Neoplasms
Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis.
Ovarian Neoplasms
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Ovarian Neoplasms
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Ovarian Neoplasms
Mutation screening of RAD51C in high-risk breast and ovarian cancer families.
Ovarian Neoplasms
Mutation screening of the BRCA1 gene in Slovak patients.
Ovarian Neoplasms
Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Ovarian Neoplasms
Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Ovarian Neoplasms
Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
Ovarian Neoplasms
Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.
Ovarian Neoplasms
Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer.
Ovarian Neoplasms
Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain).
Ovarian Neoplasms
Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan.
Ovarian Neoplasms
Mutational analysis of the BRCA1 gene in 30 Czech ovarian cancer patients.
Ovarian Neoplasms
Mutational analysis of the estrogen receptor-alpha gene in familial ovarian cancer.
Ovarian Neoplasms
Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Ovarian Neoplasms
Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers.
Ovarian Neoplasms
Mutational spectrum in breast cancer associated
Ovarian Neoplasms
Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Ovarian Neoplasms
Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation.
Ovarian Neoplasms
Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
Ovarian Neoplasms
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.
Ovarian Neoplasms
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Ovarian Neoplasms
Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.
Ovarian Neoplasms
Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.
Ovarian Neoplasms
Mutations of BRCA genes in hereditary breast and ovarian cancer.
Ovarian Neoplasms
MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
Ovarian Neoplasms
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Ovarian Neoplasms
Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic.
Ovarian Neoplasms
Mutations of the BRCA1 gene in human cancer.
Ovarian Neoplasms
Mutations of the BRCA2 gene in ovarian carcinomas.
Ovarian Neoplasms
Mutual exclusivity analysis identifies oncogenic network modules.
Ovarian Neoplasms
Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
Ovarian Neoplasms
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
Ovarian Neoplasms
Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples.
Ovarian Neoplasms
NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube.
Ovarian Neoplasms
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Ovarian Neoplasms
Nesprin-2 mediated nuclear trafficking and its clinical implications.
Ovarian Neoplasms
New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.
Ovarian Neoplasms
New players in the BRCA1-mediated DNA damage responsive pathway.
Ovarian Neoplasms
New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
Ovarian Neoplasms
New sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis in an elderly healthy female population in Croatia.
Ovarian Neoplasms
Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.
Ovarian Neoplasms
Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer.
Ovarian Neoplasms
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
Ovarian Neoplasms
Nicotinamide adenine dinucleotide (NAD) may affect DNA methyltransferase 1 through regulation of BRCA1 in ovarian cancer.
Ovarian Neoplasms
Nine novel conserved motifs in BRCA1 identified by the chicken orthologue.
Ovarian Neoplasms
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
Ovarian Neoplasms
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Ovarian Neoplasms
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
Ovarian Neoplasms
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families.
Ovarian Neoplasms
No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families.
Ovarian Neoplasms
No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
Ovarian Neoplasms
No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers.
Ovarian Neoplasms
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Ovarian Neoplasms
Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition.
Ovarian Neoplasms
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Nongenetic screening of ovarian malignancies.
Ovarian Neoplasms
Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Ovarian Neoplasms
Notification of a family history of breast cancer: issues of privacy and confidentiality.
Ovarian Neoplasms
Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
Ovarian Neoplasms
Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.
Ovarian Neoplasms
Novel Associations between BRCA1 Variants C.181 T>G (Rs28897672) and Ovarian Crisk in Saudi Females.
Ovarian Neoplasms
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Ovarian Neoplasms
Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families.
Ovarian Neoplasms
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Ovarian Neoplasms
Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry.
Ovarian Neoplasms
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Ovarian Neoplasms
Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland.
Ovarian Neoplasms
Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.
Ovarian Neoplasms
Novel complex genomic rearrangement of the BRCA1 gene.
Ovarian Neoplasms
Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
Ovarian Neoplasms
Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Ovarian Neoplasms
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Ovarian Neoplasms
Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
Ovarian Neoplasms
Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Ovarian Neoplasms
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.
Ovarian Neoplasms
Novel mechanism of platinum resistance: Rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ovarian cancer (OC) in BRCA1 germ-line mutation carriers.
Ovarian Neoplasms
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.
Ovarian Neoplasms
Novel pleiotropic BRCA2 pathogenic variants in Lebanese families.
Ovarian Neoplasms
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Ovarian Neoplasms
Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome.
Ovarian Neoplasms
Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?
Ovarian Neoplasms
Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
Ovarian Neoplasms
Occurrence of a non deleterious gene conversion event in the BRCA1 gene.
Ovarian Neoplasms
Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Ovarian Neoplasms
Of mice and (wo)men: genotype-phenotype correlations in BRCA1.
Ovarian Neoplasms
Of microbes and women: BRCA1, vaginal microbiota, and ovarian cancer.
Ovarian Neoplasms
OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Ovarian Neoplasms
Olaparib , PARP1 inhibitor in ovarian cancer.
Ovarian Neoplasms
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Ovarian Neoplasms
Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Ovarian Neoplasms
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Ovarian Neoplasms
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
Ovarian Neoplasms
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
Ovarian Neoplasms
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Ovarian Neoplasms
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Ovarian Neoplasms
Olaparib shows promise in multiple tumor types.
Ovarian Neoplasms
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Ovarian Neoplasms
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
Ovarian Neoplasms
One step direct detection of recurrent mutations in the breast cancer susceptibility gene, BRCA1.
Ovarian Neoplasms
Online tool to guide decisions for BRCA1/2 mutation carriers.
Ovarian Neoplasms
Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy.
Ovarian Neoplasms
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Ovarian Neoplasms
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
Ovarian Neoplasms
Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Ovarian Neoplasms
Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Ovarian Neoplasms
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
Ovarian Neoplasms
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Ovarian Neoplasms
Osmotic and heat stress-dependent regulation of MLK4? and MLK3 by the CHIP E3 ligase in ovarian cancer cells.
Ovarian Neoplasms
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.
Ovarian Neoplasms
Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.
Ovarian Neoplasms
Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation: Correction.
Ovarian Neoplasms
Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
Ovarian Neoplasms
Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.
Ovarian Neoplasms
Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Ovarian Neoplasms
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Ovarian Neoplasms
Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.
Ovarian Neoplasms
Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Ovarian Neoplasms
Ovarian Cancer Gene Therapy with BRCA1-An Overview.
Ovarian Neoplasms
Ovarian cancer genome.
Ovarian Neoplasms
Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.
Ovarian Neoplasms
Ovarian cancer patient with germline mutations in both BRCA1 and NBN genes.
Ovarian Neoplasms
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
Ovarian Neoplasms
Ovarian cancer risk assessment in the era of next-generation sequencing.
Ovarian Neoplasms
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Ovarian Neoplasms
Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.
Ovarian Neoplasms
Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
Ovarian Neoplasms
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors.
Ovarian Neoplasms
Ovarian cancer.
Ovarian Neoplasms
Ovarian cancer: epidemiology, biology, and prognostic factors.
Ovarian Neoplasms
Ovarian cancer: in search of better marker systems based on DNA repair defects.
Ovarian Neoplasms
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Ovarian Neoplasms
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Ovarian Neoplasms
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review).
Ovarian Neoplasms
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Ovarian Neoplasms
Ovarian tumors associated with multiple endocrine neoplasias and related syndromes (Carney complex, Peutz-Jeghers syndrome, von Hippel-Lindau disease, Cowden's disease).
Ovarian Neoplasms
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ovarian Neoplasms
Overestimation of hereditary breast cancer risk.
Ovarian Neoplasms
Overview of history and progress in BRCA1 research: the first BRCA1 decade.
Ovarian Neoplasms
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Paeonol Pretreatment Attenuates Anoxia-Reoxygenation Induced Injury in Cardiac Myocytes via a BRCA1 Dependent Pathway.
Ovarian Neoplasms
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Ovarian Neoplasms
PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Ovarian Neoplasms
Papers to appear in forthcoming issues
Ovarian Neoplasms
Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population.
Ovarian Neoplasms
PARP inhibition and synthetic lethality in ovarian cancer.
Ovarian Neoplasms
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Ovarian Neoplasms
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Ovarian Neoplasms
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
Ovarian Neoplasms
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
Ovarian Neoplasms
PARP inhibitors in the management of breast cancer: current data and future prospects.
Ovarian Neoplasms
PARP inhibitors: A new era of targeted therapy.
Ovarian Neoplasms
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Ovarian Neoplasms
Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
Ovarian Neoplasms
Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Ovarian Neoplasms
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Ovarian Neoplasms
Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
Ovarian Neoplasms
Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene.
Ovarian Neoplasms
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Ovarian Neoplasms
Pathology of Hereditary Breast and Ovarian Cancer.
Ovarian Neoplasms
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Ovarian Neoplasms
Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital.
Ovarian Neoplasms
Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Ovarian Neoplasms
Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations.
Ovarian Neoplasms
Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
Ovarian Neoplasms
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Ovarian Neoplasms
Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
Ovarian Neoplasms
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Ovarian Neoplasms
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.
Ovarian Neoplasms
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Ovarian Neoplasms
Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
Ovarian Neoplasms
Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Ovarian Neoplasms
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Ovarian Neoplasms
Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
Ovarian Neoplasms
Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Ovarian Neoplasms
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Ovarian Neoplasms
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Ovarian Neoplasms
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
Ovarian Neoplasms
PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Pharmaco(epi)genomics in ovarian cancer.
Ovarian Neoplasms
Pharmacoprevention for hereditary breast and ovarian cancer.
Ovarian Neoplasms
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Ovarian Neoplasms
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Ovarian Neoplasms
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Ovarian Neoplasms
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Ovarian Neoplasms
Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation.
Ovarian Neoplasms
Pitfalls and caveats in BRCA sequencing.
Ovarian Neoplasms
Pitfalls in genetic testing: a case of a SNP in primer-annealing region leading to allele dropout in BRCA1.
Ovarian Neoplasms
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Ovarian Neoplasms
Poly (ADP-ribose) polymerase 1 transcriptional regulation: a novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer.
Ovarian Neoplasms
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Ovarian Neoplasms
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Ovarian Neoplasms
Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.
Ovarian Neoplasms
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Ovarian Neoplasms
Population based testing of non-mucinous epithelial ovarian cancer in Scotland.
Ovarian Neoplasms
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Ovarian Neoplasms
Population screening for hereditary and familial cancer syndromes in Valka district of Latvia.
Ovarian Neoplasms
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Ovarian Neoplasms
Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers.
Ovarian Neoplasms
Positional analyses of BRCA1-dependent expression in Saccharomyces cerevisiae.
Ovarian Neoplasms
Positive regulation of the BRCA1 promoter.
Ovarian Neoplasms
Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women.
Ovarian Neoplasms
Practical implementation of frailty models in Mendelian risk prediction.
Ovarian Neoplasms
Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
Ovarian Neoplasms
Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
Ovarian Neoplasms
Pre-counseling education materials for BRCA testing: does tailoring make a difference?
Ovarian Neoplasms
Precious GEMMs: emergence of faithful models for ovarian cancer research.
Ovarian Neoplasms
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Ovarian Neoplasms
Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
Ovarian Neoplasms
Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy.
Ovarian Neoplasms
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Ovarian Neoplasms
Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
Ovarian Neoplasms
Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.
Ovarian Neoplasms
Predictive genetic tests: problems and pitfalls.
Ovarian Neoplasms
Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
Ovarian Neoplasms
Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth.
Ovarian Neoplasms
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Ovarian Neoplasms
Preliminary molecular evidence associating a novel BRCA1 synonymous variant with hereditary ovarian cancer syndrome.
Ovarian Neoplasms
Premature menopause in patients with BRCA1 gene mutation.
Ovarian Neoplasms
Preserving the Self: The Process of Decision Making About Hereditary Breast Cancer and Ovarian Cancer Risk Reduction.
Ovarian Neoplasms
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Ovarian Neoplasms
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Ovarian Neoplasms
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
Ovarian Neoplasms
Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification.
Ovarian Neoplasms
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Ovarian Neoplasms
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Ovarian Neoplasms
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years.
Ovarian Neoplasms
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Ovarian Neoplasms
Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.
Ovarian Neoplasms
Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil.
Ovarian Neoplasms
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
Ovarian Neoplasms
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Ovarian Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
Ovarian Neoplasms
Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
Ovarian Neoplasms
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations.
Ovarian Neoplasms
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Ovarian Neoplasms
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases.
Ovarian Neoplasms
Prevalence of BRCA1/2 germline mutations in 21?401 families with breast and ovarian cancer.
Ovarian Neoplasms
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
Ovarian Neoplasms
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Ovarian Neoplasms
Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
Ovarian Neoplasms
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Ovarian Neoplasms
Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.
Ovarian Neoplasms
Prevalence of the BRCA1 founder mutation c.5266dup in Brazilian individuals at-risk for the Hereditary Breast and Ovarian Cancer Syndrome.
Ovarian Neoplasms
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
Ovarian Neoplasms
Prevalence of two BRCA1 mutations, 5382insC and 300T?>?G, in ovarian cancer patients from Ukraine.
Ovarian Neoplasms
Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Ovarian Neoplasms
Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Preventing ovarian cancer through genetic testing: a population-based study.
Ovarian Neoplasms
Prevention and early detection of ovarian cancer: mission impossible?
Ovarian Neoplasms
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Ovarian Neoplasms
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Ovarian Neoplasms
Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene.
Ovarian Neoplasms
Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation.
Ovarian Neoplasms
Primary structure-based function characterization of BRCT domain replicates in BRCA1.
Ovarian Neoplasms
Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer (HBOC) Genes in Patients Lacking known BRCA Mutations.
Ovarian Neoplasms
Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Ovarian Neoplasms
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Ovarian Neoplasms
Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1.
Ovarian Neoplasms
Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.
Ovarian Neoplasms
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Ovarian Neoplasms
Progesterone Receptor A Stability Is Mediated by Glycogen Synthase Kinase-3? in the Brca1-deficient Mammary Gland.
Ovarian Neoplasms
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Ovarian Neoplasms
Prognosis of probability of BRCA1 and BRCA2 mutations carriage in women with compromised family history of breast and/or ovarian cancer.
Ovarian Neoplasms
Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.
Ovarian Neoplasms
Progress toward isolation of a breast cancer susceptibility gene, BRCA1.
Ovarian Neoplasms
Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
Ovarian Neoplasms
Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines.
Ovarian Neoplasms
Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Ovarian Neoplasms
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Ovarian Neoplasms
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
Ovarian Neoplasms
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Ovarian Neoplasms
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Ovarian Neoplasms
Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients.
Ovarian Neoplasms
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.
Ovarian Neoplasms
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
Ovarian Neoplasms
Prophylactic mastectomy: why and when?
Ovarian Neoplasms
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Ovarian Neoplasms
Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Ovarian Neoplasms
Prostate cancer susceptibility genes: lessons learned and challenges posed.
Ovarian Neoplasms
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Ovarian Neoplasms
Protein stability versus function: effects of destabilizing missense mutations on BRCA1 DNA repair activity.
Ovarian Neoplasms
Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.
Ovarian Neoplasms
Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal.
Ovarian Neoplasms
Psychological responses to BRCA1 mutation testing: preliminary findings.
Ovarian Neoplasms
Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes.
Ovarian Neoplasms
Public health aspects of breast cancer gene testing in Canada. Part 1: risks and interventions.
Ovarian Neoplasms
Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells.
Ovarian Neoplasms
Quantitative Analysis of ?-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Quantitative proteomic identification of the BRCA1 ubiquitination substrates.
Ovarian Neoplasms
Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population.
Ovarian Neoplasms
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Ovarian Neoplasms
RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Ovarian Neoplasms
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Ovarian Neoplasms
RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage.
Ovarian Neoplasms
Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples.
Ovarian Neoplasms
Rapid detection of BRCA1 mutations by the protein truncation test.
Ovarian Neoplasms
Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.
Ovarian Neoplasms
Rapid detection of copy number variations and point mutations in BRCA1/2 genes using a single workflow by ion semiconductor sequencing pipeline.
Ovarian Neoplasms
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group.
Ovarian Neoplasms
Rapid evolution of BRCA1 and BRCA2 in humans and other primates.
Ovarian Neoplasms
Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80.
Ovarian Neoplasms
Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Ovarian Neoplasms
Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Ovarian Neoplasms
Re: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
Ovarian Neoplasms
Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Ovarian Neoplasms
Reading between the lines: direct-to-consumer advertising of genetic testing in the USA.
Ovarian Neoplasms
Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.
Ovarian Neoplasms
Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
Ovarian Neoplasms
Reappearance from Obscurity: Mammalian Rad52 in Homologous Recombination.
Ovarian Neoplasms
Recent advances in molecular genetics of breast cancer.
Ovarian Neoplasms
Recent developments in ovarian cancer genetics.
Ovarian Neoplasms
Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.
Ovarian Neoplasms
Recent progress in the diagnosis and treatment of ovarian cancer.
Ovarian Neoplasms
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Ovarian Neoplasms
Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee.
Ovarian Neoplasms
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Ovarian Neoplasms
Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population.
Ovarian Neoplasms
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Ovarian Neoplasms
Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Ovarian Neoplasms
Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer.
Ovarian Neoplasms
Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland.
Ovarian Neoplasms
Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
Ovarian Neoplasms
Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
Ovarian Neoplasms
Reduction of BRCA1 expression in sporadic ovarian cancer.
Ovarian Neoplasms
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Ovarian Neoplasms
Refining clinical practice: transforming science research into the art of medicine.
Ovarian Neoplasms
Regulation of angiotensin II type 1 receptor expression in ovarian cancer: a potential role for BRCA1.
Ovarian Neoplasms
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Ovarian Neoplasms
Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
Ovarian Neoplasms
Regulation of BRCA1 by protein degradation.
Ovarian Neoplasms
Regulation of BRCA1 expression by the Rb-E2F pathway.
Ovarian Neoplasms
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Ovarian Neoplasms
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
Ovarian Neoplasms
Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.
Ovarian Neoplasms
Relationship between MUTYH, OGG1 and BRCA1 mutations and mRNA expression in breast and ovarian cancer predisposition.
Ovarian Neoplasms
Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence.
Ovarian Neoplasms
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
Ovarian Neoplasms
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).
Ovarian Neoplasms
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Ovarian Neoplasms
Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells.
Ovarian Neoplasms
RESPONSE: Re: Association Between Nonrandom X-Chromosome Inactivation and BRCA1 Mutation in Germline DNA of Patients With Ovarian Cancer.
Ovarian Neoplasms
Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel.
Ovarian Neoplasms
Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
Ovarian Neoplasms
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Ovarian Neoplasms
Risk assessment and genetic testing for ovarian cancer.
Ovarian Neoplasms
Risk factors and risk reduction of breast and ovarian cancer.
Ovarian Neoplasms
Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Ovarian Neoplasms
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Ovarian Neoplasms
Risk factors for ovarian cancer and early-onset breast cancer in Mongolia.
Ovarian Neoplasms
Risk models for familial ovarian and breast cancer.
Ovarian Neoplasms
Risk modifiers in carriers of BRCA1 mutations.
Ovarian Neoplasms
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Ovarian Neoplasms
Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland).
Ovarian Neoplasms
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Ovarian Neoplasms
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.
Ovarian Neoplasms
Risk of endometrial carcinoma associated with BRCA mutation.
Ovarian Neoplasms
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Ovarian Neoplasms
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study.
Ovarian Neoplasms
Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
Ovarian Neoplasms
Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.
Ovarian Neoplasms
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Ovarian Neoplasms
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Ovarian Neoplasms
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.
Ovarian Neoplasms
Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.
Ovarian Neoplasms
Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.
Ovarian Neoplasms
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
Ovarian Neoplasms
Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment and pathology report.
Ovarian Neoplasms
Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results.
Ovarian Neoplasms
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
Ovarian Neoplasms
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry.
Ovarian Neoplasms
Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
Ovarian Neoplasms
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Ovarian Neoplasms
RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
Ovarian Neoplasms
RNA-based analysis of BRCA1 and BRCA2 gene alterations.
Ovarian Neoplasms
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
Ovarian Neoplasms
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Ovarian Neoplasms
Role for ATM in DNA damage-induced phosphorylation of BRCA1.
Ovarian Neoplasms
Role of Apoptotic Regulators in Human Epithelial Ovarian Cancer.
Ovarian Neoplasms
Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
Ovarian Neoplasms
Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1.
Ovarian Neoplasms
Role of BRCA1 mutation screening in the management of familial ovarian cancer.
Ovarian Neoplasms
Role of genetic polymorphisms and ovarian cancer susceptibility.
Ovarian Neoplasms
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.
Ovarian Neoplasms
Role played by BRCA1 in regulating the cellular response to stress.
Ovarian Neoplasms
Role played by BRCA1 in transcriptional regulation in response to therapy.
Ovarian Neoplasms
Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation.
Ovarian Neoplasms
Roles of BRCA1 and its interacting proteins.
Ovarian Neoplasms
Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience.
Ovarian Neoplasms
Rucaparib Approved for Ovarian Cancer.
Ovarian Neoplasms
Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk.
Ovarian Neoplasms
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Ovarian Neoplasms
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Ovarian Neoplasms
Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Ovarian Neoplasms
Screening for genetic risk of breast cancer.
Ovarian Neoplasms
Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Ovarian Neoplasms
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.
Ovarian Neoplasms
Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method.
Ovarian Neoplasms
Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.
Ovarian Neoplasms
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Ovarian Neoplasms
Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
Ovarian Neoplasms
Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online.
Ovarian Neoplasms
Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers.
Ovarian Neoplasms
Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer.
Ovarian Neoplasms
Screening of the BRCA1 gene in Brazilian patients with breast and/or ovarian cancer via high-resolution melting reaction analysis.
Ovarian Neoplasms
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Ovarian Neoplasms
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Ovarian Neoplasms
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Ovarian Neoplasms
Secondary mutations of BRCA1/2 and drug resistance.
Ovarian Neoplasms
Segregation analysis of epithelial ovarian cancer in Finland.
Ovarian Neoplasms
Segregation analysis of ovarian cancer using diathesis to include other cancers.
Ovarian Neoplasms
Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition.
Ovarian Neoplasms
Selected aspects of genetic counselling for BRCA1 mutation carriers.
Ovarian Neoplasms
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Ovarian Neoplasms
Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
Ovarian Neoplasms
Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Ovarian Neoplasms
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
Ovarian Neoplasms
SEOM clinical guidelines in Hereditary Breast and ovarian cancer.
Ovarian Neoplasms
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Ovarian Neoplasms
Sequence analysis of the rat Brca1 homolog and its promoter region.
Ovarian Neoplasms
Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction.
Ovarian Neoplasms
Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer.
Ovarian Neoplasms
Sequential metal binding by the RING finger domain of BRCA1.
Ovarian Neoplasms
Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Ovarian Neoplasms
Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation.
Ovarian Neoplasms
Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen.
Ovarian Neoplasms
Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
Ovarian Neoplasms
Setting up a breast cancer family history clinic.
Ovarian Neoplasms
Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
Ovarian Neoplasms
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Ovarian Neoplasms
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Ovarian Neoplasms
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.
Ovarian Neoplasms
Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Ovarian Neoplasms
Single gold-bridged nanoprobes for identification of single point DNA mutations.
Ovarian Neoplasms
Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.
Ovarian Neoplasms
Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Ovarian Neoplasms
Single-strand conformation polymorphism analysis by capillary and microchip electrophoresis: a fast, simple method for detection of common mutations in BRCA1 and BRCA2.
Ovarian Neoplasms
Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Ovarian Neoplasms
Small RNA sequencing reveals a comprehensive miRNA signature of BRCA1-associated high-grade serous ovarian cancer.
Ovarian Neoplasms
Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions.
Ovarian Neoplasms
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Ovarian Neoplasms
Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.
Ovarian Neoplasms
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.
Ovarian Neoplasms
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Ovarian Neoplasms
Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer.
Ovarian Neoplasms
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Ovarian Neoplasms
Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.
Ovarian Neoplasms
Spanish family study on hereditary breast and/or ovarian cancer: analysis of the BRCA1 gene.
Ovarian Neoplasms
Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
Ovarian Neoplasms
Specific H-Ras minisatellite alleles in breast cancer susceptibility.
Ovarian Neoplasms
Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Ovarian Neoplasms
Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
Ovarian Neoplasms
Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study.
Ovarian Neoplasms
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.
Ovarian Neoplasms
Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.
Ovarian Neoplasms
Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families.
Ovarian Neoplasms
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Ovarian Neoplasms
Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes.
Ovarian Neoplasms
Spliceogenic analysis of BRCA1 c.439T>C (rs794727800) variant by High Resolution Melting Analysis.
Ovarian Neoplasms
Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.
Ovarian Neoplasms
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Ovarian Neoplasms
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Ovarian Neoplasms
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.
Ovarian Neoplasms
Strong preference of BRCA1 protein to topologically constrained non-B DNA structures.
Ovarian Neoplasms
Structural basis to characterise transactivation domain of BRCA1.
Ovarian Neoplasms
Structural determinants of BRCA1 translational regulation.
Ovarian Neoplasms
Structure activity relationship of plumbagin in BRCA1 related cancer cells.
Ovarian Neoplasms
Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
Ovarian Neoplasms
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Ovarian Neoplasms
Structure of an XRCC1 BRCT domain: a new protein-protein interaction module.
Ovarian Neoplasms
Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
Ovarian Neoplasms
Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Ovarian Neoplasms
Structure-based functional analysis of BRCA1 RING domain variants: Concordance of computational mutagenesis, experimental assay, and clinical data.
Ovarian Neoplasms
Structure-Function Of The Tumor Suppressor BRCA1.
Ovarian Neoplasms
Study of BRCA1 gene in hereditary breast and ovarian cancer.
Ovarian Neoplasms
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Ovarian Neoplasms
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
Ovarian Neoplasms
Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Ovarian Neoplasms
Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
Ovarian Neoplasms
SURF4 maintains stem-like properties via BIRC3 in ovarian cancer cells.
Ovarian Neoplasms
Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.
Ovarian Neoplasms
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Survival in epithelial ovarian cancer patients with prior breast cancer.
Ovarian Neoplasms
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Ovarian Neoplasms
Survival of BRCA1 negative ovarian cancer patients based on family history.
Ovarian Neoplasms
SYK expression level distinguishes control from BRCA1-mutated lymphocytes.
Ovarian Neoplasms
Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.
Ovarian Neoplasms
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Ovarian Neoplasms
Synthetic lethality: exploiting the addiction of cancer to DNA repair.
Ovarian Neoplasms
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Ovarian Neoplasms
Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage.
Ovarian Neoplasms
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
Ovarian Neoplasms
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
Ovarian Neoplasms
Tandem BRCT domains: DNA's Praetorian Guard.
Ovarian Neoplasms
Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Ovarian Neoplasms
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
Ovarian Neoplasms
Targeting DNA repair: the genome as a potential biomarker.
Ovarian Neoplasms
Targeting the DNA repair defect of BRCA tumours.
Ovarian Neoplasms
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
Ovarian Neoplasms
Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Ovarian Neoplasms
Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
Ovarian Neoplasms
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Ovarian Neoplasms
Testing for hereditary breast and ovarian cancer in the southeastern United States.
Ovarian Neoplasms
Testing for Hereditary Risk of Ovarian Cancer.
Ovarian Neoplasms
TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage.
Ovarian Neoplasms
Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
Ovarian Neoplasms
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.
Ovarian Neoplasms
The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon.
Ovarian Neoplasms
The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.
Ovarian Neoplasms
The 3020insC NOD2 gene mutation in patients with ovarian cancer.
Ovarian Neoplasms
The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Ovarian Neoplasms
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Ovarian Neoplasms
The biological effects and clinical implications of BRCA mutations: where do we go from here?
Ovarian Neoplasms
The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
Ovarian Neoplasms
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
Ovarian Neoplasms
The BRCA1 3'-UTR: 5711+421T/T_5711+1286T/T Genotype Is a Possible Breast and Ovarian Cancer Risk Factor.
Ovarian Neoplasms
The BRCA1 and BRCA2 breast cancer genes.
Ovarian Neoplasms
The Brca1 and Brca2 proteins and tumor pathogenesis.
Ovarian Neoplasms
The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies.
Ovarian Neoplasms
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
Ovarian Neoplasms
The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.
Ovarian Neoplasms
The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements.
Ovarian Neoplasms
The BRCA1 c.788G?>?T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought.
Ovarian Neoplasms
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Ovarian Neoplasms
The BRCA1 S1715N mutation segregates with breast and ovarian cancer in an extended family pedigree.
Ovarian Neoplasms
The BRCA1 Ubiquitin ligase function sets a new trend for remodelling in DNA repair.
Ovarian Neoplasms
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
Ovarian Neoplasms
The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centrosomes.
Ovarian Neoplasms
The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression.
Ovarian Neoplasms
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
Ovarian Neoplasms
The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
Ovarian Neoplasms
The BRCA2 is a histone acetyltransferase.
Ovarian Neoplasms
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
Ovarian Neoplasms
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
Ovarian Neoplasms
The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain.
Ovarian Neoplasms
The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.
Ovarian Neoplasms
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
Ovarian Neoplasms
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Ovarian Neoplasms
The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
Ovarian Neoplasms
The clinical management of BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
Ovarian Neoplasms
The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.
Ovarian Neoplasms
The contribution of BRCA1 and BRCA2 to ovarian cancer.
Ovarian Neoplasms
The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
Ovarian Neoplasms
The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
Ovarian Neoplasms
The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Ovarian Neoplasms
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
Ovarian Neoplasms
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Ovarian Neoplasms
The counseling and management of young healthy BRCA mutation carriers.
Ovarian Neoplasms
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Ovarian Neoplasms
The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families.
Ovarian Neoplasms
The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues.
Ovarian Neoplasms
The DNA damaging revolution.
Ovarian Neoplasms
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.
Ovarian Neoplasms
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
Ovarian Neoplasms
The effect of BRCA gene testing on family relationships: A thematic analysis of qualitative interviews.
Ovarian Neoplasms
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Ovarian Neoplasms
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.
Ovarian Neoplasms
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
Ovarian Neoplasms
The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
Ovarian Neoplasms
The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review.
Ovarian Neoplasms
The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
Ovarian Neoplasms
The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.
Ovarian Neoplasms
The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
Ovarian Neoplasms
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Ovarian Neoplasms
The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.
Ovarian Neoplasms
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
Ovarian Neoplasms
The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21.
Ovarian Neoplasms
The genesis and evolution of high-grade serous ovarian cancer.
Ovarian Neoplasms
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.
Ovarian Neoplasms
The genetic prediction of risk for gynecologic cancers.
Ovarian Neoplasms
The genetics of breast and ovarian cancer.
Ovarian Neoplasms
THe genetics of familial breast cancer.
Ovarian Neoplasms
The genetics of inherited breast cancer.
Ovarian Neoplasms
The genetics of ovarian cancer: concepts in testing and counseling.
Ovarian Neoplasms
The History of Patenting Genetic Material.
Ovarian Neoplasms
The HRAS1 minisatellite locus and risk of ovarian cancer.
Ovarian Neoplasms
The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds.
Ovarian Neoplasms
The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
Ovarian Neoplasms
The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
Ovarian Neoplasms
The impact of a prevention effort on the community.
Ovarian Neoplasms
The Impact of an Expanded Genetic Testing Program and Selective Oophorectomy on the Incidence of Ovarian Cancer in West Pomerania.
Ovarian Neoplasms
The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
Ovarian Neoplasms
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.
Ovarian Neoplasms
The influence of psychological distress on use of genetic testing for cancer risk.
Ovarian Neoplasms
The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance?
Ovarian Neoplasms
The K898E germline variant in the PP1-binding motif of BRCA1 causes defects in DNA Repair.
Ovarian Neoplasms
The kin-cohort study for estimating penetrance.
Ovarian Neoplasms
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
Ovarian Neoplasms
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
Ovarian Neoplasms
The molecular basis of ovarian cancer.
Ovarian Neoplasms
The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair.
Ovarian Neoplasms
The murine homolog of the human breast and ovarian cancer susceptibility gene Brca1 maps to mouse chromosome 11D.
Ovarian Neoplasms
The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients.
Ovarian Neoplasms
The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
Ovarian Neoplasms
The novel exon 11 mutation of BRCA1 gene in a high-risk family.
Ovarian Neoplasms
The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.
Ovarian Neoplasms
The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
Ovarian Neoplasms
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Ovarian Neoplasms
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
Ovarian Neoplasms
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
Ovarian Neoplasms
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
Ovarian Neoplasms
The preclinical natural history of serous ovarian cancer: defining the target for early detection.
Ovarian Neoplasms
The predictive value of BRCA1 and BRCA2 mutation testing.
Ovarian Neoplasms
The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Ovarian Neoplasms
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
Ovarian Neoplasms
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
Ovarian Neoplasms
The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.
Ovarian Neoplasms
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Ovarian Neoplasms
The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects.
Ovarian Neoplasms
The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
Ovarian Neoplasms
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
Ovarian Neoplasms
The pros and cons of genetic testing for breast and ovarian cancer risk.
Ovarian Neoplasms
The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability.
Ovarian Neoplasms
The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Ovarian Neoplasms
The RAD52-S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Ovarian Neoplasms
The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil.
Ovarian Neoplasms
The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study.
Ovarian Neoplasms
The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.
Ovarian Neoplasms
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Ovarian Neoplasms
The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
Ovarian Neoplasms
The role of BRCA1 in DNA damage response.
Ovarian Neoplasms
The role of BRCA1 in non-small cell lung cancer.
Ovarian Neoplasms
The role of BRCA1 in the cellular response to chemotherapy.
Ovarian Neoplasms
The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer.
Ovarian Neoplasms
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Ovarian Neoplasms
The role of p53 mutation in BRCA1-associated ovarian cancer.
Ovarian Neoplasms
The role of the BRCA1 tumor suppressor in DNA double-strand break repair.
Ovarian Neoplasms
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
Ovarian Neoplasms
The search for BRCA1.
Ovarian Neoplasms
The search for the familial breast/ovarian cancer gene.
Ovarian Neoplasms
The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
Ovarian Neoplasms
The short estrous cycle of mice may influence the effect of BRCA1 mutations.
Ovarian Neoplasms
The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.
Ovarian Neoplasms
The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.
Ovarian Neoplasms
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.
Ovarian Neoplasms
The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers.
Ovarian Neoplasms
The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients.
Ovarian Neoplasms
The use of ancestral haplotypes in the molecular diagnosis of familial breast cancer.
Ovarian Neoplasms
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women.
Ovarian Neoplasms
The XIST noncoding RNA functions independently of BRCA1 in X inactivation.
Ovarian Neoplasms
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond.
Ovarian Neoplasms
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Ovarian Neoplasms
THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.
Ovarian Neoplasms
Three novel germline BRCA1 mutations in early-onset breast and ovarian cancer families.
Ovarian Neoplasms
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
Ovarian Neoplasms
Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex.
Ovarian Neoplasms
Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Ovarian Neoplasms
Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
Ovarian Neoplasms
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
Ovarian Neoplasms
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Ovarian Neoplasms
Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants.
Ovarian Neoplasms
Towards classification of BRCA1 missense variants using a biophysical approach.
Ovarian Neoplasms
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Ovarian Neoplasms
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
Ovarian Neoplasms
Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
Ovarian Neoplasms
Tracking the dissemination of a culturally targeted brochure to promote awareness of hereditary breast and ovarian cancer among Black women.
Ovarian Neoplasms
Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Ovarian Neoplasms
Transcript identification in the BRCA1 candidate region.
Ovarian Neoplasms
Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter.
Ovarian Neoplasms
Transcriptional autoregulation by BRCA1.
Ovarian Neoplasms
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers.
Ovarian Neoplasms
Translating genomics in cancer care.
Ovarian Neoplasms
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report.
Ovarian Neoplasms
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Ovarian Neoplasms
Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.
Ovarian Neoplasms
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Ovarian Neoplasms
Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
Ovarian Neoplasms
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
Ovarian Neoplasms
Tumor formation in Brca1 conditional mutant mice.
Ovarian Neoplasms
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Ovarian Neoplasms
Tumor suppressor genes and their alterations in breast cancer.
Ovarian Neoplasms
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Ovarian Neoplasms
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Ovarian Neoplasms
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden.
Ovarian Neoplasms
Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom.
Ovarian Neoplasms
Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.
Ovarian Neoplasms
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Ovarian Neoplasms
Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Ovarian Neoplasms
Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Ovarian Neoplasms
Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
Ovarian Neoplasms
Two color hybridization analysis using high density oligonucleotide arrays and energy transfer dyes.
Ovarian Neoplasms
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Ovarian Neoplasms
Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds.
Ovarian Neoplasms
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer.
Ovarian Neoplasms
Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer.
Ovarian Neoplasms
Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.
Ovarian Neoplasms
Ubiquitin and breast cancer.
Ovarian Neoplasms
Ubiquitin pathway and ovarian cancer.
Ovarian Neoplasms
Ubiquitination and proteasome-mediated degradation of BRCA1 and BARD1 during steroidogenesis in human ovarian granulosa cells.
Ovarian Neoplasms
UK BRCA mutation testing in patients with ovarian cancer.
Ovarian Neoplasms
Ultrasensitive electrochemical immunoassay for BRCA1 using BMIM·BF?-coated SBA-15 as labels and functionalized graphene as enhancer.
Ovarian Neoplasms
Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer.
Ovarian Neoplasms
Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.
Ovarian Neoplasms
Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study.
Ovarian Neoplasms
Understanding germ-line mutations in BRCA1.
Ovarian Neoplasms
Understanding the functions of BRCA1 in the DNA-damage response.
Ovarian Neoplasms
Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer.
Ovarian Neoplasms
Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
Ovarian Neoplasms
Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
Ovarian Neoplasms
Unsolved mystery: the role of BRCA1 in DNA end-joining.
Ovarian Neoplasms
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer.
Ovarian Neoplasms
Update on hereditary breast cancer.
Ovarian Neoplasms
upQMPSF, a Method for the Detection of BRCA1 Exon Copy Number Variants.
Ovarian Neoplasms
Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.
Ovarian Neoplasms
Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
Ovarian Neoplasms
Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study.
Ovarian Neoplasms
Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Ovarian Neoplasms
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Ovarian Neoplasms
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
Ovarian Neoplasms
Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Ovarian Neoplasms
Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
Ovarian Neoplasms
Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.
Ovarian Neoplasms
Validity of models for predicting BRCA1 and BRCA2 mutations.
Ovarian Neoplasms
Variation in BRCA1 cancer risks by mutation position.
Ovarian Neoplasms
Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Ovarian Neoplasms
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
Ovarian Neoplasms
VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.
Ovarian Neoplasms
Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers.
Ovarian Neoplasms
What women with ovarian cancer think and know about genetic testing.
Ovarian Neoplasms
When the SWI/SNF complex remodels...the cell cycle.
Ovarian Neoplasms
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
Ovarian Neoplasms
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk: A Perspective.
Ovarian Neoplasms
Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
Ovarian Neoplasms
Women with hereditary breast cancer predispositions should avoid using their smartphones, tablets, and laptops at night.
Ovarian Neoplasms
Women's Decision Making about Risk-Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic Review.
Ovarian Neoplasms
Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
Ovarian Neoplasms
Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
Ovarian Neoplasms
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Ovarian Neoplasms
Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
Ovarian Neoplasms
Yeast cells reveal the misfolding and the cellular mislocalization of the human BRCA1 protein.
Ovarian Neoplasms
Yeast-based assays for detection and characterization of mutations in BRCA1.
Ovarian Neoplasms
Young premenopausal women with breast cancer, especially estrogen receptor negative, are at significantly increased risk for subsequent ovarian cancer.
Ovarian Neoplasms
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
Ovarian Neoplasms
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.
Ovarian Neoplasms
[A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
Ovarian Neoplasms
[A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition].
Ovarian Neoplasms
[A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers]
Ovarian Neoplasms
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
Ovarian Neoplasms
[Analysis of mutation in BRCA1 gene using hybridization with hydrogel microarrays]
Ovarian Neoplasms
[Analysis of mutations in genes BRCA1 and BRCA2 among patients with breast and ovarian cancer in northern Portugal and Galicia]
Ovarian Neoplasms
[Analysis of mutations in the BRCA1 gene in patients with cancer of the breast and/or the ovary in Portugal]
Ovarian Neoplasms
[Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
Ovarian Neoplasms
[BRCA1 and BRCA2 mutations in families studied in the Program of Genetic Counselling in Cancer of the Valencian Community (Spain).]
Ovarian Neoplasms
[BRCA1 and BRCA2 mutations in patients with familial breast cancer]
Ovarian Neoplasms
[BRCA1 and Estrogen Receptor ? Expression Regulation in Breast Cancer Cells].
Ovarian Neoplasms
[Breast and ovarian cancer susceptibility gene product BRCA1]
Ovarian Neoplasms
[Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]
Ovarian Neoplasms
[Breast cancer screening for women with a strong familial risk]
Ovarian Neoplasms
[Breast cancer susceptibility gene BRCA1 of hereditary breast cancer/ ovarian cancer syndrome]
Ovarian Neoplasms
[Characteristics of selected features of hereditary ovarian cancer in carriers of constitutional BRCA1 gene mutation]
Ovarian Neoplasms
[Clinical and molecular diagnosis of inherited breast-ovarian cancer]
Ovarian Neoplasms
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]
Ovarian Neoplasms
[Clinical aspects of familial ovarian cancer - current status and issues in Japan].
Ovarian Neoplasms
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Ovarian Neoplasms
[Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].
Ovarian Neoplasms
[Diagnostics of breast cancer in high-risk women - our own experience].
Ovarian Neoplasms
[Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
Ovarian Neoplasms
[Effect of P13K/AKT signal pathway regulation on expression of XIAP and cIAP2 in ovarian cancer cells].
Ovarian Neoplasms
[Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1]
Ovarian Neoplasms
[Evaluation of prognostic factors in gynecological cancer examined by molecular biological study]
Ovarian Neoplasms
[Familial cancer and oncogenic factors]
Ovarian Neoplasms
[Familial ovarian cancer]
Ovarian Neoplasms
[Genetic analysis of Japanese patients with Fanconi anemia: novel findings].
Ovarian Neoplasms
[Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations].
Ovarian Neoplasms
[Genetic predisposition and ovarian cancer]
Ovarian Neoplasms
[Genetic test and prophylactic treatment in breast cancer families]
Ovarian Neoplasms
[Genetic testing of BRCA1 for familial ovarian cancers]
Ovarian Neoplasms
[Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France]
Ovarian Neoplasms
[Germ-line mutations of the BRCA1 gene in northeastern France]
Ovarian Neoplasms
[Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method]
Ovarian Neoplasms
[Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
Ovarian Neoplasms
[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers]
Ovarian Neoplasms
[Hereditary breast and ovarian cancers].
Ovarian Neoplasms
[Hereditary breast and ovarian cancer].
Ovarian Neoplasms
[Hereditary ovarian cancer. The role of BRCA1 gene dysfunction in response to chemotherapy].
Ovarian Neoplasms
[Hereditary predisposition for the development of breast and ovarian carcinoma]
Ovarian Neoplasms
[Hereditary predispositions to gynaecological cancers]
Ovarian Neoplasms
[Human genes patents: yes or no? Reflections on the ruling of the Supreme Court of the United States].
Ovarian Neoplasms
[Identification and management of hereditary breast-ovarian cancers (2004 update)]
Ovarian Neoplasms
[In cases of familial ovarian cancer, always consider the risk of breast cancer]
Ovarian Neoplasms
[Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer]
Ovarian Neoplasms
[Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives]
Ovarian Neoplasms
[Inherited breast and ovarian cancers]
Ovarian Neoplasms
[Inserm ad hoc committee: Recommendations for the management of women with a genetic risk for developing cancer of the breast and/or the ovary]
Ovarian Neoplasms
[INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer]
Ovarian Neoplasms
[INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer]
Ovarian Neoplasms
[Management of hereditary ovarian cancer].
Ovarian Neoplasms
[Modalities for the functionning of a Care Center for women at high risk for breast and ovarian cancers: The French experience of Tenon Hospital]
Ovarian Neoplasms
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]
Ovarian Neoplasms
[Molecular basis of gynecological oncology--TopBP1 protein and its participation in the transcription process].
Ovarian Neoplasms
[Molecular biology of ovarian cancer]
Ovarian Neoplasms
[Molecular Diagnosis and Treatment of HBOC Syndrome].
Ovarian Neoplasms
[Molecular genetics and clinics of hereditary breast cancer]
Ovarian Neoplasms
[Molecular genetics of hereditary breast carcinoma]
Ovarian Neoplasms
[Molecular pathways of autophagy regulation by BRCA1: Implications in cancer].
Ovarian Neoplasms
[Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer].
Ovarian Neoplasms
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
Ovarian Neoplasms
[Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance]
Ovarian Neoplasms
[No association between MTHFR 677C>T polymorphism and ovarian cancer risk in BRCA1 mutation carriers in Wielkopolska region].
Ovarian Neoplasms
[Oncogenetic consultation for breast cancer]
Ovarian Neoplasms
[Possibilities of examination of familial breast cancers and ovarian cancers. Use of molecular-genetic analysis of the BRCA1 gene and the BRCA2 gene]
Ovarian Neoplasms
[Predictive genetic testing for hereditary breast cancer and hereditary nonpolyposis colorectal cancer]
Ovarian Neoplasms
[Prerequisites for preimplantation genetic diagnosis (PGD in carriers of mutations responsible for hereditary cancers]
Ovarian Neoplasms
[Primary ovarian malignant mixed mesodermal tumor (MMMT) as a second primary tumor in a patient with invasive breast carcinoma--case report].
Ovarian Neoplasms
[Prophylactic surgery of mammary and ovarian carcinoma.]
Ovarian Neoplasms
[Psychological aspects of predictive genetic diagnosis in breast and ovarian carcinoma]
Ovarian Neoplasms
[The coexistence of breast and ovarian cancer in patient with insertion-duplication of 12bp in BRCA1 gene]
Ovarian Neoplasms
[The importance of genetic factors for development of breast cancer]
Ovarian Neoplasms
[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]
Ovarian Neoplasms
[The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Ovarian Neoplasms
[The Population Need in Genetic Tests for Predisposition to Breast Cancer].
Ovarian Neoplasms
[The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009]
Ovarian Neoplasms
[The role of BRCA1 and BRCA2 genes in hereditary breast cancer]
Ovarian Neoplasms
[The search for new candidate genes involved in ovarian cancer pathogenesis by exome sequencing].
Ovarian Neoplasms
[Tumor risk consultation for predisposed women from high risk cancer families]
Paget Disease, Extramammary
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Pancreatic Cyst
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Pancreatic Cyst
Classification, morphology and molecular pathology of premalignant lesions of the pancreas.
Pancreatic Diseases
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
Pancreatic Intraductal Neoplasms
KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
Pancreatic Neoplasms
3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.
Pancreatic Neoplasms
A frameshift mutation in BRCA1 leads to hereditary breast and ovarian cancer in one part of a family and to familial pancreatic cancer in another.
Pancreatic Neoplasms
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Pancreatic Neoplasms
A mutational signature in gastric cancer suggests therapeutic strategies.
Pancreatic Neoplasms
A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
Pancreatic Neoplasms
A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
Pancreatic Neoplasms
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
Pancreatic Neoplasms
AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary.
Pancreatic Neoplasms
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Pancreatic Neoplasms
Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer.
Pancreatic Neoplasms
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
Pancreatic Neoplasms
Application of Multilayer Evidence for Annotation of C-Terminal BRCA2 Variants.
Pancreatic Neoplasms
Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Pancreatic Neoplasms
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.
Pancreatic Neoplasms
Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers.
Pancreatic Neoplasms
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
Pancreatic Neoplasms
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Pancreatic Neoplasms
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Pancreatic Neoplasms
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships.
Pancreatic Neoplasms
BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.
Pancreatic Neoplasms
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Pancreatic Neoplasms
Cancer Incidence in BRCA1 mutation carriers.
Pancreatic Neoplasms
CDK5/FBW7-dependent Ubiquitination and Degradation of EZH2 Inhibits Pancreatic Cancer Cell Migration and Invasion.
Pancreatic Neoplasms
CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR.
Pancreatic Neoplasms
Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review.
Pancreatic Neoplasms
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Pancreatic Neoplasms
Corrigendum: E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Pancreatic Neoplasms
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Pancreatic Neoplasms
Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
Pancreatic Neoplasms
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
Pancreatic Neoplasms
Delineating the effects BRCA1 and BRCA2 loss of heterozygosity in pancreatic cancer progression.
Pancreatic Neoplasms
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation.
Pancreatic Neoplasms
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Pancreatic Neoplasms
E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1.
Pancreatic Neoplasms
E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBP?.
Pancreatic Neoplasms
E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Pancreatic Neoplasms
Epidemiology of pancreatic cancer: an overview.
Pancreatic Neoplasms
Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.
Pancreatic Neoplasms
Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report.
Pancreatic Neoplasms
Familial pancreatic carcinoma in Jews.
Pancreatic Neoplasms
Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations.
Pancreatic Neoplasms
Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes.
Pancreatic Neoplasms
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.
Pancreatic Neoplasms
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
Pancreatic Neoplasms
GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments.
Pancreatic Neoplasms
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Pancreatic Neoplasms
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Pancreatic Neoplasms
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Pancreatic Neoplasms
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Pancreatic Neoplasms
Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Pancreatic Neoplasms
Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice.
Pancreatic Neoplasms
Identification of a Ubiquitination-Related Gene Risk Model for Predicting Survival in Patients With Pancreatic Cancer.
Pancreatic Neoplasms
Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews.
Pancreatic Neoplasms
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Pancreatic Neoplasms
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Pancreatic Neoplasms
Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Pancreatic Neoplasms
Inherited pancreatic cancer syndromes.
Pancreatic Neoplasms
Inherited predisposition to cancer: a historical overview.
Pancreatic Neoplasms
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Pancreatic Neoplasms
Is there any relationship between BRCA1 gene mutation and pancreatic cancer development?
Pancreatic Neoplasms
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.
Pancreatic Neoplasms
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Pancreatic Neoplasms
Lycopene Inhibits Reactive Oxygen Species-Mediated NF-?B Signaling and Induces Apoptosis in Pancreatic Cancer Cells.
Pancreatic Neoplasms
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Pancreatic Neoplasms
Maintenance Rucaparib Controls Some Pancreatic Cancers.
Pancreatic Neoplasms
MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation.
Pancreatic Neoplasms
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Pancreatic Neoplasms
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Pancreatic Neoplasms
Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes.
Pancreatic Neoplasms
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Pancreatic Neoplasms
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Pancreatic Neoplasms
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Pancreatic Neoplasms
NEDD4L downregulates autophagy and cell growth by modulating ULK1 and a glutamine transporter.
Pancreatic Neoplasms
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
Pancreatic Neoplasms
Nucleation capacity and presence of centrioles define a distinct category of centrosome abnormalities that induces multipolar mitoses in cancer cells.
Pancreatic Neoplasms
Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2.
Pancreatic Neoplasms
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer.
Pancreatic Neoplasms
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Pancreatic Neoplasms
PARP-inhibitors in BRCA-associated pancreatic cancer.
Pancreatic Neoplasms
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
Pancreatic Neoplasms
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Pancreatic Neoplasms
Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.
Pancreatic Neoplasms
Predicting the Pathogenic Potential of BRCA1 and BRCA2 Gene Variants Identified in Clinical Genetic Testing.
Pancreatic Neoplasms
Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer.
Pancreatic Neoplasms
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.
Pancreatic Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Pancreatic Neoplasms
Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.
Pancreatic Neoplasms
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Pancreatic Neoplasms
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Pancreatic Neoplasms
Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer.
Pancreatic Neoplasms
Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis.
Pancreatic Neoplasms
RNF13: a novel RING-type ubiquitin ligase over-expressed in pancreatic cancer.
Pancreatic Neoplasms
Role of BRCA1 and BRCA2 mutations in pancreatic cancer.
Pancreatic Neoplasms
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
Pancreatic Neoplasms
SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells.
Pancreatic Neoplasms
SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells.
Pancreatic Neoplasms
SMURF1 amplification promotes invasiveness in pancreatic cancer.
Pancreatic Neoplasms
Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells.
Pancreatic Neoplasms
Talking Genes in Breast and Pancreatic Malignancies.
Pancreatic Neoplasms
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
Pancreatic Neoplasms
Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan.
Pancreatic Neoplasms
The E3 ubiquitin ligase NEDD4 is translationally upregulated and facilitates pancreatic cancer.
Pancreatic Neoplasms
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
Pancreatic Neoplasms
The Prevalence of Founder Mutations Among Individuals from Families with Familial Pancreatic Cancer Syndrome.
Pancreatic Neoplasms
TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer.
Pancreatic Neoplasms
UVC Radiation Induces Downregulation of EGF Receptor via Phosphorylation at Serine 1046/1047 in Human Pancreatic Cancer Cells.
Pancreatitis
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Pancreatitis
Familial pancreatic carcinoma in Jews.
Pancreatitis
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
Pancreatitis
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.
Pancreatitis, Alcoholic
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Pancreatitis, Chronic
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Pancytopenia
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
Papilloma
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Papilloma
Interaction between BRCA1 and human papilloma virus E7: an ontology study.
Papilloma
Nucleolar localization of BRCA1 protein in human breast cancer.
Papilloma
Rapid DNA mutation identification and fingerprinting using base excision sequence scanning.
Papilloma
Repression of BRCA1 through a feedback loop involving p53.
Papilloma
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Papilloma
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
Papilloma
Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP).
Paralysis
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Paralysis
Danhong injection facilitates recovery of post-stroke motion deficit via Parkin-enhanced mitochondrial function.
Paralysis
Does parkin play a role in the peripheral nervous system? A family report.
Paralysis
Parkin polymorphisms in progressive supranuclear palsy.
Paralysis
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
Paralysis
[A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
Paramyxoviridae Infections
Emerging views of mitophagy in immunity and autoimmune diseases.
Paramyxoviridae Infections
Viral strategies for triggering and manipulating mitophagy.
Parasitemia
A Plasmodium yoelii HECT-like E3 ubiquitin ligase regulates parasite growth and virulence.
Parkinson Disease
(Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation.
Parkinson Disease
14-3-3eta is a novel regulator of parkin ubiquitin ligase.
Parkinson Disease
A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress.
Parkinson Disease
A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression.
Parkinson Disease
A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in Parkin.
Parkinson Disease
A consanguineous Turkish family with early-onset Parkinson's disease and an exon 4 parkin deletion.
Parkinson Disease
A disease state mutation unfolds the parkin ubiquitin-like domain.
Parkinson Disease
A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine.
Parkinson Disease
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations.
Parkinson Disease
A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease.
Parkinson Disease
A genetic cluster of early onset Parkinson's disease in a Colombian population.
Parkinson Disease
A LRRK2-Dependent EndophilinA Phosphoswitch Is Critical for Macroautophagy at Presynaptic Terminals.
Parkinson Disease
A meta-analysis of the relationship of the Parkin p.Val380Leu polymorphism to Parkinson's disease.
Parkinson Disease
A multidisciplinary study of patients with early-onset PD with and without parkin mutations.
Parkinson Disease
A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.
Parkinson Disease
A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease.
Parkinson Disease
A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics.
Parkinson Disease
A novel role for parkin in trauma-induced central nervous system secondary injury.
Parkinson Disease
A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
Parkinson Disease
A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling.
Parkinson Disease
A Sensitive and Quantitative mKeima Assay for Mitophagy via FACS.
Parkinson Disease
A specific subset of E2 ubiquitin-conjugating enzymes regulate Parkin activation and mitophagy differently.
Parkinson Disease
A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson's Disease Arising from Parkin Mutations.
Parkinson Disease
A Ubl/ubiquitin switch in the activation of Parkin.
Parkinson Disease
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
Parkinson Disease
Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation.
Parkinson Disease
Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2R1441G mice.
Parkinson Disease
Aberrant proteins expressed in skin fibroblasts of Parkinson's disease patients carrying heterozygous variants of glucocerebrosidase and parkin genes.
Parkinson Disease
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Parkinson Disease
Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration.
Parkinson Disease
Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson's disease-associated GPR37 receptor-dependent.
Parkinson Disease
Advances in GBA-associated Parkinson's disease - Pathology, presentation and therapies.
Parkinson Disease
AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease.
Parkinson Disease
AF-6 Protects Against Dopaminergic Dysfunction and Mitochondrial Abnormalities in Drosophila Models of Parkinson's Disease.
Parkinson Disease
Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites.
Parkinson Disease
Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains.
Parkinson Disease
alpha-Synuclein and parkin: coming together of pieces in puzzle of Parkinson's disease.
Parkinson Disease
Alterations in the common fragile site gene Parkin in ovarian and other cancers.
Parkinson Disease
Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.
Parkinson Disease
Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations.
Parkinson Disease
Altered ?-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
Parkinson Disease
Altered Mitochondrial Respiration and Other Features of Mitochondrial Function in Parkin-Mutant Fibroblasts from Parkinson's Disease Patients.
Parkinson Disease
Alternative mitochondrial quality control mediated by extracellular release.
Parkinson Disease
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
Parkinson Disease
Ambra1: A Parkin-binding protein involved in mitophagy.
Parkinson Disease
AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease.
Parkinson Disease
AMPK/ULK1-mediated phosphorylation of Parkin ACT domain mediates an early step in mitophagy.
Parkinson Disease
An autopsy case of PARK2 due to a homozygous exon 2 deletion of parkin and associated with ?-synucleinopathy.
Parkinson Disease
An essential role for UBE2A/HR6A in learning and memory and mGLUR-dependent long-term depression.
Parkinson Disease
Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson's Disease.
Parkinson Disease
Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
Parkinson Disease
Analysis of neural subtypes reveals selective mitochondrial dysfunction in dopaminergic neurons from parkin mutants.
Parkinson Disease
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease.
Parkinson Disease
Analysis of PArkin Co-Regulated Gene in a Taiwanese-Ethnic Chinese cohort with early-onset Parkinson's disease.
Parkinson Disease
Analysis of the parkin deletion in sporadic and familial Parkinson's disease. Short communication.
Parkinson Disease
Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland.
Parkinson Disease
Are parkin patients particularly suited for deep-brain stimulation?
Parkinson Disease
Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson's disease.
Parkinson Disease
Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk.
Parkinson Disease
Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group.
Parkinson Disease
Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease.
Parkinson Disease
Association studies of Parkinson's disease and parkin polymorphisms.
Parkinson Disease
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.
Parkinson Disease
Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress.
Parkinson Disease
Ataxin-3 and its e3 partners: implications for machado-joseph disease.
Parkinson Disease
ATF4 protects against neuronal death in cellular Parkinson's disease models by maintaining levels of parkin.
Parkinson Disease
Automated Analysis of Fluorescence Colocalization: Application to Mitophagy.
Parkinson Disease
Autophagy and innate immunity: Insights from invertebrate model organisms.
Parkinson Disease
Autophagy in neurodegeneration: New insights underpinning therapy for neurological diseases.
Parkinson Disease
Autoregulation of Parkin activity through its ubiquitin-like domain.
Parkinson Disease
Autosomal recessive mutations in the development of Parkinson's disease.
Parkinson Disease
Autosomal recessive parkinsonism.
Parkinson Disease
Axonemal localization of Chlamydomonas PACRG, a homologue of the human Parkin-coregulated gene product.
Parkinson Disease
Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
Parkinson Disease
BAG5 inhibits parkin and enhances dopaminergic neuron degeneration.
Parkinson Disease
Basal mitophagy is widespread in
Parkinson Disease
Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death.
Parkinson Disease
Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins.
Parkinson Disease
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity.
Parkinson Disease
Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization.
Parkinson Disease
BRCA1 degradation in response to mitochondrial damage in breast cancer cells.
Parkinson Disease
Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations.
Parkinson Disease
Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy.
Parkinson Disease
Bu-Yin-Qian-Zheng Formula Ameliorates MPP+-Induced Mitochondrial Dysfunction in Parkinson's Disease via Parkin.
Parkinson Disease
c-Abl phosphorylates ?-synuclein and regulates its degradation: implication for ?-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
Parkinson Disease
Carnosic acid protects SH-SY5Y cells against 6-hydroxydopamine-induced cell death through upregulation of parkin pathway.
Parkinson Disease
Case-Control Study of the Parkin Gene in Early-Onset Parkinson Disease.
Parkinson Disease
Caspase-1 and caspase-8 cleave and inactivate cellular parkin.
Parkinson Disease
Caspase-mediated parkin cleavage in apoptotic cell death.
Parkinson Disease
Cell type-specific upregulation of Parkin in response to ER stress.
Parkinson Disease
Cellular parkin mutants are soluble under non-stress conditions.
Parkinson Disease
Central Parkin: The evolving role of Parkin in the heart.
Parkinson Disease
Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease.
Parkinson Disease
Characterization of Dopaminergic System in the Striatum of Young Adult Park2
Parkinson Disease
Chemogenomic Profiling of Endogenous PARK2 Expression Using a Genome-Edited Coincidence Reporter.
Parkinson Disease
CHIP is an Essential Determinant of Neuronal Mitochondrial Stress Signaling.
Parkinson Disease
CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.
Parkinson Disease
Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.
Parkinson Disease
Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Parkinson Disease
Cloning and developmental expression of a chick G-protein-coupled receptor SCGPR1.
Parkinson Disease
Cloning and expression analysis of a Parkinson's disease gene, uch-L1, and its promoter in zebrafish.
Parkinson Disease
clueless, a conserved Drosophila gene required for mitochondrial subcellular localization, interacts genetically with parkin.
Parkinson Disease
Co-association of parkin and alpha-synuclein.
Parkinson Disease
Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease.
Parkinson Disease
Combined kinase inhibition modulates parkin inactivation.
Parkinson Disease
Combined Transcriptomic and Proteomic Analysis of Perk Toxicity Pathways.
Parkinson Disease
Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells.
Parkinson Disease
Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons.
Parkinson Disease
Comparative genomics and protein domain graph analyses link ubiquitination and RNA metabolism.
Parkinson Disease
Comparative genomics of the RBR family, including the Parkinson's disease-related gene parkin and the genes of the ariadne subfamily.
Parkinson Disease
Compartmentalized Regulation of Parkin-Mediated Mitochondrial Quality Control in the Drosophila Nervous System In Vivo.
Parkinson Disease
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).
Parkinson Disease
Complex interactions in Parkinson's disease: a two-phased approach.
Parkinson Disease
Complex relationship between Parkin mutations and Parkinson disease.
Parkinson Disease
Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene.
Parkinson Disease
Convergence of Parkin, PINK1, and ?-Synuclein on Stress-induced Mitochondrial Morphological Remodeling.
Parkinson Disease
Corrigendum to "Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations" [Neurobiol. Aging 65 (2018) 206-216].
Parkinson Disease
Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson's Disease.
Parkinson Disease
Critical role of mitochondrial ubiquitination and the OPTN-ATG9A axis in mitophagy.
Parkinson Disease
Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Parkinson Disease
dATF4 regulation of mitochondrial folate-mediated one-carbon metabolism is neuroprotective.
Parkinson Disease
Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease.
Parkinson Disease
Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons.
Parkinson Disease
Defending the mitochondria: The pathways of mitophagy and mitochondrial-derived vesicles.
Parkinson Disease
Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila.
Parkinson Disease
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Parkinson Disease
Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation.
Parkinson Disease
Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease.
Parkinson Disease
Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease.
Parkinson Disease
Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients.
Parkinson Disease
Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha.
Parkinson Disease
Deubiquitinase USP29 Governs MYBBP1A in the Brains of Parkinson's Disease Patients.
Parkinson Disease
Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells.
Parkinson Disease
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.
Parkinson Disease
Differential expression of splice variant and wild-type parkin in sporadic Parkinson's disease.
Parkinson Disease
Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: contribution of automated segmentation neuroimaging method.
Parkinson Disease
Diminution of eIF4E activity suppresses parkin mutant phenotypes.
Parkinson Disease
Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome.
Parkinson Disease
Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy.
Parkinson Disease
Distribution of parkin in the adult rat brain.
Parkinson Disease
Distribution, type, and origin of Parkin mutations: review and case studies.
Parkinson Disease
Diversity in the regulation of autophagy and mitophagy: lessons from Parkinson's disease.
Parkinson Disease
DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease.
Parkinson Disease
DJ-1 mutations in Parkinson's disease.
Parkinson Disease
Does parkin play a role in the peripheral nervous system? A family report.
Parkinson Disease
Dopamine covalently modifies and functionally inactivates parkin.
Parkinson Disease
Dopamine Induces Oscillatory Activities in Human Midbrain Neurons with Parkin Mutations.
Parkinson Disease
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation.
Parkinson Disease
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Parkinson Disease
Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells.
Parkinson Disease
Drosophila CHIP protects against mitochondrial dysfunction by acting downstream of Pink1 in parallel with Parkin.
Parkinson Disease
Drosophila melanogaster Parkin ubiquitinates peanut and septin1 as an E3 ubiquitin-protein ligase.
Parkinson Disease
Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities.
Parkinson Disease
Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress.
Parkinson Disease
Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin.
Parkinson Disease
Drosophila phosphatidylinositol-4 kinase fwd promotes mitochondrial fission and can suppress Pink1/parkin phenotypes.
Parkinson Disease
Drosophila PINK1 and parkin loss-of-function mutants display a range of non-motor Parkinson's disease phenotypes.
Parkinson Disease
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.
Parkinson Disease
Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity.
Parkinson Disease
E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.
Parkinson Disease
Early Dyskinesias in Parkinson's Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?
Parkinson Disease
Early Onset Parkinson's Disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report.
Parkinson Disease
Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family.
Parkinson Disease
Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil.
Parkinson Disease
Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study.
Parkinson Disease
Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients.
Parkinson Disease
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Parkinson Disease
Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum.
Parkinson Disease
Effects of MUL1 and PARKIN on the circadian clock, brain and behaviour in Drosophila Parkinson's disease models.
Parkinson Disease
Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of Parkin E3 ligase activity.
Parkinson Disease
Emerging Role of Protein-Protein Transnitrosylation in Cell Signaling Pathways.
Parkinson Disease
Endosomal Rab cycles regulate Parkin-mediated mitophagy.
Parkinson Disease
Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics.
Parkinson Disease
Enrichment of rare variants in E3 ubiquitin ligase genes in Early onset Parkinson's disease.
Parkinson Disease
ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1.
Parkinson Disease
Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations.
Parkinson Disease
Evaluation of PARKIN gene variants in West Bengal Parkinson's disease patients.
Parkinson Disease
Event-related potential changes due to early-onset Parkinson's disease in parkin (PARK2) gene mutation carriers and non-carriers.
Parkinson Disease
Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease.
Parkinson Disease
Exogenous Alpha-Synuclein Evoked Parkin Downregulation Promotes Mitochondrial Dysfunction in Neuronal Cells. Implications for Parkinson's Disease Pathology.
Parkinson Disease
Exon deletions of parkin gene in patients with Parkinson disease.
Parkinson Disease
Exon dosage analysis of parkin gene in Chinese sporadic Parkinson's disease.
Parkinson Disease
Exon dosage variations in Brazilian patients with Parkinson's disease: Analysis of SNCA, PARKIN, PINK1 and DJ-1 genes.
Parkinson Disease
Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson's disease.
Parkinson Disease
Expression and localization of the Parkin co-regulated gene in mouse CNS suggests a role in ependymal cilia function.
Parkinson Disease
Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease.
Parkinson Disease
Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways.
Parkinson Disease
Extracellular Alpha-Synuclein Oligomers Induce Parkin S-Nitrosylation: Relevance to Sporadic Parkinson's Disease Etiopathology.
Parkinson Disease
Eye movement disorders are different in Parkin-linked and idiopathic early-onset PD.
Parkinson Disease
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.
Parkinson Disease
Familial Parkinson's disease. Alpha-synuclein and parkin.
Parkinson Disease
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.
Parkinson Disease
FBS/BSA media concentration determines CCCP's ability to depolarize mitochondria and activate PINK1-PRKN mitophagy.
Parkinson Disease
Fbxo7 and Pink1 play a reciprocal role in regulating their protein levels.
Parkinson Disease
FBXO7 Y52C polymorphism as a potential protective factor in Parkinson's disease.
Parkinson Disease
Fluorescent Parkin Cell-Based Assay Development for the Screening of Drugs against Parkinson Disease.
Parkinson Disease
Folic Acid Supplementation Ameliorates Oxidative Stress, Metabolic Functions and Developmental Anomalies in a Novel Fly Model of Parkinson's Disease.
Parkinson Disease
Folic acid supplementation rescues anomalies associated with knockdown of parkin in dopaminergic and serotonergic neurons in Drosophila model of Parkinson's disease.
Parkinson Disease
Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease.
Parkinson Disease
Frequency of Heterozygous Parkin (PRKN) Variants and Penetrance of Parkinson's Disease Risk Markers in the Population-Based CHRIS Cohort.
Parkinson Disease
Frequency of heterozygous Parkin mutations in healthy subjects: Need for careful prospective follow-up examination of mutation carriers.
Parkinson Disease
Frequency of parkin mutations in late-onset Parkinson's disease.
Parkinson Disease
Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson's disease.
Parkinson Disease
Functional association of the parkin gene promoter with idiopathic Parkinson's disease.
Parkinson Disease
Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease.
Parkinson Disease
Functional interplay between Parkin and Drp1 in mitochondrial fission and clearance.
Parkinson Disease
Functional parkin promoter polymorphism in Parkinson's disease: new data and meta-analysis.
Parkinson Disease
Functional Pathway Identification With CRISPR/Cas9 Genome-wide Gene Disruption in Human Dopaminergic Neuronal Cells Following Chronic Treatment With Dieldrin.
Parkinson Disease
GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinson's disease in transgenic Parkin Q311X(A) mice.
Parkinson Disease
Gender differences and estrogen effects in parkin null mice.
Parkinson Disease
Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene.
Parkinson Disease
Generation of an induced pluripotent stem cell line (EURACi005-A) from a Parkinson's disease patient carrying a homozygous exon 3 deletion in the PRKNgene.
Parkinson Disease
Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
Parkinson Disease
Generation of R272Q, S156A and K572R RHOT1/Miro1 point mutations in iPSCs from a healthy individual using FACS-assisted CRISPR/Cas9 genome editing.
Parkinson Disease
Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci.
Parkinson Disease
Genetic analysis of Parkin in early onset Parkinson's disease (PD): Novel intron 9 g > a single nucleotide polymorphism and risk of Taiwanese PD.
Parkinson Disease
Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort.
Parkinson Disease
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Parkinson Disease
Genetic predisposition to leprosy: A major gene reveals novel pathways of immunity to Mycobacterium leprae.
Parkinson Disease
Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease.
Parkinson Disease
Genetic screening for mutations in the Nrdp1 gene in Parkinson disease patients in a Chinese population.
Parkinson Disease
Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India.
Parkinson Disease
Genetics and Parkinson's disease.
Parkinson Disease
Genetics of Parkinson's disease - a clinical perspective.
Parkinson Disease
Genetics of Parkinson's disease and parkinsonism.
Parkinson Disease
Genetics of Parkinson's disease.
Parkinson Disease
Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations.
Parkinson Disease
Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy.
Parkinson Disease
Genome-wide screen for modifiers of Parkinson's disease genes in Drosophila.
Parkinson Disease
Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
Parkinson Disease
Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease.
Parkinson Disease
Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/I272) of the parkin gene in sporadic Parkinson's disease.
Parkinson Disease
Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection.
Parkinson Disease
Glutathione s-transferase omega 1 activity is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease.
Parkinson Disease
Gonadal hormones and the control of reactive gliosis.
Parkinson Disease
GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs.
Parkinson Disease
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.
Parkinson Disease
Heparan Sulfate Structure Affects Autophagy, Lifespan, Responses to Oxidative Stress, and Cell Degeneration in Drosophila parkin Mutants.
Parkinson Disease
Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations.
Parkinson Disease
Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease.
Parkinson Disease
Heterozygous mutations in the FGF8, SHH and nodal/transforming growth factor beta pathways do not confer increased dopaminergic neuron vulnerability--a zebrafish study.
Parkinson Disease
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.
Parkinson Disease
Hexokinases link DJ-1 to the PINK1/parkin pathway.
Parkinson Disease
Hidden phenotypes of PINK1/Parkin knockout mice.
Parkinson Disease
High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease.
Parkinson Disease
Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group.
Parkinson Disease
How could Parkin-mediated ubiquitination of mitofusin promote mitophagy?
Parkinson Disease
How do Parkin mutations result in neurodegeneration?
Parkinson Disease
How to predict the risk of Parkinson disease in relatives of parkin mutation carriers: a complex puzzle of age, penetrance, and number of mutated alleles.
Parkinson Disease
HSPA1A-Independent Suppression of PARK2 C289G Protein Aggregation by Human Small Heat Shock Proteins.
Parkinson Disease
Hydrocortisone-induced parkin prevents dopaminergic cell death via CREB pathway in Parkinson's disease model.
Parkinson Disease
Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease.
Parkinson Disease
Identification and distribution of Parkin in rat brain.
Parkinson Disease
Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease.
Parkinson Disease
Identification and validation of control cell lines for accurate parkin dosage analysis.
Parkinson Disease
Identification of brain proteins that interact with 2-methylnorharman. An analog of the parkinsonian-inducing toxin, MPP+.
Parkinson Disease
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
Parkinson Disease
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease.
Parkinson Disease
Immunocytochemical Monitoring of PINK1/Parkin-Mediated Mitophagy in Cultured Cells.
Parkinson Disease
Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients.
Parkinson Disease
Impact of Autosomal Recessive Juvenile Parkinson's Disease Mutations on the Structure and Interactions of the Parkin Ubiquitin-like Domain.
Parkinson Disease
Impact of recent genetic findings in Parkinson's disease.
Parkinson Disease
Impaired in vivo dopamine release in parkin knockout mice.
Parkinson Disease
Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association.
Parkinson Disease
Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.
Parkinson Disease
Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.
Parkinson Disease
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study.
Parkinson Disease
Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1.
Parkinson Disease
Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
Parkinson Disease
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease.
Parkinson Disease
Induction of macroautophagy by overexpression of the Parkinson's disease-associated GPR37 receptor.
Parkinson Disease
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.
Parkinson Disease
Inhibition of dynamin-related protein 1 ameliorates the mitochondrial ultrastructure via PINK1 and Parkin in the mice model of Parkinson's disease.
Parkinson Disease
Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.
Parkinson Disease
Inhibitory PAS domain protein is a substrate of PINK1 and Parkin and mediates cell death in a Parkinson's disease model.
Parkinson Disease
Integrated pathways of parkin control over mitochondrial maintenance - relevance to Parkinson's disease pathogenesis.
Parkinson Disease
Interaction between Parkin and ?-Synuclein in PARK2-Mediated Parkinson's Disease.
Parkinson Disease
Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Parkinson Disease
Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity.
Parkinson Disease
Interaction of ?-synuclein and Parkin in iron toxicity on SH-SY5Y cells: implications in the pathogenesis of Parkinson's disease.
Parkinson Disease
Interplay between Parkin and p53 Governs a Physiological Homeostasis That Is Disrupted in Parkinson's Disease and Cerebral Cancer.
Parkinson Disease
Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice.
Parkinson Disease
Investigation of the Involvement of Parkin in Parkinson's Disease and Cancer by Monitoring the Changes in SH-SY5Y Cells at the Nuclear Proteome Level.
Parkinson Disease
Investigation of the neuroprotective protein parkin - solubility, ligand binding and ubiquitination.
Parkinson Disease
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Parkinson Disease
iPLA2? knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology.
Parkinson Disease
KF-1 Ubiquitin Ligase: An Anxiety Suppressor.
Parkinson Disease
Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families.
Parkinson Disease
Lack of association between p.Ser167Asn variant of Parkin and Parkinson's disease: a meta-analysis of 15 studies involving 2,280 cases and 2,459 controls.
Parkinson Disease
Lack of direct role of parkin in the steady-state level and aggregation of alpha-synuclein and the clearance of pre-formed aggregates.
Parkinson Disease
Lack of evidence for association of a parkin promoter polymorphism with early-onset Parkinson's disease in a Chinese population.
Parkinson Disease
Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease.
Parkinson Disease
Lack of Parkin Anticipates the Phenotype and Affects Mitochondrial Morphology and mtDNA Levels in a Mouse Model of Parkinson's Disease.
Parkinson Disease
Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization.
Parkinson Disease
Language Deficits as a Preclinical Window into Parkinson's Disease: Evidence from Asymptomatic Parkin and Dardarin Mutation Carriers.
Parkinson Disease
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Parkinson Disease
Lessons for Parkinson Disease From the Parkin Genotype.
Parkinson Disease
Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.
Parkinson Disease
Levodopa-responsive dystonia caused by biallelic PRKN exon inversion invisible to exome sequencing.
Parkinson Disease
Lewy bodies and parkinsonism in families with parkin mutations.
Parkinson Disease
Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers.
Parkinson Disease
Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2).
Parkinson Disease
Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families.
Parkinson Disease
Linking a compound-heterozygous Parkin mutant (Q311R and A371T) to Parkinson's disease by using proteomic and molecular approaches.
Parkinson Disease
Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD).
Parkinson Disease
Linking microtubules to Parkinson's disease: the case of parkin.
Parkinson Disease
Lipid profiling of parkin-mutant human skin fibroblasts.
Parkinson Disease
Lipidomic Alterations in the Mitochondria of Aged Parkin Null Mice Relevant to Autophagy.
Parkinson Disease
Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration.
Parkinson Disease
Loss of Microglial Parkin Inhibits Necroptosis and Contributes to Neuroinflammation.
Parkinson Disease
Loss of Parkin Impairs Mitochondrial Function and Leads to Muscle Atrophy.
Parkinson Disease
Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease.
Parkinson Disease
Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation.
Parkinson Disease
Loss of PINK1 impairs stress-induced autophagy and cell survival.
Parkinson Disease
Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease.
Parkinson Disease
Low Risk of Parkinson's Disease in Quasi-Vegan Cultures May Reflect GCN2-Mediated Upregulation of Parkin.
Parkinson Disease
LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Parkinson Disease
LRRK2 gene in Parkinson disease.
Parkinson Disease
LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
Parkinson Disease
LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10.
Parkinson Disease
Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation.
Parkinson Disease
Manganese-induced toxicity in normal and human B lymphocyte cell lines containing a homozygous mutation in parkin.
Parkinson Disease
Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach.
Parkinson Disease
Mdm2 enhances ligase activity of parkin and facilitates mitophagy.
Parkinson Disease
Mechanism of parkin activation by phosphorylation.
Parkinson Disease
Mechanisms of mitophagy.
Parkinson Disease
Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond.
Parkinson Disease
Mechanisms of neuronal homeostasis: autophagy in the axon.
Parkinson Disease
Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network.
Parkinson Disease
Meta-analysis of the influence of Parkin p.Asp394Asn variant on the susceptibility of Parkinson's disease.
Parkinson Disease
Metabolomics-based identification of metabolic alterations in PARK2.
Parkinson Disease
Mice expressing mutant parkin exhibit hallmark features of Parkinson's disease.
Parkinson Disease
Mice lacking the PSD-95-interacting E3 ligase, Dorfin/Rnf19a, display reduced adult neurogenesis, enhanced long-term potentiation, and impaired contextual fear conditioning.
Parkinson Disease
Microarray expression analysis reveals genetic pathways implicated in C621 synphilin-1-mediated toxicity.
Parkinson Disease
Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts.
Parkinson Disease
Microtubule: a common target for parkin and Parkinson's disease toxins.
Parkinson Disease
Midnolin is a novel regulator of parkin expression and is associated with Parkinson's Disease.
Parkinson Disease
miR-103a-3p regulates mitophagy in Parkinson's disease through Parkin/Ambra1 signaling.
Parkinson Disease
miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1).
Parkinson Disease
Mitochondria and neurodegeneration.
Parkinson Disease
Mitochondria get a Parkin' ticket.
Parkinson Disease
Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations.
Parkinson Disease
Mitochondrial Antigen Presentation: A Vacuolar Path to Autoimmunity in Parkinson's Disease.
Parkinson Disease
Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging.
Parkinson Disease
Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin.
Parkinson Disease
Mitochondrial defect and PGC-1? dysfunction in parkin-associated familial Parkinson's disease.
Parkinson Disease
Mitochondrial DNA heteroplasmy rises in substantial nigra of aged PINK1 KO mice.
Parkinson Disease
Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin.
Parkinson Disease
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.
Parkinson Disease
Mitochondrial dysfunction and oxidative damage in parkin-deficient mice.
Parkinson Disease
Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin.
Parkinson Disease
Mitochondrial E3 Ubiquitin Ligase Parkin: Relationships with Other Causal Proteins in Familial Parkinson's Disease and Its Substrate-Involved Mouse Experimental Models.
Parkinson Disease
Mitochondrial impairment observed in fibroblasts from South African Parkinson's disease patients with parkin mutations.
Parkinson Disease
Mitochondrial MsrB2 serves as a switch and transducer for mitophagy.
Parkinson Disease
Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines.
Parkinson Disease
Mitochondrial quality control in neurodegenerative diseases.
Parkinson Disease
Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease.
Parkinson Disease
Mitochondrial Quality Control via the PGC1?-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin.
Parkinson Disease
Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis.
Parkinson Disease
Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy.
Parkinson Disease
Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease.
Parkinson Disease
Mitophagy in degenerative joint diseases.
Parkinson Disease
Mitophagy in neurodegeneration and aging.
Parkinson Disease
Modulation of ARTS and XIAP by Parkin Is Associated with Carnosic Acid Protects SH-SY5Y Cells against 6-Hydroxydopamine-Induced Apoptosis.
Parkinson Disease
Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease.
Parkinson Disease
Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutant.
Parkinson Disease
Molecular docking analysis of phytochemicals from ethanolic extract of crescentia cujete with the auto inhibited parkin catalytic domain.
Parkinson Disease
Molecular dynamics simulations of human E3 ubiquitin ligase Parkin.
Parkinson Disease
Molecular findings in familial Parkinson disease in Spain.
Parkinson Disease
Molecular genetic analysis of the alpha-synuclein and the parkin gene in Parkinson's disease in Finland.
Parkinson Disease
Molecular insights into Parkinson's disease.
Parkinson Disease
Molecular pathogenesis of Parkinson's disease: Identification of mutations in the Parkin gene in Indian patients.
Parkinson Disease
Monitoring Mitochondrial Changes by Alteration of the PINK1-Parkin Signaling in Drosophila.
Parkinson Disease
Monitoring PINK1-Parkin Signaling Using Dopaminergic Neurons from iPS Cells.
Parkinson Disease
Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage.
Parkinson Disease
Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations.
Parkinson Disease
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
Parkinson Disease
MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin.
Parkinson Disease
Multiple antioxidants in the prevention and treatment of Parkinson's disease.
Parkinson Disease
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson's disease.
Parkinson Disease
Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease.
Parkinson Disease
Mutant ataxin-3 promotes the autophagic degradation of parkin.
Parkinson Disease
Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts.
Parkinson Disease
Mutation analysis of parkin and PINK1 genes in early-onset Parkinson's disease in China.
Parkinson Disease
Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families.
Parkinson Disease
Mutation screening and association analysis of the parkin gene in Parkinson's disease patients from South-West China.
Parkinson Disease
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa.
Parkinson Disease
Mutational Impact on "in-Between-Ring" (IBR) Domain of PARKIN on Protein Stability and Function.
Parkinson Disease
Mutational Screening of PARKIN Identified a 3' UTR Variant (rs62637702) Associated with Parkinson's Disease.
Parkinson Disease
Mutational screening of the parkin gene among South Indians with early onset Parkinson's disease.
Parkinson Disease
Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts.
Parkinson Disease
Mutations in the parkin gene are a minor cause of Parkinson's disease in the South African population.
Parkinson Disease
Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations.
Parkinson Disease
N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins.
Parkinson Disease
N-myc regulates parkin expression.
Parkinson Disease
NAC1, A POZ/BTB protein interacts with Parkin and may contribute to Parkinson's disease.
Parkinson Disease
Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
Parkinson Disease
Neddylation positively regulates the ubiquitin E3 ligase activity of parkin.
Parkinson Disease
Neurodegeneration: how does parkin prevent Parkinson's disease?
Parkinson Disease
Neurodegeneration: Impact of S-nitrosylated Parkin, DJ-1 and PINK1 on the pathogenesis of Parkinson's disease.
Parkinson Disease
Neurofilament L gene is not a genetic factor of sporadic and familial Parkinson's disease.
Parkinson Disease
Neuronal Mitophagy: Lessons from a Pathway Linked to Parkinson's Disease.
Parkinson Disease
Neurophysiological evaluation of motor corticospinal pathways by TMS in idiopathic early-onset Parkinson's disease.
Parkinson Disease
Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations.
Parkinson Disease
Neuroproteomics: an insight into ALS.
Parkinson Disease
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
Parkinson Disease
Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons.
Parkinson Disease
Nicotine increases lifespan and rescues olfactory and motor deficits in a Drosophila model of Parkinson's disease.
Parkinson Disease
Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease.
Parkinson Disease
Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
Parkinson Disease
Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An (18)F-dopa PET progression study.
Parkinson Disease
Nitric Oxide Induction of Parkin Translocation in PTEN-Induced Putative Kinase 1 (PINK1) Deficiency: Functional Role of Neuronal Nitric Oxide Synthase During Mitophagy.
Parkinson Disease
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.
Parkinson Disease
NLRP3 Inflammasomes in Parkinson's disease and their Regulation by Parkin.
Parkinson Disease
NMR structure of ubiquitin-like domain in PARKIN: gene product of familial Parkinson's disease.
Parkinson Disease
NO parkin in Parkinson's disease.
Parkinson Disease
Non-motor behavioural impairments in parkin-deficient mice.
Parkinson Disease
Non-motor Symptoms in Parkinson's Disease Patients with Parkin Mutations: More Depression and Less Executive Dysfunction.
Parkinson Disease
Nonmotor symptoms in Parkin gene-related parkinsonism.
Parkinson Disease
Novel compound heterozygous of PARKIN causes early-onset Parkinson's disease.
Parkinson Disease
Novel gene (TMEM230) linked to Parkinson's disease.
Parkinson Disease
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7).
Parkinson Disease
Novel parkin mutations detected in patients with early-onset Parkinson's disease.
Parkinson Disease
Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.
Parkinson Disease
NP7 protects from cell death induced by oxidative stress in neuronal and glial midbrain cultures from parkin null mice.
Parkinson Disease
Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease.
Parkinson Disease
Olfaction in Parkin carriers in Chinese patients with Parkinson disease.
Parkinson Disease
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study.
Parkinson Disease
Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients.
Parkinson Disease
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Parkinson Disease
Overexpression of Buffy enhances the loss of parkin and suppresses the loss of Pink1 phenotypes in Drosophila.
Parkinson Disease
Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans.
Parkinson Disease
p32 regulates mitochondrial morphology and dynamics through parkin.
Parkinson Disease
p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria.
Parkinson Disease
Pael-R is accumulated in Lewy bodies of Parkinson's disease.
Parkinson Disease
PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.
Parkinson Disease
PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
Parkinson Disease
PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons.
Parkinson Disease
Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease.
Parkinson Disease
Parkin absence accelerates microtubule aging in dopaminergic neurons.
Parkinson Disease
Parkin analysis in early onset Parkinson's disease.
Parkinson Disease
Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease.
Parkinson Disease
Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain.
Parkinson Disease
Parkin and defective ubiquitination in Parkinson's disease.
Parkinson Disease
Parkin and Hsp70 sacked by BAG5.
Parkinson Disease
Parkin and mitochondrial quality control: toward assembling the puzzle.
Parkinson Disease
Parkin and Parkinson disease.
Parkinson Disease
Parkin and Parkinson's disease.
Parkinson Disease
Parkin and Parkinson's disease: differentiated by non-dopaminergic dysfunction?
Parkinson Disease
Parkin and PINK1 functions in oxidative stress and neurodegeneration.
Parkinson Disease
Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available case-control cohorts.
Parkinson Disease
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Parkinson Disease
Parkin and synphilin-1 isoform expression changes in Lewy body diseases.
Parkinson Disease
Parkin and the molecular pathways of Parkinson's disease.
Parkinson Disease
Parkin attenuates manganese-induced dopaminergic cell death.
Parkinson Disease
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Parkinson Disease
Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain.
Parkinson Disease
Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases.
Parkinson Disease
Parkin Co-Regulated Gene is involved in aggresome formation and autophagy in response to proteasomal impairment.
Parkinson Disease
Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.
Parkinson Disease
Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration.
Parkinson Disease
Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
Parkinson Disease
Parkin deficiency accentuates chronic alcohol intake-induced tissue injury and autophagy defects in brain, liver and skeletal muscle.
Parkinson Disease
Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
Parkinson Disease
Parkin Deficiency Reduces Hippocampal Glutamatergic Neurotransmission by Impairing AMPA Receptor Endocytosis.
Parkinson Disease
Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases.
Parkinson Disease
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Parkinson Disease
Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in ?-synuclein transgenic mice.
Parkinson Disease
Parkin Disease: A Clinicopathologic Entity?
Parkinson Disease
Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity.
Parkinson Disease
Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.
Parkinson Disease
Parkin dosage mutations in patients with early-onset sporadic and familial Parkinson's disease in Chinese: an independent pathogenic role.
Parkinson Disease
Parkin expression in muscle from three patients with autosomal recessive Parkinson's disease carrying parkin mutation.
Parkinson Disease
Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
Parkinson Disease
Parkin Function in Parkinson Disease.
Parkinson Disease
Parkin function in Parkinson's disease.
Parkinson Disease
Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1.
Parkinson Disease
Parkin gene therapy could treat Parkinson's disease.
Parkinson Disease
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Parkinson Disease
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Parkinson Disease
Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts.
Parkinson Disease
Parkin genetics: one model for Parkinson's disease.
Parkinson Disease
Parkin implicated in sporadic Parkinson's disease.
Parkinson Disease
Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.
Parkinson Disease
Parkin in the regulation of fat uptake and mitochondrial biology: emerging links in the pathophysiology of Parkinson's disease.
Parkinson Disease
PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Parkinson Disease
Parkin inactivation via PARIS (ZNF746) may lead to neurodegeneration in Parkinson's disease.
Parkinson Disease
Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter.
Parkinson Disease
Parkin Induces Upregulation of 40S Ribosomal Protein SA and Posttranslational Modification of Cytokeratins 8 and 18 in Human Cervical Cancer Cells.
Parkinson Disease
Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy.
Parkinson Disease
Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.
Parkinson Disease
Parkin interacts with Ambra1 to induce mitophagy.
Parkinson Disease
Parkin Interacts with Apoptosis-Inducing Factor and Interferes with Its Translocation to the Nucleus in Neuronal Cells.
Parkinson Disease
Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination.
Parkinson Disease
Parkin interacts with the proteasome subunit alpha4.
Parkinson Disease
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.
Parkinson Disease
Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Serine65.
Parkinson Disease
Parkin is an E3 ligase for the ubiquitin-like modifier FAT10, which inhibits Parkin activation and mitophagy.
Parkinson Disease
Parkin is associated with actin filaments in neuronal and nonneural cells.
Parkinson Disease
Parkin Is Dispensable for Mitochondrial Function, but Its Ubiquitin Ligase Activity Is Critical for Macroautophagy and Neurotransmitters: Therapeutic Potential beyond Parkinson's Disease.
Parkinson Disease
Parkin is expressed in vascular endothelial cells.
Parkinson Disease
Parkin is metabolized by the ubiquitin/proteosome system.
Parkinson Disease
Parkin is not regulated by the unfolded protein response in human neuroblastoma cells.
Parkinson Disease
Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.
Parkinson Disease
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy.
Parkinson Disease
Parkin is recruited to the centrosome in response to inhibition of proteasomes.
Parkinson Disease
Parkin is the most common causative gene in a cohort of mainland Chinese patients with sporadic early-onset Parkinson's disease.
Parkinson Disease
Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress.
Parkinson Disease
Parkin is transcriptionally regulated by the aryl hydrocarbon receptor: Impact on ?-synuclein protein levels.
Parkinson Disease
Parkin is ubiquitinated by Nrdp1 and abrogates Nrdp1-induced oxidative stress.
Parkinson Disease
Parkin Knockout Inhibits Neuronal Development via Regulation of Proteasomal Degradation of p21.
Parkinson Disease
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.
Parkinson Disease
Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.
Parkinson Disease
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.
Parkinson Disease
Parkin maintains mitochondrial levels of the protective Parkinson's disease-related enzyme 17-? hydroxysteroid dehydrogenase type 10.
Parkinson Disease
Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling.
Parkinson Disease
Parkin mediates neuroprotection through activation of Notch1 signaling.
Parkinson Disease
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation.
Parkinson Disease
Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.
Parkinson Disease
Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway.
Parkinson Disease
Parkin modulates expression of HIF-1? and HIF-3? during hypoxia in gliobastoma-derived cell lines in vitro.
Parkinson Disease
Parkin mutant in the fly is largely rescued by metal-responsive transcription factor (MTF-1).
Parkinson Disease
Parkin mutation analysis in clinic patients with early-onset Parkinson's disease (Am J Med Genet 129A: 44-50, 2004).
Parkinson Disease
parkin mutation analysis in clinic patients with early-onset Parkinson's disease.
Parkinson Disease
Parkin mutation and deep brain stimulation outcome.
Parkinson Disease
Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease.
Parkinson Disease
Parkin mutation may be associated with serious akinesia in a patient with Parkinson's disease.
Parkinson Disease
Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson's disease.
Parkinson Disease
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.
Parkinson Disease
Parkin mutations in familial and sporadic Parkinson's disease among Indians.
Parkinson Disease
Parkin occurs in a stable, non-covalent, approximately 110-kDa complex in brain.
Parkinson Disease
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
Parkinson Disease
Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.
Parkinson Disease
Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan.
Parkinson Disease
PARKIN overexpression in human mesenchymal stromal cells from Wharton's jelly suppresses 6-hydroxydopamine-induced apoptosis: Potential therapeutic strategy in Parkinson's disease.
Parkinson Disease
Parkin Plays a Role in Sporadic Parkinson's Disease.
Parkinson Disease
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Parkinson Disease
Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease.
Parkinson Disease
Parkin polymorphisms: risk for Parkinson's disease in Indian population.
Parkinson Disease
Parkin potentiates ATP-induced currents due to activation of P2X receptors in PC12 cells.
Parkinson Disease
Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease.
Parkinson Disease
Parkin promotes proteasomal degradation of synaptotagmin IV by accelerating polyubiquitination.
Parkinson Disease
Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1.
Parkinson Disease
Parkin Protects Against Misfolded SOD1 Toxicity by Promoting Its Aggresome Formation and Autophagic Clearance.
Parkinson Disease
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
Parkinson Disease
Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.
Parkinson Disease
Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation.
Parkinson Disease
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair.
Parkinson Disease
Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction.
Parkinson Disease
Parkin recruitment to impaired mitochondria for nonselective ubiquitylation is facilitated by MITOL.
Parkinson Disease
Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase.
Parkinson Disease
Parkin regulates lipopolysaccharide-induced proinflammatory responses in acute lung injury.
Parkinson Disease
Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.
Parkinson Disease
Parkin regulates NF-?B by mediating site-specific ubiquitination of RIPK1.
Parkinson Disease
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Parkinson Disease
Parkin Regulates the Activity of Pyruvate Kinase M2.
Parkinson Disease
Parkin regulates translesion DNA synthesis in response to UV radiation.
Parkinson Disease
Parkin Regulation and Neurodegenerative Disorders.
Parkinson Disease
Parkin represses 6-hydroxydopamine-induced apoptosis via stabilizing scaffold protein p62 in PC12 cells.
Parkinson Disease
Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function.
Parkinson Disease
Parkin Selectively Alters the Intrinsic Threshold for Mitochondrial Cytochrome C Release.
Parkinson Disease
Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl-1.
Parkinson Disease
Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.
Parkinson Disease
Parkin stabilizes microtubules through strong binding mediated by three independent domains.
Parkinson Disease
Parkin stabilizes PINK1 through direct interaction.
Parkinson Disease
Parkin Structure and Function.
Parkinson Disease
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila.
Parkinson Disease
Parkin suppresses the expression of monoamine oxidases.
Parkinson Disease
Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells.
Parkinson Disease
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Parkinson Disease
Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation: IMPLICATION OF DYSREGULATED MITOCHONDRIAL DYNAMICS IN PARKINSON DISEASE.
Parkinson Disease
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Parkinson Disease
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
Parkinson Disease
Parkin uses the UPS to ship off dysfunctional mitochondria.
Parkinson Disease
Parkin variants in North American Parkinson's disease: cases and controls.
Parkinson Disease
Parkin western blotting is useful for identification of patients with Parkin-related Parkinson's disease.
Parkinson Disease
Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson's Disease.
Parkinson Disease
Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease.
Parkinson Disease
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation.
Parkinson Disease
PARKIN, PINK1, and DJ1 analysis in early-onset Parkinson's disease in Ireland.
Parkinson Disease
Parkin-associated Parkinson's disease.
Parkinson Disease
PARKIN-coding polymorphisms are not associated with Parkinson's disease in a population from northeastern Mexico.
Parkinson Disease
Parkin-deficient mice are not a robust model of parkinsonism.
Parkinson Disease
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.
Parkinson Disease
Parkin-deficient rats are resistant to neurotoxicity of chronic high-dose methamphetamine.
Parkinson Disease
Parkin-dependent and -independent degradation of synaptotagmin-11 in neurons and astrocytes.
Parkinson Disease
Parkin-dependent degradation of the f-box protein fbw7? promotes neuronal survival in response to oxidative stress by stabilizing mcl-1.
Parkinson Disease
Parkin-dependent regulation of the MCU complex component MICU1.
Parkinson Disease
Parkin-induced mitophagy in the pathogenesis of Parkinson disease.
Parkinson Disease
Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6.
Parkinson Disease
Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases?
Parkinson Disease
Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels.
Parkinson Disease
Parkin-Mediated Protection of Dopaminergic Neurons in a Chronic MPTP-Minipump Mouse Model of Parkinson Disease.
Parkinson Disease
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
Parkinson Disease
Parkin-mediated selective mitochondrial autophagy, mitophagy: Parkin purges damaged organelles from the vital mitochondrial network.
Parkinson Disease
Parkin-mediated Ubiquitination Regulates Phospholipase C-gamma1.
Parkinson Disease
Parkin: a multipurpose neuroprotective agent?
Parkinson Disease
Parkin: Much More than a Simple Ubiquitin Ligase.
Parkinson Disease
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Parkinson Disease
Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.
Parkinson Disease
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Parkinson Disease
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
Parkinson Disease
Parkinson's disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy.
Parkinson Disease
Parkinson's disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons.
Parkinson Disease
Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation.
Parkinson Disease
Parkinson's disease: alpha-synuclein and parkin in protein aggregation and the reversal of unfolded protein stress.
Parkinson Disease
Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin.
Parkinson Disease
Parkinson's disease: viral vector delivery of parkin generates model results in rats.
Parkinson Disease
Parkinson's genetics--creating exciting new insights.
Parkinson Disease
Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease.
Parkinson Disease
Part I: parkin-associated proteins and Parkinson's disease.
Parkinson Disease
Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.
Parkinson Disease
Pathogenetic mechanisms of parkin in Parkinson's disease.
Parkinson Disease
Pathogenic mutations inactivate parkin by distinct mechanisms.
Parkinson Disease
Pathologic and therapeutic implications for the cell biology of parkin.
Parkinson Disease
Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation.
Parkinson Disease
Pharmacological or Genetic Activation of Hsp70 Protects against Loss of Parkin Function.
Parkinson Disease
Phase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN.
Parkinson Disease
Phenotype analysis in patients with early onset Parkinson's disease with and without parkin mutations.
Parkinson Disease
Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.
Parkinson Disease
Phenotypic variability of parkin mutations in single kindred.
Parkinson Disease
Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons.
Parkinson Disease
Phosphatase and tensin homolog-induced putative kinase 1 and Parkin in diabetic heart: Role of mitophagy.
Parkinson Disease
Phospho-ubiquitin: upending the PINK-Parkin-ubiquitin cascade.
Parkinson Disease
Phosphorylated ubiquitin: a new shade of PINK1 in Parkin activation.
Parkinson Disease
Phosphorylation by PINK1 releases the UBL domain and initializes the conformational opening of the E3 ubiquitin ligase Parkin.
Parkinson Disease
Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T ?-synuclein model of Parkinson's disease.
Parkinson Disease
Phosphorylation of Parkin at serine 65 is essential for its activation in vivo.
Parkinson Disease
Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity.
Parkinson Disease
Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling.
Parkinson Disease
Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation.
Parkinson Disease
Physiological Roles of Ubiquitin Ligases Related to the Endoplasmic Reticulum.
Parkinson Disease
PICK1 inhibits the E3 ubiquitin ligase activity of Parkin and reduces its neuronal protective effect.
Parkinson Disease
PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane.
Parkinson Disease
PINK1 and Parkin flag Miro to direct mitochondrial traffic.
Parkinson Disease
PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease.
Parkinson Disease
PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility.
Parkinson Disease
PINK1 and Parkin mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease.
Parkinson Disease
PINK1 and Parkin: emerging themes in mitochondrial homeostasis.
Parkinson Disease
PINK1 and Parkin: team players in stress-induced mitophagy.
Parkinson Disease
PINK1 autophosphorylation facilitates Parkin recruitment to mitochondria: new insight in the mechanisms of quality control for mitochondria in young-onset Parkinson's disease.
Parkinson Disease
PINK1 controls mitochondrial localization of Parkin through direct phosphorylation.
Parkinson Disease
PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival.
Parkinson Disease
PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology?
Parkinson Disease
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease.
Parkinson Disease
PINK1-dependent mitophagy is driven by the UPS and can occur independently of LC3 conversion.
Parkinson Disease
PINK1-dependent phosphorylation of PINK1 and Parkin is essential for mitochondrial quality control.
Parkinson Disease
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.
Parkinson Disease
PINK1-mediated phosphorylation of Parkin boosts Parkin activity in Drosophila.
Parkinson Disease
PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy.
Parkinson Disease
PINK1-Parkin signaling in Parkinson's disease: Lessons from Drosophila.
Parkinson Disease
PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria.
Parkinson Disease
PINK1/Parkin Mediated Mitophagy, Ca2+ Signalling, and ER-Mitochondria Contacts in Parkinson's Disease.
Parkinson Disease
PINK1/Parkin mitophagy and neurodegeneration-what do we really know in vivo?
Parkinson Disease
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.
Parkinson Disease
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.
Parkinson Disease
Plasma membrane calcium ATPase downregulation in dopaminergic neurons alters cellular physiology and motor behaviour in Drosophila melanogaster.
Parkinson Disease
Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
Parkinson Disease
Point mutation in the parkin gene on patients with Parkinson's disease.
Parkinson Disease
Polymorphism in the parkin gene in sporadic Parkinson's disease.
Parkinson Disease
Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan.
Parkinson Disease
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin.
Parkinson Disease
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.
Parkinson Disease
PPEF2 Opposes PINK1-Mediated Mitochondrial Quality Control by Dephosphorylating Ubiquitin.
Parkinson Disease
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.
Parkinson Disease
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
Parkinson Disease
Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease.
Parkinson Disease
Prevalence of homozygous deletions of the parkin gene in a cohort of patients with sporadic and familial Parkinson's disease.
Parkinson Disease
Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.
Parkinson Disease
Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease.
Parkinson Disease
Probes of ubiquitin E3 ligases enable systematic dissection of parkin activation.
Parkinson Disease
Programmed cell death-2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients with autosomal recessive Parkinson's disease.
Parkinson Disease
Progress in familial Parkinson's disease.
Parkinson Disease
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
Parkinson Disease
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
Parkinson Disease
Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells.
Parkinson Disease
Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin.
Parkinson Disease
Protective role of Parkin in skeletal muscle contractile and mitochondrial function.
Parkinson Disease
Protein-protein interactions in the mammalian brain.
Parkinson Disease
Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function.
Parkinson Disease
Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function.
Parkinson Disease
Proteomic Profiling of Mitochondrial-Derived Vesicles in Brain Reveals Enrichment of Respiratory Complex Sub-assemblies and Small TIM Chaperones.
Parkinson Disease
Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease.
Parkinson Disease
Quantitative interaction proteomics of neurodegenerative disease proteins.
Parkinson Disease
Quantitative proteomic analysis of Parkin substrates in Drosophila neurons.
Parkinson Disease
rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Parkinson Disease
Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls.
Parkinson Disease
RBR E3 ubiquitin ligases: new structures, new insights, new questions.
Parkinson Disease
Reactive oxygen species trigger Parkin/PINK1 pathway-dependent mitophagy by inducing mitochondrial recruitment of Parkin.
Parkinson Disease
Recent advances in research on Parkinson disease: synuclein and parkin.
Parkinson Disease
Reduction in endogenous parkin levels renders glial cells sensitive to both caspase-dependent and caspase-independent cell death.
Parkinson Disease
Reduction of protein translation and activation of autophagy protect against PINK1 pathogenesis in Drosophila melanogaster.
Parkinson Disease
Regional and cellular expression of the parkin gene in the rat cerebral cortex.
Parkinson Disease
Regional and cellular localisation of Parkin Co-Regulated Gene in developing and adult mouse brain.
Parkinson Disease
Regulation of DNA repair by parkin.
Parkinson Disease
Regulation of Endoplasmic Reticulum-Mitochondria contacts by Parkin via Mfn2.
Parkinson Disease
Regulation of hippocampal parkin protein by corticosteroids.
Parkinson Disease
Regulation of Iron Homeostasis through Parkin-Mediated Lactoferrin Ubiquitylation.
Parkinson Disease
Regulation of mitochondrial morphology and function by stearoylation of TFR1.
Parkinson Disease
Regulation of parkin and PINK1 by neddylation.
Parkinson Disease
Regulation of Parkin E3 ubiquitin ligase activity.
Parkinson Disease
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Parkinson Disease
Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations.
Parkinson Disease
REM sleep-associated motor behaviors in Parkinson's disease patients with heterozygous Parkin mutations.
Parkinson Disease
Responsiveness to Distracting Stimuli, though Increased in Parkinson's Disease, is Decreased in Asymptomatic PINK1 and Parkin Mutation Carriers.
Parkinson Disease
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Parkinson Disease
Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants.
Parkinson Disease
Rhododendrin-Induced RNF146 Expression via Estrogen Receptor ? Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress.
Parkinson Disease
Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin.
Parkinson Disease
RING finger ubiquitin-protein isopeptide ligase Nrdp1/FLRF regulates parkin stability and activity.
Parkinson Disease
Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method.
Parkinson Disease
ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway.
Parkinson Disease
Role of glucose metabolism and ATP in maintaining PINK1 levels during Parkin-mediated mitochondrial damage responses.
Parkinson Disease
Role of PINK1 Binding to the TOM Complex and Alternate Intracellular Membranes in Recruitment and Activation of the E3 Ligase Parkin.
Parkinson Disease
ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons.
Parkinson Disease
S-Nitrosylation of Critical Protein Thiols Mediates Protein Misfolding and Mitochondrial Dysfunction in Neurodegenerative Diseases.
Parkinson Disease
S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease.
Parkinson Disease
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
Parkinson Disease
S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease.
Parkinson Disease
SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria.
Parkinson Disease
Second mutation in PARK2 is absent in patients with sporadic Parkinson's disease and heterozygous exonic deletions/duplications in parkin gene.
Parkinson Disease
Selective escape of proteins from the mitochondria during mitophagy.
Parkinson Disease
SEPT5_v2 is a parkin-binding protein.
Parkinson Disease
SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination.
Parkinson Disease
Short-term temporal memory in idiopathic and Parkin-associated Parkinson's disease.
Parkinson Disease
Siah-1 facilitates ubiquitination and degradation of synphilin-1.
Parkinson Disease
Significance of the parkin gene and protein in understanding Parkinson's disease.
Parkinson Disease
Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease.
Parkinson Disease
SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila.
Parkinson Disease
Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers.
Parkinson Disease
Small, N-terminal tags activate Parkin E3 ubiquitin ligase activity by disrupting its autoinhibited conformation.
Parkinson Disease
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Parkinson Disease
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
Parkinson Disease
Spatiotemporally controlled initiation of Parkin-mediated mitophagy within single cells.
Parkinson Disease
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
Parkinson Disease
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.
Parkinson Disease
Stress-induced phospho-ubiquitin formation causes parkin degradation.
Parkinson Disease
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
Parkinson Disease
Structural analysis of the effects of mutations in Ubl domain of Parkin leading to Parkinson's disease.
Parkinson Disease
Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin.
Parkinson Disease
Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease.
Parkinson Disease
Structural insights into Parkin substrate lysine targeting from minimal Miro substrates.
Parkinson Disease
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases.
Parkinson Disease
Structure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of Neuroprotection.
Parkinson Disease
Structure of PINK1 and mechanisms of Parkinson's disease-associated mutations.
Parkinson Disease
Structure of the human Parkin ligase domain in an autoinhibited state.
Parkinson Disease
Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease.
Parkinson Disease
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Parkinson Disease
Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles.
Parkinson Disease
Sulfhydration mediates neuroprotective actions of parkin.
Parkinson Disease
Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss.
Parkinson Disease
Switching on ubiquitylation by phosphorylating a ubiquitous activator.
Parkinson Disease
Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology.
Parkinson Disease
Synergistic recruitment of UbcH7~Ub and phosphorylated Ubl domain triggers parkin activation.
Parkinson Disease
Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition.
Parkinson Disease
Systematic examination of DNA variants in the parkin gene in patients with Parkinson's disease.
Parkinson Disease
T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease.
Parkinson Disease
Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Parkinson Disease
Targeting Mitochondrial Dysfunction: Role for PINK1 and Parkin in Mitochondrial Quality Control.
Parkinson Disease
Task matters - challenging the motor system allows distinguishing unaffected Parkin mutation carriers from mutation-free controls.
Parkinson Disease
Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease.
Parkinson Disease
The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/Parkin-mediated mitophagy of polarized mitochondria.
Parkinson Disease
The aetiology of idiopathic Parkinson's disease.
Parkinson Disease
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
Parkinson Disease
The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Parkinson Disease
The contribution of Parkin, PINK1 and DJ-1 genes to selective neuronal degeneration in Parkinson's disease.
Parkinson Disease
The Copper Metabolism MURR1 Domain Protein 1 (COMMD1) Modulates the Aggregation of Misfolded Protein Species in a Client-Specific Manner.
Parkinson Disease
The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy.
Parkinson Disease
The E3 Ligase Parkin Maintains Mitochondrial Integrity by Increasing Linear Ubiquitination of NEMO.
Parkinson Disease
The E3 Ubiquitin ligase parkin is recruited to the 26S proteasome via the proteasomal ubiquitin receptor Rpn13.
Parkinson Disease
The E3 ubiquitin ligase seven in absentia homolog 1 may be a potential new therapeutic target for Parkinson's disease.
Parkinson Disease
The effects of oxidative stress on parkin and other E3 ligases.
Parkinson Disease
The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.
Parkinson Disease
The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease.
Parkinson Disease
The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease.
Parkinson Disease
The Impairments of ?-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson's Disease.
Parkinson Disease
The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
Parkinson Disease
The KM-parkin-DB: A Sub-set MutationView Database Specialized for PARK2 (PARKIN) Variants.
Parkinson Disease
The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson's disease.
Parkinson Disease
The M458L missense mutation disrupts the catalytic properties of Parkin.
Parkinson Disease
The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
Parkinson Disease
The many faces of mitophagy.
Parkinson Disease
The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy.
Parkinson Disease
The mitochondrial kinase PINK1: functions beyond mitophagy.
Parkinson Disease
The Mitochondrial Outer Membrane Protein Tom70-Mediator in Protein Traffic, Membrane Contact Sites and Innate Immunity.
Parkinson Disease
The molecular mechanism of mitochondria autophagy in yeast.
Parkinson Disease
The neurological mutant quaking(viable) is Parkin deficient.
Parkinson Disease
The neuropathology of genetic Parkinson's disease.
Parkinson Disease
The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
Parkinson Disease
The parkin gene is not a major susceptibility locus for typical late-onset Parkinson's disease.
Parkinson Disease
The parkin gene is not involved in late-onset Parkinson's disease.
Parkinson Disease
The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls.
Parkinson Disease
The parkin protein as a therapeutic target in Parkinson's disease.
Parkinson Disease
The Parkin-Like Human Homolog of Drosophila Ariadne-1 (HHARI) Can Induce Aggresome Formation in Mammalian Cells and Is Immunologically Detectable in Lewy Bodies.
Parkinson Disease
The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila.
Parkinson Disease
The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.
Parkinson Disease
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells.
Parkinson Disease
The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity.
Parkinson Disease
The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway.
Parkinson Disease
The PINK1-Parkin axis: An Overview.
Parkinson Disease
The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process.
Parkinson Disease
The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons.
Parkinson Disease
The PINK1/Parkin pathway: a mitochondrial quality control system?
Parkinson Disease
The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations.
Parkinson Disease
The plant triterpenoid celastrol blocks PINK1-dependent mitophagy by disrupting PINK1's association with the mitochondrial protein TOM20.
Parkinson Disease
The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease.
Parkinson Disease
The protein interacting with C-kinase (PICK1) interacts with and attenuates parkin-associated endothelial-like (PAEL) receptor-mediated cell death.
Parkinson Disease
The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Parkinson Disease
The relation between depression and parkin genotype: The CORE-PD study.
Parkinson Disease
The role of parkin in familial and sporadic Parkinson's disease.
Parkinson Disease
The Role of Parkin in Parkinson's Disease: a stem cell perspective.
Parkinson Disease
The role of parkinson's disease-associated receptor GPR37 in the hippocampus: functional interplay with the adenosinergic system.
Parkinson Disease
The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics.
Parkinson Disease
The role of synphilin-1 in the pathogenesis of Parkinson's disease.
Parkinson Disease
The role of the MAGUK protein CASK in neural development and synaptic function.
Parkinson Disease
The roles of PINK1 and Parkin in Parkinson's disease.
Parkinson Disease
The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease.
Parkinson Disease
The septin CDCrel-1 is dispensable for normal development and neurotransmitter release.
Parkinson Disease
The sooner, the later - Delayed diagnosis in Parkinson's disease due to Parkin mutations.
Parkinson Disease
The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.
Parkinson Disease
The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications.
Parkinson Disease
The Transcription Factor Function of Parkin: Breaking the Dogma.
Parkinson Disease
The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax.
Parkinson Disease
The ubiquitin ligase parkin mediates resistance to intracellular pathogens.
Parkinson Disease
The ubiquitin-conjugating enzymes UBE2N, UBE2L3 and UBE2D2/3 are essential for Parkin-dependent mitophagy.
Parkinson Disease
The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons.
Parkinson Disease
The yeast complex I equivalent NADH dehydrogenase rescues pink1 mutants.
Parkinson Disease
Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in Drosophila.
Parkinson Disease
Tissue- and cell-specific mitochondrial defect in Parkin-deficient mice.
Parkinson Disease
Transcription- and phosphorylation-dependent control of a functional interplay between XBP1s and PINK1 governs mitophagy and potentially impacts Parkinson disease pathophysiology.
Parkinson Disease
Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations.
Parkinson Disease
Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease.
Parkinson Disease
Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice.
Parkinson Disease
TRIM3 attenuates apoptosis in Parkinson's disease via activating PI3K/AKT signal pathway.
Parkinson Disease
TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies.
Parkinson Disease
Tumorigenesis and neurodegeneration: two sides of the same coin?
Parkinson Disease
Twenty years since the discovery of the parkin gene.
Parkinson Disease
Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination.
Parkinson Disease
Ubiquitin phosphorylated at Ser57 hyper-activates parkin.
Parkinson Disease
Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease.
Parkinson Disease
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
Parkinson Disease
UCP4A protects against mitochondrial dysfunction and degeneration in pink1/parkin models of Parkinson's disease.
Parkinson Disease
Unraveling correlative roles of dopamine transporter (DAT) and Parkin in Parkinson's disease (PD) - A road to discovery?
Parkinson Disease
Update on Parkinson disease.
Parkinson Disease
Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations.
Parkinson Disease
Upregulation of Parkin Accelerates Osteoblastic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells and Bone Regeneration by Enhancing Autophagy and ?-Catenin Signaling.
Parkinson Disease
USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy.
Parkinson Disease
USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin.
Parkinson Disease
Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease.
Parkinson Disease
VPS13D bridges the ER to mitochondria and peroxisomes via Miro.
Parkinson Disease
XANES Measurements for Studies of Adsorbed Protein Layers at Liquid Interfaces.
Parkinson Disease
Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
Parkinson Disease
ZNF746/PARIS overexpression induces cellular senescence through FoxO1/p21 axis activation in myoblasts.
Parkinson Disease
[A new point mutation on exon 2 of parkin gene in Parkinson's disease]
Parkinson Disease
[A novel point mutation in parkin gene was identified in an early-onset case of Parkinson's disease]
Parkinson Disease
[A Parkin gene (PARK 2) and Parkinson's disease]
Parkinson Disease
[A study on PARKIN gene in three pedigrees with autosomal recessive early-onset Parkinson's disease]
Parkinson Disease
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
Parkinson Disease
[Association analysis of the parkin gene in patients with sporadic Parkinson's disease from a Han population of Sichuan province]
Parkinson Disease
[Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]
Parkinson Disease
[Genetic and environmental factors of Parkinson's disease]
Parkinson Disease
[Genetics and environmental factors of Parkinson disease]
Parkinson Disease
[Genotype and phenotype analyses of three families with autosomal recessive juvenile parkinsonism]
Parkinson Disease
[Inactivation of parkin in Parkinson disease]
Parkinson Disease
[Molecular pharmacological studies on the protection mechanism against endoplasmic reticulum stress-induced neurodegenerative disease].
Parkinson Disease
[Neurodegeneration caused by ER stress?--the pathogenetic mechanisms underlying AR-JP]
Parkinson Disease
[New polymorphism (IVS3-20 T-->C) of the parkin gene associated with the early-onset Parkinson's disease in Chinese]
Parkinson Disease
[Parkin protein and molecular mechanism of Parkinson's disease]
Parkinson Disease
[Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease]
Parkinson Disease
[Parkinson's disease: what have we learned from the genes responsible for familial forms?]
Parkinson Disease
[Pathogenesis of Parkinson's disease: a common pathway between alpha-synuclein and parkin and the mechanism of Lewy bodies formation]
Parkinson Disease
[Recent neuropathology of parkinsonian syndromes]
Parkinson Disease
[Regulation of Parkin and Parkinson's disease]
Parkinson Disease
[Regulation of the protein degradation pathway by the ubiquitin family: its implication in neurodegenerative diseases]
Parkinson Disease
[The clinical and genetic characteristics of autosomal recessive juvenile Parkinsonism in a Chinese family]
Parkinson Disease
[Two cases of sporadic juvenile Parkinson's disease caused by homozygous deletion of Parkin gene]
Parkinson Disease
[What can we learn from genes responsible for familial forms of Parkinson's disease?]
Parkinson Disease
{alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE.
Parkinsonian Disorders
14-3-3eta is a novel regulator of parkin ubiquitin ligase.
Parkinsonian Disorders
A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress.
Parkinsonian Disorders
A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing.
Parkinsonian Disorders
A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Parkinsonian Disorders
A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment.
Parkinsonian Disorders
A double RING-H2 domain in RNF32, a gene expressed during sperm formation.
Parkinsonian Disorders
A homozygous parkin p.G284R mutation in a Chinese family with autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
A mechanistic review of Parkin activation.
Parkinsonian Disorders
A molecular explanation for the recessive nature of parkin-linked Parkinson's disease.
Parkinsonian Disorders
A multidisciplinary study of patients with early-onset PD with and without parkin mutations.
Parkinsonian Disorders
A new mutation in the parkin gene in a patient with atypical autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia.
Parkinsonian Disorders
A novel role for parkin in trauma-induced central nervous system secondary injury.
Parkinsonian Disorders
A Novel Tyrosine Hydroxylase Variant in a Group of Chinese Patients with Dopa-Responsive Dystonia.
Parkinsonian Disorders
A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death.
Parkinsonian Disorders
A simple cell based assay to measure Parkin activity.
Parkinsonian Disorders
A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin.
Parkinsonian Disorders
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
Parkinsonian Disorders
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Parkinsonian Disorders
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Parkinsonian Disorders
Acute and chronic haloperidol treatments increase parkin mRNA levels in the rat brain.
Parkinsonian Disorders
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Parkinsonian Disorders
An apparently sporadic case with parkin gene mutation in a Korean woman.
Parkinsonian Disorders
An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene.
Parkinsonian Disorders
An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin.
Parkinsonian Disorders
Analysis of alpha-synuclein, parkin, tau, and UCH-L1 in a Japanese family with autosomal dominant parkinsonism.
Parkinsonian Disorders
Analysis of eighteen deletion breakpoints in the parkin gene.
Parkinsonian Disorders
Are There Common Biochemical and Molecular Mechanisms Controlling Manganism and Parkisonism.
Parkinsonian Disorders
Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease.
Parkinsonian Disorders
Autoregulation of Parkin activity through its ubiquitin-like domain.
Parkinsonian Disorders
Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis.
Parkinsonian Disorders
Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study.
Parkinsonian Disorders
Autosomal recessive parkinsonism.
Parkinsonian Disorders
Autosomal-dominantly inherited forms of Parkinson's disease.
Parkinsonian Disorders
Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of Parkin gene.
Parkinsonian Disorders
Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase.
Parkinsonian Disorders
Benign tremulous parkinsonism of the young-consider Parkin.
Parkinsonian Disorders
Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism.
Parkinsonian Disorders
Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism.
Parkinsonian Disorders
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity.
Parkinsonian Disorders
Brain parenchyma sonography detects preclinical parkinsonism.
Parkinsonian Disorders
Camptocormia, axial dystonia, and parkinsonism: phenotypic heterogeneity of a parkin mutation.
Parkinsonian Disorders
Cardiac (123)I-metaiodobenzylguanidine Scintigraphy in a Patient with Familial Parkinsonism with Parkin Gene Mutation.
Parkinsonian Disorders
Cell type-specific upregulation of Parkin in response to ER stress.
Parkinsonian Disorders
Cell-permeable parkin proteins suppress Parkinson disease-associated phenotypes in cultured cells and animals.
Parkinsonian Disorders
Characterization of parkin in bovine peripheral nerve.
Parkinsonian Disorders
Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene.
Parkinsonian Disorders
Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.
Parkinsonian Disorders
Clinical and genetic studies on familial parkinsonism: the first report on a parkin gene mutation in a Taiwanese family.
Parkinsonian Disorders
Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations.
Parkinsonian Disorders
Clinical features and [(11)C]-CFT PET analysis of PARK2, PARK6, PARK7-linked autosomal recessive early onset Parkinsonism.
Parkinsonian Disorders
Clinical findings in a large family with a parkin ex3delta40 mutation.
Parkinsonian Disorders
Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations.
Parkinsonian Disorders
Cloning and distribution of the rat parkin mRNA.
Parkinsonian Disorders
Cloning of rat parkin cDNA and distribution of parkin in rat brain.
Parkinsonian Disorders
Co-association of parkin and alpha-synuclein.
Parkinsonian Disorders
Combined kinase inhibition modulates parkin inactivation.
Parkinsonian Disorders
Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells.
Parkinsonian Disorders
Common fragile sites, extremely large genes, neural development and cancer.
Parkinsonian Disorders
Complex relationship between Parkin mutations and Parkinson disease.
Parkinsonian Disorders
Constitutive Activation of PINK1 Protein Leads to Proteasome-mediated and Non-apoptotic Cell Death Independently of Mitochondrial Autophagy.
Parkinsonian Disorders
Crystal structure and molecular dynamics simulation of ubiquitin-like domain of murine parkin.
Parkinsonian Disorders
Deciphering the Molecular Signals of PINK1/Parkin Mitophagy.
Parkinsonian Disorders
Deciphering the role of heterozygous mutations in genes associated with parkinsonism.
Parkinsonian Disorders
Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography.
Parkinsonian Disorders
Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism.
Parkinsonian Disorders
Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).
Parkinsonian Disorders
Developmental changes in the expression of parkin and UbcR7, a parkin-interacting and ubiquitin-conjugating enzyme, in rat brain.
Parkinsonian Disorders
Diagnostic considerations in juvenile parkinsonism.
Parkinsonian Disorders
Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice.
Parkinsonian Disorders
Differential expression and tissue distribution of parkin isoforms during mouse development.
Parkinsonian Disorders
Differential expression of the parkin gene in the human brain and peripheral leukocytes.
Parkinsonian Disorders
Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: contribution of automated segmentation neuroimaging method.
Parkinsonian Disorders
Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy.
Parkinsonian Disorders
Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro.
Parkinsonian Disorders
DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy.
Parkinsonian Disorders
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function.
Parkinsonian Disorders
DJ-1 regulation of mitochondrial function and autophagy through oxidative stress.
Parkinsonian Disorders
DNA damage induces nuclear translocation of parkin.
Parkinsonian Disorders
Does Impairment of the Ubiquitin-Proteasome System or the Autophagy-Lysosome Pathway Predispose Individuals to Neurodegenerative Disorders such as Parkinson's Disease?
Parkinsonian Disorders
Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease?
Parkinsonian Disorders
Dopamine covalently modifies and functionally inactivates parkin.
Parkinsonian Disorders
Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations.
Parkinsonian Disorders
Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1.
Parkinsonian Disorders
Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition.
Parkinsonian Disorders
Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity.
Parkinsonian Disorders
Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells.
Parkinsonian Disorders
Drosophila melanogaster Parkin ubiquitinates peanut and septin1 as an E3 ubiquitin-protein ligase.
Parkinsonian Disorders
Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities.
Parkinsonian Disorders
Dual Function of Phosphoubiquitin in E3 Activation of Parkin.
Parkinsonian Disorders
E3 ubiquitin-protein ligase activity of Parkin is dependent on cooperative interaction of RING finger (TRIAD) elements.
Parkinsonian Disorders
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse.
Parkinsonian Disorders
Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family.
Parkinsonian Disorders
Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil.
Parkinsonian Disorders
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Parkinsonian Disorders
Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum.
Parkinsonian Disorders
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome.
Parkinsonian Disorders
Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.
Parkinsonian Disorders
Emerging views of mitophagy in immunity and autoimmune diseases.
Parkinsonian Disorders
Enhanced Hyperthermia Induced by MDMA in Parkin Knockout Mice.
Parkinsonian Disorders
Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson's disease.
Parkinsonian Disorders
Expression profile of parkin isoforms in human gliomas.
Parkinsonian Disorders
Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways.
Parkinsonian Disorders
Eye movement disorders are different in Parkin-linked and idiopathic early-onset PD.
Parkinsonian Disorders
Familial Parkinsonism with digenic parkin and PINK1 mutations.
Parkinsonian Disorders
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.
Parkinsonian Disorders
Flavin-containing monooxygenase, a new clue of pathological proteins in the rotenone model of parkinsonism.
Parkinsonian Disorders
Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease.
Parkinsonian Disorders
Functional association of the parkin gene promoter with idiopathic Parkinson's disease.
Parkinsonian Disorders
Functional modulation of parkin through physical interaction with SUMO-1.
Parkinsonian Disorders
Functional Role of Parkin against Oxidative Stress in Neural Cells.
Parkinsonian Disorders
Gene therapy for Parkinson's disease.
Parkinsonian Disorders
Generation of induced pluripotent stem cell line (ZZUi007-A) from a 52-year-old patient with a novel CHCHD2 gene mutation in Parkinson's disease.
Parkinsonian Disorders
Genes associated with Parkinson syndrome.
Parkinsonian Disorders
Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism.
Parkinsonian Disorders
Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis.
Parkinsonian Disorders
Genetic influence on the development of Parkinson's disease.
Parkinsonian Disorders
Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India.
Parkinsonian Disorders
Genetic zebrafish models of neurodegenerative diseases.
Parkinsonian Disorders
Genetics and epigenetics of Parkinson's disease.
Parkinsonian Disorders
Genetics and iron in the systems biology of Parkinson's disease and some related disorders.
Parkinsonian Disorders
Genetics of movement disorders: an abbreviated overview.
Parkinsonian Disorders
Genetics of Parkinson's disease.
Parkinsonian Disorders
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
Parkinsonian Disorders
Genotype-phenotype correlates in Taiwanese patients with early-onset recessive parkinsonism.
Parkinsonian Disorders
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
Parkinsonian Disorders
Glial dysfunction in parkin null mice: effects of aging.
Parkinsonian Disorders
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.
Parkinsonian Disorders
Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism.
Parkinsonian Disorders
Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group.
Parkinsonian Disorders
Homozygous exon 4 deletion in parkin gene in a Korean family with autosomal recessive early onset parkinsonism.
Parkinsonian Disorders
Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism.
Parkinsonian Disorders
How do Parkin mutations result in neurodegeneration?
Parkinsonian Disorders
How does parkin ligate ubiquitin to Parkinson's disease?
Parkinsonian Disorders
How much phenotypic variation can be attributed to parkin genotype?
Parkinsonian Disorders
Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene.
Parkinsonian Disorders
Identification and characterization of a novel endogenous murine parkin mutation.
Parkinsonian Disorders
Identification and characterization of the human parkin gene promoter.
Parkinsonian Disorders
Identification of a novel gene linked to parkin via a bi-directional promoter.
Parkinsonian Disorders
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
Parkinsonian Disorders
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease.
Parkinsonian Disorders
Immunodetection of Parkin protein in vertebrate and invertebrate brains: a comparative study using specific antibodies.
Parkinsonian Disorders
Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients.
Parkinsonian Disorders
Immunohistochemical localization of a ubiquitin ligase HRD1 in murine brain.
Parkinsonian Disorders
Impact of altered phosphorylation on loss of function of juvenile Parkinsonism-associated genetic variants of the E3 ligase parkin.
Parkinsonian Disorders
Impact of recent genetic findings in Parkinson's disease.
Parkinsonian Disorders
Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice.
Parkinsonian Disorders
Impaired in vivo dopamine release in parkin knockout mice.
Parkinsonian Disorders
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study.
Parkinsonian Disorders
Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones.
Parkinsonian Disorders
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease.
Parkinsonian Disorders
Increased Levels of cAMP by the Calcium-Dependent Activation of Soluble Adenylyl Cyclase in Parkin-Mutant Fibroblasts.
Parkinsonian Disorders
Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.
Parkinsonian Disorders
Involvement of spinal motor neurons in parkin-positive autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
Is PARKIN parkinsonism a cancer predisposition syndrome?
Parkinsonian Disorders
It's a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG).
Parkinsonian Disorders
Juvenile Parkinson disease and the C212Y mutation of parkin.
Parkinsonian Disorders
Juvenile-onset parkinsonism with digenic parkin and PINK1 mutations treated with subthalamic nucleus stimulation at 45 years after disease onset.
Parkinsonian Disorders
Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease.
Parkinsonian Disorders
Late onset sporadic Parkinson's disease caused by PINK1 mutations: clinical and functional study.
Parkinsonian Disorders
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Parkinsonian Disorders
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
Parkinsonian Disorders
Lewy bodies and parkinsonism in families with parkin mutations.
Parkinsonian Disorders
Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B.
Parkinsonian Disorders
Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36.
Parkinsonian Disorders
Loss of locus coeruleus neurons and reduced startle in parkin null mice.
Parkinsonian Disorders
Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation.
Parkinsonian Disorders
Loss-of-Function Rodent Models for Parkin and PINK1.
Parkinsonian Disorders
Low doses of paraquat and polyphenols prolong life span and locomotor activity in knock-down parkin Drosophila melanogaster exposed to oxidative stress stimuli: implication in autosomal recessive juvenile Parkinsonism.
Parkinsonian Disorders
Low protein to carbohydrate ratio diet delays onset of Parkinsonism like phenotype in Drosophila melanogaster parkin null mutants.
Parkinsonian Disorders
Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation.
Parkinsonian Disorders
Mechanism of parkin activation by PINK1.
Parkinsonian Disorders
Mechanism of phospho-ubiquitin-induced PARKIN activation.
Parkinsonian Disorders
Mendelian forms of Parkinson's disease.
Parkinsonian Disorders
Metabolomics-based identification of metabolic alterations in PARK2.
Parkinsonian Disorders
Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity.
Parkinsonian Disorders
Minocycline protects, rescues and prevents knockdown transgenic parkin Drosophila against paraquat/iron toxicity: Implications for autosomic recessive juvenile parkinsonism.
Parkinsonian Disorders
Mitochondria and dopamine: new insights into recessive parkinsonism.
Parkinsonian Disorders
Mitochondria-affecting small molecules ameliorate proteostasis defects associated with neurodegenerative diseases.
Parkinsonian Disorders
Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin.
Parkinsonian Disorders
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.
Parkinsonian Disorders
Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts.
Parkinsonian Disorders
Mitochondrial hexokinase HKI is a novel substrate of the Parkin ubiquitin ligase.
Parkinsonian Disorders
Mitochondrial injury: a hot spot for parkinsonism and Parkinson's disease?
Parkinsonian Disorders
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants.
Parkinsonian Disorders
Mitochondrial pathology in muscle of a patient with a novel parkin mutation.
Parkinsonian Disorders
Mitochondrial Quality Control and Dynamics in Parkinson's Disease.
Parkinsonian Disorders
Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism.
Parkinsonian Disorders
Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease.
Parkinsonian Disorders
Modulation of parkin gene expression in noradrenergic neuronal cells.
Parkinsonian Disorders
Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene.
Parkinsonian Disorders
Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals.
Parkinsonian Disorders
Molecular genetics of Parkinson's disease.
Parkinsonian Disorders
Molecular mechanisms underlying PINK1 and Parkin catalyzed ubiquitylation of substrates on damaged mitochondria.
Parkinsonian Disorders
Morphological substrates of mental dysfunction in Lewy body disease: an update.
Parkinsonian Disorders
Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia.
Parkinsonian Disorders
Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations.
Parkinsonian Disorders
Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism.
Parkinsonian Disorders
Mutation analysis for DJ-1 in sporadic and familial parkinsonism: screening strategy in parkinsonism.
Parkinsonian Disorders
Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism.
Parkinsonian Disorders
Mutation analysis of Parkin, PINK1, DJ-1 and ATP13A2 genes in Chinese patients with autosomal recessive early-onset Parkinsonism.
Parkinsonian Disorders
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
Mutation of the Parkin gene in a Persian family: clinical progression over a 40-year period.
Parkinsonian Disorders
Mutation screening and association analysis of the parkin gene in Parkinson's disease patients from South-West China.
Parkinsonian Disorders
Mutational Impact on "in-Between-Ring" (IBR) Domain of PARKIN on Protein Stability and Function.
Parkinsonian Disorders
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations.
Parkinsonian Disorders
Naturally- and experimentally-designed restorations of the Parkin gene deficit in autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
Neddylation positively regulates the ubiquitin E3 ligase activity of parkin.
Parkinsonian Disorders
Neurodegeneration in Parkinson's disease: genetics enlightens physiopathology.
Parkinsonian Disorders
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Parkinsonian Disorders
Neuroprotection of Parkin against apoptosis is independent of inclusion body formation.
Parkinsonian Disorders
New aspects of genetic contributions to Parkinson's disease.
Parkinsonian Disorders
New developments in understanding the etiology of Parkinson's disease and in its treatment.
Parkinsonian Disorders
New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism.
Parkinsonian Disorders
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism.
Parkinsonian Disorders
New Perception of Mitochondrial Regulatory Pathway in Parkinsonism - Ubiquitin, PINK1, and Parkin.
Parkinsonian Disorders
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.
Parkinsonian Disorders
Nonmotor symptoms in Parkin gene-related parkinsonism.
Parkinsonian Disorders
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
Parkinsonian Disorders
Novel PINK1 mutations in early-onset parkinsonism.
Parkinsonian Disorders
Olfaction and Parkinson's syndromes: its role in differential diagnosis.
Parkinsonian Disorders
Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease.
Parkinsonian Disorders
Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects.
Parkinsonian Disorders
Overexpression of Nrdp1/FLRF sensitizes cells to oxidative stress.
Parkinsonian Disorders
Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Parkinsonian Disorders
Overexpression of Septin 4, the Drosophila homologue of human CDCrel-1, is toxic for dopaminergic neurons.
Parkinsonian Disorders
p32 regulates mitochondrial morphology and dynamics through parkin.
Parkinsonian Disorders
p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both.
Parkinsonian Disorders
Pael receptor is involved in dopamine metabolism in the nigrostriatal system.
Parkinsonian Disorders
Pael receptor, endoplasmic reticulum stress, and Parkinson's disease.
Parkinsonian Disorders
Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss.
Parkinsonian Disorders
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.
Parkinsonian Disorders
PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages.
Parkinsonian Disorders
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.
Parkinsonian Disorders
PARK6 is a common cause of familial parkinsonism.
Parkinsonian Disorders
PARK6-linked parkinsonism occurs in several European families.
Parkinsonian Disorders
Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.
Parkinsonian Disorders
Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease.
Parkinsonian Disorders
Parkin and endoplasmic reticulum stress.
Parkinsonian Disorders
Parkin and mitochondrial quality control: toward assembling the puzzle.
Parkinsonian Disorders
Parkin and mitophagy in cancer.
Parkinsonian Disorders
Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available case-control cohorts.
Parkinsonian Disorders
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Parkinsonian Disorders
Parkin and relatives: the RBR family of ubiquitin ligases.
Parkinsonian Disorders
Parkin and the molecular pathways of Parkinson's disease.
Parkinsonian Disorders
PARKIN as a pathogenic gene for autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Parkinsonian Disorders
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Parkinsonian Disorders
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain.
Parkinsonian Disorders
Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases.
Parkinsonian Disorders
Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism.
Parkinsonian Disorders
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Parkinsonian Disorders
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Parkinsonian Disorders
Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling.
Parkinsonian Disorders
Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
Parkinsonian Disorders
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Parkinsonian Disorders
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Parkinsonian Disorders
Parkin Disease: A Clinicopathologic Entity?
Parkinsonian Disorders
Parkin disease: a phenotypic study of a large case series.
Parkinsonian Disorders
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Parkinsonian Disorders
Parkin expression in the adult mouse brain.
Parkinsonian Disorders
Parkin expression in the developing mouse.
Parkinsonian Disorders
Parkin expression profile in dopamine d3 receptor knock-out mice brains.
Parkinsonian Disorders
Parkin gene causing benign autosomal recessive juvenile parkinsonism.
Parkinsonian Disorders
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse.
Parkinsonian Disorders
Parkin gene therapy.
Parkinsonian Disorders
Parkin gene variations and parkinsonism: association does not imply causation.
Parkinsonian Disorders
Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes.
Parkinsonian Disorders
Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.
Parkinsonian Disorders
Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination.
Parkinsonian Disorders
Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death.
Parkinsonian Disorders
Parkin is associated with actin filaments in neuronal and nonneural cells.
Parkinsonian Disorders
Parkin is associated with cellular vesicles.
Parkinsonian Disorders
Parkin is metabolized by the ubiquitin/proteosome system.
Parkinsonian Disorders
Parkin is protective against proteotoxic stress in a transgenic zebrafish model.
Parkinsonian Disorders
Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival.
Parkinsonian Disorders
Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress.
Parkinsonian Disorders
Parkin is transcriptionally regulated by the aryl hydrocarbon receptor: Impact on ?-synuclein protein levels.
Parkinsonian Disorders
Parkin mediates apparent E2-independent monoubiquitination in vitro and contains an intrinsic activity that catalyzes polyubiquitination.
Parkinsonian Disorders
Parkin mediates the degradation-independent ubiquitination of Hsp70.
Parkinsonian Disorders
Parkin modulates gene expression in control and ceramide-treated PC12 cells.
Parkinsonian Disorders
Parkin modulates heteroplasmy of truncated mtDNA in Caenorhabditis elegans.
Parkinsonian Disorders
Parkin mono-ubiquitinates BCL-2 and regulates autophagy.
Parkinsonian Disorders
Parkin Mutation Affects Clock Gene-Dependent Energy Metabolism.
Parkinsonian Disorders
Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease.
Parkinsonian Disorders
Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism.
Parkinsonian Disorders
Parkin mutations and early onset parkinsonism.
Parkinsonian Disorders
Parkin mutations and early-onset parkinsonism in a Taiwanese cohort.
Parkinsonian Disorders
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.
Parkinsonian Disorders
Parkin mutations are frequent in patients with isolated early-onset parkinsonism.
Parkinsonian Disorders
Parkin mutations are rare in patients with young-onset parkinsonism in a US population.
Parkinsonian Disorders
Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila.
Parkinsonian Disorders
Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells.
Parkinsonian Disorders
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Parkinsonian Disorders
Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity.
Parkinsonian Disorders
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Parkinsonian Disorders
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death.
Parkinsonian Disorders
Parkin promotes intracellular Abeta1-42 clearance.
Parkinsonian Disorders
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila.
Parkinsonian Disorders
Parkin regulates kainate receptors by interacting with the GluK2 subunit.
Parkinsonian Disorders
Parkin Regulation and Neurodegenerative Disorders.
Parkinsonian Disorders
Parkin suppresses c-Jun N-terminal kinase-induced cell death via transcriptional regulation in Drosophila.
Parkinsonian Disorders
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila.
Parkinsonian Disorders
Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity.
Parkinsonian Disorders
Parkin transcript variants in rat and human brain.
Parkinsonian Disorders
Parkin ubiquitinates and promotes the degradation of RanBP2.
Parkinsonian Disorders
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.
Parkinsonian Disorders
Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson's Disease.
Parkinsonian Disorders
Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease.
Parkinsonian Disorders
Parkin-associated Parkinson's disease.
Parkinsonian Disorders
Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation.
Parkinsonian Disorders
Parkin-deficient mice are not a robust model of parkinsonism.
Parkinsonian Disorders
Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity.
Parkinsonian Disorders
Parkin-phosphoubiquitin complex reveals cryptic ubiquitin-binding site required for RBR ligase activity.
Parkinsonian Disorders
Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions.
Parkinsonian Disorders
Parkin-proven disease: common founders but divergent phenotypes.
Parkinsonian Disorders
Parkin: a multifaceted ubiquitin ligase.
Parkinsonian Disorders
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Parkinsonian Disorders
Parkinson's disease: from monogenic forms to genetic susceptibility factors.
Parkinsonian Disorders
Parkinson's disease: insights from pathways.
Parkinsonian Disorders
Parkinsonism Due to Mutations in PINK1, Parkin, and DJ-1 and Oxidative Stress and Mitochondrial Pathways.
Parkinsonian Disorders
Parkinsonism genes: culprits and clues.
Parkinsonian Disorders
Peripheral neuropathy and parkinsonism: a large clinical and pathogenic spectrum.
Parkinsonian Disorders
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity.
Parkinsonian Disorders
Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation.
Parkinsonian Disorders
PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.
Parkinsonian Disorders
PINK1 is selectively stabilized on impaired mitochondria to activate Parkin.
Parkinsonian Disorders
PINK1 phosphorylates ubiquitin predominantly in astrocytes.
Parkinsonian Disorders
PINK1 rendered temperature sensitive by disease-associated and engineered mutations.
Parkinsonian Disorders
PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism.
Parkinsonian Disorders
Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan.
Parkinsonian Disorders
Porcine Parkin: molecular cloning of PARK2 cDNA, expression analysis, and identification of a splicing variant.
Parkinsonian Disorders
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.
Parkinsonian Disorders
Post translational modification of Parkin.
Parkinsonian Disorders
Post-translational modification of Parkin and its research progress in cancer.
Parkinsonian Disorders
Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report.
Parkinsonian Disorders
Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.
Parkinsonian Disorders
Profiling of Parkin-binding partners using tandem affinity purification.
Parkinsonian Disorders
Programmed cell death and new discoveries in the genetics of parkinsonism.
Parkinsonian Disorders
Progress in the clinical and molecular genetics of familial parkinsonism.
Parkinsonian Disorders
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
Parkinsonian Disorders
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
Parkinsonian Disorders
Proteasome inhibition promotes parkin-ubc13 interaction and lysine 63-linked ubiquitination.
Parkinsonian Disorders
Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function.
Parkinsonian Disorders
Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations.
Parkinsonian Disorders
Pseudo-heterozygous rearrangement mutation of parkin.
Parkinsonian Disorders
Quantitative gait analysis in parkin disease: Possible role of dystonia.
Parkinsonian Disorders
Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations.
Parkinsonian Disorders
Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls.
Parkinsonian Disorders
Recent advances in research on Parkinson disease: synuclein and parkin.
Parkinsonian Disorders
Reduction in endogenous parkin levels renders glial cells sensitive to both caspase-dependent and caspase-independent cell death.
Parkinsonian Disorders
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Parkinsonian Disorders
Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations.
Parkinsonian Disorders
Rescue of mitochondrial function in parkin-mutant fibroblasts using drug loaded PMPC-PDPA polymersomes and tubular polymersomes.
Parkinsonian Disorders
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Parkinsonian Disorders
RING finger 1 mutations in Parkin produce altered localization of the protein.
Parkinsonian Disorders
Role of parkin mutations in 111 community-based patients with early-onset parkinsonism.
Parkinsonian Disorders
Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat.
Parkinsonian Disorders
Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism.
Parkinsonian Disorders
Septin 4, the Drosophila Ortholog of Human CDCrel-1, Accumulates in parkin Mutant Brains and is Functionally Related to the Nedd4 E3 Ubiquitin Ligase.
Parkinsonian Disorders
Significance of the parkin and PINK1 gene in Jordanian families with incidences of young-onset and juvenile parkinsonism.
Parkinsonian Disorders
Significance of the parkin gene and protein in understanding Parkinson's disease.
Parkinsonian Disorders
Site-specific Interaction Mapping of Phosphorylated Ubiquitin to Uncover Parkin Activation.
Parkinsonian Disorders
Stable Isotope Labeling and Label-Free Proteomics of Drosophila parkin Null Mutants.
Parkinsonian Disorders
Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein.
Parkinsonian Disorders
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
Parkinsonian Disorders
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.
Parkinsonian Disorders
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
Parkinsonian Disorders
Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2).
Parkinsonian Disorders
Structural Biology: Parkin's Serpentine Shape Revealed in the Year of the Snake.
Parkinsonian Disorders
Structural insights into ubiquitin phosphorylation by PINK1.
Parkinsonian Disorders
Structure of PINK1 in complex with its substrate ubiquitin.
Parkinsonian Disorders
Structure of the C-terminal RING finger from a RING-IBR-RING/TRIAD motif reveals a novel zinc-binding domain distinct from a RING.
Parkinsonian Disorders
Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease.
Parkinsonian Disorders
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Parkinsonian Disorders
Subclinical sensory abnormalities in unaffected PINK1 heterozygotes.
Parkinsonian Disorders
Successful treatment of Juvenile parkinsonism with bilateral subthalamic deep brain stimulation in a 14-year-old patient with parkin gene mutation.
Parkinsonian Disorders
Suppression of Nrdp1 toxicity by Parkin in Drosophila models.
Parkinsonian Disorders
Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
Parkinsonian Disorders
Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.
Parkinsonian Disorders
SWATH-MS proteome profiling data comparison of DJ-1, Parkin, and PINK1 knockout rat striatal mitochondria.
Parkinsonian Disorders
Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Parkinsonian Disorders
Targeting Mitochondrial Dysfunction: Role for PINK1 and Parkin in Mitochondrial Quality Control.
Parkinsonian Disorders
Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
Parkinsonian Disorders
The 350-fold compacted Fugu parkin gene is structurally and functionally similar to human Parkin.
Parkinsonian Disorders
The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI.
Parkinsonian Disorders
The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates.
Parkinsonian Disorders
The cellular protein level of parkin is regulated by its ubiquitin-like domain.
Parkinsonian Disorders
The Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis.
Parkinsonian Disorders
The endoplasmic reticulum/mitochondria interface: a subcellular platform for the orchestration of the functions of the PINK1-Parkin pathway?
Parkinsonian Disorders
The genomic structure and promoter region of the human parkin gene.
Parkinsonian Disorders
The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism.
Parkinsonian Disorders
The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis.
Parkinsonian Disorders
The KM-parkin-DB: A Sub-set MutationView Database Specialized for PARK2 (PARKIN) Variants.
Parkinsonian Disorders
The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway.
Parkinsonian Disorders
The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations.
Parkinsonian Disorders
The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration.
Parkinsonian Disorders
The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
Parkinsonian Disorders
The Parkin-Like Human Homolog of Drosophila Ariadne-1 (HHARI) Can Induce Aggresome Formation in Mammalian Cells and Is Immunologically Detectable in Lewy Bodies.
Parkinsonian Disorders
The pathological role of Pael-receptor/GPR37 in AR-JP.
Parkinsonian Disorders
The PINK1/Parkin pathway regulates mitochondrial morphology.
Parkinsonian Disorders
The PINK1/Parkin pathway: a mitochondrial quality control system?
Parkinsonian Disorders
The principal PINK1 and Parkin cellular events triggered in response to dissipation of mitochondrial membrane potential occur in primary neurons.
Parkinsonian Disorders
The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Parkinsonian Disorders
The role of ubiquitin-protein ligases in neurodegenerative disease.
Parkinsonian Disorders
The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease.
Parkinsonian Disorders
The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.
Parkinsonian Disorders
The synaptic function of parkin.
Parkinsonian Disorders
The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons.
Parkinsonian Disorders
Three parkin gene mutations in a sibship with autosomal recessive early onset parkinsonism.
Parkinsonian Disorders
To Eat or Not to Eat: Neuronal Metabolism, Mitophagy, and Parkinson's Disease.
Parkinsonian Disorders
Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
Parkinsonian Disorders
Two sides of a coin: Physiological significance and molecular mechanisms for damage-induced mitochondrial localization of PINK1 and Parkin.
Parkinsonian Disorders
Ubiquitin is phosphorylated by PINK1 to activate parkin.
Parkinsonian Disorders
Ubiquitin, proteasome and parkin.
Parkinsonian Disorders
UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Parkinsonian Disorders
Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia.
Parkinsonian Disorders
Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion.
Parkinsonian Disorders
Uncovering the roles of PINK1 and parkin in mitophagy.
Parkinsonian Disorders
Update on the genetics of Parkinson's disease.
Parkinsonian Disorders
Upregulated Parkin expression protects mitochondrial homeostasis in DJ-1 konckdown cells and cells overexpressing the DJ-1 L166P mutation.
Parkinsonian Disorders
Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations.
Parkinsonian Disorders
Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease.
Parkinsonian Disorders
Versatile members of the DNAJ family show Hsp70 dependent anti-aggregation activity on RING1 mutant parkin C289G.
Parkinsonian Disorders
[Discovery of the parkin gene; the gene for young onset autosomal recessive parkinsonism (AR)]
Parkinsonian Disorders
[Exon rearrangement analysis of parkin gene in patients with isolated early-onset parkinsonism using semi-quantitative PCR]
Parkinsonian Disorders
[Future of gene therapy for Parkinson's disease]
Parkinsonian Disorders
[Impairment of the ubiquitin-proteasome system and neurodegeneration]
Parkinsonian Disorders
[Molecular genetics of PINK1]
Parkinsonian Disorders
[Mutation detection of parkin gene by denaturing high performance liquid chromatography]
Parkinsonian Disorders
[Neurodegeneration caused by ER stress?--the pathogenetic mechanisms underlying AR-JP]
Parkinsonian Disorders
[Olfactory dysfunction in Parkinson's disease: its role as a new cardinal sign in early and differential diagnosis]
Parkinsonian Disorders
[Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease]
Parkinsonian Disorders
[Parkinson's disease: what have we learned from the genes responsible for familial forms?]
Parkinsonian Disorders
[Pharmacogenetics focused on special phenotypes].
Parkinsonian Disorders
[Protective effects of HRD1 and 4-phenylbutyric acid against neuronal cell death]
Parkinsonian Disorders
[Revisit to Kii ALS--the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology]
Parkinsonian Disorders
{alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE.
Pediatric Obesity
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Periodontitis
Prioritization of Candidate Genes for Periodontitis Using Multiple Computational Tools.
Periodontitis
Regulation of Anti-Apoptotic SOD2 and BIRC3 in Periodontal Cells and Tissues.
Periodontitis
TRIM16 Promotes Osteogenic Differentiation of Human Periodontal Ligament Stem Cells by Modulating CHIP-Mediated Degradation of RUNX2.
Peripheral Nerve Injuries
Baculoviral inhibitor of apoptosis protein repeat-containing protein 3 delays early Wallerian degeneration after sciatic nerve injury.
Peripheral Nerve Injuries
Dynamic changes of PIRH2 and p27kip1 expression in injured rat sciatic nerve.
Peripheral Nervous System Diseases
Does parkin play a role in the peripheral nervous system? A family report.
Peripheral Nervous System Diseases
Parkinson's Disease-Associated Kinase PINK1 Regulates Miro Protein Level and Axonal Transport of Mitochondria.
Peripheral Nervous System Diseases
Sensory neuropathy in autosomal recessive juvenile parkinsonism (PARK2).
Peritoneal Neoplasms
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Peritoneal Neoplasms
Inefficacité du dépistage des cancers tubo-ovariens dans les situations de risque héréditaire de cancer de l'ovaire ; l'expérience du Centre Oscar-Lambret.
Peritoneal Neoplasms
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Peritoneal Neoplasms
Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
Peritonitis
BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis.
Peritonitis
Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome.
Peroneal Neuropathies
Foot Drop Dystonia Resulting from parkin (PARK2) Mutation.
Persistent Infection
The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.
Persistent Infection
TRIM5? and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment.
Peste-des-Petits-Ruminants
Quantitative Proteomics Reveals a Novel Role of the E3 Ubiquitin-Protein Ligase FANCL in the Activation of the Innate Immune Response through Regulation of TBK1 Phosphorylation during Peste des Petits Ruminants Virus Infection.
Pestivirus Infections
TRIM56 Is a Virus- and Interferon-Inducible E3 Ubiquitin Ligase That Restricts Pestivirus Infection.
Peutz-Jeghers Syndrome
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Peutz-Jeghers Syndrome
Familial pancreatic carcinoma in Jews.
Peutz-Jeghers Syndrome
Genetic testing by cancer site: ovary.
Peutz-Jeghers Syndrome
Genetic testing by cancer site: stomach.
Peutz-Jeghers Syndrome
Papers to appear in forthcoming issues
Peutz-Jeghers Syndrome
Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
Peutz-Jeghers Syndrome
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Pheochromocytoma
Extracellular Alpha-Synuclein Oligomers Induce Parkin S-Nitrosylation: Relevance to Sporadic Parkinson's Disease Etiopathology.
Phyllodes Tumor
Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast.
Phyllodes Tumor
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
Phyllodes Tumor
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Phyllodes Tumor
Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
Pick Disease of the Brain
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Pituitary Neoplasms
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.
Plague
The Yersinia Type III secretion effector YopM Is an E3 ubiquitin ligase that induced necrotic cell death by targeting NLRP3.
Plant Diseases
The Arabidopsis Botrytis Susceptible1 Interactor Defines a Subclass of RING E3 Ligases that Regulate Pathogen and Stress Responses.
Plant Diseases
The Chinese wild grapevine (Vitis pseudoreticulata) E3 ubiquitin ligase Erysiphe necator-induced RING finger protein 1 (EIRP1) activates plant defense responses by inducing proteolysis of the VpWRKY11 transcription factor.
Pleural Effusion
A novel Ubc9 -dependent pathway regulates SIRT1- ER-? Axis and BRCA1-associated TNBC lung metastasis.
Pleural Effusion
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Pneumonia
Blocking of Birc3/TLR4/Myd88 signaling protects carbapenem-resistant klebsiella pneumoniae in a mouse model of infection.
Pneumonia
Calmodulin antagonizes a calcium-activated SCF ubiquitin E3 ligase subunit, FBXL2, to regulate surfactant homeostasis.
Pneumonia
Dynamic gene expression analysis in a H1N1 influenza virus mouse pneumonia model.
Pneumonia
E3 Ligase Subunit Fbxo15 and PINK1 Kinase Regulate Cardiolipin Synthase 1 Stability and Mitochondrial Function in Pneumonia.
Pneumonia
Genetic determinants of susceptibility to silver nanoparticle-induced acute lung inflammation in mice.
Pneumonia
Itch regulation of innate and adaptive immune responses in mice and humans.
Pneumonia
March1 E3 Ubiquitin Ligase Modulates Features of Allergic Asthma in an Ovalbumin-Induced Mouse Model of Lung Inflammation.
Pneumonia
The proinflammatory role of HECTD2 in innate immunity and experimental lung injury.
Pneumonia
The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence.
Pneumonia
TRIM65 E3 ligase targets VCAM-1 degradation to limit LPS-induced lung inflammation.
Polycystic Kidney Diseases
Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis.
Polycystic Kidney, Autosomal Recessive
NEDD4-family E3 ligase dysfunction due to PKHD1/Pkhd1 defects suggests a mechanistic model for ARPKD pathobiology.
Polycystic Ovary Syndrome
Influence of tumour suppressor gene (TP53, BRCA1 and BRCA2) polymorphisms on polycystic ovary syndrome in South Indian women.
Polycythemia
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
Polycythemia
Oxygen sensing: recent insights from idiopathic erythrocytosis.
Polycythemia Vera
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Polyneuropathies
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Porcine Reproductive and Respiratory Syndrome
Autophagy and innate immunity: Insights from invertebrate model organisms.
Porcine Reproductive and Respiratory Syndrome
E3 ligase ASB8 promotes porcine reproductive and respiratory syndrome virus proliferation by stabilizing the viral Nsp1? protein and degrading host IKK? kinase.
Porcine Reproductive and Respiratory Syndrome
Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity.
Porcine Reproductive and Respiratory Syndrome
Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.
Porcine Reproductive and Respiratory Syndrome
Nucleocapsid protein of porcine reproductive and respiratory syndrome virus antagonizes the antiviral activity of TRIM25 by interfering with TRIM25-mediated RIG-I ubiquitination.
Porcine Reproductive and Respiratory Syndrome
The E3 ubiquitin ligase RNF186 and RNF186 risk variants regulate innate receptor-induced outcomes.
Porcine Reproductive and Respiratory Syndrome
Viral strategies for triggering and manipulating mitophagy.
Pre-Eclampsia
Ceramide-induced BOK promotes mitochondrial fission in preeclampsia.
Pre-Eclampsia
CLDN1 regulates trophoblast apoptosis and proliferation in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bioinformatics analysis of gene expression profiles in childhood B-precursor acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Response to rotenone is glucose-sensitive in a model of human acute lymphoblastic leukemia: involvement of oxidative stress mechanism, DJ-1, Parkin, and PINK-1 proteins.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The notch pathway promotes NF-?B activation through Asb2 in T cell acute lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Frequency of pathogenic/likely pathogenic germline variants in cancer-related genes among children with acute leukemia in Saudi Arabia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.
Premature Birth
Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are increased after labour in foetal membranes and myometrium and are essential for TNF-?-induced expression of pro-labour mediators.
Primary Dysautonomias
Normal cardiovascular reflex testing in patients with parkin disease.
Primary Dysautonomias
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Primary Myelofibrosis
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Primary Ovarian Insufficiency
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Primary Ovarian Insufficiency
Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.
Primary Ovarian Insufficiency
Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Prion Diseases
Absence of Association between Two HECTD2 Polymorphisms and Sporadic Creutzfeldt-Jakob Disease.
Prion Diseases
HECTD2 is associated with susceptibility to mouse and human prion disease.
Prion Diseases
Levels of the Mahogunin Ring Finger 1 E3 ubiquitin ligase do not influence prion disease.
Prion Diseases
MGRN1 mediated ubiquitination of ?-tubulin regulates microtubule dynamics and intracellular transport.
Prion Diseases
Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.
Prion Diseases
Prion topology and toxicity.
Prion Diseases
Regulation of Mitofusin1 by Mahogunin Ring Finger-1 and the proteasome modulates mitochondrial fusion.
Prion Diseases
RML prions act through Mahogunin and Attractin-independent pathways.
Prion Diseases
Ubiquitin-mediated regulation of the E3 ligase GP78 by MGRN1 in trans affects mitochondrial homeostasis.
Progeria
Smurf2 regulates stability and the autophagic-lysosomal turnover of lamin A and its disease-associated form progerin.
Prolactinoma
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Prostatic Neoplasms
5-Aza-2'-deoxycytidine stress response and apoptosis in prostate cancer.
Prostatic Neoplasms
?-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer.
Prostatic Neoplasms
A computational and structural analysis of germline and somatic variants affecting the DDR mechanism, and their impact on human diseases.
Prostatic Neoplasms
A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
Prostatic Neoplasms
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Prostatic Neoplasms
A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.
Prostatic Neoplasms
Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
Prostatic Neoplasms
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Prostatic Neoplasms
Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
Prostatic Neoplasms
Activated Wnt/?-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer.
Prostatic Neoplasms
AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening.
Prostatic Neoplasms
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
Prostatic Neoplasms
Allelic loss and microsatellite instability in prostate cancers in Japan.
Prostatic Neoplasms
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Prostatic Neoplasms
Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells.
Prostatic Neoplasms
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Prostatic Neoplasms
Anti-apoptotic factor Birc3 is up-regulated by ELL2 knockdown and stimulates proliferation in LNCaP cells.
Prostatic Neoplasms
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Prostatic Neoplasms
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
Prostatic Neoplasms
Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer.
Prostatic Neoplasms
Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
Prostatic Neoplasms
ATM polymorphisms as risk factors for prostate cancer development.
Prostatic Neoplasms
Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1? in Prostate Cancer Cells.
Prostatic Neoplasms
Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.
Prostatic Neoplasms
BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
Prostatic Neoplasms
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells.
Prostatic Neoplasms
BRCA1 and BRCA2 have a limited role in familial prostate cancer.
Prostatic Neoplasms
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
Prostatic Neoplasms
BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland.
Prostatic Neoplasms
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Prostatic Neoplasms
BRCA1 and p53 regulate critical prostate cancer pathways.
Prostatic Neoplasms
BRCA1 and prostate cancer.
Prostatic Neoplasms
BRCA1 and VDR gene polymorphisms are associated with prostate cancer risk in Mexican men.
Prostatic Neoplasms
BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.
Prostatic Neoplasms
BRCA1 gene in breast cancer.
Prostatic Neoplasms
BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.
Prostatic Neoplasms
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
Prostatic Neoplasms
BRCA1 interaction with human papillomavirus oncoproteins.
Prostatic Neoplasms
BRCA1 is differentially expressed in human tumor cells.
Prostatic Neoplasms
BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage.
Prostatic Neoplasms
BRCA1 Loss Induces GADD153-Mediated Doxorubicin Resistance in Prostate Cancer.
Prostatic Neoplasms
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.
Prostatic Neoplasms
BRCA1 mutations and prostate cancer in Poland.
Prostatic Neoplasms
BRCA1 mutations do not increase prostate cancer risk: Results from a meta-analysis including new data.
Prostatic Neoplasms
BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
Prostatic Neoplasms
BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection.
Prostatic Neoplasms
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
Prostatic Neoplasms
BRCA2 and Other DDR Genes in Prostate Cancer.
Prostatic Neoplasms
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Prostatic Neoplasms
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
Prostatic Neoplasms
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
Prostatic Neoplasms
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.
Prostatic Neoplasms
Changing face of metastatic prostate cancer: the law of diminishing returns holds true.
Prostatic Neoplasms
Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer.
Prostatic Neoplasms
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Prostatic Neoplasms
Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.
Prostatic Neoplasms
Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
Prostatic Neoplasms
Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21.
Prostatic Neoplasms
Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer.
Prostatic Neoplasms
Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
Prostatic Neoplasms
Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46.
Prostatic Neoplasms
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
Prostatic Neoplasms
Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.
Prostatic Neoplasms
Common variation in the BRCA1 gene and prostate cancer risk.
Prostatic Neoplasms
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Prostatic Neoplasms
Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells.
Prostatic Neoplasms
Consulting prostate cancer cohort data uncovers transcriptional control: Regulation of the MARCH6 gene.
Prostatic Neoplasms
Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells.
Prostatic Neoplasms
Corrigendum to "Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study" [Eur Urol 2014;66:489-99].
Prostatic Neoplasms
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Prostatic Neoplasms
Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Prostatic Neoplasms
Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Prostatic Neoplasms
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
Prostatic Neoplasms
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Prostatic Neoplasms
Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.
Prostatic Neoplasms
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Prostatic Neoplasms
Dynamic Coregulatory Complex Containing BRCA1, E2F1 and CtIP Controls ATM Transcription.
Prostatic Neoplasms
E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation.
Prostatic Neoplasms
Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
Prostatic Neoplasms
Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer.
Prostatic Neoplasms
Evidence of independent origin of multiple tumors from patients with prostate cancer.
Prostatic Neoplasms
Expression of androgen receptor coregulators in prostate cancer.
Prostatic Neoplasms
Ezrin ubiquitylation by the E3 ubiquitin ligase, WWP1, and consequent regulation of hepatocyte growth factor receptor activity.
Prostatic Neoplasms
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Prostatic Neoplasms
Family studies and the evidence for genetic susceptibility to prostate cancer.
Prostatic Neoplasms
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Prostatic Neoplasms
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Prostatic Neoplasms
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
Prostatic Neoplasms
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
Prostatic Neoplasms
Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Prostatic Neoplasms
Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1.
Prostatic Neoplasms
Germ-line BRCA1 mutations in selected men with prostate cancer.
Prostatic Neoplasms
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Prostatic Neoplasms
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Prostatic Neoplasms
Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
Prostatic Neoplasms
Germline BRCA1 mutations increase prostate cancer risk.
Prostatic Neoplasms
Germline Mutations in DNA Repair Genes in Patients With Metastatic Castration-resistant Prostate Cancer.
Prostatic Neoplasms
Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
Prostatic Neoplasms
High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells.
Prostatic Neoplasms
Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth.
Prostatic Neoplasms
Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival.
Prostatic Neoplasms
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
Prostatic Neoplasms
Identification of
Prostatic Neoplasms
Immunohistochemical expression of BRCA1 and lethal prostate cancer.
Prostatic Neoplasms
Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.
Prostatic Neoplasms
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Prostatic Neoplasms
Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Prostatic Neoplasms
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Prostatic Neoplasms
Insights into the targeted elimination of BRCA1-defective cancer stem cells.
Prostatic Neoplasms
Integrative clinical genomics of advanced prostate cancer.
Prostatic Neoplasms
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Prostatic Neoplasms
Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?
Prostatic Neoplasms
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
Prostatic Neoplasms
Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer.
Prostatic Neoplasms
Long Noncoding RNA Small Nucleolar RNA Host Gene 3 Mediates Prostate Cancer Migration, Invasion, and Epithelial-Mesenchymal Transition by Sponging miR-487a-3p to Regulate TRIM25.
Prostatic Neoplasms
Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Prostatic Neoplasms
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
Prostatic Neoplasms
Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
Prostatic Neoplasms
Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.
Prostatic Neoplasms
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
Prostatic Neoplasms
MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells.
Prostatic Neoplasms
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Prostatic Neoplasms
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Prostatic Neoplasms
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Prostatic Neoplasms
Mutated SPOP E3 Ligase Promotes 17?HSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Prostatic Neoplasms
Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer.
Prostatic Neoplasms
Mutations in BRCA2 and taxane resistance in prostate cancer.
Prostatic Neoplasms
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Prostatic Neoplasms
Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
Prostatic Neoplasms
Niraparib Shrinks BRCA-Mutated Prostate Tumors.
Prostatic Neoplasms
No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
Prostatic Neoplasms
NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A-DDB1 E3 ligase complex in prostate cancer.
Prostatic Neoplasms
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Olaparib effective in four advanced cancers.
Prostatic Neoplasms
Olaparib shows promise in multiple tumor types.
Prostatic Neoplasms
Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone.
Prostatic Neoplasms
Overexpression of RAD51 occurs in aggressive prostatic cancer.
Prostatic Neoplasms
Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer.
Prostatic Neoplasms
p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).
Prostatic Neoplasms
p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
Prostatic Neoplasms
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
Prostatic Neoplasms
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
Prostatic Neoplasms
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Prostatic Neoplasms
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Prostatic Neoplasms
Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.
Prostatic Neoplasms
Predicting high risk disease using serum and DNA biomarkers.
Prostatic Neoplasms
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Prostatic Neoplasms
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Prostatic Neoplasms
Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer.
Prostatic Neoplasms
Prevalent mutations in prostate cancer.
Prostatic Neoplasms
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Prostatic Neoplasms
Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy.
Prostatic Neoplasms
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Prostatic Neoplasms
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Prostatic Neoplasms
Prostate Cancer Screening in a New Era of Genetics.
Prostatic Neoplasms
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Prostatic Neoplasms
Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Prostatic Neoplasms
Prostate cancer: germline prediction for a commonly variable malignancy.
Prostatic Neoplasms
Prostate screening uptake in Australian BRCA1 and BRCA2 carriers.
Prostatic Neoplasms
Proteotranscriptomic measurements of E6-Associated Protein (E6AP) targets in DU145 prostate cancer cells.
Prostatic Neoplasms
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
Prostatic Neoplasms
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Prostatic Neoplasms
Rapid progression of prostate cancer in men with a BRCA2 mutation.
Prostatic Neoplasms
Re: akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, e3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
Prostatic Neoplasms
Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
Prostatic Neoplasms
Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.
Prostatic Neoplasms
Re: p21-Activated Kinase 6 (PAK6) Inhibits Prostate Cancer Growth via Phosphorylation of Androgen Receptor and Tumorigenic E3 Ligase Murine Double Minute-2 (Mdm2).
Prostatic Neoplasms
Re: Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Prostatic Neoplasms
Recessive oncogenes: current status.
Prostatic Neoplasms
Redox regulation in cancer: a double-edged sword with therapeutic potential.
Prostatic Neoplasms
Relevance of DNA damage repair in the management of prostate cancer.
Prostatic Neoplasms
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Prostatic Neoplasms
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.
Prostatic Neoplasms
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.
Prostatic Neoplasms
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.
Prostatic Neoplasms
Role of RNF20 in cancer development and progression - a comprehensive review.
Prostatic Neoplasms
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Prostatic Neoplasms
Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.
Prostatic Neoplasms
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Prostatic Neoplasms
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
Prostatic Neoplasms
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
Prostatic Neoplasms
Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells.
Prostatic Neoplasms
SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Prostatic Neoplasms
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Prostatic Neoplasms
Structure and expression of variant BRCA2a lacking the transactivation domain.
Prostatic Neoplasms
Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q.
Prostatic Neoplasms
Survey of differentially methylated promoters in prostate cancer cell lines.
Prostatic Neoplasms
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
TAGLN Is Downregulated by TRAF6-Mediated Proteasomal Degradation in Prostate Cancer Cells.
Prostatic Neoplasms
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Prostatic Neoplasms
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study.
Prostatic Neoplasms
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
Prostatic Neoplasms
Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Prostatic Neoplasms
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
Prostatic Neoplasms
TGF-? signaling regulates SPOP expression and promotes prostate cancer cell stemness.
Prostatic Neoplasms
The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
Prostatic Neoplasms
The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Prostatic Neoplasms
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Prostatic Neoplasms
The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.
Prostatic Neoplasms
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Prostatic Neoplasms
The emerging role of PARP inhibitors in prostate cancer.
Prostatic Neoplasms
The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Prostatic Neoplasms
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Prostatic Neoplasms
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Prostatic Neoplasms
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Prostatic Neoplasms
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Prostatic Neoplasms
The resounding effect of DNA repair deficiency in prostate cancer.
Prostatic Neoplasms
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Prostatic Neoplasms
The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
Prostatic Neoplasms
The role of BRCA1 and BRCA2 in prostate cancer.
Prostatic Neoplasms
The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis.
Prostatic Neoplasms
The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
Prostatic Neoplasms
The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI).
Prostatic Neoplasms
Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
Prostatic Neoplasms
Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma.
Prostatic Neoplasms
TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.
Prostatic Neoplasms
TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Prostatic Neoplasms
TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
Prostatic Neoplasms
TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.
Prostatic Neoplasms
Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.
Prostatic Neoplasms
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
Prostatic Neoplasms
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.
Prostatic Neoplasms
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Prostatic Neoplasms
Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer.
Prostatic Neoplasms
Ubiquitin-specific protease 14 promotes prostate cancer progression through deubiquitinating the transcriptional factor ATF2.
Prostatic Neoplasms
Ubiquitylation of epsilon-COP by PIRH2 and regulation of the secretion of PSA.
Prostatic Neoplasms
Urological cancer related to familial syndromes.
Prostatic Neoplasms
Zinc sensitizes prostate cancer cells to sorafenib and regulates the expression of Livin.
Prostatic Neoplasms
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Prostatic Neoplasms
[DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines]
Prostatic Neoplasms
[Hereditary Breast and Ovarian Cancer Syndrome].
Prostatic Neoplasms
[Recent advances on molecular pathology of prostate carcinoma]
protein acetyllysine n-acetyltransferase deficiency
SIRT3 deficiency exacerbates p53/Parkin?mediated mitophagy inhibition and promotes mitochondrial dysfunction: Implication for aged hearts.
Protein Deficiency
Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction.
protein-serine/threonine phosphatase deficiency
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Pruritus
Regulation of T cell differentiation and allergic responses by the E3 ubiquitin ligase itch.
Pseudohypoaldosteronism
Decrease of WNK4 ubiquitination by disease-causing mutations of KLHL3 through different molecular mechanisms.
Pseudohypoaldosteronism
Involvement of selective autophagy mediated by p62/SQSTM1 in KLHL3-dependent WNK4 degradation.
Pseudohypoaldosteronism
Kelch-Like Protein 2 Mediates Angiotensin II-With No Lysine 3 Signaling in the Regulation of Vascular Tonus.
Pseudomyxoma Peritonei
Molecular and clinicopathological features of appendiceal mucinous neoplasms.
Psoriasis
E3 Ligase Trim21 Ubiquitylates and Stabilizes Keratin 17 to Induce STAT3 Activation in Psoriasis.
Psoriasis
Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity.
Psoriasis
Trim21 promotes inflammation in keratinocytes of psoriatic patients.
Puberty, Precocious
Papers to appear in forthcoming issues
Pulmonary Arterial Hypertension
Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.
Pulmonary Disease, Chronic Obstructive
CUL1-Mediated Organelle Fission Pathway Inhibits the Development of Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Impaired mitophagy leads to cigarette smoke stress-induced cellular senescence: implications for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?
Pulmonary Disease, Chronic Obstructive
MicroRNA miR-24-3p reduces DNA damage responses, apoptosis, and susceptibility to chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Molecular signalling towards mitochondrial breakdown is enhanced in skeletal muscle of patients with chronic obstructive pulmonary disease (COPD).
Pulmonary Disease, Chronic Obstructive
Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Pulmonary Disease, Chronic Obstructive
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
Pulmonary Disease, Chronic Obstructive
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis.
Pulmonary Fibrosis
Cyclosporine attenuates Paraquat-induced mitophagy and pulmonary fibrosis.
Pulmonary Fibrosis
Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis.
Pulmonary Fibrosis
Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-? and the Ubiquitin-Proteasome Pathway.
Pulmonary Fibrosis
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Rectal Neoplasms
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease.
Rectal Prolapse
Gut Microbiota Contributes to Spontaneous Colitis in E3 Ligase Itch-Deficient Mice.
Reflex, Abnormal
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Reflex, Abnormal
Parkin is the most common causative gene in a cohort of mainland Chinese patients with sporadic early-onset Parkinson's disease.
REM Sleep Behavior Disorder
Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations.
REM Sleep Behavior Disorder
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Renal Insufficiency
eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Renal Insufficiency, Chronic
Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.
Reoviridae Infections
The E3 Ubiquitin Ligase Siah-1 Suppresses Avian Reovirus Infection by Targeting p10 for Degradation.
Reperfusion Injury
c-Cbl inhibition: A novel therapeutic approach for attenuating myocardial ischemia and reperfusion injury.
Reperfusion Injury
Clearance of damaged mitochondria via mitophagy is important to the protective effect of ischemic preconditioning in kidneys.
Reperfusion Injury
Ginaton improves neurological function in ischemic stroke rats via inducing autophagy and maintaining mitochondrial homeostasis.
Reperfusion Injury
Into the heart: The emerging role of the ubiquitin-proteasome system.
Respiratory Distress Syndrome
Close Relationship between cIAP2 and Human ARDS Induced by Severe H7N9 Infection.
Respiratory Insufficiency
TRAF2 Is a Novel Ubiquitin E3 Ligase for the Na,K-ATPase ?-Subunit That Drives Alveolar Epithelial Dysfunction in Hypercapnia.
Restless Legs Syndrome
Co-occurrence of restless legs syndrome and Parkin mutations in two families.
Restless Legs Syndrome
Parkin gene modifies the effect of RLS4 on the age at onset of restless legs syndrome (RLS).
Restless Legs Syndrome
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Retinal Degeneration
A Mouse Model of Retinal Recovery From Photo-Oxidative/Photo-Inflammatory Injury: Nrf2, SOD1, DJ-1, and Parkin Are Not Essential to Recovery.
Retinal Degeneration
Mice With a Combined Deficiency of Superoxide Dismutase 1 (Sod1), DJ-1 (Park7), and Parkin (Prkn) Develop Spontaneous Retinal Degeneration With Aging.
Retinal Degeneration
Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease.
Retinal Degeneration
PINK1 and Parkin cooperatively protect neurons against constitutively active TRP channel-induced retinal degeneration in Drosophila.
Retinal Neovascularization
A role for protein ubiquitination in VEGFR-2 signalling and angiogenesis.
Retinal Neovascularization
c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLC?1.
Retinitis Pigmentosa
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Retinoblastoma
A Novel Retinoblastoma Protein (RB) E3 Ubiquitin Ligase (NRBE3) Promotes RB Degradation and Is Transcriptionally Regulated by E2F1 Transcription Factor.
Retinoblastoma
Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset).
Retinoblastoma
Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins.
Retinoblastoma
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
Retinoblastoma
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
Retinoblastoma
BRCA1-Mediated Ubiquitination Inhibits Topoisomerase IIalpha Activity in Response to Oxidative Stress.
Retinoblastoma
CDC-25.2, a C. elegans ortholog of cdc25, is essential for the progression of intestinal divisions.
Retinoblastoma
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Retinoblastoma
Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase.
Retinoblastoma
Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.
Retinoblastoma
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.
Retinoblastoma
Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer.
Retinoblastoma
Hereditary common cancers: molecular and clinical genetics.
Retinoblastoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Retinoblastoma
Human CtIP: A 'double agent' in DNA repair and tumorigenesis.
Retinoblastoma
Identification and management of inherited cancer susceptibility.
Retinoblastoma
MicroRNA-154-5p regulates the HPV16 E7-pRb pathway in Cervical Carcinogenesis by targeting CUL2.
Retinoblastoma
Nuclear tumor suppressors in space and time.
Retinoblastoma
On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations.
Retinoblastoma
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Retinoblastoma
Prognostic value of CtIP/RBBP8 expression in breast cancer.
Retinoblastoma
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit.
Retinoblastoma
Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity.
Retinoblastoma
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
Retinoblastoma
The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
Retinoblastoma
[Mechanisms of high-risk human papillomavirus-induced cervical carcinogenesis]
Retroviridae Infections
A rare null allele potentially encoding a dominant-negative TRIM5alpha protein in Baka pygmies.
Retroviridae Infections
A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons.
Retroviridae Infections
A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort.
Retroviridae Infections
Adaptive evolution of primate TRIM5alpha, a gene restricting HIV-1 infection.
Retroviridae Infections
Anti-retroviral activity of TRIM5 alpha.
Retroviridae Infections
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Retroviridae Infections
Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8+ T Cells.
Retroviridae Infections
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
Retroviridae Infections
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.
Retroviridae Infections
TRIM5 Acts as More Than a Retroviral Restriction Factor.
Retroviridae Infections
TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling.
Retroviridae Infections
[Advances of TRIM5alpha on retrovirus infection restriction]
Rift Valley Fever
Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase.
Rift Valley Fever
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
ring-type e3 ubiquitin transferase deficiency
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
ring-type e3 ubiquitin transferase deficiency
A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest.
ring-type e3 ubiquitin transferase deficiency
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
ring-type e3 ubiquitin transferase deficiency
A mouse model of basal-like breast carcinoma with metaplastic elements.
ring-type e3 ubiquitin transferase deficiency
A porcine model system of BRCA1 driven breast cancer.
ring-type e3 ubiquitin transferase deficiency
A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function.
ring-type e3 ubiquitin transferase deficiency
A role for BRCA1 in uterine leiomyosarcoma.
ring-type e3 ubiquitin transferase deficiency
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.
ring-type e3 ubiquitin transferase deficiency
Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach.
ring-type e3 ubiquitin transferase deficiency
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members.
ring-type e3 ubiquitin transferase deficiency
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
ring-type e3 ubiquitin transferase deficiency
Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
ring-type e3 ubiquitin transferase deficiency
Akt2 ablation prolongs life span and improves myocardial contractile function with adaptive cardiac remodeling: role of Sirt1-mediated autophagy regulation.
ring-type e3 ubiquitin transferase deficiency
Altered Hippocampal Synaptic Physiology in Aged Parkin-Deficient Mice.
ring-type e3 ubiquitin transferase deficiency
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
ring-type e3 ubiquitin transferase deficiency
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease.
ring-type e3 ubiquitin transferase deficiency
ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency.
ring-type e3 ubiquitin transferase deficiency
BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
ring-type e3 ubiquitin transferase deficiency
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
ring-type e3 ubiquitin transferase deficiency
Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells.
ring-type e3 ubiquitin transferase deficiency
BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
ring-type e3 ubiquitin transferase deficiency
BRCA1 affects global DNA methylation through regulation of DNMT1.
ring-type e3 ubiquitin transferase deficiency
BRCA1 and BRCA2 tumor suppressors in neural crest cells are essential for craniofacial bone development.
ring-type e3 ubiquitin transferase deficiency
BRCA1 and implications for response to chemotherapy in ovarian cancer.
ring-type e3 ubiquitin transferase deficiency
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
ring-type e3 ubiquitin transferase deficiency
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
ring-type e3 ubiquitin transferase deficiency
BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
ring-type e3 ubiquitin transferase deficiency
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
ring-type e3 ubiquitin transferase deficiency
BRCA1 DEFICIENCY EXACERBATES ESTROGEN INDUCED DNA DAMAGE AND GENOMIC INSTABILITY.
ring-type e3 ubiquitin transferase deficiency
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
ring-type e3 ubiquitin transferase deficiency
Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
ring-type e3 ubiquitin transferase deficiency
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
ring-type e3 ubiquitin transferase deficiency
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
ring-type e3 ubiquitin transferase deficiency
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
ring-type e3 ubiquitin transferase deficiency
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
ring-type e3 ubiquitin transferase deficiency
BRCA1 induces antioxidant gene expression and resistance to oxidative stress.
ring-type e3 ubiquitin transferase deficiency
BRCA1 is a negative modulator of the PRC2 complex.
ring-type e3 ubiquitin transferase deficiency
BRCA1 is required for meiotic spindle assembly and spindle assembly checkpoint activation in mouse oocytes.
ring-type e3 ubiquitin transferase deficiency
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
ring-type e3 ubiquitin transferase deficiency
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
ring-type e3 ubiquitin transferase deficiency
BRCA1 participates in DNA decatenation.
ring-type e3 ubiquitin transferase deficiency
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
ring-type e3 ubiquitin transferase deficiency
BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.
ring-type e3 ubiquitin transferase deficiency
BRCA1 role in the mitigation of radiotoxicity and chromosomal instability through repair of clustered DNA lesions.
ring-type e3 ubiquitin transferase deficiency
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.
ring-type e3 ubiquitin transferase deficiency
BRCA1, a potential predictive biomarker in the treatment of breast cancer.
ring-type e3 ubiquitin transferase deficiency
BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells.
ring-type e3 ubiquitin transferase deficiency
BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining.
ring-type e3 ubiquitin transferase deficiency
BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
ring-type e3 ubiquitin transferase deficiency
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.
ring-type e3 ubiquitin transferase deficiency
Brcal required for T cell lineage development but not TCR loci rearrangement.
ring-type e3 ubiquitin transferase deficiency
Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.
ring-type e3 ubiquitin transferase deficiency
c-Cbl deficiency leads to diminished lymphocyte development and functions in an age-dependent manner.
ring-type e3 ubiquitin transferase deficiency
Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.
ring-type e3 ubiquitin transferase deficiency
Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease.
ring-type e3 ubiquitin transferase deficiency
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
ring-type e3 ubiquitin transferase deficiency
Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
ring-type e3 ubiquitin transferase deficiency
Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
ring-type e3 ubiquitin transferase deficiency
Collaboration of Brca1 and Chk2 in tumorigenesis.
ring-type e3 ubiquitin transferase deficiency
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).
ring-type e3 ubiquitin transferase deficiency
Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
ring-type e3 ubiquitin transferase deficiency
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.
ring-type e3 ubiquitin transferase deficiency
Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease.
ring-type e3 ubiquitin transferase deficiency
Cytoskeletal Alterations and Biomechanical Properties of parkin-Mutant Human Primary Fibroblasts.
ring-type e3 ubiquitin transferase deficiency
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
ring-type e3 ubiquitin transferase deficiency
Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography.
ring-type e3 ubiquitin transferase deficiency
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
ring-type e3 ubiquitin transferase deficiency
Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila.
ring-type e3 ubiquitin transferase deficiency
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
ring-type e3 ubiquitin transferase deficiency
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
ring-type e3 ubiquitin transferase deficiency
Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1?, autophagy and ketone body production.
ring-type e3 ubiquitin transferase deficiency
DSB repair pathway choice is regulated by recruitment of 53BP1 through cell cycle-dependent regulation of Sp1.
ring-type e3 ubiquitin transferase deficiency
Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.
ring-type e3 ubiquitin transferase deficiency
Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis.
ring-type e3 ubiquitin transferase deficiency
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
ring-type e3 ubiquitin transferase deficiency
E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-?B activation.
ring-type e3 ubiquitin transferase deficiency
E3 ligase TRIM25 ubiquitinates RIP3 to inhibit TNF induced cell necrosis.
ring-type e3 ubiquitin transferase deficiency
Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks.
ring-type e3 ubiquitin transferase deficiency
Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls.
ring-type e3 ubiquitin transferase deficiency
Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of Parkin E3 ligase activity.
ring-type e3 ubiquitin transferase deficiency
Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines.
ring-type e3 ubiquitin transferase deficiency
Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways.
ring-type e3 ubiquitin transferase deficiency
FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
ring-type e3 ubiquitin transferase deficiency
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
ring-type e3 ubiquitin transferase deficiency
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
ring-type e3 ubiquitin transferase deficiency
Glial dysfunction in parkin null mice: effects of aging.
ring-type e3 ubiquitin transferase deficiency
Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
ring-type e3 ubiquitin transferase deficiency
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
ring-type e3 ubiquitin transferase deficiency
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
ring-type e3 ubiquitin transferase deficiency
Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease.
ring-type e3 ubiquitin transferase deficiency
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
ring-type e3 ubiquitin transferase deficiency
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
ring-type e3 ubiquitin transferase deficiency
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
ring-type e3 ubiquitin transferase deficiency
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
ring-type e3 ubiquitin transferase deficiency
Impaired in vivo dopamine release in parkin knockout mice.
ring-type e3 ubiquitin transferase deficiency
Inactivation of c-Cbl or Cbl-b differentially affects signaling from the high affinity IgE receptor.
ring-type e3 ubiquitin transferase deficiency
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
ring-type e3 ubiquitin transferase deficiency
Increased vulnerability of parkin knock down PC12 cells to hydrogen peroxide toxicity: the role of salsolinol and NM-salsolinol.
ring-type e3 ubiquitin transferase deficiency
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
ring-type e3 ubiquitin transferase deficiency
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
ring-type e3 ubiquitin transferase deficiency
ITCH deficiency protects from diet-induced obesity.
ring-type e3 ubiquitin transferase deficiency
Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease.
ring-type e3 ubiquitin transferase deficiency
Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation.
ring-type e3 ubiquitin transferase deficiency
Mex3c regulates insulin-like growth factor 1 (IGF1) expression and promotes postnatal growth.
ring-type e3 ubiquitin transferase deficiency
Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin.
ring-type e3 ubiquitin transferase deficiency
Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.
ring-type e3 ubiquitin transferase deficiency
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
ring-type e3 ubiquitin transferase deficiency
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
ring-type e3 ubiquitin transferase deficiency
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women.
ring-type e3 ubiquitin transferase deficiency
Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.
ring-type e3 ubiquitin transferase deficiency
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
ring-type e3 ubiquitin transferase deficiency
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
ring-type e3 ubiquitin transferase deficiency
Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
ring-type e3 ubiquitin transferase deficiency
Negative Regulation of AKT Activation by BRCA1.
ring-type e3 ubiquitin transferase deficiency
NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
ring-type e3 ubiquitin transferase deficiency
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
ring-type e3 ubiquitin transferase deficiency
Ovarian cancer genome.
ring-type e3 ubiquitin transferase deficiency
p53 suppresses hyper-recombination by modulating BRCA1 function.
ring-type e3 ubiquitin transferase deficiency
Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks.
ring-type e3 ubiquitin transferase deficiency
Parkin absence accelerates microtubule aging in dopaminergic neurons.
ring-type e3 ubiquitin transferase deficiency
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency accentuates chronic alcohol intake-induced tissue injury and autophagy defects in brain, liver and skeletal muscle.
ring-type e3 ubiquitin transferase deficiency
Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency elevates hepatic ischemia/reperfusion injury accompanying decreased mitochondrial autophagy, increased apoptosis, impaired DNA damage repair and altered cell cycle distribution.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial function.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency increases vulnerability to inflammation-related nigral degeneration.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency perturbs striatal circuit dynamics.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency prevents chronic ethanol-induced hepatic lipid accumulation through ?-catenin accumulation.
ring-type e3 ubiquitin transferase deficiency
Parkin Deficiency Reduces Hippocampal Glutamatergic Neurotransmission by Impairing AMPA Receptor Endocytosis.
ring-type e3 ubiquitin transferase deficiency
Parkin deficiency results in accumulation of abnormal mitochondria in aging myocytes.
ring-type e3 ubiquitin transferase deficiency
Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in ?-synuclein transgenic mice.
ring-type e3 ubiquitin transferase deficiency
Parkin Impairs Antiviral Immunity by Suppressing the Mitochondrial Reactive Oxygen Species-Nlrp3 Axis and Antiviral Inflammation.
ring-type e3 ubiquitin transferase deficiency
Parkin interacts with Klokin1 for mitochondrial import and maintenance of membrane potential.
ring-type e3 ubiquitin transferase deficiency
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.
ring-type e3 ubiquitin transferase deficiency
Parkin is protective against proteotoxic stress in a transgenic zebrafish model.
ring-type e3 ubiquitin transferase deficiency
Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease.
ring-type e3 ubiquitin transferase deficiency
Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.
ring-type e3 ubiquitin transferase deficiency
Parkin regulates translesion DNA synthesis in response to UV radiation.
ring-type e3 ubiquitin transferase deficiency
Parkin Selectively Alters the Intrinsic Threshold for Mitochondrial Cytochrome C Release.
ring-type e3 ubiquitin transferase deficiency
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
ring-type e3 ubiquitin transferase deficiency
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect.
ring-type e3 ubiquitin transferase deficiency
Parkin-associated Parkinson's disease.
ring-type e3 ubiquitin transferase deficiency
Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain.
ring-type e3 ubiquitin transferase deficiency
PDGFR? is an essential therapeutic target for BRCA1-deficient mammary tumors.
ring-type e3 ubiquitin transferase deficiency
Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation.
ring-type e3 ubiquitin transferase deficiency
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
ring-type e3 ubiquitin transferase deficiency
PINK1/Parkin-Mediated Mitophagy Plays a Protective Role in the Bone Impairment Caused by Aluminum Exposure.
ring-type e3 ubiquitin transferase deficiency
Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
ring-type e3 ubiquitin transferase deficiency
Polydatin protects SH-SY5Y in models of Parkinson's disease by promoting Atg5-mediated but parkin-independent autophagy.
ring-type e3 ubiquitin transferase deficiency
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
ring-type e3 ubiquitin transferase deficiency
PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
ring-type e3 ubiquitin transferase deficiency
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
ring-type e3 ubiquitin transferase deficiency
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers.
ring-type e3 ubiquitin transferase deficiency
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.
ring-type e3 ubiquitin transferase deficiency
Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development.
ring-type e3 ubiquitin transferase deficiency
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
ring-type e3 ubiquitin transferase deficiency
Repression of c-Cbl leads to enhanced G-CSF Jak-STAT signaling without increased cell proliferation.
ring-type e3 ubiquitin transferase deficiency
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
ring-type e3 ubiquitin transferase deficiency
RNF111-facilitated neddylation potentiates cGAS-mediated antiviral innate immune response.
ring-type e3 ubiquitin transferase deficiency
RNF20 controls astrocytic differentiation through epigenetic regulation of STAT3 in the developing brain.
ring-type e3 ubiquitin transferase deficiency
Rnf20 deficiency in adipocyte impairs adipose tissue development and thermogenesis.
ring-type e3 ubiquitin transferase deficiency
Role played by BRCA1 in transcriptional regulation in response to therapy.
ring-type e3 ubiquitin transferase deficiency
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
ring-type e3 ubiquitin transferase deficiency
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
ring-type e3 ubiquitin transferase deficiency
Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers.
ring-type e3 ubiquitin transferase deficiency
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
ring-type e3 ubiquitin transferase deficiency
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
ring-type e3 ubiquitin transferase deficiency
Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology.
ring-type e3 ubiquitin transferase deficiency
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
ring-type e3 ubiquitin transferase deficiency
Targeting UBE4A Revives Viperin Protein in Epithelium to Enhance Host Antiviral Defense.
ring-type e3 ubiquitin transferase deficiency
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
ring-type e3 ubiquitin transferase deficiency
The correlations between BRCA1 defect and environmental factors in the risk of breast cancer.
ring-type e3 ubiquitin transferase deficiency
The E3 ligase c-Cbl regulates dendritic cell activation.
ring-type e3 ubiquitin transferase deficiency
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
ring-type e3 ubiquitin transferase deficiency
The homologous recombination component EEPD1 is required for genome stability in response to developmental stress of vertebrate embryogenesis.
ring-type e3 ubiquitin transferase deficiency
The PPAR? agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
ring-type e3 ubiquitin transferase deficiency
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
ring-type e3 ubiquitin transferase deficiency
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
ring-type e3 ubiquitin transferase deficiency
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
ring-type e3 ubiquitin transferase deficiency
TRAP1 rescues PINK1 loss-of-function phenotypes.
ring-type e3 ubiquitin transferase deficiency
TRIM25 inhibits infectious bursal disease virus replication by targeting VP3 for ubiquitination and degradation.
ring-type e3 ubiquitin transferase deficiency
Tumor susceptibility gene 101 regulates predisposition to apoptosis via ESCRT machinery accessory proteins.
ring-type e3 ubiquitin transferase deficiency
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
ring-type e3 ubiquitin transferase deficiency
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
ring-type e3 ubiquitin transferase deficiency
VCP Is Essential for Mitochondrial Quality Control by PINK1/Parkin and this Function Is Impaired by VCP Mutations.
ring-type e3 ubiquitin transferase deficiency
Western Analysis of Breast Cancer 1 Protein (BRCA1).
RNA Virus Infections
Negative regulation of the innate antiviral immune response by TRIM62 from orange spotted grouper.
RNA Virus Infections
The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation.
RNA Virus Infections
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.
Rubella
Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination.
Rubella
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Rubella
Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.
Salivary Gland Neoplasms
Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report.
Sarcoma
A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
Sarcoma
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.
Sarcoma
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Sarcoma
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Sarcoma
Familial sarcoma: challenging pedigrees.
Sarcoma
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Sarcoma
Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Sarcoma
Identification of prognostic alternative splicing events in sarcoma.
Sarcoma
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Sarcoma
Infantile Epithelioid Sarcoma with Genomic Segmental Amplification of BIRC3/YAP1 as Double Minutes Plus Trisomy 2: A Case Report.
Sarcoma
Inheritance of cancer.
Sarcoma
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Sarcoma
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study.
Sarcoma
Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.
Sarcoma
Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis.
Sarcoma
Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF).
Sarcoma
Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Sarcoma
Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Sarcoma, Avian
CBP/p300 interact with and function as transcriptional coactivators of BRCA1.
Sarcoma, Avian
Tsg101 can replace Nedd4 function in ASV Gag release but not membrane targeting.
Sarcoma, Ewing
Author Correction: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
Sarcoma, Ewing
EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
Sarcoma, Ewing
Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway.
Sarcoma, Ewing
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoprotein.
Sarcoma, Ewing
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
Sarcoma, Ewing
SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.
Sarcoma, Ewing
TRIM3 Negatively Regulates Autophagy Through Promoting Degradation of Beclin1 in Ewing Sarcoma Cells.
Sarcoma, Ewing
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.
Sarcoma, Kaposi
c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity.
Sarcoma, Kaposi
Interaction With 14-3-3 Correlates With Inactivation of the RIG-I Signalosome by Herpesvirus Ubiquitin Deconjugases.
Sarcopenia
Parkin overexpression protects from ageing-related loss of muscle mass and strength.
Sarcopenia
Parkin sarcopenia in its tracks by improving mitochondrial health.
Sarcopenia
Parkin the progression of sarcopenia.
Scleroderma, Systemic
E3 ubiquitin ligase: A potential regulator in fibrosis and systemic sclerosis.
Scrapie
Enhanced Mitophagy Activity in Prion-Infected Cultured Cells and Prion-Infected Experimental Mice via a Pink1/Parkin-Dependent Mitophagy Pathway.
Scrapie
RML prions act through Mahogunin and Attractin-independent pathways.
Seizures
An E3 ubiquitin ligase, Really Interesting New Gene (RING) Finger 41, is a candidate gene for anxiety-like behavior and beta-carboline-induced seizures.
Seminoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Sepsis
AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections.
Sepsis
BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis.
Sepsis
Effect of Deletion of cIAP2 on Intestinal Microcirculation in Mouse Endotoxemia and Poly-bacterial Sepsis.
Sepsis
Inhibition of Atrogin-1/MAFbx Expression by Adenovirus-Delivered Small Hairpin RNAs Attenuates Muscle Atrophy in Fasting Mice.
Sepsis
lncRNA MALAT1 Accelerates Skeletal Muscle Cell Apoptosis and Inflammatory Response in Sepsis by Decreasing BRCA1 Expression by Recruiting EZH2.
Sepsis
LPS impairs phospholipid synthesis by triggering beta-transducin repeat-containing protein (beta-TrCP)-mediated polyubiquitination and degradation of the surfactant enzyme acyl-CoA:lysophosphatidylcholine acyltransferase I (LPCAT1).
Sepsis
Melatonin alleviates sepsis-induced heart injury through activating the Nrf2 pathway and inhibiting the NLRP3 inflammasome.
Sepsis
Parkin Overexpression Attenuates Sepsis-Induced Muscle Wasting.
Sepsis
Prognostic Significance of the Fission1/Parkin Ratio for Sepsis: A Prospective Cohort Study.
Sepsis
Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis.
Sepsis
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Sepsis
TRIM22-Mediated Apoptosis is Associated with Bak Oligomerization in Monocytes.
Sertoli Cell Tumor
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Sertoli Cell Tumor
Papers to appear in forthcoming issues
Shock, Septic
Bioinformatics Analysis for Multiple Gene Expression Profiles in Sepsis.
Shock, Septic
Effect of norepinephrine challenge on cardiovascular determinants assessed using a mathematical model in septic shock: a physiological study.
Shock, Septic
Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production.
Shock, Septic
Serum Mitochondrial Quality Control Related Biomarker Levels are Associated with Organ Dysfunction in Septic Patients.
Shock, Septic
The ubiquitin ligase ZNRF1 promotes caveolin-1 ubiquitination and degradation to modulate inflammation.
Sigmoid Neoplasms
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
Situs Inversus
Mice with mutations in Mahogunin ring finger-1 (Mgrn1) exhibit abnormal patterning of the left-right axis.
Sjogren's Syndrome
Anti-Ro52 autoantibodies from patients with Sjogren's syndrome inhibit the E3 ligase activity of Ro52 by blocking the E3:E2 interface.
Skin Diseases
c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.
Skin Neoplasms
BRCA1 and BRCA2 families and the risk of skin cancer.
Skin Neoplasms
Parkin regulates translesion DNA synthesis in response to UV radiation.
Sleep Initiation and Maintenance Disorders
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Sleep Wake Disorders
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Small Cell Lung Carcinoma
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Small Cell Lung Carcinoma
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Small Cell Lung Carcinoma
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Smallpox
The poxvirus p28 virulence factor is an E3 ubiquitin ligase.
Solitary Fibrous Tumors
Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report.
Spinal Cord Injuries
Rapamycin Enhances Mitophagy and Attenuates Apoptosis After Spinal Ischemia-Reperfusion Injury.
Spinal Dysraphism
Health related quality of life in patients with spina bifida: a prospective assessment before and after lower urinary tract reconstruction.
Spinal Dysraphism
The Impact of BRCA1 on Spina Bifida Meningomyelocele Lesions.
Spinocerebellar Ataxias
Clustering of Parkinson disease: shared cause or coincidence?
Spinocerebellar Ataxias
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Spinocerebellar Ataxias
Most mutations that cause spinocerebellar ataxia autosomal recessive type 16 (SCAR16) destabilize the protein quality-control E3 ligase CHIP.
Spinocerebellar Ataxias
Quantitative interaction proteomics of neurodegenerative disease proteins.
Spinocerebellar Ataxias
Spinocerebellar ataxia type 48: last but not least.
Spondylitis, Ankylosing
SMAD-specific E3 ubiquitin ligase 2 promotes angiogenesis by facilitating PTX3 degradation in MSCs from patients with ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
Squamous Cell Carcinoma of Head and Neck
Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Squamous Cell Carcinoma of Head and Neck
BRCA1 and ?H2AX as independent prognostic markers in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Squamous Cell Carcinoma of Head and Neck
Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Squamous Cell Carcinoma of Head and Neck
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
Squamous Cell Carcinoma of Head and Neck
Human Homolog of Drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies.
Squamous Cell Carcinoma of Head and Neck
Inverse correlation between Naa10p and Pirh2 expression and the combined prognostic value in oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
Squamous Cell Carcinoma of Head and Neck
NF?B mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC).
Squamous Cell Carcinoma of Head and Neck
Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
Squamous Cell Carcinoma of Head and Neck
RN181 regulates the biological behaviors of oral squamous cell carcinoma cells via mediating ERK/MAPK signaling pathway.
Squamous Cell Carcinoma of Head and Neck
Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation.
Squamous Cell Carcinoma of Head and Neck
The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
Squamous Cell Carcinoma of Head and Neck
The Expression and Effection of MicroRNA-499a in High-Tobacco Exposed Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis.
Squamous Cell Carcinoma of Head and Neck
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
Squamous Cell Carcinoma of Head and Neck
Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Starvation
A proposed role for selective autophagy in regulating auxin-dependent lateral root development under phosphate starvation in Arabidopsis.
Starvation
A selective transmembrane recognition mechanism by a membrane-anchored ubiquitin ligase adaptor.
Starvation
Arabidopsis ubiquitin-specific proteases UBP12 and UBP13 shape ORE1 levels during leaf senescence induced by nitrogen deficiency.
Starvation
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
Starvation
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
Starvation
Changes in cIAP2, survivin and BimEL expression characterize the switch from autophagy to apoptosis in prolonged starvation.
Starvation
Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast.
Starvation
Dysregulation of Parkin-mediated mitophagy in thyroid Hürthle cell tumors.
Starvation
Epigenetic and transcriptional regulation of autophagy.
Starvation
Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation.
Starvation
Global identification of genes related to nutrient deficiency in intervertebral disc cells in an experimental nutrient deprivation model.
Starvation
Hepatitis B Virus X protein elevates Parkin-mediated mitophagy through Lon Peptidase in starvation.
Starvation
IKK-dependent, NF-?B-independent control of autophagic gene expression.
Starvation
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Starvation
Low protein to carbohydrate ratio diet delays onset of Parkinsonism like phenotype in Drosophila melanogaster parkin null mutants.
Starvation
Mex3c mutation affects lactation through impairing milk ejection in female mice.
Starvation
Modulating mitophagy in mitochondrial disease.
Starvation
Molecular cloning and characterization of OsUPS, a U-box containing E3 ligase gene that respond to phosphate starvation in rice (Oryza sativa).
Starvation
Overexpression of GbWRKY1 positively regulates the Pi starvation response by alteration of auxin sensitivity in Arabidopsis.
Starvation
Parkin Regulates the Activity of Pyruvate Kinase M2.
Starvation
PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation.
Starvation
Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: association with inhibition of p27 accumulation.
Starvation
Quantitative RT-PCR Gene Evaluation and RNA Interference in the Brown Marmorated Stink Bug.
Starvation
Regulation of autophagy by cytoplasmic p53.
Starvation
Restriction of trophic factors and nutrients induces PARKIN expression.
Starvation
SAG/ROC2/Rbx2/Hrt2, a component of SCF E3 ubiquitin ligase: genomic structure, a splicing variant, and two family pseudogenes.
Starvation
Suitable reference genes for RT-qPCR analysis in Dichelops melacanthus (Hemiptera: Pentatomidae).
Starvation
Sumoylation, a post-translational regulatory process in plants.
Starvation
The F-box E3 ubiquitin ligase BAF1 mediates the degradation of the brassinosteroid-activated transcription factor BES1 through selective autophagy in Arabidopsis.
Starvation
The function of LPR1 is controlled by an element in the promoter and is independent of SUMO E3 Ligase SIZ1 in response to low pi stress in Arabidopsis thaliana.
Starvation
The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
Starvation
The HECT E3 ubiquitin ligase NEDD4 interacts with and ubiquitylates SQSTM1 for inclusion body autophagy.
Starvation
The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells.
Starvation
Thiazolidinediones Mimic Glucose Starvation in Facilitating Sp1 Degradation Through the Upregulation of {beta}-TRCP.
Starvation
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Starvation
Up-Regulation of Glioma-Associated Oncogene Homolog 1 Expression by Serum Starvation Promotes Cell Survival in ER-Positive Breast Cancer Cells.
Status Epilepticus
Transcriptional Response of Polycomb Group Genes to Status Epilepticus in Mice is Modified by Prior Exposure to Epileptic Preconditioning.
Stomach Neoplasms
A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
Stomach Neoplasms
A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer.
Stomach Neoplasms
A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
Stomach Neoplasms
ASPP2 suppresses invasion and TGF-?1-induced epithelial-mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer.
Stomach Neoplasms
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
Stomach Neoplasms
BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin.
Stomach Neoplasms
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
Stomach Neoplasms
c-FLIP is a target of the E3 ligase deltex1 in gastric cancer.
Stomach Neoplasms
Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer.
Stomach Neoplasms
circRNA RNF111 regulates the growth, migration and invasion of gastric cancer cells by binding to miR?27b?3p.
Stomach Neoplasms
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Stomach Neoplasms
Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer.
Stomach Neoplasms
Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.
Stomach Neoplasms
Co-occurrence of germline BRCA1 and CDH1 pathogenic variants.
Stomach Neoplasms
Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer.
Stomach Neoplasms
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Stomach Neoplasms
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
Stomach Neoplasms
DNA damage regulates ARID1A stability via SCF ubiquitin ligase in gastric cancer cells.
Stomach Neoplasms
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
Stomach Neoplasms
DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells.
Stomach Neoplasms
DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells.
Stomach Neoplasms
ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
Stomach Neoplasms
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
Stomach Neoplasms
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
Stomach Neoplasms
Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric cancer.
Stomach Neoplasms
Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.
Stomach Neoplasms
Exosomal TRIM3 is a novel marker and therapy target for gastric cancer.
Stomach Neoplasms
Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer.
Stomach Neoplasms
FOXO3a-dependent Parkin regulates the development of gastric cancer by targeting ATP-binding cassette transporter E1.
Stomach Neoplasms
Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer.
Stomach Neoplasms
Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues.
Stomach Neoplasms
Genetic instability of BRCA1 gene at locus D17S855 is related to clinicopathological behaviors of gastric cancer from Chinese population.
Stomach Neoplasms
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Stomach Neoplasms
Genetic testing by cancer site: stomach.
Stomach Neoplasms
Germline E-cadherin mutations in familial lobular breast cancer.
Stomach Neoplasms
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.
Stomach Neoplasms
Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer.
Stomach Neoplasms
H. pylori infection confers resistance to apoptosis via Brd4-dependent BIRC3 eRNA synthesis.
Stomach Neoplasms
Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis.
Stomach Neoplasms
Identification and Validation of SNP-Containing Genes With Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis.
Stomach Neoplasms
Identification of High-Frequency Methylation Sites in RNF180 Promoter Region Affecting Expression and Their Relationship with Prognosis of Gastric Cancer.
Stomach Neoplasms
Interferon-? sensitizes human gastric cancer cells to TRAIL-induced apoptosis via activation of the c-CBL-dependent MAPK/ERK pathway.
Stomach Neoplasms
JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.
Stomach Neoplasms
Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling.
Stomach Neoplasms
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Stomach Neoplasms
Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter.
Stomach Neoplasms
Met Kinase-dependent Loss of the E3 Ligase Cbl in Gastric Cancer.
Stomach Neoplasms
Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer.
Stomach Neoplasms
mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric Cancer.
Stomach Neoplasms
Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
Stomach Neoplasms
Overexpression of E3 ubiquitin ligase tripartite motif 32 correlates with a poor prognosis in patients with gastric cancer.
Stomach Neoplasms
Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients.
Stomach Neoplasms
Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.
Stomach Neoplasms
Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients.
Stomach Neoplasms
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Stomach Neoplasms
Prognostic significance of BRCA1 expression in gastric cancer.
Stomach Neoplasms
Promoter methylation of cancer-related genes in gastric carcinoma.
Stomach Neoplasms
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Stomach Neoplasms
RBBP8/CtIP suppresses P21 expression by interacting with CtBP and BRCA1 in gastric cancer.
Stomach Neoplasms
RING finger protein 38 induces gastric cancer cell growth by decreasing the stability of the protein tyrosine phosphatase SHP-1.
Stomach Neoplasms
Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-?/catenin signaling pathway.
Stomach Neoplasms
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Stomach Neoplasms
RNF180 mediates STAT3 activity by regulating the expression of RhoC via the proteasomal pathway in gastric cancer cells.
Stomach Neoplasms
RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer.
Stomach Neoplasms
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
Stomach Neoplasms
RNF43: A Biomarker With Potential Ramifications for Therapeutic Intervention in Gastric Cancer.
Stomach Neoplasms
STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling.
Stomach Neoplasms
Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report.
Stomach Neoplasms
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Stomach Neoplasms
Testin and filamin-C downregulation by acetylated Siah2 increases invasiveness of Helicobacter pylori-infected gastric cancer cells.
Stomach Neoplasms
The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion.
Stomach Neoplasms
The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1.
Stomach Neoplasms
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Stomach Neoplasms
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
Stomach Neoplasms
The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population.
Stomach Neoplasms
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers.
Stomach Neoplasms
The Role of PRAJA and ELF in TGF-beta Signaling and Gastric Cancer.
Stomach Neoplasms
The SUMO E3 ligase CBX4 is identified as a poor prognostic marker of gastric cancer through multipronged OMIC analyses.
Stomach Neoplasms
Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy.
Stomach Neoplasms
TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein.
Stomach Neoplasms
TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-? signaling.
Stomach Neoplasms
[Epigenetics in the pathogenesis and early detection of gastric cancer].
Stomach Neoplasms
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
Stroke
Activation of TGR5 protects blood brain barrier via the BRCA1/Sirt1 pathway after middle cerebral artery occlusion in rats.
Stroke
Danhong injection facilitates recovery of post-stroke motion deficit via Parkin-enhanced mitochondrial function.
Stroke
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Stroke
Ischemic stroke induces cardiac dysfunction and alters transcriptome profile in mice.
Stroke
Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection.
Stroke
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
Supranuclear Palsy, Progressive
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Supranuclear Palsy, Progressive
Parkin polymorphisms in progressive supranuclear palsy.
Supranuclear Palsy, Progressive
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
Supranuclear Palsy, Progressive
Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein.
Syndactyly
Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.
Synovitis
cIAP2 expression and clinical significance in pigmented villonodular synovitis.
Synovitis, Pigmented Villonodular
cIAP2 expression and clinical significance in pigmented villonodular synovitis.
Synucleinopathies
Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?
Synucleinopathies
Gene therapy for Parkinson's disease.
Synucleinopathies
Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
Synucleinopathies
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
Synucleinopathies
Parkin and defective ubiquitination in Parkinson's disease.
Synucleinopathies
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Synucleinopathies
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Synucleinopathies
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Synucleinopathies
Parkin gene therapy.
Synucleinopathies
The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
Synucleinopathies
Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies.
Tauopathies
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Tauopathies
Colocalization of BRCA1 with Tau Aggregates in Human Tauopathies.
Tauopathies
Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene.
Tauopathies
Morphological substrates of mental dysfunction in Lewy body disease: an update.
Tauopathies
Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.
Tauopathies
Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
Tay-Sachs Disease
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
Tay-Sachs Disease
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
TDP-43 Proteinopathies
Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy.
TDP-43 Proteinopathies
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
ATR, BRCA1 and gammaH2AX localize to unsynapsed chromosomes at the pachytene stage in human oocytes.
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
Dynamic Coregulatory Complex Containing BRCA1, E2F1 and CtIP Controls ATM Transcription.
Telangiectasis
Effect of DNA damage on a BRCA1 complex.
Telangiectasis
Gallic acid induces DNA damage and inhibits DNA repair-associated protein expression in human oral cancer SCC-4 cells.
Telangiectasis
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Telangiectasis
Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint.
Telangiectasis
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Teratocarcinoma
Expression of c-cbl proto-oncogene is modulated during differentiation but not during induction of proliferation.
Teratoma
Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family.
Teratoma
Coexistence of the BRCA1 and KRAS mutations in a patient with salivary gland carcinoma arising in mediastinal mature teratoma.
Thrombasthenia
Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17.
Thrombocythemia, Essential
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Thrombosis
Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
Thrombosis
cIAP2 via NF-?B signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Thrombosis
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Thymoma
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
Thymoma
Deficient tyrosine phosphorylation of c-Cbl and associated proteins in phorbol ester-resistant EL4 mouse thymoma cells.
Thyroid Cancer, Papillary
BRCA2 3'-UTR Polymorphism rs15869 Alters Susceptibility to Papillary Thyroid Carcinoma via Binding hsa-mir-1178-3p.
Thyroid Cancer, Papillary
MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
Thyroid Neoplasms
Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report.
Thyroid Neoplasms
Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma.
Thyroid Neoplasms
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Thyroid Neoplasms
Hereditary common cancers: molecular and clinical genetics.
Thyroid Neoplasms
MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
Thyroid Neoplasms
Poly r(C) binding protein (PCBP) 1 expression is regulated by the E3 ligase UBE4A in thyroid carcinoma.
Thyroid Neoplasms
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2013.
Tics
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma.
Tongue Neoplasms
BRCA1 expression in leukoplakia and carcinoma of the tongue.
Tongue Neoplasms
E3 Ubiquitin ligase RNF126 regulates the progression of tongue cancer.
Tongue Neoplasms
E3 ubiquitin ligase, RNF139, inhibits the progression of tongue cancer.
Tongue Neoplasms
Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells.
Tongue Neoplasms
The E3 ubiquitin ligase RNF135 regulates the tumorigenesis activity of tongue cancer SCC25 cells.
Tremor
A Novel Mutation of PARK-2 Gene in a Patient with Early-onset Parkinson's Disease.
Tremor
Clinical findings in a large family with a parkin ex3delta40 mutation.
Tremor
Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).
Tremor
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism.
Tremor
Parkin Disease: A Clinicopathologic Entity?
Tremor
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Tremor
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
Tremor
Pseudo-orthostatic and resting leg tremor in a large Spanish family with homozygous truncating parkin mutation.
Tremor
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
Triple Negative Breast Neoplasms
"An addendum to breast cancer": the triple negative experience.
Triple Negative Breast Neoplasms
A BRCA1 deficient, NF?B driven immune signal predicts good outcome in triple negative breast cancer.
Triple Negative Breast Neoplasms
A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy.
Triple Negative Breast Neoplasms
A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.
Triple Negative Breast Neoplasms
A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine.
Triple Negative Breast Neoplasms
A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
Triple Negative Breast Neoplasms
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.
Triple Negative Breast Neoplasms
A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype.
Triple Negative Breast Neoplasms
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
Triple Negative Breast Neoplasms
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Triple Negative Breast Neoplasms
Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis.
Triple Negative Breast Neoplasms
ANKLE1 N6 -Methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability.
Triple Negative Breast Neoplasms
Antibody-drug conjugates in triple negative breast cancer.
Triple Negative Breast Neoplasms
Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).
Triple Negative Breast Neoplasms
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Triple Negative Breast Neoplasms
Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
Triple Negative Breast Neoplasms
Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers.
Triple Negative Breast Neoplasms
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Triple Negative Breast Neoplasms
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Triple Negative Breast Neoplasms
Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.
Triple Negative Breast Neoplasms
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
Triple Negative Breast Neoplasms
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
Triple Negative Breast Neoplasms
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Triple Negative Breast Neoplasms
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
Triple Negative Breast Neoplasms
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.
Triple Negative Breast Neoplasms
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
Triple Negative Breast Neoplasms
BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Triple Negative Breast Neoplasms
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
Triple Negative Breast Neoplasms
BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells.
Triple Negative Breast Neoplasms
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
Triple Negative Breast Neoplasms
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Triple Negative Breast Neoplasms
BRCA1-associated triple-negative breast cancer and potential treatment for ruthenium-based compounds.
Triple Negative Breast Neoplasms
BRCA2 mutations and triple-negative breast cancer.
Triple Negative Breast Neoplasms
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Triple Negative Breast Neoplasms
Breast cancer associated pathogenic variants among women 61?years and older with triple negative breast cancer.
Triple Negative Breast Neoplasms
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.
Triple Negative Breast Neoplasms
Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Triple Negative Breast Neoplasms
Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
Triple Negative Breast Neoplasms
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Triple Negative Breast Neoplasms
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Triple Negative Breast Neoplasms
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Triple Negative Breast Neoplasms
Clinical implications for BRCA gene mutation in breast cancer.
Triple Negative Breast Neoplasms
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Triple Negative Breast Neoplasms
Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
Triple Negative Breast Neoplasms
Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
Triple Negative Breast Neoplasms
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
Triple Negative Breast Neoplasms
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Triple Negative Breast Neoplasms
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Triple Negative Breast Neoplasms
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
Triple Negative Breast Neoplasms
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Triple Negative Breast Neoplasms
DCAF13 promotes triple-negative breast cancer metastasis by mediating DTX3 mRNA degradation.
Triple Negative Breast Neoplasms
Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Triple Negative Breast Neoplasms
Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors.
Triple Negative Breast Neoplasms
Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Triple Negative Breast Neoplasms
Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Triple Negative Breast Neoplasms
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Triple Negative Breast Neoplasms
DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.
Triple Negative Breast Neoplasms
Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
Triple Negative Breast Neoplasms
E3 ubiquitin ligase CHIP attenuates cellular proliferation and invasion abilities in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Triple Negative Breast Neoplasms
Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
Triple Negative Breast Neoplasms
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
Triple Negative Breast Neoplasms
Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Triple Negative Breast Neoplasms
EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.
Triple Negative Breast Neoplasms
Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor.
Triple Negative Breast Neoplasms
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
Triple Negative Breast Neoplasms
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.
Triple Negative Breast Neoplasms
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Triple Negative Breast Neoplasms
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Triple Negative Breast Neoplasms
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Triple Negative Breast Neoplasms
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
Triple Negative Breast Neoplasms
Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations.
Triple Negative Breast Neoplasms
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Triple Negative Breast Neoplasms
Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.
Triple Negative Breast Neoplasms
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Triple Negative Breast Neoplasms
Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in chinese women.
Triple Negative Breast Neoplasms
Genetics of triple-negative breast cancer: Implications for patient care.
Triple Negative Breast Neoplasms
Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target.
Triple Negative Breast Neoplasms
Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
Triple Negative Breast Neoplasms
High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Triple Negative Breast Neoplasms
High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
Triple Negative Breast Neoplasms
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Triple Negative Breast Neoplasms
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Triple Negative Breast Neoplasms
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Triple Negative Breast Neoplasms
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.
Triple Negative Breast Neoplasms
Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Triple Negative Breast Neoplasms
Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.
Triple Negative Breast Neoplasms
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Triple Negative Breast Neoplasms
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Triple Negative Breast Neoplasms
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Triple Negative Breast Neoplasms
Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Triple Negative Breast Neoplasms
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Inherited Breast Cancer in Nigerian Women.
Triple Negative Breast Neoplasms
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Triple Negative Breast Neoplasms
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study.
Triple Negative Breast Neoplasms
ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response.
Triple Negative Breast Neoplasms
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Triple Negative Breast Neoplasms
Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
Triple Negative Breast Neoplasms
LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p.
Triple Negative Breast Neoplasms
Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Triple Negative Breast Neoplasms
Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
Triple Negative Breast Neoplasms
LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition.
Triple Negative Breast Neoplasms
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Triple Negative Breast Neoplasms
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Triple Negative Breast Neoplasms
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
Triple Negative Breast Neoplasms
MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Triple Negative Breast Neoplasms
miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
Triple Negative Breast Neoplasms
miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
Triple Negative Breast Neoplasms
miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.
Triple Negative Breast Neoplasms
miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
Triple Negative Breast Neoplasms
miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.
Triple Negative Breast Neoplasms
miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin.
Triple Negative Breast Neoplasms
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Triple Negative Breast Neoplasms
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Triple Negative Breast Neoplasms
Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.
Triple Negative Breast Neoplasms
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
Triple Negative Breast Neoplasms
Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Triple Negative Breast Neoplasms
NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
Triple Negative Breast Neoplasms
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Triple Negative Breast Neoplasms
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Triple Negative Breast Neoplasms
Optimal surgical management for high-risk populations.
Triple Negative Breast Neoplasms
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Triple Negative Breast Neoplasms
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
Triple Negative Breast Neoplasms
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Triple Negative Breast Neoplasms
PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
Triple Negative Breast Neoplasms
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Triple Negative Breast Neoplasms
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives.
Triple Negative Breast Neoplasms
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Triple Negative Breast Neoplasms
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
Triple Negative Breast Neoplasms
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
Triple Negative Breast Neoplasms
Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Triple Negative Breast Neoplasms
Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Triple Negative Breast Neoplasms
Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
Triple Negative Breast Neoplasms
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
Triple Negative Breast Neoplasms
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Triple Negative Breast Neoplasms
Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Triple Negative Breast Neoplasms
Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: A single institute retrospective study.
Triple Negative Breast Neoplasms
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
Triple Negative Breast Neoplasms
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Triple Negative Breast Neoplasms
Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Prevalence of BRCA1/2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer.
Triple Negative Breast Neoplasms
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Triple Negative Breast Neoplasms
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
Triple Negative Breast Neoplasms
Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Triple Negative Breast Neoplasms
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Triple Negative Breast Neoplasms
Proteomic Profiling of ?-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Triple Negative Breast Neoplasms
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Triple Negative Breast Neoplasms
Resistomycin attenuates triple-negative breast cancer progression by inhibiting E3 ligase Pellino-1 and inducing SNAIL/SLUG degradation.
Triple Negative Breast Neoplasms
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Triple Negative Breast Neoplasms
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Triple Negative Breast Neoplasms
RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers.
Triple Negative Breast Neoplasms
SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2.
Triple Negative Breast Neoplasms
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
Triple Negative Breast Neoplasms
Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
Triple Negative Breast Neoplasms
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.
Triple Negative Breast Neoplasms
Targeted Next-generation Sequencing for Reliable Detection of Genetic Status in Breast Cancer.
Triple Negative Breast Neoplasms
Targeting DNA damage and repair by curcumin.
Triple Negative Breast Neoplasms
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Triple Negative Breast Neoplasms
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.
Triple Negative Breast Neoplasms
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Triple Negative Breast Neoplasms
The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
Triple Negative Breast Neoplasms
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
Triple Negative Breast Neoplasms
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer.
Triple Negative Breast Neoplasms
The Role of Genetic Testing in Patients With Breast Cancer: A Review.
Triple Negative Breast Neoplasms
Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
Triple Negative Breast Neoplasms
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Triple Negative Breast Neoplasms
Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Triple Negative Breast Neoplasms
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
Triple Negative Breast Neoplasms
Triple Negative Breast Cancer in BRCA1 Mutation Carriers With a Complete Radiologic Response to Neoadjuvant Paclitaxel: A Case Report.
Triple Negative Breast Neoplasms
Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
Triple Negative Breast Neoplasms
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Triple Negative Breast Neoplasms
Triple-negative breast cancer in African-American women: disparities versus biology.
Triple Negative Breast Neoplasms
Triple-negative breast cancer: therapeutic options.
Triple Negative Breast Neoplasms
Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.
Triple Negative Breast Neoplasms
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Triple Negative Breast Neoplasms
What is triple-negative breast cancer?
Triple Negative Breast Neoplasms
Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.
Triple Negative Breast Neoplasms
[Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age].
Triple Negative Breast Neoplasms
[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
Triple Negative Breast Neoplasms
[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
Tuberculosis
In vitro ubiquitination of Mycobacterium tuberculosis by E3 ubiquitin ligase, MKRN1.
Tuberculosis
MicroRNA-325-3p Facilitates Immune Escape of Mycobacterium tuberculosis through Targeting LNX1 via NEK6 Accumulation to Promote Anti-Apoptotic STAT3 Signaling.
Tuberculosis
Modulation of Roquin Function in Myeloid Cells Reduces Mycobacterium tuberculosis-Induced Inflammation.
Tuberculosis
TRIM14 Is a Key Regulator of the Type I IFN Response during Mycobacterium tuberculosis Infection.
Tuberculosis
TRIM22 regulates macrophage autophagy and enhances Mycobacterium tuberculosis clearance by targeting the nuclear factor-multiplicity ?B/beclin 1 pathway.
Tuberculosis
TRIM25 upregulation by Mycobacterium tuberculosis infection promotes intracellular survival of M.tb in RAW264.7 cells.
Tuberculosis, Pulmonary
TRIM25 upregulation by Mycobacterium tuberculosis infection promotes intracellular survival of M.tb in RAW264.7 cells.
Tuberous Sclerosis
Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.
Tuberous Sclerosis
Involvement of C/EBP?-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis.
Tuberous Sclerosis
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Tubular Sweat Gland Adenomas
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Unilateral Breast Neoplasms
Accuracy of the BRCAPRO model among women with bilateral breast cancer.
Unilateral Breast Neoplasms
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Unilateral Breast Neoplasms
BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia.
Unilateral Breast Neoplasms
Breast Cancer Surgery Trend Changes Since the Introduction of BRCA1/2 Mutation Screening: A Retrospective Cohort Analysis of 158 Mutation Carriers Treated at a Single Institution.
Unilateral Breast Neoplasms
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Unilateral Breast Neoplasms
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Unilateral Breast Neoplasms
Contribution of BRCA1 germline mutation in patients with sporadic breast cancer.
Unilateral Breast Neoplasms
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Unilateral Breast Neoplasms
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Unilateral Breast Neoplasms
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Unilateral Breast Neoplasms
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Unilateral Breast Neoplasms
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Unilateral Breast Neoplasms
Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer.
Unilateral Breast Neoplasms
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update.
Unilateral Breast Neoplasms
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Unilateral Breast Neoplasms
Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status.
Unilateral Breast Neoplasms
Variation of breast cancer risk among BRCA1/2 carriers.
Unilateral Breast Neoplasms
Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory.
Urinary Bladder Neoplasms
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer.
Urinary Bladder Neoplasms
ciRs-6 upregulates March1 to suppress bladder cancer growth by sponging miR-653.
Urinary Bladder Neoplasms
E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer.
Urinary Bladder Neoplasms
E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
Urinary Bladder Neoplasms
Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients.
Urinary Bladder Neoplasms
FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer.
Urinary Bladder Neoplasms
Implications of targeted next-generation sequencing for bladder cancer: report of four cases.
Urinary Bladder Neoplasms
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Urinary Bladder Neoplasms
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.
Urinary Bladder Neoplasms
Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients.
Urinary Bladder Neoplasms
Pancancer survival analysis of cancer hallmark genes.
Urinary Bladder Neoplasms
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
Urinary Bladder Neoplasms
Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation.
Urinary Bladder Neoplasms
XPC deficiency leads to centrosome amplification by inhibiting BRCA1 expression upon cisplatin-mediated DNA damage in human bladder cancer.
Urologic Neoplasms
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Usher Syndromes
The E3 ligase Ubr3 regulates Usher syndrome and MYH9 disorder proteins in the auditory organs of Drosophila and mammals.
Uterine Cervical Neoplasms
Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists.
Uterine Cervical Neoplasms
Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.
Uterine Cervical Neoplasms
BRCA1 interaction with human papillomavirus oncoproteins.
Uterine Cervical Neoplasms
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
Uterine Cervical Neoplasms
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Uterine Cervical Neoplasms
E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.
Uterine Cervical Neoplasms
Evaluation of Fanconi anaemia genes FANCA, FANCC and FANCL in cervical cancer susceptibility.
Uterine Cervical Neoplasms
Expression of HPV-induced DNA Damage Repair Factors Correlates With CIN Progression.
Uterine Cervical Neoplasms
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Uterine Cervical Neoplasms
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Uterine Cervical Neoplasms
miR-454-3p promotes proliferation and induces apoptosis in human cervical cancer cells by targeting TRIM3.
Uterine Cervical Neoplasms
Mitomycin C modulates DNA-double strand break repair genes in cervical carcinoma cells.
Uterine Cervical Neoplasms
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.
Uterine Cervical Neoplasms
Nucleolar and spindle associated protein 1 promotes metastasis of cervical carcinoma cells by activating Wnt/?-catenin signaling.
Uterine Cervical Neoplasms
p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
Uterine Cervical Neoplasms
Pancancer survival analysis of cancer hallmark genes.
Uterine Cervical Neoplasms
Parkin induces apoptotic cell death in TNF-?-treated cervical cancer cells.
Uterine Cervical Neoplasms
Parkin Induces Upregulation of 40S Ribosomal Protein SA and Posttranslational Modification of Cytokeratins 8 and 18 in Human Cervical Cancer Cells.
Uterine Cervical Neoplasms
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Uterine Cervical Neoplasms
Phosphorylation of I?B? at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.
Uterine Cervical Neoplasms
Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis.
Uterine Cervical Neoplasms
Proteomics Analysis of Andrographolide-Induced Apoptosis via the Regulation of Tumor Suppressor p53 Proteolysis in Cervical Cancer-Derived Human Papillomavirus 16-Positive Cell Lines.
Uterine Cervical Neoplasms
Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.
Uterine Neoplasms
Hereditary gynaecological malignancies: advances in screening and treatment.
Uterine Neoplasms
Hereditary non-BRCA gynaecological tumors.
Uterine Neoplasms
Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
Uterine Neoplasms
Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
Uterine Neoplasms
Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
Uterine Neoplasms
Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Vaccinia
BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-? Responses.
Vaccinia
Vaccinia Virus BBK E3 Ligase Adaptor A55 Targets Importin-Dependent NF-?B Activation and Inhibits CD8+ T-Cell Memory.
Vaccinia
Vaccinia virus protein A49 activates Wnt signalling by targetting the E3 ligase ?-TrCP.
Vascular Calcification
Nedd4 Deficiency in Vascular Smooth Muscle Promotes Vascular Calcification by Stabilizing pSmad1.
Vascular System Injuries
Suppression of c-Cbl tyrosine phosphorylation inhibits neointimal formation in balloon-injured rat arteries.
Vesicular Stomatitis
A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.
Vesicular Stomatitis
Autophagy and innate immunity: Insights from invertebrate model organisms.
Vesicular Stomatitis
The RING domain of TRIM69 promotes higher-order assembly.
Vesicular Stomatitis
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Vesicular Stomatitis
Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity.
Vesicular Stomatitis
Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State.
Viremia
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
Viremia
Susceptibility to Repeated, Low-Dose, Rectal SHIVSF162P3 Challenge Is Independent of TRIM5 Genotype in Rhesus Macaques.
Viremia
TRIM5 alpha Drives SIVsmm Evolution in Rhesus Macaques.
Virus Diseases
A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes.
Virus Diseases
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.
Virus Diseases
Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate antiviral immune response.
Virus Diseases
Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein.
Virus Diseases
Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival.
Virus Diseases
Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding.
Virus Diseases
Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection.
Virus Diseases
Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection.
Virus Diseases
Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses.
Virus Diseases
Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.
Virus Diseases
E1B-55K-Mediated Regulation of RNF4 SUMO-Targeted Ubiquitin Ligase Promotes Human Adenovirus Gene Expression.
Virus Diseases
E3 ligase FBXW7 is critical for RIG-I stabilization during antiviral responses.
Virus Diseases
E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3.
Virus Diseases
E3 Ubiquitin Ligase RNF114 Inhibits Innate Immune Response to Red-Spotted Grouper Nervous Necrosis Virus Infection in Sea Perch by Targeting MAVS and TRAF3 to Mediate Their Degradation.
Virus Diseases
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.
Virus Diseases
Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection.
Virus Diseases
Gene profiling involved in immature CD4+ T lymphocyte responsible for systemic lupus erythematosus.
Virus Diseases
Genome-wide gene expression pattern underlying differential host response to high or low pathogenic H5N1 avian influenza virus in ducks.
Virus Diseases
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Virus Diseases
HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response.
Virus Diseases
Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
Virus Diseases
Histone H2B-IFI16 Recognition of Nuclear Herpesviral Genome Induces Cytoplasmic Interferon-? Responses.
Virus Diseases
Host Intrinsic and Innate Intracellular Immunity During Herpes Simplex Virus Type 1 (HSV-1) Infection.
Virus Diseases
Identification of Glial Activation Markers by Comparison of Transcriptome Changes between Astrocytes and Microglia following Innate Immune Stimulation.
Virus Diseases
Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus.
Virus Diseases
Influenza A Virus Infection Induces Muscle Wasting via IL-6 Regulation of the E3 Ubiquitin Ligase Atrogin-1.
Virus Diseases
Innate immunity to RNA virus is regulated by temporal and reversible sumoylation of RIG-I and MDA5.
Virus Diseases
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Virus Diseases
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Virus Diseases
Intracellular antibody receptor TRIM21 prevents fatal viral infection.
Virus Diseases
iRhom2 is essential for innate immunity to RNA virus by antagonizing ER- and mitochondria-associated degradation of VISA.
Virus Diseases
ISG12a Restricts Hepatitis C Virus Infection through the Ubiquitination-Dependent Degradation Pathway.
Virus Diseases
LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity.
Virus Diseases
Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3.
Virus Diseases
Negative regulation of NEMO signaling by the ubiquitin E3 ligase MARCH2.
Virus Diseases
Negative regulation of RIG-I-mediated antiviral signaling by TRK-fused gene (TFG) protein.
Virus Diseases
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Virus Diseases
Nuclear redistribution of BRCA1 during viral infection.
Virus Diseases
OsRFPH2-10, a RING-H2 Finger E3 Ubiquitin Ligase, Is Involved in Rice Antiviral Defense in the Early Stages of Rice dwarf virus Infection.
Virus Diseases
Overexpression of feline tripartite motif-containing 25 interferes with the late stage of feline leukemia virus replication.
Virus Diseases
Positive regulatory role of c-Src-mediated TRIM25 tyrosine phosphorylation on RIG-I ubiquitination and RIG-I-mediated antiviral signaling pathway.
Virus Diseases
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Virus Diseases
Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase.
Virus Diseases
Quantitative Proteomics Reveals a Novel Role of the E3 Ubiquitin-Protein Ligase FANCL in the Activation of the Innate Immune Response through Regulation of TBK1 Phosphorylation during Peste des Petits Ruminants Virus Infection.
Virus Diseases
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Virus Diseases
Restriction of feline retroviruses: lessons from cat APOBEC3 cytidine deaminases and TRIM5alpha proteins.
Virus Diseases
RING domain is essential for the antiviral activity of TRIM25 from orange spotted grouper.
Virus Diseases
Selective autophagy controls the stability of TBK1 via NEDD4 to balance host defense.
Virus Diseases
SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production.
Virus Diseases
SUMOylation of DDX39A Alters Binding and Export of Antiviral Transcripts to Control Innate Immunity.
Virus Diseases
The E3 ligase VHL promotes follicular helper T cell differentiation via glycolytic-epigenetic control.
Virus Diseases
The E3 ubiquitin ligase Itch is required for the differentiation of follicular helper T cells.
Virus Diseases
The E3 ubiquitin ligase NEDD4 enhances killing of membrane-perturbing intracellular bacteria by promoting autophagy.
Virus Diseases
The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Virus Infection.
Virus Diseases
The long noncoding RNA Lnczc3h7a promotes a TRIM25-mediated RIG-I antiviral innate immune response.
Virus Diseases
The ORF3 protein of porcine circovirus type 2 interacts with porcine ubiquitin E3 ligase Pirh2 and facilitates p53 expression in viral infection.
Virus Diseases
The poly-proline tail of SIVmac Vpx provides gain of function for resistance to a cryptic proteasome-dependent degradation pathway.
Virus Diseases
The RING domain of TRIM69 promotes higher-order assembly.
Virus Diseases
The role of E1B55K in E4orf6/E1B55K E3 ligase complexes formed by different human adenovirus serotypes.
Virus Diseases
The Ubiquitin E3 Ligase Parkin Inhibits Innate Antiviral Immunity Through K48-Linked Polyubiquitination of RIG-I and MDA5.
Virus Diseases
Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells.
Virus Diseases
TRIM proteins: another class of viral victims.
Virus Diseases
TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus.
Virus Diseases
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
Virus Diseases
Trim23 promotes WSSV replication though negative regulation of antimicrobial peptides expression in Macrobrachium nipponense.
Virus Diseases
TRIM25 Binds RNA to Modulate Cellular Anti-viral Defense.
Virus Diseases
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys.
Virus Diseases
TRIM62 From Chicken as a Negative Regulator of Reticuloendotheliosis Virus Replication.
Virus Diseases
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Virus Diseases
Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral response.
Virus Diseases
[Hierarchical clustering analysis to detect associations between clinical and pathological features of gastric tumors and hypermethylation of suppressor genes.]
von Hippel-Lindau Disease
Identification and management of inherited cancer susceptibility.
von Hippel-Lindau Disease
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
von Hippel-Lindau Disease
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Waldenstrom Macroglobulinemia
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Werner Syndrome
Application of DNA Machineries for the Barcode Patterned Detection of Genes or Proteins.
Werner Syndrome
Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links.
Werner Syndrome
Mutator pathways unleashed by epigenetic silencing in human cancer.
Werner Syndrome
The G2-phase decatenation checkpoint is defective in Werner syndrome cells.
Williams Syndrome
Williams-Beuren syndrome TRIM50 encodes an E3 ubiquitin ligase.
Wilms Tumor
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
Wilms Tumor
Identification and management of inherited cancer susceptibility.
Wilms Tumor
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Wilms Tumor
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Wilms Tumor
WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2.
Wiskott-Aldrich Syndrome
The SH3 domain of Bruton's tyrosine kinase displays altered ligand binding properties when auto-phosphorylated in vitro.
Wolfram Syndrome
The E3 ligase Smurf1 regulates Wolfram syndrome protein stability at the endoplasmic reticulum.
Xeroderma Pigmentosum
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation.
Xeroderma Pigmentosum
Monoubiquitinated H2A destabilizes photolesion-containing nucleosomes with the concomitant release of the UV-damaged DNA-binding protein E3 ligase.
Xeroderma Pigmentosum
The CUL4A ubiquitin ligase is a potential therapeutic target in skin cancer and other malignancies.
Xeroderma Pigmentosum
The xeroderma pigmentosum group E gene product DDB2 activates nucleotide excision repair by regulating the level of p21Waf1/Cip1.
Zika Virus Infection
Zika virus increases mind bomb 1 levels, causing degradation of pericentriolar material 1 (PCM1) and dispersion of PCM1-containing granules from the centrosome.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.